50 human secreted proteins

ABSTRACT

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

[0001] This application is a non-provisional of, and claims benefit under 35 U.S.C. §119(e) based on, U.S. Provisional Application No. 60/262,066 filed on Jan. 18, 2001; this application is also a continuation-in-part, and claims priority under 35 U.S.C. §120, of U.S. application Ser. No. 09/722,329 filed on Nov. 28, 2000, which is a continuation, and claims priority under 35 U.S.C. §120, of U.S. application Ser. No. 09/262,109 filed on Mar. 4, 1999, which is a continuation-in-part, and claims priority under 35 U.S.C. §120, of PCT International Application PCT/US98/18360 filed on Sep. 3, 1998, which claims benefit under 35 U.S.C. §119(e) based on, U.S. Provisional Application Nos. 60/057,626; 60/057,663; 60/057,669 (filed on Sep. 5, 1997); 60/058,666; 60/058,667; 60/058,973; 60/058,974 (filed on Sep. 12, 1997); and, 60/090,112 (filed: on Jun. 22, 1998). Each of the above cited applications is hereby incorporated by reference in its entirety herein.

FIELD OF THE INVENTION

[0002] The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

BACKGROUND OF THE INVENTION

[0003] Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eukaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses “sorting signals,” which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

[0004] One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

[0005] Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space—a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a “linker” holding the protein to the membrane.

[0006] Thus there exists a clear need for identifying and using novel secreted polynucleotides and polypeptides. Identification and sequencing of human genes is a major goal of modern scientific research. For example, by identifying genes and determining their sequences, scientists have been able to make large quantities of valuable human “gene products.”

[0007] These include human insulin, interferon, Factor VIII, tumor necrosis factor, human growth hormone, tissue plasminogen activator, and numerous other compounds. Additionally, knowledge of gene sequences can provide the key to treatment or cure of genetic diseases (such as muscular dystrophy and cystic fibrosis).

SUMMARY OF THE INVENTION

[0008] The present invention relates to novel secreted proteins. More specifically, isolated nucleic acid molecules are provided encoding novel secreted polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

DETAILED DESCRIPTION

[0009] Polynucleotides and Polypeptides of the Invention

[0010] Features of Protein Encoded by Gene No: 1

[0011] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GTPGVSTHIWGKPDPQVTD (SEQ ID NO: 121). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0012] This gene is expressed primarily in neutrophils.

[0013] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders, particularly infection and inflammatory diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoictic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0014] The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or intervention of infection of pathogens, immune disorders, and host-to-graft response control in the tissue or organ transplantation. Additionally, the gene product can be used as the therapeutic target screening. Furthermore, this gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0015] Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0016] Features of Protein Encoded by Gene No: 2

[0017] This gene is expressed primarily in dermatofibrosarcoma protuberance, and to a lesser extent, in synovial fibroblasts, osteoclastoma, dendritic cells, lung, monocyte and human embryo.

[0018] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, integumentary, proliferating, or muscle disorders, particularly dermatofibrosarcoma protuberance. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculo-skeletal and connective tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., integumentary, developing, muscle, skeletal, immune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0019] The tissue distribution in dermatofibrosarcoma protuberance tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or intervention of dermatofibrosarcoma, as well as cancers of other tissues where expression has been observed. Furthermore, the expression in musculo-skeletal tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various muscle disorders, such as muscular dystrophy, cardiomyopathy, fibroids, myomas, and rhabdomyosarcomas.

[0020] Similarly, the tissue distribution in integumentary tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, sclerodenma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma.

[0021] Moreover, such disorders may predispose an individual (i.e. increase susceptibility) to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm). In addition, the protein may also show utility in the detection or treatment of disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0022] Features of Protein Encoded by Gene No: 3

[0023] The translation product of this gene shares sequence homology with phenylakylamine binding protein (also known as emopamil-binding protein, (EBP)) which is thought to be important in sterol isomerization and neuroprotective agent binding. EBP is known to be the one of the primary receptors for antiischemic drugs, and thus serves as a common target for therapeutics of this family (See Genbank Accession No.gi|780263). By comparison of homology, this gene may also play a similar role in either the same or other tissues or cell types.

[0024] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: MNQIFLFGQNVIHSSLHFVFVLLLLNNLFQIGFKATSFRCIVVQLNGDIGKREQI (SEQ ID NO: 123). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0025] This gene is expressed primarily in cyclohexamide treated supt cells, Alzheimer spongy forms, fetal epithelium, smooth muscle, CD34 depleted buffy coat cord blood and to a lesser extent in activated T-cells, endothelial cells, melanocytes, B-cell lymphoma, and human cerebellum.

[0026] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural, immune, or developmental disorders, particularly neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. neural, integumentary, developmental, fetal, immune, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0027] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:68 as residues: Gly-33 to Ala-38, Glu-123 to His-128, Trp-150 to Asn-161, His-195 to Ser-201.

[0028] The tissue distribution in various neural tissues combined with the homology to the EBP protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states, behavioural disorders, or inflamatory conditions such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and preception.

[0029] In addition, based upon the tissue distribution in fetal tissues, indicates that the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0030] Features of Protein Encoded by Gene No: 4

[0031] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: SPSVRAGAGPEDALKQRAEQSIXEEPGWEEEEEELMGISPI (SEQ ID NO: 124) SPKEAKVPVAKISTFPEGEPGPQSPCEENLVTSVEPPAEVTPSESSESISLVTQIANP ATAPEARVLPKDLSQKLLEASLEEQGLAVDVGETGPSPPIHSKPLTPAGHRFWWL PAGPLGPLLTPGKGLSKSRPETLTCANNRMTQGRGNLSSSPEEPVFFC, GPEDALKQRAEQSIXEEPGWFEEE, (SEQ ID NO: 125) AKVPVAKISTFPEGEPGPQSPCEE, (SEQ ID NO: 126) PAEVTPSESSESISLVTQIANPA, (SEQ ID NO: 127) LSQKLLEASLEEQGLAVDVGETGPSP, (SEQ ID NO: 128) WLPAGPLGPLLTPGKGLSKSRPETLTC, (SEQ ID NO: 129) IGGEGPVSPTSTAR PCSSKDASSSFWDRSLGSTRASGAVAGLAICVTREMLSLLSDGVTSAGGSTEVTRF SSQGLWGPGSPSGNVEILATGTFASFGDMGEMPMSSSSSSSQPGSSXMLCSARCFR ASSGPAPALTDGLYRNTDARILNGKQLLEPSWCRGPGWRGCLQGALRSPPSSPPS RTGKARRQTIPGAXLVHYSRLLGPTAGYRGEPWCHIIRAQLC QTVCPSG, (SEQ ID NO: 130) ARPCSSKDASSSFWDRSLGSTRASGA, (SEQ ID NO: 131) RFSSQGLWGPGSPSGNVEILATGTFAS, (SEQ ID NO: 132) YRNTDARILNGKQLLEPSWCRGPGW, (SEQ ID NO: 133) PGWRGCLQGALRSPPSSPPSRTGKARRQ, (SEQ ID NO: 134) and/or GGRGGRG. (SEQ ID NO: 135)

[0032] Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0033] The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

[0034] This gene is expressed primarily in hemangiopericytoma, and to a lesser extent, in hypothalamus, smooth muscle, liver, spleen, brain, bone, adipose and number of other tissues and cells.

[0035] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural and endocrine diseases and/or disorders, in addition to soft tissue cancers and proliferative conditions, such as hemangiopericytoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the blood vessels, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, hepatic, musculoskeletal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0036] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:69 as residues: Lys-14 to Glu-19, Glu-74 to Lys-84, Pro-100 to Thr-105, Gly-119 to Ala-12, Gln-135 to Asn-143, Pro-145 to Glu-150, Glu-162 to Glu-167, Glu-207 to Pro-215.

[0037] The tissue distribution in brain and other highly vascularized tissues and organs indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and intervention of disorders of blood vessels, especially angiogenesis. Moreover, expression within hemangiopericytoma and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders.

[0038] Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0039] Features of Protein Encoded by Gene No: 5

[0040] This gene is expressed primarily in both normal ovary and ovarian cancer, and to a lesser extent in Merkel cells and synovial fibroblasts.

[0041] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine and reproductive diseases and disorders, particularly proliferative conditions such as ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, endocrine, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0042] The tissue distribution in ovarian tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of disorders of the endocrine or reproductive systems. A protein product secreted by the ovary may represent a hormone that has either systemic or local effects related to reproductive function. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0043] Features of Protein Encoded by Gene No: 6

[0044] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: YQKNVTFYPFFGTILKTGFTGGKSRNSAKGSPPSARPKG (SEQ ID NO: 136), PLVCGRSGVFSAAPTPSRSPPPNQRRTGPRLPRHSRTGSLLAGAGPGLAALVTMSE TSFNLISEKCDILSILRDHPENRIYRRKIEELSKRFTAIRKTKGDGNCFYRALGYSYL ESLLGKSREIFKFKERVLQTPNDLLAAGFEEHKFRNFFNAFTVWWNW (SEQ ID NO: 137), VFSAAPTPSRSPPPNQRRTGPRL (SEQ ID NO: 138), LAALVTMSETSFNLISEKCDILSILRDHP (SEQ ID NO: 139), EELSKRFTAIRKTKGDGNCFYRALGYSYLES (SEQ ID NO: 140), and/or NDLLAAGFEEHKFRNFFNAF (SEQ ID NO: 141). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0045] This gene is expressed primarily in Hodgkins lymphoma and testes.

[0046] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, to disorders and/or diseases of the immune or reproductive system, particularly Hodkin's lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, endocrine and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, seminal fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0047] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:71 as residues: Pro-16 to Cys-32, Thr-46 to Ser-51, Gly-59 to Gly-64.

[0048] The tissue distribution Hodgkins lymphoma indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of disorders of the immune system, including immunodeficiency, immune dysfunction, allergy, autoimmune diseases, organ/tissue transplantation, or disorders of endocrine system, or reproductive problems like infertility.

[0049] Moreover, the tissue distribution in testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

[0050] Features of Protein Encoded by Gene No: 7

[0051] When tested against PC12 cell lines, supernatants removed from cells containing this gene activated the EGR1 (early growth response gene 1) promoter element. Thus, it is likely that this gene activates sensory neuron cells, and to a lesser extent in neural cells and tissues, through the EGR1 signal transduction pathway. EGR1 is a separate signal transduction pathway from Jak-STAT, genes containing the EGR1 promoter are induced in various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

[0052] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: RPLVLLRRESAFLELLAKCEKL (SEQ ID NO: 142). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0053] This gene is expressed primarily in brain tissues, especially that of brain amygdala depression, striatum depression and Alzheimers spongy form, and to a lesser extent in bladder and melanocytes.

[0054] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and psychological diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nerve system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0055] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:72 as residues: Pro-29 to Lys-37.

[0056] The tissue distribution in brain tissues, combined with the detected EGR1 biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of neurological and psychological disorders, including depression, Alzheimers disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and perception.

[0057] Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0058] Features of Protein Encoded by Gene No: 8

[0059] The translation product of this gene shares sequence homology with G-protein coupled receptors which are thought to be important in signal transduction for ligands of physiological importance. Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of prostate stromal cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of prostate cells, and to a lesser extent, other cells or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating prostate stromal cells.

[0060] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: FGYTVINT (SEQ ID NO: 143). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0061] This gene is expressed primarily in brain tissues such as striatum depression and to a lesser extent in synovial fibroblasts, osteoclastoma, fetal kidney, dendritic cells, hypothalmus, and adipose tissue.

[0062] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders of the nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0063] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:73 as residues: Asn-67 to Asn-72.

[0064] The tissue distribution in brain tissues, combined with the homology to G-protein coupled receptors indicates that polynucleotides and polypeptides corresponding to this gene are useful as a target for screening therapeutic compounds. These compounds may be used for disorders in many bodily systems, including those with central nervous system, connective tissues, bone, urinary, metabolic, immune implications. Additionally, the gene product can be expressed as therapeutic protein in whole or in part, as an antagonist, for example where the disease state results from an overexpression of the same gene. The protein is useful as a contraceptive, in addition to the detection/treatment of reproductive diseases and/or disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0065] Features of Protein Encoded by Gene No: 9

[0066] This gene is expressed only in fetal lung.

[0067] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pulmonary and developmental diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., pulmonary, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0068] The tissue distribution of this gene in fetal lung indicates that it plays a key role in development of the pulmonary system. This would suggest that misregulation of the expression of this protein product in the adult could lead to lymphoma or sarcoma formation, particularly in the lung. It may also be involved in predisposition to certain pulmonary defects such as pulmonary edema and embolism, bronchitis and cystic fibrosis. Moreover, the expression within fetal tissue indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders.

[0069] Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0070] Features of Protein Encoded by Gene No: 10

[0071] This gene is expressed primarily in bone, and to a lesser extent, in T-cells, neutrophils, and endothelial cells.

[0072] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skeletal, immune, or hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune systems and hematopoetic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. skeletal, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0073] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:75 as residues: Thr-33 to Glu-44, Tyr-63 to Arg-68.

[0074] The tissue distribution of this gene predominantly in hematopoietic cell types indicates that the gene could be important for the treatment or detection of immune or hematopoietic disorders including arthritis, asthma and immunodeficiency diseases. The expression of this gene in bone indicates a potential role in the treatment and/or detection of skeletal diorders, which include, but are not limited to, bone developmental defects, bone repair, bone diseases, and bone deformities.

[0075] Alternatively, the tissue distribution within various hematopoietic tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoetic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0076] Features of Protein Encoded by Gene No: 11

[0077] This gene is expressed primarily in fetal liver and spleen, and to a lesser extent in smooth muscle, synovial sarcoma and brain.

[0078] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, hepatic and hematopoetic diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hepatic and hematopoetic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hepatic, hematopoietic, vascular, neural, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0079] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:76 as residues: Pro-61 to Ala-67.

[0080] The tissue distribution of this gene primarily in fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment/detection of hepatic disorders including hepatoma, and hepatitis; developmental disorders and hematopoetic disorders including arthritis, asthma, immunodeficiency diseases and leukemia. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0081] Features of Protein Encoded by Gene No: 12

[0082] When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates promyelocytic cells, and to a lesser extent, immune or hematopoietic cells and tissues, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

[0083] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: EFGTSALVSTCSPIPSPDFSLLLTPSKAI (SEQ ID NO: 144). Polynucleotides encoding these polypeptides are also encompassed by the invention. Any frame shifts in this sequence can easily be clarified using known molecular biology techniques.

[0084] This gene is expressed primarily in cord blood.

[0085] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, hematopoetic, and immune diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoetic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0086] The tissue distribution in cord blood, combined with the detected GAS biological activity, indicates that the gene could be important for the treatment or detection of immune or hematopoietic disorders including arthritis, asthma, immunodeficiency diseases and leukemia. Expression of this gene product indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0087] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein is useful in regulating the immune response to developmental, proliferative, and/or differentiating tissues and cells, either directly or indirectly. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues

[0088] Features of Protein Encoded by Gene No: 13

[0089] The nucleotide sequence of this gene shows homology with a T-cell surface protein tactile precursor which is thought to be involved in the adhesive interactions of activated T and NK cells during the late phase of the immune response, when these cells are actively engaging diseased cells and moving within areas of inflamation. The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

[0090] This gene is expressed primarily in cord blood.

[0091] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoetic, immune, and reproductive diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoetic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0092] The tissue distribution of this gene in hematopoietic cell types, and its homology to T-cell surface protein precursor tactile, indicates that the gene could be important for the treatment or detection of immune, or hematopoietic disorders including arthritis, asthma, immunodeficiency diseases and leukemia. Moreover, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0093] In addition, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

[0094] Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein is useful in modulating the immune response to developing, differentiating, and proliferating cells or cell types, either directly or indirectly. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0095] Features of Protein Encoded by Gene No: 14

[0096] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: RVVHRFFKSSAFWPXEVKQPRGGPKTGSRKEGAGSRAP QPVVRSFCGSVGAEGRMEKLRLLGLRYQEYVTRHPAATAQLETAVRGFSYLLAG RFADSHELSELVYSASNLLVLLNDGILRKELRKKLPVSLSQQKLLTWLSVLE CVEVFME (SEQ ID NO: 145). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0097] This gene is expressed primarily in brain, and to a lesser extent in thymus and spleen.

[0098] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and immune diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurological and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0099] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:79 as residues: Asp-48 to Ser-54.

[0100] The tissue distribution of this gene product predominantly in brain, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. In addition the expression of this gene in the thymus and spleen indicates a possible role in the detection and treatment of immune disorders such as arthritis, asthma, immunodeficiency diseases and leukemia. Protein is useful in modulating the immune response to neural cells and tissues which include, for example, neurodegenerative conditions. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0101] Features of Protein Encoded by Gene No: 15

[0102] This gene is expressed primarily in six-week old embryo.

[0103] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental and proliferative diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetus, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, differentiating, proliferative, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0104] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:80 as residues: Thr-36 to Met-43.

[0105] The tissue distribution in embryonic tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental and degenerative disorders, as well as cancer. Similarly, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders.

[0106] Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. ifferentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0107] Features of Protein Encoded by Gene No: 16

[0108] This gene is expressed primarily in fetal brain.

[0109] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, brain tumors, developmental and neurodegenerative diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0110] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:81 as residues: His-41 to Glu-49.

[0111] The tissue distribution in fetal brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental and neurodegenerative diseases of the brain and nervous system. Examples would include; behavioral or nervous system disorders, such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, mania, dementia, paranoia, and addictive behavior, sleep disorders.

[0112] Alternatively, expression within fetal tissues indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. ifferentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0113] Features of Protein Encoded by Gene No: 17

[0114] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PGCIAGWELLS VVQGPGPRPPPRPRPRKXHSRAGCGLEXGAGGD (SEQ ID NO: 146), GVTPWGGGLQRXLPVATWCLWELVLGTLMGVCGPSCRPAPSSRAPGLGPPTPLL SSGKSPCGSSPGSRSGAMRGAPWPRFRKACVCARGKGLHDKRTRFDLN (SEQ ID NO: 147), ATWCLWELVLGTLMGVCGPS CRPAPSSRAPGLGP (SEQ ID NO: 148), and/or PTPLLSSGKSPCGSSPGSRSG AMRGAP (SEQ ID NO: 149). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0115] The gene encoding the disclosed cDNA is believed to reside on chromosome 19. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 19.

[0116] This gene is expressed primarily in fetal tissue.

[0117] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetus, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, differentiating, and cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0118] The tissue distribution in fetal tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of developmental and degenerative disorders, as well as cancer. Similarly, expression within fetal tissues indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders.

[0119] Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. ifferentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0120] Features of Protein Encoded by Gene No: 18

[0121] When tested against Reh cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activation site) promoter element. Thus, it is likely that this gene activates B-cells through the Jaks-STAT signal transduction pathway. GAS is a promoter element found upstream in many genes which are involved in the Jaks-STAT pathway. The Jaks-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

[0122] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ARDFGKCCYVNTTITIKIVYS SSTPCPETCLFCLVSSSPHHQPLSTDSFSVCIVYIISR (SEQ ID NO: 150), and/or TIKIVYSSSTPCPETCLFCLV SSSPHHQPLS (SEQ ID NO: 151). Polynucleotides encoding these polypeptides are also encompassed by the invention

[0123] This gene is expressed primarily in brain.

[0124] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, brain tumors, developmental and neurodegenerative diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, developmental, proliferating, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0125] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:83 as residues: Met-1 to Arg-8.

[0126] The tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental and neurodegenerative diseases of the brain and nervous system. Examples would include; behavioral or nervous system disorders, such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, mania, dementia, paranoia, and addictive behavior, sleep disorders. Alternatively, the detected GAS biological activity within B-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0127] In addition, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

[0128] Moreover, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0129] Features of Protein Encoded by Gene No: 19

[0130] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GTSTNPRIPRVHLLVAKD ISRTVISLVKFICSCARFHFFQQSETTWGT (SEQ ID NO: 152), and/or LVAKDISRTVISLVKFICSCAR (SEQ ID NO: 153). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0131] This gene is expressed primarily in fetal heart.

[0132] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cardiac, skeletal or developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., muscle, cardiac, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0133] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:84 as residues: Pro-42 to Asn-49, Arg-54 to Gly-59, Ile-73 to Glu-81.

[0134] The tissue distribution in fetal heart indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of cadiovascular and disorders, particularly those relating to the heart and its development. Conditions relating to heart disease, such as restenosis, atherosclerosis, stoke, angina, thrombosis, and wound healing, are all potential areas of applicability for the protein product of this gene. Similarly, expression within fetal tissues and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders.

[0135] Moreover, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. ifferentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0136] Features of Protein Encoded by Gene No: 20

[0137] Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO:85 as residues: Val-54 to Asp-59, Thr-55 to Leu-60 and Trp-98 to Cys-104. Polynucleotides encoding said polypeptides are also encompassed by the invention. In a specific embodiment, antibodies that bind said epitopes or other polypeptides of the invention are also encompassed by the invention.

[0138] In a specific embodiment, polypeptides of the invention, comprise or alternatively consist of, the following amino acid sequences: LSPPRGACR (SEQ ID NO: 154). Polynucleotides encoding these polypeptides are also encompassed by the invention as are antibodies that bind one or more of these polypeptides. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0139] Also preferred are polypeptides, comprising or alternatively consisting of, the mature polypeptide which is predicted to consist of residues 23-108 of the foregoing sequence (SEQ ID NO:85), and biologically active fragments of the mature polypeptide. Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0140]FIG. 1 show the nucleotide (SEQ ID NO:30) and deduced amino acid sequence (SEQ ID NO:85) corresponding to this gene.

[0141]FIG. 2 shows an analysis of the amino acid sequence (SEQ ID NO:85). Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown, and all were generated using the default settings of the recited computer algorithyms. In the “Antigenic Index or Jameson-Wolf” graph, the positive peaks indicate locations of the highly antigenic regions of the protein, i.e., regions from which epitope-bearing peptides of the invention can be obtained. Polypeptides comprising, or alternatively consisting of, domains defined by these graphs are contemplated by the present invention, as are polynucleotides encoding these polypeptides.

[0142] The data presented in FIG. 2 are also represented in tabular form in Table 8. The columns are labeled with the headings “Res”, “Position”, and Roman Numerals I-XIV. The column headings refer to the following features of the amino acid sequence presented in FIG. 2, and Table 8: “Res”: amino acid residue of SEQ ID NO:85 and FIG. 1; “Position”: position of the corresponding residue within SEQ ID NO:85 and FIG. 1; I: Alpha, Regions—Garnier-Robson; II: Alpha, Regions—Chou-Fasman; III: Beta, Regions—Garnier-Robson; IV: Beta, Regions—Chou-Fasman; V: Turn, Regions—Garnier-Robson; VI: Turn, Regions—Chou-Fasman; VII: Coil, Regions—Garnier-Robson; VIII: Hydrophilicity Plot—Kyte-Doolittle; IX: Hydrophobicity Plot—Hopp-Woods; X: Alpha, Amphipathic Regions—Eisenberg; XI: Beta, Amphipathic Regions—Eisenberg; XII: Flexible Regions—Karplus-Schulz; XIII: Antigenic Index—Jameson-Wolf; and XIV: Surface Probability Plot—Emini.

[0143] Preferred embodiments of the invention in this regard include fragments that comprise, or alternatively consisting of, one or more of the following regions: alpha-helix and alpha-helix forming regions (“alpha-regions”), beta-sheet and beta-sheet forming regions (“beta-regions”), turn and turn-forming regions (“turn-regions”), coil and coil-forming regions (“coil-regions”), hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions and high antigenic index regions. The data representing the structural or functional attributes of the protein set forth in FIG. 2 and/or Table 8, as described above, was generated using the various modules and algorithms of the DNA*STAR set on default parameters. In a preferred embodiment, the data presented in columns VIII, IX, XIII, and XIV of Table 8 can be used to determine regions of the protein which exhibit a high degree of potential for antigenicity. Regions of high antigenicity are determined from the data presented in columns VIII, IX, XIII, and/or XIV by choosing values which represent regions of the polypeptide which are likely to be exposed on the surface of the polypeptide in an environment in which antigen recognition may occur in the process of initiation of an immune response.

[0144] Certain preferred regions in these regards are set out in FIG. 2, but may, as shown in Table 8, be represented or identified by using tabular representations of the data presented in FIG. 2. The DNA*STAR computer algorithm used to generate FIG. 2 (set on the original default parameters) was used to present the data in FIG. 2 in a tabular format (See Table 8). The tabular format of the data in FIG. 2 is used to easily determine specific boundaries of a preferred region.

[0145] The present invention is further directed to fragments of the polynucleotide sequences described herein. By a fragment of, for example, the polynucleotide sequence of a deposited cDNA or the nucleotide sequence shown in SEQ ID NO: 30, is intended polynucleotide fragments at least about 15nt, and more preferably at least about 20 nt, at least about 25nt, still more preferably at least about 30 nt, at least about 35nt, and even more preferably, at least about 40 nt in length, at least about 45nt in length, at least about 50nt in length, at least about 60nt in length, at least about 70nt in length, at least about 80nt in length, at least about 90nt in length, at least about 100nt in length, at least about 125nt in length, at least about 150nt in length, at least about 175nt in length, which are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments 200-1500 nt in length are also useful according to the present invention, as are fragments corresponding to most, if not all, of the nucleotide sequence of a deposited cDNA or as shown in SEQ ID NO:30. By a fragment at least 20 nt in length, for example, is intended fragments which include 20 or more contiguous bases from the nucleotide sequence of a deposited cDNA or the nucleotide sequence as shown in SEQ ID NO:30. In this context “about” includes the particularly recited size, an sizes larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Representative examples of polynucleotide fragments of the invention include, for example, fragments that comprise, or alternatively, consist of, a sequence from about nucleotide 1 to about 50, from about 51 to about 100, from about 101 to about 150, from about 151 to about 200, from about 201 to about 250, from about 251 to about 300, from about 301 to about 350, from about 351 to about 400, from about 401 to about 450, from about 451 to about 500, and from about 501 to about 553 of SEQ ID NO:30, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context “about” includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. In additional embodiments, the polynucleotides of the invention encode functional attributes of the corresponding protein.

[0146] Preferred polypeptide fragments of the invention comprise, or alternatively consist of, the secreted protein having a continuous series of deleted residues from the amino or the carboxy terminus, or both. Particularly, N-terminal deletions of the polypeptide can be described by the general formula m⁻¹⁰⁸ where m is an integer from 2 to 102, where m corresponds to the position of the amino acid residue identified in SEQ ID NO:85. More in particular, the invention provides polynucleotides encoding polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group: K-2 to P-108; A-3 to P-108; L-4 to P-108; C-5 to P-108; L-6 to P-108; L-7 to P-108; L-8 to P-108; L-9 to P-108; P-10 to P-108; V-11 to P-108; L-12 to P-108; G-13 to P-108; L-14 to P-108; L-15 to P-108; V-16 to P-108; S-17 to P-108; S-18 to P-108; K-19 to P-108; T-20 to P-108; L-21 to P-108; C-22 to P-108; S-23 to P-108; M-24 to P-108; E-25 to P-108; E-26 to P-108; A-27 to P-108; I-28 to P-108; N-29 to P-108; E-30 to P-108; R-31 to P-108; I-32 to P-108; Q-33 to P-108; E-34 to P-108; V-35 to P-108; A-36 to P-108; G-37 to P-108; S-38 to P-108; L-39 to P-108; I-40 to P-108; F-41 to P-108; R-42 to P-108; A-43 to P-108; I-44 to P-108; S-45 to P-108; S-46 to P-108; I-47 to P-108; G-48 to P-108; L-49 to P-108; E-50 to P-108; C-51 to P-108; Q-52 to P-108; S-53 to P-108; V-54 to P-108; T-55 to P-108; S-56 to P-108; R-57 to P-108; G-58 to P-108; D-59 to P-108; L-60 to P-108; A-61 to P-108; T-62 to P-108; C-63 to P-108; P-64 to P-108; R-65 to P-108; G-66 to P-108; F-67 to P-108; A-68 to P-108; V-69 to P-108; T-70 to P-108; G-71 to P-108; C-72 to P-108; T-73 to P-108; C-74 to P-108; G-75 to P-108; S-76 to P-108; A-77 to P-108; C-78 to P-108; G-79 to P-108; S-80 to P-108; W-81 to P-108; D-82 to P-108; V-83 to P-108; R-84 to P-108; A-85 to P-108; E-86 to P-108; T-87 to P-108; T-88 to P-108; C-89 to P-108; H-90 to P-108; C-91 to P-108; Q-92 to P-108; C-93 to P-108; A-94 to P-108; G-95 to P-108; M-96 to P-108; D-97 to P-108; W-98 to P-108; T-99 to P-108; G-100 to P-108; A-101 to P-108; R-102 to P-108; and C-103 to P-108 of SEQ ID NO: 85. Polypeptides encoded by these polynucleotides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0147] Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification of loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind ligand, ability to generate antibodies, ability to bind antibodies) may still be retained. For example the ability of the shortened polypeptide to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a polypeptide with a large number of deleted C-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response. Accordingly, the present invention further provides polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the polypeptide shown in FIG. 1 (SEQ ID NO:85), as described by the general formula 1-n, where n is an integer from 6 to 107, where n corresponds to the position of the amino acid residue identified in SEQ ID NO:85. More in particular, the invention provides polynucleotides encoding polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group: M-1 to Q-107; M-1 to V-106; M-1 to R-105; M-1 to C-104; M-1 to C-103; M-1 to R-102; M-1 to A-101; M-1 to G-100; M-1 to T-99; M-1 to W-98; M-1 to D-97; M-1 to M-96; M-1 to G-95; M-1 to A-94; M-1 to C-93; M-1 to Q-92; M-1 to C-91; M-1 to H-90; M-1 to C-89; M-1 to T-88; M-1 to T-87; M-1 to E-86; M-1 to A-85; M-1 to R-84; M-1 to V-83; M-1 to D-82; M-1 to W-81; M-1 to S-80; M-1 to G-79; M-1 to C-78; M-1 to A-77; M-1 to S-76; M-1 to G-75; M-1 to C-74; M-1 to T-73; M-1 to C-72; M-1 to G-71; M-1 to T-70; M-1 to V-69; M-1 to A-68; M-1 to F-67; M-1 to G-66; M-1 to R-65; M-1 to P-64; M-1 to C-63; M-1 to T-62; M-1 to A-61; M-1 to L-60; M-1 to D-59; M-1 to G-58; M-1 to R-57; M-1 to S-56; M-1 to T-55; M-1 to V-54; M-1 to S-53; M-1 to Q-52; M-1 to C-51; M-1 to E-50; M-1 to L-49; M-1 to G-48; M-1 to I-47; M-1 to S-46; M-1 to S-45; M-1 to I-44; M-1 to A-43; M-1 to R-42; M-1 to F-41; M-1 to I-40; M-1 to L-39; M-1 to S-38; M-1 to G-37; M-1 to A-36; M-1 to V-35; M-1 to E-34; M-1 to Q-33; M-1 to I-32; M-1 to R-31; M-1 to E-30; M-1 to N-29; M-1 to I-28; M-1 to A-27; M-1 to E-26; M-1 to E-25; M-1 to M-24; M-1 to S-23; M-1 to C-22; M-1 to L-21; M-1 to T-20; M-1 to K-19; M-1 to S-18; M-1 to S-17; M-1 to V-16; M-1 to L-15; M-1 to L-14; M-1 to G-13; M-1 to L-12; M-1 to V-11; M-1 to P-10; M-1 to L-9; M-1 to L-8; M-1 to L-7; and M-1 to L-6; of SEQ ID NO:85. Polypeptides encoded by these polynucleotides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0148] In addition, any of the above listed N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted polypeptide. The invention also provides polypeptides comprising, or alternatively consisting of, one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues m-n of SEQ ID NO:85, where n and m are integers as described above.

[0149] Also included are polynucleotide sequences encoding a polypeptide consisting of a portion of the complete amino acid sequence encoded by a cDNA clone contained in ATCC Deposit No. 209215, where this portion excludes any integer of amino acid residues from 1 to about 102 amino acids from the amino terminus of the complete amino acid sequence encoded by a cDNA clone contained in ATCC Deposit No. 209215, or any integer of amino acid residues from 6 to about 108 amino acids from the carboxy terminus, or any combination of the above amino terminal and carboxy terminal deletions, of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209215. Polypeptides encoded by these polynucleotides also are encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0150] Additional preferred polypeptide fragments of the invention comprise, or alternatively consist of, an amino acid sequence selected from the group: M-1 to L-15; K-2 to V-16; A-3 to S-17; L-4 to S-18; C-5 to K-19; L-6 to T-20; L-7 to L-21; L-8 to C-22; L-9 to S-23; P-10 to M-24; V-11 to E-25; L-12 to E-26; G-13 to A-27; L-14 to I-28; L-15 to N-29; V-16 to E-30; S-17 to R-31; S-18 to I-32; K-19 to Q-33; T-20 to E-34; L-21 to V-35; C-22 to A-36; S-23 to G-37; M-24 to S-38; E-25 to L-39; E-26 to I-40; A-27 to F-41; I-28 to R-42; N-29 to A-43; E-30 to I-44; R-31 to S-45; I-32 to S-46; Q-33 to I-47; E-34 to G-48; V-35 to L-49; A-36 to E-50; G-37 to C-51; S-38 to Q-52; L-39 to S-53; I-40 to V-54; F-41 to T-55; R-42 to S-56; A-43 to R-57; I-44 to G-58; S-45 to D-59; S-46 to L-60; I-47 to A-61; G-48 to T-62; L-49 to C-63; E-50 to P-64; C-51 to R-65; Q-52 to G-66; S-53 to F-67; V-54 to A-68; T-55 to V-69; S-56 to T-70; R-57 to G-71; G-58 to C-72; D-59 to T-73; L-60 to C-74; A-61 to G-75; T-62 to S-76; C-63 to A-77; P-64 to C-78; R-65 to G-79; G-66 to S-80; F-67 to W-81; A-68 to D-82; V-69 to V-83; T-70 to R-84; G-71 to A-85; C-72 to E-86; T-73 to T-87; C-74 to T-88; G-75 to C-89; S-76 to H-90; A-77 to C-91; C-78 to Q-92; G-79 to C-93; S-80 to A-94; W-81 to G-95; D-82 to M-96; V-83 to D-97; R-84 to W-98; A-85 to T-99; E-86 to G-100; T-87 to A-101; T-88 to R-102; C-89 to C-103; H-90 to C-104; C-91 to R-105; Q-92 to V-106; C-93 to Q-107; and A-94 to P-108 of SEQ ID NO:85. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0151] As described herein or otherwise known in the art, the polynucleotides of the invention have uses that include, but are not limited to, serving as probes or primers in chromosome identification, chromosome mapping, and linkage analysis.

[0152] This gene is expressed primarily in placenta and in some immune tissues and cells of the immune system (e.g., Jurkat T cell lines, and normal bone marrow).

[0153] Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, fetal deficiencies, pre-natal disorders, and vascular diseases and conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, proliferating, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0154] The tissue distribution in placenta indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental anomalies, fetal deficiencies, reproductive disfunction or pre-natal disorders. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0155] The tissue distribution of the expression of this gene indicates that polynucleotides and polypeptides corresponding to this gene (as well as antibodies raised against those polypeptides) are useful for the diagnosis and treatment of diseases and disorders associated with the immune system, including, but not limited to, allergy, asthma, graft rejection, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other auotimmune conditions, infections, AIDS, chronic variable immune deficiency (CVID) and other immune deficiency syndromes, respiratory distress syndrome and inflammation, neoplasms of the immune/hematopoetic system including leukemias, lymphomas and other proliferative disorders such as multiple myeloma, Hodgkin's and non-Hodgkin's lymphoma, and myelodypsplastic syndromes. The polynucleotides and/or polypeptides corresponding to this gene (and/or antibodies raised against those polypeptides) may also be useful for stimulating the immune response to bolster the immune response to diseases such as cancer or infection.

[0156] Furthermore, the protein may also be used to determine unknown biological activities, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0157] Polynucleotides or polypeptides of the invention and/or agonists and/or antagonists thereof, are used to treat, prevent, and/or diagnose diseases and disorders of the endocrine system.

[0158] In specific embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists of those polypeptides (including antibodies) as well as fragments and variants of those polynucleotides, polypeptides agonists and antagonists, may be used to diagnose, prognose or monitor vascular diseases. In other specifc embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists of those polypeptides (including antibodies) as well as fragments and variants of those polynucleotides, polypeptides agonists and antagonists, may be used to treat, prevent, or ameliorate vascular diseases

[0159] In other preferred embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists of those polypeptides (including antibodies) as well as fragments and variants of those polynucleotides, polypeptides agonists and antagonists, may be used to diagnose, prognose or monitor diseases and disorders associated with aberrant glucose metabolism or glucose uptake into cells. In other specifc embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists of those polypeptides (including antibodies) as well as fragments and variants of those polynucleotides, polypeptides agonists and antagonists, may be used to treat, prevent, or ameliorate diseases and disorders associated with aberrant glucose metabolism or glucose uptake into cells.

[0160] It is believed that increased expression of this gene, at either the RNA or protein level, is increased in individuals (or a subset of individuals) that either have a predisposition to develop or have already developed type II diabetes mellitus (non-insulin dependent diabetes). Thus, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists of those polypeptides (including antibodies) as well as fragments and variants of those polynucleotides, polypeptides agonists and antagonists, may be used to diagnose, prognose, and/or monitor individuals with type II diabetes mellitus or individuals with a predisposition to develop type II diabetes mellitus. By “agonist,” is meant any substance that enhances the function of the polynucleotides or polypeptides of the invention. Classes of molecules that can function as agonists include, but are not limited to, small molecules, antibodies (including fragments or variants thereof, such as Fab fragments, Fab′2 fragments and scFvs), and peptidomimetics. By “antagonist,” is meant any substance that diminishes or abolishes the function of the polynucleotides or polypeptides of the invention. Classes of molecules that can function as antagonists include, but are not limited to, small molecules, antibodies (including fragments or variants thereof, such as Fab fragments, Fab′2 fragments and scFvs) antisense polynucleotides, ribozymes, and peptidomimetics.

[0161] A biological sample of persons afflicted with type II diabetes mellitus is believed to be characterized by high levels of expression of this gene when compared to that observed in individuals not having type II diabetes mellitus. Thus, polynucleotides and/or polypeptides of the invention, and/or agonists or antagonists thereof, may be used according to the methods of the invention in the diagnosis and/or prognosis of individuals with type II diabetes mellitus, a subset of individuals with type II diabetes mellitus, and/or individuals or a subset of individuals with a predisposition to develop type II diabetes mellitus. For example, a biological sample obtained from a person suspected of being afflicted with type II diabetes mellitus, “the subject,” may be analyzed for the relative expression level(s) of polynucleotides and/or polypeptides of the invention. The expression level(s) of one or more of these molecules of the invention is (are) then compared to the expression level(s) of the same molecules of the invention as expressed in a person known not to be afflicted with rheumatoid arthritis. An increase in the expression level(s) of this gene in samples obtained from the subject compared to the control suggests that the subject is afflicted with type II diabetes mellitus or a subset thereof.

[0162] In another embodiment, the polynucleotides and/or polypeptides corresponding to this gene and/or antagonists thereof (especially neutralizing or antagonistic antibodies) may be used to treat, prevent, and/or ameliorate type II diabetes. Additionally, in other embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or anatgonists thereof (especially neutralizing or antagonistic antibodies) may be used to treat, prevent, or ameliorate conditions associated with type II diabetes mellitus, including, but not limited to, seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the “Cardiovascular Disorders” section below), dyslipidemia, kidney disease (e.g., renal failure, nephropathy other diseases and disorders as described in the “Renal Disorders” section below), nerve damage, neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, infections (e.g., infectious diseases and disorders as described in the “Infectious Diseases” section below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture.

[0163] In other embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most preferably a human, in order to regulate the animal's weight. In specific embodiments the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most preferably a human, in order to control the animal's weight by modulating a biochemical pathway involving insulin. In still other embodiments the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most preferably a human, in order to control the animal's weight by modulating a biochemical pathway involving insulin-like growth factor.

[0164] In a preferred embodiment, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most preferably a human, in order to treat weight disorders, including but not limited to, obesity, cachexia, wasting disease, anorexia, and bulimia.

[0165] In other embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are useful for the treatment, prevention or amelioration of neurodegenerative disorders including, but not limited to, Alzheimer's disease, Parkinson's disease, Huntington's disease, amylotrophic lateral sclerosis and the like, as well as spinocerebellar degenerations, and other neurolgical diseases and disorders as described in the “Neural Activity and Neurological Activity diseases” section below

[0166] In another embodiment, compositions of the invention (comprising polynucleotides, polypeptides of the invention, agonists and/or antagonists thereof (including antibodies) as well as fragments and variants of the polynucleotides, polypeptides of the invention, agonists and/or antagonists of the invention) are used in combination with anti-diabetic drugs. In a specific embodiment, compositions of the invention are administered in combination with thiazolidinediones (TZDs) including, but not limited to, rosiglitazone, piogliatazone, and troglitazone. In another specific embodiment, compositions of the invention are used in combination with oral hypoglycemic sulfonylurea drugs including, but not limited to, acarbose, acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide, metformin, tolazamide, and/or tolbutamide. In still other embodiments, compositions of the invention are administered in combination with one or more of the following: a biguamide antidiabetic agent, a glitazone antidiabetic agent, and a sulfonylurea antidiabetic agent.

[0167] Features of Protein Encoded by Gene No: 21

[0168] The translation product of this gene shares sequence homology with drosophila peroxidasin which is thought to be important in extracellular matrix architecture. Moreover, the protein has homology to receptor-linked protein tyrosine phosphatases, which play important roles in inflammatory diseases and immune disorders. When tested against Jurkat T-cell lines, supernatants removed from cells containing this gene activated the GAS pathway. Thus, it is likely that this gene activates T-cells through the Jaks-STAT signal transduction pathway. GAS is a promoter element found upstream in many genes which are involved in the Jaks-STAT pathway. The Jaks-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jaks-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

[0169] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GRPTRPLRVA (SEQ ID NO: 155), AWCPQTHTTSCLMGPFCCYSPLPGDMPTMARPCPQTWVSTHVRPATGLARQSAE ALGCLWLSSGRISRSSLGTWWLWWVSSLLWNVGRPGATQSPQSHGGKMGNPWP SSPEGTQCPGGPC (SEQ ID NO: 156), CCYSPLPGDMPTMARPCPQTWVSTH (SEQ ID NO: 157), ALGC LWLSSGRISRSSLG (SEQ ID NO: 158), and/or WNVGRPGATQSPQSHG GKMGNPWPSSPE (SEQ ID NO: 159). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0170] This gene is expressed primarily in umbilical vein and to a lesser extent in endothelial and brain cells.

[0171] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, developmental and growth diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of fetal tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, neural, cancerous and wounded tissues) or bodily fluids (e.g. lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0172] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:86 as residues: Ala-55 to Thr-62, His-164 to Gly-175, Ala-197 to Glu-202.

[0173] The tissue distribution in umbilical vein cells, and homology to peroxidasin and receptor-linked protein tyrosine phosphatases indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis, and treatment of various fetal developmental and growth disorders involving the formation of extracellular matrix. Alternatively, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Activation of the GAS pathway by the gene product indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells.

[0174] This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene product demonstrates activity with regard to the GAS pathway, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis, and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein is useful in modulating the immune response to proliferative and vascular cells and tissues, particularly those having aberrant phenotypes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0175] Features of Protein Encoded by Gene No: 22

[0176] The translation product of this gene was shown to have homology to the Human M97-2 secreted protein, which is thought to be involved in immune regulation (see PCT publication number WO9740151 which is hereby incorporated by reference herein). Based on the sequence similarity, the translation product of this gene is expected to share biological activities with secreted proteins. Such activities are known in the art and described elsewhere herein.

[0177] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: LS AYRTLDNTHIHTHKNAHEPNPEKVPAGPPPSPPPPTSPLDSEDRRGTRGHLGRP AGSPPTPPRPSHHTPIITLYITQSFWFSRTRLPKYHLQKVTLAGHYFVYLFPMQKKN ENEKRGIP (SEQ ID NO: 160), LSAYRTLDNTHIHTHKNAHEPNPEKVPAG (SEQ ID NO: 161), LDSEDRR GTRGHL (SEQ ID NO: 162), IITLYITQSFWFSRTRLPKYHLQKVTLA (SEQ ID NO: 163), IDFFVVVSFLYFTDITRIVYSPSSFLLTAHWITHTYTPTK (SEQ ID NO: 165), and/or VIILFICSLC (SEQ ID NO: 164). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0178] This gene is expressed primarily in kidney medulla and to a lesser extent in brain (amygdala-depression and infant brain).

[0179] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, renal, endocrine and CNS diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal, endocrine and central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., renal, cerebral, immune, hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0180] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:87 as residues: Pro-5 to Gln-Il, Thr-29 to Ala-38.

[0181] The tissue distribution in kidney medulla indicates that the protein products of this gene is useful for the study, treatment and diagnosis of various endocrine, renal, developmental and central nervous system disorders. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma.

[0182] Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and condtions, which include, but are not limited to miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0183] Features of Protein Encoded by Gene No: 23

[0184] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: IDFFVVVSFLYFTDITRIVYSPSSFLLTAHWITHTYTPTK (SEQ ID NO: 166). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0185] This gene is expressed primarily in meningima, and to a lesser extent, in infant brain.

[0186] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the brain and CNS, particularly neuro-degenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS and developmental systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, neural, developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0187] The tissue distribution in meningima and infant brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and treatment of disorders and diseases involving the CNS and developmental pathways. The protein product of this gene is useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered bahaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system.

[0188] Moreover, expression within infant tissue indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA).

[0189] Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0190] Features of Protein Encoded by Gene No: 24

[0191] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: GVVSRGFXALLSGGRGELEAGGVAA (SEQ ID NO: 167). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0192] This gene is expressed primarily in breast lymph node.

[0193] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic, hematopoietic, and immune diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0194] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:89 as residues: Lys-27 to Ser-33.

[0195] The tissue distribution in breast lymph node indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and treatment of reproductive and immune disorders. The protein product of this gene is useful for the diagnosis and treatment of a variety of immune system disorders. Moreover, expression of this gene product indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0196] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein is useful in modulating the immune response to aberrant breast antigens, as might be present in proliferating conditions of breast cells and tissues, either directly or indirectly. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues

[0197] Features of Protein Encoded by Gene No: 25

[0198] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: DFFFFNVRRRNSQITLLPAKRLFTTSPLLQLGLSVFNLTILNVRK (SEQ ID NO: 168). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0199] This gene is expressed primarily in breast lymph node, and to a lesser extent in bone marrow.

[0200] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, immune, and hematopoietic diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g. lymph, serum, plasma, urine, breast milk, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0201] The tissue distribution in breast lymph node and bone marrow indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and treatment of various reproductive and immune disorders. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Expression of this gene product in breast lymph nodes and bone marrow indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g by boosting immune responses).

[0202] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis, and tissues. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein is useful in modulating the immune response to aberrant breast antigens, as may be present in proliferative conditions of the breast, either directly or indirectly. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0203] Features of Protein Encoded by Gene No: 26

[0204] The gene encoding the disclosed cDNA is believed to reside on the X chromosome. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for the X chromosome.

[0205] This gene is expressed primarily in placenta and to a lesser extent in fetal liver and spleen.

[0206] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders of the immune, metabolic, vascular, and developing systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. renal, vascular, immune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0207] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:91 as residues: Ile-98 to Pro-106, Pro-118 to Leu-124, Ser-136 to Arg-148.

[0208] The tissue distribution in placenta indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and treatment of disorders involving the immune, developmental and metabolic systems. The nucleotide sequence of this gene shows homology to regions of the human chromosome X, and given its tissue distribution, this gene may function in developmental pathways or the regulation thereof. In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, and pre-natal disorders.

[0209] Expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal musculai atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases.

[0210] Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and condtions, which include, but are not limited to miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0211] Features of Protein Encoded by Gene No: 27

[0212] The translation product of this gene shares sequence homology with an estrogen receptor variant which is thought to be important in reproductive, endocrine and metabolic disorders.

[0213] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: CIDHXGKRXLTVPVRIPGRPTRPCFYSLTI (SEQ ID NO: 169). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0214] This gene is expressed primarily in cancerous meningima tissue.

[0215] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and brain diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and cerebrospinal fluids, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0216] The tissue distribution in cancerous meningima tissue, combined with the homology to an estrogen receptor variant indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and treatment of brain, endocrine, reproductive and metabolic disorders. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of neural tumors.

[0217] Moreover, expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA).

[0218] Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0219] Features of Protein Encoded by Gene No: 28

[0220] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: VQQSLSIFKSLPSLLMLQRVFSCTYILAEVFGYIPTVEFLGYVVPASSPTNSVQMVT PSVCMTLSVCARGFLLHISSQTFFFFFDRVWALSPRLVAVELESRHGIPAWGNRVR LHPPPREKPN (SEQ ID NO: 170), VQQSLSIFKSLPSLLMLQRVFSCTYILAEVFGYIPTVEFLGYV (SEQ ID NO: 171), VPASSPTNSVQMVTPSVCMTLSVCARGFLLHISSQTFFFFF (SEQ ID NO: 172), and/or DRVWALSPRLVAVELESRHGIPAWGNRVRLHPPPREKPN (SEQ ID NO: 173). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0221] This gene is expressed primarily in human neutrophils.

[0222] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammatory and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the inflammatory and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0223] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:93 as residues: Asn-20 to Cys-27.

[0224] The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and/or treatment of immune and inflammatory disorders. Expression of this gene product in neutrophils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g., by boosting immune responses).

[0225] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0226] Features of Protein Encoded by Gene No: 29

[0227] This gene is expressed primarily in T cells, neutrophils, and eosinophils, and to a lesser extent in pituitary tissue.

[0228] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, endocrine, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0229] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:94 as residues: Lys-23 to Ser-30, Ala-52 to Leu-57, Pro-96 to Ser-105.

[0230] The tissue distribution in T-cells, eosinophils, neutrophils, and pituitary tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and/or treatment of various immune and endocrine disorders. Expression of this gene product in T-cells, eosinophils, and neutrophils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0231] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, expression of this gene product in T cells, eosinophils, and neutrophils also strongly indicates a role for this protein in immune function and immune surveillance.

[0232] Alternatively, the tissue distribution in pituitary tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism) hypothallamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0233] Features of Protein Encoded by Gene No: 30

[0234] The translation product of this gene shares sequence homology with Mlrq mouse protein which is thought to be important in MHC recognition by T cells. The translation product of this gene also shares homology with human platelet factors, which could suggest that this gene is important in the aggregation of immune cells, such as neutrophils. The gene encoding the disclosed cDNA is thought to reside on chromosome 15. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 15.

[0235] This gene is expressed primarily in synovial fibroblasts, and to a lesser extent in T cells and Hodgkin's lymphoma.

[0236] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune/autoimmune disorders and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and metabolic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, musculo-skeletal, cancerous and wounded tissues) or bodily fluids (e.g., lypmh, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having, such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0237] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:95 as residues: Asp-43 to Val-54, Asn-66 to Glu-74.

[0238] The tissue distribution and homology to Mlrq mouse protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and/or treatment of immune and autoimmune diseases, and cancers. Expression of this gene product in immune cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0239] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

[0240] Moreover, the expression of this gene product in synovium indicates a role in the detection and treatment of disorders and conditions affecting the skeletal system, in particular osteoporosis as well as disorders afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation), such as in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and delmatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (ie. spondyloepiphyseal dysplasia congenita, familial arthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0241] Features of Protein Encoded by Gene No: 31

[0242] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: ASLSPKPVAGLGNQGGLRRQREAEGPAGRMGPKARLGGQQQTWVEGEWVMGR ACAGWSPAGDGRGHKARQKAVMAAERSTQGPPLGHECRPPRGRRLATSVGPRC PSAQCPRARQPPRTETRSAGGLQLLPILSWAASSPHLSKLAGELEPLRPQPHIILTPL LGAMPCCTRIFCFSLTMGS (SEQ ID NO: 174), AS LSPKPVAGLGNQGGLRRQREAEGPAGRMGPKARLGGQQQTW (SEQ ID NO: 175), VEGEWVMGRACAGWSPAGDGRGHKARQKAVMAAERSTQGPPL (SEQ ID NO: 176), GHECRPPRGRRLATSVGPRCPSAQCPRARQPPRTETRSAGGLQL (SEQ ID NO: 177), and/or LPILSWAASSPHLSKLAGELEPLRPQPHIILTPLLGAMPCCTRIFCFSLTMGS (SEQ ID NO: 178). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0243] This gene is expressed primarily in neutrophils, and to a lesser extent in kidney medulla tissue.

[0244] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, renal and inflammatory disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune or renal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cells types (e.g., immune, renal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0245] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:96 as residues: Glu-21 to Gly-30, Glu-33 to Thr-47.

[0246] The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis and/or treatment of inflammatory and immune disorders. Expression of this gene product in neutrophils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0247] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0248] Alternatively, the tissue distribution in kidney tissue indicates that this gene or gene product could be used in the treatment and/or detection of kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilms Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0249] Features of Protein Encoded by Gene No: 32

[0250] This gene is expressed primarily in uterus and epididymus tissue.

[0251] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive and hormonal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0252] The tissue distribution in uterus and epididymus tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of developmental, reproductive, and endocrine disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0253] Features of Protein Encoded by Gene No: 33

[0254] This gene is expressed primarily in LPS induced neutrophils.

[0255] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation and immune defects. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, inflammed, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0256] The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of inflammatory and general immune disorders. Expression of this gene product in induced neutrophils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0257] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0258] Features of Protein Encoded by Gene No: 34

[0259] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: IRHSLPHLLVKVITLTSVKCNPIMNIARVIYCQVRNRLV (SEQ ID NO: 179), FLPLPQTAHVIASFLSFFSFCLSFFLSSKAFLLLLSFSKFFFILFFSFCCLKFSHLASLS LVVSRGVPWTRKHGGSLAEWVFGAETSRGPPSSDLID (SEQ ID NO: 180), and/or LLLFYLSFHFASHFSSLQRPFCYFCLFLSFSLSCSFLSVVSNSHIWPVFLLS SPGVYL GPGNTEGAWLSGFSVPKPPEGLLPVISLTDLETASRSVTPAVVPS (SEQ ID NO: 181). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0260] This gene is expressed primarily in LPS induced neutrophils.

[0261] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation and immune defects. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, inflammed, cancerous and wounded tissues) or bodily fluids (e.g., lypmh, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0262] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:99 as residues: Pro-9 to Cys-14.

[0263] The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of inflammatory and general immune disorders. Expression of this gene product in induced neutrophils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0264] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, expression of this gene product in neutrophils also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0265] Features of Protein Encoded by Gene No: 35

[0266] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: FFIGLETRANSIMFSKETDLSCWIRGTNPTYMIFFLFLSCSYGTVLFGTFATRG (SEQ ID NO: 182). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0267] This gene is expressed primarily in infant brain and cerebellum tissues, as well as several normal and transformed cell types.

[0268] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological diseases and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and lymphatic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., brain, neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0269] The tissue distribution in brain and cerebellum tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of cancer and/or developmental, nervous system and lymphoid disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, and schizophrenia. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0270] Features of Protein Encoded by Gene No: 36

[0271] The translation product of this gene shares sequence homology with type II collagen which is thought to be important in marix integrity and tissue homeostasis. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: PEGECCPVCP (SEQ ID NO: 183), and/or ILFNIPFCPFFVFKESSDFVSFSAGDLNDTKQSLLSLDLQKLAGGKKSN (SEQ ID NO: 185). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0272] This gene is expressed primarily in osteoblasts.

[0273] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skeletal and other mesenchymal diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculo-skeletal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., musculo-skeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0274] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:101 as residues: Asp-18 to Arg-31, Leu-38 to Gln-52.

[0275] The tissue distribution specifically in osteoblasts, and the homology to members of the collagen family of proteins, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of osteoporosis, arthritis, and other skeletal disorders. Furthermore, elevated levels of expression of this gene product in osteoblasts indicates that it may play a role in the survival, proliferation, and/or growth of osteoblasts. Therefore, it may be useful in influencing bone mass in such conditions as osteoporosis. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed disorders.

[0276] Features of Protein Encoded by Gene No: 37

[0277] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: RAAALACSCPTGIEWRELQKLSIPKAVSVVEADWIFALPLTPCPSLREGSYARTPTS GTRVACATSFDTENF (SEQ ID NO: 186), and/or SRLDFCSAPDPLSLFEGGELC (SEQ ID NO: 187). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0278] The gene encoding the disclosed cDNA is thought to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

[0279] This gene is expressed primarily in pineal gland and infant brain tissues.

[0280] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neuro-endocrine diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., brain, endocrine, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0281] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:102 as residues: Ala-38 to Lys-62.

[0282] The tissue distribution in brain and pineal gland tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of nervous system and hormonal disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception.

[0283] Moreover, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system, as well as Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothallamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0284] Features of Protein Encoded by Gene No: 38

[0285] The sequence shows significant homology to human uroplakin protein, which is thought to play a significant role as a component of the asymmetric unit membrane, which is a highly specialized biomembrane composed of terminally differentiated urothelial cells (See Genbank Accession No.: Y13645). This protein may play an important role in the regulation of the assembly of the asymmetric unit membrane. The asymmetric unit membrane forms the apical plaques of mammalian urothelium and is believed to play a role in strengthening the urothelial apical surface, thus preventing the cells from rupturing during bladder distention.

[0286] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: IS YLVKKGTATESSREIPMSTLPRRNMESIGLGMARTGGMVVITVLLSVAMFLLVL GFIIALALGSRK (SEQ ID NO: 188), MARTGGMVVITVLLSVAMFLLVLG (SEQ ID NO: 189), NMESIGLGMARTGGMVVITVLLSVA (SEQ ID NO: 190), and/or HESISYLVKKGTATESSREIPMSTLPRRNMESIGLGMARTGG (SEQ ID NO: 191). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0287] This gene is expressed primarily in bone marrow and synovial sarcoma tissues.

[0288] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic and joint diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and skeletal systems, as well as cells involved in membrane structure expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, skeletal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0289] Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 103 as residues: Gln-29 to Ser-49.

[0290] The tissue distribution in bone marrow and synovial sarcoma tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of immune and skeletal disorders and cancers. Alternatively, given the tissue distribution and homology, it is likely that this gene and its corresponding translation product may play an important role in the regulation of the assembly of the asymmetric unit membrane, which forms the apical plaques of mammalian urothelium, thus strengthening those cells and preventing them from rupturing during bladder distention. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

[0291] Features of Protein Encoded by Gene No: 39

[0292] The amino acid sequence is weakly homologous to a collagen-like protein thought to function in collagen or membrane development and/or structure. In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: TADELGCQDMNCIRQAHHVALLRSGGGADALVVLLSGLVLLVTGLTLAGLAXAP APARPLAX (SEQ ID NO: 192), and/or MSEQEAQAPGGRGLPPDMLAEQVELWWSQQPRRSALCFVVAVGLVAGCGAGG VALLSTTSSRSXEWRLATGTVLCLLALLVLVKQLMSSAVQDMNCIRQAHHVALL RSGGGADALVVLLSGLVLLVTGLTLAGLAAAPAPARPLAA (SEQ ID NO: 193). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0293] This gene is expressed primarily in lung, brain, and spinal cord tissues.

[0294] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, nervous system and respiratory diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and developmental tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, respiratory, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0295] Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 104 as residues: Pro-38 to His-47, Ala-59 to Thr-66.

[0296] The tissue distribution in brain, spinal cord, and lung tissues, and the homology to collagen-like proteins, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and/or treatment of nervous system and respiratory disorders. The translation product of this gene may also function in the regulation of the development and/or structure of collagen or membranes within the body. Furthermore, the tissue distribution in lung tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of disorders associated with developing lungs, particularly in premature infants where the lungs are the last tissues to develop. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of lung tumors.

[0297] Alternatively, the tissue distribution in brain and spinal cord tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0298] Features of Protein Encoded by Gene No: 40

[0299] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: VAALFDVPVLRSRGGDCASDGRRGRXT (SEQ ID NO: 194). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0300] This gene is expressed primarily in testesand epididymus tissues, as well as in breast and developing tissues, and to a lesser extent in several other tissues and organs.

[0301] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of endocrine, reproductive and developing organs. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and reproductive systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, endocrine, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0302] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:105 as residues: Met-i to Thr-6, Gly-45 to Asn-61, Ala-63 to Asn-72.

[0303] The tissue distribution in testes and epididymus tissues, as well as in breast and developing tissues, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders of the endocrine, reproductive and developing organs. The tissue distribution in testes and epididymus tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues

[0304] Features of Protein Encoded by Gene No: 41

[0305] This gene is expressed primarily in CD34 cells and T-cells.

[0306] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0307] Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 106 as residues: Val-13 to Lys-20, Ser-27 to Lys-32.

[0308] The tissue distribution in T-cells and CD34 cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and/or treatment of immune system disorders. Expression of this gene product in CD34 cells and T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0309] Moreover, since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore expression of this gene product in T cells also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0310] Features of Protein Encoded by Gene No: 42

[0311] The gene encoding the disclosed cDNA is thought to reside on chromosome 11. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis of chromosome 11.

[0312] This gene is expressed primarily in melanocytes and fetal lung and to a lesser extent in several other tissues and organs, such as smooth muscle tissue.

[0313] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the fetal pulmonary system, as well as skin disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing, pulmonary and dermal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., fetal, pulmonary, skin, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0314] The tissue distribution in skin and fetal lung tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of diseases of the epideimal, pulmonary and developing systems. The tissue distribution in fetal lung tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of disorders associated with developing lungs, particularly in premature infants where the lungs are the last tissues to develop. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of lung tumors, since the gene may be involved in the regulation of cell division, particularly since it is expressed in fetal tissue.

[0315] Furthermore, the tissue distribution in skin tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. Moreover, such disorders may predispose an individual (i.e. increase susceptibility) to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

[0316] Features of Protein Encoded by Gene No: 43

[0317] This gene is expressed primarily in tracheal tumor and retinal tissues.

[0318] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, diseases of the ocular and pulmonary systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the ocular and pulmonary system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., ocular, pulmonary, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0319] The tissue distribution in tracheal tumor tissue and retinal tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders of the eye, pulmonary system, and cancer. The tissue distribution in retina indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of eye disorders including blindness, color blindness, impaired vision, short and long sightedness, retinitis pigmentosa, retinitis proliferans, and retinoblastoma, retinochoroiditis, retinopathy and retinoschisis. Alternatively, the tissue distribution in tracheal tumor tissue indicates that the translation product of this gene is useful for the detection and/or treatment of cancers of the trachea, as well as cancers of other tissues where expression has been observed. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0320] Features of Protein Encoded by Gene No: 44

[0321] The translation product of this gene shows homology to cell growth regulatory proteins which are under the control of the wild-type p53 gene, the mutation of which is thought to be a contributing factor to many cases of cancer. The gene encoding the disclosed cDNA is thought to reside on chromosome 11. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis of chromosome 11.

[0322] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: EGREAGSGLSVDSRDKGHEGRGLGPFRIPQDSQVQLCQKGTFHV (SEQ ID NO: 195). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0323] This gene is expressed primarily in breast and breast cancer tissue, and to a lesser extent in haemopoietic and immune tissues, and several other tissues and organs.

[0324] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the reproductive, endocrine and haemopoietic system, and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive, endocrine and haemopoietic system, and cancerous tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, endocrine, immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0325] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:109 as residues: Cys-42 to Gly-48, Gly-52 to Ile-61.

[0326] The tissue distribution in normal and breast cancerous tissues, and the homology to cell-growth regulatory protein, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders of the reproductive, endocrine and haemopoietic organs including cancer. Given the tissue distribution and homology to cell growth regulatory proteins, it is also plausible that the translation product of this gene may play a role in the regulation of cancerous cells, or be useful as a diagnostic tool to determine tumorous growths. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0327] Features of Protein Encoded by Gene No: 45

[0328] The translation product of this gene shares sequence homology with proteins which are involved in G-coupled receptor signalling which is thought to be important in various diseases including cancer, aquired immunodeficiency, diabetes, cardiovascular disease and neurological disorders. Based on the sequence similarity, the translation product of this gene is expected to share biological activities with G-coupled receptor proteins, and their regulators. Such activities are known in the art and described elsewhere herein. This protein was subsequently gened by another group (See, for example, J. Hum. Genet. 43 (3), 202-205 (1998), which is hereby incorporated in its entirety herein by reference).

[0329] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: NHPVSYFLHNNPAFPINLHIFPQQLCSVIPTWEKSQG (SEQ ID NO: 196), SGGAKPPAKMCKGLAALPHSCLERAKEIKIKLGILLQKPDSVGDLVIPYNEKPEKP AKTQKTSLDEALQWRDSLDKLLQNNYGLASFKSFLKSEFSEENLEFWIACEDYKK IKSPAKMAEKAKQIYEEFIQTEAPKEVNIDHFTKDITMKNLVEPSLSSFDMAQKRI HALMEKDSLPRFVRSEFYQELIK (SEQ ID NO: 197), ALPHSCLERAKEIKIKLGILLQKPDSVGDLV (SEQ ID NO: 198), DSLDKLLQNNYGLASFKSFLKSEFS (SEQ ID NO: 199), ENLEFWIACEDYKKIKSPAKMAEKAKQIY (SEQ ID NO: 200), and/or DITMKNLVEPSLSSFDMAQKRIHALMEK (SEQ ID NO: 201). Polynucleotides encoding these polypeptides are also encompassed by the invention. The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

[0330] This gene is expressed primarily in adrenal gland tumor, endothelial cells and the central nervous system and to a lesser extent in several other tissue and organs.

[0331] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders of the endothelium, CNS, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endothelium and central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, endothelial, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0332] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:110 as residues: Thr-41 to Ala-50.

[0333] The tissue distribution tumors, combined with the homology to proteins which are involved in G-coupled receptor signalling indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the CNS, endothelium and cancer. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis and treatment of cancer and other proliferative disorders. Similarly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0334] Features of Protein Encoded by Gene No: 46

[0335] The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

[0336] This gene is expressed primarily in activated T-cells and adrenal gland tumor.

[0337] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders of the immune and endocrine system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and endocrine systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, endcrine, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0338] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:111 as residues: Asn-52 to Asn-60, Gly-72 to Pro-88, Pro-94 to Ile-99, Gln-127 to Lys-132, Glu-138 to Gly-144.

[0339] The tissue distribution in activated T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of disorders of the immune and endocrine system. Morever, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0340] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues.

[0341] Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper, hypoparathyroidism), hypothallamus, and testes. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0342] Features of Protein Encoded by Gene No: 47

[0343] This gene is expressed primarily in prostate and brain.

[0344] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders of the reproductive and central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS and reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, neural, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, seminal fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0345] Preferred epitopes include those comprising a sequence shown in SEQ ID NO: 112 as residues: Ser-22 to Lys-27.

[0346] The tissue distribution in prostate indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the CNS and reproductive system. Specifically, the protein is useful for the detection and/or amelioration of prostate cancer, and may be useful in modulating the immune response to aberrant prostatic cells or tissues (i.e. proliferative cells). Alteratively, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions which include, but are not limited to Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception.

[0347] In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0348] Features of Protein Encoded by Gene No: 48

[0349] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: IRHENFERSSTVDKKL (SEQ ID NO: 202), NSITYYRETFWERKSQ (SEQ ID NO: 203), IWQTSLLSYFQKLPQLPQPSAATTLIRQQPAT (SEQ ID NO: 204), and/or KQGSLPAKRRKLSEGSGVL (SEQ ID NO: 205). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0350] This gene is expressed primarily in bone marrow.

[0351] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders of the bone marrow. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and haemopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., hematopoietic, immune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0352] Preferred epitopes include those comprising a sequence shown in SEQ ID NO:113 as residues: Ser-39 to Ala-47, Phe-55 to Leu-64.

[0353] The tissue distribution in bone marrow indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of diseases of the immune and haemopoietic systems. Expression of this gene product indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0354] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0355] Features of Protein Encoded by Gene No: 49

[0356] The translation product of this gene was found to have homology to the conserved human eukaryotic initiation factor la which seems to be required for maximal rate of protein biosynthesis, enhances ribosome dissociation into subunits and stabilizes the binding of the initiator met-trna(i) to 40 s ribosomal subunits.

[0357] This gene is expressed primarily in melanocytes, fetal tissues and endothelial cells and to a lesser extent in several other tissues including cancers.

[0358] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders of the skin and developing organs. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the epidermal and fetal system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., integumentary, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0359] The tissue distribution in melanocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for tretment and diagnosis of diseases of the epidermis and developing tissues including cancers. Moreover, polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose an individual (i.e. increase susceptibility) to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm).

[0360] Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders such as arthritis, trauma, tendonitis, chrondomalacia and inflammation, autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenital familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). The protein is useful in ameliorating the affects of proliferative conditions (i.e. may be useful in directly, or indirectly inhibiting protein synthesis in cancerous cells). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0361] Features of Protein Encoded by Gene No: 50

[0362] The translation product of this gene was shown to have homology to the human macrosialin precursor which could play a role in phagocytic activities of tissue macrophages, both in intracellular lysosomal metabolim and extracellular cell-cell and cell-pathogen interactions, bind to tissue- and organ-specific lectins or selecting, allowing homing of macrophage subsets to particular sites, rapid recirculation of cd68 from endosomes, lysosomes to the plasma membrane may allow macrophages to crawl over selectin hearing substrates or other cells.

[0363] In specific embodiments, polypeptides of the invention comprise the following amino acid sequence: VKSTLGRLIVLSSALNKIFPLTLASSVLYSGRTSPPRESFVSQLNCCFSDK (SEQ ID NO: 206). Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0364] This gene is expressed primarily in tonsils, and to a lesser extent in several other tissues including dendritic cells, bone marrow, brain and pulmonary cells.

[0365] Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune or hematopoietic diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g. immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

[0366] The tissue distribution in immune cells and tissues, combined with the homology to the human macrosialin precursor indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the immune system and several other systems including the bone and pulmonary system. Expression of this gene product in immune cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

[0367] Moreover, since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

[0368] The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

[0369] Description of Table 1A

[0370] Table 1A summarizes information concerning certain polypnucleotides and polypeptides of the invention. The first column provides the gene number in the application for each clone identifier. The second column provides a unique clone identifier, “Clone ID:”, for a cDNA clone related to each contig sequence disclosed in Table 1A. Third column, the cDNA Clones identified in the second column were deposited as indicated in the third column (i.e. by ATCC Deposit No:Z and deposit date). Some of the deposits contain multiple different clones corresponding to the same gene. In the fourth column, “Vector” refers to the type of vector contained in the corresponding cDNA Clone identified in the second column. In the fifth column, the nucleotide sequence identified as “NT SEQ ID NO:X” was assembled from partially homologous (“overlapping”) sequences obtained from the corresponding cDNA clone identified in the second column and, in some cases, from additional related cDNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X. In the sixth column, “Total NT Seq.” refers to the total number of nucleotides in the contig sequence identified as SEQ ID NO:X.” The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as “5′ NT of Clone Seq.” (seventh column) and the “3′ NT of Clone Seq.” (eighth column) of SEQ ID NO:X. In the ninth column, the nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as “5′ NT of Start Codon.” Similarly, in column ten, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as “5′ NT of First AA of Signal Pep.” In the eleventh column, the translated amino acid sequence, beginning with the methionine, is identified as “AA SEQ ID NO:Y,” although other reading frames can also be routinely translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

[0371] In the twelfth and thirteenth columns of Table 1A, the first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as “First AA of Sig Pep” and “Last AA of Sig Pep.” In the fourteenth column, the predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as “Predicted First AA of Secreted Portion”. The amino acid position of SEQ ID NO:Y of the last amino acid encoded by the open reading frame is identified in the fifteenth column as “Last AA of ORF”.

[0372] SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1A and/or elsewhere herein

[0373] Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

[0374] Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1A. The nucleotide sequence of each deposited plasmid can readily be determined by sequencing the deposited plasmid in accordance with known methods

[0375] The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular plasmid can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

[0376] Also provided in Table 1A is the name of the vector which contains the cDNA plasmid. Each vector is routinely used in the art. The following additional information is provided for convenience.

[0377] Vectors Lambda Zap (U.S. Pat. Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Pat. Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Pat. Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, Calif., 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into E. coli strain XL-1 Blue, also available from Stratagene

[0378] Vectors pSport1, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, Md. 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., Focus 15:59 (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, N.Y.) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, Calif. 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).

[0379] The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or a deposited cDNA (cDNA Clone ID). The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include, but are not limited to, preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

[0380] Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X and SEQ ID NO:Y using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

[0381] The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X and/or a cDNA contained in ATCC Deposit No.Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, and/or a polypeptide encoded by a cDNA contained in ATCC deposit No.Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X and/or a polypeptide encoded by the cDNA contained in ATCC Deposit No.Z, are also encompassed by the invention. The present invention further encompasses a polynucleotide comprising, or alternatively consisting of the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the complement of the coding strand of the cDNA contained in ATCC Deposit No.Z.

[0382] Description of Table 1B

[0383] Table 1B summarizes some of the polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID:), contig sequences (contig identifier (Contig ID:) and contig nucleotide sequence identifier (SEQ ID NO:X)) and further summarizes certain characteristics of these polynucleotides and the polypeptides encoded thereby. The first column provides the gene number in the application for each clone identifier. The second column provides a unique clone identifier, “Clone ID:”, for a cDNA clone related to each contig sequence disclosed in Table 1A and/or 1B. The third column provides a unique contig identifier, “Contig ID:” for each of the contig sequences disclosed in Table 1B. The fourth column provides the sequence identifier, “SEQ ID NO:X”, for each of the contig sequences disclosed in Table 1A and/or 1B. The fifth column, “ORF (From-To)”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:X that delineate the preferred open reading frame (ORF) that encodes the amino acid sequence shown in the sequence listing and referenced in Table 1B as SEQ ID NO:Y (column 6). Column 7 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential immunogenic regions was performed according to the method of Jameson and Wolf (CABIOS, 4; 181-186 (1988)); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE (Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wis.). This method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 1B as “Predicted Epitopes”. In particular embodiments, polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the predicted epitopes described in Table 1B. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly. Column 8, “Tissue Distribution” shows the expression profile of tissue, cells, and/or cell line libraries which express the polynucleotides of the invention. The first number in column 8 (preceding the colon), represents the tissue/cell source identifier code corresponding to the key provided in Table 4. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. For those identifier codes in which the first two letters are not “AR”, the second number in column 8 (following the colon), represents the number of times a sequence corresponding to the reference polynucleotide sequence (e.g., SEQ ID NO:X) was identified in the tissue/cell source. Those tissue/cell source identifier codes in which the first two letters are “AR” designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of ³³P dCTP, using oligo(dT) to prime reverse transcription. After hybridization, high stringency washing conditions were employed to remove non-specific hybrids from the array. The remaining signal, emanating from each gene target, was measured using a Phosphorimager. Gene expression was reported as Phosphor Stimulating Luminescence (PSL) which reflects the level of phosphor signal generated from the probe hybridized to each of the gene targets represented on the array. A local background signal subtraction was performed before the total signal generated from each array was used to normalize gene expression between the different hybridizations. The value presented after “[array code]:” represents the mean of the duplicate values, following background subtraction and probe normalization. One of skill in the art could routinely use this information to identify normal and/or diseased tissue(s) which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue and/or cell expression. Column 9 provides the chromosomal location of polynucleotides corresponding to SEQ ID NO:X. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Given a presumptive chromosomal location, disease locus association was determined by comparison with the Morbid Map, derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.) 2000. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/). If the putative chromosomal location of the Query overlaps with the chromosomal location of a Morbid Map entry, an OMIM identification number is disclosed in column 10 labeled “OMIM Disease Reference(s)”. A key to the OMIM reference identification numbers is provided in Table 5.

[0384] Description of Table 1C

[0385] Table 1C summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID:), contig sequences (contig identifier (Contig ID:) contig nucleotide sequence identifiers (SEQ ID NO:X)), and genomic sequences (SEQ ID NO:B). The first column provides a unique clone identifier, “Clone ID:”, for a cDNA clone related to each contig sequence. The second column provides the sequence identifier, “SEQ ID NO:X”, for each contig sequence. The third column provides a unique contig identifier, “Contig ID:” for each contig sequence. The fourth column, provides a BAC identifier “BAC ID NO:A” for the BAC clone referenced in the corresponding row of the table. The fifth column provides the nucleotide sequence identifier, “SEQ ID NO:B” for a fragment of the BAC clone identified in column four of the corresponding row of the table. The sixth column, “Exon From-To”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).

[0386] Description of Table 1D

[0387] Table 1D: In preferred embodiments, the present invention encompasses a method of treating a disease or disorder listed in the “FEATURES OF PROTEIN” sections (below) and also as listed in the “Preferred Indications” column of Table 1D (below); comprising administering to a patient in which such treatment, prevention, or amelioration is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) represented by Table 1A and Table 1D (in the same row as the disease or disorder to be treated is listed in the “Preferred Indications” column of Table 1D) in an amount effective to treat, prevent, or ameliorate the disease or disorder.

[0388] As indicated in Table 1D, the polynucleotides, polypeptides, agonists, or antagonists of the present invention (including antibodies) can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists thereof (including antibodies) could be used to treat the associated disease.

[0389] The present invention encompasses methods of preventing, treating, diagnosing, or ameliorating a disease or disorder. In preferred embodiments, the present invention encompasses a method of treating a disease or disorder listed in the “Preferred Indications” column of Table 1D; comprising administering to a patient in which such treatment, prevention, or amelioration is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to treat, prevent, diagnose, or ameliorate the disease or disorder. The first and seccond columns of Table 1D show the “Gene No.” and “cDNA Clone ID No.”, respectively, indicating certain nucleic acids and proteins (or antibodies against the same) of the invention (including polynucleotide, polypeptide, and antibody fragments or variants thereof) that may be used in preventing, treating, diagnosing, or ameliorating the disease(s) or disorder(s) indicated in the corresponding row in Column 3 of Table 1D.

[0390] In another embodiment, the present invention also encompasses methods of preventing, treating, diagnosing, or ameliorating a disease or disorder listed in the “Preferred Indications” column of Table 1D; comprising administering to a patient combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in Column 3 of Table 1D.

[0391] The “Preferred Indication” column describes diseases, disorders, and/or conditions that may be treated, prevented, diagnosed, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

[0392] The recitation of “Cancer” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof) may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., leukemias, cancers, and/or as described below under “Hyperproliferative Disorders”).

[0393] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D may be used for example, to diagnose, treat, prevent, and/or ameliorate a neoplasm located in a tissue selected from the group consisting of: colon, abdomen, bone, breast, digestive system, liver, pancreas, prostate, peritoneum, lung, blood (e.g., leukemia), endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), uterus, eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

[0394] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a pre-neoplastic condition, selected from the group consisting of: hyperplasia (e.g., endometrial hyperplasia and/or as described in the section entitled “Hyperproliferative Disorders”), metaplasia (e.g., connective tissue metaplasia, a typical metaplasia, and/or as described in the section entitled “Hyperproliferative Disorders”), and/or dysplasia (e.g., cervical dysplasia, and bronchopulmonary dysplasia).

[0395] In another specific embodiment, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a benign dysproliferative disorder selected from the group consisting of: benign tumors, fibrocystic conditions, tissue hypertrophy, and/or as described in the section entitled “Hyperproliferative Disorders”.

[0396] The recitation of “Immune/Hematopoietic” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), blood disorders (e.g., as described below under “Immune Activity” “Cardiovascular Disorders” and/or “Blood-Related Disorders”), and infections (e.g., as described below under “Infectious Disease”).

[0397] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having the “Immune/Hematopoietic” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: anemia, pancytopenia, leukopenia, thrombocytopenia, leukemias, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, asthma, AIDS, autoimmune disease, rheumatoid arthritis, granulomatous disease, immune deficiency, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, immune reactions to transplanted organs and tissues, systemic lupus erythematosis, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and allergies.

[0398] The recitation of “Reproductive” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the reproductive system (e.g., as described below under “Reproductive System Disorders”).

[0399] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Reproductive” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cryptorchism, prostatitis, inguinal hernia, varicocele, leydig cell tumors, verrucous carcinoma, prostatitis, malacoplakia, Peyronie's disease, penile carcinoma, squamous cell hyperplasia, dysmenorrhea, ovarian adenocarcinoma, Turner's syndrome, mucopurulent cervicitis, Sertoli-leydig tumors, ovarian cancer, uterine cancer, pelvic inflammatory disease, testicular cancer, prostate cancer, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes mellitus, cystic fibrosis, Kartagener's syndrome, testicular atrophy, testicular feminization, anorchia, ectopic testis, epididymitis, orchitis, gonorrhea, syphilis, testicular torsion, vasitis nodosa, germ cell tumors, stromal tumors, dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding, cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, cervical neoplasms, pseudohermaphroditism, and premenstrual syndrome.

[0400] The recitation of “Musculoskeletal” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the immune system (e.g., as described below under “Immune Activity”).

[0401] In Specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Musculoskeletal” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bone cancers (e.g., osteochondromas, benign chondromas, chondroblastoma, chondromyxoid fibromas, osteoid osteomas, giant cell tumors, multiple myeloma, osteosarcomas), Paget's Disease, rheumatoid arthritis, systemic lupus erythematosus, osteomyelitis, Lyme Disease, gout, bursitis, tendonitis, osteoporosis, osteoarthritis, muscular dystrophy, mitochondrial myopathy, cachexia, and multiple sclerosis.

[0402] The recitation of “Cardiovascular” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the cardiovascular system (e.g., as described below under “Cardiovascular Disorders”).

[0403] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cardiovascular” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: myxomas, fibromas, rhabdomyomas, cardiovascular abnormalities (e.g., congenital heart defects, cerebral arteriovenous malformations, septal defects), heart disease (e.g., heart failure, congestive heart disease, arrhythmia, tachycardia, fibrillation, pericardial Disease, endocarditis), cardiac arrest, heart valve disease (e.g., stenosis, regurgitation, prolapse), vascular disease (e.g., hypertension, coronary artery disease, angina, aneurysm, arteriosclerosis, peripheral vascular disease), hyponatremia, hypernatremia, hypokalemia, and hyperkalemia.

[0404] The recitation of “Mixed Fetal” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”).

[0405] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Mixed Fetal” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: spina bifida, hydranencephaly, neurofibromatosis, fetal alcohol syndrome, diabetes mellitus, PKU, Down's syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, Apert syndrome, Carpenter syndrome, Conradi syndrome, Crouzon syndrome, cutis laxa, Cornelia de Lange syndrome, Ellis-van Creveld syndrome, Holt-Oram syndrome, Kartagener syndrome, Meckel-Gruber syndrome, Noonan syndrome, Pallister-Hall syndrome, Rubinstein-Taybi syndrome, Scimitar syndrome, Smith-Lemli-Opitz syndrome, thromocytopenia-absent radius (TAR) syndrome, Treacher Collins syndrome, Williams syndrome, Hirschsprung's disease, Meckel's diverticulum, polycystic kidney disease, Turner's syndrome, and gonadal dysgenesis, Klippel-Feil syndrome, Ostogenesis imperfecta, muscular dystrophy, Tay-Sachs disease, Wilm's tumor, neuroblastoma, and retinoblastoma.

[0406] The recitation of “Excretory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and renal disorders (e.g., as described below under “Renal Disorders”).

[0407] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Excretory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bladder cancer, prostate cancer, benign prostatic hyperplasia, bladder disorders (e.g., urinary incontinence, urinary retention, urinary obstruction, urinary tract Infections, interstitial cystitis, prostatitis, neurogenic bladder, hematuria), renal disorders (e.g., hydronephrosis, proteinuria, renal failure, pyelonephritis, urolithiasis, reflux nephropathy, and unilateral obstructive uropathy).

[0408] The recitation of “Neural/Sensory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the nervous system (e.g., as described below under “Neural Activity and Neurological Diseases”).

[0409] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Neural/Sensory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: brain cancer (e.g., brain stem glioma, brain tumors, central nervous system (Primary) lymphoma, central nervous system lymphoma, cerebellar astrocytoma, and cerebral astrocytoma, neurodegenerative disorders (e.g., Alzheimer's Disease, Creutzfeldt-Jakob Disease, Parkinson's Disease, and Idiopathic Presenile Dementia), encephalomyelitis, cerebral malaria, meningitis, metabolic brain diseases (e.g., phenylketonuria and pyruvate carboxylase deficiency), cerebellar ataxia, ataxia telangiectasia, and AIDS Dementia Complex, schizophrenia, attention deficit disorder, hyperactive attention deficit disorder, autism, and obsessive compulsive disorders.

[0410] The recitation of “Respiratory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the respiratory system (e.g., as described below under “Respiratory Disorders”).

[0411] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Respiratory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of the respiratory system such as larynx cancer, pharynx cancer, trachea cancer, epiglottis cancer, lung cancer, squamous cell carcinomas, small cell (oat cell) carcinomas, large cell carcinomas, and adenocarcinomas. Allergic reactions, cystic fibrosis, sarcoidosis, histiocytosis X, infiltrative lung diseases (e.g., pulmonary fibrosis and lymphoid interstitial pneumonia), obstructive airway diseases (e.g., asthma, emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis and asbestosis), pneumonia, and pleurisy.

[0412] The recitation of “Endocrine” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the respiratory system (e.g., as described below under “Respiratory Disorders”), renal disorders (e.g., as described below under “Renal Disorders”), and disorders of the endocrine system (e.g., as described below under “Endocrine Disorders”.

[0413] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having an “Endocrine” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of endocrine tissues and organs (e.g., cancers of the hypothalamus, pituitary gland, thyroid gland, parathyroid glands, pancreas, adrenal glands, ovaries, and testes), diabetes (e.g., diabetes insipidus, type I and type II diabetes mellitus), obesity, disorders related to pituitary glands (e.g., hyperpituitarism, hypopituitarism, and pituitary dwarfism), hypothyroidism, hyperthyroidism, goiter, reproductive disorders (e.g. male and female infertility), disorders related to adrenal glands (e.g., Addison's Disease, corticosteroid deficiency, and Cushing's Syndrome), kidney cancer (e.g., hypernephroma, transitional cell cancer, and Wilm's tumor), diabetic nephropathy, interstitial nephritis, polycystic kidney disease, glomerulonephritis (e.g., IgM mesangial proliferative glomerulonephritis and glomerulonephntis caused by autoimmune disorders; such as Goodpasture's syndrome), and nephrocalcinosis.

[0414] The recitation of “Digestive” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the gastrointestinal system (e.g., as described below under “Gastrointestinal Disorders”.

[0415] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Digestive” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: ulcerative colitis, appendicitis, Crohn's disease, hepatitis, hepatic encephalopathy, portal hypertension, cholelithiasis, cancer of the digestive system (e.g., biliary tract cancer, stomach cancer, colon cancer, gastric cancer, pancreatic cancer, cancer of the bile duct, tumors of the colon (e.g., polyps or cancers), and cirrhosis), pancreatitis, ulcerative disease, pyloric stenosis, gastroenteritis, gastritis, gastric atropy, benign tumors of the duodenum, distension, irritable bowel syndrome, malabsorption, congenital disorders of the small intestine, bacterial and parasitic infection, megacolon, Hirschsprung's disease, aganglionic megacolon, acquired megacolon, colitis, anorectal disorders (e.g., anal fistulas, hemorrhoids), congenital disorders of the liver (e.g., Wilson's disease, hemochromatosis, cystic fibrosis, biliary atresia, and alphal-antitrypsin deficiency), portal hypertension, cholelithiasis, and jaundice.

[0416] The recitation of “Connective/Epithelial” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), cellular and genetic abnormalities (e.g., as described below under “Diseases at the Cellular Level”), angiogenesis (e.g., as described below under “Anti-Angiogenesis Activity”), and or to promote or inhibit regeneration (e.g., as described below under “Regeneration”), and wound healing (e.g., as described below under “Wound Healing and Epithelial Cell Proliferation”).

[0417] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Connective/Epithelial” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: connective tissue metaplasia, mixed connective tissue disease, focal epithelial hyperplasia, epithelial metaplasia, mucoepithelial dysplasia, graft v. host disease, polymyositis, cystic hyperplasia, cerebral dysplasia, tissue hypertrophy, Alzheimer's disease, lymphoproliferative disorder, Waldenstron's macroglobulinemia, Crohn's disease, pernicious anemia, idiopathic Addison's disease, glomerulonephritis, bullous pemphigoid, Sjogren's syndrome, diabetes mellitus, cystic fibrosis, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, osteoporosis, osteocarthritis, periodontal disease, wound healing, relapsing polychondritis, vasculitis, polyarteritis nodosa, Wegener's granulomatosis, cellulitis, rheumatoid arthritis, psoriatic arthritis, discoid lupus erythematosus, systemic lupus erythematosus, scleroderma, CREST syndrome, Sjogren's syndrome, polymyositis, dermatomyositis, mixed connective tissue disease, relapsing polychondritis, vasculitis, Henoch-Schonlein syndrome, erythema nodosum, polyarteritis nodosa, temporal (giant cell) arteritis, Takayasu's arteritis, Wegener's granulomatosis, Reiter's syndrome, Behcet's syndrome, ankylosing spondylitis, cellulitis, keloids, Ehler Danlos syndrome, Marfan syndrome, pseudoxantoma elasticum, osteogenese imperfecta, chondrodysplasias, epidermolysis bullosa, Alport syndrome, and cutis laxa.

[0418] Description of Table 1E

[0419] Table 1E provides information related to biological activities and preferred indications for polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof). Table 1E also provides information related to assays which may be used to test polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) for the corresponding biological activities. The first column (“Gene No.”) provides the gene number in the application for each clone identifier. The second column (“cDNA Clone ID:”) provides the unique clone identifier for each clone as previously described and indicated in Tables 1A, 1B, 1C, and 1D. The third column (“AA SEQ ID NO:Y”) indicates the Sequence Listing SEQ ID Number for polypeptide sequences encoded by the corresponding cDNA clones (also as indicated in Tables 1A, 1B, and 2). The fourth column (“Biological Activity”) indicates a biological activity corresponding to the indicated polypeptides (or polynucleotides encoding said polypeptides). The fifth column (“Exemplary Activity Assay”) further describes the corresponding biological activity and provides information pertaining to the various types of assays which may be performed to test, demonstrate, or quantify the corresponding biological activity. The sixth column (“Preferred Indications”) describes particular embodiments of the invention and indications (e.g. pathologies, diseases, disorders, abnormalities, etc.) for which polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) may be used in detecting, diagnosing, preventing, and/or treating.

[0420] Table 1E describes the use of FMAT technology, inter alia, for testing or demonstrating various biological activities. Fluorometric microvolume assay technology (FMAT) is a fluorescence-based system which provides a means to perform nonradioactive cell- and bead-based assays to detect activation of cell signal transduction pathways. This technology was designed specifically for ligand binding and immunological assays. Using this technology, fluorescent cells or beads at the bottom of the well are detected as localized areas of concentrated fluorescence using a data processing system. Unbound flurophore comprising the background signal is ignored, allowing for a wide variety of homogeneous assays. FMAT technology may be used for peptide ligand binding assays, immunofluorescence, apoptosis, cytotoxicity, and bead-based immunocapture assays. See, Miraglia S et. al., “Homogeneous cell and bead based assays for highthroughput screening using flourometric microvolume assay technology,” Journal of Biomolecular Screening; 4:193-204 (1999). In particular, FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides (including polypeptide fragments and variants) to activate signal transduction pathways. For example, FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides to upregulate production of immunomodulatory proteins (such as, for example, interleukins, GM-CSF, Rantes, and Tumor Necrosis factors, as well as other cellular regulators (e.g. insulin)).

[0421] Table 1E also describes the use of kinase assays for testing, demonstrating, or quantifying biological activity. In this regard, the phosphorylation and dephosphorylation of specific amino acid residues (e.g. Tyrosine, Serine, Threonine) on cell-signal transduction proteins provides a fast, reversible means for activation and deactivation of cellular signal transduction pathways. Moreover, cell signal transduction via phosphorylation/de-phosphorylation is crucial to the regulation of a wide variety of cellular processes (e.g. proliferation, differentiation, migration, apoptosis, etc.). Accordingly, kinase assays provide a powerful tool useful for testing, confirming, and/or identifying polypeptides (including polypeptide fragments and variants) that mediate cell signal transduction events via protein phosphorylation. See e.g., Forrer, P., Tamaskovic R., and Jaussi, R. “Enzyme-Linked Immunosorbent Assay for Measurement of JNK, ERK, and p38 Kinase Activities” Biol. Chem. 379(8-9): 1101-1110 (1998).

[0422] Description of Table 2

[0423] Table 2 summarizes homology and features of some of the polypeptides of the invention. The first column provides a unique clone identifier, “Clone ID:”, corresponding to a cDNA clone disclosed in Table 1A or 1B. The second column provides the unique contig identifier, “Contig ID:” corresponding to contigs in Table 1B and allowing for correlation with the information in Table 1B. The third column provides the sequence identifier, “SEQ ID NO:X”, for the contig polynucleotide sequence. The fourth column provides the analysis method by which the homology/identity disclosed in the Table was determined. Comparisons were made between polypeptides encoded by the polynucleotides of the invention and either a non-redundant protein database (herein referred to as “NR”), or a database of protein families (herein referred to as “PFAM”) as further described below. The fifth column provides a description of the PFAM/NR hit having a significant match to a polypeptide of the invention. Column six provides the accession number of the PFAM/NR hit disclosed in the fifth column. Column seven, “Score/Percent Identity”, provides a quality score or the percent identity, of the hit disclosed in columns five and six. Columns 8 and 9, “NT From” and “NT To” respectively, delineate the polynucleotides in “SEQ ID NO:X” that encode a polypeptide having a significant match to the PFAM/NR database as disclosed in the fifth and sixth columns. In specific embodiments polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence encoded by a polynucleotide in SEQ ID NO:X as delineated in columns 8 and 9, or fragments or variants thereof.

[0424] Description of Table 3

[0425] Table 3 provides polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column provides a unique clone identifier, “Clone ID”, for a cDNA clone related to contig sequences disclosed in Table 1B. The second column provides the sequence identifier, “SEQ ID NO:X”, for contig sequences disclosed in Table 1A and/or 1B. The third column provides the unique contig identifier, “Contig ID:”, for contigs disclosed in Table 1B. The fourth column provides a unique integer ‘a’ where ‘a’ is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, and the fifth column provides a unique integer ‘b’ where ‘b’ is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ If) NO:X, and where b is greater than or equal to a +14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention. In certain embodiments, preferably excluded from the invention are at least one, two, three, four, five, ten, or more of the polynucleotide sequence(s) having the accession number(s) disclosed in the sixth column of this Table (including for example, published sequence in connection with a particular BAC clone). In further embodiments, preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone).

[0426] Description of Table 4

[0427] Table 4 provides a key to the tissue/cell source identifier code disclosed in Table 1B, column 8. Column 1 provides the tissue/cell source identifier code disclosed in Table 1B, Column 8. Columns 2-5 provide a description of the tissue or cell source. Note that “Description” and “Tissue” sources (i.e. columns 2 and 3) having the prefix “a” indicates organs, tissues, or cells derived from “adult” sources. Codes corresponding to diseased tissues are indicated in column 6 with the word “disease.” The use of the word “disease” in column 6 is non-limiting. The tissue or cell source may be specific (e.g. a neoplasm), or may be disease-associated (e.g., a tissue sample from a normal portion of a diseased organ). Furthermore, tissues and/or cells lacking the “disease” designation may still be derived from sources directly or indirectly involved in a disease state or disorder, and therefore may have a further utility in that disease state or disorder. In numerous cases where the tissue/cell source is a library, column 7 identifies the vector used to generate the library.

[0428] Description of Table 5

[0429] Table 5 provides a key to the OMIM reference identification numbers disclosed in Table 1B, column 10. OMIM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, Md.) 2000. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/). Column 2 provides diseases associated with the cytologic band disclosed in Table 1B, column 9, as determined using the Morbid Map database.

[0430] Description of Table 6

[0431] Table 6 summarizes some of the ATCC Deposits, Deposit dates, and ATCC designation numbers of deposits made with the ATCC in connection with the present application. These deposits were made in addition to those described in the Table 1A.

[0432] Description of Table 7

[0433] Table 7 shows the cDNA libraries sequenced, and ATCC designation numbers and vector information relating to these cDNA libraries.

[0434] The first column shows the first four letters indicating the Library from which each library clone was derived. The second column indicates the catalogued tissue description for the corresponding libraries. The third column indicates the vector containing the corresponding clones. The fourth column shows the ATCC deposit designation for each libray clone as indicated by the deposit information in Table 6.

[0435] Definitions

[0436] The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

[0437] In the present invention, “isolated” refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered “by the hand of man” from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be “isolated” because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term “isolated” does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

[0438] In the present invention, a “secreted” protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a “mature” protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

[0439] As used herein, a “polynucleotide” refers to a molecule having a nucleic acid sequence encoding SEQ ID NO:Y or a fragment or variant thereof (e.g., the polypeptide delinated in columns fourteen and fifteen of Table 1A); a nucleic acid sequence contained in SEQ ID NO:X (as described in column 5 of Table 1A and/or column 3 of Table 1B) or the complement thereof; a cDNA sequence contained in Clone ID: (as described in column 2 of Table 1A and/or 1B and contained within a library deposited with the ATCC); a nucleotide sequence encoding the polypeptide encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 (EXON From-To) of Table 1C or a fragment or variant thereof; or a nucleotide coding sequence in SEQ If) NO:B as defined in column 6 of Table 1C or the complement thereof. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5′ and 3′ untranslated sequences, the coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a “polypeptide” refers to a molecule having an amino acid sequence encoded by a polynucleotide of the invention as broadly defined (obviously excluding poly-Phenylalanine or poly-Lysine peptide sequences which result from translation of a polyA tail of a sequence corresponding to a cDNA).

[0440] In the present invention, “SEQ ID NO:X” was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X is deposited at Human Genome Sciences, Inc. (HGS) in a catalogued and archived library. As shown, for example, in column 2 of Table 1B, each clone is identified by a cDNA Clone ID (identifier generally referred to herein as Clone ID:). Each Clone ID is unique to an individual clone and the Clone ID is all the information needed to retrieve a given clone from the HGS library. Table 7 provides a list of the deposited cDNA libraries. One can use the Clone ID: to determine the library source by reference to Tables 6 and 7. Table 7 lists the deposited cDNA libraries by name and links each library to an ATCC Deposit. Library names contain four characters, for example, “HTWE.” The name of a cDNA clone (Clone ID) isolated from that library begins with the same four characters, for example “HTWEP07”. As mentioned below, Table 1A and/or 1B correlates the Clone ID names with SEQ ID NO:X. Thus, starting with an SEQ ID NO:X, one can use Tables 1A, 1B, 6, 7, and 9 to determine the corresponding Clone ID, which library it came from and which ATCC deposit the library is contained in. Furthermore, it is possible to retrieve a given cDNA clone from the source library by techniques known in the art and described elsewhere herein. The ATCC is located at 10801 University Boulevard, Manassas, Va. 20110-2209, USA. The ATCC deposits were made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure.

[0441] In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5′ or 3′ to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

[0442] A “polynucleotide” of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, or the complement thereof (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments described herein), the polynucleotide sequence delineated in columns 7 and 8 of Table 1A or the complement thereof, the polynucleotide sequence delineated in columns 8 and 9 of Table 2 or the complement thereof, and/or cDNA sequences contained in Clone ID: (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments, or the cDNA clone within the pool of cDNA clones deposited with the ATCC, described herein), and/or the polynucleotide sequence delineated in column 6 of Table 1C or the complement thereof.

[0443] “Stringent hybridization conditions” refers to an overnight incubation at 42 degree C. in a solution comprising 50% formamide, 5× SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5× Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1× SSC at about 65 degree C.

[0444] Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C. in a solution comprising 6× SSPE (20× SSPE=3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C. with 1× SSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5× SSC).

[0445] Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

[0446] Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3′ terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of “polynucleotide,” since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

[0447] The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically, or metabolically modified forms.

[0448] In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5′ or 3′ to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

[0449] “SEQ ID NO:X” refers to a polynucleotide sequence described in column 5 of Table 1A, while “SEQ ID NO:Y” refers to a polypeptide sequence described in column 10 of Table 1A. SEQ ID NO:X is identified by an integer specified in column 6 of Table 1A. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X. The polynucleotide sequences are shown in the sequence listing immediately followed by all of the polypeptide sequences. Thus, a polypeptide sequence corresponding to polynucleotide sequence SEQ ID NO:2 is the first polypeptide sequence shown in the sequence listing. The second polypeptide sequence corresponds to the polynucleotide sequence shown as SEQ ID NO:3, and so on.

[0450] The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS—STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

[0451] “SEQ ID NO:X” refers to a polynucleotide sequence described, for example, in Tables 1A, 1B or 2, while “SEQ ID NO:Y” refers to a polypeptide sequence described in column 11 of Table 1A and or column 6 of Table 1B. SEQ ID NO:X is identified by an integer specified in column 4 of Table 1B. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X. “Clone ID:” refers to a cDNA clone described in column 2 of Table 1A and/or 1B.

[0452] “A polypeptide having functional activity” refers to a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide for binding) to an anti-polypeptide antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.

[0453] The polypeptides of the invention can be assayed for functional activity (e.g. biological activity) using or routinely modifying assays known in the art, as well as assays described herein. Specifically, one of skill in the art may routinely assay secreted polypeptides (including fragments and variants) of the invention for activity using assays as described in the examples section below.

[0454] “A polypeptide having biological activity” refers to a polypeptide exhibiting activity similar to, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention). TABLE 1A 5′ NT NT of AA First Last ATCC SEQ 5′ NT 3′ NT 5′ NT First SEQ AA AA First Last Deposit ID Total of of of AA of ID of of AA of AA Gene cDNA No Z NO NT Clone Clone Start Signal NO Sig Sig Secreted of No Clone ID and Date Vector X Seq Seq Seq Codon Pep Y Pep Pep Portion ORF 1 HNGJT54 209215 Uni-ZAP XR 11 1110 1 1110 172 172 66 1 19 20 34 Aug. 21, 1997 2 HOSCI83 209215 Uni-ZAP XR 12 936 1 879 68 68 67 1 25 26 32 Aug. 21, 1997 3 HSAAO30 209215 pBluescript 13 921 669 914 35 35 68 1 29 30 206 Aug. 21, 1997 SK- 4 HSQBL21 209215 Uni-ZAP XR 14 2541 1905 2541 22 22 69 1 30 31 215 Aug. 21, 1997 4 HSQBL21 209215 Uni-ZAP XR 61 1588 988 1588 1105 116 1 21 Aug. 21, 1997 5 HSSMW31 209215 Uni-ZAP XR 15 1046 156 1046 418 418 70 1 20 21 33 Aug. 21, 1997 6 HTEFU41 209215 Uni-ZAP XR 16 982 158 982 337 337 71 1 48 49 187 Aug. 21, 1997 7 HDPSP54 209215 pCMVSport 17 3091 2304 3091 2356 2356 72 1 18 19 48 Aug. 21, 1997 3.0 7 HBAFC77 209215 pSport1 62 536 1 501 179 179 117 1 41 42 55 Aug. 21, 1997 8 HELFQ07 209215 Uni-ZAP XR 18 796 1 796 164 164 73 1 28 29 91 Aug. 21, 1997 9 HLHBV54 209215 Uni-ZAP XR 19 822 1 822 17 17 74 1 25 26 28 Aug. 21, 1997 10 HBSAJ16 209215 Uni-ZAP XR 20 657 1 657 34 34 75 1 26 27 86 Aug. 21, 1997 11 HCEOC41 209215 Uni-ZAP XR 21 632 1 543 126 126 76 1 17 18 124 Aug. 21, 1997 12 HCUBS50 209215 ZAP Express 22 865 1 865 88 88 77 1 34 35 38 Aug. 21, 1997 13 HCUEO60 209215 ZAP Express 23 1222 1 1222 102 102 78 1 34 35 64 Aug. 21, 1997 14 HDHEB60 209215 pCMVSport 24 1421 235 1421 568 568 79 1 24 25 108 Aug. 21, 1997 2.0 15 HE6AJ31 209215 Uni-ZAP XR 25 638 1 638 42 42 80 1 32 33 43 Aug. 21, 1997 16 HFCED59 209215 Uni-ZAP XR 26 749 142 749 285 285 81 1 30 31 49 Aug. 21, 1997 17 HFTBY59 209215 Uni-ZAP XR 27 788 3 788 264 264 82 1 24 25 29 Aug. 21, 1997 18 HFXKJ03 209215 Lambda ZAP 28 941 1 941 179 179 83 1 33 34 41 Aug. 21, 1997 II 19 HHFDG44 209215 Uni-ZAP XR 29 835 1 835 145 145 84 1 48 49 89 Aug. 21, 1997 20 HJACG02 209215 pBluescript 30 553 1 553 47 47 85 1 23 24 108 Aug. 21, 1997 SK- 21 HKGAJ54 209224 pSport1 31 1346 1 1346 31 31 86 1 27 28 303 Aug. 28, 1997 22 HKMAB92 209224 Uni-ZAP XR 32 626 1 626 215 215 87 1 35 36 56 Aug. 28, 1997 23 HLDOJ68 209224 pCMVSport 33 1018 1 1018 343 343 88 1 21 22 30 Aug. 28, 1997 3.0 24 HLMFC54 209224 Lambda ZAP 34 767 1 767 103 103 89 1 20 21 68 Aug. 28, 1997 II 25 HLMMO64 209224 Lambda ZAP 35 840 1 840 137 137 90 1 17 18 25 Aug. 28, 1997 II 26 HLWBZ21 209224 pCMVSport 36 1148 2 1148 283 283 91 1 22 23 212 Aug. 28, 1997 3.0 27 HMJAX71 209224 pSport1 37 1367 1 1367 92 92 92 1 30 31 44 Aug. 28, 1997 28 HNECU95 209224 Uni-ZAP XR 38 921 1 921 16 16 93 1 24 25 40 Aug. 28, 1997 29 HNFCK41 209224 Uni-ZAP XR 39 632 1 632 251 251 94 1 23 24 115 Aug. 28, 1997 30 HNFHD08 209224 Uni-ZAP XR 40 608 1 608 13 13 95 1 28 29 83 Aug. 28, 1997 31 HNGEW65 209224 Uni-ZAP XR 41 877 1 877 33 33 96 1 25 26 49 Aug. 28, 1997 32 HUNAE14 209224 pBluescript 42 978 1 978 65 65 97 1 32 33 34 Aug. 28, 1997 SK- 33 HNHEN68 209224 Uni-ZAP XR 43 999 1 999 100 100 98 1 24 25 44 Aug. 28, 1997 34 HNHFG05 209224 Uni-ZAP XR 44 510 1 510 120 120 99 1 37 38 42 Aug. 28, 1997 35 HODBF19 209224 Uni-ZAP XR 45 986 1 906 166 166 100 1 34 35 44 Aug. 28, 1997 36 HOEBK34 209224 Uni-ZAP XR 46 747 75 747 149 149 101 1 20 21 165 Aug. 28, 1997 36 HOEBK34 209224 Uni-ZAP XR 63 660 1 660 68 68 118 1 26 27 88 Aug. 28, 1997 37 HPBCC51 209224 pBluescript 47 340 1 340 153 153 102 1 29 30 62 Aug. 28, 1997 SK- 38 HRGDC48 209224 Uni-ZAP XR 48 567 1 567 129 129 103 1 28 29 74 Aug. 28, 1997 39 HSDJB13 209224 Uni-ZAP XR 49 1357 303 1357 937 937 104 1 31 32 73 Aug. 28, 1997 40 HTEHR24 209224 Uni-ZAP XR 50 1075 50 1075 84 84 105 1 29 30 163 Aug. 28, 1997 40 HTEHR24 209224 Uni-ZAP XR 64 1038 1 1038 41 41 119 1 28 29 124 Aug. 28, 1997 41 HAGAM03 209224 Uni-ZAP XR 51 1025 1 1025 158 158 106 1 15 16 54 Aug. 28, 1997 41 HAGAM03 209224 Uni-ZAP XR 65 1009 1 1009 147 120 1 12 13 34 Aug. 28, 1997 42 HUNAB18 209224 pBluescript 52 908 1 908 159 159 107 1 23 24 25 Aug. 28, 1997 SK- 43 HARAM05 209224 pBluescript 53 1255 1 1255 191 191 108 1 18 19 27 Aug. 28, 1997 SK- 44 HARAO51 209224 pBluescript 54 1142 579 1142 656 656 109 1 25 26 61 Aug. 28, 1997 SK- 45 HATAA15 209224 Uni-ZAP XR 55 1923 896 1921 941 941 110 1 37 38 50 Aug. 28, 1997 46 HATCK44 209224 Uni-ZAP XR 56 1228 1 1228 50 50 111 1 17 18 170 Aug. 28, 1997 47 HBIAE26 209224 Uni-ZAP XR 57 1038 1 1038 75 75 112 1 18 19 39 Aug. 28, 1997 48 HBMXG32 209224 Uni-ZAP XR 58 990 1 990 50 50 113 1 50 51 64 Aug. 28, 1997 49 HCDAN25 209224 Uni-ZAP XR 59 1767 542 1754 660 660 114 1 18 19 27 Aug. 28, 1997 50 HCDAT43 209224 Uni-ZAP XR 60 1625 1 1232 184 184 115 1 37 38 70 Aug. 28, 1997

[0455] TABLE 1B AA Tissue Distribution SEQ Library code: count OMIM Gene cDNA Contig SEQ ID ORF ID Predicted (see Table 4 for Cytologic Disease No: Clone ID ID: NO: X (From-To) NO: Y Epitopes Library Codes) Band Reference(s): 1 HNGJT54 498272 11 172-276 66 AR183: 5, AR266: 5, AR214: 4, AR161: 4, AR162: 4, AR267: 4, AR192: 4, AR269: 4, AR163: 4, AR282: 4, AR181: 4, AR236: 4, AR228: 4, AR182: 3, AR233: 3, AR221: 3, AR309: 3, AR257: 3, AR177: 3, AR288: 3, AR291: 3, AR178: 3, AR180: 3, AR169: 3, AR173: 3, AR176: 3, AR229: 3, AR231: 3, AR294: 3, AR238: 3, AR168: 3, AR270: 3, AR289: 3, AR293: 3, AR237: 3, AR255: 3, AR171: 3, AR262: 3, AR217: 3, AR230: 3, AR287: 3, AR261: 3, AR224: 3, AR268: 2, AR300: 2, AR216: 2, AR239: 2, AR207: 2, AR286: 2, AR053: 2, AR190: 2, AR285: 2, AR191: 2, AR290: 2, AR232: 2, AR179: 2, AR225: 2, AR234: 2, AR295: 2, AR196: 2, AR226: 2, AR055: 2, AR316: 2, AR235: 2, AR258: 2, AR061: 2, AR227: 2, AR175: 2, AR089: 2, AR174: 2, AR297: 2, AR200: 2, AR311: 2, AR247: 2, AR222: 2, AR104: 2, AR189: 2, AR283: 2, AR188: 2, AR271: 2, AR203: 2, AR246: 2, AR240: 2, AR096: 1, AR256: 1, AR185: 1, AR272: 1, AR060: 1, AR277: 1, AR296: 1, AR033: 1, AR260: 1, AR199: 1, AR172: 1, AR193: 1, AR243: 1, AR223: 1, AR201: 1, AR299: 1, AR211: 1, AR308: 1 S0052: 1 and S0428: 1. 2 HOSCI83 498916 12  68-166 67 S0360: 3, L0803: 3, 2q22 256030 S0414: 2, L0770: 2, L0666: 2, H0657: 1, L0005: 1, L3646: 1, H0580: 1, H0329: 1, H0735: 1, H0747: 1, H0575: 1, S0474: 1, S0003: 1, H0428: 1, H0625: 1, H0641: 1, S0422: 1, S0002: 1, L0641: 1, L0794: 1, L0766: 1, L0376: 1, L0655: 1, L0809: 1, L0792: 1, H0689: 1, H0710: 1, H0521: 1, S0390: 1, L0786: 1, L0779: 1, L0777: 1, L0731: 1, L0759: 1 and S0242: 1. 3 HSAAO30 498287 13  35-652 68 Gly-33 to Ala-38, AR273: 210, AR274: Glu-123 to His-128, 202, AR251: 171, Trp-150 to Asn-161, AR271: 128, AR052: His-195 to Ser-201. 125, AR310: 124, AR275: 116, AR309: 112, AR175: 105, AR256: 103, AR053: 101, AR265: 100, AR247: 99, AR313: 99, AR218: 98, AR263: 98, AR312: 97, AR243: 95, AR179: 91, AR177: 87, AR219: 86, AR248: 86, AR253: 79, AR213: 76, AR183: 74, AR315: 73, AR314: 73, AR280: 69, AR096: 68, AR292: 67, AR240: 66, AR283: 59, AR249: 57, AR258: 56, AR266: 56, AR295: 54, AR281: 52, AR185: 52, AR186: 52, AR293: 50, AR282: 49, AR241: 47, AR300: 47, AR198: 45, AR259: 44, AR244: 43, AR192: 42, AR299: 42, AR267: 42, AR089: 39, AR205: 39, AR268 38, AR316: 36, AR294: 36, AR033: 35, AR231: 34, AR232: 32, AR289: 32, AR238: 31, AR039: 31, AR182: 31, AR269: 30, AR055: 30, AR290: 29, AR061: 29, AR234: 29, AR270: 28, AR291: 28, AR184: 28, AR229: 28, AR237: 28, AR226: 28, AR285: 27, AR277: 24, AR286: 24, AR104: 24, AR296: 23, AR194: 23, AR246: 22, AR298: 20, AR060: 18, AR233: 18, AR284: 18, AR204: 18, AR206: 17, AR227: 15, AR202: 14 L0803: 6, L0749: 6, L0794: 5, L0748: 4, S0440: 3, L0775: 3, L0777: 3, S0422: 2, L0770: 2, L0766: 2, L0666: 2, H0265: 1, S6024: 1, H0306: 1, S0358: 1, S0444: 1, H0722: 1, S0046: 1, H0574: 1, H0632: 1, T0039: 1, H0318: 1, H0052: 1, H0081: 1, S0438: 1, H0641: 1, L0371: 1, L0638: 1, L0637: 1, L0553: 1, L0764: 1, L0804: 1, L0806: 1, L0776: 1, L0807: 1, L0518: 1, L0809: 1, L0647: 1, L0789: 1, L0791: 1, L4501: 1, L2260: 1, S3014: 1, L0740: 1, L0750: 1, L0759: 1, L0608: 1, H0653: 1 and H0136: 1. 4 HSQBL21 794195 14  22-666 69 Lys-14 to Glu-19, AR277: 29, AR219: Glu-74 to Lys-84, 27, AR283: 25, AR218: Pro-100 to Thr-105, 24, AR104: 21, AR055: Gly-119 to Ala-129, 21, AR316: 18, AR185: Gln-135 to Asn-143, 16, AR089: 16, AR282: Pro-145 to Glu-150, 15, AR299: 14, AR240: Glu-162 to Glu-167, 14, AR096: 14, AR039: Glu-207 to Pro-215. 14, AR060: 14, AR313: 12, AR300: 11 L0748: 16, S0007: 7, H0360: 7, H0046: 6, S0474: 5, L0794: 5, L0803: 5, L0747: 5, L0771: 4, L0731: 4, H0486: 3, L0666: 3, L0663: 3, L0665: 3, L0439: 3, L0758: 3, S0444: 2, H0637: 2, H0261: 2, S0222: 2, H0748: 2, H0052: 2, S0051: 2, H0622: 2, H0169: 2, S0422: 2, L0598: 2, L0637: 2, L0764: 2, H0144: 2, H0436: 2, L0754: 2, S0436: 2, H0170: 1, S0134: 1, H0650: 1, S0116: 1, S0282: 1, S0418: 1, S0376: 1, H0580: 1, H0733: 1, S0045: 1, H0393: 1, L0622: 1, L0623: 1, S0280: 1, L0021: 1, H0599: 1, H0150: 1, H0041: 1, H0571: 1, H0050: 1, S0388: 1, H0271: 1, S0003: 1, H0673: 1, L0456: 1, H0135: 1, H0412: 1, H0056: 1, H0623: 1, S0386: 1, S0112: 1, H0494: 1, S0438: 1, S0144: 1, S0344: 1, H0529: 1, L0763: 1, L0638: 1, L0646: 1, L0766: 1, L0650: 1, L0375: 1, L0805: 1, L0653: 1, L0776: 1, L0783: 1, L0543: 1, L0647: 1, L0787: 1, L0788: 1, L0664: 1, L2654: 1, L0352: 1, L3661: 1, H0547: 1, H0593: 1, H0690: 1, H0435: 1, H0670: 1, H0648: 1, H0651: 1, H0539: 1, H0521: 1, H0522: 1, S0406: 1, S3014: 1, S0027: 1, S0206: 1, L0780: 1, L0759: 1, S0434: 1, L0595: 1, H0668: 1, S0026: 1 and H0293: 1. HSQBL21 499312 61 1105-1170 116 5 498801 15 418-519 70 AR253: 6, AR235: 5, HSSMW31 AR180: 5, AR161: 4, AR162: 4, AR163: 4, AR165: 4, AR164: 4, AR166: 4, AR224: 4, AR197: 4, AR257: 4, AR282: 3, AR233: 3, AR255: 3, AR229: 3, AR269: 3, AR183: 3, AR267: 3, AR060: 3, AR216: 3, AR182: 3, AR215: 3, AR179: 3, AR221: 3, AR272: 3, AR199: 3, AR236: 3, AR288: 3, AR228: 3, AR262: 3, AR270: 3, AR175: 3, AR230: 3, AR223: 3, AR089: 3, AR237: 3, AR293: 3, AR300: 3, AR261: 3, AR290: 3, AR181: 3, AR176: 3, AR173: 2, AR172: 2, AR096: 2, AR297: 2, AR200: 2, AR240: 2, AR289: 2, AR039: 2, AR061: 2, AR174: 2, AR268: 2, AR214: 2, AR291: 2, AR191: 2, AR185: 2, AR239: 2, AR177: 2, AR299: 2, AR055: 2, AR316: 2, AR285: 2, AR201: 2, AR171: 2, AR232: 2, AR188: 2, AR296: 2, AR190: 2, AR243: 2, AR189: 2, AR266: 2, AR231: 2, AR234: 2, AR287: 2, AR247: 2, AR178: 2, AR309: 2, AR295: 2, AR226: 2, AR277: 2, AR258: 2, AR213: 2, AR196: 2, AR311: 2, AR227: 1, AR286: 1, AR033: 1, AR294: 1, AR238: 1, AR210: 1, AR193: 1, AR260: 1, AR104: 1, AR252: 1, AR312: 1, AR283: 1, AR222: 1, AR218: 1, AR219: 1, AR169: 1, AR313: 1 L0764: 3, H0328: 1, H0428: 1, H0135: 1, H0538: 1, L0367: 1 and L0749: 1. 6 HTEFU41 499329 16 337-897 71 Pro-16 to Cys-32, AR201: 10, AR252: 8, 14q21.1-q21.3 182600, Thr-46 to Ser-51, AR176: 8, AR161: 8, 232700, Gly-59 to Gly-64. AR162: 8, AR163: 7, 602086 AR215: 7, AR228: 6, AR235: 6, AR204: 6, AR172: 6, AR269: 6, AR182: 6, AR207: 6, AR233: 6, AR266: 6, AR198: 6, AR267: 6, AR197: 6, AR229: 6, AR237: 5, AR255: 5, AR177: 5, AR225: 5, AR236: 5, AR231: 5, AR191: 5, AR183: 5, AR238: 5, AR181: 5, AR165: 5, AR205: 5, AR179: 5, AR274: 5, AR216: 5, AR239: 5, AR164: 5, AR268: 5, AR168: 5, AR291: 5, AR166: 4, AR223: 4, AR257: 4, AR296: 4, AR290: 4, AR270: 4, AR287: 4, AR193: 4, AR190: 4, AR214: 4, AR171: 4, AR309: 4, AR224: 4, AR180: 4, AR175: 4, AR173: 4, AR243: 4, AR293: 4, AR264: 4, AR271: 4, AR246: 4, AR055: 4, AR294: 4, AR285: 4, AR247: 4, AR061: 4, AR053: 4, AR288: 4, AR261: 4, AR060: 4, AR195: 4, AR200: 4, AR262: 4, AR178: 4, AR234: 3, AR169: 3, AR230: 3, AR250: 3, AR174: 3, AR240: 3, AR221: 3, AR311: 3, AR300: 3, AR196: 3, AR286: 3, AR192: 3, AR275: 3, AR272: 3, AR289: 3, AR222: 3, AR297: 3, AR226: 3, AR227: 3, AR203: 3, AR185: 3, AR295: 3, AR232: 3, AR217: 3, AR199: 3, AR256: 3, AR312: 3, AR033: 3, AR188: 3, AR258: 3, AR282: 2, AR260: 2, AR316: 2, AR245: 2, AR299: 2, AR212: 2, AR089: 2, AR277: 2, AR189: 2, AR308: 2, AR211: 2, AR213: 2, AR313: 2, AR104: 2, AR283: 1, AR096: 1, AR219: 1, AR039: 1, AR242: 1 L0758: 5, L0779: 4, H0038: 2, L0794: 2, H0486: 1, H0618: 1 and L0789: 1. 7 HDPSP54 744440 17 2356-2499 72 Pro-29 to Lys-37. AR263: 53, AR207: 53, AR214: 51, AR169: 41, AR224: 40, AR222: 38, AR223: 37, AR195: 36, AR235: 32, AR217: 31, AR212: 31, AR168: 30, AR172: 30, AR311: 29, AR053: 28, AR192: 28, AR196: 28, AR171: 27, AR198: 27, AR213: 27, AR221: 27, AR161: 26, AR264: 26, AR252: 26, AR162: 25, AR170: 25, AR210: 25, AR245: 24, AR033: 23, AR225: 23, AR216: 23, AR163: 22, AR089: 22, AR261: 22, AR215: 21, AR271: 21, AR177: 21, AR181: 21, AR104: 21, AR295: 20, AR218: 20, AR236: 19, AR193: 19, AR191: 19, AR211: 19, AR197: 18, AR185: 18, AR055: 18, AR219 18, AR201: 18, AR240: 18, AR165: 17, AR316: 17, AR166: 17, AR299: 17, AR164: 17, AR060: 17, AR253: 17, AR174: 16, AR242: 16, AR288: 16, AR199: 16, AR205: 16, AR246: 15, AR282: 15, AR039: 15, AR238: 15, AR308: 15, AR229: 15, AR175: 14, AR188: 14, AR285: 14, AR297: 14, AR254: 14, AR189: 14, AR232: 14, AR277: 13, AR300: 13, AR287: 13, AR243: 13, AR230: 13, AR312: 13, AR291 13, AR286 12, AR204: 12, AR250: 12, AR226: 12, AR173 12, AR200: 12, AR239: 12, AR176: 12, AR274: 11, AR296: 11, AR096: 11, AR309: 11, AR203: 11, AR231: 11, AR270: 11, AR247: 11, AR293: 11, AR190: 11, AR283: 10, AR258: 10, AR267: 10, AR234: 10, AR289: 10, AR262: 10, AR178: 10, AR268: 10, AR227: 10, AR313: 10, AR180: 10, AR237: 10, AR179: 9, AR257: 9, AR182: 9, AR269: 9, AR255: 9, AR233: 9, AR260: 9, AR061: 9, AR183: 9, AR290: 8, AR275: 8, AR272: 8, AR266: 8, AR294: 7, AR256: 7, AR228: 6 L0740: 8, L0662: 3, L0659: 3, L0663: 3, S0422: 2, L0646: 2, L0766: 2, L0439: 2, L0779: 2, H0171: 1, S6024: 1, S0110: 1, S0360: 1, H0411: 1, H0455: 1, S0474: 1, H0510: 1, S0438: 1, L0637: 1, L5565: 1, L0771: 1, L0773: 1, L0794: 1, L0804: 1, L0787: 1, L0665: 1, L0438: 1, H0521: 1, S0406: 1, L0754: 1, L0755: 1 and L0758: 1. HBAFC77 502472 62 179-346 117 8 HELFQ07 502523 18 164-439 73 Asn-67 to Asn-72. AR235: 26, AR285: 18p11.23- 25, AR295: 25, AR236: 18p11.21 19, AR291: 16, AR288: 14, AR266: 14, AR296: 14, AR297: 13, AR287: 12, AR293: 7, AR261: 6, AR289: 6, AR197: 6, AR271: 5, AR309: 5, AR165: 4, AR164: 4, AR272: 4, AR166: 4, AR256: 4, AR161: 4, AR294: 4, AR263: 4, AR162: 4, AR253: 4, AR163: 4, AR195: 3, AR313: 3, AR243: 3, AR216: 3, AR182: 3, AR183: 3, AR269: 3, AR089: 3, AR268: 3, AR178: 3, AR176: 3, AR262: 3, AR311: 3, AR222: 3, AR207: 3, AR316: 3, AR286: 3, AR175: 3, AR168: 3, AR229: 3, AR223: 3, AR205: 3, AR255: 3, AR193: 3, AR250: 2, AR053: 2, AR274: 2, AR267: 2, AR239: 2, AR201: 2, AR180: 2, AR245: 2, AR210: 2, AR228: 2, AR173: 2, AR104: 2, AR171: 2, AR231: 2, AR237: 2, AR212: 2, AR282: 2, AR181: 2, AR312: 2, AR238: 2, AR260: 2, AR283: 2, AR270: 2, AR226: 2, AR033: 2, AR060: 2, AR232: 2, AR213: 2, AR264: 2, AR290: 2, AR240: 2, AR188: 2, AR185: 2, AR096: 2, AR233: 2, AR179: 2, AR217: 2, AR252: 1, AR275: 1, AR218: 1, AR246: 1, AR247: 1, AR225: 1, AR061: 1, AR211: 1, AR219: 1, AR300: 1, AR234: 1, AR227: 1, AR277: 1 S0242: 9, H0658: 4, L0439: 4, L0740: 4, S0222: 3, H0635: 3, H0271: 3, H0553: 3, H0521: 3, L0749: 3, S0358: 2, S0003: 2, L0142: 2, S0364: 2, S0366: 2, L0775: 2, H0547: 2, H0659: 2, S0206: 2, L0751: 2, L0588: 2, S0040: 1, S0218: 1, S0116: 1, H0341: 1, S0418: 1, L0005: 1, S0356: 1, S0444: 1, S0360: 1, H0580: 1, S0045: 1, S0046: 1, H0461: 1, H0610: 1, H0455: 1, H0270: 1, H0250: 1, H0599: 1, H0036: 1, S0346: 1, S0474: 1, H0581: 1, S0049: 1, H0052: 1, H0597: 1, H0327: 1, H0123: 1, H0012: 1, L0163: 1, S0388: 1, S0051: 1, H0267: 1, H0179: 1, H0687: 1, H0615: 1, H0039: 1, H0622: 1, L0483: 1, H0644: 1, H0628: 1, H0032: 1, H0169: 1, H0708: 1, H0634: 1, T0067: 1, H0056: 1, T0041: 1, H0494: 1, S0144: 1, S0142: 1, S0344: 1, L0761: 1, L0771: 1, L0662: 1, L0766: 1, L0803: 1, L0515: 1, L0518: 1, L0792: 1, L0664: 1, L0665: 1, H0689: 1, H0435: 1, H0648: 1, S0378: 1, S0152: 1, H0436: 1, L0748: 1, L0754: 1, L0777: 1, L0780: 1, L0485: 1, L0593: 1 and S0462: 1. 9 HLHBV54 505038 19  17-103 74 H0024: 1 10 HBSAJ16 509943 20  34-294 75 Thr-33 to Glu-44, AR313: 43, AR196: Tyr-63 to Arg-68. 27, AR161: 25, AR162: 25, AR163: 25, AR089: 21, AR166: 21, AR173: 20, AR165: 20, AR164: 19, AR300: 18, AR242: 18, AR096: 18, AR240: 17, AR275: 17, AR258: 17, AR192: 16, AR175: 16, AR185: 15, AR299: 15, AR199: 14, AR262: 14, AR257: 13, AR229: 13, AR264: 12, AR247: 12, AR312: 12, AR060: 12, AR174: 12, AR218: 12, AR274: 12, AR053: 12, AR039: 12, AR234: 11, AR212: 11, AR180: 11, AR179: 11, AR177: 11, AR316: 10, AR233: 10, AR219: 10, AR203: 10, AR178: 10, AR236: 9, AR191: 9, AR230: 9, AR198: 9, AR181: 9, AR277: 9, AR183: 9, AR204: 9, AR193: 9, AR207: 9, AR282: 9, AR226: 9, AR238: 9, AR200: 8, AR213: 8, AR255: 8, AR189: 8, AR263: 8, AR270: 8, AR308: 8, AR104: 8, AR033: 8, AR269: 8, AR195: 8, AR182: 7, AR293: 7, AR188: 7, AR297: 7, AR254: 7, AR260: 7, AR231: 7, AR176: 6, AR311: 6, AR294: 6, AR268: 6, AR287: 6, AR235: 6, AR261: 6, AR197: 6, AR237: 6, AR285: 6, AR228: 6, AR286: 6, AR239: 6, AR243: 6, AR296: 5, AR227: 5, AR283: 5, AR295: 5, AR309: 5, AR271: 5, AR250: 5, AR256: 5, AR290: 5, AR245: 4, AR267: 4, AR201: 4, AR272: 4, AR288: 4, AR291: 4, AR252: 4, AR190: 4, AR205: 3, AR055: 3, AR210: 3, AR232: 3, AR225: 3, AR211: 3, AR216: 2, AR289: 2, AR266: 2, AR171: 2, AR061: 2, AR214: 2, AR246: 2, AR223: 2, AR168: 1, AR224: 1, AR253: 1, AR217: 1 H0381: 1, H0030: 1, H0644: 1, H0494: 1 and L0766: 1. 11 HCEOC41 513037 21 126-500 76 Pro-61 to Ala-67. L0748: 16, L0779: 7, L0745: 5, L0774: 4, L0754: 4, L0761: 3, L0747: 3, L0749: 3, H0264: 2, L0769: 2, L0766: 2, L0803: 2, H0144: 2, S0374: 2, L0438: 2, S0126: 2, L0743: 2, L0439: 2, L0756: 2, L0777: 2, L0758: 2, H0656: 1, S0046: 1, H0393: 1, H0632: 1, H0122: 1, H0052: 1, H0327: 1, H0050: 1, H0024: 1, H0135: 1, H0040: 1, L0804: 1, L0776: 1, L0789: 1, L0666: 1, S0028: 1, S0206: 1, L0731: 1 and L0485: 1. 12 HCUBS50 499240 22  88-204 77 AR180: 5, AR238: 4, AR232: 3, AR239: 3, AR237: 3, AR169: 2, AR215: 2, AR274: 2, AR178: 2, AR162: 2, AR163: 2, AR270: 2, AR221: 2, AR164: 2, AR161: 2, AR264: 2, AR282: 2, AR309: 2, AR291: 2, AR216: 2, AR089: 2, AR205: 2, AR243: 2, AR104: 1, AR196: 1, AR269: 1, AR293: 1, AR240: 1, AR261: 1, AR212: 1, AR231: 1, AR277: 1, AR210: 1, AR096: 1, AR300: 1, AR311: 1, AR258: 1 H0306: 1 and L0476: 1. 13 HCUEO60 499242 23 102-296 78 AR313: 24, AR242: 23, AR192: 19, AR162: 19, AR161: 18, AR163: 17, AR039: 16, AR089: 15, AR165: 15, AR164: 15, AR198: 15, AR300: 15, AR166: 14, AR252: 14, AR104: 14, AR096: 13, AR250: 13, AR185: 12, AR174: 12, AR053: 12, AR254: 12, AR204: 12, AR270: 12, AR212: 12, AR240: 11, AR233: 11, AR197: 11, AR205: 11, AR264: 10, AR312: 9, AR193: 9, AR229: 9, AR201: 9, AR234: 9, AR247: 9, AR177: 9, AR253: 9, AR183: 9, AR283: 9, AR245: 8, AR226: 8, AR275: 8, AR266: 8, AR274: 8, AR243: 8, AR213: 7, AR207: 7, AR263: 7, AR272: 7, AR246: 7, AR239: 7, AR316: 7, AR173: 7, AR262: 7, AR299: 7, AR060: 7, AR195: 7, AR238: 7, AR179: 6, AR308: 6, AR293: 6, AR271: 6, AR309: 6, AR231: 6, AR282: 6, AR297: 6, AR269: 5, AR176: 5, AR294: 5, AR311: 5, AR277: 5, AR232: 5, AR237: 5, AR230: 5, AR255: 4, AR295: 4, AR296: 4, AR181: 4, AR033: 4, AR289: 4, AR257: 4, AR267: 4, AR055: 4, AR268: 3, AR224: 3, AR199: 3, AR061: 3, AR196: 3, AR215: 3, AR288: 3, AR258: 3, AR168: 3, AR236: 3, AR235: 3, AR221: 2, AR290: 2, AR182: 2, AR261: 2, AR175: 2, AR286: 2, AR214: 2, AR222: 2, AR180: 2, AR178: 1, AR189: 1, AR291: 1, AR216: 1, AR169: 1 H0402: 1 14 HDHEB60 499233 24 568-894 79 Asp-48 to Ser-54. AR195: 10, AR245: 9, 11pter- AR242: 9, AR309: 9, 11p15.5 AR196: 8, AR192: 8, AR225: 8, AR198: 8, AR207: 8, AR246: 8, AR169: 8, AR170: 8, AR223: 8, AR224: 7, AR214: 7, AR039: 7, AR172: 7, AR215: 7, AR201: 7, AR222: 7, AR193: 7, AR205: 7, AR221: 7, AR199: 7, AR272: 7, AR168: 7, AR089: 7, AR213: 6, AR263: 6, AR165: 6, AR216: 6, AR164: 6, AR274: 6, AR217: 6, AR261: 6, AR053: 6, AR166: 6, AR055: 6, AR312: 6, AR308: 6, AR197: 6, AR283: 5, AR240: 5, AR282: 5, AR171: 5, AR253: 5, AR235: 5, AR311: 5, AR295: 5, AR250: 5, AR275: 5, AR243: 5, AR291: 5, AR162: 5, AR297: 5, AR264: 5, AR313: 5, AR288: 5, AR316: 5, AR204: 5, AR163: 5, AR299: 5, AR161: 5, AR257: 5, AR286: 5, AR271: 5, AR189: 5, AR236: 5, AR210: 5, AR177: 5, AR060: 4, AR212: 4, AR033: 4, AR285: 4, AR188: 4, AR200: 4, AR174: 4, AR287: 4, AR096: 4, AR296: 4, AR258: 4, AR175: 4, AR218: 4, AR176: 4, AR293: 4, AR180: 4, AR191: 4, AR203: 4, AR219: 4, AR289: 4, AR277: 4, AR256: 4, AR183: 4, AR190: 4, AR247: 4, AR300: 4, AR181: 3, AR269: 3, AR173: 3, AR262: 3, AR238: 3, AR268: 3, AR178: 3, AR185: 3, AR255: 3, AR270: 3, AR294: 3, AR266: 3, AR211: 3, AR260: 3, AR229: 3, AR104: 3, AR231: 3, AR267: 3, AR239: 3, AR290: 3, AR182: 3, AR226: 3, AR232: 3, AR061: 2, AR233: 2, AR237: 2, AR227: 2, AR234: 2, AR179: 2, AR230: 2, AR228: 2 H0265: 2, S0360: 2, H0581: 2, H0052: 2, H0570: 2, H0087: 2, L0439: 2, H0445: 2, H0650: 1, S0354: 1, H0580: 1, H0586: 1, H0559: 1, H0486: 1, L0021: 1, H0618: 1, H0009: 1, S0051: 1, S0368: 1, H0553: 1, H0181: 1, H0551: 1, S0294: 1, L0646: 1, L0764: 1, L0662: 1, L0794: 1, L0658: 1, L0659: 1, L0665: 1, H0547: 1, H0682: 1, H0684: 1, H0670: 1 and S3014: 1. 15 HE6AJ31 511141 25  42-173 80 Thr-36 to Met-43. H0008: 1 16 HFCED59 511100 26 285-434 81 His-41 to Glu-49. H0009: 3, L0750: 2, L0731: 2, L0794: 1, L0791: 1 and S0052: 1. 17 HFTBY59 511045 27 264-353 82 L0751: 3, L0747: 2, L0361: 2, H0549: 1, H0550: 1, H0009: 1, H0123: 1, H0620: 1, H0594: 1, H0688: 1, L0800: 1, L0662: 1, L0766: 1, L0803: 1, L0791: 1, L0666: 1, L0663: 1, L0665: 1, H0689: 1, S0390: 1, L0439: 1, L0777: 1 and L0731: 1. 18 HFXKJ03 505207 28 179-304 83 Met-1 to Arg-8. AR161: 7, AR162: 7, AR163: 7, AR243: 6, AR250: 5, AR176: 5, AR165: 5, AR225: 5, AR193: 5, AR164: 5, AR233: 5, AR271: 4, AR246: 4, AR182: 4, AR166: 4, AR053: 4, AR228: 4, AR309: 4, AR181: 4, AR216: 4, AR266: 4, AR269: 4, AR172: 4, AR235: 4, AR183: 4, AR264: 4, AR237: 4, AR170: 4, AR275: 4, AR236: 4, AR297: 4, AR239: 4, AR291: 4, AR261: 4, AR257: 3, AR255: 3, AR293: 3, AR177: 3, AR267: 3, AR201: 3, AR171: 3, AR231: 3, AR212: 3, AR174: 3, AR274: 3, AR296: 3, AR179: 3, AR288: 3, AR229: 3, AR247: 3, AR285: 3, AR205: 3, AR270: 3, AR294: 3, AR175: 3, AR287: 3, AR290: 3, AR263: 3, AR221: 3, AR196: 3, AR191: 3, AR312: 3, AR240: 3, AR238: 3, AR223: 3, AR217: 3, AR262: 3, AR300: 3, AR207: 3, AR277: 3, AR268: 3, AR173: 3, AR230: 3, AR272: 3, AR234: 3, AR286: 3, AR192: 3, AR295: 2, AR096: 2, AR289: 2, AR061: 2, AR311: 2, AR200: 2, AR213: 2, AR204: 2, AR190: 2, AR214: 2, AR168: 2, AR232: 2, AR188: 2, AR224: 2, AR226: 2, AR313: 2, AR227: 2, AR033: 2, AR169: 2, AR308: 2, AR060: 2, AR198: 2, AR089: 2, AR178: 2, AR203: 2, AR282: 2, AR185: 2, AR195: 2, AR222: 2, AR316: 2, AR055: 2, AR199: 2, AR180: 2, AR299: 2, AR189: 1, AR258: 1, AR210: 1, AR215: 1, AR260: 1, AR211: 1, AR252: 1, AR256: 1, AR283: 1 S0282: 1, H0619: 1 and H0581: 1. 19 HHFDG44 513048 29 145-414 84 Pro-42 to Asn-49, AR055: 9, AR218: 7, Arg-54 to Gly-59, AR060: 7, AR283: 7, Ile-73 to Glu-81. AR240: 5, AR300: 5, AR282: 5, AR299: 5, AR039: 5, AR185: 4, AR089: 4, AR316: 4, AR104: 4, AR313: 3, AR096: 3, AR277: 3, AR219: 2 H0050: 5, L0777: 2, H0156: 1, L0021: 1, L0520: 1, L0659: 1, L0438: 1, H0521: 1, L0749: 1, L0756: 1 and L0755: 1. 20 HJACG02 509948 30  47-373 85 Val-54 to Asp-59. AR207: 37, AR195: 33, AR283: 32, AR263: 32, AR264: 29, AR223: 28, AR214: 28, AR089: 28, AR277: 27, AR222: 27, AR309: 27, AR311: 27, AR212: 26, AR316: 26, AR169: 26, AR224: 24, AR096: 24, AR055: 24, AR197: 23, AR213: 23, AR282: 22, AR104: 22, AR245: 22, AR171: 22, AR218: 22, AR162: 22, AR192: 21, AR217: 21, AR161: 21, AR193: 21, AR163: 20, AR308: 20, AR165: 20, AR168: 20, AR216: 20, AR170: 20, AR164: 20, AR235: 19, AR172: 19, AR053: 19, AR166: 19, AR060: 19, AR219: 19, AR242: 19, AR271: 19, AR299: 19, AR210: 19, AR039: 19, AR033: 19, AR240: 18, AR225: 18, AR313: 18, AR312: 18, AR201: 18, AR221: 17, AR261: 17, AR198: 17, AR246: 17, AR288: 17, AR252: 17, AR295: 17, AR176: 16, AR177: 16, AR215: 15, AR297: 15, AR253: 15, AR205: 15, AR270: 15, AR196: 15, AR185: 15, AR275: 15, AR286: 15, AR285: 14, AR260: 14, AR287: 14, AR233: 14, AR236: 14, AR183: 14, AR227: 13, AR175: 13, AR211: 13, AR300: 13, AR250: 13, AR294: 13, AR181: 13, AR274: 13, AR272: 13, AR229: 13, AR174: 12, AR256: 12, AR182: 12, AR234: 12, AR204: 12, AR269: 12, AR228: 12, AR293: 12, AR178: 12, AR226: 12, AR268: 11, AR266: 11, AR173: 11, AR262: 11, AR200: 11, AR243: 11, AR199: 11, AR258: 11, AR231: 11, AR291: 11, AR180: 11, AR289: 11, AR247: 11, AR239: 10, AR257: 10, AR267: 10, AR255: 10, AR188: 10, AR254: 10, AR203: 10, AR232: 10, AR238: 9, AR191: 9, AR189: 9, AR190: 9, AR061: 9, AR230: 9, AR296: 9, AR179: 9, AR290: 8, AR237: 7 S0442: 4, L0764: 4, S0408: 3, H0306: 2, H0263: 2, H0596: 2, L0800: 2, L0755: 2, S0116: 1, S0358: 1, H0489: 1, H0597: 1, T0041: 1 and L0772: 1. 21 HKGAJ54 498303 31  31-942 86 Ala-55 to Thr-62, AR218: 7, AR219: 6, His-164 to Gly-175, AR242: 6, AR315: 6, Ala-197 to Glu-202. AR225: 5, AR248: 4, AR244: 4, AR273: 4, AR263: 4, AR310: 4, AR280: 4, AR214: 4, AR282: 4, AR314: 3, AR221: 3, AR170: 3, AR311: 3, AR052: 3, AR213: 3, AR162: 3, AR217: 3, AR281: 3, AR243: 3, AR253: 2, AR270: 2, AR265: 2, AR186: 2, AR277: 2, AR055: 2, AR207: 2, AR104: 2, AR257: 2, AR316: 2, AR212: 2, AR194: 2, AR312: 2, AR206: 2, AR089: 2, AR195: 2, AR283: 2, AR171: 2, AR193: 1, AR240: 1, AR284: 1, AR199: 1, AR039: 1, AR163: 1, AR053: 1, AR183: 1, AR288: 1, AR033: 1, AR309: 1, AR060: 1, AR096: 1, AR236: 1, AR188: 1, AR266: 1, AR216: 1, AR161: 1, AR201: 1, AR205: 1 S0474: 2, S0400: 1, H0661: 1, S0045: 1, T0039: 1, S0003: 1, H0412: 1, H0056: 1, H0494: 1, H0646: 1, H0538: 1, S0422: 1, L0533: 1, H0539: 1, L0740: 1, L0777: 1, S0436: 1 and L0588: 1. 22 509950 32 215-385 87 Pro-5 to Gln-11, AR089: 19, AR185: HKMAB92 Thr-29 to Ala-38. 17, AR055: 17, AR218: 15, AR240: 14, AR060: 13, AR282: 11, AR104: 11, AR283: 10, AR277: 10, AR219: 10, AR096: 9, AR299: 9, AR316: 9, AR300: 8, AR313: 5, AR039: 5 L0770: 4, L0439: 4, L0438: 3, H0670: 3, L0748: 3, L0740: 3, H0538: 2, L0777: 2, H0171: 1, S0342: 1, S0110: 1, S0354: 1, S0444: 1, S0360: 1, H0729: 1, H0728: 1, H0734: 1, H0619: 1, H0549: 1, H0550: 1, H0587: 1, H0427: 1, H0253: 1, H0023: 1, T0010: 1, H0039: 1, H0674: 1, H0135: 1, H0488: 1, H0494: 1, S0015: 1, H0647: 1, S0210: 1, L0763: 1, L0800: 1, L0644: 1, L0521: 1, L0768: 1, L0775: 1, L0805: 1, L0659: 1, L0782: 1, L0783: 1, L0528: 1, L0789: 1, L0791: 1, L0793: 1, L0532: 1, H0725: 1, H0659: 1, H0658: 1, H0660: 1, S0013: 1, S0037: 1, S0206: 1, L0751: 1, L0605: 1, L0485: 1, L0599: 1 and S0026: 1. 23 HLDOJ68 505205 33 343-435 88 AR104: 5, AR282: 4, 17q22 109270, AR300: 2, AR185: 1 109270, L0756: 6, L0439: 3, 109270, S0346: 2, L0803: 2, 109270, L0745: 2, L0747: 2, 109270, L0411: 1, S0222: 1, 120150, H0391: 1, S0388: 1, 120150, S0051: 1, H0510: 1, 120150, S0318: 1, L0065: 1, 139250, L0637: 1, L0804: 1, 148065, L0775: 1, L0651: 1, 148080, L0805: 1, L0666: 1, 150200, L0438: 1, L0748: 1 and 154275, H0423: 1. 171190, 176960, 185800, 221820, 249000, 253250, 600525, 600852, 601844 24 HLMFC54 511095 34 103-309 89 Lys-27 to Ser-33. AR055: 8, AR277: 8, AR060: 7, AR218: 7, AR313: 6, AR104: 6, AR299: 6, AR300: 5, AR089: 5, AR185: 4, AR316: 4, AR282: 4, AR096: 4, AR283: 4, AR240: 4, AR039: 3, AR219: 3 H0255: 2 25 510980 35 137-214 90 H0255: 1, H0674: 1, HLMMO6 L0658: 1 and L0367: 1. 4 26 HLWBZ21 499231 36 283-921 91 Ile-98 to Pro-106, AR290: 5, AR246: 4, Pro-118 to Leu-124, AR268: 4, AR166: 3, Ser-136 to Arg-148. AR309: 3, AR168: 3, AR271: 2, AR223: 2, AR224: 2, AR205: 2, AR263: 2, AR245: 2, AR193: 2, AR282: 2, AR165: 2, AR214: 2, AR243: 2, AR238: 2, AR164: 1, AR060: 1, AR297: 1, AR270: 1, AR300: 1, AR055: 1, AR288: 1, AR089: 1, AR277: 1, AR299: 1, AR283: 1 L0754: 19, L0748: 17, H0553: 8, L0749: 3, H0551: 2, H0030: 1, L0143: 1, S0454: 1, L0755: 1, L0759: 1 and L0603: 1. 27 HMJAX71 499113 37  92-226 92 L0375: 3 and H0391: 1. 28 HNECU95 509957 38  16-138 93 Asn-20 to Cys-27. AR207: 20, AR053: 17, AR264: 17, AR263: 16, AR309: 15, AR192: 15, AR212: 14, AR308: 14, AR162: 13, AR161: 13, AR312: 13, AR165: 13, AR163: 13, AR311: 13, AR164: 13, AR213: 12, AR166: 12, AR196: 11, AR235: 11, AR275: 11, AR197: 11, AR195: 11, AR225: 10, AR198: 10, AR177: 10, AR223: 10, AR250: 10, AR169: 10, AR229: 10, AR180: 10, AR171: 10, AR201: 10, AR246: 10, AR245: 10, AR242: 10, AR168: 9, AR178: 9, AR261: 9, AR174: 9, AR262: 9, AR240: 9, AR224: 9, AR205: 9, AR293: 9, AR286: 9, AR236: 9, AR222: 9, AR252: 9, AR214: 9, AR217: 8, AR247: 8, AR274: 8, AR203: 8, AR189: 8, AR176: 8, AR297: 8, AR182: 8, AR170: 8, AR204: 8, AR193: 8, AR191: 8, AR243: 8, AR257: 8, AR172: 8, AR313: 8, AR258: 8, AR200: 8, AR188: 8, AR271: 8, AR295: 7, AR181: 7, AR283: 7, AR231: 7, AR272: 7, AR300: 7, AR233: 7, AR288: 7, AR289: 7, AR269: 7, AR277: 7, AR239: 7, AR183: 7, AR228: 7, AR173: 7, AR282: 7, AR294: 7, AR033: 7, AR215: 7, AR255: 7, AR268: 7, AR175: 7, AR270: 7, AR234: 7, AR291: 6, AR216: 6, AR199: 6, AR179: 6, AR285: 6, AR237: 6, AR238: 6, AR190: 6, AR296: 6, AR267: 6, AR230: 6, AR226: 6, AR316: 5, AR061: 5, AR299: 5, AR185: 5, AR287: 5, AR290: 5, AR089: 5, AR232: 5, AR227: 5, AR039: 4, AR211: 4, AR210: 4, AR096: 4, AR104: 4, AR055: 4, AR260: 4, AR221: 3, AR060: 3, AR256: 3, AR218: 3, AR254: 2, AR219: 2, AR253: 1 L0766: 10, L0758: 7, L0777: 6, L0761: 5, L0794: 5, L0744: 5, S0358: 4, L0771: 4, L0807: 4, L0741: 4, L0740: 4, L0731: 4, L0768: 3, L0776: 3, L0779: 3, L0759: 3, S0442: 2, L0800: 2, L0764: 2, L0806: 2, L0805: 2, L0789: 2, L0749: 2, L0786: 2, S0434: 2, S0436: 2, L0601: 2, L0785: 1, S0116: 1, S0376: 1, S0360: 1, H0637: 1, H0156: 1, H0318: 1, H0581: 1, H0052: 1, H0194: 1, H0251: 1, H0050: 1, HO 179: 1, H0271: 1, H0674: 1, S0386: 1, H0560: 1, S0002: 1, S0426: 1, L0763: 1, L0769: 1, L0662: 1, L0804: 1, L0774: 1, L0775: 1, L0655: 1, S0428: 1, H0144: 1, H0593: 1, S0152: 1, H0521: 1, L0780: 1, S0011: 1, H0136: 1, S0196: 1 and H0543: 1. 29 HNFCK41 513050 39 251-595 94 Lys-23 to Ser-30, AR096: 33, AR104: Ala-52 to Leu-57, 30, AR219: 26, AR299: Pro-96 to Ser-105. 25, AR316: 22, AR218: 20, AR185: 17, AR240: 16, AR089: 16, AR300: 14, AR313: 14, AR039: 12, AR277: 11, AR055: 9, AR060: 8, AR282: 8, AR283: 4 H0457: 15, H0271: 11, H0141: 6, H0255: 6, H0521: 5, L0758: 5, S0354: 4, S0358: 4, S0444: 4, S0278: 4, H0179: 4, H0494: 4, S0440: 4, L0771: 4, L0783: 4, H0436: 4, S0434: 4, H0556: 3, H0747: 3, H0069: 3, L0776: 3, L0659: 3, H0710: 3, S0436: 3, H0661: 2, S0418: 2, S0420: 2, H0580: 2, S0476: 2, S0222: 2, H0486: 2, H0013: 2, H0618: 2, H0581: 2, H0083: 2, H0266: 2, S0003: 2, H0424: 2, S0036: 2, H0090: 2, H0038: 2, H0634: 2, H0616: 2, S0344: 2, S0002: 2, L0770: 2, L0646: 2, L0662: 2, L0381: 2, L0655: 2, L0657: 2, L0809: 2, L0666: 2, L0665: 2, S0216: 2, H0703: 2, H0435: 2, H0670: 2, H0539: 2, S0406: 2, S0027: 2, L0748: 2, L0439: 2, L0751: 2, L0591: 2, H0543: 2, H0624: 1, H0717: 1, H0650: 1, H0656: 1, H0402: 1, S0376: 1, S0360: 1, S0045: 1, S0046: 1, H0619: 1, S6026: 1, H0261: 1, H0438: 1, H0586: 1, H0101: 1, H0427: 1, H0036: 1, T0048: 1, H0318: 1, S0474: 1, H0421: 1, H0052: 1, H0205: 1, H0231: 1, L0738: 1, H0150: 1, H0081: 1, T0010: 1, H0416: 1, T0006: 1, H0213: 1, H0598: 1, H0135: 1, H0040: 1, H0087: 1, H0264: 1, H0488: 1, H0623: 1, H0334: 1, H0561: 1, S0438: 1, S0422: 1, L0369: 1, L0769: 1, L0667: 1, L0773: 1, L0648: 1, L0364: 1, L0766: 1, L0649: 1, L0375: 1, L0378: 1, L0806: 1, L0653: 1, L0636: 1, S0052: 1, S0428: 1, H0702: 1, S0374: 1, H0762: 1, L0438: 1, H0547: 1, H0593: 1, S0328: 1, S0146: 1, H0576: 1, H0631: 1, S3014: 1, L0779: 1, L0759: 1, H0445: 1, S0011: 1, S0026: 1, S0242: 1, S0196: 1 and H0506: 1. 30 HNFHD08 509945 40  13-264 95 Asp-43 to Val-54, AR316: 28, AR039: 15 Asn-66 to Glu-74. 26, AR089: 17, AR299: 15, AR060: 8, AR300: 7, AR055: 7, AR219: 6, AR240: 5, AR313: 5, AR282: 4, AR218: 4, AR185: 3, AR104: 3, AR283: 3, AR096: 3, AR277: 2 S0408: 24, S0444: 19, S0358: 13, S0442: 10, H0069: 8, S0242: 8, S0440: 7, S0406: 7, H0638: 6, S0376: 6, L0775: 6, S0374: 6, H0250: 4, L0749: 4, L0758: 4, S0278: 3, H0635: 3, L0769: 3, L0747: 3, S0196: 3, H0140: 2, H0294: 2, S0360: 2, S0410: 2, H0271: 2, H0634: 2, S0142: 2, L0762: 2, L0764: 2, L0657: 2, L0666: 2, L0665: 2, S0330: 2, H0518: 2, H0525: 2, S0404: 2, L0731: 2, S0436: 2, L0591: 2, L0608: 2, S0040: 1, S0114: 1, H0484: 1, H0671: 1, S0354: 1, L0021: 1, H0204: 1, H0596: 1, L0040: 1, H0597: 1, H0231: 1, L0738: 1, H0123: 1, H0179: 1, L0055: 1, H0674: 1, H0038: 1, H0412: 1, H0059: 1, H0100: 1, S0352: 1, S0438: 1, H0633: 1, S0344: 1, L0770: 1, L0796: 1, L0761: 1, L0765: 1, L0767: 1, L0768: 1, L0649: 1, L0549: 1, L0804: 1, L0650: 1, L0774: 1, L0806: 1, L0783: 1, L0809: 1, L0529: 1, H0659: 1, L0602: 1, H0522: 1, H0694: 1, L0748: 1, L0740: 1, L0754: 1, L0756: 1, L0779: 1, L0752: 1, L0755: 1, L0588: 1 and H0543: 1. 31 513038 41  33-182 96 Glu-21 to Gly-30, AR313: 29, AR039: HNGEW65 Glu-33 to Thr-47. 23, AR241: 20, AR229: 16, AR182: 16, AR293: 15, AR184: 15, AR299: 14, AR089: 14, AR269: 14, AR300: 14, AR227: 13, AR247: 13, AR096: 13, AR258: 13, AR296: 13, AR270: 12, AR263: 12, AR177: 12, AR240: 12, AR312: 11, AR185: 11, AR183: 11, AR316: 11, AR238: 11, AR060: 10, AR290: 10, AR310: 10, AR219: 10, AR226: 10, AR192: 10, AR265: 10, AR268: 10, AR244: 10, AR198: 10, AR249: 9, AR233: 9, AR104: 9, AR292: 9, AR280: 9, AR259: 9, AR277: 9, AR218: 8, AR052: 8, AR053: 8, AR251: 8, AR271: 8, AR055: 8, AR175: 8, AR285: 8, AR298: 8, AR204: 8, AR282: 8, AR314: 7, AR234: 7, AR267: 7, AR248: 7, AR294: 7, AR286: 7, AR289: 7, AR033: 7, AR315: 7, AR291: 6, AR231: 6, AR246: 6, AR243: 6, AR237: 6, AR284: 5, AR253: 5, AR179: 5, AR256: 5, AR295: 5, AR186: 5, AR061: 5, AR232: 5, AR274: 5, AR275: 5, AR213: 5, AR273: 5, AR206: 5, AR194: 4, AR309: 4, AR266: 4, AR283: 4, AR205: 4, AR281: 2 S0052: 2 and H0156: 1 32 HUNAE14 509954 42  65-169 97 AR313: 63, AR277: 55, AR039: 52, AR219: 39, AR316: 38, AR089: 38, AR218: 37, AR283: 34, AR185: 33, AR299: 33, AR240: 32, AR096: 32, AR300: 31, AR104: 28, AR055: 26, AR282: 24, AR060: 19 H0549: 1 and T0069: 1. 33 HNHEN68 511170 43 100-234 98 AR215: 7, AR269: 6, AR313: 5, AR266: 5, AR165: 5, AR164: 4, AR161: 4, AR162: 4, AR166: 4, AR282: 4, AR163: 4, AR089: 4, AR275: 4, AR181: 3, AR053: 3, AR264: 3, AR207: 3, AR197: 3, AR214: 3, AR178: 3, AR312: 3, AR311: 3, AR229: 3, AR193: 3, AR195: 2, AR243: 2, AR245: 2, AR247: 2, AR096: 2, AR060: 2, AR296: 2, AR175: 2, AR182: 2, AR291: 2, AR173: 2, AR297: 2, AR267: 2, AR237: 2, AR226: 2, AR104: 2, AR300: 2, AR179: 2, AR277: 2, AR268: 2, AR039: 2, AR295: 2, AR185: 2, AR228: 2, AR293: 2, AR216: 2, AR171: 2, AR213: 2, AR238: 2, AR316: 2, AR271: 2, AR289: 2, AR201: 1, AR234: 1, AR308: 1, AR286: 1, AR285: 1, AR231: 1, AR200: 1, AR290: 1, AR299: 1, AR190: 1, AR239: 1, AR217: 1, AR196: 1, AR183: 1, AR198: 1, AR176: 1 S0053: 1 34 HNHFG05 511173 44 120-248 99 Pro-9 to Cys-14. AR055: 7, AR060: 6, AR300: 4, AR104: 4, AR218: 4, AR240: 4, AR185: 4, AR089: 4, AR299: 3, AR283: 3, AR219: 3, AR282: 3, AR316: 3, AR277: 3, AR096: 2, AR313: 2, AR039: 2 S0053: 2 35 HODBF19 509958 45 166-297 100 AR313: 34, AR219: 23, AR218: 22, AR299: 22, AR316: 21, AR096: 17, AR089: 15, AR039: 14, AR300: 13, AR055: 13, AR185: 12, AR060: 9, AR104: 8, AR277: 7, AR282: 6, AR283: 5, AR240: 5 L0439: 12, L3817: 8, H0543: 7, L3816: 6, H0529: 6, L3825: 6, L3827: 6, H0547: 6, H0519: 6, L0758: 6, H0046: 5, L3818: 5, L0794: 5, L0804: 5, L0759: 5, H0013: 4, H0561: 4, S0422: 4, H0521: 4, L0750: 4, L0779: 4, L0593: 4, H0657: 3, H0486: 3, H0052: 3, L0471: 3, L0803: 3, L0655: 3, L3823: 3, L3826: 3, L3828: 3, H0677: 3, H0624: 2, S0114: 2, S0005: 2, H0497: 2, H0318: 2, S0474: 2, H0581: 2, H0024: 2, H0615: 2, H0090: 2, H0040: 2, T0042: 2, H0494: 2, H0625: 2, L0769: 2, L3905: 2, L0626: 2, L0766: 2, L0776: 2, L0659: 2, H0144: 2, H0520: 2, H0518: 2, H0522: 2, S0028: 2, L0754: 2, L0752: 2, L0731: 2, H0445: 2, L0592: 2, H0542: 2, H0170: 1, H0395: 1, S0342: 1, H0650: 1, S0116: 1, H0341: 1, H0663: 1, S0442: 1, S0408: 1, S0410: 1, H0734: 1, H0411: 1, H0600: 1, H0587: 1, H0574: 1, T0039: 1, H0004: 1, H0457: 1, H0023: 1, H0015: 1, H0051: 1, S6028: 1, S0312: 1, S0214: 1, H0328: 1, H0553: 1, L0055: 1, L0456: 1, H0124: 1, H0135: 1, H0634: 1, H0551: 1, S0438: 1, S0440: 1, S0150: 1, H0641: 1, H0767: 1, H0646: 1, H0652: 1, S0144: 1, S0142: 1, L0770: 1, L0761: 1, L0372: 1, L0764: 1, L0662: 1, L0387: 1, L0775: 1, L0515: 1, L0517: 1, L0809: 1, L5622: 1, L0787: 1, L0666: 1, L0664: 1, L0665: 1, S0052: 1, S0126: 1, H0684: 1, H0435: 1, H0648: 1, H0672: 1, H0651: 1, H0539: 1, S0380: 1, S0152: 1, H0134: 1, S0404: 1, H0631: 1, S0037: 1, S0027: 1, L0780: 1, L0755: 1, S0031: 1, H0595: 1, L0589: 1, L0581: 1, L0362: 1, H0665: 1, H0423: 1 and S0446: 1. 36 HOEBK34 768325 46 149-643 101 Asp-18 to Arg-31, AR055: 5, AR060: 3, 162400, Leu-38 to Gln-52. AR225: 3, AR169: 3, 227645, AR246: 2, AR272: 2, 229700, AR207: 2, AR163: 2, 278700, AR162: 2, AR089: 2, 601309, AR291: 2, AR039: 2, 601309, AR193: 2, AR271: 2, 602088 AR266: 2, AR217: 2, AR218: 2, AR168: 2, AR161: 2, AR283: 1, AR263: 1, AR289: 1, AR240: 1, AR264: 1, AR096: 1, AR316: 1, AR243: 1, AR257: 1, AR255: 1, AR104: 1, AR166: 1, AR185: 1, AR230: 1, AR300: 1 L0803: 2, S0126: 2, S0250: 1, S0438: 1 and L0774: 1. HOEBK34 509951 63  68-334 118 Asp-18 to Arg-31, Leu-38 to Leu-53. 37 HPBCC51 509942 47 153-338 102 Ala-38 to Lys-62. S0410: 17, L0803: 4, L0755: 4, L0771: 3, L0809: 3, L0439: 3, L0777: 3, L0662: 2, L0794: 2, L0659: 2, L0789: 2, L0747: 2, S0442: 1, S0354: 1, S0360: 1, H0586: 1, H0081: 1, T0006: 1, H0059: 1, H0647: 1, L0769: 1, L0667: 1, L0766: 1, L0804: 1, L0775: 1, L0805: 1, L0542: 1, L0664: 1, L0665: 1, S0052: 1, L0438: 1, H0690: 1, H0539: 1, S0406: 1, L0743: 1, L0748: 1, L0749: 1, L0779: 1 and S0276: 1. 38 HRGDC48 513040 48 129-353 103 Gln-29 to Ser-49. AR282: 7, AR171: 4, 11q23 107680, AR161: 3, AR162: 3, 107680, AR223: 3, AR163: 3, 107680, AR193: 3, AR253: 3, 107680, AR169: 3, AR172: 3, 107680, AR165: 3, AR207: 3, 107720, AR178: 3, AR176: 3, 133780, AR270: 3, AR204: 2, 147791, AR164: 2, AR221: 2, 159555, AR166: 2, AR177: 2, 168000, AR180: 2, AR309: 2, 186740, AR268: 2, AR175: 2, 186830, AR288: 2, AR275: 2, 188025, AR181: 2, AR214: 2, 203750, AR277: 2, AR060: 2, 261640, AR263: 2, AR183: 2, 600048, AR226: 2, AR271: 2, 601382, AR296: 2, AR261: 2, 602574, AR287: 2, AR300: 2, 602574 AR272: 2, AR308: 2, AR285: 2, AR316: 2, AR089: 2, AR289: 2, AR293: 2, AR237: 2, AR240: 2, AR205: 2, AR239: 1, AR257: 1, AR232: 1, AR264: 1, AR233: 1, AR216: 1, AR255: 1, AR229: 1, AR290: 1, AR311: 1, AR269: 1, AR173: 1, AR211: 1, AR267: 1, AR185: 1, AR228: 1, AR231: 1, AR168: 1, AR313: 1, AR203: 1, AR189: 1, AR291: 1, AR256: 1, AR196: 1, AR299: 1, AR061: 1, AR033: 1, AR238: 1, AR230: 1, AR213: 1, AR055: 1, AR210: 1, AR294: 1, AR234: 1, AR201: 1, AR252: 1 H0421: 1, H0135: 1 and H0134: 1. 39 HSDJB13 498308 49  937-1155 104 Pro-38 to His-47, AR180: 5, AR169: 5, Ala-59 to Thr-66. AR245: 4, AR253: 4, AR242: 4, AR215: 3, AR161: 3, AR171: 3, AR162: 3, AR163: 3, AR207: 2, AR263: 2, AR197: 2, AR213: 2, AR170: 2, AR165: 2, AR217: 2, AR096: 2, AR089: 2, AR300: 2, AR287: 2, AR189: 1, AR299: 1, AR204: 1, AR053: 1, AR312: 1, AR172: 1, AR264: 1, AR283: 1, AR257: 1, AR181: 1, AR178: 1, AR193: 1, AR237: 1, AR247: 1, AR313: 1, AR222: 1, AR296: 1, AR294: 1 L0803: 5, L0764: 4, H0617: 3, L0771: 3, L0809: 3, L0751: 3, S0458: 3, H0549: 2, S0051: 2, L0761: 2, L0800: 2, L0508: 2, L0664: 2, H0689: 2, S0436: 2, H0170: 1, S0354: 1, S0358: 1, H0208: 1, H0438: 1, H0282: 1, S0010: 1, H0085: 1, H0059: 1, L0502: 1, L0770: 1, L0646: 1, L0643: 1, L0794: 1, L0774: 1, L0805: 1, L0511: 1, L0517: 1, L0665: 1, H0658: 1, H0696: 1, S0404: 1, S0406: 1, L0439: 1, L0755: 1, S0260: 1, L0599: 1 and H0506: 1. 40 HTEHR24 835894 50  84-572 105 Met-1 to Thr-6, AR161: 5, AR162: 5, Gly-45 to Asn-61, AR163: 5, AR176: 5, Ala-63 to Asn-72. AR180: 4, AR060: 3, AR055: 3, AR269: 3, AR300: 3, AR181: 3, AR228: 3, AR170: 3, AR166: 3, AR233: 3, AR257: 3, AR168: 3, AR177: 3, AR165: 3, AR255: 3, AR164: 3, AR216: 3, AR172: 3, AR236: 2, AR201: 2, AR288: 2, AR271: 2, AR229: 2, AR200: 2, AR268: 2, AR225: 2, AR239: 2, AR178: 2, AR266: 2, AR309: 2, AR179: 2, AR247: 2, AR234: 2, AR237: 2, AR286: 2, AR291: 2, AR282: 2, AR240: 2, AR290: 2, AR238: 2, AR182: 2, AR089: 2, AR270: 2, AR253: 2, AR227: 2, AR207: 2, AR223: 2, AR287: 2, AR275: 2, AR297: 2, AR293: 2, AR174: 2, AR264: 2, AR294: 2, AR203: 2, AR193: 2, AR185: 2, AR235: 2, AR190: 2, AR231: 2, AR175: 2, AR196: 2, AR261: 2, AR198: 2, AR104: 2, AR316: 2, AR171: 2, AR262: 2, AR195: 2, AR295: 2, AR311: 2, AR285: 2, AR061: 2, AR296: 2, AR222: 2, AR274: 2, AR267: 2, AR189: 1, AR191: 1, AR312: 1, AR277: 1, AR283: 1, AR226: 1, AR214: 1, AR205: 1, AR299: 1, AR250: 1, AR217: 1, AR230: 1, AR308: 1, AR096: 1, AR183: 1, AR289: 1, AR213: 1, AR204: 1, AR313: 1, AR173: 1, AR246: 1, AR272: 1, AR232: 1 L0766: 8, L0803: 5, L0758: 5, H0038: 4, H0144: 3, L0743: 3, H0550: 2, H0013: 2, L0471: 2, H0616: 2, L0794: 2, L0774: 2, L0776: 2, H0710: 2, H0521: 2, L0754: 2, L0745: 2, H0341: 1, H0728: 1, H0735: 1, H0392: 1, H0069: 1, H0635: 1, H0318: 1, H0581: 1, H0309: 1, H0457: 1, H0012: 1, H0083: 1, H0179: 1, H0039: 1, S0036: 1, H0090: 1, S0440: 1, L0763: 1, L0761: 1, L0372: 1, L0800: 1, L0662: 1, L0806: 1, L0805: 1, L0659: 1, L5622: 1, L0788: 1, L0791: 1, L0793: 1, L0666: 1, S0428: 1, S0126: 1, S0027: 1, S0028: 1, L0740: 1, L0756: 1, L0752: 1, L0731: 1, L0588: 1, L0591: 1, S0026: 1, S0242: 1, H0423: 1 and H0293: 1. HTEHR24 513039 64  41-415 119 Met-1 to Thr-6, Gly-45 to Asn-74. 41 HAGAM03 846100 51 158-319 106 Val-13 to Lys-20, AR313: 30, AR039: Ser-27 to Lys-32. 24, AR299: 15, AR277: 14, AR089: 14, AR300: 13, AR096: 12, AR185: 12, AR316: 11, AR219: 11, AR055: 10, AR218: 9, AR240: 9, AR060: 9, AR104: 9, AR282: 8, AR283: 5 S0218: 1, H0306: 1, H0402: 1 and S0010: 1. HAGAM03 513656 65 147-251 120 Val-10 to Lys-17, Ser-24 to Lys-29. 42 HUNAB18 509946 52 159-236 107 L0747: 13, L0740: 10, 11pter-p15.5 H0521: 8, L0731: 7, L0662: 5, L0809: 5, S0126: 5, L0757: 5, L0750: 4, L0755: 4, S0212: 3, H0644: 3, L0776: 3, L0659: 3, L0777: 3, L0021: 2, L0471: 2, H0024: 2, H0673: 2, H0413: 2, L0769: 2, L0764: 2, L0792: 2, H0522: 2, S3014: 2, L0439: 2, L0751: 2, L0749: 2, L0752: 2, L0758: 2, L0759: 2, H0556: 1, S0360: 1, H0340: 1, H0580: 1, H0369: 1, H0587: 1, H0574: 1, H0544: 1, H0123: 1, H0014: 1, H0015: 1, H0051: 1, S0003: 1, H0328: 1, H0428: 1, H0628: 1, H0169: 1, H0361: 1, H0090: 1, H0551: 1, T0069: 1, T0041: 1, T0042: 1, S0144: 1, L0762: 1, L0763: 1, L0770: 1, L0794: 1, L0766: 1, L0649: 1, L0804: 1, L0375: 1, L0806: 1, L0783: 1, L0663: 1, H0519: 1, S0146: 1, S0206: 1, L0743: 1, L0744: 1, L0779: 1, S0260: 1, L0596: 1, L0591: 1, H0653: 1, S0242: 1, S0194: 1 and S0276: 1. 43 514743 53 191-274 108 AR283: 1048, AR055: HARAM05 645, AR219: 167, AR218: 136, AR240: 103, AR316: 96, AR096: 73, AR104: 70, AR313: 66, AR089: 60, AR039: 58, AR277: 55, AR185: 55, AR282: 50, AR299: 46, AR060: 42, AR300: 42 T0082: 1 and H0164: 1. 44 HARAO51 513323 54 656-841 109 Cys-42 to Gly-48, AR283: 314, AR055: Gly-52 to Ile-61. 124, AR218: 49, AR219: 49, AR277: 45, AR313: 41, AR316: 38, AR039: 38, AR104: 35, AR096: 32, AR089: 32, AR185: 29, AR282: 27, AR240: 26, AR299: 26, AR300: 25, AR060: 22 H0617: 27, H0181: 6, S0360: 3, L0794: 3, L0655: 3, L0665: 3, S0378: 3, H0402: 2, H0150: 2, H0606: 2, L0662: 2, L0804: 2, L0666: 2, H0436: 2, L0743: 2, H0685: 1, H0671: 1, H0306: 1, S0358: 1, S0300: 1, H0549: 1, T0082: 1, H0618: 1, H0318: 1, L0738: 1, H0188: 1, H0616: 1, L0763: 1, L0372: 1, L0646: 1, L0775: 1, L0659: 1, L0809: 1, L0663: 1, H0690: 1, H0682: 1, H0658: 1, S0406: 1, L0744: 1, L0758: 1 and H0543: 1. 45 HATAA15 514240 55  941-1093 110 Thr-41 to Ala-50. H0156: 91, S0045: 29, 1q23 104770, L0662: 24, L0005: 20, 107300, S0414: 16, H0623: 14, 107670, H0051: 11, H0547: 11, 131210, S0046: 10, L0471: 10, 134638, H0056: 10, H0412: 9, 136132, L0439: 9, L0752: 9, 145001, L0758: 9, L0105: 8, 146740, L0750: 8, H0624: 6, 146740, L0803: 6, H0575: 5, 146740, L0659: 5, L0664: 5, 146790, H0696: 5, S0406: 5, 173610, H0171: 4, H0713: 4, 176310, S0051: 4, H0038: 4, 186780, L0771: 4, L0775: 4, 191030, L0776: 4, L0647: 4, 227400, L0663: 4, S0328: 4, 227400, L0740: 4, L0754: 4, 601412, L0777: 4, L0588: 4, 601652, L0002: 3, S0358: 3, 602491 S0360: 3, L0717: 3, H0437: 3, H0427: 3, H0052: 3, H0545: 3, H0268: 3, H0413: 3, H0509: 3, S0210: 3, L0598: 3, L0763: 3, L0805: 3, H0520: 3, L0747: 3, S0260: 3, S0434: 3, H0170: 2, L3643: 2, H0716: 2, S0282: 2, H0735: 2, H0619: 2, H0369: 2, S0222: 2, H0592: 2, L3817: 2, H0486: 2, L3655: 2, T0082: 2, S0050: 2, H0373: 2, S6028: 2, H0031: 2, H0100: 2, L0794: 2, L0804: 2, L0784: 2, L0809: 2, L0666: 2, L0665: 2, L3827: 2, H0519: 2, S0330: 2, S0380: 2, S0146: 2, L0742: 2, L0779: 2, L0755: 2, L0759: 2, S0031: 2, L0485: 2, L0599: 2, L3813: 2, H0506: 2, L0600: 2, S0029: 1, H0661: 1, S0356: 1, S0444: 1, H0733: 1, H0339: 1, H0411: 1, H0431: 1, H0587: 1, L0622: 1, H0013: 1, S0280: 1, H0590: 1, S0346: 1, S0049: 1, H0196: 1, H0597: 1, L0738: 1, H0563: 1, H0569: 1, H0050: 1, H0023: 1, H0024: 1, H0200: 1, L0163: 1, T0010: 1, H0328: 1, H0622: 1, H0553: 1, H0644: 1, H0708: 1, H0400: 1, S0036: 1, H0591: 1, H0433: 1, T0042: 1, S0438: 1, S0472: 1, H0652: 1, L0796: 1, L0646: 1, L0641: 1, L0768: 1, L0375: 1, L0655: 1, L0661: 1, L0527: 1, L0783: 1, L0519: 1, L0543: 1, L0790: 1, L0791: 1, L0793: 1, H0144: 1, H0725: 1, S0374: 1, H0723: 1, H0691: 1, H0726: 1, L3811: 1, L3826: 1, L3828: 1, H0593: 1, H0689: 1, H0672: 1, H0539: 1, S0013: 1, H0555: 1, S3014: 1, L0744: 1, L0756: 1, L0780: 1, L0731: 1, H0343: 1, S0436: 1, L0589: 1, L0593: 1, L0603: 1, H0667: 1 and H0543: 1. 46 HATCK44 514716 56  50-562 111 Asn-52 to Asn-60, AR313: 32, AR039: Gly-72 to Pro-88, 28, AR218: 18, AR299: Pro-94 to Ile-99, 16, AR096: 16, AR277: Gln-127 to Lys-132, 15, AR089: 15, AR185: Glu-138 to Gly-144. 14, AR316: 13, AR219: 12, AR300: 12, AR055: 12, AR240: 11, AR104: 10, AR060: 10, AR283: 10, AR282: 8 L0747: 6, H0040: 2, H0551: 2, L0777: 2, S0192: 2, L0615: 1, H0650: 1, S0418: 1, L0534: 1, T0060: 1, H0069: 1, H0156: 1, S0010: 1, S0346: 1, H0263: 1, H0596: 1, S0003: 1, H0111: 1, H0598: 1, H0634: 1, H0264: 1, H0268: 1, L0766: 1, L0565: 1, H0696: 1, S0044: 1, L0748: 1, L0439: 1, L0740: 1, H0543: 1, H0423: 1 and H0422: 1. 47 HBIAE26 514418 57  75-194 112 Ser-22 to Lys-27. AR161: 11, AR162: 11, AR163: 11, AR313: 9, AR242: 8, AR165: 8, AR039: 7, AR164: 7, AR166: 7, AR207: 6, AR201: 6, AR204: 6, AR089: 6, AR096: 6, AR197: 6, AR309: 6, AR053: 5, AR193: 5, AR264: 5, AR299: 5, AR060: 5, AR182: 5, AR173: 5, AR185: 5, AR198: 5, AR236: 5, AR300: 5, AR181: 5, AR228: 5, AR271: 5, AR176: 5, AR277: 5, AR055: 5, AR262: 5, AR196: 5, AR247: 5, AR250: 4, AR258: 4, AR312: 4, AR257: 4, AR175: 4, AR316: 4, AR229: 4, AR178: 4, AR179: 4, AR293: 4, AR269: 4, AR274: 4, AR240: 4, AR261: 4, AR246: 4, AR104: 4, AR266: 4, AR177: 4, AR191: 4, AR233: 4, AR275: 4, AR192: 4, AR268: 4, AR183: 4, AR213: 4, AR205: 4, AR231: 4, AR297: 4, AR288: 4, AR174: 3, AR212: 3, AR294: 3, AR270: 3, AR267: 3, AR238: 3, AR180: 3, AR215: 3, AR255: 3, AR245: 3, AR199: 3, AR287: 3, AR226: 3, AR296: 3, AR234: 3, AR203: 3, AR218: 3, AR285: 3, AR282: 3, AR311: 3, AR195: 3, AR200: 3, AR239: 3, AR283: 3, AR263: 3, AR217: 3, AR222: 3, AR272: 3, AR291: 3, AR237: 3, AR033: 3, AR290: 3, AR188: 3, AR243: 3, AR253: 3, AR189: 3, AR225: 3, AR295: 3, AR230: 3, AR170: 3, AR061: 2, AR219: 2, AR286: 2, AR308: 2, AR227: 2, AR256: 2, AR232: 2, AR216: 2, AR190: 2, AR171: 2, AR289: 2, AR211: 2, AR223: 2, AR235: 1, AR214: 1 S0049: 1 and S0146: 1. 48 514459 58  50-244 113 Ser-39 to Ala-47, AR207: 5, AR053: 5, HBMXG32 Phe-55 to Leu-64. AR263: 4, AR162: 4, AR161: 4, AR163: 4, AR165: 4, AR039: 4, AR164: 4, AR166: 4, AR309: 4, AR253: 4, AR193: 4, AR195: 3, AR274: 3, AR180: 3, AR272: 3, AR254: 3, AR313: 3, AR240: 3, AR299: 3, AR282: 3, AR212: 3, AR264: 3, AR170: 3, AR215: 3, AR277: 3, AR205: 3, AR308: 3, AR268: 3, AR286: 3, AR197: 2, AR196: 2, AR213: 2, AR173: 2, AR267: 2, AR089: 2, AR311: 2, AR312: 2, AR238: 2, AR283: 2, AR229: 2, AR198: 2, AR262: 2, AR247: 2, AR201: 2, AR271: 2, AR285: 2, AR316: 2, AR055: 2, AR222: 2, AR171: 2, AR096: 2, AR297: 2, AR236: 2, AR188: 2, AR250: 2, AR275: 2, AR181: 2, AR178: 2, AR060: 2, AR293: 2, AR234: 2, AR291: 2, AR177: 2, AR225: 2, AR226: 2, AR261: 2, AR185: 2, AR257: 2, AR199: 2, AR033: 2, AR174: 2, AR290: 2, AR175: 2, AR227: 2, AR179: 2, AR204: 2, AR104: 2, AR182: 2, AR300: 2, AR224: 2, AR239: 2, AR270: 1, AR210: 1, AR231: 1, AR218: 1, AR061: 1, AR189: 1, AR294: 1, AR233: 1, AR289: 1, AR288: 1, AR228: 1, AR191: 1, AR287: 1, AR216: 1, AR211: 1, AR203: 1, AR192: 1 S0116: 1 49 HCDAN25 514555 59 660-743 114 AR218: 100, AR219: 1 51, AR096: 31, AR316: 24, AR039: 23, AR104: 16, AR313: 16, AR300: 16, AR089: 16, AR060: 14, AR055: 13, AR299: 13, AR240: 11, AR185: 10, AR283: 9, AR282: 8, AR277: 7 L0766: 13, S0126: 12, L0803: 10, H0543: 10, L0731: 8, S0422: 7, L0759: 7, L0740: 6, H0657: 5, H0341: 5, L0794: 5, L0665: 5, H0539: 5, S0356: 4, S0358: 4, S0007: 4, S0010: 4, H0024: 4, H0266: 4, S0022: 4, H0040: 4, H0494: 4, L0666: 4, S0152: 4, S0040: 3, H0717: 3, S0045: 3, H0581: 3, H0046: 3, H0673: 3, H0551: 3, L0805: 3, L0748: 3, L0439: 3, H0423: 3, H0170: 2, H0656: 2, S0418: 2, S0360: 2, H0580: 2, S0046: 2, H0036: 2, H0545: 2, H0375: 2, S6028: 2, S0214: 2, L0483: 2, S0036: 2, H0090: 2, H0591: 2, H0038: 2, H0641: 2, L0372: 2, L5574: 2, L0776: 2, L0659: 2, L0517: 2, L0526: 2, L0809: 2, L0663: 2, L0664: 2, H0144: 2, H0547: 2, H0648: 2, S0380: 2, H0631: 2, S0027: 2, L0744: 2, L0786: 2, L0777: 2, L0780: 2, L0752: 2, L0757: 2, L0758: 2, L0596: 2, L0591: 2, L0361: 2, L0601: 2, S0194: 2, S0276: 2, H0542: 2, H0422: 2, H0624: 1, H0171: 1, H0159: 1, H0685: 1, L0415: 1, S0116: 1, S0001: 1, H0483: 1, H0661: 1, H0663: 1, H0662: 1, H0306: 1, S0442: 1, S0376: 1, S0444: 1, S0410: 1, H0208: 1, S0132: 1, S0476: 1, H0619: 1, H0411: 1, S0278: 1, H0549: 1, S0222: 1, H0592: 1, H0586: 1, H0486: 1, H0013: 1, H0069: 1, H0599: 1, H0098: 1, H0575: 1, H0318: 1, S0474: 1, H0251: 1, T0103: 1, H0597: 1, L0738: 1, H0327: 1, H0014: 1, H0051: 1, H0083: 1, S0003: 1, H0428: 1, H0031: 1, H0644: 1, H0111: 1, H0032: 1, H0135: 1, H0634: 1, H0063: 1, T0067: 1, H0272: 1, H0412: 1, H0413: 1, H0560: 1, H0561: 1, S0450: 1, S0440: 1, H0509: 1, S0150: 1, H0646: 1, L0598: 1, H0529: 1, L0520: 1, L0502: 1, L0763: 1, L0800: 1, L0648: 1, L0649: 1, L0774: 1, L0806: 1, L0656: 1, L0783: 1, L0519: 1, L0545: 1, L0787: 1, L0792: 1, S0310: 1, H0520: 1, H0519: 1, H0593: 1, H0682: 1, H0659: 1, H0660: 1, S0328: 1, S0330: 1, H0704: 1, H0134: 1, H0555: 1, S3012: 1, S0390: 1, S0028: 1, L0751: 1, L0749: 1, L0756: 1, L0753: 1, L0755: 1, S0031: 1, S0260: 1, S0434: 1, L0592: 1, L0599: 1, L0604: 1, L0593: 1, S0106: 1, S0011: 1, H0668: 1, S0026: 1, H0216: 1, S0242: 1, S0424: 1 and H0352: 1. 50 HCDAT43 514335 60 184-396 115 AR219: 7, AR096: 7, 17p13 138190, AR240: 6, AR218: 6, 254210, AR104: 4, AR316: 4, 271900, AR313: 3, AR055: 3, 600179, AR039: 3, AR283: 3, 600977, AR185: 3, AR277: 2, 601202, AR060: 2, AR299: 2, 601777 AR089: 2, AR282: 2, AR300: 2 S0116: 1, H0251: 1, H0545: 1, H0641: 1, L0793: 1 and S0404: 1

[0456] The first column in Table 1B provides the gene number in the application corresponding to the clone identifier. The second column in Table 1B provides a unique “Clone ID:” for a cDNA clone related to each contig sequence disclosed in Table 1B. This clone ID references the cDNA clone which contains at least the 5′ most sequence of the assembled contig and at least a portion of SEQ ID NO:X was determined by directly sequencing the referenced clone. The reference clone may have more sequence than described in the sequence listing or the clone may have less. In the vast majority of cases, however, the clone is believed to encode a full-length polypeptide. In the case where a clone is not full-length, a full-length cDNA can be obtained by methods described elsewhere herein.

[0457] The third column in Table 1B provides a unique “Contig ID” identification for each contig sequence. The fourth column provides the “SEQ ID NO:” identifier for each of the contig polynucleotide sequences disclosed in Table 1B. The fifth column, “ORF (From-To)”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence “SEQ ID NO:X” that delineate the preferred open reading frame (ORF) shown in the sequence listing and referenced in Table 1B, column 6, as SEQ ID NO:Y. Where the nucleotide position number “To” is lower than the nucleotide position number “From”, the preferred ORF is the reverse complement of the referenced polynucleotide sequence.

[0458] The sixth column in Table 1B provides the corresponding SEQ ID NO:Y for the polypeptide sequence encoded by the preferred ORF delineated in column 5. In one embodiment, the invention provides an amino acid sequence comprising, or alternatively consisting of, a polypeptide encoded by the portion of SEQ ID NO:X delineated by “ORF (From-To)”. Also provided are polynucleotides encoding such amino acid sequences and the complementary strand thereto.

[0459] Column 7 in Table 1B lists residues comprising epitopes contained in the polypeptides encoded by the preferred ORF (SEQ ID NO:Y), as predicted using the algorithm of Jameson and Wolf, (1988) Comp. Appl. Biosci. 4:181-186. The Jameson-Wolf antigenic analysis was performed using the computer program PROTEAN (Version 3.11 for the Power MacIntosh, DNASTAR, Inc., 1228 South Park Street Madison, Wis.). In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, at least one, two, three, four, five or more of the predicted epitopes as described in Table 1B. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly.

[0460] Column 8, in Table 1B, provides an expression profile and library code: count for each of the contig sequences (SEQ If) NO:X) disclosed in Table 1B, which can routinely be combined with the information provided in Table 4 and used to determine the tissues, cells, and/or cell line libraries which predominantly express the polynucleotides of the invention. The first number in column 8 (preceding the colon), represents the tissue/cell source identifier code corresponding to the code and description provided in Table 4. For those identifier codes in which the first two letters are not “AR”, the second number in column 8 (following the colon) represents the number of times a sequence corresponding to the reference polynucleotide sequence was identified in the tissue/cell source. Those tissue/cell source identifier codes in which the first two letters are “AR” designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of ³³P dCTP, using oligo(dT) to prime reverse transcription. After hybridization, high stringency washing conditions were employed to remove non-specific hybrids from the array. The remaining signal, emanating from each gene target, was measured using a Phosphorimager. Gene expression was reported as Phosphor Stimulating Luminescence (PSL) which reflects the level of phosphor signal generated from the probe hybridized to each of the gene targets represented on the array. A local background signal subtraction was performed before the total signal generated from each array was used to normalize gene expression between the different hybridizations. The value presented after “[array code]:” represents the mean of the duplicate values, following background subtraction and probe normalization. One of skill in the art could routinely use this information to identify normal and/or diseased tissue(s) which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue and/or cell expression.

[0461] Column 9 in Table 1B provides a chromosomal map location for certain polynucleotides of the invention. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Each sequence in the UniGene database is assigned to a “cluster”; all of the ESTs, cDNAs, and STSs in a cluster are believed to be derived from a single gene. Chromosomal mapping data is often available for one or more sequence(s) in a UniGene cluster; this data (if consistent) is then applied to the cluster as a whole. Thus, it is possible to infer the chromosomal location of a new polynucleotide sequence by determining its identity with a mapped UniGene cluster.

[0462] A modified version of the computer program BLASTN (Altshul, et al., J. Mol. Biol. 215:403-410 (1990), and Gish, and States, Nat. Genet. 3:266-272) (1993) was used to search the UniGene database for EST or cDNA sequences that contain exact or near-exact matches to a polynucleotide sequence of the invention (the ‘Query’). A sequence from the UniGene database (the ‘Subject’) was said to be an exact match if it contained a segment of 50 nucleotides in length such that 48 of those nucleotides were in the same order as found in the Query sequence. If all of the matches that met this criteria were in the same UniGene cluster, and mapping data was available for this cluster, it is indicated in Table 1B under the heading “Cytologic Band”. Where a cluster had been further localized to a distinct cytologic band, that band is disclosed; where no banding information was available, but the gene had been localized to a single chromosome, the chromosome is disclosed.

[0463] Once a presumptive chromosomal location was determined for a polynucleotide of the invention, an associated disease locus was identified by comparison with a database of diseases which have been experimentally associated with genetic loci. The database used was the Morbid Map, derived from OMIM™ (“Online Mendelian Inheritance in Man”; McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.) 2000; World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/). If the putative chromosomal location of a polynucleotide of the invention (Query sequence) was associated with a disease in the Morbid Map database, an OMIM reference identification number was noted in column 10, Table 1B, labelled “OMIM Disease Reference(s). Table 5 is a key to the OMIM reference identification numbers (column 1), and provides a description of the associated disease in Column 2.

[0464] Table 1C summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID:), contig sequences (contig identifier (Contig ID:) contig nucleotide sequence identifiers (SEQ ID NO:X)), and genomic sequences (SEQ ID NO:B). The first column provides a unique clone identifier, “Clone ID:”, for a cDNA clone related to each contig sequence. The second column provides the sequence identifier, “SEQ ID NO:X”, for each contig sequence. The third column provides a unique contig identifier, “Contig ID:” for each contig sequence. The fourth column, provides a BAC identifier “BAC ID NO:A” for the BAC clone referenced in the corresponding row of the table. The fifth column provides the nucleotide sequence identifier, “SEQ ID NO:B” for a fragment of the BAC clone identified in column four of the corresponding row of the table. The sixth column, “Exon From-To”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof). TABLE 1C cDNA SEQ ID SEQ ID EXON Clone ID NO: X CONTIG ID: BAC ID: A NO: B From-To HNGJT54 11 498272 AC069508 207  1-1100 HNGJT54 11 498272 AC062017 208  1-1098 HOSCI83 12 498916 ACO11329 209 1-952 HOSCI83 12 498916 AC010130 210  1-2029 HOSCI83 12 498916 AC011329 211 1-318 HOSCI83 12 498916 AC010130 212 1-227 245-744  HOSCI83 12 498916 AC010130 213 1-322 HSSMW31 15 498801 AC025945 214  1-2077 HSSMW31 15 498801 AC026220 215  1-2072 HSSMW31 15 498801 AC026886 216  1-2072 HSSMW31 15 498801 AC025945 217 1-176 HSSMW31 15 498801 AC025945 218 1-484 HSSMW31 15 498801 AC026220 219 1-481 HSSMW31 15 498801 AC026886 220 1-481 HSSMW31 15 498801 AC026886 221 1-176 HDPSP54 17 744440 AL162612 222  1-3929 HDPSP54 17 744440 AF216672 223 1-142 987-1415  2195-2297  2814-2938  4202-4401  4713-5485  5626-9374  HDPSP54 17 744440 AC011170 224 1-869 HDPSP54 17 744440 AC011134 225 1-150 1430-1566  1684-1803  5501-6426  7175-7250  7991-8143  8978-9406  10186-10288  10805-10929  12193-12392  12704-13476  13617-17365  HDPSP54 17 744440 AC018593 226  1-3928 HDPSP54 17 744440 AC025992 227  1-3928 HDPSP54 17 744440 AL162612 228 1-379 HDPSP54 17 744440 AF216672 229 1-297 HDPSP54 17 744440 AC018593 230 1-379 HDPSP54 17 744440 AC025992 231 1-379 HELFQ07 18 502523 AC009454 232  1-2462 HELFQ07 18 502523 AP001269 233  1-3397 HELFQ07 18 502523 AC009454 234 1-234 HELFQ07 18 502523 AP001269 235 1-234 HLHBV54 19 505038 AC004630 236  1-1157 HLHBV54 19 505038 AC004630 237 1-402 HBSAJ16 20 509943 AL133246 238 1-639 HBSAJ16 20 509943 AC019092 239 1-184 HBSAJ16 20 509943 AC011101 240 1-100 HBSAJ16 20 509943 AC026556 241 1-114 HBSAJ16 20 509943 AC016042 242 1-138 HBSAJ16 20 509943 AC010882 243 1-135 HBSAJ16 20 509943 AC022276 244 1-166 HBSAJ16 20 509943 AL133246 245 1-552 HBSAJ16 20 509943 AC019092 246 1-268 HCEOC41 21 513037 AC002126 247 1-165 732-4017  HCUBS50 22 499240 AC058782 248 1-852 HCUBS50 22 499240 AC021778 249 1-852 HCUBS50 22 499240 AC058782 250 1-187 362-714  864-1265  4504-4941  5470-5540  HCUBS50 22 499240 AC058782 251 1-235 HCUBS50 22 499240 AC021778 252 1-167 HCUBS50 22 499240 AC021778 253 1-235 HCUEO60 23 499242 AC007459 254 1-242 HCUEO60 23 499242 AC005197 255 1-243 772-824  1756-1999  2978-3035  4341-5379  6108-6219  6943-7024  8370-8527  11341-11417  11851-11924  12065-12280  HCUEO60 23 499242 AC002369 256 1-586 2559-2651  3329-3426  3756-5088  HCUEO60 23 499242 AL390917 257 1-181 HCUEO60 23 499242 AC073404 258 1-142 HCUEO60 23 499242 AC021401 259 1-319 HCUEO60 23 499242 AC013758 260 1-316 HCUEO60 23 499242 AC009868 261 1-322 HCUEO60 23 499242 AC073909 262 1-286 HCUEO60 23 499242 AL354657 263 1-305 HCUEO60 23 499242 AL353701 264 1-168 HCUEO60 23 499242 AL161634 265 1-300 HCUEO60 23 499242 AC068196 266 1-316 HCUEO60 23 499242 AC021901 267 1-283 HCUEO60 23 499242 AC018740 268 1-280 942-1052  HCUEO60 23 499242 AC021921 269 1-170 HCUEO60 23 499242 AC069483 270 1-300 HCUEO60 23 499242 AC022051 271 1-294 HCUEO60 23 499242 AC019092 272 1-184 HCUEO60 23 499242 AC060817 273 1-299 HCUEO60 23 499242 AC027264 274 1-147 HCUEO60 23 499242 AL353139 275 1-316 HCUEO60 23 499242 AC069362 276 1-131 HCUEO60 23 499242 AC011175 277 1-318 HCUEO60 23 499242 AC024337 278 1-235 HCUEO60 23 499242 AC055805 279 1-143 HCUEO60 23 499242 AC055788 280 1-170 HCUEO60 23 499242 AC012110 281 1-98  HCUEO60 23 499242 AC016524 282 1-296 HCUEO60 23 499242 AL162727 283 1-135 HCUEO60 23 499242 AC026980 284 1-171 HCUEO60 23 499242 AL353663 285 1-141 HCUEO60 23 499242 AC031987 286 1-125 HCUEO60 23 499242 AC009899 287 1-175 HCUEO60 23 499242 AC009097 288 1-101 HCUEO60 23 499242 AC009095 289 1-196 HCUEO60 23 499242 AC025181 290 1-159 HCUEO60 23 499242 AP001929 291 1-301 HCUEO60 23 499242 AL355605 292 1-154 HCUEO60 23 499242 AL162590 293 1-305 2532-2548  HCUEO60 23 499242 AC068594 294 1-313 HCUEO60 23 499242 AC027772 295 1-189 HCUEO60 23 499242 AC027408 296 1-207 HCUEO60 23 499242 AC012201 297 1-150 HCUEO60 23 499242 AC027584 298 1-162 HCUEO60 23 499242 AC016538 299 1-301 HCUEO60 23 499242 AL354718 300 1-727 817-2117  3927-4151  4659-5096  5312-5593  HCUEO60 23 499242 AL162592 301 1-300 HCUEO60 23 499242 AC067800 302 1-308 HCUEO60 23 499242 AC008470 303 1-129 HCUEO60 23 499242 AC027142 304 1-311 HCUEO60 23 499242 AC023309 305 1-193 HCUEO60 23 499242 AC027516 306 1-727 817-2116  3927-4151  4659-5096  5312-5593  HCUEO60 23 499242 AC024361 307 1-177 HCUEO60 23 499242 AP001176 308 1-307 HCUEO60 23 499242 AC073446 309 1-140 HCUEO60 23 499242 AC026936 310 1-280 HCUEO60 23 499242 AC024475 311 1-187 HCUEO60 23 499242 AC009858 312 1-39  HCUEO60 23 499242 AC021164 313 1-315 3876-3905  HCUEO60 23 499242 AC068682 314 1-153 HCUEO60 23 499242 AC026107 315 1-275 HCUEO60 23 499242 AC067779 316 1-166 HCUEO60 23 499242 AC068755 317 1-190 HCUEO60 23 499242 AC034243 318 1-312 2334-2364  HCUEO60 23 499242 AC034198 319 1-198 1261-1367  HCUEO60 23 499242 AC015604 320 1-261 HCUEO60 23 499242 AC027147 321 1-276 HCUEO60 23 499242 AL136171 322 1-61  HCUEO60 23 499242 AC068519 323 1-312 HCUEO60 23 499242 AC027544 324 1-158 HCUEO60 23 499242 AC016319 325 1-191 HCUEO60 23 499242 AC011036 326 1-193 HCUEO60 23 499242 AC055861 327 1-281 HCUEO60 23 499242 AC044860 328 1-310 HCUEO60 23 499242 AC023369 329 1-309 HCUEO60 23 499242 AC073849 330 1-309 HCUEO60 23 499242 AC072051 331 1-310 HCUEO60 23 499242 AC026144 332 1-183 HCUEO60 23 499242 AC016439 333 1-164 HCUEO60 23 499242 AC027095 334 1-93  HCUEO60 23 499242 AC025975 335 1-136 HCUEO60 23 499242 AC012124 336 1-260 HCUEO60 23 499242 AC015587 337 1-273 HCUEO60 23 499242 AL353577 338 1-279 HCUEO60 23 499242 AC026488 339 1-308 HCUEO60 23 499242 AC016042 340 1-138 HCUEO60 23 499242 AP002347 341 1-296 HCUEO60 23 499242 AC068315 342 1-248 HCUEO60 23 499242 AC068289 343 1-192 HCUEO60 23 499242 AC055119 344 1-320 HCUEO60 23 499242 AC023583 345 1-153 HCUEO60 23 499242 AC022795 346 1-300 HCUEO60 23 499242 AC016142 347 1-150 HCUEO60 23 499242 AC011114 348 1-287 HCUEO60 23 499242 AC026496 349 1-266 HCUEO60 23 499242 AL355975 350 1-322 HCUEO60 23 499242 AC068705 351 1-727 817-2023  HCUEO60 23 499242 AC023864 352 1-142 HCUEO60 23 499242 AL354696 353 1-181 HCUEO60 23 499242 AL096841 354 1-281 HCUEO60 23 499242 AC073219 355 1-123 HCUEO60 23 499242 AC027414 356 1-270 HCUEO60 23 499242 AC023008 357 1-296 HCUEO60 23 499242 AC021384 358 1-301 HCUEO60 23 499242 AL162741 359 1-45  HCUEO60 23 499242 AC041031 360 1-297 HCUEO60 23 499242 AC040985 361 1-177 HCUEO60 23 499242 AC022766 362 1-318 HCUEO60 23 499242 AC009083 363 1-275 HCUEO60 23 499242 AC004803 364 1-154 HCUEO60 23 499242 AC027442 365 1-307 HCUEO60 23 499242 AC022276 366 1-166 HCUEO60 23 499242 AC002369 367 1-228 HCUEO60 23 499242 AL390917 368 1-131 HCUEO60 23 499242 AC068196 369 1-214 HCUEO60 23 499242 AC019092 370 1-268 HCUEO60 23 499242 AC012110 371  1-1782 4643-4802  HCUEO60 23 499242 AL355605 372 1-906 HCUEO60 23 499242 AC027584 373 1-368 HCUEO60 23 499242 AL354718 374 1-926 1014-1890  HCUEO60 23 499242 AC027142 375 1-409 632-823  HCUEO60 23 499242 AC073446 376 1-52  2626-2925  HCUEO60 23 499242 AC009858 377 1-212 HCUEO60 23 499242 AC023583 378 1-59  1391-1548  HCUEO60 23 499242 AC023864 379  1-1485 1590-4704  HCUEO60 23 499242 AL162741 380 1-102 HE6AJ31 25 511141 AC011417 381 1-623 HFCED59 26 511100 AC010605 382 1-381 821-2009  HFCED59 26 511100 AC020715 383 1-381 821-1676  1928-2010  HFCED59 26 511100 AC010605 384 1-695 HFCED59 26 511100 AC010605 385 1-106 HFCED59 26 511100 AC020715 386 1-380 HFCED59 26 511100 AC020715 387 1-695 HFXKJ03 28 505207 AC035150 388  1-1396 HFXKJ03 28 505207 AC006213 389  1-1395 HFXKJ03 28 505207 AC035150 390 1-777 806-2341  HFXKJ03 28 505207 AC006213 391 1-780 809-2344  HHFDG44 29 513048 AC007068 392 1-858 886-1156  HHFDG44 29 513048 AC007068 393 1-342 HJACG02 30 509948 AC008763 394 1-47  243-371  736-823  1144-1381  HJACG02 30 509948 AC008763 395 1-32  407-497  818-1357  2275-2380  2384-2560  HKMAB92 32 509950 AC005551 396  1-1607 1616-3033  HKMAB92 32 509950 AC005551 397  1-1554 1561-3292  HLDOJ68 33 505205 AC007638 398  1-3770 HLDOJ68 33 505205 AC007638 399 1-309 1074-1562  1838-2052  HLDOJ68 33 505205 AC007638 400 1-257 HLMMO64 35 510980 AC010625 401 1-833 HNFCK41 39 513050 AL031283 402 1-148 465-700  1278-1770  2587-4473  HNFCK41 39 513050 AL031283 403 1-665 HNFCK41 39 513050 AL031283 404 1-101 HNFHD08 40 509945 AL357672 405 1-652 1292-2231  2308-2842  HNFHD08 40 509945 AC025580 406 1-652 1290-2229  2306-3382  4822-5228  7386-7411  HNFHD08 40 509945 AC009886 407 1-652 1292-2231  2308-3385  HNFHD08 40 509945 AL357672 408 1-482 HNFHD08 40 509945 AC025580 409 1-481 HNFHD08 40 509945 AC009886 410 1-481 HNFHD08 40 509945 AC009886 411 1-407 HNGEW65 41 513038 AC000086 412 1-869 HNGEW65 41 513038 AC000086 413 1-305 HUNAE14 42 509954 AC021161 414 1-173 931-2073  2175-2252  HNHEN68 43 511170 AC008905 415 1-974 HNHEN68 43 511170 AC008865 416 1-974 HNHEN68 43 511170 AC008401 417 1-975 HODBF19 45 509958 AC022220 418  1-1029 HPBCC51 47 509942 AC025531 419 1-57  400-534  793-997  1179-2926  HPBCC51 47 509942 AC025531 420 1-82  243-722  861-1233  HRGDC48 48 513040 AP000877 421 1-79  508-970  HRGDC48 48 513040 AP000854 422 1-79  509-971  HRGDC48 48 513040 AP002357 423 1-79  508-970  HSDJB13 49 498308 AL354972 424 1-82  658-993  1322-1463  1517-1876  2183-2340  2575-4002  HUNAB18 52 509946 AC009806 425  1-2959 HUNAB18 52 509946 AC009806 426 1-962 HARAM05 53 514743 AC016118 427  1-1199 HATCK44 56 514716 AC006023 428 1-208 2211-2520  2939-3243  4588-5798  5842-9009  HATCK44 56 514716 AC074279 429  1-1213 1256-4424  HATCK44 56 514716 AC069391 430  1-1211 1254-4422  HATCK44 56 514716 AC006023 431 1-163 HATCK44 56 514716 AC006023 432 1-391 HATCK44 56 514716 AC074279 433 1-391 HATCK44 56 514716 AC074279 434 1-308 HATCK44 56 514716 AC069391 435 1-308 HBIAE26 57 514418 AL138904 436  1-1019 HBIAE26 57 514418 AL138904 437  1-1005

[0465] Tables 1D and 1E: The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

[0466] The present invention encompasses methods of preventing, treating, diagnosing, or ameliorating a disease or disorder. In preferred embodiments, the present invention encompasses a method of treating a disease or disorder listed in the “Preferred Indications” columns of Table 1D and Table 1E; comprising administering to a patient in which such treatment, prevention, or amelioration is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to treat, prevent, diagnose, or ameliorate the disease or disorder. The first and seccond columns of Table 1D show the “Gene No.” and “cDNA Clone ID No.”, respectively, indicating certain nucleic acids and proteins (or antibodies against the same) of the invention (including polynucleotide, polypeptide, and antibody fragments or variants thereof) that may be used in preventing, treating, diagnosing, or ameliorating the disease(s) or disorder(s) indicated in the corresponding row in Column 3 of Table 1D.

[0467] In another embodiment, the present invention also encompasses methods of preventing, treating, diagnosing, or ameliorating a disease or disorder listed in the “Preferred Indications” column of Table 1D and Table 1E; comprising administering to a patient combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in Column 3 of Table 1D.

[0468] The “Preferred Indications” columns of Table 1D and Table 1E describe diseases, disorders, and/or conditions that may be treated, prevented, diagnosed, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

[0469] The recitation of “Cancer” in the “Preferred Indications” columns indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof) may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., leukemias, cancers, and/or as described below under “Hyperproliferative Disorders”).

[0470] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D may be used for example, to diagnose, treat, prevent, and/or ameliorate a neoplasm located in a tissue selected from the group consisting of: colon, abdomen, bone, breast, digestive system, liver, pancreas, prostate, peritoneum, lung, blood (e.g., leukemia), endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), uterus, eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

[0471] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a pre-neoplastic condition, selected from the group consisting of: hyperplasia (e.g., endometrial hyperplasia and/or as described in the section entitled “Hyperproliferative Disorders”), metaplasia (e.g., connective tissue metaplasia, a typical metaplasia, and/or as described in the section entitled “Hyperproliferative Disorders”), and/or dysplasia (e.g., cervical dysplasia, and bronchopulmonary dysplasia).

[0472] In another specific embodiment, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a benign dysproliferative disorder selected from the group consisting of: benign tumors, fibrocystic conditions, tissue hypertrophy, and/or as described in the section entitled “Hyperproliferative Disorders”.

[0473] The recitation of “Immune/Hematopoietic” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), blood disorders (e.g., as described below under “Immune Activity” “Cardiovascular Disorders” and/or “Blood-Related Disorders”), and infections (e.g., as described below under “Infectious Disease”).

[0474] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having the “Immune/Hematopoietic” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: anemia, pancytopenia, leukopenia, thrombocytopenia, leukemias, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, asthma, AIDS, autoimmune disease, rheumatoid arthritis, granulomatous disease, immune deficiency, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, immune reactions to transplanted organs and tissues, systemic lupus erythematosis, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and allergies.

[0475] The recitation of “Reproductive” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the reproductive system (e.g., as described below under “Reproductive System Disorders”).

[0476] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Reproductive” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cryptorchism, prostatitis, inguinal hernia, varicocele, leydig cell tumors, verrucous carcinoma, prostatitis, malacoplakia, Peyronie's disease, penile carcinoma, squamous cell hyperplasia, dysmenorrhea, ovarian adenocarcinoma, Turner's syndrome, mucopurulent cervicitis, Sertoli-leydig tumors, ovarian cancer, uterine cancer, pelvic inflammatory disease, testicular cancer, prostate cancer, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes mellitus, cystic fibrosis, Kartagener's syndrome, testicular atrophy, testicular feminization, anorchia, ectopic testis, epididymitis, orchitis, gonorrhea, syphilis, testicular torsion, vasitis nodosa, germ cell tumors, stromal tumors, dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding, cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, cervical neoplasms, pseudohermaphroditism, and premenstrual syndrome.

[0477] The recitation of “Musculoskeletal” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the immune system (e.g., as described below under “Immune Activity”).

[0478] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Musculoskeletal” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bone cancers (e.g., osteochondromas, benign chondromas, chondroblastoma, chondromyxoid fibromas, osteoid osteomas, giant cell tumors, multiple myeloma, osteosarcomas), Paget's Disease, rheumatoid arthritis, systemic lupus erythematosus, osteomyelitis, Lyme Disease, gout, bursitis, tendonitis, osteoporosis, osteoarthritis, muscular dystrophy, mitochondrial myopathy, cachexia, and multiple sclerosis.

[0479] The recitation of “Cardiovascular” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the cardiovascular system (e.g., as described below under “Cardiovascular Disorders”).

[0480] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cardiovascular” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: myxomas, fibromas, rhabdomyomas, cardiovascular abnormalities (e.g., congenital heart defects, cerebral artenovenous malformations, septal defects), heart disease (e.g., heart failure, congestive heart disease, arrhythmia, tachycardia, fibrillation, pericardial Disease, endocarditis), cardiac arrest, heart valve disease (e.g., stenosis, regurgitation, prolapse), vascular disease (e.g., hypertension, coronary artery disease, angina, aneurysm, arteriosclerosis, peripheral vascular disease), hyponatremia, hypernatremia, hypokalemia, and hyperkalemia.

[0481] The recitation of “Mixed Fetal” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”).

[0482] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Mixed Fetal” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: spina bifida, hydranencephaly, neurofibromatosis, fetal alcohol syndrome, diabetes mellitus, PKU, Down's syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, Apert syndrome, Carpenter syndrome, Conradi syndrome, Crouzon syndrome, cutis laxa, Cornelia de Lange syndrome, Ellis-van Creveld syndrome, Holt-Oram syndrome, Kartagener syndrome, Meckel-Gruber syndrome, Noonan syndrome, Pallister-Hall syndrome, Rubinstein-Taybi syndrome, Scimitar syndrome, Smith-Lemli-Opitz syndrome, thromocytopenia-absent radius (TAR) syndrome, Treacher Collins syndrome, Williams syndrome, Hirschsprung's disease, Meckel's diverticulum, polycystic kidney disease, Turner's syndrome, and gonadal dysgenesis, Klippel-Feil syndrome, Ostogenesis imperfecta, muscular dystrophy, Tay-Sachs disease, Wilm's tumor, neuroblastoma, and retinoblastoma.

[0483] The recitation of “Excretory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and renal disorders (e.g., as described below under “Renal Disorders”).

[0484] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Excretory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bladder cancer, prostate cancer, benign prostatic hyperplasia, bladder disorders (e.g., urinary incontinence, urinary retention, urinary obstruction, urinary tract Infections, interstitial cystitis, prostatitis, neurogenic bladder, hematuria), renal disorders (e.g., hydronephrosis, proteinuria, renal failure, pyelonephritis, urolithiasis, reflux nephropathy, and unilateral obstructive uropathy).

[0485] The recitation of “Neural/Sensory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the nervous system (e.g., as described below under “Neural Activity and Neurological Diseases”).

[0486] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Neural/Sensory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: brain cancer (e.g., brain stem glioma, brain tumors, central nervous system (Primary) lymphoma, central nervous system lymphoma, cerebellar astrocytoma, and cerebral astrocytoma, neurodegenerative disorders (e.g., Alzheimer's Disease, Creutzfeldt-Jakob Disease, Parkinson's Disease, and Idiopathic Presenile Dementia), encephalomyelitis, cerebral malaria, meningitis, metabolic brain diseases (e.g., phenylketonuria and pyruvate carboxylase deficiency), cerebellar ataxia, ataxia telangiectasia, and AIDS Dementia Complex, schizophrenia, attention deficit disorder, hyperactive attention deficit disorder, autism, and obsessive compulsive disorders.

[0487] The recitation of “Respiratory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the respiratory system (e.g., as described below under “Respiratory Disorders”).

[0488] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Respiratory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of the respiratory system such as larynx cancer, pharynx cancer, trachea cancer, epiglottis cancer, lung cancer, squamous cell carcinomas, small cell (oat cell) carcinomas, large cell carcinomas, and adenocarcinomas. Allergic reactions, cystic fibrosis, sarcoidosis, histiocytosis X, infiltrative lung diseases (e.g., pulmonary fibrosis and lymphoid interstitial pneumonia), obstructive airway diseases (e.g., asthma, emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis and asbestosis), pneumonia, and pleurisy.

[0489] The recitation of “Endocrine” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the respiratory system (e.g., as described below under “Respiratory Disorders”), renal disorders (e.g., as described below under “Renal Disorders”), and disorders of the endocrine system (e.g., as described below under “Endocrine Disorders”.

[0490] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having an “Endocrine” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of endocrine tissues and organs (e.g., cancers of the hypothalamus, pituitary gland, thyroid gland, parathyroid glands, pancreas, adrenal glands, ovaries, and testes), diabetes (e.g., diabetes insipidus, type I and type II diabetes mellitus), obesity, disorders related to pituitary glands (e.g., hyperpituitarism, hypopituitarism, and pituitary dwarfism), hypothyroidism, hyperthyroidism, goiter, reproductive disorders (e.g. male and female infertility), disorders related to adrenal glands (e.g., Addison's Disease, corticosteroid deficiency, and Cushing's Syndrome), kidney cancer (e.g., hypernephroma, transitional cell cancer, and Wilm's tumor), diabetic nephropathy, interstitial nephritis, polycystic kidney disease, glomerulonephritis (e.g., IgM mesangial proliferative glomerulonephritis and glomerulonephritis caused by autoimmune disorders; such as Goodpasture's syndrome), and nephrocalcinosis.

[0491] The recitation of “Digestive” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the gastrointestinal system (e.g., as described below under “Gastrointestinal Disorders”.

[0492] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Digestive” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: ulcerative colitis, appendicitis, Crohn's disease, hepatitis, hepatic encephalopathy, portal hypertension, cholelithiasis, cancer of the digestive system (e.g., biliary tract cancer, stomach cancer, colon cancer, gastric cancer, pancreatic cancer, cancer of the bile duct, tumors of the colon (e.g., polyps or cancers), and cirrhosis), pancreatitis, ulcerative disease, pyloric stenosis, gastroenteritis, gastritis, gastric atropy, benign tumors of the duodenum, distension, irritable bowel syndrome, malabsorption, congenital disorders of the small intestine, bacterial and parasitic infection, megacolon, Hirschsprung's disease, aganglionic megacolon, acquired megacolon, colitis, anorectal disorders (e.g., anal fistulas, hemorrhoids), congenital disorders of the liver (e.g., Wilson's disease, hemochromatosis, cystic fibrosis, biliary atresia, and alphal-antitrypsin deficiency), portal hypertension, cholelithiasis, and jaundice.

[0493] The recitation of “Connective/Epithelial” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), cellular and genetic abnormalities (e.g., as described below under “Diseases at the Cellular Level”), angiogenesis (e.g., as described below under “Anti-Angiogenesis Activity”), and or to promote or inhibit regeneration (e.g., as described below under “Regeneration”), and wound healing (e.g., as described below under “Wound Healing and Epithelial Cell Proliferation”).

[0494] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Connective/Epithelial” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: connective tissue metaplasia, mixed connective tissue disease, focal epithelial hyperplasia, epithelial metaplasia, mucoepithelial dysplasia, graft v. host disease, polymyositis, cystic hyperplasia, cerebral dysplasia, tissue hypertrophy, Alzheimer's disease, lymphoproliferative disorder, Waldenstron's macroglobulinemia, Crohn's disease, pernicious anemia, idiopathic Addison's disease, glomerulonephritis, bullous pemphigoid, Sjogren's syndrome, diabetes mellitus, cystic fibrosis, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, osteoporosis, osteocarthritis, periodontal disease, wound healing, relapsing polychondritis, vasculitis, polyarteritis nodosa, Wegener's granulomatosis, cellulitis, rheumatoid arthritis, psoriatic arthritis, discoid lupus erythematosus, systemic lupus erythematosus, scleroderma, CREST syndrome, Sjogren's syndrome, polymyositis, dermatomyositis, mixed connective tissue disease, relapsing polychondritis, vasculitis, Henoch-Schonlein syndrome, erythema nodosum, polyarteritis nodosa, temporal (giant cell) arteritis, Takayasu's arteritis, Wegener's granulomatosis, Reiter's syndrome, Behcet's syndrome, ankylosing spondylitis, cellulitis, keloids, Ehler Danlos syndrome, Marfan syndrome, pseudoxantoma elasticum, osteogenese imperfecta, chondrodysplasias, epidermolysis bullosa, Alport syndrome, and cutis laxa. TABLE 1D cDNA Clone Gene No. ID Preferred Indications 1 HNGJT54 Immune/Hematopoetic 2 HOSCI83 Cancer 3 HSAAO30 Cancer 4 HSQBL21 Cancer 5 HSSMW31 Musculoskeletal, Reproductive 6 HTEFU41 Immune/Hematopoetic, Reproductive 7 HDPSP54 Cancer 8 HELFQ07 Cancer 9 HLHBV54 Respiratory 10 HBSAJ16 Connective/Epithelial, Musculoskeletal, Reproductive 11 HCEOC41 Cancer 12 HCUBS50 Immune/Hematopoetic 13 HCUEO60 Immune/Hematopoetic 14 HDHEB60 Cancer 15 HE6AJ31 Mixed Fetal 16 HFCED59 Immune/Hematopoetic, Neural/Sensory 17 HFTBY59 Cancer 18 HFXKJ03 Cardiovascular, Immune/Hematopoetic, Neural/Sensory 19 HHFDG44 Cardiovascular, Endocrine, Immune/Hematopoetic 20 HJACG02 Digestive, Immune/Hematopoetic 21 HKGAJ54 Cancer 22 HKMAB92 Cancer 23 HLDOJ68 Cancer 24 HLMFC54 Immune/Hematopoetic 25 HLMMO64 Immune/Hematopoetic, Reproductive 26 HLWBZ21 Immune/Hematopoetic, Reproductive 27 HMJAX71 Neural/Sensory 28 HNECU95 Cancer 29 HNFCK41 Cancer 30 HNFHD08 Cancer 31 HNGEW65 Endocrine, Immune/Hematopoetic 32 HUNAE14 Reproductive 33 HNHEN68 Immune/Hematopoetic 34 HNHFG05 Immune/Hematopoetic 35 HODBF19 Cancer 36 HOEBK34 Digestive, Musculoskeletal 37 HPBCC51 Cancer 38 HRGDC48 Immune/Hematopoetic, Musculoskeletal 39 HSDJB13 Cancer 40 HTEHR24 Cancer 41 HAGAM03 Immune/Hematopoetic, Neural/Sensory 42 HUNAB18 Cancer 43 HARAM05 Neural/Sensory, Respiratory 44 HARAO51 Cancer 45 HATAA15 Cancer 46 HATCK44 Cancer 47 HBIAE26 Neural/Sensory, Reproductive 48 HBMXG32 Immune/Hematopoetic 49 HCDAN25 Cancer 50 HCDAT43 Cancer

[0495] Table 1E provides information related to biological activities and preferred indications for polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof). Table 1E also provides information related to assays which may be used to test polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) for the corresponding biological activities. The first column (“Gene No.”) provides the gene number in the application for each clone identifier. The second column (“cDNA Clone ID:”) provides the unique clone identifier for each clone as previously described and indicated in Tables 1A, 1B, 1C, and ID. The third column (“AA SEQ ID NO:Y”) indicates the Sequence Listing SEQ ID Number for polypeptide sequences encoded by the corresponding cDNA clones (also as indicated in Tables 1A, 1B, and 2). The fourth column (“Biological Activity”) indicates a biological activity corresponding to the indicated polypeptides (or polynucleotides encoding said polypeptides). The fifth column (“Exemplary Activity Assay”) further describes the corresponding biological activity and also provides information pertaining to the various types of assays which may be performed to test, demonstrate, or quantify the corresponding biological activity. The sixth column (“Preferred Indictions”) describes particular embodiments of the invention as well as indications (e.g. pathologies, diseases, disorders, abnormalities, etc.) for which polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) may be used in detecting, diagnosing, preventing, and/or treating.

[0496] Table 1E describes the use of, inter alia, FMAT technology for testing or demonstrating various biological activities. Fluorometric microvolume assay technology (FMAT) is a fluorescence-based system which provides a means to perform nonradioactive cell- and bead-based assays to detect activation of cell signal transduction pathways. This technology was designed specifically for ligand binding and immunological assays. Using this technology, fluorescent cells or beads at the bottom of the well are detected as localized areas of concentrated fluorescence using a data processing system. Unbound flurophore comprising the background signal is ignored, allowing for a wide variety of homogeneous assays. FMAT technology may be used for peptide ligand binding assays, immunofluorescence, apoptosis, cytotoxicity, and bead-based immunocapture assays. See, Miraglia S et. al., “Homogeneous cell and bead based assays for highthroughput screening using flourometric microvolume assay technology,” Journal of Biomolecular Screening; 4:193-204 (1999). In particular, FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides (including polypeptide fragments and variants) to activate signal transduction pathways. For example, FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides to upregulate production of immunomodulatory proteins (such as, for example, interleukins, GM-CSF, Rantes, and Tumor Necrosis factors, as well as other cellular regulators (e.g. insulin)).

[0497] Table 1E also describes the use of kinase assays for testing, demonstrating, or quantifying biological activity. In this regard, the phosphorylation and de-phosphorylation of specific amino acid residues (e.g. Tyrosine, Serine, Threonine) on cell-signal transduction proteins provides a fast, reversible means for activation and de-activation of cellular signal transduction pathways. Moreover, cell signal transduction via phosphorylation/de-phosphorylation is crucial to the regulation of a wide variety of cellular processes (e.g. proliferation, differentiation, migration, apoptosis, etc.). Accordingly, kinase assays provide a powerful tool useful for testing, confirming, and/or identifying polypeptides (including polypeptide fragments and variants) that mediate cell signal transduction events via protein phosphorylation. See e.g., Forrer, P., Tamaskovic R., and Jaussi, R. “Enzyme-Linked Immunosorbent Assay for Measurement of JNK, ERK, and p38 Kinase Activities” Biol. Chem. 379(8-9): 1101-1110 (1998). TABLE 1E AA SEQ ID Gene cDNA NO: Biological No. Clone ID Y Activity Exemplary Activity Assay Preferred Indication 1 HNGJT54 66 Activation of Assays for the activation of transcription Preferred indications include blood disorders (e.g., as transcription through the cAMP response element are described below under “Immune Activity,” “Blood- through cAMP well-known in the art and may be used or Related Disorders,” and/or “Cardiovascular Disorders”), response routinely modified to assess the ability of and infection (e.g., an infectious disease as described element in polypeptides of the invention (including below under “Infectious Disease”). Preferred immune cells antibodies and agonists or antagonists of the indications include autoimmune diseases (e.g., (such as T- invention) to increase cAMP and regulate rheumatoid arthritis, systemic lupus erythematosis, cells). CREB transcription factors, and modulate multiple sclerosis and/or as described below), expression of genes involved in a wide immunodeficiencies (e.g., as described below), boosting variety of cell functions. Exemplary assays a T cell-mediated immune response, and suppressing a for transcription through the cAMP response T cell-mediated immune response. Additional preferred element that may be used or routinely indications include inflammation and inflammatory modified to test cAMP-response element disorders. Highly preferred indications include activity of polypeptides of the invention neoplastic diseases (e.g., leukemia, lymphoma, and/or as (including antibodies and agonists or described below under “Hyperproliferative Disorders”). antagonists of the invention) include assays Highly preferred indications include neoplasms and disclosed in Berger et al., Gene 66:1-10 cancers, such as, for example, leukemia, lymphoma (1998); Cullen and Malm, Methods in (e.g., T cell lymphoma, Burkitt's lymphoma, non- Enzymol 216:362-368 (1992): Henthorn et Hodgkins lymphoma, Hodgkin's disease), melanoma, al., Proc Natl Acad Sci USA 85:6342-6346 and prostate, breast, lung, colon, pancreatic, esophageal, (1988); Black et al., Virus Genes 15(2):105- stomach, brain, liver and urinary cancer. Other 117 (1997); and Belkowski et al., J Immunol preferred indications include benign dysproliferative 161(2):659-665 (1998), the contents of each disorders and pre-neoplastic conditions, such as, for of which are herein incorporated by example, hyperplasia, metaplasia, and/or dysplasia. reference in its entirety. T cells that may be Preferred indications include anemia, pancytopenia, used according to these assays are publicly leukopenia, thrombocytopenia, acute lymphocytic available (e.g., through the ATCC). anemia (ALL), plasmacytomas, multiple myeloma, Exemplary mouse T cells that may be used arthritis, AIDS, granulomatous disease, inflammatory according to these assays include the CTLL bowel disease, sepsis, neutropenia, neutrophilia, cell line, which is a suspension culture of IL- psoriasis, suppression of immune reactions to 2 dependent cytotoxic T cells. transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and asthma and allergy. 1 HNGJT54 66 Activation of Assays for the activation of transcription A preferred embodiment of the invention includes a transcription through the Serum Response Element (SRE) method for inhibiting (e.g., reducing) TNF alpha through serum are well-known in the art and may be used or production. An alternative preferred embodiment of the response routinely modified to assess the ability of invention includes a method for stimulating (e.g., element in polypeptides of the invention (including increasing) TNF alpha production. Preferred immune cells antibodies and agonists or antagonists of the indications include blood disorders (e.g., as described (such as T- invention) to regulate the serum response below under “Immune Activity,” “Blood-Related cells). factors and modulate the expression of genes Disorders,” and/or “Cardiovascular Disorders”), Highly involved in growth. Exemplary assays for preferred indications include autoimmune diseases (e.g., transcription through the SRE that may be rheumatoid arthritis, systemic lupus erythematosis, used or routinely modified to test SRE Crohn's disease, multiple sclerosis and/or as described activity of the polypeptides of the invention below), immunodeficiencies (e.g., as described below), (including antibodies and agonists or boosting a T cell-mediated immune response, and antagonists of the invention) include assays suppressing a T cell-mediated immune response. disclosed in Berger et al., Gene 66:1-10 Additional highly preferred indications include (1998); Cullen and Malm, Methods in inflammation and inflammatory disorders, and treating Enzymol 216:362-368 (1992); Henthorn et joint damage in patients with rheumatoid arthritis. An al., Proc Natl Acad Sci USA 85:6342-6346 additional highly preferred indication is sepsis. (1988); and Black et al., Virus Genes Highly preferred indications include neoplastic diseases 12(2):105-117 (1997), the content of each of (e.g., leukemia, lymphoma, and/or as described below which are herein incorporated by reference in under “Hyperproliferative Disorders”). Additionally, its entirety. T cells that may be used highly preferred indications include neoplasms and according to these assays are publicly cancers, such as, for example, leukemia, lymphoma, available (e.g., through the ATCC). melanoma, glioma (e.g., malignant glioma), solid Exemplary mouse T cells that may be used tumors, and prostate, breast, lung, colon, pancreatic, according to these assays include the CTLL esophageal, stomach, brain, liver and urinary cancer. cell line, which is an IL-2 dependent Other preferred indications include benign suspension culture of T cells with cytotoxic dysproliferative disorders and pre-neoplastic conditions, activity. such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under “Infectious Disease”). 1 HNGJT54 66 Production of MCP-1 FMAT. Assays for A highly preferred embodiment of the invention MCP-1 immunomodulatory proteins that are includes a method for stimulating (e.g., increasing) produced by a large variety of cells and act to MCP-1 production. An alternative highly preferred induce chemotaxis and activation of embodiment of the invention includes a method for monocytes and T cells are well known in the inhibiting (e.g., reducing) MCP-1 production. A art and may be used or routinely modified to highly preferred indication is infection (e.g., an assess the ability of polypeptides of the infectious disease as described below under “Infectious invention (including antibodies and agonists Disease”). Additional highly preferred indications or antagonists of the invention) to mediate include inflammation and inflammatory disorders. immunomodulation, induce chemotaxis, and Preferred indications include blood disorders (e.g., as modulate immune cell activation. described below under “Immune Activity,” “Blood- Exemplary assays that test for Related Disorders,” and/or “Cardiovascular Disorders”). immunomodulatory proteins evaluate the Highly preferred indications include autoimmune production of cell surface markers, such as diseases (e.g., rheumatoid arthritis, systemic lupus monocyte chemoattractant protein (MCP), erythematosis, multiple sclerosis and/or as described and the activation of monocytes and T cells. below) and immunodeficiencies (e.g., as described Such assays that may be used or routinely below). Preferred indications also include anemia, modified to test immunomodulatory and pancytopenia, leukopenia, thrombocytopenia, Hodgkin's diffferentiation activity of polypeptides of disease, acute lymphocytic anemia (ALL), the invention (including antibodies and plasmacytomas, multiple myeloma, Burkitt's agonists or antagonists of the invention) lymphoma, arthritis, AIDS, granulomatous disease, include assays disclosed in Miraglia et al., J inflammatory bowel disease, sepsis, neutropenia, Biomolecular Screening 4:193-204(1999); neutrophilia, psoriasis, suppression of immune reactions Rowland et al., “Lymphocytes: a practical to transplanted organs and tissues, hemophilia, approach” Chapter 6:138-160 (2000); hypercoagulation, diabetes mellitus, endocarditis, Satthaporn and Eremin, J R Coll Surg Ednb meningitis (bacterial and viral), Lyme Disease, asthma, 45(1):9-19 (2001); and Verhasselt et al., J and allergy Preferred indications also include Immunol 158:2919-2925 (1997), the neoplastic diseases (e.g., leukemia, lymphoma, and/or as contents of each of which are herein described below under “Hyperproliferative Disorders”). incorporated by reference in its entirety. Highly preferred indications include neoplasms and Human dendritic cells that may be used cancers, such as, leukemia, lymphoma, prostate, breast, according to these assays may be isolated lung, colon, pancreatic, esophageal, stomach, brain, using techniques disclosed herein or liver, and urinary cancer. Other preferred indications otherwise known in the art. Human dendritic include benign dysproliferative disorders and pre- cells are antigen presenting cells in neoplastic conditions, such as, for example, hyperplasia, suspension culture, which, when activated by metaplasia, and/or dysplasia. antigen and/or cytokines, initiate and upregulate T cell proliferation and functional activities. 7 HDPSP54 72 Activation of Kinase assay. JNK kinase assays for signal A highly preferred embodiment of the invention Endothelial Cell transduction that regulate cell proliferation, includes a method for stimulating endothelial cell JNK Signaling activation, or apoptosis are well known in the growth. An alternative highly preferred embodiment of Pathway. art and may be used or routinely modified to the invention includes a method for inhibiting assess the ability of polypeptides of the endothelial cell growth. A highly preferred invention (including antibodies, and agonists embodiment of the invention includes a method for or antagonists of the invention) to promote or stimulating endothelial cell proliferation. An alternative inhibit cell proliferation, activation, and highly preferred embodiment of the invention includes a apoptosis. Exemplary assays for JNK kinase method for inhibiting endothelial cell proliferation. activity that may be used or routinely A highly preferred embodiment of the invention modified to test JNK kinase-induced activity includes a method for stimulating apoptosis of of polypeptides of the invention (including endothelial cells. An alternative highly preferred antibodies and agonists or antagonists of the embodiment of the invention includes a method for invention) include the assays disclosed in inhibiting apoptosis of endothelial cells. A highly Forrer et al., Biol Chem 379(8-9):1101-1110 preferred embodiment of the invention includes a (1998); Gupta et al., Exp Cell Res 247(2): method for stimulating endothelial cell activation. An 495-504 (1999); Kyriakis J M, Biochem Soc alternative highly preferred embodiment of the Symp 64:29-48 (1999); Chang and Karin, invention includes a method for inhibiting the activation Nature 410(6824):37-40 (2001); and Cobb of and/or inactivating endothelial cells. A highly M H, Prog Biophys Mol Biol 71(3-4):479- preferred embodiment of the invention includes a 500 (1999); the contents of each of which are method for stimulating angiogenisis. An alternative herein incorporated by reference in its highly preferred embodiment of the invention includes a entirety. Endothelial cells that may be used method for inhibiting angiogenesis. A highly according to these assays are publicly preferred embodiment of the invention includes a available (e.g., through the ATCC). method for reducing cardiac hypertrophy. An alternative Exemplary endothelial cells that may be used highly preferred embodiment of the invention include a according to these assays include human method for inducing cardiac hypertrophy. Highly umbilical vein endothelial cells (HUVEC), preferred indications include neoplastic diseases (e.g., as which are endothelial cells which line venous described below under “Hyperproliferative Disorders”), blood vessels, and are involved in functions and disorders of the cardiovascular system (e.g., heart that include, but are not limited to, disease, congestive heart failure, hypertension, aortic angiogenesis, vascular permeability, vascular stenosis, cardiomyopathy, valvular regurgitation, left tone, and immune cell extravasation. ventricular dysfunction, atherosclerosis and atherosclerotic vascular disease, diabetic nephropathy, intracardiac shunt, cardiac hypertrophy, myocardial infarction, chronic hemodynamic overload, and/or as described below under “Cardiovascular Disorders”). Highly preferred indications include cardiovascular, endothelial and/or angiogenic disorders (e.g., systemic disorders that affect vessels such as diabetes mellitus, as well as diseases of the vessels themselves, such as of the arteries, capillaries, veins and/or lymphatics). Highly preferred are indications that stimulate angiogenesis and/or cardiovascularization. Highly preferred are indications that inhibit angiogenesis and/or cardiovascularization. Highly preferred indications include antiangiogenic activity to treat solid tumors, leukemias, and Kaposi's sarcoma, and retinal disorders. Highly preferred indications include neoplasms and cancer, such as, Kaposi's sarcoma, hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, lymphangioma, lymphangiosarcoma. Highly preferred indications also include cancers such as, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Highly preferred indications also include arterial disease, such as, atherosclerosis, hypertension, coronary artery disease, inflammatory vasculitides, Reynaud's disease and Reynaud's phenomenom, aneurysms, restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; and other vascular disorders such as peripheral vascular disease, and cancer. Highly preferred indications also include trauma such as wounds, burns, and injured tissue (e.g., vascular injury such as, injury resulting from balloon angioplasty, and atheroschlerotic lesions), implant fixation, scarring, ischemia reperfusion injury, rheumatoid arthritis, cerebrovascular disease, renal diseases such as acute renal failure, and osteoporosis. Additional highly preferred indications include stroke, graft rejection, diabetic or other retinopathies, thrombotic and coagulative disorders, vascularitis, lymph angiogenesis, sexual disorders, age-related macular degeneration, and treatment/prevention of endometriosis and related conditions. Additional highly preferred indications include fibromas, heart disease, cardiac arrest, heart valve disease, and vascular disease. Preferred indications include blood disorders (e.g., as described below under “Immune Activity,” “Blood-Related Disorders,” and/or “Cardiovascular Disorders”). Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosis, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional preferred indications include inflammation and inflammatory disorders (such as acute and chronic inflammatory diseases, e.g., inflammatory bowel disease and Crohn's disease), and pain management. 7 HDPSP54 72 Regulation of Caspase Apoptosis. Assays for caspase A highly preferred indication is diabetes mellitus. apoptosis in pancreatic beta cells. apoptosis are well known in the art and may An additional highly preferred indication is a be used or routinely modified to assess the complication associated with diabetes (e.g., diabetic ability of polypeptides of the invention (including antibodies and agonists or renal failure, nephropathy and/or other diseases and antagonists of the invention) to promote disorders as described in the “Renal Disorders” section caspase protease-mediated apoptosis. below), diabetic neuropathy, nerve disease and nerve Apoptosis in pancreatic beta is associated damage (e.g., due to diabetic neuropathy), blood vessel with induction and progression of diabetes. blockage, heart disease, stroke, impotence (e.g., due to Exemplary assays for caspase apoptosis that diabetic neuropathy or blood vessel blockage), seizures, may be used or routinely modified to test mental confusion, drowsiness, nonketotic capase apoptosis activity of polypeptides of hyperglycemic-hyperosmolar coma, cardiovascular the invention (including antibodies and disease (e.g., heart disease, atherosclerosis, agonists or antagonists of the invention) microvascular disease, hypertension, stroke, and other include the assays disclosed in: Loweth, A C, diseases and disorders as described in the et al., FEBS Lett, 400(3):285-8 (1997); Saini, “Cardiovascular Disorders” section below), K S, et al., Biochem Mol Biol Int, dyslipidemia, endocrine disorders (as described in the 39(6):1229-36 (1996); Krautheim, A., et al., “Endocrine Disorders” section below), neuropathy, Br J Pharmacol, 129(4):687-94 (2000); vision impairment (e.g., diabetic retinopathy and Chandra J, et al., Diabetes. 50 Suppl 1:S44-7 blindness), ulcers and impaired wound healing, and (2001); Suk K, et al., J Immunol, infection (e.g., infectious diseases and disorders as 166(7):4481-9 (2001); Tejedo J, et al., FEBS described in the “Infectious Diseases” section below, Lett, 459(2):238-43 (1999); Zhang, S., et al., especially of the urinary tract and skin). An FEBS Lett, 455(3):315-20 (1999); Lee et al., additional highly preferred indication is obesity and/or FEBS Lett 485(2-3):122-126 (2000); Nor et complications associated with obesity. Additional al., J Vasc Res 37(3):209-218 (2000); and highly preferred indications include weight loss or Karsan and Harlan, J Atheroscler Thromb alternatively, weight gain. Aditional highly 3(2):75-80 (1996); the contents of each of preferred indications are complications associated with which are herein incorporated by reference in insulin resistance. its entirety. Pancreatic cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary pancreatic cells that may be used according to these assays include RIN-m. RIN-m is a rat adherent pancreatic beta cell insulinoma cell line derived from a radiation induced transplantable rat islet cell tumor. The cells produce and secrete islet polypeptide hormones, and produce insulin, somatostatin, and possibly glucagon. ATTC: #CRL-2057 Chick et al. Proc. Natl. Acad. Sci. 1977 74:628; AF et al. Proc. Natl. Acad. Sci. 1980 77:3519. 7 HDPSP54 72 Production of Assays for production of IL-10 and Highly preferred indications include allergy and asthma. IL-10 and activation of T-cells are well known in the Additional highly preferred indications include immune activation of T- art and may be used or routinely modified to and hematopoietic disorders (e.g., as described below cells. assess the ability of polypeptides of the under “Immune Activity,” and “Blood-Related invention (including antibodies and agonists Disorders”), autoimmune diseases (e.g., rheumatoid or antagonists of the invention) to stimulate arthritis, systemic lupus erythematosis, Crohn's disease, or inhibit production of IL-10 and/or multiple sclerosis and/or as described below), activation of T-cells. Exemplary assays that immunodeficiencies (e.g., as described below), boosting may be used or routinely modified to assess a T cell-mediated immune response, and suppressing a the ability of polypeptides and antibodies of T cell-mediated immune response. the invention (including agonists or antagonists of the invention) to modulate IL- 10 production and/or T-cell proliferation include, for example, assays such as disclosed and/or cited in: Robinson, D S, et al., “Th-2 cytokines in allergic disease” Br Med Bull; 56 (4):956-968 (2000), and Cohn, et al., “T-helper type 2 cell-directed therapy for asthma” Pharmacology & Therapeutics; 88:187-196 (2000); the contents of each of which are herein incorporated by reference in their entirety. Exemplary cells that may be used according to these assays include Th2 cells. IL10 secreted from Th2 cells may be measured as a marker of Th2 cell activation. Th2 cells are a class of T cells that secrete IL4, IL10, IL13, IL5 and IL6. Factors that induce differentiation and activation of Th2 cells play a major role in the initiation and pathogenesis of allergy and asthma. Primary T helper 2 cells are generated via in vitro culture under Th2 polarizing conditions using peripheral blood lymphocytes isolated from cord blood. 12 HCUBS50 77 Activation of Assays for the activation of transcription Preferred indications include neoplastic diseases transcription through the AP1 response element are known (e.g., as described below under “Hyperproliferative through AP1 in the art and may be used or routinely Disorders”), blood disorders (e.g., as described below response modified to assess the ability of polypeptides under “Immune Activity,” “Cardiovascular Disorders,” element in of the invention (including antibodies and and/or “Blood-Related Disorders”), and infection (e.g., immune cells agonists or antagonists of the invention) to an infectious disease as described below under (such as T- modulategrowth and other cell functions. “Infectious Disease”). Highly preferred indications cells). Exemplary assays for transcription through include autoimmune diseases (e.g., rheumatoid arthritis, the AP1 response element that may be used systemic lupus erythematosis, multiple sclerosis and/or or routinely modified to test AP1-response as described below) and immunodeficiencies (e.g., as element activity of polypeptides of the described below). Additional highly preferred invention (including antibodies and agonists indications include inflammation and inflammatory or antagonists of the invention) include disorders. Highly preferred indications also include assays disclosed in Berger et al., Gene 66:1- neoplastic diseases (e.g., leukemia, lymphoma, and/or as 10 (1988); Cullen and Malm, Methods in described below under “Hyperproliferative Disorders”). Enzymol 216:362-368 (1992); Henthorn et Highly preferred indications include neoplasms and al., Proc Natl Acad Sci USA 85:6342-6346 cancers, such as, leukemia, lymphoma, prostate, breast, (1988); Rellahan et al., J Biol Chem lung, colon, pancreatic, esophageal, stomach, brain, 272(49):30806-30811 (1997); Chang et al., liver, and urinary cancer. Other preferred indications Mol Cell Biol 18(9):4986-4993 (1998); and include benign dysproliferative disorders and pre- Fraser et al., Eur J Immunol 29(3):838-844 neoplastic conditions, such as, for example, hyperplasia, (1999), the contents of each of which are metaplasia, and/or dysplasia. Preferred indications herein incorporated by reference in its include arthritis, asthma, AIDS, allergy, anemia, entirety. Mouse T cells that may be used pancytopenia, leukopenia, thrombocytopenia, Hodgkin's according to these assays are publicly disease, acute lymphocytic anemia (ALL), available (e.g., through the ATCC). plasmacytomas, multiple myeloma, Burkitt's Exemplary mouse T cells that may be used lymphoma, granulomatous disease, inflammatory bowel according to these assays include the HT2 disease, sepsis, psoriasis, suppression of immune cell line, which is an IL-2 dependent reactions to transplanted organs and tissues, suspension culture cell line that also endocarditis, meningitis, and Lyme Disease. responds to IL-4. 13 HCUEO60 78 Activation of Assays for the activation of transcription A preferred embodiment of the invention includes a transcription through the Serum Response Element (SRE) method for inhibiting (e.g., reducing) TNF alpha through serum are well-known in the art and may be used or production. An alternative highly preferred embodiment response routinely modified to assess the ability of of the invention includes a method for stimulating (e.g., element in polypeptides of the invention (including increasing) TNF alpha production. Preferred immune cells antibodies and agonists or antagonists of the indications include blood disorders (e.g., as described (such as natural invention) to regulate serum response below under “Immune Activity,” “Blood-Related killer cells). factors and modulate the expression of genes Disorders,” and/or “Cardiovascular Disorders”), Highly involved in growth and upregulate the preferred indications include autoimmune diseases (e.g., function of growth-related genes in many rheumatoid arthritis, systemic lupus erythematosis, cell types. Exemplary assays for Crohn's disease, multiple sclerosis and/or as described transcription through the SRE that may be below), immunodeficiencies (e.g., as described below), used or routinely modified to test SRE boosting a T cell-mediated immune response, and activity of the polypeptides of the invention suppressing a T cell-mediated immune response. (including antibodies and agonists or Additional highly preferred indications include antagonists of the invention) include assays inflammation and inflammatory disorders, and treating disclosed in Berger et al., Gene 66:1-10 joint damage in patients with rheumatoid arthritis. An (1998); Cullen and Malm, Methods in additional highly preferred indication is sepsis. Enzymol 216:362-368 (1992); Henthorn et Highly preferred indications include neoplastic diseases al., Proc Natl Acad Sci USA 85:6342-6346 (e.g., leukemia, lymphoma, and/or as described below (1988); Benson et al., J Immunol under “Hyperproliferative Disorders”). Additionally, 153(9):3862-3873 (1994); and Black et al., highly preferred indications include neoplasms and Virus Genes 12(2):105-117 (1997), the cancers, such as, for example, leukemia, lymphoma, content of each of which are herein melanoma, glioma (e.g., malignant glioma), solid incorporated by reference in its entirety. T tumors, and prostate, breast, lung, colon, pancreatic, cells that may be used according to these esophageal, stomach, brain, liver and urinary cancer. assays are publicly available (e.g., through Other preferred indications include benign the ATCC). Exemplary T cells that may be dysproliferative disorders and pre-neoplastic conditions, used according to these assays include the such as, for example, hyperplasia, metaplasia, and/or NK-YT cell line, which is a human natural dysplasia. Preferred indications include anemia, killer cell line with cytolytic and cytotoxic pancytopenia, leukopenia, thrombocytopenia, Hodgkin's activity. disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under “Infectious Disease”). 14 HDHEB60 79 Myoblast cell Assays for muscle cell proliferation are well Highly preferred indications include diabetes, proliferation known in the art and may be used or myopathy, muscle cell atrophy, cancers of muscle (such routinely modified to assess the ability of as, rhabdomyoma, and rhabdosarcoma), cardiovascular polypeptides of the invention (including disorders (such as congestive heart failure, cachexia, antibodies and agonists or antagonists of the myxomas, fibromas, congenital cardiovascular invention) to stimulate or inhibit myoblast abnormalities, heart disease, cardiac arrest, heart valve cell proliferation. Exemplary assays for disease, vascular disease, and also as described below myoblast cell proliferation that may be used under “Cardiovascular Disorders”), stimulating or routinely modified to test activity of myoblast proliferation, and inhibiting myoblast polypeptides and antibodies of the invention proliferation. (including agonists or antagonists of the invention) include, for example, assays disclosed in: Soeta, C, et al. “Possible role for the c-ski gene in the proliferation of myogenic cells in regenerating skeletal muscles of rats” Dev Growth Differ Apr; 43(2):155-64 (2001); Ewton DZ, et al., “IGF binding proteins-4, -5 and -6 may play specialized roles during L6 myoblast proliferation and differentiation” J Endocrinol Mar; 144(3):539-53 (1995); and, Pampusch MS, et al., “Effect of transforming growth factor beta on proliferation of L6 and embryonic porcine myogenic cells” J Cell Physiol Jun; 143(3):524-8 (1990); the contents of each of which are herein incorporated by reference in their entirety. Exemplary myoblast cells that may be used according to these assays include the rat myoblast L6 cell line. Rat myoblast L6 cells are an adherent rat myoblast cell line, isolated from primary cultures of rat thigh muscle, that fuse to form multinucleated myotubes and striated fibers after culture in differentiation media. 14 HDHEB60 79 Activation of Assays for the activation of transcription A highly preferred indication is allergy. transcription through the Signal Transducers and Another highly preferred indication is asthma. through STAT6 Activators of Transcription (STAT6) Additional highly preferred indications include response response element are well-known in the art inflammation and inflammatory disorders. element in and may be used or routinely modified to Preferred indications include blood disorders (e.g., as immune cells assess the ability of polypeptides of the described below under “Immune Activity,” “Blood- (such as natural invention (including antibodies and agonists Related Disorders,” and/or “Cardiovascular Disorders”). killer cells). or antagonists of the invention) to regulate Preferred indications include autoimmune diseases (e.g., STAT6 transcription factors and modulate rheumatoid arthritis, systemic lupus erythematosis, the expression of multiplegenes. Exemplary multiple sclerosis and/or as described below) and assays for transcription through the STAT6 immunodeficiencies (e.g., as described below). response element that may be used or Preferred indications include neoplastic diseases (e.g., routinely modified to test STAT6 response leukemia, lymphoma, melanoma, and/or as described element activity of the polypeptides of the below under “Hyperproliferative Disorders”). Preferred invention (including antibodies and agonists indications include neoplasms, such as, for example, or antagonists of the invention) include leukemia, lymphoma, melanoma, and prostate, breast, assays disclosed in Berger et al., Gene 66:1- lung, colon, pancreatic, esophageal, stomach, brain, 10 (1998); Cullen and Malm, Methods in liver and urinary cancer. Other preferred indications Enzymol 216:362-368 (1992); Henthorn et include benign dysproliferative disorders and pre- al., Proc Natl Acad Sci USA 85:6342-6346 neoplastic conditions, such as, for example, hyperplasia, (1988); Georas et al., Blood 92(12):4529- metaplasia, and/or dysplasia. Preferred 4538 (1998); Moffatt et al., Transplantation indications include anemia, pancytopenia, leukopenia, 69(7):1521-1523 (2000); Curiel et al., Eur J thrombocytopenia, Hodgkin's disease, acute Immunol 27(8):1982-1987 (1997); and lymphocytic anemia (ALL), plasmacytomas, multiple Masuda et al., J Biol Chem 275(38):29331- myeloma, Burkitt's lymphoma, arthritis, AIDS, 29337 (2000), the contents of each of which granulomatous disease, inflammatory bowel disease, are herein incorporated by reference in its sepsis, neutropenia, neutrophilia, psoriasis, suppression entirety. T cells that may be used according of immune reactions to transplanted organs and tissues, to these assays are publicly available (e.g., hemophilia, hypercoagulation, diabetes mellitus, through the ATCC). Exemplary rat natural endocarditis, meningitis, and Lyme Disease. killer cells that may be used, according to Additional preferred indications include infection (e.g., these assays are publicly available (e.g., an infectious disease as described below under through the ATCC). “Infectious Disease”). 14 HDHEB60 79 Activation of Assays for the activation of transcription Preferred indications include neoplastic diseases transcription through the AP1 response element are well- (e.g., as described below under “Hyperproliferative through AP1 known in the art and may be used or Disorders”), blood disorders (e.g., as described below response routinely modified to assess the ability of under “Immune Activity,” “Cardiovascular Disorders,” element in polypeptides of the invention (including and/or “Blood-Related Disorders”), and infection (e.g., immune cells antibodies and agonists or antagonists of the an infectious disease as described below under (such as T- invention) to modulategrowth and other cell “Infectious Disease”). Highly preferred indications cells). functions. Exemplary assays for include autoimmune diseases (e.g., rheumatoid arthritis, transcription through the AP1 response systemic lupus erythematosis, multiple sclerosis and/or element that may be used or routinely as described below) and immunodeficiencies (e.g., as modified to test AP1-response element described below). Additional highly preferred activity of polypeptides of the invention indications include inflammation and inflammatory (including antibodies and agonists or disorders. Highly preferred indications also include antagonists of the invention) include assays neoplastic diseases (e.g., leukemia, lymphoma, and/or as disclosed in Berger et al., Gene 66:1-10 described below under “Hyperproliferative Disorders”). (1988); Cullen and Malm, Methods in Highly preferred indications include neoplasms and Enzymol 216:362-368 (1992); Henthorn et cancers, such as, leukemia, lymphoma, prostate, breast, al., Proc Natl Acad Sci USA 85:6342-6346 lung, colon, pancreatic, esophageal, stomach, brain, (1988); Rellahan et al., J Biol Chem liver, and urinary cancer. Other preferred indications 272(49):30806-30811 (1997); Chang et al., include benign dysproliferative disorders and pre- Mol Cell Biol 18(9):4986-4993 (1998); and neoplastic conditions, such as, for example, hyperplasia, Fraser et al., Eur J Immunol 29(3):838-844 metaplasia, and/or dysplasia. Preferred indications (1999), the contents of each of which are include arthritis, asthma, AIDS, allergy, anemia, herein incorporated by reference in its pancytopenia, leukopenia, thrombocytopenia, Hodgkin's entirety. Human T cells that may be used disease, acute lymphocytic anemia (ALL), according to these assays are publicly plasmacytomas, multiple myeloma, Burkitt's available (e.g., through the ATCC). lymphoma, granulomatous disease, inflammatory bowel Exemplary human T cells that may be used disease, sepsis, psoriasis, suppression of immune according to these assays include the SUPT reactions to transplanted organs and tissues, cell line, which is an IL-2 and IL-4 endocarditis, meningitis, and Lyme Disease. responsive suspension-culture cell line. 14 HDHEB60 79 Activation of Assays for the activation of transcription Highly preferred indications include neoplastic diseases transcription through the Gamma Interferon Activation (e.g., leukemia, lymphoma, and/or as described below through GAS Site (GAS) response element are well-known under “Hyperproliferative Disorders”). Highly preferred response in the art and may be used or routinely indications include neoplasms and cancers, such as, for element in modified to assess the ability of polypeptides example, leukemia, lymphoma (e.g., T cell lymphoma, immune cells of the invention (including antibodies and Burkitt's lymphoma, non-Hodgkins lymphoma, (such as T- agonists or antagonists of the invention) to Hodgkin's disease), melanoma, and prostate, breast, cells). regulate STAT transcription factors and lung, colon, pancreatic, esophageal, stomach, brain, modulate gene expression involved in a wide liver and urinary cancer. Other preferred indications variety of cell functions. Exemplary assays include benign dysproliferative disorders and pre- for transcription through the GAS response neoplastic conditions, such as, for example, hyperplasia, element that may be used or routinely metaplasia, and/or dysplasia. Preferred indications modified to test GAS-response element include autoimmune diseases (e.g., rheumatoid arthritis, activity of polypeptides of the invention systemic lupus erythematosis, multiple sclerosis and/or (including antibodies and agonists or as described below), immunodeficiencies (e.g., as antagonists of the invention) include assays described below), boosting a T cell-mediated immune disclosed in Berger et al., Gene 66:1-10 response, and suppressing a T cell-mediated immune (1998); Cullen and Malm, Methods in response. Additional preferred indications include Enzymol 216:362-368 (1992); Henthorn et inflammation and inflammatory disorders. Highly al., Proc Natl Acad Sci USA 85:6342-6346 preferred indications include blood disorders (e.g., as (1988); Matikainen et al., Blood 93(6):1980- described below under “Immune Activity,” “Blood- 1991 (1999); and Henttinen et al., J Immunol Related Disorders,” and/or “Cardiovascular Disorders”), 155(10):4582-4587 (1995), the contents of and infection (e.g., viral infections, tuberculosis, each of which are herein incorporated by infections associated with chronic granulomatosus reference in its entirety. Exemplary human T disease and malignant osteoporosis, and/or an infectious cells, such as the SUPT cell line, that may be disease as described below under “Infectious Disease”). used according to these assays are publicly An additional preferred indication is idiopathic available (e.g., through the ATCC). pulmonary fibrosis. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and asthma and allergy. 14 HDHEB60 79 Activation of Assays for the activation of transcription A highly preferred indication is allergy. transcription through the Signal Transducers and Another highly preferred indication is asthma. through STAT6 Activators of Transcription (STAT6) Additional highly preferred indications include response response element are well-known in the art inflammation and inflammatory disorders. element in and may be used or routinely modified to Preferred indications include blood disorders (e.g., as immune cells assess the ability of polypeptides of the described below under “Immune Activity,” “Blood- (such as T- invention (including antibodies and agonists Related Disorders,” and/or “Cardiovascular Disorders”). cells). or antagonists of the invention) to regulate Preferred indications include autoimmune diseases (e.g., STAT6 transcription factors and modulate rheumatoid arthritis, systemic lupus erythematosis, the expression of multiple genes. Exemplary multiple sclerosis and/or as described below) and assays for transcription through the STAT6 immunodeficiencies (e.g., as described below). response element that may be used or Preferred indications include neoplastic diseases (e.g., routinely modified to test STAT6 response leukemia, lymphoma, melanoma, and/or as described element activity of the polypeptides of the below under “Hyperproliferative Disorders”). Preferred invention (including antibodies and agonists indications include neoplasms and cancers, such as, or antagonists of the invention) include leukemia, lymphoma, melanoma, and prostate, breast, assays disclosed in Berger et al., Gene 66:1- lung, colon, pancreatic, esophageal, stomach, brain, 10 (1998); Cullen and Malm, Methods in liver and urinary cancer. Other preferred indications Enzymol 216:362-368 (1992); Henthorn et include benign dysproliferative disorders and pre- al., Proc Natl Acad Sci USA 85:6342-6346 neoplastic conditions, such as, for example, hyperplasia, (1988); Georas et al., Blood 92(12):4529- metaplasia, and/or dysplasia. Preferred indications 4538 (1998); Moffatt et al., Transplantation include anemia, pancytopenia, leukopenia, 69(7):1521-1523 (2000); Curiel et al., Eur J thrombocytopenia, Hodgkin's disease, acute Immunol 27(8):1982-1987.(1997); and lymphocytic anemia (ALL), plasmacytomas, multiple Masuda et al., J Biol Chem 275(38):29331- myeloma, Burkitt's lymphoma, arthritis, AIDS, 29337 (2000), the contents of each of which granulomatous disease, inflammatory bowel disease, are herein incorporated by reference in its sepsis, neutropenia, neutrophilia, psoriasis, suppression entirety. T cells that may be used according of immune reactions to transplanted organs and tissues, to these assays are publicly available (e.g., hemophilia, hypercoagulation, diabetes mellitus, through the ATCC). Exemplary T cells that endocarditis, meningitis, and Lyme Disease. may be used according to these assays An additional preferred indication is infection (e.g., an include the SUPT cell line, which is a infectious disease as described below under “Infectious suspension culture of IL-2 and IL-4 Disease”). responsive T cells. 14 HDHEB60 79 Activation of Assays for the activation of transcription Highly preferred indications include inflammation transcription through the NFKB response element are and inflammatory disorders. Highly preferred through NFKB well-known in the art and may be used or indications include blood disorders (e.g., as described response routinely modified to assess the ability of below under “Immune Activity,” “Blood-Related element in polypeptides of the invention (including Disorders,” and/or “Cardiovascular Disorders”). Highly immune cells antibodies and agonists or antagonists of the preferred indications include autoimmune diseases (e.g., (such as T- invention) to regulate NFKB transcription rheumatoid arthritis, systemic lupus erythematosis, cells). factors and modulate expression of multiple sclerosis and/or as described below), and immunomodulatory genes. Exemplary immunodeficiencies (e.g., as described below). An assays for transcription through the NFKB additional highly preferred indication is infection (e.g., response element that may be used or AIDS, and/or an infectious disease as described below rountinely modified to test NFKB-response under “Infectious Disease”). Highly preferred element activity of polypeptides of the indications include neoplastic diseases (e.g., melanoma, invention (including antibodies and agonists leukemia, lymphoma, and/or as described below under or antagonists of the invention) include “Hyperproliferative Disorders”). Highly preferred assays disclosed in Berger et al., Gene 66:1- indications include neoplasms and cancers, such 10 (1998); Cullen and Malm, Methods in as, melanoma, renal cell carcinoma, leukemia, Enzymol 216:362-368 (1992); Henthorn et lymphoma, and prostate, breast, lung, colon, pancreatic, al., Proc Natl Acad Sci USA 85:6342-6346 esophageal, stomach, brain, liver and urinary cancer. (1988); Black et al., Virus Gnes 15(2):105- Other preferred indications include benign 117 (1997); and Fraser et al., 29(3):838-844 dysproliferative disorders and pre-neoplastic conditions, (1999), the contents of each of which are such as, for example, hyperplasia, metaplasia, and/or herein incorporated by reference in its dysplasia. Preferred indications also include anemia, entirety. T cells that may be used according pancytopenia, leukopenia, thrombocytopenia, Hodgkin's to these assays are publicly available (e.g., disease, acute lymphocytic anemia (ALL), through the ATCC). Exemplary human T plasmacytomas, multiple myeloma, Burkitt's cells that may be used according to these lymphoma, arthritis, AIDS, granulomatous disease, assays include the SUPT cell line, which is a inflammatory bowel disease, sepsis, neutropenia, suspension culture of IL-2 and IL-4 neutrophilia, psoriasis, hemophilia, hypercoagulation, responsive T cells. diabetes mellitus, endocarditis, meningitis, Lyme Disease, suppression of immune reactions to transplanted organs, asthma and allergy. 14 HDHEB60 79 Activation of Assays for the activation of transcription Highly preferred indications include blood disorders transcription through the Nuclear Factor of Activated T (e.g., as described below under “Immune Activity,” through NFAT cells (NFAT) response element are well- “Blood-Related Disorders,” and/or “Cardiovascular response known in the art and may be used or Disorders”). Highly preferred indications include element in routinely modified to assess the ability of autoimmune diseases (e.g., rheumatoid arthritis, immune cells polypeptides of the invention (including systemic lupus erythematosis, multiple sclerosis and/or (such as natural antibodies and agonists or antagonists of the as described below), immunodeficiencies (e.g., as killer cells). invention) to regulate NFAT transcription described below), boosting a T cell-mediated immune factors and modulate expression of genes response, and suppressing a T cell-mediated immune involved in immunomodulatory functions. response. Additional highly preferred indications Exemplary assays for transcription through include inflammation and inflammatory disorders. An the NFAT response element that may be additional highly preferred indication is infection (e.g., used or routinely modified to test NFAT- an infectious disease as described below under response element activity of polypeptides of “Infectious Disease”). Preferred indications include the invention (including antibodies and neoplastic diseases (e.g., leukemia, lymphoma, and/or as agonists or antagonists of the invention) described below under “Hyperproliferative Disorders”). include assays disclosed in Berger et al., Preferred indications include neoplasms and cancers, Gene 66:1-10 (1998); Cullen and Malm, such as, for example, leukemia, lymphoma, and Methods in Enzymol 216:362-368 (1992); prostate, breast, lung, colon, pancreatic, esophageal, Henthorn et al., Proc Nad Acad Sci USA stomach, brain, liver and urinary cancer. Other 85:6342-6346 (1988); Aramburu et al., J Exp preferred indications include benign dysproliferative Med 182(3):801-810 (1995); De Boer et al., disorders and pre-neoplastic conditions, such as, for Int J Biochem Cell Biol 31(10):1221-1236 example, hyperplasia, metaplasia, and/or dysplasia. (1999); Fraser et al., Eur J Immunol Preferred indications also include anemia, pancytopenia, 29(3):838-844 (1999); and Yeseen et al., J leukopenia, thrombocytopenia, Hodgkin's disease, acute Biol Chem 268(19):14285-14293 (1993), the lymphocytic anemia (ALL), plasmacytomas, multiple contents of each of which are herein myeloma, Burkitt's lymphoma, arthritis, AIDS, incorporated by reference in its entirety. NK granulomatous disease, inflammatory bowel disease, cells that may be used according to these sepsis, neutropenia, neutrophilia, psoriasis, suppression assays are publicly available (e.g., through of immune reactions to transplanted organs and tissues, the ATCC). Exemplary human NK cells that hemophilia, hypercoagulation, diabetes mellitus, may be used according to these assays endocarditis, meningitis, Lyme Disease, asthma and include the NK-YT cell line, which is a allergy. human natural killer cell line with cytolytic and cytotoxic activity. 18 HFXKJ03 83 Activation of Assays for the activation of transcription A preferred embodiment of the invention includes a transcription through the Serum Response Element (SRE) method for inhibiting (e.g., reducing) TNF alpha through serum are well-known in the art and may be used or production. An alternative highly preferred embodiment response routinely modified to assess the ability of of the invention includes a method for stimulating (e.g., element in polypeptides of the invention (including increasing) TNF alpha production. Preferred immune cells antibodies and agonists or antagonists of the indications include blood disorders (e.g., as described (such as natural invention) to regulate serum response below under “Immune Activity,” “Blood-Related killer cells). factors and modulate the expression of genes Disorders,” and/or “Cardiovascular Disorders”), Highly involved in growth and upregulate the preferred indications include autoimmune diseases (e.g., function of growth-related genes in many rheumatoid arthritis, systemic lupus erythematosis, cell types. Exemplary assays for Crohn's disease, multiple sclerosis and/or as described transcription through the SRE that may be below), immunodeficiencies (e.g., as described below), used or routinely modified to test SRE boosting a T cell-mediated immune response, and activity of the polypeptides of the invention suppressing a T cell-mediated immune response. (including antibodies and agonists or Additional highly preferred indications include antagonists of the invention) include assays inflammation and inflammatory disorders, and treating disclosed in Berger et al., Gene 66:1-10 joint damage in patients with rheumatoid arthritis. An (1998); Cullen and Malm, Methods in additional highly preferred indication is sepsis. Enzymol 216:362-368 (1992): Henthorn et Highly preferred indications include neoplastic diseases al., Proc Natl Acad Sci USA 85:6342-6346 (e.g., leukemia, lymphoma, and/or as described below (1988); Benson et al., J Immunol under “Hyperproliferative Disorders”). Additionally, 153(9):3862-3873 (1994); and Black et al., highly preferred indications include neoplasms and Virus Genes 12(2):105-117 (1997), the cancers, such as, for example, leukemia, lymphoma, content of each of which are herein melanoma, glioma (e.g., malignant glioma), solid incorporated by reference in its entirety. T tumors, and prostate, breast, lung, colon, pancreatic, cells that may be used according to these esophageal, stomach, brain, liver and urinary cancer. assays are publicly available (e.g., through Other preferred indications include benign the ATCC). Exemplary T cells that may be dysproliferative disorders and pre-neoplastic conditions, used according to these assays include the such as, for example, hyperplasia, metaplasia, and/or NK-YT cell line, which is a human natural dysplasia. Preferred indications include anemia, killer cell line with cytolytic and cytotoxic pancytopenia, leukopenia, thrombocytopenia, Hodgkin's activity. disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under “Infectious Disease”). 36 HOEBK34 101 Activation of Assays for the activation of transcription Preferred indications include blood disorders (e.g., as transcription through the cAMP response element are described below under “Immune Activity,” “Blood- through cAMP well-known in the art and may be used or Related Disorders,” and/or “Cardiovascular Disorders”), response routinely modified to assess the ability of and infection (e.g., an infectious disease as described element in polypeptides of the invention (including below under “Infectious Disease”). Preferred immune cells antibodies and agonists or antagonists of the indications include autoimmune diseases (e.g., (such as T- invention) to increase cAMP and regulate rheumatoid arthritis, systemic lupus erythematosis, cells). CREB transcription factors, and modulate multiple sclerosis and/or as described below), expression of genes involved in a wide immunodeficiencies (e.g., as described below), boosting variety of cell functions. Exemplary assays a T cell-mediated immune response, and suppressing a for transcription through the cAMP response T cell-mediated immune response. Additional preferred element that may be used or routinely indications include inflammation and inflammatory modified to test cAMP-response element disorders. Highly preferred indications include activity of polypeptides of the invention neoplastic diseases (e.g., leukemia, lymphoma, and/or as (including antibodies and agonists or described below under “Hyperproliferative Disorders”). antagonists of the invention) include assays Highly preferred indications include neoplasms and disclosed in Berger et al., Gene 66:1-10 cancers, such as, for example, leukemia, lymphoma (1998); Cullen and Malm, Methods in (e.g., T cell lymphoma, Burkitt's lymphoma, non- Enzymol 216:362-368 (1992); Henthorn et Hodgkins lymphoma, Hodgkin's disease), melanoma, al., Proc Natl Acad Sci USA 85:6342-6346 and prostate, breast, lung, colon, pancreatic, esophageal, (1988); Black et al., Virus Genes 15(2):105- stomach, brain, liver and urinary cancer. Other 117 (1997); and Belkowski et al., J Immunol preferred indications include benign dysproliferative 161(2):659-665 (1998), the contents of each disorders and pre-neoplastic conditions, such as, for of which are herein incorporated by example, hyperplasia, metaplasia, and/or dysplasia. reference in its entirety. T cells that may be Preferred indications include anemia, pancytopenia, used according to these assays are publicly leukopenia, thrombocytopenia, acute lymphocytic available (e.g., through the ATCC). anemia (ALL), plasmacytomas, multiple myeloma, Exemplary mouse T cells that may be used arthritis, AIDS, granulomatous disease, inflammatory according to these assays include the CTLL bowel disease, sepsis, neutropenia, neutrophilia, cell line, which is a suspension culture of IL- psoriasis, suppression of immune reactions to 2 dependent cytotoxic T cells. transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and asthma and allergy. 36 HOEBK34 101 Production of MCP-1 FMAT. Assays for A highly preferred embodiment of the invention MCP-1 immunomodulatory proteins that are includes a method for stimulating (e.g., increasing) produced by a large variety of cells and act to MCP-1 production. An alternative highly preferred induce chemotaxis and activation of embodiment of the invention includes a method for monocytes and T cells are well known in the inhibiting (e.g., reducing) MCP-1 production. A art and may be used or routinely modified to highly preferred indication is infection (e.g., an assess the ability of polypeptides of the infectious disease as described below under “Infectious invention (including antibodies and agonists Disease”). Additional highly preferred indications or antagonists of the invention) to mediate include inflammation and inflammatory disorders. immunomodulation, induce chemotaxis, and Preferred indications include blood disorders (e.g., as modulate immune cell activation. described below under “Immune Activity,” “Blood- Exemplary assays that test for Related Disorders,” and/or “Cardiovascular Disorders”). immunomodulatory proteins evaluate the Highly preferred indications include autoimmune production of cell surface markers, such as diseases (e.g., rheumatoid arthritis, systemic lupus monocyte chemoattractant protein (MCP), erythematosis, multiple sclerosis and/or as described and the activation of monocytes and T cells. below) and immunodeficiencies (e.g., as described Such assays that may be used or routinely below). Preferred indications also include anemia, modified to test immunomodulatory and pancytopenia, leukopenia, thrombocytopenia, Hodgkin's diffferentiation activity of polypeptides of disease, acute lymphocytic anemia (ALL), the invention (including antibodies and plasmacytomas, multiple myeloma, Burkitt's agonists or antagonists of the invention) lymphoma, arthritis, AIDS, granulomatous disease, include assays disclosed in Miraglia et al., J inflammatory bowel disease, sepsis, neutropenia, Biomolecular Screening 4:193-204(1999); neutrophilia, psoriasis, suppression of immune reactions Rowland et al., “Lymphocytes: a practical to transplanted organs and tissues, hemophilia, approach” Chapter 6:138-160 (2000); hypercoagulation, diabetes mellitus, endocarditis, Satthaporn and Eremin, J R Coll Surg Ednb meningitis (bacterial and viral), Lyme Disease, asthma, 45(1):9-19 (2001); and Verhasselt et al., J and allergy Preferred indications also include Immunol 158:2919-2925 (1997), the neoplastic diseases (e.g., leukemia, lymphoma, and/or as contents of each of which are herein described below under “Hyperproliferative Disorders”). incorporated by reference in its entirety. Highly preferred indications include neoplasms and Human dendritic cells that may be used cancers, such as, leukemia, lymphoma, prostate, breast, according to these assays may be isolated lung, colon, pancreatic, esophageal, stomach, brain, using techniques disclosed herein or liver, and urinary cancer. Other preferred indications otherwise known in the art. Human dendritic include benign dysproliferative disorders and pre- cells are antigen presenting cells in neoplastic conditions, such as, for example, hyperplasia, suspension culture, which, when activated by metaplasia, and/or dysplasia. antigen and/or cytokines, initiate and upregulate T cell proliferation and functional activities. 36 HOEBK34 101 Upregulation of CD69 FMAT. CD69 is an activation marker A highly preferred embodiment of the invention CD69 and that is expressed on activated T cells, B cells, includes a method for activating T cells. An alternative activation of T and NK cells. CD69 is not expressed on highly preferred embodiment of the invention includes a cells resting T cells, B cells, or NK cells. CD69 method for inhibiting the activation of and/or has been found to be associated with inactivating T cells. A highly preferred embodiment inflammation. Assays for of the invention includes a method for activation B cells. immunomodulatory proteins expressed in T An alternative highly preferred embodiment of the cells, B cells, and leukocytes are well known invention includes a method for inhibiting the activation in the art and may be used or routinely of and/or inactivating B cells. A highly preferred modified to assess the ability of polypeptides embodiment of the invention includes a method for of the invention (including antibodies and activating NK cells. An alternative highly preferred agonists or antagonists of the invention) to embodiment of the invention includes a method for modulate the activation of T cells, and/or inhibiting activation of and/or inactivation NK cells. mediate humoral or cell-mediated immunity. Highly preferred indications include inflammation and Exemplary assays that test for inflammatory disorders (e.g., as described below under immunomodulatory proteins evaluate the “Immune Activity”) Preferred indications include upregulation of cell surface markers, such as blood disorders (e.g., as described below under CD69, and the activation of T cells. Such “Immune Activity,” “Blood-Related Disorders,” and/or assays that may be used or routinely “Cardiovascular Disorders”). Highly preferred modified to test immunomodulatory activity indications include autoimmune diseases (e.g., of polypeptides of the invention (including rheumatoid arthritis, systemic lupus erythematosis, antibodies and agonists or antagonists of the multiple sclerosis and/or as described below), invention) include, for example, the assays immunodeficiencies (e.g., as described below), boosting disclosed in Miraglia et al., J Biomolecular a T cell-mediated immune response and alternatively Screening 4:193-204 (1999); Rowland et al., suppressing a T cell-mediated immune response, and “Lymphocytes: a practical approach” boosting a B cell-mediated immune response and Chapter 6:138-160 (2000); Ferenczi et al., J alternatively suppressing a B cell-mediated immune Autoimmun 14(l):63-78 (200); Werfel et al., response. An additional highly preferred indication Allergy 52(4):465-469 (1997); Taylor- includes infection (e.g., as described below under Fishwick and Siegel, Eur J Immunol “Infectious Disease”). Preferred indications also 25(12):3215-3221 (1995); and Afetra et al., include anemia, pancytopenia, leukopenia, Ann Rheum Dis 52(6):457-460 (1993), the thrombocytopenia, Hodgkin's disease, acute contents of each of which are herein lymphocytic anemia (ALL), plasmacytomas, multiple incorporated by reference in its entirety. myeloma, Burkitt's lymphoma, arthritis, AIDS, Human T cells that may be used according to granulomatous disease, inflammatory bowel disease, these assays may be isolated using sepsis, neutropenia, neutrophilia, psoriasis, suppression techniques disclosed herein or otherwise of immune reactions to transplanted organs and tissues, known in the art. Human T cells are primary hemophilia, hypercoagulation, diabetes mellitus, human lymphocytes that mature in the endocarditis, meningitis, Lyme Disease, inflammation thymus and express a T Cell receptor and and inflammatory disorders, asthma, and allergies. CD3, CD4, or CD8. These cells mediate Preferred indications also include neoplastic diseases humoral or cell-mediated immunity and may (e.g., leukemia, lymphoma, and/or as described below be preactivated to enhance responsiveness to under “Hyperproliferative Disorders”). Preferred immunomodulatory factors. indications include neoplasms, such as, for example, leukemia, lymphoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. 36 HOEBK34 101 Upregulation of CD152 FMAT. CD152 (a.k.a. CTLA-4) A highly preferred embodiment of the invention CD152 and expression is restricted to activated T cells. includes a method for activating T cells. An alternative activation of T CD152 is a negative regulator of T cell highly preferred embodiment of the invention includes a cells proliferation. Reduced CD152 expression method for inhibiting the activation of and/or has been linked to hyperproliferative and inactivating T cells. A highly preferred embodiment autoimmune diseases. Overexpression of of the invention includes a method for inhibiting T cell CD152 may lead to impaired proliferation. An alternative highly preferred immunoresponses. Assays for embodiment of the invention includes a method for immunomodulatory proteins important in the stimulating T cell proliferation. Highly preferred maintenance of T cell homeostasis and indications include blood disorders (e.g., as described expressed almost exclusively on CD4+ and below under “Immune Activity,” “Blood-Related CD8+ T cells are well known in the art and Disorders,” and/or “Cardiovascular Disorders”), Highly may be used or routinely modified to assess preferred indications include autoimmune diseases (e.g., the ability of polypeptides of the invention rheumatoid arthritis, systemic lupus erythematosis, (including antibodies and agonists or multiple sclerosis and/or as described below), antagonists of the invention) to modulate the immunodeficiencies (e.g., as described below), boosting activation of T cells, maintain T cell a T cell-mediated immune response, and suppressing a homeostasis, and/or mediate humoral or cell- T cell-mediated immune response. Highly preferred mediated immunity. Exemplary assays that indications include neoplastic diseases (e.g., leukemia, test for immunomodulatory proteins evaluate lymphoma, and/or as described below under the upregulation of cell surface markers, “Hyperproliferative Disorders”). Additionally, highly such as CD152, and the activation of T cells. preferred indications include neoplasms and cancers, Such assays that may be used or routinely such as, for example, leukemia, lymphoma, melanoma, modified to test immunomodulatory activity and prostate, breast, lung, colon, pancreatic, esophageal, of polypeptides of the invention (including stomach, brain, liver and urinary cancer. Other antibodies and agonists or antagonists of the preferred indications include benign dysproliferative invention) include, for example, the assays disorders and pre-neoplastic conditions, such as, for disclosed in Miraglia et al., J Biomolecular example, hyperplasia, metaplasia, and/or dysplasia. Screening 4:193-204 (1999); Rowland et al., Preferred indications include anemia, pancytopenia, “Lymphocytes: a practical approach” leukopenia, thrombocytopenia, Hodgkin's disease, acute Chapter 6:138-160 (2000); McCoy et al., lymphocytic anemia (ALL), plasmacytomas, multiple Immunol Cell Biol 77(1):1-10 (1999); myeloma, Burkitt's lymphoma, arthritis, AIDS, Oostervegal et al., Curr Opin Immunol granulomatous disease, inflammatory bowel disease, 11(3):294-300 (1999); and Saito T, Curr sepsis, neutropenia, neutrophilia, psoriasis, immune Opin Immunol 10(3):313-321 (1998), the reactions to transplanted organs and tissues, contents of each of which are herein hemophilia, hypercoagulation, diabetes mellitus, incorporated by reference in its entirety. endocarditis, meningitis, Lyme Disease, inflammation Human T cells that may be used according to and inflammatory disorders, and asthma and allergy. these assays may be isolated using An additional preferred indication is infection (e.g., as techniques disclosed herein or otherwise described below under “Infectious Disease”). known in the art. Human T cells are primary human lymphocytes that mature in the thymus and express a T Cell receptor and CD3, CD4, or CD8. These cells mediate humoral or cell-mediated immunity and may be preactivated to enhance responsiveness to immunomodulatory factors. 40 HTEHR24 105 Production of IL-4 FMAT. Assays for immunomodulatory A highly preferred embodiment of the invention IL-4 proteins secreted by TH2 cells that stimulate includes a method for stimulating (e.g., increasing) IL-4 B cells, T cells, macrophages and mast cells production. An alternative highly preferred embodiment and promote polarization of CD4+ cells into of the invention includes a method for inhibiting (e.g., TH2 cells are well known in the art and may reducing) IL-4 production. A highly preferred be used or routinely modified to assess the indication includes asthma. A highly preferred ability of polypeptides of the invention indication includes allergy. A highly preferred (including antibodies and agonists or indication includes rhinitis. Additional highly antagonists of the invention) to mediate preferred indications include inflammation and immunomodulation, stimulate immune cells, inflammatory disorders. Highly preferred modulate immune cell polarization, and/or indications include neoplastic diseases (e.g., leukemia, mediate humoral or cell-mediated immunity. lymphoma, melanoma, and/or as described below under Exemplary assays that test for “Hyperproliferative Disorders”). Preferred indications immunomodulatory proteins evaluate the include neoplasms and cancers, such as, for example, production of cytokines, such as IL-4, and leukemia, lymphoma, melanoma, and prostate, breast, the stimulation of immune cells, such as B lung, colon, pancreatic, esophageal, stomach, brain, cells, T cells, macrophages and mast cells. liver and urinary cancer. Other preferred indications Such assays that may be used or routinely include benign dysproliferative disorders and pre- modified to test immunomodulatory activity neoplastic conditions, such as, for example, hyperplasia, of polypeptides of the invention (including metaplasia, and/or dysplasia. Preferred indications antibodies and agonists or antagonists of the include blood disorders (e.g., as described below under invention) include the assays disclosed in “Immune Activity,” “Blood-Related Disorders,” and/or Miraglia et al., J Biomolecular Screening “Cardiovascular Disorders”). Preferred indications 4:193-204 (1999); Rowland et al., include autoimmune diseases (e.g., rheumatoid arthritis, “Lymphocytes: a practical approach” systemic lupus erythematosis, multiple sclerosis and/or Chapter 6:138-160 (2000); Gonzalez et al., J as described below) and immunodeficiencies (e.g., as Clin Lab Anal 8(5):277-283 (1194); Yssel et described below). Preferred indications include al., Res Immunol 144(8):610-616 (1993); anemia, pancytopenia, leukopenia, thrombocytopenia, Bagley et al., Nat Immunol 1(3):257-261 Hodgkin's disease, acute lymphocytic anemia (ALL), (2000); and van der Graaff et al., plasmacytomas, multiple myeloma, Burkitt's Rheumatology (Oxford) 38(3):214-220 lymphoma, arthritis, AIDS, granulomatous disease, (1999), the contents of each of which are inflammatory bowel disease, sepsis, neutropenia, herein incorporated by reference in its neutrophilia, psoriasis, suppression of immune reactions entirety. Human T cells that may be used to transplanted organs and tissues, hemophilia, according to these assays may be isolated hypercoagulation, diabetes mellitus, endocarditis, using techniques disclosed herein or meningitis, and Lyme Disease. An additonal otherwise known in the art. Human T cells preferred indication is infection (e.g., an infectious are primary human lymphocytes that mature disease as described below under “Infectious Disease”). in the thymus and express a T cell receptor and CD3, CD4, or CD8. These cells mediate humoral or cell-mediated immunity and may be preactivated to enhance responsiveness to immunomodulatory factors. 40 HTEHR24 105 Upregulation of CD152 FMAT. CD152 (a.k.a. CTLA-4) A highly preferred embodiment of the invention CD152 and expression is restricted to activated T cells. includes a method for activating T cells. An alternative activation of T CD152 is a negative regulator of T cell highly preferred embodiment of the invention includes a cells proliferation. Reduced CD152 expression method for inhibiting the activation of and/or has been linked to hyperproliferative and inactivating T cells. A highly preferred embodiment autoimmune diseases. Overexpression of of the invention includes a method for inhibiting T cell CD152 may lead to impaired proliferation. An alternative highly preferred immunoresponses. Assays for embodiment of the invention includes a method for immunomodulatory proteins important in the stimulating T cell proliferation. Highly preferred maintenance of T cell homeostasis and indications include blood disorders (e.g., as described expressed almost exclusively on CD4+ and below under “Immune Activity,” “Blood-Related CD8+ T cells are well known in the art and Disorders,” and/or “Cardiovascular Disorders”), Highly may be used or routinely modified to assess preferred indications include autoimmune diseases (e.g., the ability of polypeptides of the invention rheumatoid arthritis, systemic lupus erythematosis, (including antibodies and agonists or multiple sclerosis and/or as described below), antagonists of the invention) to modulate the immunodeficiencies (e.g., as described below), boosting activation of T cells, maintain T cell a T cell-mediated immune response, and suppressing a homeostasis, and/or mediate humoral or cell- T cell-mediated immune response. Highly preferred mediated immunity. Exemplary assays that indications include neoplastic diseases (e.g., leukemia, test for immunomodulatory proteins evaluate lymphoma, and/or as described below under the upregulation of cell surface markers, “Hyperproliferative Disorders”). Additionally, highly such as CD152, and the activation of T cells. preferred indications include neoplasms and cancers, Such assays that may be used or routinely such as, for example, leukemia, lymphoma, melanoma, modified to test immunomodulatory activity and prostate, breast, lung, colon, pancreatic, esophageal, of polypeptides of the invention (including stomach, brain, liver and urinary cancer. Other antibodies and agonists or antagonists of the preferred indications include benign dysproliferative invention) include, for example, the assays disorders and pre-neoplastic conditions, such as, for disclosed in Miraglia et al., J Biomolecular example, hyperplasia, metaplasia, and/or dysplasia. Screening 4:193-204 (1999); Rowland et al., Preferred indications include anemia, pancytopenia, “Lymphocytes: a practical approach” leukopenia, thrombocytopenia, Hodgkin's disease, acute Chapter 6:138-160 (2000); McCoy et al., lymphocytic anemia (ALL), plasmacytomas, multiple Immunol Cell Biol 77(1):1-10 (1999); myeloma, Burkitt's lymphoma, arthritis, AIDS, Oostervegal et al., Curr Opin Immunol granulomatous disease, inflammatory bowel disease, 11(3):294-300 (1999); and Saito T, Curr sepsis, neutropenia, neutrophilia, psoriasis, immune Opin Immunol 10(3):313-321 (1998), the reactions to transplanted organs and tissues, contents of each of which are herein hemophilia, hypercoagulation, diabetes mellitus, incorporated by reference in its entirety. endocarditis, meningitis, Lyme Disease, inflammation Human T cells that may be used according to and inflammatory disorders, and asthma and allergy. these assays may be isolated using An additional preferred indication is infection (e.g., as techniques disclosed herein or otherwise described below under “Infectious Disease”). known in the art. Human T cells are primary human lymphocytes, that mature in the thymus and express a T Cell receptor and CD3, CD4, or CD8. These cells mediate humoral or cell-mediated immunity and may be preactivated to enhance responsiveness to immunomodulatory factors. 47 HBIAE26 112 Insulin Assays for measuring secretion of insulin are A highly preferred indication is diabetes mellitus. An Secretion well-known in the art and may be used or additional highly preferred indication is a complication routinely modified to assess the ability of associated with diabetes (e.g., diabetic retinopathy, polypeptides of the invention (including diabetic nephropathy, kidney disease (e.g., renal failure, antibodies and agonists or antagonists of the nephropathy and/or other diseases and disorders as invention) to stimulate insulin secretion. For described in the “Renal Disorders” section below), example, insulin secretion is measured by diabetic neuropathy, nerve disease and nerve damage FMAT using anti-rat insulin antibodies. (e.g., due to diabetic neuropathy), blood vessel Insulin secretion from pancreatic beta cells is blockage, heart disease, stroke, impotence (e.g., due to upregulated by glucose and also by certain diabetic neuropathy or blood vessel blockage), seizures, proteins/peptides, and disregulation is a key mental confusion, drowsiness, nonketotic component in diabetes. Exemplary assays hyperglycemic-hyperosmolar coma, cardiovascular that may be used or routinely modified to test disease (e.g., heart disease, atherosclerosis, for stimulation of insulin secretion (from microvascular disease, hypertension, stroke, and other pancreatic cells) by polypeptides of the diseases and disorders as described in the invention (including antibodies and agonists “Cardiovascular Disorders” section below), or antagonists of the invention) include dyslipidemia, endocrine disorders (as described in the assays disclosed in: Shimizu, H., et al., “Endocrine Disorders” section below), neuropathy, Endocr J, 47(3):261-9 (2000); Salapatek, vision impairment (e.g., diabetic retinopathy and A. M., et al., Mol Endocrinol, 13(8):1305-17 blindness), ulcers and impaired wound healing, and (1999); Filipsson, K., et al., Ann N Y Acad infection (e.g., infectious diseases and disorders as Sci, 865:441-4 (1998); Olson, L. K., et al., J described in the “Infectious Diseases” section below, Biol Chem, 271(28):16544-52 (1996); and, especially of the urinary tract and skin). An Miraglia S et. al., Journal of Biomolecular additional highly preferred indication is obesity and/or Screening, 4:193-204 (1999), the contents of complications associated with obesity. Additional each of which is herein incorporated by highly preferred indications include weight loss or reference in its entirety. Pancreatic cells that alternatively, weight gain. Additional highly preferred may be used according to these assays are indications are complications associated with insulin publicly available (e.g., through the ATCC) resistance. and/or may be routinely generated. Exemplary pancreatic cells that may be used according to these assays include HITT15 Cells. HITT15 are an adherent epithelial cell line established from Syrian hamster islet cells transformed with SV40. These cells express glucagon, somatostatin, and glucocorticoid receptors. The cells secrete insulin, which is stimulated by glucose and glucagon and suppressed by somatostatin or glucocorticoids. ATTC# CRL-1777 Refs: Lord and Ashcroft. Biochem. J. 219:547- 551; Santerre et al. Proc. Natl. Acad. Sci. USA 78:4339-4343, 1981.

[0498] TABLE 2 SEQ ID Score/ cDNA Contig NO: Analysis PFam/ PFam/NR Percent NT NT Clone ID ID: X Method NR Description Accession Number Identity From To HSAAO30 498287 13 WUblastx.64 (Q9BY08) EMOPAMIL Q9BY08 100% 755 270 BINDING RELATED PROTEIN. HTEFU41 499329 16 WUblastx.64 (Q9H6TI) CDNA: Q9H6T1  85% 788 405 FLJ21916 FIS. CLONE  97% 403  86 HEP03994. HBSAJ16 509943 20 WUblastx.64 (Q9H8D8) CDNA Q9H8D8  80%  13 258 FLJ13726 FIS, CLONE PLACE3000059, HIGHLY SIMILAR TO MUS HDHEB60 499233 24 WUblastx.64 (Q9Y5Y5) PEROXISOMAL Q9Y5Y5  67% 277 1284  BIOGENESIS FACTOR 16. HFXKJ03 505207 28 WUblastx.64 (O62658) LINE-1 O62658  34% 492 292 ELEMENT ORF2.  37% 908 525 HJACG02 509948 30 WUblastx.64 (Q9HD89) CYSTEINE- Q9HD89 100%  92 370 RICH SECRETED PROTEIN (C/EBP- EPSILON REGULATED MYEL HKGAJ54 498303 31 HIMMER PFAM: Immunoglobulin PF00047 52.8    481 657 2.1.1 domain WUblastx.64 (BAB55411) CDNA BAB55411  96% 846 929 FLU14946 fis, clone  90% 109 849 PLACE2000034, w HLWBZ21 499231 36 WUblastx.64 (Q9HBJ0) PLAC1. Q9HBJ0  79% 283 909 HNFHD08 509945 40 WUblastx.64 (Q9C002) NORMAL Q9C002 100%  13 261 MUCOSA OF ESOPHAGUS SPECIFIC 1. HOEBK34 768325 46 HMMER PFAM: von Willebrand PF00093 54.1    455 619 2.1.1 factor type C domain WUblastx.64 (O94769) O94769  90% 149 643 EXTRACELLULAR MATRIX PROTEIN. HOEBK34 509951 63 WUblastx.64 (O94769) O94769  96% 593 336 EXTRACELLULAR  93% 345 100 MATRIX PROTEIN. HRGDC48 513040 48 WUblastx.64 uroplakin II—human pir|T09609|T09609 100% 163 216 100%  12 161 HTEHR24 835894 50 WUblastx.64 (Q9HBV2) SPERM Q9HBV2  76% 992 117 MEMBRANE ANTIGEN SMARC32. HTEHR24 513039 64 WUblastx.64 (Q9HBV2) SPERM Q9HBV2  62%  41 529 MEMBRANE ANTIGEN  76% 692 922 SMARC32.  96% 514 693 HATAA15 514240 55 WUblastx.64 (O15539) REGULATOR RGS5_HUMAN  90% 265 807 OF G-PROTEIN SIGNALING 5 (RGS5). HATCK44 514716 56 WUblastx.64 (Q9UDR4) Q9UDR4  90% 511 540 WUGSC:H_DJ1147A01.1  91%  83 508 PROTEIN (FRAGMENT). HBJAE26 514418 57 WUblastx.64 (AAK55521) PRO0764. AAK55521  83% 1009  974  65% 983 744

[0499] Table 2 further characterizes certain encoded polypeptides of the invention, by providing the results of comparisons to protein and protein family databases. The first column provides a unique clone identifier, “Clone ID NO:”, corresponding to a cDNA clone disclosed in Table 1A and/or Table 1B. The second column provides the unique contig identifier, “Contig ID:” which allows correlation with the information in Table 1B. The third column provides the sequence identifier, “SEQ ID NO:”, for the contig polynucleotide sequences. The fourth column provides the analysis method by which the homology/identity disclosed in the Table was determined. The fifth column provides a description of the PFAM/NR hit identified by each analysis. Column six provides the accession number of the PFAM/NR hit disclosed in the fifth column. Column seven, score/percent identity, provides a quality score or the percent identity, of the hit disclosed in column five. Comparisons were made between polypeptides encoded by polynucleotides of the invention and a non-redundant protein database (herein referred to as “NR”), or a database of protein families (herein referred to as “PFAM”), as described below.

[0500] The NR database, which comprises the NBRF PIR database, the NCBI GenPept database, and the SIB SwissProt and TrEMBL databases, was made non-redundant using the computer program nrdb2 (Warren Gish, Washington University in Saint Louis). Each of the polynucleotides shown in Table 1B, column 3 (e.g., SEQ ID NO:X or the ‘Query’ sequence) was used to search against the NR database. The computer program BLASTX was used to compare a 6-frame translation of the Query sequence to the NR database (for information about the BLASTX algorithm please see Altshul et al., J. Mol. Biol. 215:403-410 (1990), and Gish and States, Nat. Genet. 3:266-272 (1993). A description of the sequence that is most similar to the Query sequence (the highest scoring ‘Subject’) is shown in column five of Table 2 and the database accession number for that sequence is provided in column six. The highest scoring ‘Subject’ is reported in Table 2 if (a) the estimated probability that the match occurred by chance alone is less than 1.0e-07, and (b) the match was not to a known repetitive element. BLASTX returns alignments of short polypeptide segments of the Query and Subject sequences which share a high degree of similarity; these segments are known as High-Scoring Segment Pairs or HSPs. Table 2 reports the degree of similarity between the Query and the Subject for each HSP as a percent identity in Column 7. The percent identity is determined by dividing the number of exact matches between the two aligned sequences in the HSP, dividing by the number of Query amino acids in the HSP and multiplying by 100. The polynucleotides of SEQ ID NO:X which encode the polypeptide sequence that generates an HSP are delineated by columns 8 and 9 of Table 2.

[0501] The PFAM database, PFAM version 2.1, (Sonnhammer, Nucl. Acids Res., 26:320-322, 1998))consists of a series of multiple sequence alignments; one alignment for each protein family. Each multiple sequence alignment is converted into a probability model called a Hidden Markov Model, or HMM, that represents the position-specific variation among the sequences that make up the multiple sequence alignment (see, e.g., Durbin, et al., Biological sequence analysis: probabilistic models of proteins and nucleic acids, Cambridge University Press, 1998 for the theory of HMMs). The program HMMER version 1.8 (Sean Eddy, Washington University in Saint Louis) was used to compare the predicted protein sequence for each Query sequence (SEQ ID NO:Y in Table 1B) to each of the HMMs derived from PFAM version 2.1. A HMM derived from PFAM version 2.1 was said to be a significant match to a polypeptide of the invention if the score returned by HMMER 1.8 was greater than 0.8 times the HMMER 1.8 score obtained with the most distantly related known member of that protein family. The description of the PFAM family which shares a significant match with a polypeptide of the invention is listed in column 5 of Table 2, and the database accession number of the PFAM hit is provided in column 6. Column 7 provides the score returned by HMMER version 1.8 for the alignment. Columns 8 and 9 delineate the polynucleotides of SEQ ID NO:X which encode the polypeptide sequence which show a significant match to a PFAM protein family.

[0502] As mentioned, columns 8 and 9 in Table 2, “NT From” and “NT To”, delineate the polynucleotides of “SEQ ID NO:X” that encode a polypeptide having a significant match to the PFAM/NR database as disclosed in the fifth column. In one embodiment, the invention provides a protein comprising, or alternatively consisting of, a polypeptide encoded by the polynucleotides of SEQ ID NO:X delineated in columns 8 and 9 of Table 2. Also provided are polynucleotides encoding such proteins, and the complementary strand thereto.

[0503] The nucleotide sequence SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, the nucleotide sequences of SEQ ID NO:X are useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in ATCC Deposit No:Z. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling immediate applications in chromosome mapping, linkage analysis, tissue identification and/or typing, and a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to these polypeptides, or fragments thereof, and/or to the polypeptides encoded by the cDNA clones identified in, for example, Table 1A and/or 1B.

[0504] Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

[0505] Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and a predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing cDNA ATCC Deposit No:Z (e.g., as set forth in columns 2 and 3 of Table 1A and/or as set forth, for example, in Table 1B, 6, and 7). The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. Further, techniques known in the art can be used to verify the nucleotide sequences of SEQ ID NO:X.

[0506] The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

[0507] RACE Protocol for Recovery of Full-Length Genes

[0508] Partial cDNA clones can be made full-length by utilizing the rapid amplification of cDNA ends (RACE) procedure described in Frohman, M. A., et al., Proc. Natl. Acad. Sci. USA, 85:8998-9002 (1988). A cDNA clone missing either the 5′ or 3′ end can be reconstructed to include the absent base pairs extending to the translational start or stop codon, respectively. In some cases, cDNAs are missing the start codon of translation, therefor. The following briefly describes a modification of this original 5′ RACE procedure. Poly A+ or total RNA is reverse transcribed with Superscript II (Gibco/BRL) and an antisense or complementary primer specific to the cDNA sequence. The primer is removed from the reaction with a Microcon Concentrator (Amicon). The first-strand cDNA is then tailed with dATP and terminal deoxynucleotide transferase (Gibco/BRL). Thus, an anchor sequence is produced which is needed for PCR amplification. The second strand is synthesized from the dA-tail in PCR buffer, Taq DNA polymerase (Perkin-Elmer Cetus), an oligo-dT primer containing three adjacent restriction sites (XhoI, SalI and ClaI) at the 5′ end and a primer containing just these restriction sites. This double-stranded cDNA is PCR amplified for 40 cycles with the same primers as well as a nested cDNA-specific antisense primer. The PCR products are size-separated on an ethidium bromide-agarose gel and the region of gel containing cDNA products the predicted size of missing protein-coding DNA is removed. cDNA is purified from the agarose with the Magic PCR Prep kit (Promega), restriction digested with XhoI or SalI, and ligated to a plasmid such as pBluescript SKII (Stratagene) at XhoI and EcoRV sites. This DNA is transformed into bacteria and the plasmid clones sequenced to identify the correct protein-coding inserts. Correct 5′ ends are confirmed by comparing this sequence with the putatively identified homologue and overlap with the partial cDNA clone. Similar methods known in the art and/or commercial kits are used to amplify and recover 3′ ends.

[0509] Several quality-controlled kits are commercially available for purchase. Similar reagents and methods to those above are supplied in kit form from Gibco/BRL for both 5′ and 3′ RACE for recovery of full length genes. A second kit is available from Clontech which is a modification of a related technique, SLIC (single-stranded ligation to single-stranded cDNA), developed by Dumas et al., Nucleic Acids Res., 19:5227-32 (1991). The major differences in procedure are that the RNA is alkaline hydrolyzed after reverse transcription and RNA ligase is used to join a restriction site-containing anchor primer to the first-strand cDNA. This obviates the necessity for the dA-tailing reaction which results in a polyT stretch that is difficult to sequence past.

[0510] An alternative to generating 5′ or 3′ cDNA from RNA is to use cDNA library double-stranded DNA. An asymmetric PCR-amplified antisense cDNA strand is synthesized with an antisense cDNA-specific primer and a plasmid-anchored primer. These primers are removed and a symmetric PCR reaction is performed with a nested cDNA-specific antisense primer and the plasmid-anchored primer.

[0511] RNA Ligase Protocol for Generating the 5′ or 3′ End Sequences to Obtain Full Length Genes

[0512] Once a gene of interest is identified, several methods are available for the identification of the 5′ or 3′ portions of the gene which may not be present in the original cDNA plasmid. These methods include, but are not limited to, filter probing, clone enrichment using specific probes and protocols similar and identical to 5′ and 3′ RACE. While the full length gene may be present in the library and can be identified by probing, a useful method for generating the 5′ or 3′ end is to use the existing sequence information from the original cDNA to generate the missing information. A method similar to 5′ RACE is available for generating the missing 5′ end of a desired full-length gene. (This method was published by Fromont-Racine et al., Nucleic Acids Res., 21(7):1683-1684 (1993)). Briefly, a specific RNA oligonucleotide is ligated to the 5′ ends of a population of RNA presumably containing full-length gene RNA transcript and a primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest, is used to PCR amplify the 5′ portion of the desired full length gene which may then be sequenced and used to generate the full length gene. This method starts with total RNA isolated from the desired source, poly A RNA may be used but is not a prerequisite for this procedure. The RNA preparation may then be treated with phosphatase if necessary to eliminate 5′ phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase if used is then inactivated and the RNA is treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5′ ends of messenger RNAs. This reaction leaves a 5′ phosphate group at the 5′ end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase. This modified RNA preparation can then be used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction can then be used as a template for PCR amplification of the desired 5′ end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5′ end sequence belongs to the relevant gene.

[0513] The present invention also relates to vectors or plasmids which include such DNA sequences, as well as the use of the DNA sequences. The material deposited with the ATCC (e.g., as described in columns 2 and 3 of Table 1A, and/or as set forth in Table 1B, Table 6, or Table 7) is a mixture of cDNA clones derived from a variety of human tissue and cloned in either a plasmid vector or a phage vector, as described, for example, in Table 1A and Table 7. These deposits are referred to as “the deposits” herein. The tissues from which some of the clones were derived are listed in Table 7, and the vector in which the corresponding cDNA is contained is also indicated in Table 7. The deposited material includes cDNA clones corresponding to SEQ ID NO:X described, for example, in Table 1A and/or 1B (ATCC Deposit No:Z). A clone which is isolatable from the ATCC Deposits by use of a sequence listed as SEQ ID NO:X, may include the entire coding region of a human gene or in other cases such clone may include a substantial portion of the coding region of a human gene. Furthermore, although the sequence listing may in some instances list only a portion of the DNA sequence in a clone included in the ATCC Deposits, it is well within the ability of one skilled in the art to sequence the DNA included in a clone contained in the ATCC Deposits by use of a sequence (or portion thereof) described in, for example Tables 1A and/or 1B or 2, by procedures hereinafter further described, and others apparent to those skilled in the art.

[0514] Also provided in Table 1A and 7 is the name of the vector which contains the cDNA clone. Each vector is routinely used in the art. The following additional information is provided for convenience.

[0515] Vectors Lambda Zap (U.S. Pat. Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Pat. Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Pat. Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, Calif., 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into E. coli strain XL-1 Blue, also available from Stratagene.

[0516] Vectors pSport1, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, Md. 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., Focus 15:59-(1993). Vector lafmid BA (Bento Soares, Columbia University, New York, N.Y.) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, Calif. 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).

[0517] The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or the deposited clone (ATCC Deposit No:Z). The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

[0518] Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X or the complement thereof, polypeptides encoded by genes corresponding to SEQ ID NO:X or the complement thereof, and/or the cDNA contained in ATCC Deposit No:Z, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

[0519] The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

[0520] The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

[0521] The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the polypeptides of the present invention in methods which are well known in the art.

[0522] The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or the cDNA sequence contained in ATCC Deposit No:Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X or a complement thereof, a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z, and/or the polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1C. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z, and/or a polypeptide sequence encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1C are also encompassed by the invention. The present invention further encompasses a polynucleotide comprising, or alternatively consisting of, the complement of the nucleic acid sequence of SEQ ID NO:X, a nucleic acid sequence encoding a polypeptide encoded by the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the cDNA contained in ATCC Deposit No:Z.

[0523] Moreover, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in Table 1C column 6, or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in Table 1C column 6, or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table 1C, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1C, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table 1C, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in Table 1C, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[0524] Further, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1), or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1), or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1C, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1) and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1) and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[0525] Further, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1C which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1C, column 2), or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in column 6 of Table 1C which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1C, column 2), or any combination thereof. In further embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1C, column 2) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1C, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1C, column 2) and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table 1C which correspond to the same contig sequence identifier SEQ ID NO:X (see Table 1C, column 2) and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (See Table 1C, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[0526] Moreover, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in the same row of Table 1C column 6, or any combination thereof. Additional, representative examples of polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in the same row of Table 1C column 6, or any combination thereof. In preferred embodiments, the polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in the same row of Table 1C column 6, wherein sequentially delineated sequences in the table (i.e. corresponding to those exons located closest to each other) are directly contiguous in a 5′ to 3′ orientation. In further embodiments, above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1C, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1C, column 5). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1C, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in the same row of Table 1C, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0527] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1C, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1C, column 2) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0528] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in column 6 of Table 1C which correspond to the same Clone ID (see Table 1C, column 1), and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A, 1B, or 1C) or fragments or variants thereof. In preferred embodiments, the delineated sequence(s) and polynucleotide sequence of SEQ ID NO:X correspond to the same Clone ID. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0529] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the sequences delineated in the same row of column 6 of Table 1C, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A, 1B, or 1C) or fragments or variants thereof. In preferred embodiments, the delineated sequence(s) and polynucleotide sequence of SEQ ID NO:X correspond to the same row of column 6 of Table 1C. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0530] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3′ 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5′ 10 polynucleotides of the sequence of SEQ ID NO:X are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0531] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3′ 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5′ 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X are directly contiguous Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0532] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3′ 10 polynucleotides of the sequence of SEQ ID NO:X and the 5′ 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table 1C are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0533] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3′ 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X and the 5′ 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table 1C are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides, are also encompassed by the invention.

[0534] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3′ 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5′ 10 polynucleotides of another sequence in column 6 are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0535] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3′ 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5′ 10 polynucleotides of another sequence in column 6 corresponding to the same Clone ID (see Table 1C, column 1) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0536] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3′ 10 polynucleotides of one sequence in column 6 corresponding to the same contig sequence identifer SEQ ID NO:X (see Table 1C, column 2) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides. Under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0537] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3′ 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5′ 10 polynucleotides of another sequence in column 6 corresponding to the same row are directly contiguous. In preferred embodiments, the 3′ 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C is directly contiguous with the 5′ 10 polynucleotides of the next sequential exon delineated in Table 1C, column 6. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0538] Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. Accordingly, for each contig sequence (SEQ ID NO:X) listed in the fifth column of Table 1A and/or the fourth column of Table 1B, preferably excluded are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, b is an integer of 15 to the final nucleotide of SEQ ID NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a +14. More specifically, preferably excluded are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a and b are integers as defined in columns 4 and 5, respectively, of Table 3. In specific embodiments, the polynucleotides of the invention do not consist of at least one, two, three, four, five, ten, or more of the specific polynucleotide sequences referenced by the Genbank Accession No. as disclosed in column 6 of Table 3 (including for example, published sequence in connection with a particular BAC clone). In further embodiments, preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone). In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety. TABLE 3 SEQ ID EST Disclaimer cDNA NO: Contig Range Range Clone ID X ID: of a of b Accession #'s HNGJT54 11 498272 1-1096 15- 1110 HOSCI83 12 498916 1-922 15-936 AI755114, BF000565, AI990591, AI939494 AI338485, AI675134, AI435119, AI040192, AW237506, AA969266, AA775866, AI754598, AW968767, AI094145, AI359739, AV715257, AI741685, BF948285, AI858477, AI858488, AI695283, AW020915, AA490605, AV713142, AW298036, AA045440, D60310, AW296352, D60508, AI927277, AA583754, AW074458, D60311, AV756538, AI468974, AI700924, BF245081, C15061, BF701631, AI802542, AI361174, AL513553, AL513631, AI537677, AL513693, AI497733, AL514357, AL514627, AL513779, AI873644, AI636719, AI923768, AI476109, BF032868, AL513907, AL514691, AI598061, AL514457, AL514155, AI475371, BE886728, AI815855, AI270183, AW051088, AW262565, AI365256, AI583065, AI613017, AL514473, AL513977, AI619502, AI863382, AL513597, BE968711, AL513713, AI627909, AI564719, AL514085, BG026746, BE966443, AL513901, AI560099, AI950892, BG179993, BE964614, AI929108, AW075351, AI637584, AI684036, BF725644, AI433157, AI783861, BF812961, BF924882, AI274745, BE613880, AL515019, AI799199, AL513999, BG031815, AW079572, BE879047, AI885974, AL514867, BG108147, AI469532, AI491852, BF812938, AI590227, BF925729, AV703695, AI334445, BG163618, BG120816, AL514097, AL045500, BE966699, AV729649, BF904265, AW235745, BF726198, BG110517, AW302965, BF814357, AW071417, AL514063, BF725463, AA572758, AW026882, BF527014, AL045266, AW104724, AL514793, AI340603, BG058398, AA738104, AI921753, AL121365, AI539153, AI521100, BG109270, AI800433, AV733734, AL514701, BG257535, AV704670, AL135661, BG253626, BE964994, AI445025, AW161579, BG113299, AI917253, AI738854, AI702433, BE964876, AV729890, BE879906, AI269862, AV681630, BG058039, AI475817, BG107576, AW268220, AL514721, BE965621, AV682252, BF792961, BE880674, AI571909, BE047737, AI922901, BF968511, AW999049, AL514025, AW087445, AI648663, BF970768, BF343172, BG164371, BE048071, AW169671, BF342070, AI909697, AI572676, AL110306, AI620003, BE964495, AI590021, AW778801, BE963035, AL119863, AL036361, AI521012, BE620444, BE781369, BE725868, AL036187, AL513979, BE048081, AL514325, AI886206, AL513991, AW827289, BE785868, BF814525, AA427700, BF970658, AL119791, AL514093, BF793324, AI480118, BE965355, BG108324, AI241763, AL513817, AA640779, BE966547, BE621256, BF752252, BG168185, AW238730, BF968205, BF904244, BG260037, AA613907, AI334884, AI590120, BF038131, BE966577, AI478123, AL514983, AL514087, BG029829, BE964636, AW023590, BE909398, BE965724, BE048319, BF816811, BF885000, AA470491, BE965307, AI800453, BE965432, AI608936, AV707062, AI340519, AB011141, AC006427, AL359618, AF130105, AK026452, I48978, AF090900, I89947, I48979, AL110225, A08916, AL122050, AK025092, AF177401, AF116631, AF079765, AL133557, AK024538, AK026784, AF113694, AL049452, AF113690, AK026855, S78214, AL117460, AF130092, AF125948, U42766, AL133080, AL137459, AL050149, AL133016, A08913, AF118070, I89931, AL359615, AL157431, AF116691, Y11587, AK025484, AL137538, AX019230, AL133640, AL050393, AK027113, AF097996, AL110221, AF130077, AK026647, AF090934, AJ238278, AL390167, AF090901, AK025084, AE104032, AL050277, AL162006, AX019229, AL389978, Y11254, AF119909, AK026927, AL359620, AL122110, AR087170, AK026583, AF017152, AL080137, U72620, AL133093, AB048953, AL049314, E02349, AB052191, AK026045, AL442082, AF113013, AK025254, AL110196, AL050116, AF113676, AL050146, AL122093, AL359941, AL162083, AL117457, X63574, AF078844, A08910, AF130066, AF119878, AF087943, I33392, AK027116, AK025958, AF090903, AR079032, AF130082, AX006092, AF146568, AL080060, AB034701, E03348, AF113689, AB041801, AF130075, A08909, AK026959, AF113691, AR059958, AF242189, AF116649, AF125949, AF116644, AL122123, AK026592, AK026597, AF260436, AF219137, AF116646, AF116639, AB049758, L31396, AL442072, AF090896, L31397, Y16645, AL050024, AK026480, AJ000937, X70685, AL050108, AK000391, AL133560, AL117394, AF130110, AL133606, AL122121, AB051158, A93016, AF116688, AK026504, AK027096, AF118064, A65341, AK000137, AL049464, AL117585, AF207829, AL096744, S68736, AK000618, AR011880, I09360, AF111851, AL359596, AL353957, AB048974, AL389939, AK026865, AF130104, AF314091, AF091084, AF113019, AF113677, AL133113, AF090943, AK026086, AL049938, AF119875, AK026642, AB048954, X84990, AF130059, AF138861, AL080124, AL050138, AL133565, AB019565, AL049466, AK000083, AF017437, AL137557, AL137550, AK000445, AK026741, AJ242859, AL049430, AK026532, AF111847, AL117435, S61953, AF118094, AK026353, U00763, AF166267, AK025339, AK026744, AL359601, AL137527, X65873, X82434, AK027213, AK025967, AL049283, AK026542, AK026947, AF116682, E07108, AK026627, Y09972, AF158248, AK000652, AX046603, AB047615, AB050510, AF116602, AL080127, AB052200, AK025772, AF106862, AL389982, AK024588, AB048964, AB047904, AF218014, AL133075, AL162062, AK026534, A08912, AF119899, AF116610, AF113699, AF119865, AK025414, AK026630, AL122098, AF130087, AF175983, AF130099, I00734, AK000323, AL353940, AL133568, E07361, I03321, AF119871, E15569, AK025209, and AF119860. HSAAO30 13 498287 1-907 15-921 BF968868, AV699649, BG179104, BG254504, BE791990, BE616383, AI858023, AW193675, BE730920, AI631156, BF732801, AW001751, AW628966, BE326663, BE616600, AW970214, AW194760, AI422020, AA777740, AA534641, AW183719, BF062914, BE042540, AW673757, BE551130, BF110105, BE880900, AI292009, AI378513, AW970301, AA576295, AI215655, AI656651, AI675093, AA773847, BF588553, AI078480, AI092626, AI079288, AI309961, AI824045, W84713, AI312792, AW022431, AI038946, H49343, AI080103, AW316565, AI347879, AI301692, W78859, AI421882, AW242588, AA340141, AW072623, AA677833, BE219143, AW136582, AI758990, AI917838, AI915860, N36924, AI206865, AW970216, AA825183, BF241336, AI470581, T82186, AW449453, AW956162, F35838, BF509376, AW956156, H49344, AI985011, AA373288, AA218797, W85854, F27088, AI753314, AW273554, AW956157, AW673120, AI564542, N53927, AI720282, BF844532, BE535921, AI263156, and AL135901. HSQBL21 14 794195 1-2527 15- AL530933, BE744244, 2541 BF529474, AU133400, AU120669, AU142406, AU117001, AU131949, BE889798, BE783480, BE886518, AW160833, BG177156, BE312635, AA521306, BG258600, AI346509, BE543207, AW014616, BE395449, AU154742, AU160803, BE867184, AW662413, AW043807, AW000956, BF434533, AU159740, BE350868, AU153954, AL530932, AA031263, BF897515, BF223978, AU153595, AU146675, AU152826, AA524349, AU143944, AI340333, AW128969, AI826348, AW305306, BF062439, AI453543, AI564106, AW304346, BE314550, H71784, BF867933, AI161344, AW000974, AI262022, BE878383, BE504256, BE326650, BE504858, AI039240, AA635538, AW162372, AI309252, AI962737, N76604, AI815896, W69677, AI935385, AW271271, AI948839, AA488102, BG177469, AA010408, AW513419, AI289056, BF055132, AI638198, BE219405, AW008633, BE676811, AA345935, AA532714, BE886078, AI815618, AA632276, AA040180, N54492, BE307394, AA570140, AW025830, W69676, R98609, AW510423, AW073235, AI694628, BF307330, H71783, AI886412, AA582538, BF798373, AW578114, AW014409, R98610, AU134927, N69270, AI917180, BF886580, AI383709, AW078973, BF888376, R96473, AA011236, BE139647, BF893781, R96472, W23106, R15330, AW044241, H37813, BF897459, AA377991, F16253, H75768, BE090852, R78149, BF091918, AA323463, AA770070, H37864, AI222936, BF737167, T19092, Z25234, N94090, H75904, BE884386, AA322306, AA031337, AI367688, W07590, AI823334, AV764371, AA040181, H67441, BF990425, R77788, BE967456, AI630685, BF798370, AA219406, BF091159, BF091899, AA055851, Z19066, AA693496, AA609001, H67387, R45504, AI872776, AI472899, D58479, BG004347, BF091195, BF366350, AA379762, C01873, AA367973, AW132078, AI436065, BF934891, N67327, R24771, BE765933, AI670001, AW997941, F21760, AV745723, AW374683, T19904, AI873765, AV745724, T17187, BE410713, AA248727, AW952409, AV658332, AV705632, AW960326, AW953515, AV703593, AV703159, AW949795, AV703222, AV648263, AV652027, AV708723, AV705433, AV729263, AK001138, AK021440, A91160, Y11505, AF217994, U38894, and N67887. HSSMW31 15 498801 1-1032 15- AW964174, AA570564, 1046 AI076833, AW265063, AW006805, AA480656, AW004789, AA378739, AW844618, AV702985, AV707405, AV727550, and AV709358. HTEFU41 16 499329 1-968 15-982 AI656232, AA398564, AA393168, AW206062, AI018242, AI701714, AI376517, AW572800, AA402461, BF223906, AI948840, AA937307, AI807115, AI698262, AA293813, AA723655, AI221770, BE877927, T07781, AA884626, AW498604, BE281380, BE280678, BE900252, BE731181, BE902530, AW732863, and AK025569. HDPSP54 17 744440 1-3077 15- BG256849, BG261011, 3091 BG178729, BG110345, AI923220, BE466885, BF667257, AW271504, AW243442, BE466659, BG171469, AV661528, AW271637, AW516811, N36059, AI804888, BE882420, AI650826, BF815232, AW964507, AI921747, BE936373, BF984751, BG259707, AI392784, AW076096, AI807747, AW103424, AA604757, AA633209, AW778887, AW418987, AW242326, BE622192, BF666519, BF978796, AW014203, AI925261, BF853590, AWI31363, AW514756, N33223, AI819108, AI126250, AV649748, AI953896, AV714556, AI524472, BF697124, BE218100, AW629098, N21567, AI694687, AI700209, AA731730, AA577191, BE219931, N33824, BE567212, AW778908, AW087660, AI990562, BF792681, R52426, AI559108, AA743389, N35579, N25189, N30972, BF667662, AI339587, N24947, AI376459, AA742979, N27426, R23308, AI125720, AA954281, AI801129, AW087669, AI701246, AI245517, T26975, BF572334, BE177998, BE564497, AI636147, AI640713, N41938, H97662, AI243263, BE967025, AI572028, BE543895, H29641, BE762905, BE246305, Z46022, H29640, BG223352, AI270534, AI983198, H99399, BF965116, BF692452, Z42169, AI521060, BF102948, R82562, AV646807, N34709, AV646406, R23233, AA373475, BE005657, AA319637, T34245, BG104469, W20047, AW962829, BF572695, AI369988, AI741908, BE830524, H29549, D78710, Z41637, H29548, AA833897, AI367191, AA659275, AW899997, E01708, BF697465, AI246035, AI219239, BF154447, AI221561, AI273738, AI281168, BE005723, BE170424, AI685342, BE882847, and AB007962. HELFQ07 18 502523 1-782 15-796 AL530401, BE738039, AI921618, BE780450, BE891128, BE148651, AA081104, AI768606, N37039, AI859376, AI798036, BF195000, AI378609, AI399777, BF589457, AW970325, AW970242, BE885895, AI276791, C06350, AI094439, AI300096, AV702283, AI278326, AA676214, AI371217, AI371109, AW013796, W85875, D56503, AI811706, R28552, BE708593, BE172693, Z28585, C17683, BE542063, AI610234, AW022811, BE908835, AA228803, AW297940, BF341570, AL531037, BE897600, C18794, BE708430, C16994, T95651, AA875850, AW970243, H18815, H99784, N24584, AW799846. AW799789, AW799843, AL522249, AW799839, AW799640, AW799698, BF693899, AJ227887, and AF281064. HLHBV54 19 505038 1-808 15-822 AA360013, AI951706, AI082282, AA622294, AA714756, AA737783, AA745179, AI248449, AA729007, H81312, AA694352, RI1224, AA004319, T98271, AA588480, AA714472, BG056843, AA844901, AW998616, AU117887, AA809135, BF221964, AW265584, AA578170, AW873418, AA516513, AW238390, BE084204, BE814191, AW998814, AA548579, AA548593, AA548033, AW275452, AW238686, AA503411, AW998633, AA005189, BE814155, AW998827, BG059515, AW998671, AW881892, BG223369, AW998642, RI1483, AW998802, AW998695, AA483269, AW237870, AA506862, BG152800, AA484488, AW238351, BE044887, AA484414, BF478281, AA524954, AA501701, AA501636, AA501847, AA484558, AA483248, BE814214, AA501706, BE766819, AA558284, AW265502, BG099299, AA715515, AA484434, AA484446, AA501761, AW270364, AA507527, AA507732, AA484456, AA484461, AA501851, AW237862, BG099286, BF942327, AA480578, AA508818, AA484582, AA483254, AA480572, BE350438, AA420637, AA502733, AA525252, AA484425, AA484360, AA484423, AA484507, AA480402, AA501831, AA558392, AA558729, AA484537, AA484344, AA501694, BG222253, AA501827, AW265356, AA469344, AA501708, AA469337, AA501763, AA484594, AA508718, AA484584, AA501837, BE505038, AA501848, AA501674, AA484352, AA484336, BE814217, AA484550, AA484420, AA484430, AA484382, AA484573, AA484460, AW265304, AA503586, AA484566, AW276872, AA533299, AA526452, AW602223, AA484546, BG230498, AA715334, AW270381, AI870255, BG223404, AA508544, AA484459, AW867921, AW960253, AA484442, AA507503, BG152291, AA809111, U13369, M27830, M11167, M29181, M11120, X00525, V01270, X82564, K01366, X59474, AL031432, AJ133038, and X04886. HBSAJ16 20 509943 1-643 15-657 BF668217, AA610491, AI284640, AI963720, AV764307, AV710066, AL046409, AI270117, BF677892, AI431303, AA501809, AAS51903, AW419262, AI801482, AA521323, AA526787, AW439558, AL119691, AA584201, AW833862, BF915839, AW500125, AI334443, AA631507, AW265385, AV763971, AV760937, AV763354, AA613203, BE150580, AV7J8260, AV762098, AA719292, AW193265, AI708009, AA521399, AW960468, AV759274, AV764578, AA531372, T53128, AI613280, BE139146, AA243489, AW021207, BG249643, AV763255, AV761786, AW069769, AI687343, BF347791, BF347740, AV728425, AW080811, BF697673, BE047069, AL138265, AI064864, AI570261, AW872575, AA806796, AA455483, AI305766, BE253048, AW088202, AA469451, AV763550, AW502975, AA834707, AW303196, AW274349, AA490183, AV763195, BG059314, AW406755, AI358229, AA468505, AW301350, AI281881, AA493471, AV725423, AW062724, AA468022, AV762397, AV764241, AV761362, AV762139, AA682912, AV756693, AA828749, AV760777, AV733830, AV735370, AV761843, AV713243, BF919090, AL038072, BF918590, AA584167, AI053790, AW963497, AA548058, AV762395, AL041690, AV762535, AA491814, AV762505, AI624698, AV761745, AW070892, AA650211, AA649642, BE297262, AV762064, BF130107, AI368256, AV763670, BF902055, BF475381, BF793766, AA230025, AA523837, AV762111, BF681619, BG059450, AA724333, AW575605, AA623002, AV760057, AI345157, AI732865, AW953071, BF691714, AV762826, AI350211, AW276817, AA610688, AL042420, AW438539, AL042853, F36273, AA127426, AA847069, AV760039, AA846568, AV759172, BF725315, AI446464, AI744188, AV760704, AI016704, BFS41120, AL048925, AI471543, AA576336, AA244357, AI345654, BF681427, AW274346, T74524, AI471481, AW270619, H07953, BF854876, AI245693, BE350772, AA129446, AI791659, AL133246, AF015155, U57007, D83989, AF077058, U57009, X74558, X54181, X54178, U18391, U18392, U18398, U18394, X55925, U57005, X54176, X53550, X55924, X54179, U57006, U18395, I51997, U67801, AF015157, X54175, X54180, X55931, U18393, U57008, AK023788, AB033115, AK023848, AF265555, X55923, U18387, AF015148, X75335, AF015156, AF015151, AC022027, AL009051, Z22650, X76070, X55927, AF015153, AC006120, U02532, AC004832, X54177, X55926, AC022148, U18396, AC005619, AC003665, AL121753, U04355, U57004, AC022448, AC011510, AC004099, U67831, AC005229, AC008115, AC002316, Z98257, AF088219, U67832, U18399, AF015149, AL096712, AC004675, AC0005180, AF227510, AC002126, AC007919, AL354720, AC011455, AC007541, U18390, AC007050, AC010422, AL450226, X55929, AC006274, AL158141, AP000359, U67825, AL137039, AF123462, AC007051, AC016579, AL136179, AL023807, AB003151, AC078889, S43650, AL365475, AC011484, AC003101, AP001716, AC016027, AP000141, AL163248, AC016830, AL133415, AC005763, AF217796, AC008753, AE232289, M37551, AC005667, AC022407, AC006312, AC073323, AP000555, AC004659, Z98750, AC002395, AL033529, AL109935, AL109797, AP001442, AC006211, AC011742, AC004975, AL139286, AC004686, AC007308, AC005488, AL353715, AL139383, AL008718, AC008443, AC007666, AC008543, AC005913, AC011489, AL031704, AL024498, AP000088, D87675, AL353194, U18400, AL132987, AL139092, AP000694, AC020629, AC005553, AC007193, AC006537, AP001708, AC011495, AL034380, AC007450, AC002546, AL136441, AL355889, AP000557, AL135749, AC007298, AL121591, AF015147, U67828, AL031985, U95742, AC005519, AC020916, AC002563, AL121926, AC006486, AC011895, AC002470, AP000351, AF240786, AC024247, AC008521, AP000348, AC008372, AC004227, AL158159, AC009305, AL160175, Z98745, AP000352, AC017067, AC005682, AC007216, AC006111, AD000092, AC005103, AC010478, AL133353, U82668, AP001712, AF047825, AL136527, AC023490, AC005203, AL135744, AC005701, AL133325, AL049757, AL049557, AC007536, AC007404, AL109743, AC012082, AC006238, AL159168, Z70042, AC020893, AP001725, AC007957, AC008764, AC009498, AC002996, AC004922, AL109920, AL353807, AC025588, AP000689, AC010498, AC004030, AC025920, AL109614, Z69666, AF015160, AL132653, AC001066, AC005808, AL023882, AL049537, AC003007, AP001710, AC008102, AL136223, AC027689, Z49816, AL161670, AL158830, AC005722, AC004383, AL022238, AC009228, AC005678, AL050097, AL049699, AC005531, and AL022316. HCEOC41 21 513037 1-618 15-632 BE296655, BF951723, BE300113, H67311, AA872197, and AC002126. HCUBS50 22 499240 1-851 15-865 T02949 and Z62487. HCUEO60 23 499242 1-1208 15- AV748967, AV762395, 1222 AV761362, AV762397, BG104686, AV760057, BF668217, BF677892, AL046409, AV763971, AI284640, AV761489, AI334443, AI963720, AV728425, BG249643, AV763449, AW303196, AW301350, AV735370, AV725423, AV762111, AW274349, BF541120, AV762098, BF241967, AV763255, AV759274, AV761786, AI270117, AV740801, AV763540, BF337291, AV763670, AV762064, AL138265, BF697673, AW833862, AW023672, AV761843, AI305766, BG167139, AI431303, AW419262, AI133164, AW268973, AW088846, AW193265, AV762505, AI696962, BF131362, BF684828, AW472872, AL138455, BE562953, AW963497, AW965008, AA490183, AI281881, AA581903, AA521323, BF827410, AI610920, AV762092, BF311000, AV760937, AV732891, AV763354, AL042853, AV762535, AW979060, AV759505, AW327868, AL119691, AV762826, AW975987, AI754658, AL038785, AI345654, AW501386, AV762645, AV652936, AV763558, AI613280, AV760777, AV733830, AI064864, BE049139, AV761941, BF680074, AV764307, BF965007, AV702857, AW662543, AV734666, AA491814, AV729809, AI345681, AI679782, AL046205, AW500125, AV759352, AW265393, AV757425, AF330238, BF725504, AV699574, AV764228, H71429, AW974109, AV764235, BG109996, BF915247, AW503666, AW502975, AV759204, AA491284, AV761106, AW518220, AW972871, AA521399, AV725431, AI307608, BE276880, AV759507, AA610491, AV764578, AI345675, AW975049, AW973397, AV762009, AV761884, BF991286, AV735495, AI570261, AL041690, AA680243, AV762959, AI144101, AV760486, AL045053, AA587604, AI368745, BF679304, AV710066, AV760466, BF793766, AV761745, AW969629, AA526787, AV763633, AF074677, AI732865, AI350211, AI890348, AW953071, BE150580, AW576391, AW513362, AL037683, AA469451, AU147104, AI708009, AW410400, F36273, BG222267, AV762067, BG036665, AW872676, BE160727, AV719316, AW270270, AW029038, AI732120, AA482711, AW021583, AV763847, AV742057, AV759172, BF691714, AV713243, AA877817, AW088202, AV729947, AV759214, AW960468, AA682912, AV762139, AW072923, AV759580, AV764530, AI345518, AV760106, AI355206, AI625244, AV760736, AV763122, AW872575, AA468022, AW769399, AV729881, AV760207, BF915628, AW028429, AV759322, AA533725, BF676981, AL042420, AI473943, AI133102, AV759518, AW438643, BE674881, BE046438, AW408717, AV733627, AI457397, AV733732, AW088616, AV762015, AV757607, BG059568, AW162049, AA584201, AW406755, AW975217, AI929531, AI821271, AV756693, AW970564, AI289067, AA629992, AV762154, AU145314, AW970896, AI357901, AV764241, AW956640, AI061334, AW265385, BF130605, AI567674, AA501784, AA394271, AI339850, AW858127, AI561060, M37551, D83989, X55924, AF015148, AF015156, U18391, U18395, U18394, X55925, AL353812, X54180, U57007, U57006, X54175, AF077058, AB020859, U18393, X55926, U57009, AL390056, AC012351, AC007383, U02531, AL138810, AJ298105, U67221, AC008430, U18392, X76070, X54181, U57005, U18387, Z84488, AC008543, AP001692, U18399, U18398, AP001342, AL138919, AL139289, X54176, AF015157, AC005341, X54178, X75335, AL391839, AL049633, AC003101, U02532, AF020803, AC013357, AL359846, U57008, AC002460, AF015149, AC005681, AC006004, AC004862, AC005529, AC007462, AC010513, X54179, Z22650, AC005901, AP000095, AL050312, AP000239, AC012380, Z99129, AC008372, AC022274, Z81369, Z97181, AF015167, AL079295, U18396, U67801, I51997, X55927, AL031680, U67231, AP001666, AF302689, X55923, AC005701, AF015153, AJ229041, U67211, Z94721, AC007043, AC008474, Z49816, AL035455, AC002465, AL138976, AL031729, AF127577, AC010748, AL021707, AC004987, AL031054, AC006367, AC005919, AC008269, AL136969, AF015151, AL022318, AC022404, AL355384, AC005052, AC005694, AP001724, AC026165, AC007132, AL158218, AR081997, AC002430, AL049868, AL121983, X54177, AC007384, AC005527, AL121825, AC062033, AL031311, AP015160, AL109965, AC022311, AC006449, U12580, U18390, AL109759, AL080250, AL157902, X88791, Z95400, U12584, AL023876, AL078594, AF215937, AP000038, AP000106, AL031286, AC007514, AF109907, AP000365, AC006312, AL008582, AL096701, AC005076, AL445259, AF168787, AP001705, AC006337, M96868, AC007685, AC006989, AC004617, AC004808, X53550, AC006511, AC007488, AL137858, Z98046, AC004957, AL035681, AC034242, AL023284, AC009403, AL021391, AF015147, AP000556, AC004686, AC004485, Z74696, M16110, AC004216, AL133551, AP001224, U69730, AL159997, AC008506, AC006012, AL450224, U67233, AP000548, AL354857, AC020893, AP001216, AL365214, AC078842, AC006005, AC077690, AC005080, AC006251, AL021453, AL161670, S43650, AC004638, AC005376, AC004760, Z95124, AJ003147, AL096829, AC027328, AC006479, AP000244, AL450226, AC004861, AC016637, AL162742, AC007751, AJ009615, AE001549, U47924, AC015971, AP000558, AL136311, AP001685, AL136090, AL133264, AL023882, AC008379, AL137039, AL163282, AL136526, AC011475, AL034451, AL033543, AC009230, AF002992, AP001670, AC019215, AL162740, AC022596, AL035411, AC022148, AC004799, X55932, AP001426, AL096771, Z92844, AC005004, AC005082, AC005703, AC040163, AC004940, AL133397, AC008518, and AC004139. HDHEB60 24 499233 1-1407 15- AL524364, AL527936, 1421 BE729676, BE734215, B0034535, BE879791, BG030700, BE782405, BG031399, BF219970, AW961043, AW245732, BE540977, BF125197, BE264862, BE264047, AA523441, BF348672, BF125434, AW250195, AW860381, AW246993, AI654715, AW168308, AI949310, AW068175, BE259690, AI393119, AW938768, BE279977, AW938746, BE857719, AW190234, AI871661, AA494392, AW900867, AA338903, BG006350, AL527587, BF091980, AA602247, BF804618, AW364083, AA357684, AW178944, R40832, BF374357, AW662637, AL524365, R42008, C20713, BF360339, BF915537, AW088134, BG035330, AI800433, AI559667, AI800453, AI536557, BE907440, AI689463, AI922091, AW151132, BF529043, AI285417, AI804505, AI952433, BF914091, AW118557, AI926593, AW151136, AI498579, AI539771, BE897632, AI432644, BG254284, BF304748, AI537677, AI494201, BF812963, AI500659, BG180468, BE883591, AI868831, AI866465, AI815232, AI866691, AI801325, BF812438, AI500523, AI538850, AW089221, BE968552, BE885490, AI887775, AI582932, AI590043, AI284517, AI923989, AI872423, AW172981, AI500706, AI445237, AI491776, AI289791, AW151138, BF811804, AI521560, AI889189, AI500662, AI582912, AW172723, AI284509, AI539800, AI889168, AI440263, AI538885, AI927233, AI866573, AI633493, AI434256, AI866469, AI434242, AI805769, AI888661, AI284513, AI500714, AI888118, AI277008, AI285439, AI436429, AI859991, BE964045, AI355779, AI623736, AI889147, AI371228, AI581033, AI431307, AI440252, AI491710, AI440238, AL047422, AI866786, AI567971, AI610557, AI860003, AI431316, AI242736, AI539260, AI828574, AI887499, AW151979, AL038575, AI539781, AI702065, AI539707, AI885949, AI285419, AW089557, AI559957, AI521571, AI469775, AI866581, AL047398, AW074057, AI815150, AI567953, AI446495, BE906230, AI867068, AI225248, AI698352, AI815239, AI371229, AI921420, AI624279, BF913616, BG252929, AI701890, AI687614, AA464646, BF038804, AI919345, AW858243, AI282249, AI962040, AI829330, AW078839, BE895765, AI554821, AI561170, BE764656, AI636811, AL515375, AI500146, AL042365, AW059765, AI263331, AI610756, AI440260, AI690946, BF814072, AI890907, BF811802, AW129310, AI866458, AI431238, BF815930, AI648567, BF925348, AL514069, BE540578, AA830821, AI924051, AI433157, BE964497, AI273179, BE621206, BG108452, AI371251, AI866510, AI499986, BE968711, AW151974, AW073697, AI866461, AI923046, BF339011, AI049859, BF752892, AI436458, BF526393, AI379711, AI918408, AI334445, AW169643, AL048403, AI915201, AA878808, BF764538, AI349814, AI953880, AI702902, AI800171, BE881675, AI819663, AI432656, AF118240, AB016531, AK025906, U30290, AK027081, AL133070, Y16258, Y16257, E02756, Y16256, AR053103, AK000247, AL080162, X93495, AF017790, Z22828, U92992, AF137367, X62773, AX040958, AX040974, X52128, AL080127, AB048910, AB025103, AK024550, AF114168, AY004290, AK027116, AL133084, AL137275, AF056191, AK026086, AB047609, AF114170, AL122098, E12579, AE111847, M92439, AP001343, L13297, AK026038, AJ004832, X72889, AK026865, AK026021, AK025084, AK025958, AL133049, AL161953, S77771, AL137429, Y10823, AL389978, AF067420, AK026642, AK026590, I26207, E12580, AF260566, AF108357, AX027129, AL117432, AB047248, AK026749, AF151109, AI8777, AK026164, AB049629, AK025092, AK026627, AL161802, AL353745, D83989, U80742, AK026648, AX046716, AL137556, A08910, AL078630, AF175983, AL080154, AK026532, AC004690, A08909, AK026389, AR083266, AF022813, AL049423, AL049314, AL137536, AK025541, A08913, AF026008, AF036268, X59414, AL080126, AL389935, AK026631, AK024622, I00734, I41145, S61953, AB019565, I89931, E03348, Y10080, A08908, AK025391, AK000432, X70685, AK026522, AX014095, AK026541, AK027161, AB047941, AF116644, AL157464, AK026793, AF242376, AJ238278, AK025431, X84990, AK026603, AB044390, AP116649, AK027142, E00617, E00717, E00778, AL137656, A08912, AL133565, AL137665, AF019298, AF182215, A08911, AC003032, AC005057, AC010137, AL353802, AC005968, AL157360, AC007298, AL133629, AR087170, AF030165, AL122100, AL133053, AF109155, Y00093, AR038854, AF002985, A08907, A57389, AL122049, L10353, D44497, AX005848, AX005804, AL137557, AK000655, AE218023, AL162062, AK027188, AF188698, AR034821, X63574, AF218034, AR068466, S76508, AF130066, AC021020, I89934, AF119337, AF151076, AL080158, E08631, U67211, AL050138, AR073709, U77594, AF113691, AL110159, AF169154, A32826, A30330, A32827, A30331, AF271350, AL080060, AL136884, AK027114, A65340, AX046603, AP118070, AB050418, AF107847, U90884, AF162782, AK025209, AB038698, AX015416, AB049758, AL157431, AL137660, AL080129, AL110222, U51587, U72620, I48978, AL135933, AL157878, I29004, X66417, AL035458, Y10655, X66862, Y11344, AK000445, AK026571, AB026675, S69510, AF112208, AF124728, AL162085, AF321617, AL137662, AL137480, A93016, Z94277, AC006222, AC010088, AK026591, AR064250, AK000450, AK024524, AL133067, AL049339, U92068, AK026057, AK027082, AL117626, AF162270, I46765, AK026947, AK025484, S68736, AL137527, and AX019230. HE6AJ31 25 511141 1-624 15-638 AA330891 HFCED59 26 511100 1-735 15-749 AA131578, BE467436, AAI31627, AW450523, AI990776, W21384, N93048, AC010605, AC018769, AL050342, AC004931, and AL135937. HFTBY59 27 511045 1-774 15-788 BF111298, BE206276, AI435456, BE541862, AI570160, AI873867, AA456637, AV693447, BE294354, AA825770, AI832089, AV694551, AW450607, P36570, AW572346, AW474291, AI890364, AI709000, BG152630, BF939150, BE645622, P30249, AI823311, AA025297, AA444053, AA029233, BE907145, AA024536, T59918, AV700945, AA411014, AA293180, T59862, AW297216, R57489, AC008747, and AC022143. HPXKJ03 28 505207 1-927 15-941 AI041718, AC006213, and AC035150. HHEDG44 29 513048 1-821 15-835 AI620063, AI022675, AC007068, AL034371, AL034394, AC008860, and AC016612. HKGAJ54 31 498303 1-1332 15- H97115, AA130346, 1346 and AA193462. HKMAB92 32 509950 1-612 15-626 N35995, AA493711, T57002, N21491, AA650030, AI093722, P09835, Z25379, AA573152, AA541730, BE163296, R39024, AA865667, AW905871, R42314, AW081029, AA729145, AA350447, AW139210, AI393498, P08817, AW449202, AI906851, AW338984, AI088818, BG054755, T94411, AI418641, BF507381, AI970892, BF437813, AI696468, AI910796, T93903, AI242755, AI208336, AI624663, BE245956, AV699193, AA648118, and AC005551. HLDOJ68 33 505205 1-1004 15- W60931, AI758232, 1018 AI950098, AI692711, BP055185, AI858258, N75249, W60800, AA021027, N47887, N62523, AI288031, BP445821, AA057181, N58831, R45351, AA978050, T23441, R59192, F04390, R46006, AI982889, N79422, AW194832, R08366, R39959, N51143, P02649, N79699, D12035, BE833428, BE746998, AL118677, BE872658, AA432219, AF035305, and AL133659. HLMFC54 34 511095 1-753 15-767 AA630817, AA825925, AI183936, AA905137, AA954504, AA234367, AI193766, AA766106, R94732, AA814592, and R99296. HLMMO64 35 510980 1-826 15-840 AI874307, AA553650, AI698549, and BE814820. HLWBZ21 36 499231 1-1134 15- T49682, T67011, 1148 T67055, T67056, T87602, T82931, R22637, R22636, R30945, R30989, R32486, R32592, R79951, R80044, R82490, R82542, H01682, H01681, H01933, H01936, H04183, H04184, H04439, H12455, H12503, R95669, H63072, H63156, H64584, H64583, H64585, H75752, H75886, H91702, H94813, H95349, H97730, and W86841. HMJAX71 37 499113 1-1353 15- AI733458, AA953101, 1367 AI791773, AA583169, AV716506, BG110768, BG250789, BE885131, BE876652, AI952780, AW020415, AA834534, BF792136, AA835851, AI521589, AL514487, AI827154, AA035214, AW237299, AA780801, BF337141, AI362494, BF764539, AI337314, AA582684, AA429215, AV650703, AC004887, AP001328, AC005962, Z83838, AL024498, AC004837, AC009484, AC010200, AL162742, AL078477, AL031658, AC004458, AL133500, U95743, AL390028, Z68223, AL137059, AC037193, AC023511, AL035451, AC005881, AL138756, AC008042, AF195953, AL354750, AC066583, AL442167, AL163285, AC008124, AF165142, AC068811, AL122057, AL109810, AC019155, AC003962, AC008014, AF067844, AL133325, AC006512, AC002365, AL355382, AL354696, U80017, AC005863, AC009953, AC005304, AC007182, AC009365, AC009600, AC005071, AC011299, AC019210, AP001720, AL049778, AC005831, AC020751, AC068314, AC010739, AC007956, AC010209, AC010458, AL034417, Z83846, AL163280, AL357793, AC009721, AL163303, AC004605, AC002416, AL160033, AL121916, U66059, AC026704, AC007405, and AL133344. HNECU95 38 509957 1-907 15-921 AI695678, AW390491, AW390488, AW935121, AA764903, BF828577, AA668172, BF961983, AI111171, BE770221, AI433008, BF310123, AA662117, AI821062, BE901529, AW079659, AI805349, AW083846, AW879550, AW833044, BE067425, AL042753, BF342223, AL042567, BE902562, BF337291, AW827205, BF824803, AI874222, BF857083, AA722215, AW081103, BF868994, AI440117, AV652027, AL042853, BF725761, AA738097, AI561147, AI557808, AI499298, AA688217, BF854113, AI208328, AI821259, AA805966, AI368745, BG249643, AL043289, AI114443, AI085242, BE156651, BG029528, AL138455, AW962384, AL039478, BE150580, AW995665, AI434080, T62495, AV682853, AI133029, BF676981, AW880044, BF244530, BF726425, AA853473, AW369785, AA886181, BE070711, BF889059, AV682003, AI249880, AI611016, AV658084, N52358, AI249447, BE061633, AW963750, BF878955, BF813822, BF996665, BE974031, AI732975, AV732334, AA687139, AL135357, AV654226, BF874758, AW812695, BE562953, BE672622, AA577824, AI801536, BF853693, AL042538, BF030666, AA814721, BF337962, AI345797, AW962444, BF339483, BF347791, AV759518, BE277210, AI358408, AA618452, T27702, AL045943, AV760019, AV738534, AI088768, AF075343, AA877935, BG116618, AI874096, AA129746, BF347740, F00107, AW813715, BE066002, AI369580, BF382045, AA584125, BF764474, BE276480, T57065, AW832960, AI334443, AI914923, AI350069, N67251, BF343686, BE070818, BE138599, AL049003, BE378571, BF874773, AV726088, BF918950, AA047715, AI049709, BF752996, AA678657, BF925617, BF764476, Z82243, AC006965, Z94277, Z93016, AL078604, AP000245, AC007056, AP000206, AP000128, AL135940, AC007487, AC008009, AL354776, AC006368, AC009408, AL163210, AL121574, AP001709, AF235093, AC009482, AL353810, U91326, AP000250, AP000208, AP000247, AL139099, AC010879, AC011475, AP001710, AC009315, AC005912, AC004971, AC008812, AJ010598, AC008403, AC016025, AC007749, Z98949, AC073316, AC000046, AC020550, AC000052, AL139327, AP000211, AP000133, AP000030, AL078586, AL022721, U82670, AL096776, AL078594, AC005516, AC006285, AC004019, U47924, Z93244, AC011464, AC006329, AC010271, AC034242, AC009123, AL137073, AL022393, AC007370, AC011489, AL139289, AL117329, AL021391, AL135901, AC007151, Z83844, AC007032, AC018767, AC004843, AC024563, AP000130, AC010432, AC007376, AL133387, AF003626, AC005829, AL354720, AL031656, AL021808, AC002531, AC020750, AC005048, AC005553, AC003005, AL034417, AP000045, AC004006, AC008760, AL035397, AP001731, AC005296, AL049540, AL136139, AC006581, AC006483, AL023879, AC008687, AL121997, AC004826, AL008735, AP000020, AL133405, AL049748, AL022147, AC005037, AF126531, AC009756, AL109921, AJ009611, AC010605, AC027644, AC006961, AC006141, AL035658, AC005091, AL023284, Z69838, AC012502, AC007100, AL034395, AP001346, and AL096814. HNFCK41 39 513050 1-618 15-632 BE293762, BE546801, AW249830, BE619562, BG259194, BF846561, BG031201, BE618954, AW192655, AW248533, BF846715, BF688815, AI955261, BE903914, BE903873, AW467422, BF969941, AW102806, AA531025, BF306003, BE874483, T87352, AW662547, AI439913, AA603314, BF526333, AA412527, AW410193, AA808624, AA968806, AA531268, BF091726, AW803183, AA912085, AA576916, AW089933, AW167145, AA565855, AI469500, AL530649, AI807904, AI589887, BF309173, BE139660, AA622691, H17042, BE676515, AA304811, BG235881, AA974816, AA548401, AL530650, AI272846, T33280, AI1510S3, AI245943, AA915997, AI807995, AA582766, AW023576, AI446811, AA860082, AA765063, AW512836, AW778765, AW673244, AI860453, AI418569, AW248976, AA410960, AA488616, AI002161, AI418269, AW338829, Z40863, AI308789, T78859, AI749124, AW276318, AA988509, AI934103, BE293459, AA993309, BE546635, BE163734, AW250492, BE546049, AI559868, AW837839, AI201122, AI624416, BE828521, BE538652, AA971591, BF978101, AX011626, and AL031283. HINFHD08 40 509945 1-594 15-608 AW665458, AW511338, AW439531, AI625959, BF681514, AI769125, BE564091, AA602361, AA620995, BF247234, AA814213, AW958543, AW072439, AI309978, AI459916, AA894782, BF681180, AA768430, AI624249, AA758348, AW085192, AA502169, AW238689, AI207367, AW958544, AI335741, AI698931, AA977860, BF438749, AW183889, AI719362, AA910458, BE044283, D20798, BF030621, AA298786, AA298794, AW176616, AJ278553, AJ289822, BE698291, AA493534, AW062525, AA508670, AW062526, AI708525, AW062521, AA507528, BE830565, AW176424, AA298773, AW176431, AA298774, AW176398, AW751210, AW751222, AW751219, T24638, D25825, Z19720, AK026298, and A75340. HNGEW65 41 513038 1-863 15-877 AC000086 HUNAE14 42 509954 1-964 15-978 AI978654, AA298855, AW051042, BF346320, AV760391, AV760389, AL042539, AL048969, BE386554, AV760466, AA760655, AW341978, AW969824, AL134669, AV733824, AV759518, BF344153, AW271917, AV762975, N49425, AV756663, AV662292, AL041706, AI708424, AA494076, AA992646, AA602906, AA584765, AW975169, AL047349, AV759632, AL042753, AW410187, AI744830, AA622801, BF725761, BF589824, AI609972, AI925869, AV763418, AP001725, AC008569, AC068799, AC003695, AP001711, AE196779, AC000353, AL133445, AC007193, Z98950, AC011500, M89651, AC008101, AC008736, AC006449, AC004383, Z85996, AC005225, AC005755, AC002470, AC021016, AL121949, AC018751, AL023583, AC006160, AC004491, AL035587, AL034429, AC016830, U91321, AC005332, AC004125, AC008551, AL117694, AL118525, AL161936, AL022336, AL121658, AL110114, AC007216, AC007298, AL033529, AL137145, AC011490, AC007748, AC007384, AC008745, AL031680, Z98036, AC006077, AC016027, AC002073, AC002300, AC004975, AC008403, AL137162, AC004166, AC006038, AC010422, AL354889, AC002378, Z97056, AC006261, AL050308, AC002551, AL035685, AC009238, AC069080, AP000501, U91323, AC011497, AL031311, AC083863, AC011465, AL360227, U80017, AL022323, AL136300, AJ246003, AC011508, AF001552, AC009086, Z85987, Z82244, AL160175, AC002059, AC007620, AC005049, AL118520, AL121753, AL121586, AC005015, AC007993, AC004867, AL359382, AC007225, AC002430, AC005098, AL159977, AC020906, AL022316, AC008848, AC002544, AL133453, AC004805, AC011895, AC004990, AC011444, AL031281, AC002352, AC007425, AL139095, AC005081, AC005527, AL031727, AC020898, AC011475, AC008635, AC006014, AC025435, AC004560, AL139352, AC006530, AL078461, AL049712, AC009087, AC018764, AL161731, AL121845, AL034405, AC018738, AC012076, AL096791, AC005522, AC005529, AC010519, AL117258, AL138787, U95743, AJ003147, AL109935, AC007597, AC000025, AL109623, Z84487, AC011491, AL138878, AC020750, AL445490, AC005781, AL137139, AL035684, AC004966, AP001714, AC007308, AC008738, AC004971, AC005480, AL117381, AC020916, AL121903, AL031774, AP000692, Z98051, AL049776, AC005484, AC008537, AL078591, NL121712, AL035089, AJ009611, AC006120, AL022165, J277546, U63721, AC002477, AC007404, Z82203, AF243527, AC002070, Y18000, Z93023, AC020917, AC006312, AL031279, AL049843, AC005694, AL035400, AP001759, AL138706, AC005482, AC004987, Z95115, AC027644, AC016144, AC008750, AL158193, AC006111, AC005914, AC011495, AC007850, AL031427, AC004883, AL391833, AC009600, AL049692, AC009362, AL121897, AC007199, AC006330, AC009481, AC000052, AL050318, AL117377, AC002314, AL034417, U89335, AC004084, AP001746, AC007842, AC004655, AC006441, AC005000, Z94801, L78810, AL049697, AC006071, AC005104, AC005330, AC008267, AC016995, AC006994, AL035404, AC005736, AC004846, Z83844, and AL139123. HNHEN68 43 511170 1-985 15-999 AC008865 and AC008905. HNHFG05 44 511173 1-496 15-510 AW973803, BE832968, AI635539, AAI91610, AI651353, AA558355, AA209399, AA703827, AA207252, AA207241, AA679798, AAI60541, AA703680, AA487896, AAI60961, AA703757, AA773027, AA704093, AA084356, U13369, and X12818. HODBF19 45 509958 1-972 15-986 AL515516, AI928344, BG026331, AI279820, AI862572, BE466212, AI745207, AW675673, AA173800, AW173057, AW965412, AI743283, BE242577, BG109854, BF793516, AW576901, BF846563, BF436594, AI378611, AW467151, AA046772, AU144464, AI375704, AI948915, BE613237, AI184922, AL535181, AI356563, BF694877, AI971694, BE222415, AW418976, AL035876, AI277317, AI051678, AU150951, BE612781, AA992643, AL560137, AW673736, AI028330, BF132392, AI933073, AI916832, AI652463, AI298162, AI351596, BE774566, AA766273, AA553679, AW592068, AI222127, AI492160, BF111478, AW022641, N93861, AW844810, AI078391, AW181890, AI354925, AA843361, BF111167, AI912000, AI682681, AW338624, AA883509, AW768411, AU156458, AW768414, R43033, AA449836, BE242525, AI655283, R78392, AI825229, AW131976, T58878, AW206820, AA334305, AW518622, H14498, BF755920, R41913, AA397402, AA420728, AA420790, BE041551, AA046633, R38100, AI538911, AI916051, F10785, AW779089, R61845, AA449887, BE699181, BE549669, BE935969, BE542469, BE935995, AW673319, BF885379, AI688910, AA079883, BF745467, BE926384, AA470491, BG163618, AL513553, BG108350, AI564719, R67202, AL513631, AW301409, AL514025, AL514627, AL513999, AL514015, BG032704, AI885974, AI281773, AI636719, AI554245, AI680498, AL513693, AL513907, AW129106, AI476109, AW167410, AL513597, BF882343, BF527014, AW071349, AI815855, BG260037, AL514919, AI569616, BG113385, AL121365, BGI12718, AI499393, AL515413, AW268251, AL514087, BG031815, AW071417, AI433157, AL514867, AI673710, AI567360, AA427700, BF054789, AI382201, AL514791, AL134830, AI889306, AW673679, AL514155, AW302988, AL043326, BG110684, AA225339, BG180996, AV757827, BG114104, AI446606, AW103371, AL514793, AL045500, AW274192, BF726348, BE018334, AI800433, AI620003, AL135661, AV682212, AV703695, AI696398, BG257535, AV729890, AI818683, AL036361, AL514085, AL040243, AV757705, BG036846, AI249257, AW087445, AI318280, BG179993, BG178488, AL038605, AI702406, AI564723, AL036631, AL036146, BE887488, AW169653, AL038715, AW150578, BF344031, AV756560, BF792469, BG151247, AI697137, AL513779, BE875211, AW827249, AI537677, AW169671, AI799183, BG180034, BF968205, BF970652, AI340582, BE874133, BF342070, AI133559, AI308032, AL036274, AV716358, AV721491, AV713079, AV682462, BG108244, AV681848, AV681759, AI469532, AI620284, AV716568, AW104724, BE965121, AI636456, AI521012, AV710608, BF792740, AV711924, BE789764, BG109125, AI635461, AL121328, AL121270, AV682466, AV682218, AV757737, AV756232, BF924882, AL079963, AL514701, AI439478, AL121573, AF116631, AL137459, I48979, AF130075, AK026741, AK025092, AF119899, AL133640, AK026855, I89947, I48978, AK026532, AL049452, S68736, AF113694, AF113690, AX019230, AF218014, AF130104, AF130105, AF116646, Y16645, AL080124, AK026592, AF130059, AK026647, AF116691, A08916, AX019229, AF116644, AL110196, AI162006, AF090900, AL133565, AL133606, AL117460, AL050116, AB019565, AP116639, AK026045, AK000618, AL133075, AF090903, AL050149, AF090901, AL133560, AL442082, A08913, I89931, AJ238278, AL117457, AF130082, AL110225, Y11254, AL049314, AF116602, AL110221, AF078844, AL050146, AF116688, AK025084, AL133016, AF104032, AF090934, AF125949, AL050393, AF090943, S78214, Y11587, AL359596, AK026784, AB048953, AF113013, AB041801, AF113699, AF119909, AF017152, AR079032, AR087170, AK026534, AL442072, AL122121, AF118064, AF113691, AL122050, AL096744, AF090896, AF118070, AK024538, AL390167, AL133557, AB049758, AF138861, AL157431, AL122093, U42766, AB048964, AK025958, L31396, AF314091, AF111847, L31397, AF119875, AK000445, AF119878, AL050108, AF177401, AJ242859, AK000083, AB051158, AL049300, AK026865, AF146568, AL137527, AR011880, A93016, AK025339, AL359601, AF113019, AF113689, AK026504, AL137557, AL133093, AL133080, AB047615, AF207829, AF130092, AR059958, AL359615, AK000652, AF091084, AX046603, AK026744, X84990, AP113676, AF158248, AL080060, AL137550, AL049466, AF079765, AK027096, AL049938, AL389978, AF111851, AF242189, AK026533, AL162083, AF113677, AK025772, AL117394, X82434, AF097996, AK026608, AF106862, E03348, AL050277, AL359618, AK026583, AF183393, AL117585, AK026452, AFL16649, AX006092, AL080137, AL049464, U91329, AL122123, AF225424, AK000212, AF219137, AK026542, AF125948, AL359941, AF017437, AB048954, A03736, AK025967, AJ000937, AK025491, AL353940, AL050138, X63574, A65341, AK000137, A08910, E07361, AL389982, AK026630, AL117435, AL137283, AL050024, AF177336, AF116682, AK025414, AK027204, AF130066, AK027113, AB047904, I33392, X70685, E02349, AK026959, AK026353, AP116654, AB052191, AB052200, AF130110, AK025391, AL049430, E07108, AK000323, AL049382, AK000432, A77033, A77035, AL117583, X65873, I03321, AK025484, X72889, AX026824, AX026823, A58524, A58523, AL122098, U00763, AF118094, AP130077, AK026927, AK024524, AP116610, A08909, AL137538, AK026086, AP119871, AK026528, Z82022, AL137648, AF130099, AL133113, U72620, AB034701, AK027164, AK026629, X96540, AL137463, A12297, AK000647, and AK026947. HOEBK34 46 768325 1-733 15-747 BE463714, AI016683, AW779895, AA632933, BE180615, AX047349, AL157827, and AB011792. HPBCC51 47 509942 1-326 15-340 BE463610, AW269888, AA946790, AI767848, AI810072, AW611551, BF223651, AW615264, AW241855, AI246433, AA913884, AI138675, AA479085, AI151495, AW007971, BP592831, AI868429, AI360448, AI207306, AI910754, AI703342, AW518844, AI809437, AI868382, AI184394, H78128, BE245972, H26736, AI094044, AW953792, AA363768, AA808146, H16094, AI805182, BF033007, AI805336, AI658481, AI805520, AW207064, AW204916, AW070733, AI348167, R42284, AW467328, AI188678, AI680370, AI272742, AA024629, AI650830, Z40805, AI658706, AA554417, AA916820, AI675350, AI919059, AI829345, AL120853, BG026746, AL036631, AI866090, BF726183, AV757496, AI890628, BG113662, BF061286, AV682809, AI345746, BF342070, AI251205, BF924882, BF970449, BG029053, BE965432, AI494201, AI699011, BE965053, AI540832, BE879903, AW087938, BF340231, BG120816, AW198075, AV682212, BF344734, BE672647, B0112879, AI468872, BE620444, AI364788, AW130863, BF752836, BF726237, AW827289, BF895953, BG111377, AL036214, BG112718, AL079963, AW301410, AI349812, BG170430, BF061283, AA603709, BG032476, AL110306, AA225339, BF344652, BF526020, BF904180, AI929108, BE785868, AI623682, BE965067, AI537677, AA830821, AI497733, AL041772, AI888671, BE047852, BF213155, AI699865, AW023859, AI919593, AI950688, BE880937, AI925156, AW082040, BF764538, AA614183, AI269862, AW074763, AW403717, BG120492, AV757903, AW118557, BF924884, AI434833, BG029667, AW020095, BG121335, AL036274, AV729627, AI434453, AI699862, AI567582, BF794042, AI866741, BG058150, AI433968, AI872910, BG151388, AV733397, BG261119, AI859464, AI887450, AI805688, BG109347, AI874151, BE047737, BE965192, AI433384, AV652906, BE964981, AV682620, AI568138, AW022699, AV649839, AI349645, BF970114, BG164558, AV649810, BF107493, AI498579, AI471361, AI400725, AL043981, BF726421, AI345347, AI355849, BE964497, AI784230, BF854113, AI302559, AA807088, AI620284, AV742698, AL038605, BF814357, BF752252, AL036638, BG180996, BF033757, BF813386, AV682738, AL119791, BG113188, AW834302, AW951273, AV733027, BF915208, AW088134, BE966498, AI866082, BE968711, AI446373, AI340627, AL037454, BG110517, BG167098, AA640779, AI345608, AI625464, BF814541, AV756382, AI919345, AL037558, AI866820, AW081255, AI440274, AW088899, BE783206, AV755459, AW087445, BF816037, AI470293, BG260037, AI520809, BF092710, AW265004, BE877142, AL039086, AI340519, BE965481, AI697324, BF814516, AI345471, BF909758, AW002362, AV720938, BE966011, AW161156, AV709679, AW162189, AI744173, AI358701, AI677797, BG168185, BG110577, AI923989, AV743631, AF217980, AF218014, AK025414, AK026784, AL133014, AL137521, A08910, AK024538, AK026600, AL133606, AL359596, AF113222, AK000486, AK026452, AL122118, A08916, AK027116, AF116688, AF119909, A08909, AF177336, AL117457, AF217991, I00734, AF111112, I89947, E00617, E00717, E00778, I48978, A08913, AF225424, U58996, U96683, AL080124, AK025906, AK026592, AF113694, AL359583, AL359623, AL122050, AL353940, AF106657, AF118094, AB048974, AL389939, AL050108, AL122121, AL133016, AR038969, AL137526, AB052191, AR011880, AR038854, Z72491, AK000450, S78214, AB049758, AF130110, AB019565, AF130066, Y16645, AK026642, AF132676, AL353957, AF061836, AK025798, AX020124, AR079032, I89931, AF175983, AF057300, AF057299, AK026865, AL133104, AR087170, AL050393, U35846, X53587, X92070, AK026608, A12297, AF162270, Y11254, AK024601, AL137550, AB049900, AL117583, AK025092, AK026506, AL162002, AF078844, AF067790, AK026086, AF119875, X87582, AR000496, AJ299431, AK000137, U39656, X84990, AL133557, AK026647, AK000652, AK026464, AK027114, AE090934, AX046603, AJ000937, AK000432, AF130100, AB048954, AB051158, AK025524, S68736, AL137476, AR013797, AF100931, AK024992, E05822, AB047887, AK025349, AK026630, AK026542, A18777, AL157482, AL133568, AL359620, AL137294, AX019230, AK027081, AL049382, AL122111, X52128, AL080137, AK026533, AF113689, AL137557, I03321, AF130055, AK026480, L30117, AL137459, AK000083, AL122098, AF116649, AL117440, AL096720, AK026551, AF090901, X93495, AF116631, AL133565, U91329, AK026534, AF271350, S61953, AF094850, AL137429, A08912, AL133067, E03348, AF017437, Y08769, I48979, AL050024, Y11587, AF087943, AK026583, X62580, AK026045, AL049314, AB050534, AR070212, AK026885, AK025084, AF130092, AR059958, AF116646, AL110221, U87620, AF125948, AK025484, AX019229, AF008439, AJ012755, AB034701, AF155148, AL080086, AF113690, AF119899, AL389978, AF118070, AL049430, Z82022, AL162006, AB052200, AK025254, AK025708, AF113676, AF177401, AK026628, AL157431, AL162085, AL133072, A08908, AF130104, AL080060, E02253, AF119896, AL133080, AF118090, AF090900, AL359618, AF130077, AF125949, AF111847, AF261883, AF207829, AK025383, AJ006417, AB049848, U72620, X72889, AC002467, AK024524, AL133093, A65341, AX005848, AX005804, AK025958, AK025632, AE017152, AF116602, E08631, AF113013, AL137273, AL137300, X65873, AL117432, AL110222, AK026532, AF104032, AK000718, AL050277, AK026408, AF119337, AB033881, AL049466, and AF097996. HRGDC48 48 513040 1-553 15-567 BF382615, Y13645, AF000562, L20633, and AF178937. HSDJB13 49 498308 1-1343 15- BE617082, AL532888, 1357 BE304821, AI280863, BE069241, AA533624, AW935725, AV709406, AV727790, AI859586, AV725114, AV708470, AW935740, AA578712, T75352, AI910336, AW081083, BE069286, AW629916, AI628756, and AA477891. HTEHR24 50 835894 1-1061 15- AI419884, AI809484, 1075 AA824354, AF203447, and AL136096. HAGAM03 51 846100 1-1011 15- AW514115, AL031282, 1025 AC004491, AL035420, and AC004167. HUNAB18 52 509946 1-894 15-908 AI830593, AI126507, AI753463, BF062430, N28840, AI887027, BG179730, AI801215, AI521602, N36511, BF326625, AA043072, AI493880, AA909906, AW069197, AI081391, W61196, AI685747, AW298069, AI375838, W47409, AI828644, W60212, AA968787, AA443812, AA573079, AA022733, AU154263, AU146877, AI247918, AA041397, W46826, AI798583, AA705747, AI973068, AI092459, AA099204, AA683548, N30882, AW029252, AA706079, AI422311, AA402829, AA047114, AA299137, AA442885, W07776, BF448913, AI084165, N72862, BE930452, AA621651, H05695, AI565055, H46602, AA042953, AA047271, N31185, W46796, AA708817, AA515530, AI693145, N32665, H08672, AV709167, AA037636, R53390, R44224, AA402681, AA628671, W31132, BF980051, AA854596, BG250141, C01726, H94531, N91839, AA844076, AI769934, W60211, BG058095, N22712, AI865921, BE715285, AI688104, AI216520, BE715338, BF224140, AI306526, AA022825, AA780598, AI668964, AF237771, and AK001655. HARAM05 53 514743 1-1241 15- AA317800 1255 HARAO51 54 513323 1-1128 15- AI769689, BE675601, 1142 AI863005, AI678000, BG108572, AI986207, AW471273, AW189963, AI590161, AI335104, AI469257, AA317806, AI954604, AV654529, AI399986, R73463, BF923901, AA856793, AI708253, BF868360, AI217945, BF882300, R73462, AI224459, H21954, AI651948, BF881000, AI287290, BE671802, AI919161, R48743, R50074, AI521061, AA505828, AW956075, AI766992, BE908648, R50073, T57442, AI868191, AI553687, AI500040, BF884210, BF868674, AA653763, AA335672, AA335980, AI424272, AW572622, AI932452, BF748430, R07536, R48744, AA975476, AW196184, AW024744, AW629411, AA600947, BF095230, AA436942, T25141, AW242177, BF344675, AI281867, AI382670, N29277, AW167918, AW083730, AA833760, AW167448, AA464646, AW105601, AI690748, BF814521, AI811785, AI826225, AI648408, AI344785, AI453487, AI624120, BF343172, AL036638, BG107670, BG168549, AW128983, BF055899, BF339322, AL039086, BF061283, BG058217, AI611348, AW078945, BF054877, F36033, AL513723, AV756658, AW303152, AW022682, BG180034, AI589947, AI468959, AI345778, AA807088, AI916419, AI521594, AI624548, AV741327, AI620639, AI590118, BE047737, AW079336, BE966699, AI954504, AI573167, AI866798, AV654896, AW102900, AI610667, AI612015, AI335426, AI348777, BE906584, AI306705, AA287231, AW089572, BE789764, AW169604, AV702833, F36308, AI862144, AL041105, AW194185, AI866770, AI868204, AW130356, R36271, AI445115, AW880037, AW196105, AW090393, AW089689, BE897269, AI922075, AW058233, AI431424, AL036980, AI580674, AI494201, AW168705, AI567612, AI890507, AI308032, AI423105, AW196299, AI280747, AI915243, AL515085, BF061286, AV682124, BE138644, BE879516, AI335208, AW827204, AI567351, AV717299, AI274745, BE781369, AI680498, AI568060, AI689420, BC166654, AW089006, AI589261, AI817244, AI699143, BG028116, W33163, AW073697, AW074993, AW072484, AI349614, AI950664, BE897632, AI539808, BE965230, B6033267, AI343112, AW193134, AW072588, AI559484, AW050578, AV696257, BE966990, AW263804, AI874151, AI648508, AW243886, AW268253, AW301300, AI282355, AV660728, AI349598, AL036925, AI890806, AI889168, AI680388, AW075207, AL036664, AI349256, AI554821, AI934012, AI589267, AI312152, AI343037, AW269097, AI955906, AI470293, AI345735, BE886728, BE138684, AI251221, AW827289, AW075084, BE895585, AI638798, AA012905, BE964078, BF872670, AI312399, AI349937, AW162194, AI933926, AI334884, AI307543, AI345251, BE138712, BG115134, AW071412, AI254226, AI307210, AW168503, N29481, AI307708, AW071395, AI312325, AI500659, AI702301, AL040586, AK026288, AF015416, AL050092, AK024538, AF119899, E02221, AL389935, S79832, AK026462, AF022363, AK026746, AK026164, AL359615, AK027096, S36676, AK027164, AL133014, A18777, S69510, AF078844, AF017437, Y10080, AK026631, AF116691, AK024524, AK025349, A15345, AF113694, AF111851, AE111849, AF162270, AL137480, A08916, AK024594, AF159141, AX046842, AK026629, A08913, A52563, AK026534, I89947, I48978, AF166267, E02349, AK026506, AF119856, A08912, U42766, X53587, A08910, AK000418, I89931, A08909, AK000137, AL122098, AK025798, U72620, AL359623, S75997, AR038969, AR087170, A08908, X92070, AF116631, AR038854, AK026855, AK026597, AL162062, AF130099, AL137665, AB034701, S61953, Y10655, AL137557, AF113222, AK026630, I09499, AB051158, AF242525, AL117394, AL049314, M30514, AF119860, AB048975, AK027144, AR079032, AL442082, AL133072, AL389982, AF314091, AB047248, AF067728, AX042059, AK026353, AF132676, AF061836, AK027182, AK025491, AL122100, AL110221, AF111847, A12297, AF137367, AL137292, AL137271, AK025391, AL110225, AF061943, AK024545, AK000432, AF051325, X52128, AB038698, AF125948, AL133010, I00734, AL049464, AL390167, AF116676, AL133558, AB048964, AK000647, AJ242859, AB047904, AL122045, E00617, E00717, E00778, AK000391, AF116644, AF266204, AF139986, AL137548, AL110171, AF119883, AF113019, AF119894, AB033881, AL049300, X79812, Y11254, AF065135, X62580, AL133081, U58996, AK026950, AL133557, AB007812, I92592, AL137558, L31396, AK000206, AL137533, U68387, AL353940, AL137656, S68736, AF056191, AL050138, AL110222, A03736, L31397, AF008439, I68732, U49908, AL133560, A93016, I89934, I89944, AL117440, AF000145, AF116639, AL359624, AF218031, AF130054, AX005848, AX005804, AK026744, AB048954, AL117460, AF155221, E01314, AL133665, AL050108, U80742, AF207829, AL389939, AF230496, AK026408, AF067790, AK027081, AB050410, AL049452, A90832, AF217987, AF159615, AK025524, AF125949, U49434, AF208026, AK026542, AR068751, X81464, AL122049, AE113689, L19437, AK024588, AK00618, AF026124, AF090943, AL389978, AL390154, AB047941, AF153205, AK027146, U68233, AF000301, AL137658, AK026551, AL080126, AF113691, I41145, AL080074, AL050277, AX040958, AB016226, AP116688, AF100931, AL137283, A1118070, U67958, AK025906, X70685, AK024622, AR070212, AL117583, AK000212, AL117585, AB046642, AL133075, AL157431, AF146568, AL359620, AL137521, U91329, AF057300, AJ005690, AF057299, AF130059, and AX026824. HATAA15 55 514240 1-1909 15- AL516736, AL514350, 1923 AL515897, AL514736, AL518711, AL515561, AL518726, AL517317, AU121031, AL514666, AL517305, AL514802, AL514762, AL517062, AL518255, AL515896, AU126410, AL518210, AL519094, AL518211, AI183997, AL516735, AU129471, AU120268, AL514349, AU130764, AL518459, AL133805, BF980126, BF205918. AU138261, AU136300, AU139601, BE887606, AL515560, BG179196, BE890175, BE883860, AL518209, BE968766, BE883911, BF681683, BE888392, AI674877, BF337086, BE885223, BF979505, BE259988, AI082260, AU128396, BE883415, BE884004, AV725061, AV754558, AU157546, AV751557, BF672039, AI760068, BE439842, AL515020, AU150685, AI377216, AW152660, BE677394, BF675314, BF105241, AI085591, AW084653, AI399904, AI683711, AI808111, AU152661, AA113823, AA102498, AI889827, AA906007, AL517061, AA082139, AI367381, AI697457, AL517316, AI344487, AW029427, AA834949, AW473890, AA453393, AW149615, AI801315, AA258303, AW129981, AI209104, AW273127, AA247476, AW071505, AA614448, BF573890, AA813452, AI056117, AW753678, AI620657, N34362, AA3S1453, R35272, AA258304, AA635407, AA523693, AA653596, BF091499, AL518458, AU156632, AI168045, AA774421, AA186398, AA593683, AW753673, AA977852, BE326676, AA318901, AA296960, AI610597, BF335342, AW028939, AI270505, AA443826, AA318837, AW007864, AA668470, D31257, N34348, BE764828, AI061191, BE932810, BF476142, AL048709, AI273948, AI537531, AV734536, AI225010, AI347230, AA318924, AA360019, AV750909, BF573903, AW889068, AA319641, T30696, D61853, H85251, AA318921, N79849, D62645, T49103, AA836894, AV754422, T30755, AA331582, AW026632, AW513900, BF734943, D63062, BE766309, BE766235, BF735406, BE765778, AL514665, BE766494, BF366321, BE765890, H24276, BE765772, AA319147, BF734900, AA355570, AI648359, AA319399, H22882, Z30204, BF734903, BE327579, AA319838, AU077002, AA903418, AA319676, AA382306, D63006, D62995, N56154, R50943, BE002930, AA319560, AA318848, AA348466, AA318998, AA322526, D63036, AA319749, AW889318, AW961850, AA317229, AA678630, AA319208, AA319277, AA903333, D62750, AI701776, AA319816, AA095238, R39417, BE765820, AA330356, R39651, AL518710, AA319644, AI142651, AW362375, AW844624, AA326276, R38334, W38473, BE463793, BF735759, AL517304, AA855105, AA026803, BF735699, AW263075, BF592165, AV681837, AI801634, N83619, BE440093, BF735537, AI567657, AW382159, R39580, AW073002, AA845454, H18300, AL514735, D61960, AL514801, N42826, N55817, AA319175, AA351452, BE766414, BE766417, AB008109, AF159570, AF030108, AR075100, U67188, AF241259, AF139872, and U32435. HATCK44 56 514716 1-1214 15- W52658, W52764, 1228 W81691, W65382, W61121, AW799294, AA478677, AA478676, W81690, AW799114, BE745598, BF707421, AW601647, AW604419, AW368573, AW854045, AA873573, AC006023, AJ297709, AJ297710, AC004084, AC005520, AL024507, Z82171, AC004686, AC010458, AL031289, AC021016, AC009116, AC006348, AC084693, AL109797, AC002470, AC004166, AB013139, AL109758, AL133230, AC007382, AL135978, AL360227, AF069291, AL035419, AC008551, AC005081, AL034549, AC011479, AC005837, AC002300, AC005753, AC004890, Z93930, AC008102, AP000493, AF111167, AC004906, AF205588, AP001727, AC004967, Z98044, AL355385, AJ003147, AC002287, AC005519, AL035361, AC018633, AC003957, AC006449, AX039602, AC007455, AC005522, and AC022436. HBIAE26 57 514418 1-1024 15- AW237905, AI635440, 1038 AL079734, AV729929, H73550, AI669421, BE092488, AC004076, AL139353, AC008569, AC011479, AL031659, AL353807, AL136979, AC015651, Z93023, AC011484, AC005015, AC006120, AL109797, AC005736, AC006008, AL022336, AC006329, AC002302, AL035669, AC005522, AC005840, AC021016, AL138787, AP001695, AC005512, AL034420, AC005088, AC011500, AC000353, AC011469, AL139384, U91321, AC005355, AL024498, AC020552, AC008641, Z97876, AC005046, AL022326, AC007388, AL390374, AC026431, AC011497, AC010267, AL135978, AL133454, AC008752, AC002045, AC006211, AC002301, AC004106, AC004089, AP001752, AL138733, AC006449, AC015550, AL035420, AC004900, AC008786, AL109743, AL121578, AC018639, AL033383, AC024561, AC010618, AC020916, AL157877, AC018758, AL035071, AC002470, AC004922, AL035422, AC006597, AC006480, AC007597, AC005531, AC008264, AL049539, AC006538, AL034417, AC005920, AL121826, AC005480, AC083871, AC007683, AC011452, AC008155, AP000555, AC009470, AF064861, AB003151, AL136105, AL049776, AC008745, AL031774, AC005913, AC006970, AC007227, AL079342, AL163249, AC005998, AC005051, AC007860, AC005102, AC007066, AC025435, Z98304, AC004166, AC005089, AC00S5519, Z82244, AC011491, AC007225, L020993, AL035072, AC003029, AF196969, AL121897, AP001718, AP000501, AC007285, AL163279, AL137802, AL050321, AL135839, and AL008718. HBMXG32 58 514459 1-976 15-990 AW827240, AL138455, AL042753, BE252421, BF337291, AW827066, BE901529, AW827205, BF923684, AV703956, AL042853, AV759518, AV655096, AI821062, BF725761, BE156651, AV682853, BF853693, AW827115, AV760019, AV760391, AV760389, BG180622, BF850931, AW772536, AL037683, AW513715, BE906410, BF342223, AV763276, BB378571, BG033220, AI612875, AI343078, AA129746, BF961983, AI433008, BF853807, F00107, AL043289, BE902562, AV698043, AL042567, BG106270, AW879550, AV757772, AV762645, BF676981, AA618452, BF339483, AA662117, AW833044, AW995665, AI085242, AA764903, AI524427, AW089495, T27702, AA598742, BF824803, AW967257, AA809897, AL135357, AW021195, AI208328, BG249643, BG035834, BF868994, AA738097, AI439324, AW079656, AL133391, AC007297, AL137918, AC018448, AC006160, AC009145, AC007394, AF307337, AL392185, AC006213, AL031276, AC010386, D87675, AC006206, AC022448, AC010498, AC002457, AC073316, AC002287, AC005036, AC006965, AC002365, AC006026, AC006057, AC005411, AL117693, AL096712, AL031346, AL359272, AE168681, AP000088, AL022159, AC003081, AP000426, AL133246, AL121983, AL117372, AL035091, AL121753, AL022318, AC018719, AC026371, AL132718, AL163280, AC004840, AP001329, AC016652, AC007378, AP001694, AL136441, Z82198, AC005013, AL136090, AC007214, AL121989, AL133244, AF049895, AC069247, AL031654, AC004103, AC016656, AC006925, AC016620, AP000493, AC026199, AL049699, AC007611, AP000344, AP001707, AL357153, AP001052, AL109826, AC004142, AL122021, AL160237, AC019171, AL035461, AL136168, AC006041, AJ011930, AL022336, AC007282, AC026201, AL138878, AL160033, AL024498, AC016955, AL442064, AC010627, AC008816, AL035634, AL096861, AL139353, AL157915, AL163300, AL049552, AC083871, AP001752, AL109935, AC006451, AL121574, AC022311, AC004028, AL354942, AC018712, AC011299, AL158064, and AC005234. HCDAN25 59 514555 1-1753 15- BF968401, BG180338, 1767 AW993915, N36872, BG119807, BG258369, AA425704, AW362929, AI800601, AW962867, AI832613, AL133865, AW965303, AW014504, BG149698, AW960330, AI521922, BE971244, BF034737, AI523253, N63589, AI741579, AW296913, AI739302, AI862055, AI741878, AA659737, AI698775, BE614297, BE877874, AV703230, BF209900, AI351670, AI554960, AL133935, BG252508, AW087329, AA835999, AW474493, AI973144, AA831663, T10343, AL120144, AA805488, AA306946, AI880525, N36866, AW339220, BE877381, AA421250, BF697171, H28885, BE568821, AW073929, C06453, BG142104, H06170, AA281733, R45776, BF381585, AI761912, BG252539, AW130120, H84171, AA931568, AI702575, AA488130, AI829311, AA058524, BG032245, BE542684, T34482, H98228, AAI92832, T34440, BE005631, AI142640, AA280712, AA384691, AW021788, AA146909, AA370792, AA147008, AA463570, AW806213, AW806214, AA054487, AA327754, AA778711, AL079816, BF337550, B13566629, AI868049, C75278, AA569759, AA662331, AA029033, T92136, BE085160, AA844335, H28886, AA621139, T93563, AA568486, AA773482, BE866924, T28631, BG231243, BF964378, AW368934, BE881198, AA868312, AJ239425, BF984911, BE891511, AL137798, AL021920, and AF180525. HCDAT43 60 514335 1-1611 15- R55342, BG166458, 1625 AA974457, AI955828, N50986, AI016326, AI697007, AA643093, AI590700, AI360308, AI566617, AI188961, AI299938, AI922808, AI701318, H77636, AI445756, AI916479, AA279176, AW340643, AA594251, AI446321, AA527511, AI807099, R53605, AA970540, BF244436, AI089033, AI692778, BE138822, C00619, AI446291, AI935303, AA865666, AI868237, AA653982, BF347509, AA421296, BG250555, AI078039, AW582539, AI590967, AA985046, AW294871, AI692823, AA827035, BE910362, AW152613, AW339670, AW189927, AW571912, AW273497, AW117879, AI567271, AI933398, AI758785, AW770862, AI912451, AW305219, BE844220, AI470303, AI418115, BE543994, AW068604, AW961337, AA513451, BF365869, AA989635, AI796392, AA939202, BF516291, R71915, AI734858, R01597, AW075369, AJ400877, A67424, AC007421, S57235, AL117342, and X68486.

[0539] Description of Table 4

[0540] Table 4 provides a key to the tissue/cell source identifier code disclosed in Table 1B, column 8. Column 1 provides the tissue/cell source identifier code disclosed in Table 1B, Column 8. Columns 2-5 provide a description of the tissue or cell source. Note that “Description” and “Tissue” sources (i.e. columns 2 and 3) having the prefix “a_” indicates organs, tissues, or cells derived from “adult” sources. Codes corresponding to diseased tissues are indicated in column 6 with the word “disease.” The use of the word “disease” in column 6 is non-limiting. The tissue or cell source may be specific (e.g. a neoplasm), or may be disease-associated (e.g., a tissue sample from a normal portion of a diseased organ). Furthermore, tissues and/or cells lacking the “disease” designation may still be derived from sources directly or indirectly involved in a disease state or disorder, and therefore may have a further utility in that disease state or disorder. In numerous cases where the tissue/cell source is a library, column 7 identifies the vector used to generate the library. TABLE 4 Cell Code Description Tissue Organ Line Disease Vector AR022 a_Heart a_Heart AR023 a_Liver a_Liver AR024 a_mammary gland a_mammary gland AR025 a_Prostate a_Prostate AR026 a_small intestine a_small intestine AR027 a_Stomach a_Stomach AR028 Blood B cells Blood B cells AR029 Blood B cells Blood B cells activated activated AR030 Blood B cells resting Blood B cells resting AR031 Blood T cells Blood T cells activated activated AR032 Blood T cells resting Blood T cells resting AR033 brain brain AR034 breast breast AR035 breast cancer breast cancer AR036 Cell Line CAOV3 Cell Line CAOV3 AR037 cell line PA-1 cell line PA-1 AR038 cell line transformed cell line transformed AR039 colon colon AR040 colon (9808co65R) colon (9808co65R) AR041 colon (9809co15) colon (9809co15) AR042 colon cancer colon cancer AR043 colon cancer colon cancer (9808co64R) (9808co64R) AR044 colon cancer colon cancer 9809co14 9809co14 AR045 corn clone 5 corn clone 5 AR046 corn clone 6 corn clone 6 AR047 corn clone2 corn clone2 AR048 corn clone3 corn clone3 AR050 Donor II B Cells Donor II B Cells 24 hrs 24 hrs AR051 Donor II B Cells Donor II B Cells 72 hrs 72 hrs AR052 Donor II B-Cells Donor II B-Cells 24 hrs. 24 hrs. AR053 Donor II B-Cells Donor II B-Cells 72 hrs 72 hrs AR054 Donor II Resting B Donor II Resting Cells B Cells AR055 Heart Heart AR056 Human Lung Human Lung (clonetech) (clonetech) AR057 Human Mammary Human (clontech) Mammary (clontech) AR058 Human Thymus Human Thymus (clonetech) (clonetech) AR059 Jurkat (unstimulated) Jurkat (unstimulated) AR060 Kidney Kidney AR061 Liver Liver AR062 Liver (Clontech) Liver (Clontech) AR063 Lymphocytes Lymphocytes chronic lymphocytic chronic leukaemia lymphocytic leukaemia AR064 Lymphocytes diffuse Lymphocytes large B cell diffuse large B lymphoma cell lymphoma AR065 Lymphocytes Lymphocytes follicular lymphoma follicular lymphoma AR066 normal breast normal breast AR067 Normal Ovarian Normal Ovarian (4004901) (4004901) AR068 Normal Ovary Normal Ovary 9508G045 9508G045 AR069 Normal Ovary Normal Ovary 9701G208 9701G208 AR070 Normal Ovary Normal Ovary 9806G005 9806G005 AR071 Ovarian Cancer Ovarian Cancer AR072 Ovarian Cancer Ovarian Cancer (9702G001) (9702G001) AR073 Ovarian Cancer Ovarian Cancer (9707G029) (9707G029) AR074 Ovarian Cancer Ovarian Cancer (9804G011) (9804G011) AR075 Ovarian Cancer Ovarian Cancer (9806G019) (9806G019) AR076 Ovarian Cancer Ovarian Cancer (9807G017) (9807G017) AR077 Ovarian Cancer Ovarian Cancer (9809G001) (9809G001) AR078 ovarian cancer 15799 ovarian cancer 15799 AR079 Ovarian Cancer Ovarian Cancer 17717AID 17717AID AR080 Ovarian Cancer Ovarian Cancer 4004664B1 4004664B1 AR081 Ovarian Cancer Ovarian Cancer 4005315A1 4005315A1 AR082 ovarian cancer ovarian cancer 94127303 94127303 AR083 Ovarian Cancer Ovarian Cancer 96069304 96069304 AR084 Ovarian Cancer Ovarian Cancer 9707G029 9707G029 AR085 Ovarian Cancer Ovarian Cancer 9807G045 9807G045 AR086 ovarian cancer ovarian cancer 9809G001 9809G001 AR087 Ovarian Cancer Ovarian Cancer 9905C032RC 9905C032RC AR088 Ovarian cancer 9907 Ovarian cancer COO 3rd 9907 COO 3rd AR089 Prostate Prostate AR090 Prostate (clonetech) Prostate (clonetech) AR091 prostate cancer prostate cancer AR092 prostate cancer prostate cancer #15176 #15176 AR093 prostate cancer prostate cancer #15509 #15509 AR094 prostate cancer prostate cancer #15673 #15673 AR095 Small Intestine Small Intestine (Clontech) (Clontech) AR096 Spleen Spleen AR097 Thymus T cells Thymus T cells activated activated AR098 Thymus T cells Thymus T cells resting resting AR099 Tonsil Tonsil AR100 Tonsil geminal Tonsil geminal center centroblast center centroblast AR101 Tonsil germinal Tonsil germinal center B cell center B cell AR102 Tonsil lymph node Tonsil lymph node AR103 Tonsil memory B Tonsil memory cell B cell AR104 Whole Brain Whole Brain AR105 Xenograft ES-2 Xenograft ES-2 AR106 Xenograft SW626 Xenograft SW626 AR124 002 : Monocytes 002 : Monocytes untreated (1 hr) untreated (1 hr) AR125 002 : Monocytes 002 : Monocytes untreated (5 hrs) untreated (5 hrs) AR130 003 : Placebo-treated 003 : Placebo- Rat Lacrimal Gland treated Rat Lacrimal Gland AR131 003 : Placebo-treated 003 : Placebo- Rat Submandibular treated Rat Gland Submandibular Gland AR135 004 : Monocytes 004 : Monocytes untreated (5 hrs) untreated (5 hrs) AR136 004 : Monocytes 004 : Monocytes untreated 1 hr untreated 1 hr AR168 3T3P10 1.0 μM 3T3P10 1.0 μM insulin insulin AR169 3T3P10 10 nM 3T3P10 10 nM Insulin Insulin AR170 3T3P10 10 μM 3T3P10 10 μM insulin insulin AR171 3T3P10 No Insulin 3T3P10 No Insulin AR172 3T3P4 3T3P4 AR173 Adipose (41892) Adipose (41892) AR174 Adipose Diabetic Adipose (41611) Diabetic (41611) AR175 Adipose Diabetic Adipose (41661) Diabetic (41661) AR176 Adipose Diabetic Adipose (41689) Diabetic (41689) AR177 Adipose Diabetic Adipose (41706) Diabetic (41706) AR178 Adipose Diabetic Adipose (42352) Diabetic (42352) AR179 Adipose Diabetic Adipose (42366) Diabetic (42366) AR180 Adipose Diabetic Adipose (42452) Diabetic (42452) AR181 Adipose Diabetic Adipose (42491) Diabetic (42491) AR182 Adipose Normal Adipose Normal (41843) (41843) AR183 Adipose Normal Adipose Normal (41893) (41893) AR184 Adipose Normal Adipose Normal (42452) (42452) AR185 Adrenal Gland Adrenal Gland AR186 Adrenal Gland + Adrenal Gland + Whole Brain Whole Brain AR188 Breast (18275A2B) Breast (18275A2B) AR189 Breast (4004199) Breast (4004199) AR190 Breast (4004399) Breast (4004399) AR191 Breast (4004943B7) Breast (4004943B7) AR192 Breast (4005570B1) Breast (4005570B1) AR193 Breast Cancer Breast Cancer (4004127A30) (4004127A30) AR194 Breast Cancer Breast Cancer (400443A21) (400443A21) AR195 Breast Cancer Breast Cancer (4004643A2) (4004643A2) AR196 Breast Cancer Breast Cancer (4004710A7) (4004710A7) AR197 Breast Cancer Breast Cancer (4004943A21) (4004943A21) AR198 Breast Cancer Breast Cancer (400553A2) (400553A2) AR199 Breast Cancer Breast Cancer (9805C046R) (9805C046R) AR200 Breast Cancer Breast Cancer (9806C012R) (9806C012R) AR201 Breast Cancer Breast Cancer (ODQ45913) (ODQ 45913) AR202 Breast Cancer Breast Cancer (ODQ45913) (ODQ45913) AR203 Breast Cancer Breast Cancer (ODQ4591B) (ODQ4591B) AR204 Colon Cancer Colon Cancer (15663) (15663) AR205 Colon Cancer Colon Cancer (4005144A4) (4005144A4) AR206 Colon Cancer Colon Cancer (4005413A4) (4005413A4) AR207 Colon Cancer Colon Cancer (4005570B1) (4005570B1) AR208 Control RNA #1 Control RNA #1 AR209 Control RNA #2 Control RNA #2 AR210 Cultured Cultured Preadipocyte (blue) Preadipocyte (blue) AR211 Cultured Cultured Preadipocyte (Red) Preadipocyte (Red) AR212 Donor II B-Cells Donor II B-Cells 24 hrs 24 hrs AR213 Donor II Resting Donor II Resting B-Cells B-Cells AR214 H114EP12 10 nM H114EP12 Insulin 10 nM Insulin AR215 H114EP12 (10 nM H114EP12 insulin) (10 nM insulin) AR216 H114EP12 (2.6 μg/μl) H114EP12 (2.6 μg/μl) AR217 H114EP12 (3.6 μg/μl) H114EP12 (3.6 μg/μl) AR218 HUVEC #1 HUVEC #1 AR219 HUVEC #2 HUVEC #2 AR221 L6 undiff. L6 undiff. AR222 L6 Undifferentiated L6 Undifferentiated AR223 L6P8 + 10 nM Insulin L6P8 + 10 nM Insulin AR224 L6P8 + HS L6P8 + HS AR225 L6P8 10 nM Insulin L6P8 10 nM Insulin AR226 Liver (00-06-A007B) Liver (00-06- A007B) AR227 Liver (96-02-A075) Liver (96-02- A075) AR228 Liver (96-03-A144) Liver (96-03- A144) AR229 Liver (96-04-A138) Liver (96-04- A138) AR230 Liver (97-10-A074B) Liver (97-10- A074B) AR231 Liver (98-09-A242A) Liver (98-09- A242A) AR232 Liver Diabetic Liver Diabetic (1042) (1042) AR233 Liver Diabetic Liver Diabetic (41616) (41616) AR234 Liver Diabetic Liver Diabetic (41955) (41955) AR235 Liver Diabetic(42352R) Liver Diabetic (42352R) AR236 Liver Diabetic Liver Diabetic (42366) (42366) AR237 Liver Diabetic Liver Diabetic (42483) (42483) AR238 Liver Diabetic Liver Diabetic (42491) (42491) AR239 Liver Diabetic (99- Liver Diabetic 09-A281A) (99-09-A281A) AR240 Lung Lung AR241 Lung (27270) Lung (27270) AR242 Lung (2727Q) Lung (2727Q) AR243 Lung Cancer Lung Cancer (4005116A1) (4005116A1) AR244 Lung Cancer Lung Cancer (4005121A5) (4005121A5) AR245 Lung Cancer Lung Cancer (4005121A5)) (4005121A5)) AR246 Lung Cancer Lung Cancer (4005340A4) (4005340A4) AR247 Mammary Gland Mammary Gland AR248 Monocyte (CT) Monocyte (CT) AR249 Monocyte (OCT) Monocyte (OCT) AR250 Monocytes (CT) Monocytes (CT) AR251 Monocytes (INFG 18 Monocytes hr) (INFG 18 hr) AR252 Monocytes (INFG Monocytes 18 hr) (INFG 18 hr) AR253 Monocytes (INFG 8-11) Monocytes (INFG 8-11) AR254 Monocytes (O CT) Monocytes (O CT) AR255 Muscle (91-01- Muscle (91-01-A105) A105) AR256 Muscle (92-04- Muscle (92-04- A059) A059) AR257 Muscle (97-11- Muscle (97-11-A056d) A056d) AR258 Muscle (99-06- Muscle (99-06-A210A) A210A) AR259 Muscle (99-07- Muscle (99-07-A203B) A203B) AR260 Muscle (99-7- Muscle (99-7- A203B) A203B) AR261 Muscle Diabetic Muscle Diabetic (42352R) (42352R) AR262 Muscle Diabetic Muscle Diabetic (42366) (42366) AR263 NK-19 Control NK-19 Control AR264 NK-19 IL Treated NK-19 IL 72 hrs Treated 72 hrs AR265 NK-19 UK Treated NK-19 UK 72 hrs Treated 72 hrs AR266 Omentum Normal Omentum (94-08-B009) Normal (94-08-B009) AR267 Omentum Normal Omentum (97-01-A039A) Normal (97-01-A039A) AR268 Omentum Normal Omentum (97-04-A114C) Normal (97-04 A114C) AR269 Omentum Normal Omentum (97-06-A117C) Normal (97-06-A117C) AR270 Omentum Normal Omentum (97-09-B004C) Normal (97-09-B004C) AR271 Ovarian Cancer Ovarian Cancer (17717AID) (17717AID) AR272 Ovarian Cancer Ovarian Cancer (9905C023RC) (9905C023RC) AR273 Ovarian Cancer Ovarian Cancer (9905C032RC) (9905C032RC) AR274 Ovary (9508G045) Ovary (9508G045) AR275 Ovary (9701G208) Ovary (9701G208) AR276 Ovary 9806G005 Ovary 9806G005 AR277 Pancreas Pancreas AR278 Placebo Placebo AR279 rIL2 Control rIL2 Control AR280 RSS288L RSS288L AR281 RSS288LC RSS288LC AR282 Salivary Gland Salivary Gland AR283 Skeletal Muscle Skeletal Muscle AR284 Skeletal Muscle (91- Skeletal Muscle 01-A105) (91-01-A105) AR285 Skeletal Muscle Skeletal Muscle (42180) (42180) AR286 Skeletal Muscle Skeletal Muscle (42386) (42386) AR287 Skeletal Muscle Skeletal Muscle (42461) (42461) AR288 Skeletal Muscle (91- Skeletal Muscle 01-A105) (91-01-A105) AR289 Skeletal Muscle (92- Skeletal Muscle 04-A059) (92-04-A059) AR290 Skeletal Muscle (96- Skeletal Muscle 08-A171) (96-08-A171) AR291 Skeletal Muscle (97- Skeletal Muscle 07-A190A) (97-07-A190A) AR292 Skeletal Muscle Skeletal Muscle Diabetic (42352) Diabetic (42352) AR293 Skeletal Muscle Skeletal Muscle Diabetic (42366) Diabetic (42366) AR294 Skeletal Muscle Skeletal Muscle Diabetic (42395) Diabetic (42395) AR295 Skeletal Muscle Skeletal Muscle Diabetic (42483) Diabetic (42483) AR296 Skeletal Muscle Skeletal Muscle Diabetic (42491) Diabetic (42491) AR297 Skeletal Muscle Skeletal Muscle Diabetic 42352 Diabetic 42352 AR298 Skeletal Musle Skeletal Musle (42461) (42461) AR299 Small Intestine Small Intestine AR300 Stomach Stomach AR301 T-Cell + T-Cell + HDPBQ71.fc 1449 HDPBQ71.fc 16 hrs 1449 16 hrs AR302 T-Cell + T-Cell + HDPBQ71.fc 1449 HDPBQ71.fc 6 hrs 1449 6 hrs AR303 T-Cell + IL2 16 hrs T-Cell + IL2 16 hrs AR304 T-Cell + IL2 6 hrs T-Cell + IL2 6 hrs AR306 T-Cell Untreated T-Cell Untreated 16 hrs 16 hrs AR307 T-Cell Untreated T-Cell Untreated 6 hrs 6 hrs AR308 T-Cells 24 hours T-Cells 24 hours AR309 T-Cells 24 hrs T-Cells 24 hrs AR310 T-Cells 24 hrs. T-Cells 24 hrs. AR311 T-Cells 24 hrs T-Cells 24 hrs AR312 T-Cells 4 days T-Cells 4 days AR313 Thymus Thymus AR314 TRE TRE AR315 TREC TREC H0004 Human Adult Spleen Human Adult Spleen Uni-ZAP XR Spleen H0008 Whole 6 Week Old Uni-ZAP XR Embryo H0009 Human Fetal Brain Uni-ZAP XR H0012 Human Fetal Kidney Human Fetal Kidney Uni-ZAP XR Kidney H0013 Human 8 Week Human 8 Week Embryo Uni-ZAP XR Whole Embryo Old Embryo H0014 Human Gall Bladder Human Gall Gall Uni-ZAP XR Bladder Bladder H0015 Human Gall Bladder, Human Gall Gall Uni-ZAP XR fraction II Bladder Bladder H0024 Human Fetal Lung Human Fetal Lung Uni-ZAP XR III Lung H0030 Human Placenta Uni-ZAP XR H0031 Human Placenta Human Placenta Placenta Uni-ZAP XR H0032 Human Prostate Human Prostate Prostate Uni-ZAP XR H0036 Human Adult Small Human Adult Small Int. Uni-ZAP XR Intestine Small Intestine H0038 Human Testes Human Testes Testis Uni-ZAP XR H0039 Human Pancreas Human Pancreas Pancreas disease Uni-ZAP XR Tumor Tumor H0040 Human Testes Human Testes Testis disease Uni-ZAP XR Tumor Tumor H0041 Human Fetal Bone Human Fetal Bone Uni-ZAP XR Bone H0046 Human Endometrial Human Uterus disease Uni-ZAP XR Tumor Endometrial Tumor H0050 Human Fetal Heart Human Fetal Heart Uni-ZAP XR Heart H0051 Human Human Brain Uni-ZAP XR Hippocampus Hippocampus H0052 Human Cerebellum Human Brain Uni-ZAP XR Cerebellum H0056 Human Umbilical Human Umbilical Uni-ZAP XR Vein, Endo. remake Umbilical Vein vein Endothelial Cells H0059 Human Uterine Human Uterine Uterus disease Lambda ZAP Cancer Cancer II H0063 Human Thymus Human Thymus Thymus Uni-ZAP XR H0069 Human Activated T- Activated T- Blood Cell Uni-ZAP XR Cells Cells Line H0081 Human Fetal Human Fetal Skin Uni-ZAP XR Epithelium (Skin) Skin H0083 Human JURKAT Jurkat Cells Uni-ZAP XR MEMBRANE BOUND POLYSOMES H0085 Human Colon Human Colon Lambda ZAP II H0087 Human Thymus Human Thymus pBluescript H0090 Human T-Cell T-Cell T-Cell disease Uni-ZAP XR Lymphoma Lymphoma H0098 Human Adult Liver, Human Adult Liver Uni-ZAP XR subtracted Liver H0100 Human Whole Six Human Whole Embryo Uni-ZAP XR Week Old Embryo Six Week Old Embryo H0101 Human 7 Weeks Old Human Whole 7 Embryo Lambda ZAP Embryo, subtracted Week Old II Embryo H0111 Human Placenta, Human Placenta Placenta pBluescript subtracted H0122 Human Adult Human Skeletal Sk Muscle Uni-ZAP XR Skeletal Muscle Muscle H0123 Human Fetal Dura Human Fetal Brain Uni-ZAP XR Mater Dura Mater H0124 Human Human Sk Muscle disease Uni-ZAP XR Rhabdomyosarcoma Rhabdomyosarc oma H0134 Raji Cells, Cyclohexamide Blood Cell Uni-ZAP XR cyclohexamide Treated Cem, Line treated Jurkat, Raji, and Supt H0135 Human Synovial Human Synovial Synovium Uni-ZAP XR Sarcoma Sarcoma HO 136 Supt Cells, Cyclohexamide Blood Cell Uni-ZAP XR cyclohexamide Treated Cem, Line treated Jurkat, Raji, and Supt H0140 Activated T-Cells, 8 Activated T- Blood Cell Uni-ZAP XR hrs. Cells Line H0141 Activated T-Cells, 12 Activated T- Blood Cell Uni-ZAP XR hrs. Cells Line H0144 Nine Week Old 9 Wk Old Early Embryo Uni-ZAP XR Early Stage Human Stage Human H0150 Human Epididymus Epididymis Testis Uni-ZAP XR H0156 Human Adrenal Human Adrenal Adrenal disease Uni-ZAP XR Gland Tumor Gland Tumor Gland H0159 Activated T-Cells, 8 Activated T- Blood Cell Uni-ZAP XR hrs., ligation 2 Cells Line H0164 Human Trachea Human Trachea Trachea disease Uni-ZAP XR Tumor Tumor H0169 Human Prostate Human Prostate Prostate disease Uni-ZAP XR Cancer, Stage C Cancer, stage C fraction H0170 12 Week Old Early Twelve Week Embryo Uni-ZAP XR Stage Human Old Early Stage Human H0171 12 Week Old Early Twelve Week Embryo Uni-ZAP XR Stage Human, II Old Early Stage Human H0179 Human Neutrophil Human Blood Cell Uni-ZAP XR Neutrophil Line H0181 Human Primary Human Primary Breast disease Uni-ZAP XR Breast Cancer Breast Cancer H0188 Human Normal Human Normal Breast Uni-ZAP XR Breast Breast H0194 Human Cerebellum, Human Brain pBluescript subtracted Cerebellum H0196 Human Human Heart Uni-ZAP XR Cardiomyopathy, Cardiomyopathy subtracted H0200 Human Greater Human Greater peritoneum Uni-ZAP XR Omentum, fract II Omentum remake, H0204 Human Colon Human Colon Colon pBluescript Cancer, subtracted Cancer H0205 Human Colon Human Colon Colon pBluescript Cancer, differential Cancer H0208 Early Stage Human Human Fetal Lung pBluescript Lung, subtracted Lung H0213 Human Pituitary, Human Pituitary Uni-ZAP XR subtracted H0216 Supt cells, Cyclohexamide Blood Cell pBluescript cyclohexamide Treated Cem, Line treated, subtracted Jurkat, Raji, and Supt H0231 Human Colon, Human Colon pBluescript subtraction H0250 Human Activated Human Uni-ZAP XR Monocytes Monocytes H0251 Human Human Cartilage disease Uni-ZAP XR Chondrosarcoma Chondrosarcoma H0253 Human adult testis, Human Adult Testis Uni-ZAP XR large inserts Testis H0255 breast lymph node Breast Lymph Lymph Lambda ZAP CDNA library Node Node II H0261 H. cerebellum, Human Brain Uni-ZAP XR Enzyme subtracted Cerebellum H0263 Human colon cancer Human Colon Colon disease Lambda ZAP Cancer II H0264 Human tonsils Human Tonsil Tonsil Uni-ZAP XR H0265 Activated T-Cell T-Cells Blood Cell Uni-ZAP XR (12 hs)/Thiouridine Line labelledEco H0266 Human HMEC Vein Cell Lambda ZAP Microvascular Line II Endothelial Cells, fract. A H0267 Human HMEC Vein Cell Lambda ZAPII Microvascular Line Endothelial Cells, fract. B H0268 Human Umbilical HUVE Cells Umbilical Cell Lambda ZAP Vein Endothelial vein Line II Cells, fract. A H0270 HPAS (Human Human Pancreas Pancreas Uni-ZAP XR pancreas, subtracted) H0271 Human Neutrophil, Human Blood Cell Uni-ZAP XR Activated Neutrophil - Line Activated H0272 HUMAN TONSILS, Human Tonsil Tonsil Uni-ZAP XR FRACTION 2 H0282 HBGB”s differential Human Primary Breast Uni-ZAP XR consolidation Breast Cancer H0293 WI 38 cells Uni-ZAP XR H0294 Amniotic Cells - Amniotic Cells - Placenta Cell Uni-ZAP XR TNF induced TNF induced Line H0306 CD34 depleted Buffy CD34 Depleted Cord ZAP Express Coat (Cord Blood) Buffy Coat Blood (Cord Blood) H0309 Human Chronic Synovium, Synovium disease Uni-ZAP XR Synovitis Chronic Synovitis/ Osteoarthritis H0318 HUMAN B CELL Human B Cell Lymph disease Uni-ZAP XR LYMPHOMA Lymphoma Node H0327 human corpus Human Corpus Brain Uni-ZAP XR colosum Callosum H0328 human ovarian Ovarian Cancer Ovary disease Uni-ZAP XR cancer H0329 Dermatofibrosarcoma Dermatofibrosar Skin disease Uni-ZAP XR Protuberance coma Protuberans H0334 Kidney cancer Kidney Cancer Kidney disease Uni-ZAP XR H0339 Duodenum Duodenum Uni-ZAP XR H0340 Corpus Callosum Corpus Uni-ZAP XR Collosum-93052 H0341 Bone Marrow Cell Bone Marrow Bone Cell Uni-ZAP XR Line (RS4; 11) Cell Line Marrow Line RS4; 11 H0343 stomach cancer Stomach Cancer - disease Uni-ZAP XR (human) 5383A (human) H0352 wilm”s Tumor Wilm”s Tumor disease Uni-ZAP XR H0360 Hemangiopericytoma Hemangiopericy disease toma H0361 Human rejected Human Rejected disease pBluescript kidney Kidney H0369 H. Atrophic Atrophic Uni-ZAP XR Endometrium Endometrium and myometrium H0373 Human Heart Human Adult Heart pCMVSport 1 Heart H0375 Human Lung Human Lung pCMVSport 1 H0381 Bone Cancer Bone Cancer disease Uni-ZAP XR H0391 H. Meniingima, M6 Human brain pSport1 Meningima H0392 H. Meningima, Ml Human brain pSport1 Meningima H0393 Fetal Liver, Human Fetal Liver pBluescript subtraction II Liver H0395 A1-CELL LINE Redd-Sternberg ZAP Express cell H0400 Human Striatum Human Brain, Brain Lambda ZAP Depression, re-rescue Striatum II Depression H0402 CD34 depleted Buffy CD34 Depleted Cord ZAP Express Coat (Cord Blood), Buffy Coat Blood re-excision (Cord Blood) H0411 H Female Bladder, Human Female Bladder pSport1 Adult Adult Bladder H0412 Human Umbilical HUVE Cells Umbilical Cell pSport1 vein endothelial vein Line cells, IL-4 induced H0413 Human Umbilical HUVE Cells Umbilical Cell pSport1 Vein Endothelial vein Line Cells, uninduced H0416 Human Neutrophils, Human Blood Cell pBluescript Activated, re- Neutrophil - Line excision Activated H0421 Human Bone Bone Marrow pBluescript Marrow, re-excision H0422 T-Cell PHA 16 hrs T-Cells Blood Cell pSport1 Line H0423 T-Cell PHA 24 hrs T-Cells Blood Cell pSport1 Line H0424 Human Pituitary, Human Pituitary pBluescript subt IX H0427 Human Adipose Human Adipose, pSport1 left hiplipoma H0428 Human Ovary Human Ovary Ovary pSport1 Tumor H0431 H. Kidney Medulla, Kidney medulla Kidney pBluescript re-excision H0433 Human Umbilical HUVE Cells Umbilical Cell pBluescript Vein Endothelial vein Line cells, frac B, re- excision H0435 Ovarian Tumor Ovarian Tumor, Ovary pCMVSport Oct. 3, 1995 OV350721 2.0 H0436 Resting T-Cell T-Cells Blood Cell pSport1 Library, II Line H0437 H Umbilical Vein HUVE Cells Umbilical Cell Lambda ZAP Endothelial Cells, vein Line II frac A, re-excision H0438 H. Whole Brain #2, Human Whole ZAP Express re-excision Brain #2 H0445 Spleen, Chronic Human Spleen, Spleen disease pSport1 lymphocytic CLL leukemia H0455 H. Striatum Human Brain, Brain pBluescript Depression, subt Striatum Depression H0457 Human Eosinophils Human pSport1 Eosinophils H0461 H. Kidney Medulla, Kidney medulla Kidney pBluescript subtracted H0483 Breast Cancer cell Breast Cancer pSport1 line, MDA 36 Cell line, MDA 36 H0484 Breast Cancer Cell Breast Cancer pSport1 line, angiogenic Cell line, Angiogenic, 36T3 H0486 Hodgkin”s Hodgkin”s disease pCMVSport Lymphoma II Lymphoma II 2.0 H0488 Human Tonsils, Human Tonsils pCMVSport Lib 2 2.0 H0489 Crohn”s Disease Ileum Intestine disease pSport1 H0494 Keratinocyte Keratinocyte pCMVSport 2.0 H0497 HEL cell line HEL cell line HEL pSport1 92.1.7 H0506 Ulcerative Colitis Colon Colon pSport1 H0509 Liver, Hepatoma Human Liver, Liver disease pCMVSport Hepatoma, 3.0 patient 8 H0510 Human Liver, Human Liver, Liver pCMVSport normal normal, Patient # 3.0 8 H0518 pBMC stimulated w/ pBMC pCMVSport poly I/C stimulated with 3.0 poly I/C H0519 NTERA2, control NTERA2, pCMVSport Teratocarcinoma 3.0 cell line H0520 NTERA2 + retinoic NTERA2, pSport1 acid, 14 days Teratocarcinoma cell line H0521 Primary Dendritic Primary pCMVSport Cells, lib 1 Dendritic cells 3.0 H0522 Primary Dendritic Primary pCMVSport cells, frac 2 Dendritic cells 3.0 H0525 PCR, pBMC I/C pBMC PCRII treated stimulated with poly I/C H0529 Myoloid Progenitor TF-1 Cell Line; pCMVSport Cell Line Myoloid 3.0 progenitor cell line H0538 Merkel Cells Merkel cells Lymph pSport1 node H0539 Pancreas Islet Cell Pancreas Islet Pancreas disease pSport1 Tumor Cell Tumour H0542 T Cell helper I Helper T cell pCMVSport 3.0 H0543 T cell helper II Helper T cell pCMVSport 3.0 H0544 Human endometrial Human pCMVSport stromal cells endometrial 3.0 stromal cells H0545 Human endometrial Human pCMVSport stromal cells-treated endometrial 3.0 with progesterone stromal cells- treated with proge H0547 NTERA2 NTERA2, pSport1 teratocarcinoma cell Teratocarcinoma line + retinoic acid (14 cell line days) H0549 H. Epididiymus, Human Uni-ZAP XR caput & corpus Epididiymus, caput and corpus H0550 H. Epididiymus, Human Uni-ZAP XR cauda Epididiymus, cauda H0551 Human Thymus Human Thymus pCMVSport Stromal Cells Stromal Cells 3.0 H0553 Human Placenta Human Placenta pCMVSport 3.0 H0555 Rejected Kidney, lib Human Rejected Kidney disease pCMVSport 4 Kidney 30 H0556 Activated T- T-Cells Blood Cell Uni-ZAP XR cell(12 h)/Thiouridine - Line re-excision H0559 HL-60, PMA 4 H, re-excision HL-60 Cells, Blood Cell Uni-ZAP XR PMA stimulated Line 4 H H0560 KMH2 KMH2 pCMVSport 3.0 H0561 L428 L428 pCMVSport 3.0 H0563 Human Fetal Brain, Human Fetal pCMVSport normalized 50021F Brain 2.0 H0569 Human Fetal Brain, Human Fetal pCMVSport normalized CO Brain 2.0 H0570 Human Fetal Brain, Human Fetal pCMVSport normalized C500H Brain 2.0 H0571 Human Fetal Brain, Human Fetal pCMVSport normalized C500HE Brain 2.0 H0574 Hepatocellular Hepatocellular Liver disease Lambda ZAP Tumor; re-excision Tumor II H0575 Human Adult Human Adult Lung Uni-ZAP XR Pulmonary; re- Pulmonary excision H0576 Resting T-Cell; re- T-Cells Blood Cell Lambda ZAP excision Line II H0580 Dendritic cells, Pooled dendritic pCMVSport pooled cells 3.0 H0581 Human Bone Human Bone Bone pCMVSport Marrow, treated Marrow Marrow 3.0 H0586 Healing groin healing groin groin disease pCMVSport wound, 6.5 hours wound, 6.5 3.0 post incision hours post incision - 2/ H0587 Healing groin Groin-Oct. 19, 1997 groin disease pCMVSport wound; 7.5 hours 3.0 post incision H0590 Human adult small Human Adult Small Int. Uni-ZAP XR intestine, re-excision Small Intestine H0591 Human T-cell T-Cell T-Cell disease Uni-ZAP XR lymphoma; re- Lymphoma excision H0592 Healing groin wound - HGS wound disease pCMVSport zero hr post-incision healing project; 3.0 (control) abdomen H0593 Olfactory Olfactory pCMVSport Epithelium; nasal cavity Epithelium from 3.0 roof of left nasal cacit H0594 Human Lung Human Lung Lung disease Lambda ZAP Cancer; re-excision Cancer II H0595 Stomach cancer Stomach Cancer disease Uni-ZAP XR (human); re-excision -5383A (human) H0596 Human Colon Human Colon Colon Lambda ZAP Cancer; re-excision Cancer II H0597 Human Colon; re- Human Colon Lambda ZAP excision II H0598 Human Stomach; re-excision Human Stomach Stomach Uni-ZAP XR H0599 Human Adult Human Adult Heart Uni-ZAP XR Heart, re-excision Heart H0600 Healing Abdomen Abdomen disease pCMVSport wound; 70&90 min 3.0 post incision H0606 Human Primary Human Primary Breast disease Uni-ZAP XR Breast Cancer; re- Breast Cancer excision H0610 H. Leukocytes, H. Leukocytes pCMVSport 1 normalized cot 5A H0615 Human Ovarian Ovarian Cancer Ovary disease Uni-ZAP XR Cancer Reexcision H0616 Human Testes, Human Testes Testis Uni-ZAP XR Reexcision H0617 Human Primary Human Primary Breast disease Uni-ZAP XR Breast Cancer Breast Cancer Reexcision H0618 Human Adult Testes, Human Adult Testis Uni-ZAP XR Large Inserts, Testis Reexcision H0619 Fetal Heart Human Fetal Heart Uni-ZAP XR Heart H0620 Human Fetal Kidney; Human Fetal Kidney Uni-ZAP XR Reexcision Kidney H0622 Human Pancreas Human Pancreas Pancreas disease Uni-ZAP XR Tumor; Reexcision Tumor H0623 Human Umbilical Human Umbilical Uni-ZAP XR Vein; Reexcision Umbilical Vein vein Endothelial Cells H0624 12 Week Early Stage Twelve Week Embryo Uni-ZAP XR Human II; Old Early Stage Reexcision Human H0625 Ku 812F Basophils Ku 812F pSport1 Line Basophils H0628 Human Pre- Human Pre- Uni-ZAP XR Differentiated Differentiated Adipocytes Adipocytes H0631 Saos2, Saos2 Cell Line; pSport1 Dexamethosome Dexamethosome Treated Treated H0632 Hepatocellular Hepatocellular Liver Lambda ZAP Tumor; re-excision Tumor II H0633 Lung Carcinoma TNFalpha disease pSport1 A549 TNFalpha activated A549-- activated Lung Carcinoma H0634 Human Testes Human Testes Testis disease Uni-ZAP XR Tumor, re-excision Tumor H0635 Human Activated T- Activated T- Blood Cell Uni-ZAP XR Cells, re-excision Cells Line H0637 Dendritic Cells From Dentritic cells pSport1 CD34 Cells from CD34 cells H0638 CD40 activated CD40 activated pSport1 monocyte dendridic monocyte cells dendridic cells H0641 LPS activated LPS activated pSport1 derived dendritic monocyte cells derived dendritic cells H0644 Human Placenta Human Placenta Placenta Uni-ZAP XR (re-excision) H0646 Lung, Cancer Metastatic pSport1 (4005313 A3): squamous cell Invasive Poorly lung carcinoma, Differentiated Lung poorly di Adenocarcinoma, H0647 Lung, Cancer Invasive poorly disease pSport1 (4005163 B7): differentiated Invasive, Poorly lung Diff. adenocarcinoma Adenocarcinoma, Metastatic H0648 Ovary, Cancer: Papillary Cstic disease pSport1 (4004562 B6) neoplasm of low Papillary Serous malignant Cystic Neoplasm, potentia Low Malignant Pot H0650 B-Cells B-Cells pCMVSport 3.0 H0651 Ovary, Normal: Normal Ovary pSport1 (9805C040R) H0652 Lung, Normal: Normal Lung pSport1 (4005313 B1) H0653 Stromal Cells Stromal Cells pSport1 H0656 B-cells B-cells pSport1 (unstimulated) (unstimulated) H0657 B-cells (stimulated) B-cells pSport1 (stimulated) H0658 Ovary, Cancer 9809C332- Ovary & disease pSport1 (9809C332): Poorly Poorly Fallopian differentiated differentiate Tubes adenocarcinoma H0659 Ovary, Cancer Grade II Ovary disease pSport1 (15395A1F): Grade Papillary II Papillary Carcinoma, Carcinoma Ovary H0660 Ovary, Cancer: Poorly disease pSport1 (15799A1F) Poorly differentiated differentiated carcinoma, carcinoma ovary H0661 Breast, Cancer: Breast cancer disease pSport1 (4004943 A5) H0662 Breast, Normal: Normal Breast - Breast pSport1 (4005522B2) #4005522(B2) H0663 Breast, Cancer: Breast Cancer - Breast disease pSport1 (4005522 A2) #4005522(A2) H0665 Stromal cells 3.88 Stromal cells pSport1 3.88 H0667 Stromal Stromal pSport1 cells(HBM3.18) cell(HBM 3.18) H0668 stromal cell clone 2.5 stromal cell pSport1 clone 2.5 H0670 Ovary, Ovarian Cancer - pSport1 Cancer(4004650 4004650A3 A3): Well- Differentiated Micropapillary Serous Carcinoma H0671 Breast, Cancer: Breast Cancer- pSport1 (9802C02OE) Sample # 9802C02OE H0672 Ovary, Cancer: Ovarian Ovary pSport1 (4004576 A8) Cancer(4004576 A8) H0673 Human Prostate Human Prostate Prostate Uni-ZAP XR Cancer, Stage B2; re- Cancer, stage B2 excision H0674 Human Prostate Human Prostate Prostate Uni-ZAP XR Cancer, Stage C; re-excission Cancer, stage C H0677 TNFR degenerate B-Cells PCRII oligo H0682 Serous Papillary serous papillary pCMVSport Adenocarcinoma adenocarcinoma 3.0 (9606G304SPA 3B) H0684 Serous Papillary Ovarian Cancer- Ovaries pCMVSport Adenocarcinoma 9810G606 3.0 H0685 Adenocarcinoma of Adenocarcinoma pCMVSport Ovary, Human Cell of Ovary, 3.0 Line, # OVCAR-3 Human Cell Line, # OVCAR- H0687 Human normal Human normal Ovary pCMVSport ovary (#9610G215) ovary(#9610G215) 3.0 H0688 Human Ovarian Human Ovarian pCMVSport Cancer(#9807G017) cancer(#9807G0 3.0 17), mRNA from Maura Ru H0689 Ovarian Cancer Ovarian Cancer, pCMVSport #9806G019 3.0 H0690 Ovarian Cancer, # Ovarian Cancer, pCMVSport 9702G001 #9702G001 3.0 H0691 Normal Ovary, normal ovary, pCMVSport #9710G208 #9710G208 3.0 H0694 Prostate gland Prostate gland, prostate pCMVSport adenocarcinoma adenocarcinoma, gland 3.0 mod/diff, gleason S0001 Brain frontal cortex Brain frontal Brain Lambda ZAP cortex II S0002 Monocyte activated Monocyte- blood Cell Uni-ZAP XR activated Line S0003 Human Osteoclastoma bone disease Uni-ZAP XR Osteoclastoma S0007 Early Stage Human Human Fetal Uni-ZAP XR Brain Brain S0010 Human Amygdala Amygdala Uni-ZAP XR S0011 STROMAL - Osteoclastoma bone disease Uni-ZAP XR OSTEOCLASTOMA S0013 Prostate Prostate prostate Uni-ZAP XR S0015 Kidney medulla Kidney medulla Kidney Uni-ZAP XR S0022 Human Osteoclastoma Uni-ZAP XR Osteoclastoma Stromal Cells Stromal Cells - unamplified S0026 Stromal cell TF274 stromal cell Bone Cell Uni-ZAP XR marrow Line S0027 Smooth muscle, Smooth muscle Pulmanary Cell Uni-ZAP XR serum treated artery Line S0028 Smooth Smooth muscle Pulmanary Cell Uni-ZAP XR muscle, control artery Line S0029 brain stem Brain stem brain Uni-ZAP XR S0031 Spinal cord Spinal cord spinal cord Uni-ZAP XR S0036 Human Substantia Human Uni-ZAP XR Nigra Substantia Nigra S0037 Smooth muscle, IL1b Smooth muscle Pulmanary Cell Uni-ZAP XR induced artery Line S0040 Adipocytes Human Uni-ZAP XR Adipocytes from Osteoclastoma S0044 Prostate BPH prostate BPH Prostate disease Uni-ZAP XR S0045 Endothelial cells- Endothelial cell endothelial Cell Uni-ZAP XR control cell-lung Line S0046 Endothelial-induced Endothelial cell endothelial Cell Uni-ZAP XR cell-lung Line S0049 Human Brain, Human Brain, Uni-ZAP XR Striatum Striatum S0050 Human Frontal Human Frontal disease Uni-ZAP XR Cortex, Cortex, Schizophrenia Schizophrenia S0051 Human Human disease Uni-ZAP XR Hypothalmus, Schizo Hypothalamus, phrenia Schizophrenia S0052 neutrophils control human blood Cell Uni-ZAP XR neutrophils Line S0053 Neutrophils IL-1 and human blood Cell Uni-ZAP XR LPS induced neutrophil Line induced S0106 STRIATUM BRAIN disease Uni-ZAP XR DEPRESSION S0110 Brain Amygdala Brain disease Uni-ZAP XR Depression S0112 Hypothalamus Brain Uni-ZAP XR S0114 Anergic T-cell Anergic T-cell Cell Uni-ZAP XR Line S0116 Bone marrow Bone marrow Bone Uni-ZAP XR marrow S0126 Osteoblasts Osteoblasts Knee Cell Uni-ZAP XR Line S0132 Epithelial-TNFa and Airway Uni-ZAP XR INF induced Epithelial S0134 Apoptotic T-cell apoptotic cells Cell Uni-ZAP XR Line S0142 Macrophage-oxLDL macrophage- blood Cell Uni-ZAP XR oxidized LDL Line treated S0144 Macrophage (GM- Macrophage Uni-ZAP XR CSF treated) (GM-CSF treated) S0146 prostate-edited prostate BPH Prostate Uni-ZAP XR S0150 LNCAP prostate cell LNCAP Cell Prostate Cell Uni-ZAP XR line Line Line S0152 PC3 Prostate cell line PC3 prostate cell Uni-ZAP XR line S0192 Synovial Fibroblasts Synovial pSport1 (control) Fibroblasts S0194 Synovial hypoxia Synovial pSport1 Fibroblasts S0196 Synovial IL-1/TNF Synovial pSport1 stimulated Fibroblasts S0206 Smooth Muscle- Smooth muscle Pulmanary Cell pBluescript HASTE normalized artery Line S0210 Messangial cell, frac2 Messangial cell pSport1 S0212 Bone Marrow Bone Marrow pSport1 Stromal Cell, Stromal untreated Cell, untreated S0214 Human Osteoclastoma bone disease Uni-ZAP XR Osteoclastoma, re-excision S0216 Neutrophils IL-1 and human blood Cell Uni-ZAP XR LPS induced neutrophil Line induced S0218 Apoptotic T-cell, re- apoptotic cells Cell Uni-ZAP XR excision Line S0222 H. Frontal H. Brain, Frontal Brain disease Uni-ZAP XR cortex, epileptic; re- Cortex, Epileptic excision S0242 Synovial Fibroblasts Synovial pSport1 (Il1/TNF), subt Fibroblasts S0250 Human Osteoblasts Human Femur disease pCMVSport II Osteoblasts 2.0 S0260 Spinal Cord, re- Spinal cord spinal cord Uni-ZAP XR excision S0276 Synovial hypoxia- Synovial Synovial pSport1 RSF subtracted fobroblasts tissue (rheumatoid) S0278 H Macrophage (GM- Macrophage Uni-ZAP XR CSF treated), re-excision (GM-CSF treated) S0280 Human Adipose Human Adipose Uni-ZAP XR Tissue, re-excision Tissue S0282 Brain Frontal Cortex, Brain frontal Brain Lambda ZAPII re-excision cortex S0294 Larynx Tumor Larynx Tumor Larynx, vocal disease pSport1 cord S0300 Frontal Frontal Lobe Brain Uni-ZAP XR lobe, dementia; re-excision dementia/Alzhei mer”s S0310 Normal trachea Normal trachea pSport1 S0312 Human Human disease pSport1 osteoarthritic; fraction osteoarthritic II cartilage S0318 Human Normal Human Normal pSport1 Cartilage Fraction II Cartilage S0328 Palate carcinoma Palate carcinoma Uvula disease pSport1 S0330 Palate normal Palate normal Uvula pSport1 S0342 Adipocytes; re- Human Uni-ZAP XR excision Adipocytes from Osteoclastoma S0344 Macrophage-oxLDL; macrophage- blood Cell Uni-ZAP XR re-excision oxidized LDL Line treated S0346 Human Amygdala Uni-ZAP XR Amygdala; re- excision S0352 Larynx Carcinoma Larynx disease pSport1 carcinoma S0354 Colon Normal II Colon Normal Colon pSport1 S0356 Colon Carcinoma Colon Colon disease pSport1 Carcinoma S0358 Colon Normal II Colon Normal Colon pSport1 S0360 Colon Tumor II Colon Tumor Colon disease pSport1 S0364 Human Quadriceps Quadriceps pSport1 muscle S0366 Human Soleus Soleus Muscle pSport1 S0368 Human Pancreatic Islets of pSport1 Langerhans Langerhans S0374 Normal colon Normal colon pSport1 S0376 Colon Tumor Colon Tumor disease pSport1 S0378 Pancreas normal Pancreas Normal pSport1 PCA4 No PCA4 No S0380 Pancreas Tumor Pancreas Tumor disease pSport1 PCA4 Tu PCA4 Tu S0386 Human Whole Brain, Whole brain Brain ZAP Express re-excision S0388 Human Human disease Uni-ZAP XR Hypothalamus, schizo Hypothalamus, phrenia, re-excision Schizophrenia S0390 Smooth muscle, Smooth muscle Pulmanary Cell Uni-ZAP XR control; re-excision artery Line S0400 Brain; normal Brain; normal pSport1 S0404 Rectum normal Rectum, normal pSport1 S0406 Rectum Tumour Rectum Tumour pSport1 S0408 Colon, normal Colon, normal pSport1 S0410 Colon, Tumour Colon, Tumour pSport1 S0414 Hippocampus, Hippocampus, Other Alzheimer Alzheimer Subtracted Subtracted S0418 CHME Cell CHME Cell pCMVSport Line; treated 5 hrs Line; treated 3.0 S0420 CHME Cell CHME Cell line, pSport1 Line, untreated untreatetd S0422 Mo7e Cell Line GM- Mo7e Cell Line pCMVSport CSF treated (1 ng/ml) GM-CSF treated 3.0 (1 ng/ml) S0424 TF-1 Cell Line GM- TF-1 Cell Line pSport1 CSF Treated GM-CSF Treated S0426 Monocyte activated; Monocyte- blood Cell Uni-ZAP XR re-excision activated Line S0428 Neutrophils control; human blood Cell Uni-ZAP XR re-excision neutrophils Line S0434 Stomach Normal Stomach Normal disease pSport1 S0436 Stomach Tumour Stomach disease pSport1 Tumour S0438 Liver Normal Liver Normal pSport1 Met5No Met5No S0440 Liver Tumour Met 5 Liver Tumour pSport1 Tu S0442 Colon Normal Colon Normal pSport1 S0444 Colon Tumor Colon Tumor disease pSport1 S0446 Tongue Tumour Tongue Tumour pSport1 S0450 Larynx Tumour Larynx Tumour pSport1 S0454 Placenta Placenta Placenta pSport1 S0458 Thyroid Normal Thyroid normal pSport1 (SDCA2 No) S0462 Thyroid Thyroiditis Thyroid pSport1 Thyroiditis S0472 Lung Mesothelium PYBT pSport1 S0474 Human blood Platelets Blood Other platelets platelets S3012 Smooth Muscle Smooth muscle Pulmanary Cell pBluescript serum Treated, artery Line Norm S3014 Smooth muscle, Smooth muscle Pulmanary Cell pBluescript serum induced, re-exc artery Line S6024 Alzheimers, spongy Alzheimer”s/Spo Brain disease Uni-ZAP XR change ngy change S6026 Frontal Lobe, Frontal Lobe Brain Uni-ZAP XR Dementia dementia/Alzhei mer”s S6028 Human Manic Human Manic Brain disease Uni-ZAP XR Depression Tissue depression tissue T0006 Human Pineal Gland Human Pinneal pBluescript Gland SK- T0010 Human Infant Brain Human Infant Other Brain T0039 HSA 172 Cells Human HSA 172 pBluescript cell line SK- T0041 Jurkat T-cell G1 Jurkat T-cell pBluescript phase SK- T0042 Jurkat T-Cell, S Jurkat T-Cell pBluescript phase Line SK- T0048 Human Aortic Human Aortic pBluescript Endothelium Endothilium SK- T0060 Human White Human White pBluescript Adipose Fat SK- T0067 Human Thyroid Human Thyroid pBluescript SK- T0069 Human Uterus, Human Uterus, pBluescript normal normal SK- T0082 Human Adult Retina Human Adult pBluescript Retina SK- T0103 Human colon pBluescript carcinoma (HCC) SK- cell line L0002 Atrium cDNA library Human heart L0005 Clontech Human aorta polyA + mRNA (#6572) L0021 Human adult (K. Okubo) L0040 Human colon mucosa L0055 Human promyelocyte L0065 Liver HepG2 cell line L0105 Human aorta polyA+ aorta (T Fujiwara) L0142 Human placenta placenta cDNA (T Fujiwara) L0143 Human placenta placenta polyA+ (T Fujiwara) L0163 Human heart cDNA heart (Y Nakamura) L0352 Normalized infant BA, M13- brain, Bento Soares derived L0361 Stratagene ovary ovary Bluescript SK (#937217) L0362 Stratagene ovarian Bluescript cancer (#937219) SK- L0364 NCI_CGAP_GC5 germ cell Tumor Bluescript SK- L0367 NCI_CGAP_Sch1 Schwannoma Bluescript Tumor SK- L0369 NCI_CGAP_AA1 adrenal adenoma adrenal Bluescript gland SK- L0371 NCI_CGAP_Br3 breast tumor breast Bluescript SK- L0372 NCI_CGAP_Co12 colon tumor colon Bluescript SK- L0375 NCI_CGAP_Kid6 kidney tumor kidney Bluescript SK- L0376 NCI_CGAP_Lar1 larynx larynx Bluescript SK- L0378 NCI_CGAP_Lu1 lung tumor lung Bluescript SK- L0381 NCI_CGAP_HN4 squamous cell pharynx Bluescript carcinoma SK- L0387 NCI_CGAP_GCB0 germinal center tonsil Bluescript B-cells SK- L0411 1-NIB Lafmid BA L0415 b4HB3MA Cot8- Lafmid BA HAP-Ft L0438 normalized infant total brain brain lafmid BA brain cDNA L0439 Soares infant brain whole Lafmid BA 1NIB brain L0456 Human retina cDNA retina eye lambda gt10 Tsp509I-cleaved sublibrary L0471 Human fetal heart, Lambda ZAP Lambda ZAP Express Express L0476 Fetal brain, Lambda ZAP Stratagene II L0483 Human pancreatic Lambda islet ZAPII L0485 STRATAGENE skeletal muscle leg muscle Lambda Human skeletal ZAPII muscle cDNA library, cat #936215. L0502 NCI_CGAP_Br15 adenocarcinoma breast pAMP1 L0508 NCI_CGAP_Lu25 bronchioalveolar lung pAMP1 carcinoma L0511 NCI_CGAP_Ov34 borderline ovary pAMP1 ovarian carcinoma L0515 NCI_CGAP_Ov32 papillary serous ovary pAMP1 carcinoma L0517 NCI_CGAP_Pr1 pAMP10 L0518 NCI_CGAP_Pr2 pAMP10 L0519 NCI_CGAP_Pr3 pAMP10 L0520 NCI_CGAP_Alv1 alveolar pAMP10 rhabdomyosarco ma L0521 NCI_CGAP_Ew1 Ewing”s pAMP10 sarcoma L0526 NCI_CGAP_Pr12 metastatic pAMP10 prostate bone lesion L0527 NCI_CGAP_Ov2 ovary pAMP10 L0528 NCI_CGAP_Pr5 prostate pAMP10 L0529 NCI_CGAP_Pr6 prostate pAMP10 L0532 NCI_CGAP_Thy1 thyroid pAMP10 L0533 NCI_CGAP_HSC1 stem cells bone pAMP10 marrow L0534 Chromosome 7 Fetal brain brain pAMP10 Brain cDNA Library L0542 NCI_CGAP_Pr11 normal prostatic prostate pAMP10 epithelial cells L0543 NCI_CGAP_Pr9 normal prostatic prostate pAMP10 epithelial cells L0545 NCI_CGAP_Pr4.1 prostatic prostate pAMP10 intraepithelial neoplasm - high grade L0549 NCI_CGAP_HN10 carcinoma in pAMP10 situ from retromolar trigone L0553 NCI_CGAP_Co22 colonic colon pAMP10 adenocarcinoma L0565 Normal Human Bone Hip pBluescript Trabecular Bone Cells L0581 Stratagene liver liver pBluescript (#937224) SK L0588 Stratagene pBluescript endothelial cell SK- 937223 L0589 Stratagene fetal pBluescript retina 937202 SK- L0591 Stratagene HeLa cell pBluescript s3 937216 SK- L0592 Stratagene hNT pBluescript neuron (#937233) SK- L0593 Stratagene pBluescript neuroepithelium SK- (#937231) L0595 Stratagene NT2 neuroepithelial brain pBluescript neuronal precursor cells SK- 937230 L0596 Stratagene colon colon pBluescript (#937204) SK- L0598 Morton Fetal cochlea ear pBluescript Cochlea SK- L0599 Stratagene lung lung pBluescript (#937210) SK- L0600 Weizmann Olfactory olfactory nose pBluescript Epithelium epithelium SK- L0601 Stratagene pancreas pancreas pBluescript (#937208) SK- L0602 Pancreatic Islet pancreatic islet pancreas pBluescript SK- L0603 Stratagene placenta placenta pBluescript (#937225) SK- L0604 Stratagene muscle muscle skeletal pBluescript 937209 muscle SK- L0605 Stratagene fetal fetal spleen spleen pBluescript spleen (#937205) SK- L0608 Stratagene lung lung carcinoma lung NCI- pBluescript carcinoma 937218 H69 SK- L0615 22 week old Human pBluescriptII fetal liver cDNA SK(-) library L0622 HM1 pcDNAII (Invitrogen) L0623 HM3 pectoral muscle pcDNAII (after (Invitrogen) mastectomy) L0626 NCI_CGAP_GC1 bulk germ cell pCMV- seminoma SPORT2 L0636 NCI_CGAP_Pit1 four pooled brain pCMV- pituitary SPORT6 adenomas L0637 NCI_CGAP_Brn53 three pooled brain pCMV- meningiomas SPORT6 L0638 NCI_CGAP_Brn35 tumor, 5 pooled brain pCMV- (see description) SPORT6 L0641 NCI_CGAP_Col7 juvenile colon pCMV- granulosa tumor SPORT6 L0643 NCI_CGAP_Co19 moderately colon pCMV- differentiated SPORT6 adenocarcinoma L0644 NCI_CGAP_Co20 moderately colon pCMV- differentiated SPORT6 adenocarcinoma L0646 NCI_CGAP_Co14 moderately- colon pCMV- differentiated SPORT6 adenocarcinoma L0647 NCI_CGAP_Sar4 five pooled connective pCMV- sarcomas, tissue SPORT6 including myxoid liposarcoma L0648 NCI_CGAP_Eso2 squamous cell esophagus pCMV- carcinoma SPORT6 L0649 NCI_CGAP_GU1 2 pooled high- genitouri- pCMV- grade nary tract SPORT6 transitional cell tumors L0650 NCI_CGAP_Kid13 2 pooled Wilms” kidney pCMV- tumors, one SPORT6 primary and one metast L0651 NCI_CGAP_Kid8 renal cell tumor kidney pCMV- SPORT6 L0653 NCI_CGAP_Lu28 two pooled lung pCMV- squamous cell SPORT6 carcinomas L0655 NCI_CGAP_Lym12 lymphoma, lymph pCMV- follicular mixed node SPORT6 small and large cell L0656 NCI_CGAP_Ov38 normal ovary pCMV- epithelium SPORT6 L0657 NCI_CGAP_Ov23 tumor, 5 pooled ovary pCMV- (see description) SPORT6 L0658 NCI_CGAP_Ov35 tumor, 5 pooled ovary pCMV- (see description) SPORT6 L0659 NCI_CGAP_Pan1 adenocarcinoma pancreas pCMV- SPORT6 L0661 NCI_CGAP_Mel15 malignant skin pCMV- melanoma, SPORT6 metastatic to lymph node L0662 NCI_CGAP_Gas4 poorly stomach pCMV- differentiated SPORT6 adenocarcinoma with signet r L0663 NCI_CGAP_Ut2 moderately- uterus pCMV- differentiated SPORT6 endometrial adenocarcino L0664 NCI_CGAP_Ut3 poorly- uterus pCMV- differentiated SPORT6 endometrial adenocarcinoma, L0665 NCI_CGAP_Ut4 serous papillary uterus pCMV- carcinoma, high SPORT6 grade, 2 pooled t L0666 NCI_CGAP_Ut1 well- uterus pCMV- differentiated SPORT6 endometrial adenocarcinoma, 7 L0667 NCI_CGAP_CML1 myeloid cells, 18 whole pCMV- pooled CML blood SPORT6 cases, BCR/ABL rearra L0717 Gessler Wilms tumor pSport1 L0731 Soares_pregnant_(—) uterus pT7T3-Pac uterus_NbHPU L0738 Human colorectal pT7T3D cancer L0740 Soares melanocyte melanocyte pT7T3D 2NbHM (Pharmacia) with a modified polylinker L0741 Soares adult brain brain pT7T3D N2b4HB55Y (Pharmacia) with a modified polylinker L0742 Soares adult brain brain pT7T3D N2b5HB55Y (Pharmacia) with a modified polylinker L0743 Soares breast breast pT7T3D 2NbHBst (Pharmacia) with a modified polylinker L0744 Soares breast breast pT7T3D 3NbHBst (Pharmacia) with a modified polylinker L0745 Soares retina retina eye pT7T3D N2b4HR (Pharmacia) with a modified polylinker L0747 Soares_fetal_heart_(—) heart pT7T3D NbHH19W (Pharmacia) with a modified polylinker L0748 Soares fetal liver Liver and pT7T3D spleen 1NFLS Spleen (Pharmacia) with a modified polylinker L0749 Soares_fetal_liver_(—) Liver and pT7T3D spleen_1NFLS_S1 Spleen (Pharmacia) with a modified polylinker L0750 Soares_fetal_lung_(—) lung pT7T3D NbHL19W (Pharmacia) with a modified polylinker L0751 Soares ovary Tumor ovarian tumor ovary pT7T3D NbHOT (Pharmacia) with a modified polylinker L0752 Soares_parathyroid_(—) parathyroid parathyroid pT7T3D tumor_NbHPA tumor gland (Pharmacia) with a modified polylinker L0753 Soares_pineal_(—) pineal pT7T3D gland_N3HPG gland (Pharmacia) with a modified polylinker L0754 Soares placenta placenta pT7T3D Nb2HP (Pharmacia) with a modified polylinker L0755 Soares_placenta_(—) placenta pT7T3D 8to9weeks_(—) (Pharmacia) 2NbHP8to9W with a modified polylinker L0756 Soares_multiple_(—) multiple pT7T3D sclerosis_2NbHMSP sclerosis lesions (Pharmacia) with a modified polylinker V_TYPE L0757 Soares_senescent_(—) senescent pT7T3D fibroblasts_NbHSF fibroblast (Pharmacia) with a modified polylinker V_TYPE L0758 Soares_testis_NHT pT7T3D-Pac (Pharmacia) with a modified polylinker L0759 Soares_total_fetus_(—) pT7T3D-Pac Nb2HF8_9w (Pharmacia) with a modified polylinker L0761 NCI_CGAP_CLL1 B-cell, chronic pT7T3D-Pac lymphotic (Pharmacia) leukemia with a modified polylinker L0762 NCI_CGAP_Br1.1 breast pT7T3D-Pac (Pharmacia) with a modified polylinker L0763 NCI_CGAP_Br2 breast pT7T3D-Pac (Pharmacia) with a modified polylinker L0764 NCI_CGAP_Co3 colon pT7T3D-Pac (Pharmacia) with a modified polylinker L0765 NCI_CGAP_Co4 colon pT7T3D-Pac (Pharmacia) with a modified polylinker L0766 NCI_CGAP_GCB1 germinal center pT7T3D-Pac B cell (Pharmacia) with a modified polylinker L0767 NCI_CGAP_GC3 pooled germ cell pT7T3D-Pac Tumors (Pharmacia) with a modified polylinker L0768 NCI_CGAP_GC4 pooled germ cell pT7T3D-Pac tumors (Pharmacia) with a modified polylinker L0769 NCI_CGAP_Brn25 anaplastic brain pT7T3D-Pac oligodendroglioma (Pharmacia) with a modified polylinker L0770 NCI_CGAP_Brn23 glioblastoma brain pT7T3D-Pac (pooled) (Pharmacia) with a modified polylinker L0771 NCI_CGAP_Co8 adenocarcinoma colon pT7T3D-Pac (Pharmacia) with a modified polylinker L0772 NCI_CGAP_Co10 colon Tumor colon pT7T3D-Pac RER+ (Pharmacia) with a modified polylinker L0773 NCI_CGAP_Co9 colon Tumor colon pT7T3D-Pac RER+ (Pharmacia) with a modified polylinker L0774 NCI_CGAP_Kid3 kidney pT7T3D-Pac (Pharmacia) with a modified polylinker L0775 NCI_CGAP_Kid5 2 pooled tumors kidney pT7T3D-Pac (clear cell type) (Pharmacia) with a modified polylinker L0776 NCI_CGAP_Lu5 carcinoid lung pT7T3D-Pac (Pharmacia) with a modified polylinker L0777 Soares_NhHMPu_S1 Pooled Human mixed (see pT7T3D-Pac melanocyte, below) (Pharmacia) fetal heart, and with a pregnant modified polylinker L0779 Soares_NFL_T_GB pooled pT7T3D-Pac C_S1 (Pharmacia) with a modified polylinker L0780 Soares_NSF_F8_(—) pooled pT7T3D-Pac 9W_OT_PA_P_S1 (Pharmacia) with a modified polylinker L0782 NCI_CGAP_Pr21 normal prostate prostate pT7T3D-Pac (Pharmacia) with a modified polylinker L0783 NCI_CGAP_Pr22 normal prostate prostate pT7T3D-Pac (Pharmacia) with a modified polylinker L0784 NCI_CGAP_Lei2 leiomyosarcoma soft tissue pT7T3D-Pac (Pharmacia) with a modified polylinker L0785 Barstead spleen spleen pT7T3D-Pac HPLRB2 (Pharmacia) with a modified polylinker L0786 Soares_NbHFB whole pT7T3D-Pac brain (Pharmacia) with a modified polylinker L0787 NCI_CGAP_Sub1 pT7T3D-Pac (Pharmacia) with a modified polylinker L0788 NCI_CGAP_Sub2 pT7T3D-Pac (Pharmacia) with a modified polylinker L0789 NCI_CGAP_Sub3 pT7T3D-Pac (Pharmacia) with a modified polylinker L0790 NCI_CGAP_Sub4 pT7T3D-Pac (Pharmacia) with a modified polylinker L0791 NCI_CGAP_Sub5 pT7T3D-Pac (Pharmacia) with a modified polylinker L0792 NCI_CGAP_Sub6 pT7T3D-Pac (Pharmacia) with a modified polylinker L0793 NCI_CGAP_Sub7 pT7T3D Pac (Pharmacia) with a modified polylinker L0794 NCI_CGAP_GC6 pooled germ cell pT7T3D Pac tumors (Pharmacia) with a modified polylinker L0796 NCI_CGAP_Brn50 medulloblastom brain pT7T3D-Pac a (Pharmacia) with a modified polylinker L0800 NCI_CGAP_Co16 colon Tumor, colon pT7T3D Pac RER+ (Pharmacia) with a modified polylinker L0803 NCI_CGAP_Kid11 kidney pT7T3D-Pac (Pharmacia) with a modified polylinker L0804 NCI_CGAP_Kid12 2 pooled tumors kidney pT7T3D-Pac (clear cell type) (Pharmacia) with a modified polylinker L0805 NCI_CGAP_Lu24 carcinoid lung pT7T3D-Pac (Pharmacia) with a modified polylinker L0806 NCI_CGAP_Lu19 squamous cell lung pT7T3D-Pac carcinoma, (Pharmacia) poorly with a differentiated (4 modified polylinker L0807 NCI_CGAP_Ov18 fibrotheoma ovary pT7T3D-Pac (Pharmacia) with a modified polylinker L0809 NCI_CGAP_Pr28 prostate pT7T3D-Pac (Pharmacia) with a modified polylinker L2251 Human fetal lung Fetal lung L2260 NIH_MGC_69 large cell lung pCMV- carcinoma, SPORT6 undifferentiated L2654 NIH_MGC_9 adenocarcinoma ovary pOTB7 cell line L3643 ADB Adrenal gland pBluescriptsk(-) L3646 DCA pTrip1Ex2 L3655 HTC Hypothalamus pBluescript sk(-) L3661 NPA pituitary pBluescriptsk(-) L3811 NPC pituitary pBluescriptsk(-) L3813 TP pituitary Tumor pTrip1Ex2 L3816 HEMBA1 whole embryo, pME18SFL3 mainly head L3817 HEMBB1 whole embryo, pME18SFL3 mainly body L3818 MAMMA1 mammary gland pME18SFL3 L3905 NCI_CGAP_Brn67 anaplastic brain pCMV- oligodendroglio SPORT6 ma with 1p/19q loss L4501 NCI_CGAP_Sub8 pT7T3D-Pac (Pharmacia) with a modified polylinker L5565 NCI_CGAP_Brn66 glioblastoma brain pCMV- with probably SPORT6 TP53 mutation and witho L5574 NCI_CGAP_HN19 normal nasopharynx pAMP10 Epithelium L5622 NCI_CGAP_Skn3 skin pCMV- SPORT6

[0541] Description of Table 5

[0542] Table 5 provides a key to the OMIM reference identification numbers disclosed in Table 1B, column 10. OMIM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, Md.) 2000. World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/). Column 2 provides diseases associated with the cytologic band disclosed in Table 1B, column 9, as determined using the Morbid Map database. TABLE 5 OMIM Reference Description 104770 Amyloidosis, secondary, susceptibility to 107300 Antithrombin III deficiency 107670 Apolipoprotein A-II deficiency 107680 ApoA-I and apoC-III deficiency, combined 107680 Corneal clouding, autosomal recessive 107680 Amyloidosis, 3 or more types 107680 Hypertriglyceridemia, one form 107680 Hypoalphalipoproteinemia 107720 Hypertriglyceridemia 109270 Renal tubular acidosis, distal, 179800 109270 Spherocytosis, hereditary 109270 [Acanthocytosis, one form] 109270 [Elliptocytosis, Malaysian-Melanesian type] 109270 Hemolytic anemia due to band 3 defect 120150 Osteogenesis imperfecta, 4 clinical forms, 166200, 166210, 259420, 166220 120150 Osteoporosis, idiopathic, 166710 120150 Ehlers-Danlos syndrome, type VIIA1, 130060 131210 Atherosclerosis, susceptibility to 133780 Vitreoretinopathy, exudative, familial 134638 Systemic lupus erythematosus, susceptibility, 152700 136132 [Fish-odor syndrome], 602079 138190 Diabetes mellitus, noninsulin-dependent 139250 Isolated growth hormone deficiency, Illig type with absent GH and Kowarski type with bioinactive GH 145001 Hyperparathyroidism-jaw tumor syndrome 146740 Neutropenia, alloimmune neonatal 146740 Viral infections, recurrent 146740 Lupus erythematosus, systemic, susceptibility, 152700 146790 Lupus nephritis, susceptibility to 147791 Jacobsen syndrome 148065 White sponge nevus, 193900 148080 Epidermolytic hyperkeratosis, 113800 150200 [Placental lactogen deficiency] 154275 Malignant hyperthermia susceptibility 2 159555 Leukemia, myeloid/lymphoid or mixed-lineage 162400 Neuropathy, hereditary sensory and autonomic, type 1 168000 Paraganglioma, familial nonchromaffin, 1 171190 Hypertension, essential, 145500 173610 Platelet alpha/delta storage pool deficiency 176310 Leukemia, acute pre-B-cell 176960 Pituitary tumor, invasive 182600 Spastic paraplegia-3A 185800 Symphalangism, proximal 186740 Immunodeficiency due to defect in CD3-gamma 186780 CD3, zeta chain, deficiency 186830 Immunodeficiency, T-cell receptor/CD3 complex 188025 Thrombocytopenia, Paris-Trousseau type 191030 Nemaline myopathy-1, 161800 203750 3-ketothiolase deficiency 221820 Gliosis, familial progressive subcortical 227400 Thromboembolism susceptibility due to factor V Leiden 227400 Hemorrhagic diathesis due to factor V deficiency 227645 Fanconi anemia, type C 229700 Fructose-bisphosphatase deficiency 232700 Glycogen storage disease VI 249000 Meckel syndrome 253250 Mulibrey nanism 254210 Myasthenia gravis, familial infantile 256030 Nemaline myopathy-2 261640 Phenylketonuria due to PTS deficiency 271900 Canavan disease 278700 Xeroderma pigmentosum, group A 600048 Breast cancer-3 600179 Leber congenital amaurosis, type I, 204000 600525 Trichodontoosseous syndrome, 190320 600852 Retinitis pigmentosa-17 600977 Cone dystrophy, progressive 601202 Cataract, anterior polar-2 601309 Basal cell carcinoma, sporadic 601309 Basal cell nevus syndrome, 109400 601382 Charcot-Marie-Tooth neuropathy-4B 601412 Deafness, autosomal dominant 7 601652 Glaucoma 1A, primary open angle, juvenile-onset, 137750 601777 Cone dystrophy, progressive 601844 Pseudohypoaldosteronism type II 602086 Arrhythmogenic right ventricular dysplasia-3 602088 Nephronophthisis, infantile 602491 Hyperlipidemia, familial combined, 1 602574 Deafness, autosomal dominant 12, 601842 602574 Deafness, autosomal dominant 8, 601543

[0543] Mature Polypeptides

[0544] The present invention also encompasses mature forms of a polypeptide having the amino acid sequence of SEQ ID NO:Y and/or the amino acid sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. Moreover, fragments or variants of these polypeptides (such as, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to these polypeptides, or polypeptides encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of the polynucleotide encoding these polypeptides) are also encompassed by the invention. In preferred embodiments, these fragments or variants retain one or more functional acitivities of the full-length or mature form of the polypeptide (e.g., biological activity (such as, for example, activity in detecting, preventing, treating and/or indicated disorders), antigenicity (ability to bind, or compete with a polypeptide of the invention for binding, to an anti-polypeptide of the invention antibody), immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention). Antibodies that bind the polypeptides of the invention, and polynucleotides encoding these polypeptides are also encompassed by the invention.

[0545] According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretary leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

[0546] Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues −13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

[0547] In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1A.

[0548] In specific embodiments, polypeptides of the invention comprise, or alternatively consist of, the predicted mature form of the polypeptide as delineated in columns 14 and 15 of Table 1A. Moreover, fragments or variants of these polypeptides (such as, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to these polypeptides, or polypeptides encoded by a polynucleotide that hybridizes under stringent conditions to the complementary strand of the polynucleotide encoding these polypeptides) are also encompassed by the invention. In preferred embodiments, these fragments or variants retain one or more functional acitivities of the full-length or mature form of the polypeptide (e.g., biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an anti-polypeptide of the invention antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention). Antibodies that bind the polypeptides of the invention, and polynucleotides encoding these polypeptides are also encompassed by the invention.

[0549] Polynucleotides encoding proteins comprising, or consisting of, the predicted mature form of polypeptides of the invention (e.g., polynucleotides having the sequence of SEQ ID NO: X (Table 1A, column 4), the sequence delineated in columns 7 and 8 of Table 1A, and a sequence encoding the mature polypeptide delineated in columns 14 and 15 of Table 1A (e.g., the sequence of SEQ ID NO:X encoding the mature polypeptide delineated in columns 14 and 15 of Table 1)) are also encompassed by the invention, as are fragments or variants of these polynucleotides (such as, fragments as described herein, polynucleotides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to these polyncueotides, and nucleic acids which hybridizes under stringent conditions to the complementary strand of the polynucleotide).

[0550] As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 15 residues of the predicted cleavage point (i.e., having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 more or less contiguous residues of SEQ ID NO:Y at the N-terminus when compared to the predicted mature form of the polypeptide (e.g., the mature polypeptide delineated in columns 14 and 15 of Table 1). Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

[0551] Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as desribed below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

[0552] Polynucleotide and Polypeptide Variants

[0553] The present invention is also directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X or the complementary strand thereto, nucleotide sequences encoding the polypeptide of SEQ ID NO:Y, the nucleotide sequence of SEQ ID NO:X that encodes the polypeptide sequence as defined in columns 13 and 14 of Table 1A, nucleotide sequences encoding the polypeptide sequence as defined in columns 13 and 14 of Table 1A, the nucleotide sequence of SEQ ID NO:X encoding the polypeptide sequence as defined in column 7 of Table 1B, nucleotide sequences encoding the polypeptide as defined in column 7 of Table 1B, the nucleotide sequence as defined in columns 8 and 9 of Table 2, nucleotide sequences encoding the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2, the nucleotide sequence as defined in column 6 of Table 1C, nucleotide sequences encoding the polypeptide encoded by the nucleotide sequence as defined in column 6 of Table 1C, the cDNA sequence contained in ATCC Deposit NO:Z, nucleotide sequences encoding the polypeptide encoded by the cDNA sequence contained in ATCC Deposit NO:Z, and/or nucleotide sequences encoding a mature (secreted) polypeptide encoded by the cDNA sequence contained in ATCC Deposit NO:Z.

[0554] The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y, the polypeptide as defined in columns 13 and 14 of Table 1A, the polypeptide sequence as defined in column 7 of Table 1B, a polypeptide sequence encoded by the polynucleotide sequence in SEQ ID NO:X, a polypeptide sequence encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2, a polypeptide sequence encoded by the nucleotide sequence as defined in column 6 of Table 1C, a polypeptide sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X, the polypeptide sequence encoded by the cDNA sequence contained in ATCC Deposit NO:Z and/or a mature (secreted) polypeptide encoded by the cDNA sequence contained in ATCC Deposit NO:Z.

[0555] “Variant” refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

[0556] Thus, one aspect of the invention provides an isolated nucleic acid molecule comprising, or alternatively consisting of, a polynucleotide having a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence described in SEQ ID NO:X or contained in the cDNA sequence of ATCC Deposit No:Z; (b) a nucleotide sequence in SEQ ID NO:X or the cDNA in ATCC Deposit No:Z which encodes the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in ATCC Deposit No:Z; (c) a nucleotide sequence in SEQ ID NO:X or the cDNA in ATCC Deposit No:Z which encodes a mature polypeptide (i.e., a secreted polypeptide (e.g., as delineated in columns 14 and 15 of Table 1A)); (d) a nucleotide sequence in SEQ ID NO:X or the cDNA sequence of ATCC Deposit No:Z, which encodes a biologically active fragment of a polypeptide; (e) a nucleotide sequence in SEQ ID NO:X or the cDNA sequence of ATCC Deposit No:Z, which encodes an antigenic fragment of a polypeptide; (f) a nucleotide sequence encoding a polypeptide comprising the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in ATCC Deposit No:Z; (g) a nucleotide sequence encoding a mature polypeptide of the amino acid sequence of SEQ ID NO:Y (i.e., a secreted polypeptide (e.g., as delineated in columns 14 and 15 of Table 1A)) or a mature polypeptide of the amino acid sequence encoded by the cDNA in ATCC Deposit No:Z; (h) a nucleotide sequence encoding a biologically active fragment of a polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in ATCC Deposit No:Z; (i) a nucleotide sequence encoding an antigenic fragment of a polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in ATCC Deposit No:Z; and (h) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), or (i) above.

[0557] The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, identical to, for example, any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i), or (j) above, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence of the cDNA contained in ATCC Deposit No:Z or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a polypeptide sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in ATCC Deposit No:Z, the nucleotide coding sequence in SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto, a nucleotide sequence encoding the polypeptide encoded by the nucleotide sequence in SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto, the nucleotide coding sequence in SEQ ID NO:B as defined in column 6 of Table 1C or the complementary strand thereto, a nucleotide sequence encoding the polypeptide encoded by the nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1C or the complementary strand thereto, the nucleotide sequence in SEQ ID NO:X encoding the polypeptide sequence as defined in column 7 of Table 1B or the complementary strand thereto, nucleotide sequences encoding the polypeptide as defined in column 7 of Table 1B or the complementary strand thereto, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein). Polynucleotides which hybridize to the complement of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides and nucleic acids.

[0558] In a preferred embodiment, the invention encompasses nucleic acid molecules which comprise, or alternatively, consist of a polynucleotide which hybridizes under stringent hybridization conditions, or alternatively, under lower stringency conditions, to a polynucleotide in (a), (b), (c), (d), (e), (f), (g), (h), or (i), above, as are polypeptides encoded by these polynucleotides. In another preferred embodiment, polynucleotides which hybridize to the complement of these nucleic acid molecules under stringent hybridization conditions, or alternatively, under lower stringency conditions, are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

[0559] In another embodiment, the invention provides a purified protein comprising, or alternatively consisting of, a polypeptide having an amino acid sequence selected from the group consisting of: (a) the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in ATCC Deposit No:Z; (b) the amino acid sequence of a mature (secreted) form of a polypeptide having the amino acid sequence of SEQ ID NO:Y (e.g., as delineated in columns 14 and 15 of Table 1A) or a mature form of the amino acid sequence encoded by the cDNA in ATCC Deposit No:Z mature; (c) the amino acid sequence of a biologically active fragment of a polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in ATCC Deposit No:Z; and (d) the amino acid sequence of an antigenic fragment of a polypeptide having the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in ATCC Deposit No:Z.

[0560] The present invention is also directed to proteins which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%, identical to, for example, any of the amino acid sequences in (a), (b), (c), or (d), above, the amino acid sequence shown in SEQ ID NO:Y, the amino acid sequence encoded by the cDNA contained in ATCC Deposit No:Z, the amino acid sequence of the polypeptide encoded by the nucleotide sequence in SEQ ID NO:X as defined in columns 8 and 9 of Table 2, the amino acid sequence of the polypeptide encoded by the nucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1C, the amino acid sequence as defined in column 7 of Table 1B, an amino acid sequence encoded by the nucleotide sequence in SEQ ID NO:X, and an amino acid sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X. Fragments of these polypeptides are also provided (e.g., those fragments described herein). Further proteins encoded by polynucleotides which hybridize to the complement of the nucleic acid molecules encoding these amino acid sequences under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention, as are the polynucleotides encoding these proteins.

[0561] By a nucleic acid having a nucleotide sequence at least, for example, 95% “identical” to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence referred to in Table 1B or 2 as the ORF (open reading frame), or any fragment specified as described herein.

[0562] As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is expressed as percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

[0563] If the subject sequence is shorter than the query sequence because of 5′ or 3′ deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5′ and 3′ truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5′ or 3′ ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5′ and 3′ of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5′ and 3′ bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

[0564] For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5′ end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5′ end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5′ and 3′ ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5′ or 3′ of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5′ and 3′ of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

[0565] By a polypeptide having an amino acid sequence at least, for example, 95% “identical” to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

[0566] As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence of a polypeptide referred to in Table 1A (e.g., the amino acid sequence delineated in columns 14 and 15) or a fragment thereof, Table 1B (e.g., the amino acid sequence identified in column 6) or a fragment thereof, Table 2 (e.g., the amino acid sequence of the polypeptide encoded by the polynucleotide sequence defined in columns 8 and 9 of Table 2) or a fragment thereof, the amino acid sequence of the polypeptide encoded by the polynucleotide sequence in SEQ ID NO:B as defined in column 6 of Table 1C or a fragment thereof, the amino acid sequence of the polypeptide encoded by the nucleotide sequence in SEQ ID NO:X or a fragment thereof, or the amino acid sequence of the polypeptide encoded by cDNA contained in ATCC Deposit No:Z, or a fragment thereof, the amino acid sequence of a mature (secreted) polypeptide encoded by cDNA contained in ATCC Deposit No:Z, or a fragment thereof, can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci.6:237-245 (1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is expressed as percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

[0567] If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

[0568] For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequnce are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

[0569] The polynucleotide variants of the invention may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, polypeptide variants in which less than 50, less than 40, less than 30, less than 20, less than 10, or 5-50, 5-25, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).

[0570] Naturally occurring variants are called “allelic variants,” and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985)). These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

[0571] Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the polypeptide of the present invention without substantial loss of biological function. As an example, Ron et al. (J. Biol. Chem. 268: 2984-2988 (1993)) reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

[0572] Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem. 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that “[m]ost of the molecule could be altered with little effect on either [binding or biological activity].” In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

[0573] Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

[0574] Thus, the invention further includes polypeptide variants which show a functional activity (e.g., biological activity) of the polypeptides of the invention. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity.

[0575] The present application is directed to nucleic acid molecules at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleic acid sequences disclosed herein, (e.g., encoding a polypeptide having the amino acid sequence of an N and/or C terminal deletion), irrespective of whether they encode a polypeptide having functional activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having functional activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having functional activity include, inter alia, (1) isolating a gene or allelic or splice variants thereof in a cDNA library; (2) in situ hybridization (e.g., “FISH”) to metaphase chromosomal spreads to provide precise chromosomal location of the gene, as described in Verma et al., Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York (1988); (3) Northern Blot analysis for detecting mRNA expression in specific tissues (e.g., normal or diseased tissues); and (4) in situ hybridization (e.g., histochemistry) for detecting mRNA expression in specific tissues (e.g., normal or diseased tissues).

[0576] Preferred, however, are nucleic acid molecules having sequences at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the nucleic acid sequences disclosed herein, which do, in fact, encode a polypeptide having functional activity. By a polypeptide having “functional activity” is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein and/or a mature (secreted) protein of the invention. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an anti-polypeptide of the invention antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

[0577] The functional activity of the polypeptides, and fragments, variants and derivatives of the invention, can be assayed by various methods.

[0578] For example, in one embodiment where one is assaying for the ability to bind or compete with a full-length polypeptide of the present invention for binding to an anti-polypetide antibody, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), “sandwich” immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

[0579] In another embodiment, where a ligand is identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky et al., Microbiol. Rev. 59:94-123 (1995). In another embodiment, the ability of physiological correlates of a polypeptide of the present invention to bind to a substrate(s) of the polypeptide of the invention can be routinely assayed using techniques known in the art.

[0580] In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the present invention and fragments, variants and derivatives thereof to elicit polypeptide related biological activity (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope of the invention.

[0581] Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to, for example, the nucleic acid sequence of the cDNA contained in ATCC Deposit No:Z, the nucleic acid sequence referred to in Table 1B (SEQ ID NO:X), the nucleic acid sequence disclosed in Table 1A (e.g., the nucleic acid sequence delineated in columns 7 and 8), the nucleic acid sequence disclosed in Table 2 (e.g., the nucleic acid sequence delineated in columns 8 and 9) or fragments thereof, will encode polypeptides “having functional activity.” In fact, since degenerate variants of any of these nucleotide sequences all encode the same polypeptide, in many instances, this will be clear to the skilled artisan even without performing the above described comparison assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having functional activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one aliphatic amino acid with a second aliphatic amino acid), as further described below.

[0582] For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

[0583] The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

[0584] The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. See Cunningham and Wells, Science 244:1081-1085 (1989). The resulting mutant molecules can then be tested for biological activity.

[0585] As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gin, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

[0586] Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitutions with one or more of the amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, serum albumin (preferably human serum albumin) or a fragment thereof, or leader or secretory sequence, or a sequence facilitating purification, or (v) fusion of the polypeptide with another compound, such as albumin (including but not limited to recombinant albumin (see, e.g., U.S. Pat. No. 5,876,969, issued Mar. 2, 1999, EP Patent 0 413 622, and U.S. Pat. No. 5,766,883, issued Jun. 16, 1998, herein incorporated by reference in their entirety)). Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

[0587] For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. See Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).

[0588] A further embodiment of the invention relates to polypeptides which comprise the amino acid sequence of a polypeptide having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions from a polypeptide sequence disclosed herein. Of course it is highly preferable for a polypeptide to have an amino acid sequence which, for example, comprises the amino acid sequence of a polypeptide of SEQ ID NO:Y, the amino acid sequence of the mature (e.g., secreted) polypeptide of SEQ ID NO:Y, an amino acid sequence encoded by SEQ ID NO:X, an amino acid sequence encoded by the portion of SEQ ID NO:X as defined in columnns 8 and 9 of Table 2, an amino acid sequence encoded by the complement of SEQ ID NO:X, an amino acid sequence encoded by cDNA contained in ATCC Deposit No:Z, and/or the amino acid sequence of a mature (secreted) polypeptide encoded by cDNA contained in ATCC Deposit No:Z, or a fragment thereof, which contains, in order of ever-increasing preference, at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions.

[0589] In specific embodiments, the polypeptides of the invention comprise, or alternatively, consist of, fragments or variants of a reference amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO:Y or fragments thereof (e.g., the mature form and/or other fragments described herein); (b) the amino acid sequence encoded by SEQ ID NO:X or fragments thereof; (c) the amino acid sequence encoded by the complement of SEQ ID NO:X or fragments thereof; (d) the amino acid sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or fragments thereof; and (e) the amino acid sequence encoded by cDNA contained in ATCC Deposit No:Z or fragments thereof; wherein the fragments or variants have 1-5,5-10, 5-25, 5-50, 10-50 or 50-150, amino acid residue additions, substitutions, and/or deletions when compared to the reference amino acid sequence. In preferred embodiments, the amino acid substitutions are conservative. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0590] Polynucleotide and Polypeptide Fragments

[0591] The present invention is also directed to polynucleotide fragments of the polynucleotides (nucleic acids) of the invention. In the present invention, a “polynucleotide fragment” refers to a polynucleotide having a nucleic acid sequence which, for example: is a portion of the cDNA contained in ATCC Deposit No:Z or the complementary strand thereto; is a portion of the polynucleotide sequence encoding the polypeptide encoded by the cDNA contained in ATCC Deposit No:Z or the complementary strand thereto; is a portion of the polynucleotide sequence encoding the mature (secreted) polypeptide encoded by the cDNA contained in ATCC Deposit No:Z or the complementary strand thereto; is a portion of a polynucleotide sequence encoding the mature amino acid sequence as defined in columns 14 and 15 of Table 1A or the complementary strand thereto; is a portion of a polynucleotide sequence encoding the amino acid sequence encoded by the region of SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto; is a portion of the polynucleotide sequence of SEQ ID NO:X as defined in columns 8 and 9 of Table 2 or the complementary strand thereto; is a portion of the polynucleotide sequence in SEQ ID NO:X or the complementary strand thereto; is a polynucleotide sequence encoding a portion of the polypeptide of SEQ ID NO:Y; is a polynucleotide sequence encoding a portion of a polypeptide encoded by SEQ ID NO:X; is a polynucleotide sequence encoding a portion of a polypeptide encoded by the complement of the polynucleotide sequence in SEQ ID NO:X; is a portion of a polynucleotide sequence encoding the amino acid sequence encoded by the region of SEQ ID NO:B as defined in column 6 of Table 1C or the complementary strand thereto; or is a portion of the polynucleotide sequence of SEQ ID NO:B as defined in column 6 of Table 1C or the complementary strand thereto.

[0592] The polynucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment “at least 20 nt in length,” for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in ATCC Deposit No:Z, or the nucleotide sequence shown in SEQ ID NO:X or the complementary stand thereto. In this context “about” includes the particularly recited value or a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., at least 160, 170, 180, 190, 200, 250, 500, 600, 1000, or 2000 nucleotides in length) are also encompassed by the invention.

[0593] Moreover, representative examples of polynucleotide fragments of the invention comprise, or alternatively consist of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 601-650, 651-700, 701-750, 751-800, 801-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, 2001-2050, 2051-2100, 2101-2150, 2151-2200, 2201-2250, 2251-2300, 2301-2350, 2351-2400, 2401-2450, 2451-2500, 2501-2550, 2551-2600, 2601-2650, 2651-2700, 2701-2750, 2751-2800, 2801-2850, 2851-2900, 2901-2950, 2951-3000, 3001-3050, 3051-3100, 3101-3150, 3151-3200, 3201-3250, 3251-3300, 3301-3350, 3351-3400, 3401-3450, 3451-3500, 3501-3550, 3551-3600, 3601-3650, 3651-3700, 3701-3750, 3751-3800, 3801-3850, 3851-3900, 3901-3950, 3951-4000, 4001-4050, 4051-4100, 4101-4150, 4151-4200, 4201-4250, 4251-4300, 4301-4350, 4351-4400, 4401-4450, 4451-4500, 4501-4550, 4551-4600, 4601-4650, 4651-4700, 4701-4750, 4751-4800, 4801-4850, 4851-4900, 4901-4950, 4951-5000, 5001-5050, 5051-5100, 5101-5150, 5151-5200, 5201-5250, 5251-5300, 5301-5350, 5351-5400, 5401-5450, 5451-5500, 5501-5550, 5551-5600, 5601-5650, 5651-5700, 5701-5750, 5751-5800, 5801-5850, 5851-5900, 5901-5950, 5951-6000, 6001-6050, 6051-6100, 6101-6150, 6151-6200, 6201-6250, 6251-6300, 6301-6350, 6351-6400, 6401-6450, 6451-6500, 6501-6550, 6551-6600, 6601-6650, 6651-6700, 6701-6750, 6751-6800, 6801-6850, 6851-6900, 6901-6950, 6951-7000, 7001-7050, 7051-7100, 7101-7150, 7151-7200, 7201-7250, 7251-7300 or 7301 to the end of SEQ ID NO:X, or the complementary strand thereto. In this context “about” includes the particularly recited range or a range larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has a functional activity (e.g., biological activity). More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to one or more of these polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

[0594] Further representative examples of polynucleotide fragments of the invention comprise, or alternatively consist of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 601-650, 651-700, 701-750, 751-800, 801-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, 2001-2050, 2051-2100, 2101-2150, 2151-2200, 2201-2250, 2251-2300, 2301-2350, 2351-2400, 2401-2450, 2451-2500, 2501-2550, 2551-2600, 2601-2650, 2651-2700, 2701-2750, 2751-2800, 2801-2850, 2851-2900, 2901-2950, 2951-3000, 3001-3050, 3051-3100, 3101-3150, 3151-3200, 3201-3250, 3251-3300, 3301-3350, 3351-3400, 3401-3450, 3451-3500, 3501-3550, 3551-3600, 3601-3650, 3651-3700, 3701-3750, 3751-3800, 3801-3850, 3851-3900, 3901-3950, 3951-4000, 4001-4050, 4051-4100, 4101-4150, 4151-4200, 4201-4250, 4251-4300, 4301-4350, 4351-4400, 4401-4450, 4451-4500, 4501-4550, 4551-4600, 4601-4650, 4651-4700, 4701-4750, 4751-4800, 4801-4850, 4851-4900, 4901-4950, 4951-5000, 5001-5050, 5051-5100, 5101-5150, 5151-5200, 5201-5250, 5251-5300, 5301-5350, 5351-5400, 5401-5450, 5451-5500, 5501-5550, 5551-5600, 5601-5650, 5651-5700, 5701-5750, 5751-5800, 5801-5850, 5851-5900, 5901-5950, 5951-6000, 6001-6050, 6051-6100, 6101-6150, 6151-6200, 6201-6250, 6251-6300, 6301-6350, 6351-6400, 6401-6450, 6451-6500, 6501-6550, 6551-6600, 6601-6650, 6651-6700, 6701-6750, 6751-6800, 6801-6850, 6851-6900, 6901-6950, 6951-7000, 7001-7050, 7051-7100, 7101-7150, 7151-7200, 7201-7250, 7251-7300 or 7301 to the end of the cDNA sequence contained in ATCC Deposit No:Z, or the complementary strand thereto. In this context “about” includes the particularly recited range or a range larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has a functional activity (e.g., biological activity). More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to one or more of these polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

[0595] Moreover, representative examples of polynucleotide fragments of the invention comprise, or alternatively consist of, a nucleic acid sequence comprising one, two, three, four, five, six, seven, eight, nine, ten, or more of the above described polynucleotide fragments of the invention in combination with a polynucleotide sequence delineated in Table 1C column 6. Additional, representative examples of polynucleotide fragments of the invention comprise, or alternatively consist of, a nucleic acid sequence comprising one, two, three, four, five, six, seven, eight, nine, ten, or more of the above described polynucleotide fragments of the invention in combination with a polynucleotide sequence that is the complementary strand of a sequence delineated in column 6 of Table 1C. In further embodiments, the above-described polynucleotide fragments of the invention comprise, or alternatively consist of, sequences delineated in Table 1C, column 6, and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table 1C, column 5). In additional embodiments, the above-described polynucleotide fragments of the invention comprise, or alternatively consist of, sequences delineated in Table 1C, column 6, and have a nucleic acid sequence which is different from that published for the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). In additional embodiments, the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated Table 1C, column 6, and have a nucleic acid sequence which is different from that contained in the BAC clone identified as BAC ID NO:A (see Table 1C, column 4). Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides and polypeptides are also encompassed by the invention.

[0596] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more fragments of the sequences delineated in column 6 of Table 1C, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1C, column 2) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0597] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more fragments of the sequences delineated in column 6 of Table 1C which correspond to the same ATCC Deposit No:Z (see Table 1C, column 1), and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A, 1B, or 1C) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0598] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more fragments of the sequences delineated in the same row of column 6 of Table 1C, and the polynucleotide sequence of SEQ ID NO:X (e.g., as defined in Table 1A, 1B, or 1C) or fragments or variants thereof. Polypeptides encoded by these polynucleotides, other polynucleotides that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention.

[0599] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3′ 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5′ 10 polynucleotides of the sequence of SEQ ID NO:X are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids that encode these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0600] In additional specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3′ 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5′ 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X (e.g., as described herein) are directly contiguous Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0601] In further specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3′ 10 polynucleotides of a fragment or variant of the sequence of SEQ ID NO:X and the 5′ 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table 1C are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0602] In specific embodiments, polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3′ 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C and the 5′ 10 polynucleotides of another sequence in column 6 are directly contiguous. In preferred embodiments, the 3′ 10 polynucleotides of one of the sequences delineated in column 6 of Table 1C is directly contiguous with the 5′ 10 polynucleotides of the next sequential exon delineated in Table 1C, column 6. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention. Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.

[0603] In the present invention, a “polypeptide fragment” refers to an amino acid sequence which is a portion of the amino acid sequence contained in SEQ ID NO:Y, is a portion of the mature form of SEQ ID NO:Y as defined in columns 14 and 15 of Table 1A, a portion of an amino acid sequence encoded by the portion of SEQ ID NO:X as defined in columnns 8 and 9 of Table 2, is a portion of an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:X, is a portion of an amino acid sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X, is a portion of the amino acid sequence of a mature (secreted) polypeptide encoded by the cDNA contained in ATCC Deposit No:Z, and/or is a portion of an amino acid sequence encoded by the cDNA contained in ATCC Deposit No:Z. Protein (polypeptide) fragments may be “free-standing,” or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 101-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-320, 321-340, 341-360, 361-380, 381-400, 401-420, 421-440, 441-460, 461-480, 481-500, 501-520, 521-540, 541-560, 561-580, 581-600, 601-620, 621-640, 641-660, 661-680, 681-700, 701-720, 721-740, 741-760, 761-780, 781-800, 801-820, 821-840, 841-860, 861-880, 881-900, 901-920, 921-940, 941-960, 961-980, 981-1000, 1001-1020, 1021-1040, 1041-1060, 1061-1080, 1081-1100, 1101-1120, 1121-1140, 1141-1160, 1161-1180, 1181-1200, 1201-1220, 1221-1240, 1241-1260, 1261-1280, 1281-1300, 1301-1320, 1321-1340, 1341-1360, 1361-1380, 1381-1400, 1401-1420, 1421-1440, or 1441 to the end of the coding region of cDNA and SEQ ID NO: Y. In a preferred embodiment, polypeptide fragments of the invention include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 101-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-320, 321-340, 341-360, 361-380, 381-400, 401-420, 421-440, 441-460, 461-480, 481-500, 501-520, 521-540, 541-560, 561-580, 581-600, 601-620, 621-640, 641-660, 661-680, 681-700, 701-720, 721-740, 741-760, 761-780, 781-800, 801-820, 821-840, 841-860, 861-880, 881-900, 901-920, 921-940, 941-960, 961-980, 981-1000, 1001-1020, 1021-1040, 1041-1060, 1061-1080, 1081-1100, 1101-1120, 1121-1140, 1141-1160, 1161-1180, 1181-1200, 1201-1220, 1221-1240, 1241-1260, 1261-1280, 1281-1300, 1301-1320, 1321-1340, 1341-1360, 1361-1380, 1381-1400, 1401-1420, 1421-1440, or 1441 to the end of the coding region of SEQ ID NO:Y. Moreover, polypeptide fragments of the invention may be at least about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context “about” includes the particularly recited ranges or values, or ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

[0604] Even if deletion of one or more amino acids from the N-terminus of a protein results in modification of loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still be retained. For example, the ability of shortened muteins to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptides generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted N-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

[0605] Accordingly, polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

[0606] The present invention further provides polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence of a polypeptide disclosed herein (e.g., a polypeptide of SEQ ID NO:Y, a polypeptide as defined in columns 14 and 15 of Table 1A, a polypeptide encoded by the polynucleotide sequence contained in SEQ ID NO:X or the complement thereof, a polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, a polypeptide encoded by the portion of SEQ ID NO:B as defined in column 6 of Table 1C, a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z, and/or a mature polypeptide encoded by the cDNA contained in ATCC Deposit No:Z). In particular, N-terminal deletions may be described by the general formula m-q, where q is a whole integer representing the total number of amino acid residues in a polypeptide of the invention (e.g., the polypeptide disclosed in SEQ ID NO:Y, the mature (secreted) portion of SEQ ID NO:Y as defined in columns 14 and 15 of Table 1A, or the polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2), and m is defined as any integer ranging from 2 to q-6. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0607] The present invention further provides polypeptides having one or more residues from the carboxy terminus of the amino acid sequence of a polypeptide disclosed herein (e.g., a polypeptide of SEQ ID NO:Y, the mature (secreted) portion of SEQ ID NO:Y as defined in columns 14 and 15 of Table 1A, a polypeptide encoded by the polynucleotide sequence contained in SEQ ID NO:X, a polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, a polypeptide encoded by the portion of SEQ ID NO:B as defined in column 6 of Table 1C, a polypeptide encoded, by the cDNA contained in ATCC Deposit No:Z, and/or a mature polypeptide encoded by the cDNA contained in ATCC Deposit No:Z). In particular, C-terminal deletions may be described by the general formula 1-n, where n is any whole integer ranging from 6 to q-1, and where n corresponds to the position of amino acid residue in a polypeptide of the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0608] In addition, any of the above described N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted polypeptide. The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues m-n of a polypeptide encoded by SEQ ID NO:X (e.g., including, but not limited to, the preferred polypeptide disclosed as SEQ ID NO:Y, the mature (secreted) portion of SEQ ID NO:Y as defined in columns 14 and 15 of Table 1A, and the polypeptide encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2), the cDNA contained in ATCC Deposit No:Z, and/or the complement thereof, where n and m are integers as described above. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0609] Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification of loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind a ligand) may still be retained. For example the ability of the shortened mutein to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted C-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

[0610] The present application is also directed to proteins containing polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a polypeptide sequence set forth herein. In preferred embodiments, the application is directed to proteins containing polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to polypeptides having the amino acid sequence of the specific N- and C-terminal deletions. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0611] Any polypeptide sequence encoded by, for example, the polynucleotide sequences set forth as SEQ ID NO:X or the complement thereof, (presented, for example, in Tables 1A and 2), the cDNA contained in ATCC Deposit No:Z, or the polynucleotide sequence as defined in column 6 of Table 1C, may be analyzed to determine certain preferred regions of the polypeptide. For example, the amino acid sequence of a polypeptide encoded by a polynucleotide sequence of SEQ ID NO:X (e.g., the polypeptide of SEQ ID NO:Y and the polypeptide encoded by the portion of SEQ ID NO:X as defined in columnns 8 and 9 of Table 2) or the cDNA contained in ATCC Deposit No:Z may be analyzed using the default parameters of the DNASTAR computer algorithm (DNASTAR, Inc., 1228 S. Park St., Madison, Wis. 53715 USA; http://www.dnastar.com/).

[0612] Polypeptide regions that may be routinely obtained using the DNASTAR computer algorithm include, but are not limited to, Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions; Chou-Fasman alpha-regions, beta-regions, and turn-regions; Kyte-Doolittle hydrophilic regions and hydrophobic regions; Eisenberg alpha- and beta-amphipathic regions; Karplus-Schulz flexible regions; Emini surface-forming regions; and Jameson-Wolf regions of high antigenic index. Among highly preferred polynucleotides of the invention in this regard are those that encode polypeptides comprising regions that combine several structural features, such as several (e.g., 1, 2, 3 or 4) of the features set out above.

[0613] Additionally, Kyte-Doolittle hydrophilic regions and hydrophobic regions, Emini surface-forming regions, and Jameson-Wolf regions of high antigenic index (i.e., containing four or more contiguous amino acids having an antigenic index of greater than or equal to 1.5, as identified using the default parameters of the Jameson-Wolf program) can routinely be used to determine polypeptide regions that exhibit a high degree of potential for antigenicity. Regions of high antigenicity are determined from data by DNASTAR analysis by choosing values which represent regions of the polypeptide which are likely to be exposed on the surface of the polypeptide in an environment in which antigen recognition may occur in the process of initiation of an immune response.

[0614] Preferred polypeptide fragments of the invention are fragments comprising, or alternatively, consisting of, an amino acid sequence that displays a functional activity (e.g. biological activity) of the polypeptide sequence of which the amino acid sequence is a fragment. By a polypeptide displaying a “functional activity” is meant a polypeptide capable of one or more known functional activities associated with a full-length protein, such as, for example, biological activity, antigenicity, immunogenicity, and/or multimerization, as described herein.

[0615] Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

[0616] In preferred embodiments, polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the antigenic fragments of the polypeptide of SEQ ID NO:Y, or portions thereof. Polynucleotides encoding these polypeptides are also encompassed by the invention.

[0617] Epitopes and Antibodies

[0618] The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of: the polypeptide sequence shown in SEQ ID NO:Y; a polypeptide sequence encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2; the polypeptide sequence encoded by the portion of SEQ ID NO:B as defined in column 6 of Table 1C or the complement thereto; the polypeptide sequence encoded by the cDNA contained in ATCC Deposit No:Z; or the polypeptide sequence encoded by a polynucleotide that hybridizes to the sequence of SEQ ID NO:X, the complement of the sequence of SEQ ID NO:X, the complement of a portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, or the cDNA sequence contained in ATCC Deposit No:Z under stringent hybridization conditions or alternatively, under lower stringency hybridization as defined supra. The present invention further encompasses polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X, or a fragment thereof), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or alternatively, under lower stringency hybridization conditions defined supra.

[0619] The term “epitopes,” as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An “immunogenic epitope,” as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term “antigenic epitope,” as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

[0620] Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Pat. No. 4,631,211.)

[0621] In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

[0622] Non-limiting examples of epitopes of polypeptides that can be used to generate antibodies of the invention include a polypeptide comprising, or alternatively consisting of, at least one, two, three, four, five, six or more of the portion(s) of SEQ ID NO:Y specified in column 7 of Table 1B. These polypeptide fragments have been determined to bear antigenic epitopes of the proteins of the invention by the analysis of the Jameson-Wolf antigenic index which is included in the DNAStar suite of computer programs. By “comprise” it is intended that a polypeptide contains at least one, two, three, four, five, six or more of the portion(s) of SEQ ID NO:Y shown in column 7 of Table 1B, but it may contain additional flanking residues on either the amino or carboxyl termini of the recited portion. Such additional flanking sequences are preferably sequences naturally found adjacent to the portion; i.e., contiguous sequence shown in SEQ ID NO:Y. The flanking sequence may, however, be sequences from a heterolgous polypeptide, such as from another protein described herein or from a heterologous polypeptide not described herein. In particular embodiments, epitope portions of a polypeptide of the invention comprise one, two, three, or more of the portions of SEQ ID NO:Y shown in column 7 of Table 1B.

[0623] Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

[0624] Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier-coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 μg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

[0625] As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention (e.g., those comprising an immunogenic or antigenic epitope) can be fused to heterologous polypeptide sequences. For example, polypeptides of the present invention (including fragments or variants thereof), may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof, resulting in chimeric polypeptides. By way of another non-limiting example, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) may be fused with albumin (including but not limited to recombinant human serum albumin or fragments or variants thereof (see, e.g., U.S. Pat. No. 5,876,969, issued Mar. 2, 1999, EP Patent 0 413 622, and U.S. Pat. No. 5,766,883, issued Jun. 16, 1998, herein incorporated by reference in their entirety)). In a preferred embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with the mature form of human serum albumin (i.e., amino acids 1-585 of human serum albumin as shown in FIGS. 1 and 2 of EP Patent 0 322 094) which is herein incorporated by reference in its entirety. In another preferred embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with polypeptide fragments comprising, or alternatively consisting of, amino acid residues 1-z of human serum albumin, where z is an integer from 369 to 419, as described in U.S. Pat. No. 5,766,883 herein incorporated by reference in its entirety. Polypeptides and/or antibodies of the present invention (including fragments or variants thereof) may be fused to either the N- or C-terminal end of the heterologous protein (e.g., immunoglobulin Fc polypeptide or human serum albumin polypeptide). Polynucleotides encoding fusion proteins of the invention are also encompassed by the invention.

[0626] Such fusion proteins as those described above may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion desulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin (HA) tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972-897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni2+ nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

[0627] Fusion Proteins

[0628] Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, polypeptides of the present invention which are shown to be secreted can be used as targeting molecules once fused to other proteins.

[0629] Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

[0630] In certain preferred embodiments, proteins of the invention are fusion proteins comprising an amino acid sequence that is an N and/or C-terminal deletion of a polypeptide of the invention. In preferred embodiments, the invention is directed to a fusion protein comprising an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a polypeptide sequence of the invention. Polynucleotides encoding these proteins are also encompassed by the invention.

[0631] Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

[0632] As one of skill in the art will appreciate that, as discussed above, polypeptides of the present invention, and epitope-bearing fragments thereof, can be combined with heterologous polypeptide sequences. For example, the polypeptides of the present invention may be fused with heterologous polypeptide sequences, for example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), or albumin (including, but not limited to, native or recombinant human albumin or fragments or variants thereof (see, e.g., U.S. Pat. No. 5,876,969, issued Mar. 2, 1999, EP Patent 0 413 622, and U.S. Pat. No. 5,766,883, issued Jun. 16, 1998, herein incorporated by reference in their entirety)), resulting in chimeric polypeptides. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties (EP-A 0232 262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

[0633] Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a polypeptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, Calif., 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the “HA” tag, corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)).

[0634] Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as “DNA shuffling”). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Pat. Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

[0635] Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

[0636] Recombinant and Synthetic Production of Polypeptides of the Invention

[0637] The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by synthetic and recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

[0638] The polynucleotides of the invention may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

[0639] The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

[0640] As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418, glutamine synthase, or neomycin resistance for eukaryotic cell culture, and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No. 201178)); insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

[0641] Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlbad, Calif.). Other suitable vectors will be readily apparent to the skilled artisan.

[0642] Vectors which use glutamine synthase (GS) or DHFR as the selectable markers can be amplified in the presence of the drugs methionine sulphoximine or methotrexate, respectively. An advantage of glutamine synthase based vectors are the availabilty of cell lines (e.g., the murine myeloma cell line, NSO) which are glutamine synthase negative. Glutamine synthase expression systems can also function in glutamine synthase expressing cells (e.g., Chinese Hamster Ovary (CHO) cells) by providing additional inhibitor to prevent the functioning of the endogenous gene. A glutamine synthase expression system and components thereof are detailed in PCT publications: WO87/04462; WO86/05807; WO89/01036; WO89/10404; and WO91/06657, which are hereby incorporated in their entireties by reference herein. Additionally, glutamine synthase expression vectors can be obtained from Lonza Biologics, Inc. (Portsmouth, N.H.). Expression and production of monoclonal antibodies using a GS expression system in murine myeloma cells is described in Bebbington et al., Bio/technology 10:169(1992) and in Biblia and Robinson Biotechnol. Prog. 11:1 (1995) which are herein incorporated by reference.

[0643] The present invention also relates to host cells containing the above-described vector constructs described herein, and additionally encompasses host cells containing nucleotide sequences of the invention that are operably associated with one or more heterologous control regions (e.g., promoter and/or enhancer) using techniques known of in the art. The host cell can be a higher eukaryotic cell, such as a mammalian cell (e.g., a human derived cell), or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. A host strain may be chosen which modulates the expression of the inserted gene sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus expression of the genetically engineered polypeptide may be controlled. Furthermore, different host cells have characteristics and specific mechanisms for the translational and post-translational processing and modification (e.g., phosphorylation, cleavage) of proteins. Appropriate cell lines can be chosen to ensure the desired modifications and processing of the foreign protein expressed.

[0644] Introduction of the nucleic acids and nucleic acid constructs of the invention into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

[0645] In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., the coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Pat. No. 5,641,670, issued Jun. 24, 1997; International Publication Number WO 96/29411; International Publication Number WO 94/12650; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

[0646] Polypeptides of the invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography (“HPLC”) is employed for purification.

[0647] Polypeptides of the present invention can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

[0648] In one embodiment, the yeast Pichia pastoris is used to express polypeptides of the invention in a eukaryotic system. Pichia pastoris is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O₂. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, Pichia pastoris must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O₂. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (AOX1) is highly active. In the presence of methanol, alcohol oxidase produced from the AOX1 gene comprises up to approximately 30% of the total soluble protein in Pichia pastoris. See Ellis, S. B., et al., Mol. Cell. Biol. 5:1111-21 (1985); Koutz, P. J, et al., Yeast 5:167-77 (1989); Tschopp, J. F., et al., Nucl. Acids Res. 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the AOX1 regulatory sequence is expressed at exceptionally high levels in Pichia yeast grown in the presence of methanol.

[0649] In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a Pichea yeast system essentially as described in “Pichia Protocols: Methods in Molecular Biology,” D. R. Higgins and J. Cregg, eds. The Humana Press, Totowa, N.J., 1998. This expression vector allows expression and secretion of a polypeptide of the invention by virtue of the strong AOX1 promoter linked to the Pichia pastoris alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

[0650] Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

[0651] In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

[0652] In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Pat. No. 5,641,670, issued Jun. 24, 1997; International Publication No. WO 96/29411, published Sep. 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijistra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

[0653] In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W. H. Freeman & Co., N.Y., and Hunkapiller et al., Nature, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid, α-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, b-alanine, fluoro-amino acids, designer amino acids such as b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

[0654] The invention encompasses polypeptides of the present invention which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

[0655] Additional post-translational modifications encompassed by the invention include, for example, e.g., N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

[0656] Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include iodine (¹²¹I, ¹²³I, ¹²⁵I, ¹³¹I), carbon (¹⁴C), sulfur (³⁵S), tritium (³H), indium (¹¹¹In, ¹¹²In, ^(113m)In, ^(115m)In), technetium (⁹⁹Tc, ^(99m)Tc), thallium (²⁰¹Ti), gallium (⁶⁸Ga, ⁶⁷Ga), palladium (¹⁰³Pd), molybdenum (⁹⁹Mo), xenon (¹³³Xe), fluorine (¹⁸F), ¹⁵³Sm, ¹⁷⁷Lu, ¹⁵⁹Gd, ¹⁴⁹Pm, ¹⁴⁰La, ¹⁷⁵Yb, ¹⁶⁶Ho, ⁹⁰, ⁴⁷Sc, ⁶Re, ¹⁸Re, ¹⁴²Pr, ¹⁰⁵Rh, and ⁹⁷Ru.

[0657] In specific embodiments, a polypeptide of the present invention or fragment or variant thereof is attached to macrocyclic chelators that associate with radiometal ions, including but not limited to, ¹⁷⁷Lu, ⁹⁰Y, ¹⁶⁶Ho, and ¹⁵³Sm, to polypeptides. In a preferred embodiment, the radiometal ion associated with the macrocyclic chelators is ¹¹¹In. In another preferred embodiment, the radiometal ion associated with the macrocyclic chelator is ⁹⁰Y. In specific embodiments, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA). In other specific embodiments, DOTA is attached to an antibody of the invention or fragment thereof via a linker molecule. Examples of linker molecules useful for conjugating DOTA to a polypeptide are commonly known in the art—see, for example, DeNardo et al., Clin Cancer Res. 4(10):2483-90 (1998); Peterson et al., Bioconjug. Chem. 10(4):553-7 (1999); and Zimmerman et al, Nucl. Med. Biol. 26(8):943-50 (1999); which are hereby incorporated by reference in their entirety.

[0658] As mentioned, the proteins of the invention may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Polypeptides of the invention may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS—STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

[0659] Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Pat. No. 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

[0660] The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term “about” indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 45,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

[0661] As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Pat. No. 5,643,575; Morpurgo et al., Appl. Biochem. Biotechnol. 56:59-72 (1996); Vorobjev et al., Nucleosides Nucleotides 18:2745-2750 (1999); and Caliceti et al., Bioconjug. Chem. 10:638-646 (1999), the disclosures of each of which are incorporated herein by reference.

[0662] The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, such as, for example, the method disclosed in EP 0 401 384 (coupling PEG to G-CSF), herein incorporated by reference; see also Malik et al., Exp. Hematol. 20:1028-1035 (1992), reporting pegylation of GM-CSF using tresyl chloride. For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

[0663] As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

[0664] One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

[0665] As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado et al., Crit. Rev. Thera. Drug Carrier Sys. 9:249-304 (1992); Francis et al., Intern. J. of Hematol. 68:1-18 (1998); U.S. Pat. No. 4,002,531; U.S. Pat. No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

[0666] One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride (ClSO₂CH₂CF₃). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoreothane sulphonyl group.

[0667] Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Pat. No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1′-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number of additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in International Publication No. WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

[0668] The number of polyethylene glycol moieties attached to each protein of the invention (i.e., the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3,2-4, 3-5,4-6, 5-7,6-8, 7-9,8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are discussed, for example, in Delgado et al., Crit. Rev. Thera. Drug Carrier Sys. 9:249-304 (1992).

[0669] The polypeptides of the invention can be recovered and purified from chemical synthesis and recombinant cell cultures by standard methods which include, but are not limited to, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography (“HPLC”) is employed for purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured during isolation and/or purification.

[0670] The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, Therapeutics) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

[0671] Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer refers to a multimer containing only polypeptides corresponding to a protein of the invention (e.g., the amino acid sequence of SEQ ID NO:Y, an amino acid sequence encoded by SEQ ID NO:X or the complement of SEQ ID NO:X, the amino acid sequence encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, and/or an amino acid sequence encoded by cDNA contained in ATCC Deposit No:Z (including fragments, variants, splice variants, and fusion proteins, corresponding to these as described herein)). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (e.g., containing two polypeptides having identical or different amino acid sequences) or a homotrimer (e.g., containing three polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

[0672] As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (i.e., polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

[0673] Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked by, for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in SEQ ID NO:Y, encoded by the portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, and/or encoded by the cDNA contained in ATCC Deposit No:Z). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein. In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., U.S. Pat. No. 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in a Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

[0674] Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

[0675] Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

[0676] In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

[0677] The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C-terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety).

[0678] Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated by reference in its entirety).

[0679] Antibodies

[0680] Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of the invention (e.g., a polypeptide or fragment or variant of the amino acid sequence of SEQ ID NO:Y or a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z, and/or an epitope, of the present invention) as determined by immunoassays well known in the art for assaying specific antibody-antigen binding. Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab′) fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), intracellularly-made antibodies (i.e., intrabodies), and epitope-binding fragments of any of the above. The term “antibody,” as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In preferred embodiments, the immunoglobulin molecules of the invention are IgG1. In other preferred embodiments, the immunoglobulin molecules of the invention are IgG4.

[0681] Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab′ and F(ab′)₂, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, “human” antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Pat. No. 5,939,598 by Kucherlapati et al.

[0682] The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Pat. Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

[0683] Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, or by size in contiguous amino acid residues, or listed in the Tables and Figures. Preferred epitopes of the invention include the predicted epitopes shown in column 7 of Table 1B, as well as polynucleotides that encode these epitopes. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

[0684] Antibodies of the present invention may also be described or specified in terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or Kd less than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶M, 5×10⁻⁷ M, 10⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M.

[0685] The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

[0686] Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

[0687] The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Pat. No. 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res. 58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

[0688] Antibodies of the present invention may be used, for example, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have utility in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); incorporated by reference herein in its entirety.

[0689] As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalent and non-covalent conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Pat. No. 5,314,995; and EP 396,387; the disclosures of which are incorporated herein by reference in their entireties.

[0690] The antibodies of the invention include derivatives that are modified, i.e, by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

[0691] The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

[0692] Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology. The term “monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

[0693] Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples. In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP2O available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

[0694] Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

[0695] Another well known method for producing both polyclonal and monoclonal human B cell lines is transformation using Epstein Barr Virus (EBV). Protocols for generating EBV-transformed B cell lines are commonly known in the art, such as, for example, the protocol outlined in Chapter 7.22 of Current Protocols in Immunology, Coligan et al., Eds., 1994, John Wiley & Sons, NY, which is hereby incorporated in its entirety by reference. The source of B cells for transformation is commonly human peripheral blood, but B cells for transformation may also be derived from other sources including, but not limited to, lymph nodes, tonsil, spleen, tumor tissue, and infected tissues. Tissues are generally made into single cell suspensions prior to EBV transformation. Additionally, steps may be taken to either physically remove or inactivate T cells (e.g., by treatment with cyclosporin A) in B cell-containing samples, because T cells from individuals seropositive for anti-EBV antibodies can suppress B cell immortalization by EBV.

[0696] In general, the sample containing human B cells is innoculated with EBV, and cultured for 3-4 weeks. A typical source of EBV is the culture supernatant of the B95-8 cell line (ATCC #VR-1492). Physical signs of EBV transformation can generally be seen towards the end of the 3-4 week culture period. By phase-contrast microscopy, transformed cells may appear large, clear, hairy and tend to aggregate in tight clusters of cells. Initially, EBV lines are generally polyclonal. However, over prolonged periods of cell cultures, EBV lines may become monoclonal or polyclonal as a result of the selective outgrowth of particular B cell clones. Alternatively, polyclonal EBV transformed lines may be subcloned (e.g., by limiting dilution culture) or fused with a suitable fusion partner and plated at limiting dilution to obtain monoclonal B cell lines. Suitable fusion partners for EBV transformed cell lines include mouse myeloma cell lines (e.g., SP2/0, X63-Ag8.653), heteromyeloma cell lines (human×mouse; e.g, SPAM-8, SBC-H20, and CB-F7), and human cell lines (e.g., GM 1500, SKO-007, RPMI 8226, and KR-4). Thus, the present invention also provides a method of generating polyclonal or monoclonal human antibodies against polypeptides of the invention or fragments thereof, comprising EBV-transformation of human B cells.

[0697] Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab′)₂ fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab′)₂ fragments). F(ab′)₂ fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

[0698] For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

[0699] As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab′ and F(ab′)₂ fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques 12(6):864-869 (1992); and Sawai et al., AJR1 34:26-34 (1995); and Better et al., Science 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

[0700] Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Pat. Nos. 4,946,778 and 5,258,498; Huston et al., Methods in Enzymology 203:46-88 (1991); Shu et al., PNAS 90:7995-7999 (1993); and Skerra et al., Science 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., (1989) J. Immunol. Methods 125:191-202; U.S. Pat. Nos. 5,807,715; 4,816,567; and 4,816397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Pat. Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Pat. No. 5,565,332).

[0701] Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Pat. Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

[0702] Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Pat. Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; 5,939,598; 6,075,181; and 6,114,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, Calif.) and Genpharm (San Jose, Calif.) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

[0703] Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as “guided selection.” In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

[0704] Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotype antibodies that “mimic” polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that “mimic” the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand(s)/receptor(s). For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligand(s)/receptor(s), and thereby block its biological activity. Alternatively, antibodies which bind to and enhance polypeptide multimerization and/or binding, and/or receptor/ligand multimerization, binding and/or signaling can be used to generate anti-idiotypes that function as agonists of a polypeptide of the invention and/or its ligand/receptor. Such agonistic anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens as agonists of the polypeptides of the invention or its ligand(s)/receptor(s). For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligand(s)/receptor(s), and thereby promote or enhance its biological activity.

[0705] Intrabodies of the invention can be produced using methods known in the art, such as those disclosed and reviewed in Chen et al., Hum. Gene Ther. 5:595-601 (1994); Marasco, W. A., Gene Ther. 4:11-15 (1997); Rondon and Marasco, Annu. Rev. Microbiol. 51:257-283 (1997); Proba et al., J. Mol. Biol. 275:245-253 (1998); Cohen et al., Oncogene 17:2445-2456 (1998); Ohage and Steipe, J. Mol. Biol. 291:1119-1128 (1999); Ohage et al., J. Mol. Biol. 291:1129-1134 (1999); Wirtz and Steipe, Protein Sci. 8:2245-2250 (1999); Zhu et al., J. Immunol. Methods 231:207-222 (1999); and references cited therein.

[0706] Polynucleotides Encoding Antibodies

[0707] The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or alternatively, under lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y, to a polypeptide encoded by a portion of SEQ ID NO:X as defined in columns 8 and 9 of Table 2, and/or to a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z.

[0708] The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

[0709] Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable to the 3′ and 5′ ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

[0710] Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

[0711] In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well know in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

[0712] In addition, techniques developed for the production of “chimeric antibodies” (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

[0713] Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038-1041 (1988)).

[0714] Methods of Producing Antibodies

[0715] The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques. Methods of producing antibodies include, but are not limited to, hybridoma technology, EBV transformation, and other methods discussed herein as well as through the use recombinant DNA technology, as discussed below.

[0716] Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Pat. No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

[0717] The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

[0718] A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as Escherichia coli, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., Gene 45:101 (1986); Cockett et al., Bio/Technology 8:2 (1990)).

[0719] In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

[0720] In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

[0721] In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

[0722] In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, W138, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.

[0723] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

[0724] A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgprt- or aprt-cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215 (1993)); and hygro, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

[0725] The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

[0726] Vectors which use glutamine synthase (GS) or DHFR as the selectable markers can be amplified in the presence of the drugs methionine sulphoximine or methotrexate, respectively. An advantage of glutamine synthase based vectors are the availabilty of cell lines (e.g., the murine myeloma cell line, NSO) which are glutamine synthase negative. Glutamine synthase expression systems can also function in glutamine synthase expressing cells (e.g. Chinese Hamster Ovary (CHO) cells) by providing additional inhibitor to prevent the functioning of the endogenous gene. A glutamine synthase expression system and components thereof are detailed in PCT publications: WO87/04462; WO86/05807; WO89/01036; WO89/10404; and WO91/06657 which are incorporated in their entireties by reference herein. Additionally, glutamine synthase expression vectors that may be used according to the present invention are commercially available from suplliers, including, for example Lonza Biologics, Inc. (Portsmouth, N.H.). Expression and production of monoclonal antibodies using a GS expression system in murine myeloma cells is described in Bebbington et al., Bio/technology 10:169(1992) and in Biblia and Robinson Biotechnol. Prog. 11:1 (1995) which are incorporated in their entirities by reference herein.

[0727] The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

[0728] Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

[0729] The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Pat. No. 5,474,981; Gillies et al., PNAS 89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452 (1991), which are incorporated by reference in their entireties.

[0730] The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Pat. Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337-11341 (1992) (said references incorporated by reference in their entireties).

[0731] As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See EP 394,827; and Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide-linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. See, for example, Fountoulakis et al., J. Biochem. 270:3958-3964 (1995). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. See, for example, EP A 232,262. Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fe portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fe portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995)).

[0732] Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, Calif., 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the “HA” tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the “flag” tag.

[0733] The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Pat. No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include 125I, 131I, 111In or 99Tc.

[0734] Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, 213Bi. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0735] The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α-interferon, β-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF-alpha, TNF-beta, AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi et al., Int. Immunol., 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 (“IL-1”), interleukin-2 (“L-2”), interleukin-6 (“L-6”), granulocyte macrophage colony stimulating factor (“GM-CSF”), granulocyte colony stimulating factor (“G-CSF”), or other growth factors.

[0736] Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

[0737] Techniques for conjugating such therapeutic moiety to antibodies are well known. See, for example, Arnon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”, in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., “Antibodies For Drug Delivery”, in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review”, in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); “Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”, Immunol. Rev. 62:119-58 (1982).

[0738] Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Pat. No. 4,676,980, which is incorporated herein by reference in its entirety.

[0739] An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

[0740] Immunophenotyping

[0741] The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. Translation products of the gene of the present invention may be useful as cell-specific markers, or more specifically as cellular markers that are differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, “panning” with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Pat. No. 5,985,660; and Morrison et al., Cell, 96:737-49 (1999)).

[0742] These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and “non-self” cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

[0743] Assays For Antibody Binding

[0744] The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), “sandwich” immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, and protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

[0745] Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X-100, 1% sodium deoxycholate,

[0746] 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C., adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C., washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al., eds., (1994), Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, section 10.16.1.

[0747] Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%-20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g., ³²P or ¹²⁵I) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, (1994), Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, section 10.8.1.

[0748] ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, (1994), Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, section 11.2.1.

[0749] The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or ¹²⁵I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3H or ¹²⁵I) in the presence of increasing amounts of an unlabeled second antibody.

[0750] Antibodies of the invention may be characterized using immunocytochemisty methods on cells (e.g., mammalian cells, such as CHO cells) transfected with a vector enabling the expression of an antigen or with vector alone using techniques commonly known in the art. Antibodies that bind antigen transfected cells, but not vector-only transfected cells, are antigen specific.

[0751] Therapeutic uses

[0752] Table 1D: In preferred embodiments, the present invention encompasses a method of treating a disease or disorder listed in the “Preferred Indications” column of Table 1D; comprising administering to a patient in which such treatment, prevention, or amelioration is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) represented by Table 1A and Table 1D (in the same row as the disease or disorder to be treated is listed in the “Preferred Indications” column of Table 1D) in an amount effective to treat, prevent, or ameliorate the disease or disorder.

[0753] As indicated in Table 1D, the polynucleotides, polypeptides, agonists, or antagonists of the present invention (including antibodies) can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists thereof (including antibodies) could be used to treat the associated disease.

[0754] The present invention encompasses methods of preventing, treating, diagnosing, or ameliorating a disease or disorder. In preferred embodiments, the present invention encompasses a method of treating a disease or disorder listed in the “Preferred Indications” column of Table 1D; comprising administering to a patient in which such treatment, prevention, or amelioration is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to treat, prevent, diagnose, or ameliorate the disease or disorder. The first and seccond columns of Table 1D show the “Gene No.” and “cDNA Clone ID No.”, respectively, indicating certain nucleic acids and proteins (or antibodies against the same) of the invention (including polynucleotide, polypeptide, and antibody fragments or variants thereof) that may be used in preventing, treating, diagnosing, or ameliorating the disease(s) or disorder(s) indicated in the corresponding row in Column 3 of Table 1D.

[0755] In another embodiment, the present invention also encompasses methods of preventing, treating, diagnosing, or ameliorating a disease or disorder listed in the “Preferred Indications” column of Table 1D; comprising administering to a patient combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in Column 3 of Table 1D.

[0756] The “Preferred Indication” column describes diseases, disorders, and/or conditions that may be treated, prevented, diagnosed, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

[0757] The recitation of “Cancer” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof) may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., leukemias, cancers, and/or as described below under “Hyperproliferative Disorders”).

[0758] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D may be used for example, to diagnose, treat, prevent, and/or ameliorate a neoplasm located in a tissue selected from the group consisting of: colon, abdomen, bone, breast, digestive system, liver, pancreas, prostate, peritoneum, lung, blood (e.g., leukemia), endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), uterus, eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

[0759] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a pre-neoplastic condition, selected from the group consisting of: hyperplasia (e.g., endometrial hyperplasia and/or as described in the section entitled “Hyperproliferative Disorders”), metaplasia (e.g., connective tissue metaplasia, a typical metaplasia, and/or as described in the section entitled “Hyperproliferative Disorders”), and/or dysplasia (e.g., cervical dysplasia, and bronchopulmonary dysplasia).

[0760] In another specific embodiment, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cancer” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a benign dysproliferative disorder selected from the group consisting of: benign tumors, fibrocystic conditions, tissue hypertrophy, and/or as described in the section entitled “Hyperproliferative Disorders”.

[0761] The recitation of “Immune/Hematopoietic” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), blood disorders (e.g., as described below under “Immune Activity” “Cardiovascular Disorders” and/or “Blood-Related Disorders”), and infections (e.g., as described below under “Infectious Disease”).

[0762] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having the “Immune/Hematopoietic” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: anemia, pancytopenia, leukopenia, thrombocytopenia, leukemias, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, asthma, AIDS, autoimmune disease, rheumatoid arthritis, granulomatous disease, immune deficiency, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, immune reactions to transplanted organs and tissues, systemic lupus erythematosis, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and allergies.

[0763] The recitation of “Reproductive” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the reproductive system (e.g., as described below under “Reproductive System Disorders”).

[0764] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Reproductive” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cryptorchism, prostatitis, inguinal hernia, varicocele, leydig cell tumors, verrucous carcinoma, prostatitis, malacoplakia, Peyronie's disease, penile carcinoma, squamous cell hyperplasia, dysmenorrhea, ovarian adenocarcinoma, Turner's syndrome, mucopurulent cervicitis, Sertoli-leydig tumors, ovarian cancer, uterine cancer, pelvic inflammatory disease, testicular cancer, prostate cancer, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes mellitus, cystic fibrosis, Kartagener's syndrome, testicular atrophy, testicular feminization, anorchia, ectopic testis, epididymitis, orchitis, gonorrhea, syphilis, testicular torsion, vasitis nodosa, germ cell tumors, stromal tumors, dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding, cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, cervical neoplasms, pseudohermaphroditism, and premenstrual syndrome.

[0765] The recitation of “Musculoskeletal” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the immune system (e.g., as described below under “Immune Activity”).

[0766] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Musculoskeletal” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bone cancers (e.g., osteochondromas, benign chondromas, chondroblastoma, chondromyxoid fibromas, osteoid osteomas, giant cell tumors, multiple myeloma, osteosarcomas), Paget's Disease, rheumatoid arthritis, systemic lupus erythematosus, osteomyelitis, Lyme Disease, gout, bursitis, tendonitis, osteoporosis, osteoarthritis, muscular dystrophy, mitochondrial myopathy, cachexia, and multiple sclerosis.

[0767] The recitation of “Cardiovascular” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), and disorders of the cardiovascular system (e.g., as described below under “Cardiovascular Disorders”).

[0768] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Cardiovascular” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: myxomas, fibromas, rhabdomyomas, cardiovascular abnormalities (e.g., congenital heart defects, cerebral arteriovenous malformations, septal defects), heart disease (e.g., heart failure, congestive heart disease, arrhythmia, tachycardia, fibrillation, pericardial Disease, endocarditis), cardiac arrest, heart valve disease (e.g., stenosis, regurgitation, prolapse), vascular disease (e.g., hypertension, coronary artery disease, angina, aneurysm, arteriosclerosis, peripheral vascular disease), hyponatremia, hypernatremia, hypokalemia, and hyperkalemia.

[0769] The recitation of “Mixed Fetal” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”).

[0770] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Mixed Fetal” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: spina bifida, hydranencephaly, neurofibromatosis, fetal alcohol syndrome, diabetes mellitus, PKU, Down's syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, Apert syndrome, Carpenter syndrome, Conradi syndrome, Crouzon syndrome, cutis laxa, Cornelia de Lange syndrome, Ellis-van Creveld syndrome, Holt-Oram syndrome, Kartagener syndrome, Meckel-Gruber syndrome, Noonan syndrome, Pallister-Hall syndrome, Rubinstein-Taybi syndrome, Scimitar syndrome, Smith-Lemli-Opitz syndrome, thromocytopenia-absent radius (TAR) syndrome, Treacher Collins syndrome, Williams syndrome, Hirschsprung's disease, Meckel's diverticulum, polycystic kidney disease, Turner's syndrome, and gonadal dysgenesis, Klippel-Feil syndrome, Ostogenesis imperfecta, muscular dystrophy, Tay-Sachs disease, Wilm's tumor, neuroblastoma, and retinoblastoma.

[0771] The recitation of “Excretory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and renal disorders (e.g., as described below under “Renal Disorders”).

[0772] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Excretory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bladder cancer, prostate cancer, benign prostatic hyperplasia, bladder disorders (e.g., urinary incontinence, urinary retention, urinary obstruction, urinary tract Infections, interstitial cystitis, prostatitis, neurogenic bladder, hematuria), renal disorders (e.g., hydronephrosis, proteinuria, renal failure, pyelonephritis, urolithiasis, reflux nephropathy, and unilateral obstructive uropathy).

[0773] The recitation of “Neural/Sensory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the nervous system (e.g., as described below under “Neural Activity and Neurological Diseases”).

[0774] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Neural/Sensory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: brain cancer (e.g., brain stem glioma, brain tumors, central nervous system (Primary) lymphoma, central nervous system lymphoma, cerebellar astrocytoma, and cerebral astrocytoma, neurodegenerative disorders (e.g., Alzheimer's Disease, Creutzfeldt-Jakob Disease, Parkinson's Disease, and Idiopathic Presenile Dementia), encephalomyelitis, cerebral malaria, meningitis, metabolic brain diseases (e.g., phenylketonuria and pyruvate carboxylase deficiency), cerebellar ataxia, ataxia telangiectasia, and AIDS Dementia Complex, schizophrenia, attention deficit disorder, hyperactive attention deficit disorder, autism, and obsessive compulsive disorders.

[0775] The recitation of “Respiratory” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the respiratory system (e.g., as described below under “Respiratory Disorders”).

[0776] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Respiratory” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of the respiratory system such as larynx cancer, pharynx cancer, trachea cancer, epiglottis cancer, lung cancer, squamous cell carcinomas, small cell (oat cell) carcinomas, large cell carcinomas, and adenocarcinomas. Allergic reactions, cystic fibrosis, sarcoidosis, histiocytosis X, infiltrative lung diseases (e.g., pulmonary fibrosis and lymphoid interstitial pneumonia), obstructive airway diseases (e.g., asthma, emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis and asbestosis), pneumonia, and pleurisy.

[0777] The recitation of “Endocrine” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the respiratory system (e.g., as described below under “Respiratory Disorders”), renal disorders (e.g., as described below under “Renal Disorders”), and disorders of the endocrine system (e.g., as described below under “Endocrine Disorders”.

[0778] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having an “Endocrine” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of endocrine tissues and organs (e.g., cancers of the hypothalamus, pituitary gland, thyroid gland, parathyroid glands, pancreas, adrenal glands, ovaries, and testes), diabetes (e.g., diabetes insipidus, type I and type II diabetes mellitus), obesity, disorders related to pituitary glands (e.g., hyperpituitarism, hypopituitarism, and pituitary dwarfism), hypothyroidism, hyperthyroidism, goiter, reproductive disorders (e.g. male and female infertility), disorders related to adrenal glands (e.g., Addison's Disease, corticosteroid deficiency, and Cushing's Syndrome), kidney cancer (e.g., hypernephroma, transitional cell cancer, and Wilm's tumor), diabetic nephropathy, interstitial nephritis, polycystic kidney disease, glomerulonephritis (e.g., IgM mesangial proliferative glomerulonephritis and glomerulonephritis caused by autoimmune disorders; such as Goodpasture's syndrome), and nephrocalcinosis.

[0779] The recitation of “Digestive” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”) and diseases or disorders of the gastrointestinal system (e.g., as described below under “Gastrointestinal Disorders”.

[0780] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Digestive” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: ulcerative colitis, appendicitis, Crohn's disease, hepatitis, hepatic encephalopathy, portal hypertension, cholelithiasis, cancer of the digestive system (e.g., biliary tract cancer, stomach cancer, colon cancer, gastric cancer, pancreatic cancer, cancer of the bile duct, tumors of the colon (e.g., polyps or cancers), and cirrhosis), pancreatitis, ulcerative disease, pyloric stenosis, gastroenteritis, gastritis, gastric atropy, benign tumors of the duodenum, distension, irritable bowel syndrome, malabsorption, congenital disorders of the small intestine, bacterial and parasitic infection, megacolon, Hirschsprung's disease, aganglionic megacolon, acquired megacolon, colitis, anorectal disorders (e.g., anal fistulas, hemorrhoids), congenital disorders of the liver (e.g., Wilson's disease, hemochromatosis, cystic fibrosis, biliary atresia, and alphal-antitrypsin deficiency), portal hypertension, cholelithiasis, and jaundice.

[0781] The recitation of “Connective/Epithelial” in the “Preferred Indication” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), cellular and genetic abnormalities (e.g., as described below under “Diseases at the Cellular Level”), angiogenesis (e.g., as described below under “Anti-Angiogenesis Activity”), and or to promote or inhibit regeneration (e.g., as described below under “Regeneration”), and wound healing (e.g., as described below under “Wound Healing and Epithelial Cell Proliferation”).

[0782] In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a “Connective/Epithelial” recitation in the “Preferred Indication” column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: connective tissue metaplasia, mixed connective tissue disease, focal epithelial hyperplasia, epithelial metaplasia, mucoepithelial dysplasia, graft v. host disease, polymyositis, cystic hyperplasia, cerebral dysplasia, tissue hypertrophy, Alzheimer's disease, lymphoproliferative disorder, Waldenstron's macroglobulinemia, Crohn's disease, pernicious anemia, idiopathic Addison's disease, glomerulonephritis, bullous pemphigoid, Sjogren's syndrome, diabetes mellitus, cystic fibrosis, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, osteoporosis, osteocarthritis, periodontal disease, wound healing, relapsing polychondritis, vasculitis, polyarteritis nodosa, Wegener's granulomatosis, cellulitis, rheumatoid arthritis, psoriatic arthritis, discoid lupus erythematosus, systemic lupus erythematosus, scleroderma, CREST syndrome, Sjogren's syndrome, polymyositis, dermatomyositis, mixed connective tissue disease, relapsing polychondritis, vasculitis, Henoch-Schonlein syndrome, erythema nodosum, polyarteritis nodosa, temporal (giant cell) arteritis, Takayasu's arteritis, Wegener's granulomatosis, Reiter's syndrome, Behcet's syndrome, ankylosing spondylitis, cellulitis, keloids, Ehler Danlos syndrome, Marfan syndrome, pseudoxantoma elasticum, osteogenese imperfecta, chondrodysplasias, epidermolysis bullosa, Alport syndrome, and cutis laxa.

[0783] Table 1E also provides information regarding biological activities and preferred therapeutic uses (i.e. see, “Preferred Indications” column) for polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof). Table 1E also provides information regarding assays which may be used to test polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) for the corresponding biological activities. The first column (“Gene No.”) provides the gene number in the application for each clone identifier. The second column (“cDNA ATCC Deposit No:Z”) provides the unique clone identifier for each clone as previously described and indicated in Tables 1A, 1B, 1C, and ID. The third column (“AA SEQ ID NO:Y”) indicates the Sequence Listing SEQ ID Number for polypeptide sequences encoded by the corresponding cDNA clones (also as indicated in Tables 1A, 1B, and 2). The fourth column (“Biological Activity”) indicates a biological activity corresponding to the indicated polypeptides (or polynucleotides encoding said polypeptides). The fifth column (“Exemplary Activity Assay”) further describes the corresponding biological activity and also provides information pertaining to the various types of assays which may be performed to test, demonstrate, or quantify the corresponding biological activity. The sixth column (“Preferred Indications”) describes particular embodiments of the invention as well as indications (e.g. pathologies, diseases, disorders, abnormalities, etc.) for which polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) may be used in detecting, diagnosing, preventing, and/or treating.

[0784] The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

[0785] In a specific and preferred embodiment, the present invention is directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more diseases, disorders, or conditions, including but not limited to: neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, pulmonary disorders, cardiovascular disorders, renal disorders, proliferative disorders, and/or cancerous diseases and conditions., and/or as described elsewhere herein. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (e.g., antibodies directed to the full length protein expressed on the cell surface of a mammalian cell; antibodies directed to an epitope of a polypeptide of the invention (such as, for example, a predicted linear epitope shown in column 7 of Table 1B; or a conformational epitope, including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

[0786] A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

[0787] The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

[0788] The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

[0789] It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or Kd less than 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M, 10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M, 10⁻⁹ M, 5×10⁻¹⁰ M, 10⁻¹⁰ M, 5×10⁻¹¹ M, 10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹²M, 5×10⁻¹³ M, 10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, and 10⁻¹⁵ M.

[0790] Gene Therapy

[0791] In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

[0792] Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

[0793] For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

[0794] In a preferred embodiment, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

[0795] Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

[0796] In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Pat. No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989)).

[0797] In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., Biotherapy 6:291-302 (1994), which describes the use of a retroviral vector to deliver the mdrl gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994); Kiem et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg, Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr. Opin. in Genetics and Devel. 3:110-114 (1993).

[0798] Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, Current Opinion in Genetics and Development 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155 (1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

[0799] Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., Proc. Soc. Exp. Biol. Med. 204:289-300 (1993); U.S. Pat. No. 5,436,146).

[0800] Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

[0801] In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

[0802] The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

[0803] Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

[0804] In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

[0805] In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

[0806] In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by the presence or absence of an appropriate inducer of transcription.

[0807] Demonstration of Therapeutic or Prophylactic Activity

[0808] The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

[0809] Therapeutic/Prophylactic Administration and Composition

[0810] The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably a polypeptide or antibody of the invention. In a preferred embodiment, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

[0811] Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

[0812] Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

[0813] In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

[0814] In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.)

[0815] In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard et al., J.Neurosurg. 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, e.g., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)).

[0816] Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

[0817] In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered in vivo to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Pat. No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

[0818] The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

[0819] In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0820] The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

[0821] The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

[0822] For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

[0823] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

[0824] Diagnosis and Imaging

[0825] Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

[0826] The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0827] Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen et al., J. Cell. Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (³⁵S), tritium (3H), indium (112In), and technetium (99Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0828] One facet of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

[0829] It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99 mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S. W. Burchiel et al., “Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments.” (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S. W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

[0830] Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

[0831] In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

[0832] Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

[0833] In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Pat. No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patent using positron emission-tomography. In yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

[0834] Kits

[0835] The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

[0836] In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

[0837] In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

[0838] In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

[0839] In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, Mo.).

[0840] The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

[0841] Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

[0842] Uses of the Polynucleotides

[0843] Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

[0844] The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome, thus each polynucleotide of the present invention can routinely be used as a chromosome marker using techniques known in the art. Table 1B, column 9 provides the chromosome location of some of the polynucleotides of the invention.

[0845] Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably at least 15 bp (e.g., 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can optionally be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to SEQ ID NO:X will yield an amplified fragment.

[0846] Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries, and computer mapping techniques (See, e.g., Shuler, Trends Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety).

[0847] Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., “Human Chromosomes: a Manual of Basic Techniques,” Pergamon Press, New York (1988).

[0848] For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

[0849] Thus, the present invention also provides a method for chromosomal localization which involves (a) preparing PCR primers from the polynucleotide sequences in Table 1B and/or Table 2 and SEQ ID NO:X and (b) screening somatic cell hybrids containing individual chromosomes.

[0850] The polynucleotides of the present invention would likewise be useful for radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g. Dear, “Genome Mapping: A Practical Approach,” IRL Press at Oxford University Press, London (1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999) each of which is hereby incorporated by reference in its entirety.

[0851] Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library)). Column 10 of Table 1B provides an OMIM reference identification number of diseases associated with the cytologic band disclosed in column 9 of Table 1B, as determined using techniques described herein and by reference to Table 5. Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

[0852] Thus, once coinheritance is established, differences in a polynucleotide of the invention and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

[0853] Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using the polynucleotides of the invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker. Diagnostic and prognostic methods, kits and reagents encompassed by the present invention are briefly described below and more thoroughly elsewhere herein (see e.g., the sections labeled “Antibodies”, “Diagnostic Assays”, and “Methods for Detecting Diseases”).

[0854] Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder. Additional non-limiting examples of diagnostic methods encompassed by the present invention are more thoroughly described elsewhere herein (see, e.g., Example 12).

[0855] In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the invention, where each probe has one strand containing a 31′mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

[0856] Where a diagnosis of a related disorder, including, for example, diagnosis of a tumor, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

[0857] By “measuring the expression level of polynucleotides of the invention” is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the invention or the level of the mRNA encoding the polypeptide of the invention in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the related disorder or being determined by averaging levels from a population of individuals not having a related disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

[0858] By “biological sample” is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains polypeptide of the present invention or the corresponding mRNA. As indicated, biological samples include body fluids (such as semen, lymph, vaginal pool, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

[0859] The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides of the invention are attached to a solid support. In one exemplary method, the support may be a “gene chip” or a “biological chip” as described in U.S. Pat. Nos. 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the invention attached may be used to identify polymorphisms between the isolated polynucleotide sequences of the invention, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, such as for example, in neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, pulmonary disorders, digestive disorders, metabolic disorders, cardiovascular disorders, renal disorders, proliferative disorders, and/or cancerous diseases and conditions. Such a method is described in U.S. Pat. Nos. 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

[0860] The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides of the invention are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by Nielsen et al., Science 254, 1497 (1991); and Egholm et al., Nature 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point (T.sub.m) by 8°-20° C., vs. 4°-16° C. for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

[0861] The compounds of the present invention have uses which include, but are not limited to, detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

[0862] Pathological cell proliferative disorders are often associated with inappropriate activation of proto-oncogenes. (Gelmann, E. P. et al., “The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology,” in Neoplastic Diseases of the Blood, Vol 1., Wiemik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Gelmann et al., supra) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Gelmann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Gelmann et al., supra)

[0863] For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580). However, it has been shown that exposure of IL-60 cells to a DNA construct that is complementary to the 5′ end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness is not be limited to treatment, prevention, and/or prognosis of proliferative disorders of cells and tissues of hematopoietic origin, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

[0864] In addition to the foregoing, a polynucleotide of the present invention can be used to control gene expression through triple helix formation or through antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); “Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix—see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense—Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988)). Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. The oligonucleotide described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of polypeptide of the present invention antigens. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease, and in particular, for the treatment of proliferative diseases and/or conditions. Non-limiting antisense and triple helix methods encompassed by the present invention are more thoroughly described elsewhere herein (see, e.g., the section labeled “Antisense and Ribozyme (Antagonists)”).

[0865] Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell. Additional non-limiting examples of gene therapy methods encompassed by the present invention are more thoroughly described elsewhere herein (see, e.g., the sections labeled “Gene Therapy Methods”, and Examples 16, 17 and 18).

[0866] The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of “Dog Tags” which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

[0867] The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

[0868] Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992)). Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

[0869] There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers prepared from the sequences of the present invention, specific to tissues, including but not limited to those shown in Table 1B. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination. Additional non-limiting examples of such uses are further described herein.

[0870] The polynucleotides of the present invention are also useful as hybridization probes for differential identification of the tissue(s) or cell type(s) present in a biological sample. Similarly, polypeptides and antibodies directed to polypeptides of the present invention are useful to provide immunological probes for differential identification of the tissue(s) (e.g., immunohistochemistry assays) or cell type(s) (e.g., immunocytochemistry assays). In addition, for a number of disorders of the above tissues or cells, significantly higher or lower levels of gene expression of the polynucleotides/polypeptides of the present invention may be detected in certain tissues (e.g., tissues expressing polypeptides and/or polynucleotides of the present invention, for example, those disclosed in column 8 of Table 1B, and/or cancerous and/or wounded tissues) or bodily fluids (e.g., semen, lymph, vaginal pool, serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to a “standard” gene expression level, i.e., the expression level in healthy tissue from an individual not having the disorder.

[0871] Thus, the invention provides a diagnostic method of a disorder, which involves: (a) assaying gene expression level in cells or body fluid of an individual; (b) comparing the gene expression level with a standard gene expression level, whereby an increase or decrease in the assayed gene expression level compared to the standard expression level is indicative of a disorder.

[0872] In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to “subtract-out” known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a “gene chip” or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

[0873] Uses of the Polypeptides

[0874] Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

[0875] Polypeptides and antibodies directed to polypeptides of the present invention are useful to provide immunological probes for differential identification of the tissue(s) (e.g., immunohistochemistry assays such as, for example, ABC immunoperoxidase (Hsu et al., J. Histochem. Cytochem. 29:577-580 (1981)) or cell type(s) (e.g., immunocytochemistry assays).

[0876] Antibodies can be used to assay levels of polypeptides encoded by polynucleotides of the invention in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell. Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (¹³¹I, ¹²⁵I, ¹²³I, ¹²¹I), carbon (¹⁴C), sulfur (³⁵S), tritium (³H), indium (^(115m)In, ^(113m)In, ¹¹²In, ¹¹¹In), and technetium (⁹⁹Tc, ^(99m)Tc), thallium (²⁰¹Ti), gallium (⁶⁸Ga, ⁶⁷Ga), palladium (¹⁰³Pd), molybdenum (⁹⁹Mo), xenon (¹³³Xe), fluorine (¹⁸F), ¹⁵³Sm, ¹⁷⁷Lu, ¹⁵⁹Gd, ¹⁴⁹Pm, ¹⁴⁰La, ¹⁷⁵Yb, ¹⁶⁶Ho, ⁹⁰Y, ⁴⁷Sc, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁴²Pr, ¹⁰⁵Rh, ⁹⁷Ru; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0877] In addition to assaying levels of polypeptide of the present invention in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

[0878] A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ¹³¹I, ¹¹²In, ^(99m)Tc, (¹³¹I, ¹²⁵I, ¹²³I, ¹²¹I), carbon (¹⁴C), sulfur (³⁵S), tritium (³H), indium (^(115m)In, ^(113m)In, ¹¹²In, ¹¹¹In), and technetium (⁹⁹Tc, ^(99m)Tc), thallium (²⁰¹Ti), gallium (⁶⁸Ga, ⁶⁷Ga), palladium (¹⁰³Pd), molybdenum (⁹⁹Mo), xenon (¹³³Xe), fluorine (¹⁸F, ¹⁵³Sm, ¹⁷⁷Lu, ¹⁵⁹Gd, ¹⁴⁹ Pm, ¹⁴⁰La, ¹⁷⁵Yb, ¹⁶⁶Ho, ⁹⁰Y, ⁴⁷Sc, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁴²Pr, ¹⁰⁵Rh, ⁹⁷Ru), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously or intraperitoneally) into the mammal to be examined for immune system disorder. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of ^(99m)Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which express the polypeptide encoded by a polynucleotide of the invention. In vivo tumor imaging is described in S. W. Burchiel et al., “Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments” (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S. W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

[0879] In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (e.g., polypeptides encoded by polynucleotides of the invention and/or antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

[0880] In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention in association with toxins or cytotoxic prodrugs.

[0881] By “toxin” is meant one or more compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNAse, alpha toxin, ricin, abrin, Pseudomonas exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. “Toxin” also includes a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, ²¹³Bi, or other radioisotopes such as, for example, ¹⁰³Pd, ¹³³Xe, ¹³¹I, ⁶⁸Ge, ⁵⁷Co, ⁶⁵Zn, ⁸⁵Sr, ³²P, ³⁵S, ⁹⁰Y, ¹⁵³Sm, ¹⁵³Gd, ¹⁶⁹Yb, ⁵¹Cr, ⁵⁴Mn, ⁷⁵Se, ¹¹³Sn, ⁹⁰Yttrium, ¹¹⁷Tin, ¹⁸⁶Rhenium, 166Holmium, and 188Rhenium; luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin. In a specific embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention or antibodies of the invention in association with the radioisotope ⁹⁰Y. In another specific embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention or antibodies of the invention in association with the radioisotope ¹¹¹In. In a further specific embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention or antibodies of the invention in association with the radioisotope ¹³¹I.

[0882] Techniques known in the art may be applied to label polypeptides of the invention (including antibodies). Such techniques include, but are not limited to, the use of bifunctional conjugating agents (see e.g., U.S. Pat. Nos. 5,756,065; 5,714,631; 5,696,239; 5,652,361; 5,505,931; 5,489,425; 5,435,990; 5,428,139; 5,342,604; 5,274,119; 4,994,560; and 5,808,003; the contents of each of which are hereby incorporated by reference in its entirety).

[0883] Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression level of a polypeptide of the present invention in cells or body fluid of an individual; and (b) comparing the assayed polypeptide expression level with a standard polypeptide expression level, whereby an increase or decrease in the assayed polypeptide expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0884] Moreover, polypeptides of the present invention can be used to treat or prevent diseases or conditions such as, for example, neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, pulmonary disorders, cardiovascular disorders, renal disorders, proliferative disorders, and/or cancerous diseases and conditions. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor supressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune response to proliferative cells or tissues).

[0885] Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease (as described supra, and elsewhere herein). For example, administration of an antibody directed to a polypeptide of the present invention can bind, and/or neutralize the polypeptide, and/or reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

[0886] At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the biological activities described herein.

[0887] Diagnostic Assays

[0888] The compounds of the present invention are useful for diagnosis, treatment, prevention and/or prognosis of various disorders in mammals, preferably humans. Such disorders include, but are not limited to, those described in the legends for Tables 1D and 1E and as indicated in the “Preferred Indications” columns in Table 1D and Table 1E; and, also as described herein under the section heading “Biological Activities”.

[0889] For a number of disorders, substantially altered (increased or decreased) levels of gene expression can be detected in tissues, cells or bodily fluids (e.g., sera, plasma, urine, semen, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to a “standard” gene expression level, that is, the expression level in tissues or bodily fluids from an individual not having the disorder. Thus, the invention provides a diagnostic method useful during diagnosis of a disorder, which involves measuring the expression level of the gene encoding the polypeptide in tissues, cells or body fluid from an individual and comparing the measured gene expression level with a standard gene expression level, whereby an increase or decrease in the gene expression level(s) compared to the standard is indicative of a disorder. These diagnostic assays may be performed in vivo or in vitro, such as, for example, on blood samples, biopsy tissue or autopsy tissue.

[0890] The present invention is also useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed gene expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

[0891] In certain embodiments, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose and/or prognose diseases and/or disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1B, column 8 (Tissue Distribution Library Code).

[0892] By “assaying the expression level of the gene encoding the polypeptide” is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the invention or the level of the mRNA encoding the polypeptide of the invention in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide expression level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having the disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

[0893] By “biological sample” is intended any biological sample obtained from an individual, cell line, tissue culture, or other source containing polypeptides of the invention (including portions thereof) or mRNA. As indicated, biological samples include body fluids (such as sera, plasma, urine, synovial fluid and spinal fluid) and tissue sources found to express the full length or fragments thereof of a polypeptide or mRNA. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

[0894] Total cellular RNA can be isolated from a biological sample using any suitable technique such as the single-step guanidinium-thiocyanate-phenol-chloroform method described in Chomczynski and Sacchi, Anal. Biochem. 162:156-159 (1987). Levels of mRNA encoding the polypeptides of the invention are then assayed using any appropriate method. These include Northern blot analysis, SI nuclease mapping, the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR), and reverse transcription in combination with the ligase chain reaction (RT-LCR).

[0895] The present invention also relates to diagnostic assays such as quantitative and diagnostic assays for detecting levels of polypeptides of the invention, in a biological sample (e.g., cells and tissues), including determination of normal and abnormal levels of polypeptides. Thus, for instance, a diagnostic assay in accordance with the invention for detecting over-expression of polypeptides of the invention compared to normal control tissue samples may be used to detect the presence of tumors. Assay techniques that can be used to determine levels of a polypeptide, such as a polypeptide of the present invention in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. Assaying polypeptide levels in a biological sample can occur using any art-known method.

[0896] Assaying polypeptide levels in a biological sample can occur using antibody-based techniques. For example, polypeptide expression in tissues can be studied with classical immunohistological methods (Jalkanen et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell. Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting polypeptide gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (¹²⁵I, ¹²¹I), carbon (¹⁴C), sulfur (³⁵S), tritium (³H), indium (¹¹²In), and technetium (^(99m)Tc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

[0897] The tissue or cell type to be analyzed will generally include those which are known, or suspected, to express the gene of inteest (such as, for example, cancer). The protein isolation methods employed herein may, for example, be such as those described in Harlow and Lane (Harlow, E. and Lane, D., 1988, “Antibodies: A Laboratory Manual”, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.), which is incorporated herein by reference in its entirety. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells that could be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the gene.

[0898] For example, antibodies, or fragments of antibodies, such as those described herein, may be used to quantitatively or qualitatively detect the presence of gene products or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, flow cytometric, or fluorimetric detection.

[0899] In a preferred embodiment, antibodies, or fragments of antibodies directed to any one or all of the predicted epitope domains of the polypeptides of the invention (shown in column 7 of Table 1B) may be used to quantitatively or qualitatively detect the presence of gene products or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, flow cytometric, or fluorimetric detection.

[0900] In an additional preferred embodiment, antibodies, or fragments of antibodies directed to a conformational epitope of a polypeptide of the invention may be used to quantitatively or qualitatively detect the presence of gene products or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, flow cytometric, or fluorimetric detection.

[0901] The antibodies (or fragments thereof), and/or polypeptides of the present invention may, additionally, be employed histologically, as in immunofluorescence, immunoelectron microscopy or non-immunological assays, for in situ detection of gene products or conserved variants or peptide fragments thereof. In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody or polypeptide of the present invention. The antibody (or fragment thereof) or polypeptide is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the gene product, or conserved variants or peptide fragments, or polypeptide binding, but also its distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such in situ detection.

[0902] Immunoassays and non-immunoassays for gene products or conserved variants or peptide fragments thereof will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells which have been incubated in cell culture, in the presence of a detectably labeled antibody capable of binding gene products or conserved variants or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well-known in the art.

[0903] The biological sample may be brought in contact with and immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled antibody or detectable polypeptide of the invention. The solid phase support may then be washed with the buffer a second time to remove unbound antibody or polypeptide. Optionally the antibody is subsequently labeled. The amount of bound label on solid support may then be detected by conventional means.

[0904] By “solid phase support or carrier” is intended any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

[0905] The binding activity of a given lot of antibody or antigen polypeptide may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

[0906] In addition to assaying polypeptide levels or polynucleotide levels in a biological sample obtained from an individual, polypeptide or polynucleotide can also be detected in vivo by imaging. For example, in one embodiment of the invention, polypeptides and/or antibodies of the invention are used to image diseased cells, such as neoplasms. In another embodiment, polynucleotides of the invention (e.g., polynucleotides complementary to all or a portion of an mRNA) and/or antibodies (e.g., antibodies directed to any one or a combination of the epitopes of a polypeptide of the invention, antibodies directed to a conformational epitope of a polypeptide of the invention, or antibodies directed to the full length polypeptide expressed on the cell surface of a mammalian cell) are used to image diseased or neoplastic cells.

[0907] Antibody labels or markers for in vivo imaging of polypeptides of the invention include those detectable by X-radiography, NMR, MRI, CAT-scans or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma. Where in vivo imaging is used to detect enhanced levels of polypeptides for diagnosis in humans, it may be preferable to use human antibodies or “humanized” chimeric monoclonal antibodies. Such antibodies can be produced using techniques described herein or otherwise known in the art. For example methods for producing chimeric antibodies are known in the art. See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Pat. No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).

[0908] Additionally, any polypeptides of the invention whose presence can be detected, can be administered. For example, polypeptides of the invention labeled with a radio-opaque or other appropriate compound can be administered and visualized in vivo, as discussed, above for labeled antibodies. Further, such polypeptides can be utilized for in vitro diagnostic procedures.

[0909] A polypeptide-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, ¹³¹I, ¹¹²In, ^(99m)Tc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously or intraperitoneally) into the mammal to be examined for a disorder. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of ^(99m)Tc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the antigenic protein. In vivo tumor imaging is described in S. W. Burchiel et al., “Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments” (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S. W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

[0910] With respect to antibodies, one of the ways in which an antibody of the present invention can be detectably labeled is by linking the same to a reporter enzyme and using the linked product in an enzyme immunoassay (EIA) (Voller, A., “The Enzyme Linked Immunosorbent Assay (ELISA)”, 1978, Diagnostic Horizons 2:1-7, Microbiological Associates Quarterly Publication, Walkersville, Md.); Voller et al., J. Clin. Pathol. 31:507-520 (1978); Butler, J. E., Meth. Enzymol. 73:482-523 (1981); Maggio, E. (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, Fla.,; Ishikawa, E. et al., (eds.), 1981, Enzyme Immunoassay, Kgaku Shoin, Tokyo). The reporter enzyme which is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Reporter enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. Additionally, the detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the reporter enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

[0911] Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect polypeptides through the use of a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by means including, but not limited to, a gamma counter, a scintillation counter, or autoradiography.

[0912] It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, ophthaldehyde and fluorescamine.

[0913] The antibody can also be detectably labeled using fluorescence emitting metals such as ¹⁵²Eu, or others of the lanthamide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

[0914] The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

[0915] Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

[0916] Methods for Detecting Diseases

[0917] In general, a disease may be detected in a patient based on the presence of one or more proteins of the invention and/or polynucleotides encoding such proteins in a biological sample (for example, blood, sera, urine, and/or tumor biopsies) obtained from the patient. In other words, such proteins may be used as markers to indicate the presence or absence of a disease or disorder, including cancer and/or as described elsewhere herein. In addition, such proteins may be useful for the detection of other diseases and cancers. The binding agents provided herein generally permit detection of the level of antigen that binds to the agent in the biological sample. Polynucleotide primers and probes may be used to detect the level of mRNA encoding polypeptides of the invention, which is also indicative of the presence or absence of a disease or disorder, including cancer. In general, polypeptides of the invention should be present at a level that is at least three fold higher in diseased tissue than in normal tissue.

[0918] There are a variety of assay formats known to those of ordinary skill in the art for using a binding agent to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, supra. In general, the presence or absence of a disease in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c) comparing the level of polypeptide with a predetermined cut-off value.

[0919] In a preferred embodiment, the assay involves the use of a binding agent(s) immobilized on a solid support to bind to and remove the polypeptide of the invention from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding agent/polypeptide complex. Such detection reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use within such assays include polypeptides of the invention and portions thereof, or antibodies, to which the binding agent binds, as described above.

[0920] The solid support may be any material known to those of skill in the art to which polypeptides of the invention may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Pat. No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term “immobilization” refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for the suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 ug, and preferably about 100 ng to about 1 ug, is sufficient to immobilize an adequate amount of binding agent.

[0921] Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

[0922] Gene Therapy Methods

[0923] Also encompassed by the invention are gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of the polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the present invention operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

[0924] Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the present invention ex vivo, with the engineered cells then being provided to a patient to be treated with the polypeptide of the present invention. Such methods are well-known in the art. For example, see Belldegrun, A., et al., J. Natl. Cancer Inst. 85: 207-216 (1993); Ferrantini, M. et al., Cancer Research 53: 1107-1112 (1993); Ferrantini, M. et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura, H., et al., Cancer Research 50: 5102-5106 (1990); Santodonato, L., et al., Human Gene Therapy 7:1-10 (1996); Santodonato, L., et al., Gene Therapy 4:1246-1255 (1997); and Zhang, J. -F. et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

[0925] As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

[0926] In one embodiment, the polynucleotide of the present invention is delivered as a naked polynucleotide. The term “naked” polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotide of the present invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Pat. Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

[0927] The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

[0928] Any strong promoter known to those skilled in the art can be used for driving the expression of the polynucleotide sequence. Suitable promoters include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters, such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotide of the present invention.

[0929] Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

[0930] The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

[0931] For the naked nucleic acid sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

[0932] The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

[0933] The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called “gene guns”. These delivery methods are known in the art.

[0934] The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

[0935] In certain embodiments, the polynucleotide constructs are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA (1989) 86:6077-6081, which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem. (1990) 265:10189-10192, which is herein incorporated by reference), in functional form.

[0936] Cationic liposomes are readily available. For example, N-[1-2,3-dioleyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Feigner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416, which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

[0937] Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication No. WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., P. Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

[0938] Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphoshatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

[0939] For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

[0940] The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred. The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., Methods of Immunology (1983), 101:512-527, which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated. SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include Ca 2-EDTA chelation (Papahadjopoulos et al., Biochim. Biophys. Acta (1975) 394:483; Wilson et al., Cell 17:77 (1979)); ether injection (Deamer, D. and Bangham, A., Biochim. Biophys. Acta 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun. 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA 76:3348 (1979)); detergent dialysis (Enoch, H. and Strittmatter, P., Proc. Natl. Acad. Sci. USA 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem. 255:10431 (1980); Szoka, F. and Papahadjopoulos, D., Proc. Natl. Acad. Sci. USA 75:145 (1978); Schaefer-Ridder et al., Science 215:166 (1982)), which are herein incorporated by reference.

[0941] Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

[0942] U.S. Pat. No. 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Pat. Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication no. WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Pat. Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication no. WO 94/9469 provide methods for delivering DNA-cationic lipid complexes to mammals.

[0943] In certain embodiments, cells are engineered, ex vivo or in vivo, using a retroviral particle containing RNA which comprises a sequence encoding a polypeptide of the present invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

[0944] The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14×, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO₄ precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

[0945] The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding a polypeptide of the present invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either in vitro or in vivo. The transduced eukaryotic cells will express a polypeptide of the present invention.

[0946] In certain other embodiments, cells are engineered, ex vivo or in vivo, with polynucleotide contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses a polypeptide of the present invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al. Am. Rev. Respir. Dis.109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld, M. A. et al. (1991) Science 252:431-434; Rosenfeld et al., (1992) Cell 68:143-155). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green, M. et al. (1979) Proc. Natl. Acad. Sci. USA 76:6606).

[0947] Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel. 3:499-503 (1993); Rosenfeld et al., Cell 68:143-155 (1992); Engelhardt et al., Human Genet. Ther. 4:759-769 (1993); Yang et al., Nature Genet. 7:362-369 (1994); Wilson et al., Nature 365:691-692 (1993); and U.S. Pat. No. 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express E1 and E1, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

[0948] Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1, E1, E3, E4, E2a, or L1 through L5.

[0949] In certain other embodiments, the cells are engineered, ex vivo or in vivo, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, N., Curr. Topics in Microbiol. Immunol. 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Pat. Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

[0950] For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct. These viral particles are then used to transduce eukaryotic cells, either ex vivo or in vivo. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express a polypeptide of the invention.

[0951] Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding a polypeptide of the present invention) via homologous recombination (see, e.g., U.S. Pat. No. 5,641,670, issued Jun. 24, 1997; International Publication No. WO 96/29411, published Sep. 26, 1996; International Publication No. WO 94/12650, published Aug. 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), which are herein encorporated by reference. This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

[0952] Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5′ end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

[0953] The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5′ and 3′ ends. Preferably, the 3′ end of the first targeting sequence contains the same restriction enzyme site as the 5′ end of the amplified promoter and the 5′ end of the second targeting sequence contains the same restriction site as the 3′ end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

[0954] The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

[0955] The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

[0956] The polynucleotide encoding a polypeptide of the present invention may contain a secretory signal sequence that facilitates secretion of the protein. Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5′ end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

[0957] Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., “gene guns”), gelfoam sponge depots, other commercially available depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the rat livers (Kaneda et al., Science 243:375 (1989)).

[0958] A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries. Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

[0959] Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

[0960] Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site. In specific embodiments, suitable delivery vehicles for use with systemic administration comprise liposomes comprising polypeptides of the invention for targeting the vehicle to a particular site.

[0961] Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA 189:11277-11281, 1992, which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

[0962] Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian.

[0963] Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly preferred.

[0964] Biological Activities

[0965] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, can be used in assays to test for one or more biological activities. If these polynucleotides or polypeptides, or agonists or antagonists of the present invention, do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides, and agonists or antagonists could be used to treat the associated disease.

[0966] Members of the secreted family of proteins are believed to be involved in biological activities associated with, for example, cellular signaling. Accordingly, compositions of the invention (including polynucleotides, polypeptides and antibodies of the invention, and fragments and variants thereof) may be used in diagnosis, prognosis, prevention and/or treatment of diseases and/or disorders associated with aberrant activity of secreted polypeptides.

[0967] In preferred embodiments, compositions of the invention (including polynucleotides, polypeptides and antibodies of the invention, and fragments and variants thereof) may be used in the diagnosis, prognosis, prevention and/or treatment of diseases and/or disorders relating to diseases and disorders of the endocrine system, the nervous system (See, for example, “Neurological Disorders” section below), and the immune system (See, for example, “Immune Activity” section below).

[0968] In certain embodiments, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose and/or prognose diseases and/or disorders associated with the tissue(s) in which the polypeptide of the invention is expressed including one, two, three, four, five, or more tissues disclosed in Table 1B, column 8 (Tissue Distribution Library Code).

[0969] Thus, polynucleotides, translation products and antibodies of the invention are useful in the diagnosis, detection and/or treatment of diseases and/or disorders associated with activities that include, but are not limited to, prohormone activation, neurotransmitter activity, cellular signaling, cellular proliferation, cellular differentiation, and cell migration.

[0970] More generally, polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis, prognosis, prevention and/or treatment of diseases and/or disorders associated with the following systems.

[0971] Immune Activity

[0972] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing and/or prognosing diseases, disorders, and/or conditions of the immune system, by, for example, activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

[0973] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to treat diseases and disorders of the immune system and/or to inhibit or enhance an immune response generated by cells associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1B, column 8 (Tissue Distribution Library Code).

[0974] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing, and/or prognosing immunodeficiencies, including both congenital and acquired immunodeficiencies. Examples of B cell immunodeficiencies in which immunoglobulin levels B cell function and/or B cell numbers are decreased include: X-linked agammaglobulinemia (Bruton's disease), X-linked infantile agammaglobulinemia, X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, X-linked lymphoproliferative syndrome (XLP), agammaglobulinemia including congenital and acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemi a, hypogammaglobulinemia, unspecified hypogammaglobulinemi a, recessive agammaglobulinemia (Swiss type), Selective IgM deficiency, selective IgA deficiency, selective IgG subclass deficiencies, IgG subclass deficiency (with or without IgA deficiency), Ig deficiency with increased IgM, IgG and IgA deficiency with increased IgM, antibody deficiency with normal or elevated Igs, Ig heavy chain deletions, kappa chain deficiency, B cell lymphoproliferative disorder (BLPD), common variable immunodeficiency (CVID), common variable immunodeficiency (CVI) (acquired), and transient hypogammaglobulinemia of infancy.

[0975] In specific embodiments, ataxia-telangiectasia or conditions associated with ataxia-telangiectasia are treated, prevented, diagnosed, and/or prognosing using the polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof.

[0976] Examples of congenital immunodeficiencies in which T cell and/or B cell function and/or number is decreased include, but are not limited to: DiGeorge anomaly, severe combined immunodeficiencies (SCID) (including, but not limited to, X-linked SCID, autosomal recessive SCID, adenosine deaminase deficiency, purine nucleoside phosphorylase (PNP) deficiency, Class II MHC deficiency (Bare lymphocyte syndrome), Wiskott-Aldrich syndrome, and ataxia telangiectasia), thymic hypoplasia, third and fourth pharyngeal pouch syndrome, 22q11.2 deletion, chronic mucocutaneous candidiasis, natural killer cell deficiency (NK), idiopathic CD4+ T-lymphocytopenia, immunodeficiency with predominant T cell defect (unspecified), and unspecified immunodeficiency of cell mediated immunity.

[0977] In specific embodiments, DiGeorge anomaly or conditions associated with DiGeorge anomaly are treated, prevented, diagnosed, and/or prognosed using polypeptides or polynucleotides of the invention, or antagonists or agonists thereof.

[0978] Other immunodeficiencies that may be treated, prevented, diagnosed, and/or prognosed using polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof, include, but are not limited to, chronic granulomatous disease, Chediak-Higashi syndrome, myeloperoxidase deficiency, leukocyte glucose-6-phosphate dehydrogenase deficiency, X-linked lymphoproliferative syndrome (XLP), leukocyte adhesion deficiency, complement component deficiencies (including C1, C2, C3, C4, C5, C6, C7, C8 and/or C9 deficiencies), reticular dysgenesis, thymic alymphoplasia-aplasia, immunodeficiency with thymoma, severe congenital leukopenia, dysplasia with immunodeficiency, neonatal neutropenia, short limbed dwarfism, and Nezelof syndrome-combined immunodeficiency with Igs.

[0979] In a preferred embodiment, the immunodeficiencies and/or conditions associated with the immunodeficiencies recited above are treated, prevented, diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0980] In a preferred embodiment polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost immunoresponsiveness among immunodeficient individuals. In specific embodiments, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost immunoresponsiveness among B cell and/or T cell immunodeficient individuals.

[0981] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing and/or prognosing autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides and polypeptides of the invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

[0982] Autoimmune diseases or disorders that may be treated, prevented, diagnosed and/or prognosed by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, one or more of the following: systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, autoimmune thyroiditis, Hashimoto's thyroiditis, autoimmune hemolytic anemia, hemolytic anemia, thrombocytopenia, autoimmune thrombocytopenia purpura, autoimmune neonatal thrombocytopenia, idiopathic thrombocytopenia purpura, purpura (e.g., Henloch-Scoenlein purpura), autoimmunocytopenia, Goodpasture's syndrome, Pemphigus vulgaris, myasthenia gravis, Grave's disease (hyperthyroidism), and insulin-resistant diabetes mellitus.

[0983] Additional disorders that are likely to have an autoimmune component that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, type II collagen-induced arthritis, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, neuritis, uveitis ophthalmia, polyendocrinopathies, Reiter's Disease, Stiff-Man Syndrome, autoimmune pulmonary inflammation, autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disorders.

[0984] Additional disorders that are likely to have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the invention include, but are not limited to, scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by glomerular basement membrane antibodies or immune complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

[0985] Additional disorders that may have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondria antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial antibodies), cardiotomy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

[0986] In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention. In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0987] In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0988] In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0989] In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention

[0990] In preferred embodiments, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a immunosuppressive agent(s).

[0991] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, prognosing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells, including but not limited to, leukopenia, neutropenia, anemia, and thrombocytopenia. Alternatively, Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with an increase in certain (or many) types of hematopoietic cells, including but not limited to, histiocytosis.

[0992] Allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, diagnosed and/or prognosed using polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, prognose, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

[0993] Additionally, polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof, may be used to treat, prevent, diagnose and/or prognose IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema. In specific embodiments, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

[0994] Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention have uses in the diagnosis, prognosis, prevention, and/or treatment of inflammatory conditions. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells involved in an inflammatory response, these molecules can be used to prevent and/or treat chronic and acute inflammatory conditions. Such inflammatory conditions include, but are not limited to, for example, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome), ischemia-reperfusion injury, endotoxin lethality, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, over production of cytokines (e.g., TNF or IL-1.), respiratory disorders (e.g., asthma and allergy); gastrointestinal disorders (e.g., inflammatory bowel disease); cancers (e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (e.g., multiple sclerosis; ischemic brain injury and/or stroke, traumatic brain injury, neurodegenerative disorders (e.g., Parkinson's disease and Alzheimer's disease); AIDS-related dementia; and prion disease); cardiovascular disorders (e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (e.g., hepatitis, rheumatoid arthritis, gout, trauma, pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus, and allogenic transplant rejection).

[0995] Because inflammation is a fundamental defense mechanism, inflammatory disorders can effect virtually any tissue of the body. Accordingly, polynucleotides, polypeptides, and antibodies of the invention, as well as agonists or antagonists thereof, have uses in the treatment of tissue-specific inflammatory disorders, including, but not limited to, adrenalitis, alveolitis, angiocholecystitis, appendicitis, balanitis, blepharitis, bronchitis, bursitis, carditis, cellulitis, cervicitis, cholecystitis, chorditis, cochlitis, colitis, conjunctivitis, cystitis, dermatitis, diverticulitis, encephalitis, endocarditis, esophagitis, eustachitis, fibrositis, folliculitis, gastritis, gastroenteritis, gingivitis, glossitis, hepatosplenitis, keratitis, labyrinthitis, laryngitis, lymphangitis, mastitis, media otitis, meningitis, metritis, mucitis, myocarditis, myosititis, myringitis, nephritis, neuritis, orchitis, osteochondritis, otitis, pericarditis, peritendonitis, peritonitis, pharyngitis, phlebitis, poliomyelitis, prostatitis, pulpitis, retinitis, rhinitis, salpingitis, scleritis, sclerochoroiditis, scrotitis, sinusitis, spondylitis, steatitis, stomatitis, synovitis, syringitis, tendonitis, tonsillitis, urethritis, and vaginitis.

[0996] In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat organ transplant rejections and graft-versus-host disease. Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD. In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing experimental allergic and hyperacute xenograft rejection.

[0997] In other embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat immune complex diseases, including, but not limited to, serum sickness, post streptococcal glomerulonephritis, polyarteritis nodosa, and immune complex-induced vasculitis.

[0998] Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected, and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

[0999] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a vaccine adjuvant that enhances immune responsiveness to an antigen. In a specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance tumor-specific immune responses.

[1000] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, respiratory syncytial virus, Dengue, rotavirus, Japanese B encephalitis, influenza A and B, parainfluenza, measles, cytomegalovirus, rabies, Junin, Chikungunya, Rift Valley Fever, herpes simplex, and yellow fever.

[1001] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B.

[1002] In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: Vibrio cholerae, Mycobacterium leprae, Salmonella typhi, Salmonella paratyphi, Meisseria meningitidis, Streptococcus pneumoniae, Group B streptococcus, Shigella spp., Enterotoxigenic Escherichia coli, Enterohemorrhagic E. coli, and Borrelia burgdorferi.

[1003] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to Plasmodium (malaria) or Leishmania.

[1004] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat infectious diseases including silicosis, sarcoidosis, and idiopathic pulmonary fibrosis; for example, by preventing the recruitment and activation of mononuclear phagocytes.

[1005] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.

[1006] In one embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production and immunoglobulin class switching (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.

[1007] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell responsiveness to pathogens.

[1008] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an activator of T cells.

[1009] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.

[1010] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to induce higher affinity antibodies.

[1011] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to increase serum immunoglobulin concentrations.

[1012] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to accelerate recovery of immunocompromised individuals.

[1013] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among aged populations and/or neonates.

[1014] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an immune system enhancer prior to, during, or after bone marrow transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific embodiment, compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

[1015] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell function that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

[1016] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, and recovery from surgery.

[1017] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonism of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.

[1018] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to direct an individual's immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

[1019] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.

[1020] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable Immunodificiency.

[1021] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect. In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in the pretreatment of bone marrow samples prior to transplant.

[1022] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence/immunodeficiency such as observed among SCID patients.

[1023] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leishmania.

[1024] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of regulating secreted cytokines that are elicited by polypeptides of the invention.

[1025] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in one or more of the applications decribed herein, as they may apply to veterinary medicine.

[1026] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of blocking various aspects of immune responses to foreign agents or self. Examples of diseases or conditions in which blocking of certain aspects of immune responses may be desired include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and diseases/disorders associated with pathogens.

[1027] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythematosus and multiple sclerosis.

[1028] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in disrupting immune responses, and blocking sepsis.

[1029] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for chronic hypergammaglobulinemia evident in such diseases as monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonal gammopathies, and plasmacytomas.

[1030] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain autoimmune and chronic inflammatory and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes.

[1031] The polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat idiopathic hyper-eosinophilic syndrome by, for example, preventing eosinophil production and migration.

[1032] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit complement mediated cell lysis.

[1033] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit antibody dependent cellular cytotoxicity.

[1034] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed for treating atherosclerosis, for example, by preventing monocyte infiltration in the artery wall.

[1035] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed to treat adult respiratory distress syndrome (ARDS).

[1036] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be useful for stimulating wound and tissue repair, stimulating angiogenesis, and/or stimulating the repair of vascular or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.

[1037] In a specific embodiment, polynucleotides or polypeptides, and/or agonists thereof are used to diagnose, prognose, treat, and/or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carnii. Other diseases and disorders that may be prevented, diagnosed, prognosed, and/or treated with polynucleotides or polypeptides, and/or agonists of the present invention include, but are not limited to, HIV infection, HTLV-BLV infection, lymphopenia, phagocyte bactericidal dysfunction anemia, thrombocytopenia, and hemoglobinuria.

[1038] In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease (“CVID”; also known as “acquired agammaglobulinemia” and “acquired hypogammaglobulinemia”) or a subset of this disease.

[1039] In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to diagnose, prognose, prevent, and/or treat cancers or neoplasms including immune cell or immune tissue-related cancers or neoplasms. Examples of cancers or neoplasms that may be prevented, diagnosed, or treated by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, acute myelogenous leukemia, chronic myelogenous leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic anemia (ALL) Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, EBV-transformed diseases, and/or diseases and disorders described in the section entitled “Hyperproliferative Disorders” elsewhere herein.

[1040] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

[1041] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of decreasing the involvement of B cells and Ig associated with Chronic Myclogenous Leukemia.

[1042] In specific embodiments, the compositions of the invention are used as an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy.

[1043] Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, ribozymes or soluble forms of the polypeptides of the present invention (e.g., Fc fusion protein; see, e.g., Example 9). Agonists of the invention include, for example, binding or stimulatory antibodies, and soluble forms of the polypeptides (e.g., Fe fusion proteins; see, e.g., Example 9), polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

[1044] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741). Administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention to such animals is useful for the generation of monoclonal antibodies against the polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention.

[1045] Blood-Related Disorders

[1046] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hemostatic (the stopping of bleeding) or thrombolytic (clot dissolving) activity. For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies, hemophilia), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

[1047] In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, diagnose, prognose, and/or treat thrombosis, arterial thrombosis, venous thrombosis, thromboembolism, pulmonary embolism, atherosclerosis, myocardial infarction, transient ischemic attack, unstable angina. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used for the prevention of occulsion of saphenous grafts, for reducing the risk of periprocedural thrombosis as might accompany angioplasty procedures, for reducing the risk of stroke in patients with atrial fibrillation including nonrheumatic atrial fibrillation, for reducing the risk of embolism associated with mechanical heart valves and or mitral valves disease. Other uses for the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, include, but are not limited to, the prevention of occlusions in extrcorporeal devices (e.g., intravascular canulas, vascular access shunts in hemodialysis patients, hemodialysis machines, and cardiopulmonary bypass machines).

[1048] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to prevent, diagnose, prognose, and/or treat diseases and disorders of the blood and/or blood forming organs associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1B, column 8 (Tissue Distribution Library Code).

[1049] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hematopoietic activity (the formation of blood cells). For example, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to increase the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of anemias and leukopenias described below. Alternatively, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to decrease the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of leukocytoses, such as, for example eosinophilia.

[1050] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, treat, or diagnose blood dyscrasia.

[1051] Anemias are conditions in which the number of red blood cells or amount of hemoglobin (the protein that carries oxygen) in them is below normal. Anemia may be caused by excessive bleeding, decreased red blood cell production, or increased red blood cell destruction (hemolysis). The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias. Anemias that may be treated prevented or diagnosed by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include iron deficiency anemia, hypochromic anemia, microcytic anemia, chlorosis, hereditary sideroblastic anemia, idiopathic acquired sideroblastic anemia, red cell aplasia, megaloblastic anemia (e.g., pernicious anemia, (vitamin B12 deficiency) and folic acid deficiency anemia), aplastic anemia, hemolytic anemias (e.g., autoimmune helolytic anemia, microangiopathic hemolytic anemia, and paroxysmal nocturnal hemoglobinuria). The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias associated with diseases including but not limited to, anemias associated with systemic lupus erythematosus, cancers, lymphomas, chronic renal disease, and enlarged spleens. The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias arising from drug treatments such as anemias associated with methyldopa, dapsone, and/or sulfadrugs. Additionally, rhe polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias associated with abnormal red blood cell architecture including but not limited to, hereditary spherocytosis, hereditary elliptocytosis, glucose-6-phosphate dehydrogenase deficiency, and sickle cell anemia.

[1052] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing hemoglobin abnormalities, (e.g., those associated with sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and hemoglobin E disease). Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating thalassemias, including, but not limited to major and minor forms of alpha-thalassemia and beta-thalassemia.

[1053] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating bleeding disorders including, but not limited to, thrombocytopenia (e.g., idiopathic thrombocytopenic purpura, and thrombotic thrombocytopenic purpura), Von Willebrand's disease, hereditary platelet disorders (e.g., storage pool disease such as Chediak-Higashi and Hermansky-Pudlak syndromes, thromboxane A2 dysfunction, thromboasthenia, and Bernard-Soulier syndrome), hemolytic-uremic syndrome, hemophelias such as hemophelia A or Factor VII deficiency and Christmas disease or Factor IX deficiency, Hereditary Hemorhhagic Telangiectsia, also known as Rendu-Osler-Weber syndrome, allergic purpura (Henoch Schonlein purpura) and disseminated intravascular coagulation.

[1054] The effect of the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention on the clotting time of blood may be monitored using any of the clotting tests known in the art including, but not limited to, whole blood partial thromboplastin time (PTT), the activated partial thromboplastin time (aPTT), the activated clotting time (ACT), the recalcified activated clotting time, or the Lee-White Clotting time.

[1055] Several diseases and a variety of drugs can cause platelet dysfunction. Thus, in a specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating acquired platelet dysfunction such as platelet dysfunction accompanying kidney failure, leukemia, multiple myeloma, cirrhosis of the liver, and systemic lupus erythematosus as well as platelet dysfunction associated with drug treatments, including treatment with aspirin, ticlopidine, nonsteroidal anti-inflammatory drugs (used for arthritis, pain, and sprains), and penicillin in high doses.

[1056] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders characterized by or associated with increased or decreased numbers of white blood cells. Leukopenia occurs when the number of white blood cells decreases below normal. Leukopenias include, but are not limited to, neutropenia and lymphocytopenia. An increase in the number of white blood cells compared to normal is known as leukocytosis. The body generates increased numbers of white blood cells during infection. Thus, leukocytosis may simply be a normal physiological parameter that reflects infection. Alternatively, leukocytosis may be an indicator of injury or other disease such as cancer. Leokocytoses, include but are not limited to, eosinophilia, and accumulations of macrophages. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukopenia. In other specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukocytosis.

[1057] Leukopenia may be a generalized decreased in all types of white blood cells, or may be a specific depletion of particular types of white blood cells. Thus, in specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating decreases in neutrophil numbers, known as neutropenia. Neutropenias that may be diagnosed, prognosed, prevented, and/or treated by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, infantile genetic agranulocytosis, familial neutropenia, cyclic neutropenia, neutropenias resulting from or associated with dietary deficiencies (e.g., vitamin B 12 deficiency or folic acid deficiency), neutropenias resulting from or associated with drug treatments (e.g., antibiotic regimens such as penicillin treatment, sulfonamide treatment, anticoagulant treatment, anticonvulsant drugs, anti-thyroid drugs, and cancer chemotherapy), and neutropenias resulting from increased neutrophil destruction that may occur in association with some bacterial or viral infections, allergic disorders, autoimmune diseases, conditions in which an individual has an enlarged spleen (e.g., Felty syndrome, malaria and sarcoidosis), and some drug treatment regimens.

[1058] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating lymphocytopenias (decreased numbers of B and/or T lymphocytes), including, but not limited lymphocytopenias resulting from or associated with stress, drug treatments (e.g., drug treatment with corticosteroids, cancer chemotherapies, and/or radiation therapies), AIDS infection and/or other diseases such as, for example, cancer, rheumatoid arthritis, systemic lupus erythematosus, chronic infections, some viral infections and/or hereditary disorders (e.g., DiGeorge syndrome, Wiskott-Aldrich Syndome, severe combined immunodeficiency, ataxia telangiectsia).

[1059] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with macrophage numbers and/or macrophage function including, but not limited to, Gaucher's disease, Niemann-Pick disease, Letterer-Siwe disease and Hand-Schuller-Christian disease.

[1060] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with eosinophil numbers and/or eosinophil function including, but not limited to, idiopathic hypereosinophilic syndrome, eosinophilia-myalgia syndrome, and Hand-Schuller-Christian disease.

[1061] In yet another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukemias and lymphomas including, but not limited to, acute lymphocytic (lymphpblastic) leukemia (ALL), acute myeloid (myelocytic, myelogenous, myeloblastic, or myelomonocytic) leukemia, chronic lymphocytic leukemia (e.g., B cell leukemias, T cell leukemias, Sezary syndrome, and Hairy cell leukenia), chronic myelocytic (myeloid, myelogenous, or granulocytic) leukemia, Hodgkin's lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, and mycosis fungoides.

[1062] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders of plasma cells including, but not limited to, plasma cell dyscrasias, monoclonal gammaopathies, monoclonal gammopathies of undetermined significance, multiple myeloma, macroglobulinemia, Waldenstrom's macroglobulinemia, cryoglobulinemia, and Raynaud's phenomenon.

[1063] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing myeloproliferative disorders, including but not limited to, polycythemia vera, relative polycythemia, secondary polycythemia, myelofibrosis, acute myelofibrosis, agnogenic myelod metaplasia, thrombocythemia, (including both primary and seconday thrombocythemia) and chronic myelocytic leukemia.

[1064] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as a treatment prior to surgery, to increase blood cell production.

[1065] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to enhance the migration, phagocytosis, superoxide production, antibody dependent cellular cytotoxicity of neutrophils, eosionophils and macrophages.

[1066] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to stem cells pheresis. In another specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to platelet pheresis.

[1067] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase cytokine production.

[1068] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in preventing, diagnosing, and/or treating primary hematopoietic disorders.

[1069] Hyperproliferative Disorders

[1070] In certain embodiments, polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used to treat or detect hyperproliferative disorders, including neoplasms. Polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, Polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

[1071] For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

[1072] Examples of hyperproliferative disorders that can be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

[1073] Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: Acute Childhood Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adrenocortical Carcinoma, Adult (Primary) Hepatocellular Cancer, Adult (Primary) Liver Cancer, Adult Acute Lymphocytic Leukemia, Adult Acute Myeloid Leukemia, Adult Hodgkin's Disease, Adult Hodgkin's Lymphoma, Adult Lymphocytic Leukemia, Adult Non-Hodgkin's Lymphoma, Adult Primary Liver Cancer, Adult Soft Tissue Sarcoma, AIDS-Related Lymphoma, AIDS-Related Malignancies, Anal Cancer, Astrocytoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer, Brain Stem Glioma, Brain Tumors, Breast Cancer, Cancer of the Renal Pelvis and Ureter, Central Nervous System (Primary) Lymphoma, Central Nervous System Lymphoma, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Childhood (Primary) Hepatocellular Cancer, Childhood (Primary) Liver Cancer, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Brain Stem Glioma, Childhood Cerebellar Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Extracranial Germ Cell Tumors, Childhood Hodgkin's Disease, Childhood Hodgkin's Lymphoma, Childhood Hypothalamic and Visual Pathway Glioma, Childhood Lymphoblastic Leukemia, Childhood Medulloblastoma, Childhood Non-Hodgkin's Lymphoma, Childhood Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood Primary Liver Cancer, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Childhood Visual Pathway and Hypothalamic Glioma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Colon Cancer, Cutaneous T-Cell Lymphoma, Endocrine Pancreas Islet Cell Carcinoma, Endometrial Cancer, Ependymoma, Epithelial Cancer, Esophageal Cancer, Ewing's Sarcoma and Related Tumors, Exocrine Pancreatic Cancer, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer, Female Breast Cancer, Gaucher's Disease, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Tumors, Germ Cell Tumors, Gestational Trophoblastic Tumor, Hairy Cell Leukemia, Head and Neck Cancer, Hepatocellular Cancer, Hodgkin's Disease, Hodgkin's Lymphoma, Hypergammaglobulinemia, Hypopharyngeal Cancer, Intestinal Cancers, Intraocular Melanoma, Islet Cell Carcinoma, Islet Cell Pancreatic Cancer, Kaposi's Sarcoma, Kidney Cancer, Laryngeal Cancer, Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer, Lymphoproliferative Disorders, Macroglobulinemia, Male Breast Cancer, Malignant Mesothelioma, Malignant Thymoma, Medulloblastoma, Melanoma, Mesothelioma, Metastatic Occult Primary Squamous Neck Cancer, Metastatic Primary Squamous Neck Cancer, Metastatic Squamous Neck Cancer, Multiple Myeloma, Multiple Myeloma/Plasma Cell Neoplasm, Myelodysplastic Syndrome, Myelogenous Leukemia, Myeloid Leukemia, Myeloproliferative Disorders, Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin's Lymphoma During Pregnancy, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Occult Primary Metastatic Squamous Neck Cancer, Oropharyngeal Cancer, Osteo-/Malignant Fibrous Sarcoma, Osteosarcoma/Malignant Fibrous Histiocytoma, Osteosarcoma/Malignant Fibrous Histiocytoma of Bone, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Pancreatic Cancer, Paraproteinemias, Purpura, Parathyroid Cancer, Penile Cancer, Pheochromocytoma, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Primary Central Nervous System Lymphoma, Primary Liver Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Cancer, Renal Pelvis and Ureter Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcoidosis Sarcomas, Sezary Syndrome, Skin Cancer, Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Neck Cancer, Stomach Cancer, Supratentorial Primitive Neuroectodermal and Pineal Tumors, T-Cell Lymphoma, Testicular Cancer, Thymoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Renal Pelvis and Ureter Cancer, Trophoblastic Tumors, Ureter and Renal Pelvis Cell Cancer, Urethral Cancer, Uterine Cancer, Uterine Sarcoma, Vaginal Cancer, Visual Pathway and Hypothalamic Glioma, Vulvar Cancer, Waldenstrom's Macroglobulinemia, Wilms' Tumor, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

[1074] In another preferred embodiment, polynucleotides or polypeptides, or agonists or antagonists of the present invention are used to diagnose, prognose, prevent, and/or treat premalignant conditions and to prevent progression to a neoplastic or malignant state, including but not limited to those disorders described above. Such uses are indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W. B. Saunders Co., Philadelphia, pp. 68-79.)

[1075] Hyperplasia is a form of controlled cell proliferation, involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. Hyperplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, angiofollicular mediastinal lymph node hyperplasia, angiolymphoid hyperplasia with eosinophilia, a typical melanocytic hyperplasia, basal cell hyperplasia, benign giant lymph node hyperplasia, cementum hyperplasia, congenital adrenal hyperplasia, congenital sebaceous hyperplasia, cystic hyperplasia, cystic hyperplasia of the breast, denture hyperplasia, ductal hyperplasia, endometrial hyperplasia, fibromuscular hyperplasia, focal epithelial hyperplasia, gingival hyperplasia, inflammatory fibrous hyperplasia, inflammatory papillary hyperplasia, intravascular papillary endothelial hyperplasia, nodular hyperplasia of prostate, nodular regenerative hyperplasia, pseudoepitheliomatous hyperplasia, senile sebaceous hyperplasia, and verrucous hyperplasia.

[1076] Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, agnogenic myeloid metaplasia, apocrine metaplasia, a typical metaplasia, autoparenchymatous metaplasia, connective tissue metaplasia, epithelial metaplasia, intestinal metaplasia, metaplastic anemia, metaplastic ossification, metaplastic polyps, myeloid metaplasia, primary myeloid metaplasia, secondary myeloid metaplasia, squamous metaplasia, squamous metaplasia of amnion, and symptomatic myeloid metaplasia.

[1077] Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation. Dysplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, anhidrotic ectodermal dysplasia, anterofacial dysplasia, asphyxiating thoracic dysplasia, atriodigital dysplasia, bronchopulmonary dysplasia, cerebral dysplasia, cervical dysplasia, chondroectodermal dysplasia, cleidocranial dysplasia, congenital ectodermal dysplasia, craniodiaphysial dysplasia, craniocarpotarsal dysplasia, craniometaphysial dysplasia, dentin dysplasia, diaphysial dysplasia, ectodenmal dysplasia, enamel dysplasia, encephalo-ophthalmic dysplasia, dysplasia epiphysialis hemimelia, dysplasia epiphysialis multiplex, dysplasia epiphysialis punctata, epithelial dysplasia, faciodigitogenital dysplasia, familial fibrous dysplasia of jaws, familial white folded dysplasia, fibromuscular dysplasia, fibrous dysplasia of bone, florid osseous dysplasia, hereditary renal-retinal dysplasia, hidrotic ectodermal dysplasia, hypohidrotic ectodermal dysplasia, lymphopenic thymic dysplasia, mammary dysplasia, mandibulofacial dysplasia, metaphysial dysplasia, Mondini dysplasia, monostotic fibrous dysplasia, mucoepithelial dysplasia, multiple epiphysial dysplasia, oculoauriculovertebral dysplasia, oculodentodigital dysplasia, oculovertebral dysplasia, odontogenic dysplasia, ophthalmomandibulomelic dysplasia, periapical cemental dysplasia, polyostotic fibrous dysplasia, pseudoachondroplastic spondyloepiphysial dysplasia, retinal dysplasia, septo-optic dysplasia, spondyloepiphysial dysplasia, and ventriculoradial dysplasia.

[1078] Additional pre-neoplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, benign dysproliferative disorders (e.g., benign tumors, fibrocystic conditions, tissue hypertrophy, intestinal polyps, colon polyps, and esophageal dysplasia), leukoplakia, keratoses, Bowen's disease, Farmer's Skin, solar cheilitis, and solar keratosis.

[1079] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, oantntagonists corresponding to that polypeptide, may be used to diagnose and/or prognose disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1B, column 8 (Tissue Distribution Library Code).

[1080] In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat cancers and neoplasms, including, but not limited to those described herein. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat acute myelogenous leukemia.

[1081] Additionally, polynucleotides, polypeptides, and/or agonists or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

[1082] In preferred embodiments, polynucleotides, polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

[1083] Additional diseases or conditions associated with increased cell survival that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, emangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[1084] Diseases associated with increased apoptosis that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

[1085] Hyperproliferative diseases and/or disorders that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, neoplasms located in the liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

[1086] Similarly, other hyperproliferative disorders can also be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstron's macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

[1087] Another preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

[1088] Thus, the present invention provides a method for treating cell proliferative disorders by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

[1089] Another embodiment of the present invention provides a method of treating cell-proliferative disorders in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the poynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

[1090] Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By “repressing expression of the oncogenic genes” is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

[1091] For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

[1092] The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

[1093] By “cell proliferative disease” is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

[1094] Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By “biologically inhibiting” is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

[1095] The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described disorders. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

[1096] A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

[1097] In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation disorders as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

[1098] The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example., which serve to increase the number or activity of effector cells which interact with the antibodies.

[1099] It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragements thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragements thereof. Preferred binding affinities include those with a dissociation constant or Kd less than 5×10⁻⁶M, 10⁻⁶M, 5×10⁻⁷M, 10⁻⁷M, 5×10⁻⁸M, 10⁻⁸M, 5×10⁹M, 10⁻⁹M, 5×10⁻¹⁰M, 10⁻¹⁰M, 5×10⁻¹¹M, 10⁻¹¹M, 5×10⁻¹²M, 10⁻¹²M, 5×10⁻¹³M, 10⁻¹³M, 5×10⁻¹⁴M, 10⁻¹⁴M, 5×10⁻¹⁵M, and 10⁻¹⁵M.

[1100] Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph I B, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

[1101] Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuviants, such as apoptonin, galectins, thioredoxins, anti-inflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

[1102] Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such thereapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

[1103] In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodes associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodes of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

[1104] Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention ‘vaccinated’ the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

[1105] Renal Disorders

[1106] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders of the renal system. Renal disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention include, but are not limited to, kidney failure, nephritis, blood vessel disorders of kidney, metabolic and congenital kidney disorders, urinary disorders of the kidney, autoimmune disorders, sclerosis and necrosis, electrolyte imbalance, and kidney cancers.

[1107] Kidney diseases which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention include, but are not limited to, acute kidney failure, chronic kidney failure, atheroembolic renal failure, end-stage renal disease, inflammatory diseases of the kidney (e.g., acute glomerulonephritis, postinfectious glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, membranous glomerulonephritis, familial nephrotic syndrome, membranoproliferative glomerulonephritis I and II, mesangial proliferative glomerulonephritis, chronic glomerulonephritis, acute tubulointerstitial nephritis, chronic tubulointerstitial nephritis, acute post-streptococcal glomerulonephritis (PSGN), pyelonephritis, lupus nephritis, chronic nephritis, interstitial nephritis, and post-streptococcal glomerulonephritis), blood vessel disorders of the kidneys (e.g., kidney infarction, atheroembolic kidney disease, cortical necrosis, malignant nephrosclerosis, renal vein thrombosis, renal underperfusion, renal retinopathy, renal ischemia-reperfusion, renal artery embolism, and renal artery stenosis), and kidney disorders resulting form urinary tract disease (e.g., pyelonephritis, hydronephrosis, urolithiasis (renal lithiasis, nephrolithiasis), reflux nephropathy, urinary tract infections, urinary retention, and acute or chronic unilateral obstructive uropathy.)

[1108] In addition, compositions of the invention can be used to diagnose, prognose, prevent, and/or treat metabolic and congenital disorders of the kidney (e.g., uremia, renal amyloidosis, renal osteodystrophy, renal tubular acidosis, renal glycosuria, nephrogenic diabetes insipidus, cystinuria, Fanconi's syndrome, renal fibrocystic osteosis (renal rickets), Hartnup disease, Bartter's syndrome, Liddle's syndrome, polycystic kidney disease, medullary cystic disease, medullary sponge kidney, Alport's syndrome, nail-patella syndrome, congenital nephrotic syndrome, CRUSH syndrome, horseshoe kidney, diabetic nephropathy, nephrogenic diabetes insipidus, analgesic nephropathy, kidney stones, and membranous nephropathy), and autoimmune disorders of the kidney (e.g., systemic lupus erythematosus (SLE), Goodpasture syndrome, IgA nephropathy, and IgM mesangial proliferative glomerulonephritis).

[1109] Compositions of the invention can also be used to diagnose, prognose, prevent, and/or treat sclerotic or necrotic disorders of the kidney (e.g., glomerulosclerosis, diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), necrotizing glomerulonephritis, and renal papillary necrosis), cancers of the kidney (e.g., nephroma, hypernephroma, nephroblastoma, renal cell cancer, transitional cell cancer, renal adenocarcinoma, squamous cell cancer, and Wilm's tumor), and electrolyte imbalances (e.g., nephrocalcinosis, pyuria, edema, hydronephritis, proteinuria, hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypophosphatemia, and hyperphosphatemia).

[1110] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

[1111] Cardiovascular Disorders

[1112] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose cardiovascular disorders, including, but not limited to, peripheral artery disease, such as limb ischemia.

[1113] Cardiovascular disorders include, but are not limited to, cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include, but are not limited to, aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

[1114] Cardiovascular disorders also include, but are not limited to, heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardi al diseases, myocardial ischemia, pericardi al effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

[1115] Arrhythmias include, but are not limited to, sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

[1116] Heart valve diseases include, but are not limited to, aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

[1117] Myocardial diseases include, but are not limited to, alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

[1118] Myocardial ischemias include, but are not limited to, coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

[1119] Cardiovascular diseases also include vascular diseases such as aneurysms, angiodysplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

[1120] Aneurysms include, but are not limited to, dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

[1121] Arterial occlusive diseases include, but are not limited to, arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

[1122] Cerebrovascular disorders include, but are not limited to, carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subaraxhnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

[1123] Embolisms include, but are not limited to, air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromoboembolisms. Thrombosis include, but are not limited to, coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

[1124] Ischemic disorders include, but are not limited to, cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes, but is not limited to, aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

[1125] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

[1126] Respiratory Disorders

[1127] Polynucleotides or polypeptides, or agonists or antagonists of the present invention may be used to treat, prevent, diagnose, and/or prognose diseases and/or disorders of the respiratory system.

[1128] Diseases and disorders of the respiratory system include, but are not limited to, nasal vestibulitis, nonallergic rhinitis (e.g., acute rhinitis, chronic rhinitis, atrophic rhinitis, vasomotor rhinitis), nasal polyps, and sinusitis, juvenile angiofibromas, cancer of the nose and juvenile papillomas, vocal cord polyps, nodules (singer's nodules), contact ulcers, vocal cord paralysis, laryngoceles, pharyngitis (e.g., viral and bacterial), tonsillitis, tonsillar cellulitis, parapharyngeal abscess, laryngitis, laryngoceles, and throat cancers (e.g., cancer of the nasopharynx, tonsil cancer, larynx cancer), lung cancer (e.g., squamous cell carcinoma, small cell (oat cell) carcinoma, large cell carcinoma, and adenocarcinoma), allergic disorders (eosinophilic pneumonia, hypersensitivity pneumonitis (e.g., extrinsic allergic alveolitis, allergic interstitial pneumonitis, organic dust pneumoconiosis, allergic bronchopulmonary aspergillosis, asthma, Wegener's granulomatosis (granulomatous vasculitis), Goodpasture's syndrome)), pneumonia (e.g., bacterial pneumonia (e.g., Streptococcus pneumoniae (pneumoncoccal pneumonia), Staphylococcus aureus (staphylococcal pneumonia), Gram-negative bacterial pneumonia (caused by, e.g., Klebsiella and Pseudomas spp.), Mycoplasma pneumoniae pneumonia, Hemophilus influenzae pneumonia, Legionella pneumophila (Legionnaires' disease), and Chlamydia psittaci (Psittacosis)), and viral pneumonia (e.g., influenza, chickenpox (varicella).

[1129] Additional diseases and disorders of the respiratory system include, but are not limited to bronchiolitis, polio (poliomyelitis), croup, respiratory syncytial viral infection, mumps, erythema infectiosum (fifth disease), roseola infantum, progressive rubella panencephalitis, german measles, and subacute sclerosing panencephalitis), fungal pneumonia (e.g., Histoplasmosis, Coccidioidomycosis, Blastomycosis, fungal infections in people with severely suppressed immune systems (e.g., cryptococcosis, caused by Cryptococcus neoformans; aspergillosis, caused by Aspergillus spp.; candidiasis, caused by Candida; and mucormycosis)), Pneumocystis carinii (pneumocystis pneumonia), a typical pneumonias (e.g., Mycoplasma and Chlamydia spp.), opportunistic infection pneumonia, nosocomial pneumonia, chemical pneumonitis, and aspiration pneumonia, pleural disorders (e.g., pleurisy, pleural effusion, and pneumothorax (e.g., simple spontaneous pneumothorax, complicated spontaneous pneumothorax, tension pneumothorax)), obstructive airway diseases (e.g., asthma, chronic obstructive pulmonary disease (COPD), emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis, black lung (coal workers' pneumoconiosis), asbestosis, berylliosis, occupational asthsma, byssinosis, and benign pneumoconioses), Infiltrative Lung Disease (e.g., pulmonary fibrosis (e.g., fibrosing alveolitis, usual interstitial pneumonia), idiopathic pulmonary fibrosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, histiocytosis X (e.g., Letterer-Siwe disease, Hand-Schüller-Christian disease, eosinophilic granuloma), idiopathic pulmonary hemosiderosis, sarcoidosis and pulmonary alveolar proteinosis), Acute respiratory distress syndrome (also called, e.g., adult respiratory distress syndrome), edema, pulmonary embolism, bronchitis (e.g., viral, bacterial), bronchiectasis, atelectasis, lung abscess (caused by, e.g., Staphylococcus aureus or Legionella pneumophila), and cystic fibrosis.

[1130] Anti-Angiogenesis Activity

[1131] The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad et al., Cell 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye disorders, and psoriasis. See, e.g., reviews by Moses et al., Biotech. 9:630-634 (1991); Folkman et al., N. Engl. J. Med., 333:1757-1763 (1995); Auerbach et al., J. Microvasc. Res. 29:401-411 (1985); Folkman, Advances in Cancer Research, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, Am. J. Opthalmol. 94:715-743 (1982); and Folkman et al., Science 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, Science 235:442-447 (1987).

[1132] The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman et al., Medicine, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

[1133] Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

[1134] Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; artheroscleric plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uvietis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scieroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

[1135] For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

[1136] Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists of the invention are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

[1137] Moreover, Ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman et al., Am. J. Ophthal. 85:704-710 (1978) and Gartner et al., Surv. Ophthal. 22:291-312 (1978).

[1138] Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

[1139] Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

[1140] Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to “protect” the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

[1141] Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

[1142] Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

[1143] Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreous injection and/or via intraocular implants.

[1144] Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

[1145] Moreover, disorders and/or states, which can be treated, prevented, diagnosed, and/or prognosed with the the polynucleotides, polypeptides, agonists and/or agonists of the invention include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uvietis, delayed wound healing, endometriosis, vascluogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa), ulcers (Helicobacter pylori), Bartonellosis and bacillary angiomatosis.

[1146] In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a “morning after” method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

[1147] Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

[1148] Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

[1149] Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

[1150] Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

[1151] The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter “d group” transition metals.

[1152] Lighter “d group” transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

[1153] Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

[1154] Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

[1155] A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP-PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate (“GST”; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4- chloroanthronilic acid disodium or “CCA”; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

[1156] Diseases at the Cellular Level

[1157] Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, diagnosed, and/or prognosed using polynucleotides or polypeptides, as well as antagonists or agonists of the present invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

[1158] In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

[1159] Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[1160] Diseases associated with increased apoptosis that could be treated, prevented, diagnosed, and/or prognesed using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, include, but are not limited to, AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

[1161] Wound Healing and Epithelial Cell Proliferation

[1162] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote dermal reestablishment subsequent to dermal loss

[1163] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are types of grafts that polynucleotides or polypeptides, agonists or antagonists of the present invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, can be used to promote skin strength and to improve the appearance of aged skin.

[1164] It is believed that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. Polynucleotides or polypeptides, agonists or antagonists of the present invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

[1165] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may have a cytoprotective effect on the small intestine mucosa. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

[1166] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to treat gastric and doudenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with polynucleotides or polypeptides, agonists or antagonists of the present invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat diseases associate with the under expression.

[1167] Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to prevent and heal damage to the lungs due to various pathological states. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and brochiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using polynucleotides or polypeptides, agonists or antagonists of the present invention. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

[1168] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins known in the art).

[1169] In addition, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

[1170] Neural Activity and Neurological Diseases

[1171] The polynucleotides, polypeptides and agonists or antagonists of the invention may be used for the diagnosis and/or treatment of diseases, disorders, damage or injury of the brain and/or nervous system. Nervous system disorders that can be treated with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the methods of the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, or syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to, degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including, but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

[1172] In one embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of hypoxia. In a further preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat or prevent neural cell injury associated with cerebral hypoxia. In one non-exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention, are used to treat or prevent neural cell injury associated with cerebral ischemia. In another non-exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with cerebral infarction.

[1173] In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a stroke. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a stroke.

[1174] In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a heart attack. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a heart attack.

[1175] The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture either in the presence or absence of hypoxia or hypoxic conditions; (2) increased sprouting of neurons in culture or in vivo; (3) increased production of a neuron-associated molecule in culture or in vivo, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction in vivo. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, in Zhang et al., Proc Natl Acad Sci USA 97:3637-42 (2000) or in Arakawa et al., J. Neurosci., 10:3507-15 (1990); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al., Exp. Neurol., 70:65-82 (1980), or Brown et al., Ann. Rev. Neurosci., 4:17-42 (1981); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

[1176] In specific embodiments, motor neuron disorders that may be treated according to the invention include, but are not limited to, disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

[1177] Further, polypeptides or polynucleotides of the invention may play a role in neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus, compositions of the invention (including polynucleotides, polypeptides, and agonists or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders associated with these roles, including, but not limited to, learning and/or cognition disorders. The compositions of the invention may also be useful in the treatment or prevention of neurodegenerative disease states and/or behavioural disorders. Such neurodegenerative disease states and/or behavioral disorders include, but are not limited to, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, compositions of the invention may also play a role in the treatment, prevention and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

[1178] Additionally, polypeptides, polynucleotides and/or agonists or antagonists of the invention, may be useful in protecting neural cells from diseases, damage, disorders, or injury, associated with cerebrovascular disorders including, but not limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia, periventricular, and vascular headache (e.g., cluster headache or migraines).

[1179] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or detector of a particular nervous system disease or disorder.

[1180] Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency, pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis.

[1181] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency, vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache and migraine.

[1182] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden-Spatz Syndrome.

[1183] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

[1184] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include meningitis such as arachnoiditis, aseptic meningtitis such as viral meningtitis which includes lymphocytic choriomeningitis, Bacterial meningtitis which includes Haemophilus Meningtitis, Listeria Meningtitis, Meningococcal Meningtitis such as Waterhouse-Friderichsen Syndrome, Pneumococcal Meningtitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningtitis, subdural effusion, meningoencephalitis such as uvemeningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

[1185] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral sceloris which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon-Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucolipidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydrangencephaly, Arnold-Chairi Deformity, encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

[1186] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia, apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia, broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia, myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Homer's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism, spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyloclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Homer's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.

[1187] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

[1188] Endocrine Disorders

[1189] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders and/or diseases related to hormone imbalance, and/or disorders or diseases of the endocrine system.

[1190] Hormones secreted by the glands of the endocrine system control physical growth, sexual function, metabolism, and other functions. Disorders may be classified in two ways: disturbances in the production of hormones, and the inability of tissues to respond to hormones. The etiology of these hormone imbalance or endocrine system diseases, disorders or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy, injury or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular disease or disorder related to the endocrine system and/or hormone imbalance.

[1191] Endocrine system and/or hormone imbalance and/or diseases encompass disorders of uterine motility including, but not limited to: complications with pregnancy and labor (e.g., pre-term labor, post-term pregnancy, spontaneous abortion, and slow or stopped labor); and disorders and/or diseases of the menstrual cycle (e.g., dysmenorrhea and endometriosis).

[1192] Endocrine system and/or hormone imbalance disorders and/or diseases include disorders and/or diseases of the pancreas, such as, for example, diabetes mellitus, diabetes insipidus, congenital pancreatic agenesis, pheochromocytoma—islet cell tumor syndrome; disorders and/or diseases of the adrenal glands such as, for example, Addison's Disease, corticosteroid deficiency, virilizing disease, hirsutism, Cushing's Syndrome, hyperaldosteronism, pheochromocytoma; disorders and/or diseases of the pituitary gland, such as, for example, hyperpituitarism, hypopituitarism, pituitary dwarfism, pituitary adenoma, panhypopituitarism, acromegaly, gigantism; disorders and/or diseases of the thyroid, including but not limited to, hyperthyroidism, hypothyroidism, Plummer's disease, Graves' disease (toxic diffuse goiter), toxic nodular goiter, thyroiditis (Hashimoto's thyroiditis, subacute granulomatous thyroiditis, and silent lymphocytic thyroiditis), Pendred's syndrome, myxedema, cretinism, thyrotoxicosis, thyroid hormone coupling defect, thymic aplasia, Hurthle cell tumours of the thyroid, thyroid cancer, thyroid carcinoma, Medullary thyroid carcinoma; disorders and/or diseases of the parathyroid, such as, for example, hyperparathyroidism, hypoparathyroidism; disorders and/or diseases of the hypothalamus.

[1193] In addition, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases of the testes or ovaries, including cancer. Other disorders and/or diseases of the testes or ovaries further include, for example, ovarian cancer, polycystic ovary syndrome, Klinefelter's syndrome, vanishing testes syndrome (bilateral anorchia), congenital absence of Leydig's cells, cryptorchidism, Noonan's syndrome, myotonic dystrophy, capillary haemangioma of the testis (benign), neoplasias of the testis and neo-testis.

[1194] Moreover, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases such as, for example, polyglandular deficiency syndromes, pheochromocytoma, neuroblastoma, multiple Endocrine neoplasia, and disorders and/or cancers of endocrine tissues.

[1195] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose, prognose, prevent, and/or treat endocrine diseases and/or disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1B, column 8 (Tissue Distribution Library Code).

[1196] Reproductive System Disorders

[1197] The polynucleotides or polypeptides, or agonists or antagonists of the invention may be used for the diagnosis, treatment, or prevention of diseases and/or disorders of the reproductive system. Reproductive system disorders that can be treated by the compositions of the invention, include, but are not limited to, reproductive system injuries, infections, neoplastic disorders, congenital defects, and diseases or disorders which result in infertility, complications with pregnancy, labor, or parturition, and postpartum difficulties.

[1198] Reproductive system disorders and/or diseases include diseases and/or disorders of the testes, including testicular atrophy, testicular feminization, cryptorchism (unilateral and bilateral), anorchia, ectopic testis, epididymitis and orchitis (typically resulting from infections such as, for example, gonorrhea, mumps, tuberculosis, and syphilis), testicular torsion, vasitis nodosa, germ cell tumors (e.g., seminomas, embryonal cell carcinomas, teratocarcinomas, choriocarcinomas, yolk sac tumors, and teratomas), stromal tumors (e.g., Leydig cell tumors), hydrocele, hematocele, varicocele, spermatocele, inguinal hernia, and disorders of sperm production (e.g., immotile cilia syndrome, aspermia, asthenozoospermia, azoospermia, oligospermia, and teratozoospermia).

[1199] Reproductive system disorders also include disorders of the prostate gland, such as acute non-bacterial prostatitis, chronic non-bacterial prostatitis, acute bacterial prostatitis, chronic bacterial prostatitis, prostatodystonia, prostatosis, granulomatous prostatitis, malacoplakia, benign prostatic hypertrophy or hyperplasia, and prostate neoplastic disorders, including adenocarcinomas, transitional cell carcinomas, ductal carcinomas, and squamous cell carcinomas.

[1200] Additionally, the compositions of the invention may be useful in the diagnosis, treatment, and/or prevention of disorders or diseases of the penis and urethra, including inflammatory disorders, such as balanoposthitis, balanitis xerotica obliterans, phimosis, paraphimosis, syphilis, herpes simplex virus, gonorrhea, non-gonococcal urethritis, chlamydia, mycoplasma, trichomonas, HIV, AIDS, Reiter's syndrome, condyloma acuminatum, condyloma latum, and pearly penile papules; urethral abnormalities, such as hypospadi as, epispadi as, and phimosis; premalignant lesions, including Erythroplasi a of Queyrat, Bowen's disease, Bowenoid paplosis, giant condyloma of Buscke-Lowenstein, and varrucous carcinoma; penile cancers, including squamous cell carcinomas, carcinoma in situ, verrucous carcinoma, and disseminated penile carcinoma; urethral neoplastic disorders, including penile urethral carcinoma, bulbomembranous urethral carcinoma, and prostatic urethral carcinoma; and erectile disorders, such as priapism, Peyronie's disease, erectile dysfunction, and impotence.

[1201] Moreover, diseases and/or disorders of the vas deferens include vasculititis and CBAVD (congenital bilateral absence of the vas deferens); additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the seminal vesicles, including hydatid disease, congenital chloride diarrhea, and polycystic kidney disease.

[1202] Other disorders and/or diseases of the male reproductive system include, for example, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes mellitus, cystic fibrosis, Kartagener's syndrome, high fever, multiple sclerosis, and gynecomastia.

[1203] Further, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the vagina and vulva, including bacterial vaginosis, candida vaginitis, herpes simplex virus, chancroid, granuloma inguinale, lymphogranuloma venereum, scabies, human papillomavirus, vaginal trauma, vulvar trauma, adenosis, chlamydia vaginitis, gonorrhea, trichomonas vaginitis, condyloma acuminatum, syphilis, molluscum contagiosum, atrophic vaginitis, Paget's disease, lichen sclerosus, lichen planus, vulvodynia, toxic shock syndrome, vaginismus, vulvovaginitis, vulvar vestibulitis, and neoplastic disorders, such as squamous cell hyperplasia, clear cell carcinoma, basal cell carcinoma, melanomas, cancer of Bartholin's gland, and vulvar intraepithelial neoplasia.

[1204] Disorders and/or diseases of the uterus include dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding (e.g., due to aberrant hormonal signals), and neoplastic disorders, such as adenocarcinomas, keiomyosarcomas, and sarcomas. Additionally, the polypeptides, polynucleotides, or agonists or antagonists of the invention may be useful as a marker or detector of, as well as in the diagnosis, treatment, and/or prevention of congenital uterine abnormalities, such as bicornuate uterus, septate uterus, simple unicornuate uterus, unicornuate uterus with a noncavitary rudimentary horn, unicornuate uterus with a non-communicating cavitary rudimentary horn, unicornuate uterus with a communicating cavitary horn, arcuate uterus, uterine didelfus, and T-shaped uterus.

[1205] Ovarian diseases and/or disorders include anovulation, polycystic ovary syndrome (Stein-Leventhal syndrome), ovarian cysts, ovarian hypofunction, ovarian insensitivity to gonadotropins, ovarian overproduction of androgens, right ovarian vein syndrome, amenorrhea, hirutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, Sertoli-Leydig tumors, endometriod carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, and Ovarian Krukenberg tumors).

[1206] Cervical diseases and/or disorders include cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, and cervical neoplasms (including, for example, cervical carcinoma, squamous metaplasia, squamous cell carcinoma, adenosquamous cell neoplasia, and columnar cell neoplasia).

[1207] Additionally, diseases and/or disorders of the reproductive system include disorders and/or diseases of pregnancy, including miscarriage and stillbirth, such as early abortion, late abortion, spontaneous abortion, induced abortion, therapeutic abortion, threatened abortion, missed abortion, incomplete abortion, complete abortion, habitual abortion, missed abortion, and septic abortion; ectopic pregnancy, anemia, Rh incompatibility, vaginal bleeding during pregnancy, gestational diabetes, intrauterine growth retardation, polyhydramnios, HELLP syndrome, abruptio placentae, placenta previa, hyperemesis, preeclampsia, eclampsia, herpes gestationis, and urticaria of pregnancy. Additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases that can complicate pregnancy, including heart disease, heart failure, rheumatic heart disease, congenital heart disease, mitral valve prolapse, high blood pressure, anemia, kidney disease, infectious disease (e.g., rubella, cytomegalovirus, toxoplasmosis, infectious hepatitis, chlamydia, HIV, AIDS, and genital herpes), diabetes mellitus, Graves' disease, thyroiditis, hypothyroidism, Hashimoto's thyroiditis, chronic active hepatitis, cirrhosis of the liver, primary biliary cirrhosis, asthma, systemic lupus eryematosis, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenic purpura, appendicitis, ovarian cysts, gallbladder disorders, and obstruction of the intestine.

[1208] Complications associated with labor and parturition include premature rupture of the membranes, pre-term labor, post-term pregnancy, postmaturity, labor that progresses too slowly, fetal distress (e.g., abnormal heart rate (fetal or maternal), breathing problems, and abnormal fetal position), shoulder dystocia, prolapsed umbilical cord, amniotic fluid embolism, and aberrant uterine bleeding.

[1209] Further, diseases and/or disorders of the postdelivery period, including endometritis, myometritis, parametritis, peritonitis, pelvic thrombophlebitis, pulmonary embolism, endotoxemia, pyelonephritis, saphenous thrombophlebitis, mastitis, cystitis, postpartum hemorrhage, and inverted uterus.

[1210] Other disorders and/or diseases of the female reproductive system that may be diagnosed, treated, and/or prevented by the polynucleotides, polypeptides, and agonists or antagonists of the present invention include, for example, Turner's syndrome, pseudohermaphroditism, premenstrual syndrome, pelvic inflammatory disease, pelvic congestion (vascular engorgement), frigidity, anorgasmia, dyspareunia, ruptured fallopian tube, and Mittelschmerz.

[1211] Infectious Disease

[1212] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

[1213] Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circovindae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxyiridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

[1214] Similarly, bacterial and fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacteria, bacterial families, and fungi: Actinomyces (e.g., Norcardia), Acinetobacter, Cryptococcus neoformans, Aspergillus, Bacillaceae (e.g., Bacillus anthrasis), Bacteroides (e.g., Bacteroides fragilis), Blastomycosis, Bordetella, Borrelia (e.g., Borrelia burgdorferi), Brucella, Candidia, Campylobacter, Chlamydia, Clostridium (e.g., Clostridium botulinum, Clostridium dificile, Clostridium perfringens, Clostridium tetani), Coccidioides, Corynebacterium (e.g., Corynebacterium diptheriae), Cryptococcus, Dermatocycoses, E. coli (e.g., Enterotoxigenic E. coli and Enterohemorrhagic E. coli), Enterobacter (e.g. Enterobacter aerogenes), Enterobacteriaceae (Klebsiella, Salmonella (e.g., Salmonella typhi, Salmonella enteritidis, Salmonella typhi), Serratia, Yersinia, Shigella), Erysipelothrix, Haemophilus (e.g., Haemophilus influenza type B), Helicobacter, Legionella (e.g., Legionella pneumophila), Leptospira, Listeria (e.g., Listeria monocytogenes), Mycoplasma, Mycobacterium (e.g., Mycobacterium leprae and Mycobacterium tuberculosis), Vibrio (e.g., Vibrio cholerae), Neisseriaceae (e.g., Neisseria gonorrhea, Neisseria meningitidis), Pasteurellacea, Proteus, Pseudomonas (e.g., Pseudomonas aeruginosa), Rickettsiaceae, Spirochetes (e.g., Treponema spp., Leptospira spp., Borrelia spp.), Shigella spp., Staphylococcus (e.g., Staphylococcus aureus), Meningiococcus, Pneumococcus and Streptococcus (e.g., Streptococcus pneumoniae and Groups A, B, and C Streptococci), and Ureaplasmas. These bacterial, parasitic, and fungal families can cause diseases or symptoms, including, but not limited to: antibiotic-resistant infections, bacteremia, endocarditis, septicemia, eye infections (e.g., conjunctivitis), uveitis, tuberculosis, gingivitis, bacterial diarrhea, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, dental caries, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, dysentery, paratyphoid fever, food poisoning, Legionella disease, chronic and acute inflammation, erythema, yeast infections, typhoid, pneumonia, gonorrhea, meningitis (e.g., mengitis types A and B), chlamydia, syphillis, diphtheria, leprosy, brucellosis, peptic ulcers, anthrax, spontaneous abortions, birth defects, pneumonia, lung infections, ear infections, deafness, blindness, lethargy, malaise, vomiting, chronic diarrhea, Crohn's disease, colitis, vaginosis, sterility, pelvic inflammatory diseases, candidiasis, paratuberculosis, tuberculosis, lupus, botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections, noscomial infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, diptheria, botulism, and/or meningitis type B.

[1215] Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardias, Helminthiasis, Leishmaniasis, Schistisoma, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparium, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

[1216] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

[1217] Regeneration

[1218] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997)). The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteocarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

[1219] Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

[1220] Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

[1221] Similarly, nerve and brain tissue could also be regenerated by using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stoke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotides or polypeptides, as well as agonists or antagonists of the present invention.

[1222] Gastrointestinal Disorders

[1223] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose gastrointestinal disorders, including inflammatory diseases and/or conditions, infections, cancers (e.g., intestinal neoplasms (carcinoid tumor of the small intestine, non-Hodgkin's lymphoma of the small intestine, small bowl lymphoma)), and ulcers, such as peptic ulcers.

[1224] Gastrointestinal disorders include dysphagia, odynophagia, inflammation of the esophagus, peptic esophagitis, gastric reflux, submucosal fibrosis and stricturing, Mallory-Weiss lesions, leiomyomas, lipomas, epidermal cancers, adeoncarcinomas, gastric retention disorders, gastroenteritis, gastric atrophy, gastric/stomach cancers, polyps of the stomach, autoimmune disorders such as pernicious anemia, pyloric stenosis, gastritis (bacterial, viral, eosinophilic, stress-induced, chronic erosive, atrophic, plasma cell, and Menetrier's), and peritoneal diseases (e.g., chyloperioneum, hemoperitoneum, mesenteric cyst, mesenteric lymphadenitis, mesenteric vascular occlusion, panniculitis, neoplasms, peritonitis, pneumoperitoneum, bubphrenic abscess,).

[1225] Gastrointestinal disorders also include disorders associated with the small intestine, such as malabsorption syndromes, distension, irritable bowel syndrome, sugar intolerance, celiac disease, duodenal ulcers, duodenitis, tropical sprue, Whipple's disease, intestinal lymphangiectasia, Crohn's disease, appendicitis, obstructions of the ileum, Meckel's diverticulum, multiple diverticula, failure of complete rotation of the small and large intestine, lymphoma, and bacterial and parasitic diseases (such as Traveler's diarrhea, typhoid and paratyphoid, cholera, infection by Roundworms (Ascariasis lumbricoides), Hookworms (Ancylostoma duodenale), Threadworms (Enterobius vermicularis), Tapeworms (Taenia saginata, Echinococcus granulosus, Diphyllobothrium spp., and T. solium).

[1226] Liver diseases and/or disorders include intrahepatic cholestasis (alagille syndrome, biliary liver cirrhosis), fatty liver (alcoholic fatty liver, reye syndrome), hepatic vein thrombosis, hepatolentricular degeneration, hepatomegaly, hepatopulmonary syndrome, hepatorenal syndrome, portal hypertension (esophageal and gastric varices), liver abscess (amebic liver abscess), liver cirrhosis (alcoholic, biliary and experimental), alcoholic liver diseases (fatty liver, hepatitis, cirrhosis), parasitic (hepatic echinococcosis, fascioliasis, amebic liver abscess), jaundice (hemolytic, hepatocellular, and cholestatic), cholestasis, portal hypertension, liver enlargement, ascites, hepatitis (alcoholic hepatitis, animal hepatitis, chronic hepatitis (autoimmune, hepatitis B, hepatitis C, hepatitis D, drug induced), toxic hepatitis, viral human hepatitis (hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E), Wilson's disease, granulomatous hepatitis, secondary biliary cirrhosis, hepatic encephalopathy, portal hypertension, varices, hepatic encephalopathy, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular adenoma, hemangiomas, bile stones, liver failure (hepatic encephalopathy, acute liver failure), and liver neoplasms (angiomyolipoma, calcified liver metastases, cystic liver metastases, epithelial tumors, fibrolamellar hepatocarcinoma, focal nodular hyperplasia, hepatic adenoma, hepatobiliary cystadenoma, hepatoblastoma, hepatocellular carcinoma, hepatoma, liver cancer, liver hemangioendothelioma, mesenchymal hamartoma, mesenchymal tumors of liver, nodular regenerative hyperplasia, benign liver tumors (Hepatic cysts [Simple cysts, Polycystic liver disease, Hepatobiliary cystadenoma, Choledochal cyst], Mesenchymal tumors [Mesenchymal hamartoma, Infantile hemangioendothelioma, Hemangioma, Peliosis hepatis, Lipomas, Inflammatory pseudotumor, Miscellaneous], Epithelial tumors [Bile duct epithelium (Bile duct hamartoma, Bile duct adenoma), Hepatocyte (Adenoma, Focal nodular hyperplasia, Nodular regenerative hyperplasia)], malignant liver tumors [hepatocellular, hepatoblastoma, hepatocellular carcinoma, cholangiocellular, cholangiocarcinoma, cystadenocarcinoma, tumors of blood vessels, angiosarcoma, Karposi's sarcoma, hemangioendothelioma, other tumors, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, carcinoid, squamous carcinoma, primary lymphoma]), peliosis hepatis, erythrohepatic porphyria, hepatic porphyria (acute intermittent porphyria, porphyria cutanea tarda), Zellweger syndrome).

[1227] Pancreatic diseases and/or disorders include acute pancreatitis, chronic pancreatitis (acute necrotizing pancreatitis, alcoholic pancreatitis), neoplasms (adenocarcinoma of the pancreas, cystadenocarcinoma, insulinoma, gastrinoma, and glucagonoma, cystic neoplasms, islet-cell tumors, pancreoblastoma), and other pancreatic diseases (e.g., cystic fibrosis, cyst (pancreatic pseudocyst, pancreatic fistula, insufficiency)).

[1228] Gallbladder diseases include gallstones (cholelithiasis and choledocholithiasis), postcholecystectomy syndrome, diverticulosis of the gallbladder, acute cholecystitis, chronic cholecystitis, bile duct tumors, and mucocele.

[1229] Diseases and/or disorders of the large intestine include antibiotic-associated colitis, diverticulitis, ulcerative colitis, acquired megacolon, abscesses, fungal and bacterial infections, anorectal disorders (e.g., fissures, hemorrhoids), colonic diseases (colitis, colonic neoplasms [colon cancer, adenomatous colon polyps (e.g., villous adenoma), colon carcinoma, colorectal cancer], colonic diverticulitis, colonic diverticulosis, megacolon [Hirschsprung disease, toxic megacolon]; sigmoid diseases [proctocolitis, sigmoin neoplasms]), constipation, Crohn's disease, diarrhea (infantile diarrhea, dysentery), duodenal diseases (duodenal neoplasms, duodenal obstruction, duodenal ulcer, duodenitis), enteritis (enterocolitis), HIV enteropathy, ileal diseases (ileal neoplasms, ileitis), immunoproliferative small intestinal disease, inflammatory bowel disease (ulcerative colitis, Crohn's disease), intestinal atresia, parasitic diseases (anisakiasis, balantidiasis, blastocystis infections, cryptosporidiosis, dientamoebiasis, amebic dysentery, giardiasis), intestinal fistula (rectal fistula), intestinal neoplasms (cecal neoplasms, colonic neoplasms, duodenal neoplasms, ileal neoplasms, intestinal polyps, jejunal neoplasms, rectal neoplasms), intestinal obstruction (afferent loop syndrome, duodenal obstruction, impacted feces, intestinal pseudo-obstruction [cecal volvulus], intussusception), intestinal perforation, intestinal polyps (colonic polyps, gardner syndrome, peutz-jeghers syndrome), jejunal diseases Oejunal neoplasms), malabsorption syndromes (blind loop syndrome, celiac disease, lactose intolerance, short bowl syndrome, tropical sprue, whipple's disease), mesenteric vascular occlusion, pneumatosis cystoides intestinalis, protein-losing enteropathies (intestinal lymphagiectasis), rectal diseases (anus diseases, fecal incontinence, hemorrhoids, proctitis, rectal fistula, rectal prolapse, rectocele), peptic ulcer (duodenal ulcer, peptic esophagitis, hemorrhage, perforation, stomach ulcer, Zollinger-Ellison syndrome), postgastrectomy syndromes (dumping syndrome), stomach diseases (e.g., achlorhydria, duodenogastric reflux (bile reflux), gastric antral vascular ectasia, gastric fistula, gastric outlet obstruction, gastritis (atrophic or hypertrophic), gastroparesis, stomach dilatation, stomach diverticulum, stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, hyperplastic gastric polyp), stomach rupture, stomach ulcer, stomach volvulus), tuberculosis, visceroptosis, vomiting (e.g., hematemesis, hyperemesis gravidarum, postoperative nausea and vomiting) and hemorrhagic colitis.

[1230] Further diseases and/or disorders of the gastrointestinal system include biliary tract diseases, such as, gastroschisis, fistula (e.g., biliary fistula, esophageal fistula, gastric fistula, intestinal fistula, pancreatic fistula), neoplasms (e.g., biliary tract neoplasms, esophageal neoplasms, such as adenocarcinoma of the esophagus, esophageal squamous cell carcinoma, gastrointestinal neoplasms, pancreatic neoplasms, such as adenocarcinoma of the pancreas, mucinous cystic neoplasm of the pancreas, pancreatic cystic neoplasms, pancreatoblastoma, and peritoneal neoplasms), esophageal disease (e.g., bullous diseases, candidiasis, glycogenic acanthosis, ulceration, barrett esophagus varices, atresia, cyst, diverticulum (e.g., Zenker's diverticulum), fistula (e.g., tracheoesophageal fistula), motility disorders (e.g., CREST syndrome, deglutition disorders, achalasia, spasm, gastroesophageal reflux), neoplasms, perforation (e.g., Boerhaave syndrome, Mallory-Weiss syndrome), stenosis, esophagitis, diaphragmatic hernia (e.g., hiatal hernia); gastrointestinal diseases, such as, gastroenteritis (e.g., cholera morbus, norwalk virus infection), hemorrhage (e.g., hematemesis, melena, peptic ulcer hemorrhage), stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, stomach cancer)), hernia (e.g., congenital diaphragmatic hernia, femoral hernia, inguinal hernia, obturator hernia, umbilical hernia, ventral hernia), and intestinal diseases (e.g., cecal diseases (appendicitis, cecal neoplasms)). Chemotaxis

[1231] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may have chemotaxis activity. A chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

[1232] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may increase chemotaxic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotaxic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

[1233] It is also contemplated that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could be used as an inhibitor of chemotaxis.

[1234] Binding Activity

[1235] A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

[1236] Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991)). Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

[1237] Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

[1238] The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

[1239] Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

[1240] Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

[1241] Additionally, the receptor to which the polypeptide of the present invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labeled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

[1242] Following fixation and incubation, the slides are subjected to auto-radiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

[1243] As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

[1244] Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as “DNA shuffling”) may be employed to modulate the activities of the polypeptide of the present invention thereby effectively generating agonists and antagonists of the polypeptide of the present invention. See generally, U.S. Pat. Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, S. Trends Biotechnol. 16(2):76-82 (1998); Hansson, L. O., et al., J. Mol. Biol. 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. Biotechniques 24(2):308-13 (1998); each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptide of the present invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

[1245] Other preferred fragments are biologically active fragments of the polypeptide of the present invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

[1246] Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and ³[H] thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of ³[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of ³[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

[1247] In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

[1248] All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues.

[1249] Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the present invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the present invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

[1250] Targeted Delivery

[1251] In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

[1252] As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

[1253] In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

[1254] By “toxin” is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNAse, alpha toxin, ricin, abrin, Pseudomonas exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By “cytotoxic prodrug” is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

[1255] Drug Screening

[1256] Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

[1257] This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

[1258] Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

[1259] Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on Sep. 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

[1260] This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

[1261] Antisense And Ribozyme (Antagonists)

[1262] In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to cDNA sequences contained in cDNA ATCC Deposit No:Z identified for example, in Table 1A and/or 1B. In one embodiment, antisense sequence is generated internally, by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, J., Neurochem. 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, J., Neurochem. 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, Fla. (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

[1263] For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5 end and a HindIII site on the 3 end. Next, the pair of oligonucleotides is heated at 90° C. for one minute and then annealed in 2× ligation buffer (20 mM TRIS HCl pH 7.5, 10 mM MgCl2, 10 MM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

[1264] For example, the 5′ coding portion of a polynucleotide that encodes the polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

[1265] In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding the polypeptide of the present invention or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bemoist and Chambon, Nature 29:304-310 (1981), the promoter contained in the 3′ long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster, et al., Nature 296:39-42 (1982)), etc.

[1266] The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of the present invention. However, absolute complementarity, although preferred, is not required. A sequence “complementary to at least a portion of an RNA,” referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

[1267] Oligonucleotides that are complementary to the 5′ end of the message, e.g., the 5′ untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3′ untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., 1994, Nature 372:333-335. Thus, oligonucleotides complementary to either the 5′- or 3′-non-translated, non-coding regions of polynucleotide sequences described herein could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5′ untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5′-, 3′- or coding region of mRNA of the present invention, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

[1268] The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO88/09810, published Dec. 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published Apr. 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

[1269] The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine,

[1270] 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N-6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

[1271] The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

[1272] In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

[1273] In yet another embodiment, the antisense oligonucleotide is an α-anomeric oligonucleotide. An α-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2′-0-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

[1274] Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

[1275] While antisense nucleotides complementary to the coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.

[1276] Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published Oct. 4, 1990; Sarver et al, Science 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5′-UG-3′. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within the nucleotide sequence of SEQ ID NO:X. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5′ end of the mRNA; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

[1277] As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.) and should be delivered to cells which express in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct “encoding” the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

[1278] Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

[1279] The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon angioplasty.

[1280] The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

[1281] The antagonist/agonist may also be employed to treat the diseases described herein.

[1282] Thus, the invention provides a method of treating disorders or diseases, including but not limited to the disorders or diseases listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

[1283] Binding Peptides and Other Molecules

[1284] The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind polypeptides of the invention, and the binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the polypeptides of the invention. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

[1285] This method comprises the steps of:

[1286] a. contacting polypeptides of the invention with a plurality of molecules; and

[1287] b. identifying a molecule that binds the polypeptides of the invention.

[1288] The step of contacting the polypeptides of the invention with the plurality of molecules may be effected in a number of ways. For example, one may contemplate immobilizing the polypeptides on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized polypeptides. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized polypeptides of the invention. The molecules having a selective affinity for the polypeptides can then be purified by affinity selection. The nature of the solid support, process for attachment of the polypeptides to the solid support, solvent, and conditions of the affinity isolation or selection are largely conventional and well known to those of ordinary skill in the art.

[1289] Alternatively, one may also separate a plurality of polypeptides into substantially separate fractions comprising a subset of or individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant phage). Individual isolates can then be “probed” by the polypeptides of the invention, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the polypeptides and the individual clone. Prior to contacting the polypeptides with each fraction comprising individual polypeptides, the polypeptides could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for polypeptides of the invention. Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the polypeptides of the invention can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

[1290] In certain situations, it may be desirable to wash away any unbound polypeptides from a mixture of the polypeptides of the invention and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction. Such a wash step may be particularly desirable when the polypeptides of the invention or the plurality of polypeptides are bound to a solid support.

[1291] The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide libraries which can be screened for molecules that specifically bind polypeptides of the invention. Many libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, Science 251:767-773; Houghten et al., 1991, Nature 354:84-86; Lam et al., 1991, Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop et al., 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer et al., 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb et al., 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten et al., 1992, Biotechniques 13:412; Jayawickreme et al., 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon et al., 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

[1292] Examples of phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin et al., 1990, Science, 249:404-406; Christian, R. B., et al., 1992, J. Mol. Biol. 227:711-718); Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

[1293] In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

[1294] By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

[1295] The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, Bio/Technology 13:351-360 list benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs, beta-mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

[1296] Non-peptide libraries can be classified broadly into two types: decorated monomers and oligomers. Decorated monomer libraries employ a relatively simple scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

[1297] Non-peptide oligomer libraries utilize a large number of monomers that are assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

[1298] Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992; BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al., 1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and CT Publication No. WO 94/18318.

[1299] In a specific embodiment, screening to identify a molecule that binds polypeptides of the invention can be carried out by contacting the library members with polypeptides of the invention immobilized on a solid phase and harvesting those library members that bind to the polypeptides of the invention. Examples of such screening methods, termed “panning” techniques are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited herein.

[1300] In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to polypeptides of the invention.

[1301] Where the binding molecule is a polypeptide, the polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term “biased” is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

[1302] Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine. Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

[1303] As mentioned above, in the case of a binding molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably, about 6 to about 22 amino acids. In another embodiment, a binding polypeptide has in the range of 15-100 amino acids, or 20-50 amino acids.

[1304] The selected binding polypeptide can be obtained by chemical synthesis or recombinant expression.

[1305] Other Activities

[1306] A polypeptide, polynucleotide, agonist, or antagonist of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. The polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

[1307] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

[1308] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed stimulate neuronal growth and to treat and prevent neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

[1309] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

[1310] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

[1311] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

[1312] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

[1313] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

[1314] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, caricadic rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

[1315] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

[1316] The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

[1317] Other Preferred Embodiments

[1318] Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 5 of Table 1B or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in ATCC Deposit No:Z.

[1319] Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of the portion of SEQ ID NO:X as defined in column 5, “ORF (From-To)”, in Table 1B.

[1320] Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of the portion of SEQ ID NO:X as defined in columns 8 and 9, “NT From” and “NT To” respectively, in Table 2.

[1321] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 5 of Table 1B or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in ATCC Deposit No:Z.

[1322] Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 5 of Table 1B or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in ATCC Deposit No:Z.

[1323] A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of the portion of SEQ ID NO:X defined in column 5, “ORF (From-To)”, in Table 1B.

[1324] A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of the portion of SEQ ID NO:X defined in columns 8 and 9, “NT From” and “NT To”, respectively, in Table 2.

[1325] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 5 of Table 1B or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in ATCC Deposit No:Z.

[1326] Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, the nucleotide sequence as defined in column 5 of Table 1B or columns 8 and 9 of Table 2 or the complementary strand thereto, and/or cDNA contained in ATCC Deposit No:Z, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

[1327] Also preferred is a composition of matter comprising a DNA molecule which comprises the cDNA contained in ATCC Deposit No:Z.

[1328] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides of the cDNA sequence contained in ATCC Deposit No:Z.

[1329] Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of an open reading frame sequence encoded by cDNA contained in ATCC Deposit No:Z.

[1330] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by cDNA contained in ATCC Deposit No:Z.

[1331] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by cDNA contained in ATCC Deposit No:Z.

[1332] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by cDNA contained in ATCC Deposit No:Z.

[1333] A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 5 of Table 1B or columns 8 and 9 of Table 2 or the complementary strand thereto; and a nucleotide sequence encoded by cDNA contained in ATCC Deposit No:Z; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

[1334] Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

[1335] A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 5 of Table 1B or columns 8 and 9 of Table 2 or the complementary strand thereto; and a nucleotide sequence of the cDNA contained in ATCC Deposit No:Z.

[1336] The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

[1337] Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 5 of Table 1B or columns 8 and 9 of Table 2 or the complementary strand thereto; or the cDNA contained in ATCC Deposit No:Z which encodes a protein, wherein the method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 5 of Table 1B or columns 8 and 9 of Table 2 or the complementary strand thereto; and a nucleotide sequence of cDNA contained in ATCC Deposit No:Z.

[1338] The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

[1339] Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto; the nucleotide sequence as defined in column 5 of Table 1B or columns 8 and 9 of Table 2 or the complementary strand thereto; and a nucleotide sequence encoded by cDNA contained in ATCC Deposit No:Z. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

[1340] Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a DNA microarray or “chip” of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250, 300, 500, 1000, 2000, 3000, or 4600 nucleotide sequences, wherein at least one sequence in said DNA microarray or “chip” is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1A and/or 1B; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA “Clone ID” in Table 1A and/or 1B.

[1341] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in ATCC Deposit No:Z.

[1342] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in ATCC Deposit No:Z.

[1343] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in ATCC Deposit No:Z.

[1344] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or a polypeptide encoded by cDNA contained in ATCC Deposit No:Z.

[1345] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a polypeptide encoded by contained in ATCC Deposit No:Z

[1346] Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a portion of said polypeptide encoded by cDNA contained in ATCC Deposit No:Z; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and/or the polypeptide sequence of SEQ ID NO:Y.

[1347] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z.

[1348] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of a polypeptide encoded by cDNA contained in ATCC Deposit No:Z.

[1349] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z.

[1350] Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z.

[1351] Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

[1352] Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z.

[1353] Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

[1354] Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z.

[1355] Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

[1356] Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleic acid sequence identified in Table 1A, 1B or Table 2 encoding a polypeptide, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z.

[1357] In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

[1358] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z.

[1359] Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

[1360] Also preferred is a polypeptide molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z.

[1361] Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

[1362] Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a human protein comprising an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto; the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2; and a polypeptide encoded by the cDNA contained in ATCC Deposit No:Z. The isolated polypeptide produced by this method is also preferred.

[1363] Also preferred is a method of treatment of an individual in need of an increased level of a protein activity, which method comprises administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to increase the level of said protein activity in said individual.

[1364] Also preferred is a method of treatment of an individual in need of a decreased level of a protein activity, which method comprised administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to decrease the level of said protein activity in said individual.

[1365] Also preferred is a method of treatment of an individual in need of a specific delivery of toxic compositions to diseased cells (e.g., tumors, leukemias or lymphomas), which method comprises administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide of the invention, including, but not limited to a binding agent, or antibody of the claimed invention that are associated with toxin or cytotoxic prodrugs.

[1366] Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

[1367] Description of Table 6

[1368] Table 6 summarizes some of the ATCC Deposits, Deposit dates, and ATCC designation numbers of deposits made with the ATCC in connection with the present application. These deposits were made in addition to those described in the Table 1 A. TABLE 6 ATCC Deposits Deposit Date ATCC Designation Number LP01, LP02, LP03, May 20, 1997 209059, 209060, 209061, LP04, LP05, LP06, 209062, 209063, 209064, LP07, LP08, LP09, 209065, 209066, 209067, LP10, LP11, 209068, 209069 LP12 Jan. 12, 1998 209579 LP13 Jan. 12, 1998 209578 LP14 Jul. 16, 1998 203067 LP15 Jul. 16, 1998 203068 LP16 Feb. 1, 1999 203609 LP17 Feb. 1, 1999 203610 LP20 Nov. 17, 1998 203485 LP21 Jun. 18, 1999 PTA-252 LP22 Jun. 18, 1999 PTA-253 LP23 Dec. 22, 1999 PTA-1081

EXAMPLES Example 1 Isolation of a Selected cDNA Clone from the Deposited Sample

[1369] Each ATCC Deposit No:Z is contained in a plasmid vector. Table 7 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The following correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 7 as being isolated in the vector “Lambda Zap,” the corresponding deposited clone is in “pBluescript.” Vector Used to Construct Library Corresponding Deposited Plasmid Lambda Zap pBluescript (pBS) Uni-Zap XR pBluescript (pBS) Zap Express pBK lafmid BA plafmid BA pSport1  pSport1 pCMVSport 2.0  pCMVSport 2.0 pCMVSport 3.0  pCMVSport 3.0 pCR ®2.1  pCR ®2.1

[1370] Vectors Lambda Zap (U.S. Pat. Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Pat. Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Pat. Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, Calif., 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK−, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region (“S” is for SacI and “K” is for KpnI which are the first sites on each respective end of the linker). “+” or “−” refer to the orientation of the f1 origin of replication (“ori”), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

[1371] Vectors pSport1, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, Md. 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993)). Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, Calif. 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991)). Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 7, as well as the corresponding plasmid vector sequences designated above.

[1372] The deposited material in the sample assigned the ATCC Deposit Number cited by reference to Tables 1, 2, 6 and 7 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each ATCC Deposit No:Z. TABLE 7 ATCC Libraries owned by Catalog Catalog Description Vector Deposit HUKA HUKB HUKC HUKD HUKE Human Uterine Cancer Lambda ZAP II LP01 HUKF HUKG HCNA HCNB Human Colon Lambda Zap II LP01 HFFA Human Fetal Brain, random primed Lambda Zap II LP01 HTWA Resting T-Cell Lambda ZAP II LP01 HBQA Early Stage Human Brain, random Lambda ZAP II LP01 primed HLMB HLMF HLMG HLMH HLMI breast lymph node CDNA library Lambda ZAP II LP01 HLMJ HLMM HLMN HCQA HCQB human colon cancer Lamda ZAP II LP01 HMEA HMEC HMED HMEE HMEF Human Microvascular Endothelial Lambda ZAP II LP01 HMEG HMEI HMEJ HMEK HMEL Cells, fract. A HUSA HUSC Human Umbilical Vein Endothelial Lambda ZAP II LP01 Cells, fract. A HLQA HLQB Hepatocellular Tumor Lambda ZAP II LP01 HHGA HHGB HHGC HHGD Hemangiopericytoma Lambda ZAP II LP01 HSDM Human Striatum Depression, re-rescue Lambda ZAP II LP01 HUSH H Umbilical Vein Endothelial Cells, Lambda ZAP II LP01 frac A, re-excision HSGS Salivary gland, subtracted Lambda ZAP II LP01 HFXA HFXB HFXC HFXD HFXE Brain frontal cortex Lambda ZAP II LP01 HFXF HFXG HFXH HPQA HPQB HPQC PERM TF274 Lambda ZAP II LP01 HFXJ HFXK Brain Frontal Cortex, re-excision Lambda ZAP II LP01 HCWA HCWB HCWC HCWD HCWE CD34 positive cells (Cord Blood) ZAP Express LP02 HCWF HCWG HCWH HCWI HCWJ HCWK HCUA HCUB HCUC CD34 depleted Buffy Coat (Cord ZAP Express LP02 Blood) HRSM A-14 cell line ZAP Express LP02 HRSA A1-CELL LINE ZAP Express LP02 HCUD HCUE HCUF HCUG HCUH CD34 depleted Buffy Coat (Cord ZAP Express LP02 HCUI Blood), re-excision HBXE HBXF HBXG H. Whole Brain #2, re-excision ZAP Express LP02 HRLM L8 cell line ZAP Express LP02 HBXA HBXB HBXC HBXD Human Whole Brain #2 - Oligo dT > ZAP Express LP02 1.5 Kb HUDA HUDB HUDC Testes ZAP Express LP02 HHTM HHTN HHTO H. hypothalamus, frac A, re-excision ZAP Express LP02 HHTL H. hypothalamus, frac A ZAP Express LP02 HASA HASD Human Adult Spleen Uni-ZAP XR LP03 HFKC HFKD HFKE HFKF HFKG Human Fetal Kidney Uni-ZAP XR LP03 HE8A HE8B HE8C HE8D HE8E HE8F Human 8 Week Whole Embryo Uni-ZAP XR LP03 HE8M HE8N HGBA HGBD HGBE HGBF HGBG Human Gall Bladder Uni-ZAP XR LP03 HGBH HGBI HLHA HLHB HLHC HLHD HLHE Human Fetal Lung III Uni-ZAP XR LP03 HLHF HLHG HLHH HLHQ HPMA HPMB HPMC HPMD HPME Human Placenta Uni-ZAP XR LP03 HPMF HPMG HPMH HPRA HPRB HPRC HPRD Human Prostate Uni-ZAP XR LP03 HSIA HSIC HSID HSIE Human Adult Small Intestine Uni-ZAP XR LP03 HTEA HTEB HTEC HTED HTEE Human Testes Uni-ZAP XR LP03 HTEF HTEG HTEH HTEI HTEJ HTEK HTPA HTPB HTPC HTPD HTPE Human Pancreas Tumor Uni-ZAP XR LP03 HTTA HTTB HTTC HTTD HTTE HTTF Human Testes Tumor Uni-ZAP XR LP03 HAPA HAPB HAPC HAPM Human Adult Pulmonary Uni-ZAP XR LP03 HETA HETB HETC HETD HETE Human Endometrial Tumor Uni-ZAP XR LP03 HETF HETG HETH HETI HHFB HHFC HHFD HHFE HHFF Human Fetal Heart Uni-ZAP XR LP03 HHFG HHFH HHFI HHPB HHPC HHPD HHPE HHPF Human Hippocampus Uni-ZAP XR LP03 HHPG HHPH HCE1 HCE2 HCE3 HCE4 HCE5 HCEB Human Cerebellum Uni-ZAP XR LP03 HCEC HCED HCEE HCEF HCEG HUVB HUVC HUVD HUVE Human Umbilical Vein, Endo. remake Uni-ZAP XR LP03 HSTA HSTB HSTC HSTD Human Skin Tumor Uni-ZAP XR LP03 HTAA HTAB HTAC HTAD HTAE Human Activated T-Cells Uni-ZAP XR LP03 HFEA HFEB HFEC Human Fetal Epithelium (Skin) Uni-ZAP XR LP03 HJPA HJPB HJPC HJPD HUMAN JURKAT MEMBRANE Uni-ZAP XR LP03 BOUND POLYSOMES HESA Human epithelioid sarcoma Uni-Zap XR LP03 HLTA HLTB HLTC HLTD HLTE HLTF Human T-Cell Lymphoma Uni-ZAP XR LP03 HFTA HFTB HFTC HFTD Human Fetal Dura Mater Uni-ZAP XR LP03 HRDA HRDB HRDC HRDD HRDE Human Rhabdomyosarcoma Uni-ZAP XR LP03 HRDF HCAA HCAB HCAC Cem cells cyclohexamide treated Uni-ZAP XR LP03 HRGA HRGB HRGC HRGD Raji Cells, cyclohexamide treated Uni-ZAP XR LP03 HSUA HSUB HSUC HSUM Supt Cells, cyclohexamide treated Uni-ZAP XR LP03 HT4A HT4C HT4D Activated T-Cells, 12 hrs. Uni-ZAP XR LP03 HE9A HE9B HE9C HE9D HE9E HE9F Nine Week Old Early Stage Human Uni-ZAP XR LP03 HE9G HE9H HE9M HE9N HATA HATB HATC HATD HATE Human Adrenal Gland Tumor Uni-ZAP XR LP03 HT5A Activated T-Cells, 24 hrs. Uni-ZAP XR LP03 HFGA HFGM Human Fetal Brain Uni-ZAP XR LP03 HNEA HNEB HNEC HNED HNEE Human Neutrophil Uni-ZAP XR LP03 HBGB HBGD Human Primary Breast Cancer Uni-ZAP XR LP03 HBNA HBNB Human Normal Breast Uni-ZAP XR LP03 HCAS Cem Cells, cyclohexamide treated, Uni-ZAP XR LP03 subtra HHPS Human Hippocampus, subtracted pBS LP03 HKCS HKCU Human Colon Cancer, subtracted pBS LP03 HRGS Raji cells, cyclohexamide treated, pBS LP03 subtracted HSUT Supt cells, cyclohexamide treated, pBS LP03 differentially expressed HT4S Activated T-Cells, 12 hrs, subtracted Uni-ZAP XR LP03 HCDA HCDB HCDC HCDD HCDE Human Chondrosarcoma Uni-ZAP XR LP03 HOAA HOAB HOAC Human Osteosarcoma Uni-ZAP XR LP03 HTLA HTLB HTLC HTLD HTLE Human adult testis, large inserts Uni-ZAP XR LP03 HTLF HLMA HLMC HLMD Breast Lymph node cDNA library Uni-ZAP XR LP03 H6EA H6EB H6EC HL-60, PMA 4 H Uni-ZAP XR LP03 HTXA HTXB HTXC HTXD HTXE Activated T-Cell (12hs)/Thiouridine Uni-ZAP XR LP03 HTXF HTXG HTXH labelledEco HNFA HNFB HNFC HNFD HNFE Human Neutrophil, Activated Uni-ZAP XR LP03 HNFF HNFG HNFH HNFJ HTOB HTOC HUMAN TONSILS, FRACTION 2 Uni-ZAP XR LP03 HMGB Human OB MG63 control fraction I Uni-ZAP XR LP03 HOPB Human OB HOS control fraction I Uni-ZAP XR LP03 HORB Human OB HOS treated (10 nM E2) Uni-ZAP XR LP03 fraction I HSVA HSVB HSVC Human Chronic Synovitis Uni-ZAP XR LP03 HROA HUMAN STOMACH Uni-ZAP XR LP03 HBJA HBJB HBJC HBJD HBJE HBJF HUMAN B CELL LYMPHOMA Uni-ZAP XR LP03 HBJG HBJH HBJI HBJJ HBJK HCRA HCRB HCRC human corpus colosum Uni-ZAP XR LP03 HODA HODB HODC HODD human ovarian cancer Uni-ZAP XR LP03 HDSA Dermatofibrosarcoma Protuberance Uni-ZAP XR LP03 HMWA HMWB HMWC HMWD Bone Marrow Cell Line (RS4, 11) Uni-ZAP XR LP03 HMWE HMWF HMWG HMWH HMWI HMWJ HSOA stomach cancer (human) Uni-ZAP XR LP03 HERA SKIN Uni-ZAP XR LP03 HMDA Brain-medulloblastoma Uni-ZAP XR LP03 HGLA HGLB HGLD Glioblastoma Uni-ZAP XR LP03 HEAA H. Atrophic Endometrium Uni-ZAP XR LP03 HBCA HBCB H. Lymph node breast Cancer Uni-ZAP XR LP03 HPWT Human Prostate BPH, re-excision Uni-ZAP XR LP03 HFVG HFVH HFVI Fetal Liver, subtraction II pBS LP03 HNFI Human Neutrophils, Activated, re- pBS LP03 excision HBMB HBMC HBMD Human Bone Marrow, re-excision pBS LP03 HKML HKMM HKMN H. Kidney Medulla, re-excision pBS LP03 HKIX HKIY H. Kidney Cortex, subtracted pBS LP03 HADT H. Amygdala Depression, subtracted pBS LP03 H6AS Hl-60, untreated, subtracted Uni-ZAP XR LP03 H6ES HL-60, PMA 4 H, subtracted Uni-ZAP XR LP03 H6BS HL-60, RA 4 h, Subtracted Uni-ZAP XR LP03 H6CS HL-60, PMA 1 d, subtracted Uni-ZAP XR LP03 HTXJ HTXK Activated T-cell(12 h)/Thiouridine-re- Uni-ZAP XR LP03 excision HMSA HMSB HMSC HMSD HMSE Monocyte activated Uni-ZAP XR LP03 HMSF HMSG HMSH HMSI HMSJ HMSK HAGA HAGB HAGC HAGD HAGE Human Amygdala Uni-ZAP XR LP03 HAGF HSRA HSRB HSRE STROMAL-OSTEOCLASTOMA Uni-ZAP XR LP03 HSRD HSRF HSRG HSRH Human Osteoclastoma Stromal Cells - Uni-ZAP XR LP03 unamplified HSQA HSQB HSQC HSQD HSQE Stromal cell TF274 Uni-ZAP XR LP03 HSQF HSQG HSKA HSKB HSKC HSKD HSKE Smooth muscle, serum treated Uni-ZAP XR LP03 HSKF HSKZ HSLA HSLB HSLC HSLD HSLE Smooth muscle, control Uni-ZAP XR LP03 HSLF HSLG HSDA HSDD HSDE HSDF HSDG Spinal cord Uni-ZAP XR LP03 HSDH HPWS Prostate-BPH subtracted II pBS LP03 HSKW HSKX HSKY Smooth Muscle- HASTE normalized pBS LP03 HFPB HFPC HFPD H. Frontal cortex, epileptic; re-excision Uni-ZAP XR LP03 HSDI HSDJ HSDK Spinal Cord, re-excision Uni-ZAP XR LP03 HSKN HSKO Smooth Muscle Serum Treated, Norm pBS LP03 HSKG HSKH HSKI Smooth muscle, serum induced, re-exc pBS LP03 HFCA HFCB HFCC HFCD HFCE Human Fetal Brain Uni-ZAP XR LP04 HFCF HPTA HPTB HPTD Human Pituitary Uni-ZAP XR LP04 HTHB HTHC HTHD Human Thymus Uni-ZAP XR LP04 HE6B HE6C HE6D HE6E HE6F HE6G Human Whole Six Week Old Embryo Uni-ZAP XR LP04 HE6S HSSA HSSB HSSC HSSD HSSE HSSF Human Synovial Sarcoma Uni-ZAP XR LP04 HSSG HSSH HSSI HSSJ HSSK HE7T 7 Week Old Early Stage Human, Uni-ZAP XR LP04 subtracted HEPA HEPB HEPC Human Epididymus Uni-ZAP XR LP04 HSNA HSNB HSNC HSNM HSNN Human Synovium Uni-ZAP XR LP04 HPFB HPFC HPFD HPFE Human Prostate Cancer, Stage C Uni-ZAP XR LP04 fraction HE2A HE2D HE2E HE2H HE2I HE2M 12 Week Old Early Stage Human Uni-ZAP XR LP04 HE2N HE2O HE2B HE2C HE2F HE2G HE2P HE2Q 12 Week Old Early Stage Human, II Uni-ZAP XR LP04 HPTS HPTT HPTU Human Pituitary, subtracted Uni-ZAP XR LP04 HAUA HAUB HAUC Amniotic Cells - TNF induced Uni-ZAP XR LP04 HAQA HAQB HAQC HAQD Amniotic Cells - Primary Culture Uni-ZAP XR LP04 HWTA HWTB HWTC wilm's tumor Uni-ZAP XR LP04 HBSD Bone Cancer, re-excision Uni-ZAP XR LP04 HSGB Salivary gland, re-excision Uni-ZAP XR LP04 HSJA HSJB HSJC Smooth muscle-ILb induced Uni-ZAP XR LP04 HSXA HSXB HSXC HSXD Human Substantia Nigra Uni-ZAP XR LP04 HSHA HSHB HSHC Smooth muscle, IL1b induced Uni-ZAP XR LP04 HOUA HOUB HOUC HOUD HOUE Adipocytes Uni-ZAP XR LP04 HPWA HPWB HPWC HPWD HPWE Prostate BPH Uni-ZAP XR LP04 HELA HELB HELC HELD HELE Endothelial cells-control Uni-ZAP XR LP04 HELF HELG HELH HEMA HEMB HEMC HEMD HEME Endothelial-induced Uni-ZAP XR LP04 HEMF HEMG HEMH HBIA HBIB HBIC Human Brain, Striatum Uni-ZAP XR LP04 HHSA HHSB HHSC HHSD HHSE Human Hypothalmus, Schizophrenia Uni-ZAP XR LP04 HNGA HNGB HNGC HNGD HNGE neutrophils control Uni-ZAP XR LP04 HNGF HNGG HNGH HNGI HNGJ HNHA HNHB HNHC HNHD HNHE Neutrophils IL-1 and LPS induced Uni-ZAP XR LP04 HNHF HNHG HNHH HNHI HNHJ HSDB HSDC STRIATUM DEPRESSION Uni-ZAP XR LP04 HHPT Hypothalamus Uni-ZAP XR LP04 HSAT HSAU HSAV HSAW HSAX Anergic T-cell Uni-ZAP XR LP04 HSAY HSAZ HBMS HBMT HBMU HBMV HBMW Bone marrow Uni-ZAP XR LP04 HBMX HOEA HOEB HOEC HOED HOEE Osteoblasts Uni-ZAP XR LP04 HOEF HOEJ HAIA HAIB HAIC HAID HAIE HAIF Epithelial-TNFa and INF induced Uni-ZAP XR LP04 HTGA HTGB HTGC HTGD Apoptotic T-cell Uni-ZAP XR LP04 HMCA HMCB HMCC HMCD HMCE Macrophage-oxLDL Uni-ZAP XR LP04 HMAA HMAB HMAC HMAD HMAE Macrophage (GM-CSF treated) Uni-ZAP XR LP04 HMAF HMAG HPHA Normal Prostate Uni-ZAP XR LP04 HPIA HPIB HPIC LNCAP prostate cell line Uni-ZAP XR LP04 HPJA HPJB HPJC PC3 Prostate cell line Uni-ZAP XR LP04 HOSE HOSF HOSG Human Osteoclastoma, re-excision Uni-ZAP XR LP04 HTGE HTGF Apoptotic T-cell, re-excision Uni-ZAP XR LP04 HMAJ HMAK H Macrophage (GM-CSF treated), re- Uni-ZAP XR LP04 excision HACB HACC HACD Human Adipose Tissue, re-excision Uni-ZAP XR LP04 HFPA H. Frontal Cortex, Epileptic Uni-ZAP XR LP04 HFAA HFAB HFAC HFAD HFAE Alzheimer's, spongy change Uni-ZAP XR LP04 HFAM Frontal Lobe, Dementia Uni-ZAP XR LP04 HMIA HMIB HMIC Human Manic Depression Tissue Uni-ZAP XR LP04 HTSA HTSE HTSF HTSG HTSH Human Thymus pBS LP05 HPBA HPBB HPBC HPBD HPBE Human Pineal Gland pBS LP05 HSAA HSAB HSAC HSA 172 Cells pBS LP05 HSBA HSBB HSBC HSBM HSC172 cells pBS LP05 HJAA HJAB HJAC HJAD Jurkat T-cell G1 phase pBS LP05 HJBA HJBB HJBC HJBD Jurkat T-Cell, S phase pBS LP05 HAFA HAFB Aorta endothelial cells + TNF-a pBS LP05 HAWA HAWB HAWC Human White Adipose pBS LP05 HTNA HTNB Human Thyroid pBS LP05 HONA Normal Ovary, Premenopausal pBS LP05 HARA HARB Human Adult Retina pBS LP05 HLJA HLJB Human Lung pCMVSport 1 LP06 HOFM HOFN HOFO H. Ovarian Tumor, II, OV5232 pCMVSport 2.0 LP07 HOGA HOGB HOGC OV Oct. 3, 1995 pCMVSport 2.0 LP07 HCGL CD34 + cells, II pCMVSport 2.0 LP07 HDLA Hodgkin's Lymphoma I pCMVSport 2.0 LP07 HDTA HDTB HDTC HDTD HDTE Hodgkin's Lymphoma II pCMVSport 2.0 LP07 HKAA HKAB HKAC HKAD HKAE Keratinocyte pCMVSport2.0 LP07 HKAF HKAG HKAH HCIM CAPFINDER, Crohn's Disease, lib 2 pCMVSport 2.0 LP07 HKAL Keratinocyte, lib 2 pCMVSport2.0 LP07 HKAT Keratinocyte, lib 3 pCMVSport2.0 LP07 HNDA Nasal polyps pCMVSport2.0 LP07 HDRA H. Primary Dendritic Cells, lib 3 pCMVSport2.0 LP07 HOHA HOHB HOHC Human Osteoblasts II pCMVSport2.0 LP07 HLDA HLDB HLDC Liver, Hepatoma pCMVSport3.0 LP08 HLDN HLDO HLDP Human Liver, normal pCMVSport3.0 LP08 HMTA pBMC stimulated w/ poly I/C pCMVSport3.0 LP08 HNTA NTERA2, control pCMVSport3.0 LP08 HDPA HDPB HDPC HDPD HDPF Primary Dendritic Cells, lib 1 pCMVSport3.0 LP08 HDPG HDPH HDPI HDPJ HDPK HDPM HDPN HDPO HDPP Primary Dendritic cells, frac 2 pCMVSport3.0 LP08 HMUA HMUB HMUC Myoloid Progenitor Cell Line pCMVSport3.0 LP08 HHEA HHEB HHEC HHED T Cell helper I pCMVSport3.0 LP08 HHEM HHEN HHEO HHEP T cell helper II pCMVSport3.0 LP08 HEQA HEQB HEQC Human endometrial stromal cells pCMVSport3.0 LP08 HJMA HJMB Human endometrial stromal cells- pCMVSport3.0 LP08 treated with progesterone HSWA HSWB HSWC Human endometrial stromal cells- pCMVSport3.0 LP08 treated with estradiol HSYA HSYB HSYC Human Thymus Stromal Cells pCMVSport3.0 LP08 HLWA HLWB HLWC Human Placenta pCMVSport3.0 LP08 HRAA HRAB HRAC Rejected Kidney, lib 4 pCMVSport3.0 LP08 HMTM PCR, pBMC I/C treated PCRII LP09 HMJA H. Meniingima, M6 pSport 1 LP10 HMKA HMKB HMKC HMKD HMKE H. Meningima, M1 pSport 1 LP10 HUSG HUSI Human umbilical vein endothelial cells, pSport 1 LP10 IL-4 induced HUSX HUSY Human Umbilical Vein Endothelial pSport 1 LP10 Cells, uninduced HOFA Ovarian Tumor I, OV5232 pSport 1 LP10 HCFA HCFB HCFC HCFD T-Cell PHA 16 hrs pSport 1 LP10 HCFL HCFM HCFN HCFO T-Cell PHA 24 hrs pSport 1 LP10 HADA HADC HADD HADE HADF Human Adipose pSport 1 LP10 HADG HOVA HOVB HOVC Human Ovary pSport 1 LP10 HTWB HTWC HTWD HTWE HTWF Resting T-Cell Library, II pSport 1 LP10 HMMA Spleen metastic melanoma pSport 1 LP10 HLYA HLYB HLYC HLYD HLYE Spleen, Chronic lymphocytic leukemia pSport 1 LP10 HCGA CD34 + cell, I pSport 1 LP10 HEOM HEON Human Eosinophils pSport 1 LP10 HTDA Human Tonsil, Lib 3 pSport 1 LP10 HSPA Salivary Gland, Lib 2 pSport 1 LP10 HCHA HCHB HCHC Breast Cancer cell line, MDA 36 pSport 1 LP10 HCHM HCHN Breast Cancer Cell line, angiogenic pSport 1 LP10 HCIA Crohn's Disease pSport 1 LP10 HDAA HDAB HDAC HEL cell line pSport 1 LP10 HABA Human Astrocyte pSport 1 LP10 HUFA HUFB HUFC Ulcerative Colitis pSport 1 LP10 HNTM NTERA2 + retinoic acid, 14 days pSport 1 LP10 HDQA Primary Dendritic cells, CapFinder2, pSport 1 LP10 frac 1 HDQM Primary Dendritic Cells, CapFinder, pSport 1 LP10 frac 2 HLDX Human Liver, normal, CapFinder pSport 1 LP10 HULA HULB HULC Human Dermal Endothelial pSport1 LP10 Cells, untreated HUMA Human Dermal Endothelial cells, treated pSport1 LP10 HCJA Human Stromal Endometrial pSport1 LP10 fibroblasts, untreated HCJM Human Stromal endometrial fibroblasts, pSport1 LP10 treated w/ estradiol HEDA Human Stromal endometrial fibroblasts, pSport1 LP10 treated with progesterone HFNA Human ovary tumor cell OV350721 pSport1 LP10 HKGA HKGB HKGC HKGD Merkel Cells pSport1 LP10 HISA HISB HISC Pancreas Islet Cell Tumor pSport1 LP10 HLSA Skin, burned pSport1 LP10 HBZA Prostate, BPH, Lib 2 pSport 1 LP10 HBZS Prostate BPH, Lib 2, subtracted pSport 1 LP10 HFIA HFIB HFIC Synovial Fibroblasts (control) pSport 1 LP10 HFIH HFII HFIJ Synovial hypoxia pSport 1 LP10 HFIT HFIU HFIV Synovial IL-1/TNF stimulated pSport 1 LP10 HGCA Messangial cell, frac 1 pSport1 LP10 HMVA HMVB HMVC Bone Marrow Stromal Cell, untreated pSport1 LP10 HFIX HFIY HFIZ Synovial Fibroblasts (Il1/TNF), subt pSport1 LP10 HFOX HFOY HFOZ Synovial hypoxia-RSF subtracted pSport1 LP10 HMQA HMQB HMQC HMQD Human Activated Monocytes Uni-ZAP XR LP11 HLIA HLIB HLIC Human Liver pCMVSport 1 LP012 HHBA HHBB HHBC HHBD HHBE Human Heart pCMVSport 1 LP012 HBBA HBBB Human Brain pCMVSport 1 LP012 HLJA HLJB HLJC HLJD HLJE Human Lung pCMVSport 1 LP012 HOGA HOGB HOGC Ovarian Tumor pCMVSport 2.0 LP012 HTJM Human Tonsils, Lib 2 pCMVSport 2.0 LP012 HAMF HAMG KMH2 pCMVSport 3.0 LP012 HAJA HAJB HAJC L428 pCMVSport 3.0 LP012 HWBA HWBB HWBC HWBD HWBE Dendritic cells, pooled pCMVSport 3.0 LP012 HWAA HWAB HWAC HWAD HWAE Human Bone Marrow, treated pCMVSport 3.0 LP012 HYAA HYAB HYAC B Cell lymphoma pCMVSport 3.0 LP012 HWHG HWHH HWHI Healing groin wound, 6.5 hours post pCMVSport 3.0 LP012 incision HWHP HWHQ HWHR Healing groin wound; 7.5 hours post pCMVSport 3.0 LP012 incision HARM Healing groin wound - zero hr post- pCMVSport 3.0 LP012 incision (control) HBIM Olfactory epithelium, nasalcavity pCMVSport 3.0 LP012 HWDA Healing Abdomen wound, 70&90 min pCMVSport 3.0 LP012 post incision HWEA Healing Abdomen Wound; 15 days post pCMVSport 3.0 LP012 incision HWJA Healing Abdomen Wound, 21&29 days pCMVSport 3.0 LP012 HNAL Human Tongue, frac 2 pSport1 LP012 HMJA H. Meniingima, M6 pSport1 LP012 HMKA HMKB HMKC HMKD HMKE H. Meningima, M1 pSport1 LP012 HOFA Ovarian Tumor I, OV5232 pSport1 LP012 HCFA HCFB HCFC HCFD T-Cell PHA 16 hrs pSport1 LP012 HCFL HCFM HCFN HCFO T-Cell PHA 24 hrs pSport1 LP012 HMMA HMMB HMMC Spleen metastic melanoma pSport1 LP012 HTDA Human Tonsil, Lib 3 pSport1 LP012 HDBA Human Fetal Thymus pSport1 LP012 HDUA Pericardium pSport1 LP012 HBZA Prostate, BPH, Lib 2 pSport1 LP012 HWCA Larynx tumor pSport1 LP012 HWKA Normal lung pSport1 LP012 HSMB Bone marrow stroma, treated pSport1 LP012 HBHM Normal trachea pSport1 LP012 HLFC Human Larynx pSport1 LP012 HLRB Siebben Polyposis pSport1 LP012 HNIA Mammary Gland pSport1 LP012 HNJB Palate carcinoma pSport1 LP012 HNKA Palate normal pSport1 LP012 HMZA Pharynx carcinoma pSport1 LP012 HABG Cheek Carcinoma pSport1 LP012 HMZM Pharynx Carcinoma pSport1 LP012 HDRM Larynx Carcinoma pSport1 LP012 HVAA Pancreas normal PCA4 No pSport1 LP012 HICA Tongue carcinoma pSport1 LP012 HUKA HUKB HUKC HUKD HUKE Human Uterine Cancer Lambda ZAP II LP013 HFFA Human Fetal Brain, random primed Lambda ZAP II LP013 HTUA Activated T-cell labeled with 4-thioluri Lambda ZAP II LP013 HBQA Early Stage Human Brain, random Lambda ZAP II LP013 primed HMEB Human microvascular Endothelial cells, Lambda ZAP II LP013 fract. B HUSH Human Umbilical Vein Endothelial Lambda ZAP II LP013 cells, fract. A, re-excision HLQC HLQD Hepatocellular tumor, re-excision Lambda ZAP II LP013 HTWJ HTWK HTWL Resting T-cell, re-excision Lambda ZAP II LP013 HF6S Human Whole 6 week Old Embryo (II), pBluescript LP013 subt HHPS Human Hippocampus, subtracted pBluescript LP013 HLIS LNCAP, differential expression pBluescript LP013 HLHS HLHT Early Stage Human Lung, Subtracted pBluescript LP013 HSUS Supt cells, cyclohexamide treated, pBluescript LP013 subtracted HSUT Supt cells, cyclohexamide treated, pBluescript LP013 differentially expressed HSDS H. Striatum Depression, subtracted pBluescript LP013 HPTZ Human Pituitary, Subtracted VII pBluescript LP013 HSDX H. Striatum Depression, subt II pBluescript LP013 HSDZ H. Striatum Depression, subt pBluescript LP013 HPBA HPBB HPBC HPBD HPBE Human Pineal Gland pBluescript SK- LP013 HRTA Colorectal Tumor pBluescript SK- LP013 HSBA HSBB HSBC HSBM HSC172 cells pBluescript SK- LP013 HJAA HJAB HJAC HJAD Jurkat T-cell G1 phase pBluescript SK- LP013 HJBA HJBB HJBC HJBD Jurkat T-cell, S1 phase pBluescript SK- LP013 HTNA HTNB Human Thyroid pBluescript SK- LP013 HAHA HAHB Human Adult Heart Uni-ZAP XR LP013 HE6A Whole 6 week Old Embryo Uni-ZAP XR LP013 HFCA HFCB HFCC HFCD HFCE Human Fetal Brain Uni-ZAP XR LP013 HFKC HFKD HFKE HFKF HFKG Human Fetal Kidney Uni-ZAP XR LP013 HGBA HGBD HGBE HGBF HGBG Human Gall Bladder Uni-ZAP XR LP013 HPRA HPRB HPRC HPRD Human Prostate Uni-ZAP XR LP013 HTEA HTEB HTEC HTED HTEE Human Testes Uni-ZAP XR LP013 HTTA HTTB HTTC HTTD HTTE Human Testes Tumor Uni-ZAP XR LP013 HYBA HYBB Human Fetal Bone Uni-ZAP XR LP013 HFLA Human Fetal Liver Uni-ZAP XR LP013 HHFB HHFC HHFD HHFE HHFF Human Fetal Heart Uni-ZAP XR LP013 HUVB HUVC HUVD HUVE Human Umbilical Vein, End. remake Uni-ZAP XR LP013 HTHB HTHC HTHD Human Thymus Uni-ZAP XR LP013 HSTA HSTB HSTC HSTD Human Skin Tumor Uni-ZAP XR LP013 HTAA HTAB HTAC HTAD HTAE Human Activated T-cells Uni-ZAP XR LP013 HFEA HFEB HFEC Human Fetal Epithelium (skin) Uni-ZAP XR LP013 HJPA HJPB HJPC HJPD Human Jurkat Membrane Bound Uni-ZAP XR LP013 Polysomes HESA Human Epithelioid Sarcoma Uni-ZAP XR LP013 HALS Human Adult Liver, Subtracted Uni-ZAP XR LP013 HFTA HFTB HFTC HFTD Human Fetal Dura Mater Uni-ZAP XR LP013 HCAA HCAB HCAC Cem cells, cyclohexamide treated Uni-ZAP XR LP013 HRGA HRGB HRGC HRGD Raji Cells, cyclohexamide treated Uni-ZAP XR LP013 HE9A HE9B HE9C HE9D HE9E Nine Week Old Early Stage Human Uni-ZAP XR LP013 HSFA Human Fibrosarcoma Uni-ZAP XR LP013 HATA HATB HATC HATD HATE Human Adrenal Gland Tumor Uni-ZAP XR LP013 HTRA Human Trachea Tumor Uni-ZAP XR LP013 HE2A HE2D HE2E HE2H HE2I 12 Week Old Early Stage Human Uni-ZAP XR LP013 HE2B HE2C HE2F HE2G HE2P 12 Week Old Early Stage Human, II Uni-ZAP XR LP013 HNEA HNEB HNEC HNED HNEE Human Neutrophil Uni-ZAP XR LP013 HBGA Human Primary Breast Cancer Uni-ZAP XR LP013 HPTS HPTT HPTU Human Pituitary, subtracted Uni-ZAP XR LP013 HMQA HMQB HMQC HMQD Human Activated Monocytes Uni-ZAP XR LP013 HOAA HOAB HOAC Human Osteosarcoma Uni-ZAP XR LP013 HTOA HTOD HTOE HTOF HTOG human tonsils Uni-ZAP XR LP013 HMGB Human OB MG63 control fraction I Uni-ZAP XR LP013 HOPB Human OB HOS control fraction I Uni-ZAP XR LP013 HOQB Human OB HOS treated (1 nM E2) Uni-ZAP XR LP013 fraction I HAUA HAUB HAUC Amniotic Cells - TNF induced Uni-ZAP XR LP013 HAQA HAQB HAQC HAQD Amniotic Cells - Primary Culture Uni-ZAP XR LP013 HROA HROC HUMAN STOMACH Uni-ZAP XR LP013 HBJA HBJB HBJC HBJD HBJE HUMAN B CELL LYMPHOMA Uni-ZAP XR LP013 HODA HODB HODC HODD human ovarian cancer Uni-ZAP XR LP013 HCPA Corpus Callosum Uni-ZAP XR LP013 HSOA stomach cancer (human) Uni-ZAP XR LP013 HERA SKIN Uni-ZAP XR LP013 HMDA Brain-medulloblastoma Uni-ZAP XR LP013 HGLA HGLB HGLD Glioblastoma Uni-ZAP XR LP013 HWTA HWTB HWTC wilm's tumor Uni-ZAP XR LP013 HEAA H. Atrophic Endometrium Uni-ZAP XR LP013 HAPN HAPO HAPP HAPQ HAPR Human Adult Pulmonary; re-excision Uni-ZAP XR LP013 HLTG HLTH Human T-cell lymphoma, re-excision Uni-ZAP XR LP013 HAHC HAHD HAHE Human Adult Heart, re-excision Uni-ZAP XR LP013 HAGA HAGB HAGC HAGD HAGE Human Amygdala Uni-ZAP XR LP013 HSJA HSJB HSJC Smooth muscle-ILb induced Uni-ZAP XR LP013 HSHA HSHB HSHC Smooth muscle, IL1b induced Uni-ZAP XR LP013 HPWA HPWB HPWC HPWD HPWE Prostate BPH Uni-ZAP XR LP013 HPIA HPIB HPIC LNCAP prostate cell line Uni-ZAP XR LP013 HPJA HPJB HPJC PC3 Prostate cell line Uni-ZAP XR LP013 HBTA Bone Marrow Stroma, TNF&LPS ind Uni-ZAP XR LP013 HMCF HMCG HMCH HMCI HMCJ Macrophage-oxLDL, re-excision Uni-ZAP XR LP013 HAGG HAGH HAGI Human Amygdala, re-excision Uni-ZAP XR LP013 HACA H. Adipose Tissue Uni-ZAP XR LP013 HKFB K562 + PMA (36 hrs), re-excision ZAP Express LP013 HCWT HCWU HCWV CD34 positive cells (cord blood), re-ex ZAP Express LP013 HBWA Whole brain ZAP Express LP013 HBXA HBXB HBXC HBXD Human Whole Brain #2 - Oligo dT > ZAP Express LP013 1.5 Kb HAVM Temporal cortex-Alzheizmer pT-Adv LP014 HAVT Hippocampus, Alzheimer Subtracted pT-Adv LP014 HHAS CHME Cell Line Uni-ZAP XR LP014 HAJR Larynx normal pSport 1 LP014 HWLE HWLF HWLG HWLH Colon Normal pSport 1 LP014 HCRM HCRN HCRO Colon Carcinoma pSport 1 LP014 HWLI HWLJ HWLK Colon Normal pSport 1 LP014 HWLQ HWLR HWLS HWLT Colon Tumor pSport 1 LP014 HBFM Gastrocnemius Muscle pSport 1 LP014 HBOD HBOE Quadriceps Muscle pSport 1 LP014 HBKD HBKE Soleus Muscle pSport 1 LP014 HCCM Pancreatic Langerhans pSport 1 LP014 HWGA Larynx carcinoma pSport 1 LP014 HWGM HWGN Larynx carcinoma pSport 1 LP014 HWLA HWLB HWLC Normal colon pSport 1 LP014 HWLM HWLN Colon Tumor pSport 1 LP014 HVAM HVAN HVAO Pancreas Tumor pSport 1 LP014 HWGQ Larynx carcinoma pSport 1 LP014 HAQM HAQN Salivary Gland pSport 1 LP014 HASM Stomach, normal pSport 1 LP014 HBCM Uterus; normal pSport 1 LP014 HCDM Testis; normal pSport 1 LP014 HDJM Brain; normal pSport 1 LP014 HEFM Adrenal Gland, normal pSport 1 LP014 HBAA Rectum normal pSport 1 LP014 HFDM Rectum tumour pSport 1 LP014 HGAM Colon, normal pSport 1 LP014 HHMM Colon, tumour pSport 1 LP014 HCLB HCLC Human Lung Cancer Lambda Zap II LP015 HRLA L1 Cell line ZAP Express LP015 HHAM Hypothalamus, Alzheimer's pCMVSport 3.0 LP015 HKBA Ku 812F Basophils Line pSport 1 LP015 HS2S Saos2, Dexamethosome Treated pSport 1 LP016 HA5A Lung Carcinoma A549 TNFalpha pSport 1 LP016 activated HTFM TF-1 Cell Line GM-CSF Treated pSport 1 LP016 HYAS Thyroid Tumour pSport 1 LP016 HUTS Larynx Normal pSport 1 LP016 HXOA Larynx Tumor pSport 1 LP016 HEAH Ea.hy.926 cell line pSport 1 LP016 HINA Adenocarcinoma Human pSport 1 LP016 HRMA Lung Mesothelium pSport 1 LP016 HLCL Human Pre-Differentiated Adipocytes Uni-Zap XR LP017 HS2A Saos2 Cells pSport 1 LP020 HS2I Saos2 Cells, Vitamin D3 Treated pSport 1 LP020 HUCM CHME Cell Line, untreated pSport 1 LP020 HEPN Aryepiglottis Normal pSport 1 LP020 HPSN Sinus Piniformis Tumour pSport 1 LP020 HNSA Stomach Normal pSport 1 LP020 HNSM Stomach Tumour pSport 1 LP020 HNLA Liver Normal Met5No pSport 1 LP020 HUTA Liver Tumour Met 5 Tu pSport 1 LP020 HOCN Colon Normal pSport 1 LP020 HOCT Colon Tumor pSport 1 LP020 HTNT Tongue Tumour pSport 1 LP020 HLXN Larynx Normal pSport 1 LP020 HLXT Larynx Tumour pSport 1 LP020 HTYN Thymus pSport 1 LP020 HPLN Placenta pSport 1 LP020 HTNG Tongue Normal pSport 1 LP020 HZAA Thyroid Normal (SDCA2 No) pSport 1 LP020 HWES Thyroid Thyroiditis pSport 1 LP020 HFHD Ficolled Human Stromal Cells, 5Fu pTrip1Ex2 LP021 treated HFHM, HFHN Ficolled Human Stromal Cells, pTrip1Ex2 LP021 Untreated HPCI Hep G2 Cells, lambda library lambda Zap-CMV XR LP021 HBCA, HBCB, HBCC H. Lymph node breast Cancer Uni-ZAP XR LP021 HCOK Chondrocytes pSPORT1 LP022 HDCA, HDCB, HDCC Dendritic Cells From CD34 Cells pSPORT1 LP022 HDMA, HDMB CD40 activated monocyte dendritic pSPORT1 LP022 cells HDDM, HDDN, HDDO LPS activated derived dendritic cells pSPORT1 LP022 HPCR Hep G2 Cells, PCR library lambda Zap-CMV XR LP022 HAAA, HAAB, HAAC Lung, Cancer (4005313A3): Invasive pSPORT1 LP022 Poorly Differentiated Lung Adenocarcinoma HIPA, HIPB, HIPC Lung, Cancer (4005163 B7): Invasive, pSPORT1 LP022 Poorly Diff. Adenocarcinoma, Metastatic HOOH, HOOI Ovary, Cancer: (4004562 B6) Papillary pSPORT1 LP022 Serous Cystic Neoplasm, Low Malignant Pot HIDA Lung, Normal: (4005313 B1) pSPORT1 LP022 HUJA, HUJB, HUJC, HUJD, HUJE B-Cells pCMVSport 3.0 LP022 HNOA, HNOB, HNOC, HNOD Ovary, Normal: (9805C040R) pSPORT1 LP022 HNLM Lung, Normal: (4005313 B1) pSPORT1 LP022 HSCL Stromal Cells pSPORT1 LP022 HAAX Lung, Cancer: (4005313 A3) Invasive pSPORT1 LP022 Poorly-differentiated Metastatic lung adenocarcinoma HUUA, HUUB, HUUC, HUUD B-cells (unstimulated) pTrip1Ex2 LP022 HWWA, HWWB, HWWC, HWWD, HWWE, B-cells (stimulated) pSPORT1 LP022 HWWF, HWWG HCCC Colon, Cancer: (9808C064R) pCMVSport 3.0 LP023 HPDO HPDP HPDQ HPDR HPD Ovary, Cancer (9809C332): Poorly pSport 1 LP023 differentiated adenocarcinoma HPCO HPCP HPCQ HPCT Ovary, Cancer (15395A1F): Grade II pSport 1 LP023 Papillary Carcinoma HOCM HOCO HOCP HOCQ Ovary, Cancer: (15799A1F) Poorly pSport 1 LP023 differentiated carcinoma HCBM HCBN HCBO Breast, Cancer: (4004943 A5) pSport 1 LP023 HNBT HNBU HNBV Breast, Normal: (4005522B2) pSport 1 LP023 HBCP HBCQ Breast, Cancer: (4005522 A2) pSport 1 LP023 HBCJ Breast, Cancer: (9806C012R) pSport 1 LP023 HSAM HSAN Stromal cells 3.88 pSport 1 LP023 HVCA HVCB HVCC HVCD Ovary, Cancer: (4004332 A2) pSport 1 LP023 HSCK HSEN HSEO Stromal cells (HBM3.18) pSport 1 LP023 HSCP HSCQ stromal cell clone 2.5 pSport 1 LP023 HUXA Breast Cancer: (4005385 A2) pSport 1 LP023 HCOM HCON HCOO HCOP HCOQ Ovary, Cancer (4004650 A3): Well- pSport 1 LP023 Differentiated Micropapillary Serous Carcinoma HBNM Breast, Cancer: (9802C020E) pSport 1 LP023 HVVA HVVB HVVC HVVD HVVE Human Bone Marrow, treated pSport 1 LP023

[1373] Two nonlimiting examples are provided below for isolating a particular clone from the deposited sample of plasmid cDNAs cited for that clone in Table 7. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to the nucleotide sequence of SEQ ID NO:X.

[1374] Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ³²P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, N.Y. (1982)). The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

[1375] Alternatively, two primers of 17-20 nucleotides derived from both ends of the nucleotide sequence of SEQ ID NO:X are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μl of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl₂, 0.01% (w/v) gelatin, 20 μM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94° C. for 1 min; annealing at 55° C. for 1 min; elongation at 72° C. for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

[1376] Several methods are available for the identification of the 5′ or 3′ non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5′ and 3′ “RACE” protocols which are well known in the art. For instance, a method similar to 5′ RACE is available for generating the missing 5′ end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993)).

[1377] Briefly, a specific RNA oligonucleotide is ligated to the 5′ ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5′ portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

[1378] This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5′ phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5′ ends of messenger RNAs. This reaction leaves a 5′ phosphate group at the 5′ end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

[1379] This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5′ end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5′ end sequence belongs to the desired gene.

Example 2 Isolation of Genomic Clones Corresponding to a Polynucleotide

[1380] A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the sequence corresponding to SEQ ID NO:X according to the method described in Example 1. (See also, Sambrook.)

Example 3 Tissue Specific Expression Analysis

[1381] The Human Genome Sciences, Inc. (HGS) database is derived from sequencing tissue and/or disease specific cDNA libraries. Libraries generated from a particular tissue are selected and the specific tissue expression pattern of EST groups or assembled contigs within these libraries is determined by comparison of the expression patterns of those groups or contigs within the entire database. ESTs and assembled contigs which show tissue specific expression are selected.

[1382] The original clone from which the specific EST sequence was generated, or in the case of an assembled contig, the clone from which the 5′ most EST sequence was generated, is obtained from the catalogued library of clones and the insert amplified by PCR using methods known in the art. The PCR product is denatured and then transferred in 96 or 384 well format to a nylon membrane (Schleicher and Scheull) generating an array filter of tissue specific clones. Housekeeping genes, maize genes, and known tissue specific genes are included on the filters. These targets can be used in signal normalization and to validate assay sensitivity. Additional targets are included to monitor probe length and specificity of hybridization.

[1383] Radioactively labeled hybridization probes are generated by first strand cDNA synthesis per the manufacturer's instructions (Life Technologies) from mRNA/RNA samples prepared from the specific tissue being analyzed (e.g., prostate, prostate cancer, ovarian, ovarian cancer, etc.). The hybridization probes are purified by gel exclusion chromatography, quantitated, and hybridized with the array filters in hybridization bottles at 65° C. overnight. The filters are washed under stringent conditions and signals are captured using a Fuji phosphorimager.

[1384] Data is extracted using AIS software and following background subtraction, signal normalization is performed. This includes a normalization of filter-wide expression levels between different experimental runs. Genes that are differentially expressed in the tissue of interest are identified.

Example 4 Chromosomal Mapping of the Polynucleotides

[1385] An oligonucleotide primer set is designed according to the sequence at the 5′ end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions: 30 seconds, 95° C.; 1 minute, 56° C.; 1 minute, 70° C. This cycle is repeated 32 times followed by one 5 minute cycle at 70° C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions are analyzed on either 8% polyacrylamide gels or 3.5% agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5 Bacterial Expression of a Polypeptide

[1386] A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5′ and 3′ ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5′ end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, Calif.). This plasmid vector encodes antibiotic resistance (Amp^(r)), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

[1387] The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^(r)). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

[1388] Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

[1389] Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000× g). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4° C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid (“Ni-NTA”) affinity resin column (available from QIAGEN, Inc., supra). Proteins with a 6× His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., supra).

[1390] Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8. The column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

[1391] The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-IM urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 μM immidazole. Immidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 40 C or frozen at −800 C.

[1392] In addition to the above expression vector, the present invention further includes an expression vector, called pHE4a (ATCC Accession Number 209645, deposited on Feb. 25, 1998) which contains phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on Feb. 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, Md.). The promoter and operator sequences are made synthetically.

[1393] DNA can be inserted into the pHE4a by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5′ primer) and XbaI, BamHI, XhoI, or Asp718 (3′ primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

[1394] The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6 Purification of a Polypeptide from an Inclusion Body

[1395] The following alternative method can be used to purify a polypeptide expressed in E coli when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10° C.

[1396] Upon completion of the production phase of the E. coli fermentation, the cell culture is cooled to 4-10° C. and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

[1397] The cells are then lysed by passing the solution through a microfluidizer (Microfuidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000× g for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

[1398] The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000× g centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4° C. overnight to allow further GuHCl extraction.

[1399] Following high speed centrifugation (30,000× g) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4° C. without mixing for 12 hours prior to further purification steps.

[1400] To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 μm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

[1401] Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A₂₈₀ monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

[1402] The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 μg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7 Cloning and Expression of a Polypeptide in a Baculovirus Expression System

[1403] In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 (“SV40”) is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from E. coli under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

[1404] Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

[1405] Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon, is amplified using the PCR protocol described in Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., “A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures,” Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

[1406] The amplified fragment is isolated from a 1% agarose gel using a commercially available kit (“Geneclean,” BIO 101 Inc., La Jolla, Calif.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

[1407] The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit (“Geneclean” BIO 101 Inc., La Jolla, Calif.).

[1408] The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. E. coli B101 or other suitable E. coli hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, Calif.) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

[1409] Five μg of a plasmid containing the polynucleotide is co-transfected with 1.0 μg of a commercially available linearized baculovirus DNA (“BaculoGold™ baculovirus DNA, Pharmingen, San Diego, Calif.), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One μg of BaculoGold™ virus DNA and 5 μg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, Md.). Afterwards, 10 μl Lipofectin plus 90 μl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C. for four days.

[1410] After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, supra. An agarose gel with “Blue Gal” (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a “plaque assay” of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 40 C.

[1411] To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection (“MOI”) of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, Md.). After 42 hours, 5 μCi of ³⁵S-methionine and 5 μCi ³⁵S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

[1412] Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8 Expression of a Polypeptide in Mammalian Cells

[1413] The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

[1414] Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSport 2.0, and pCMVSport 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse N11H3T3 and C127 cells, Cos 1, Cos 7 and CVI, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

[1415] Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as DHFR, gpt, neomycin, or hygromycin allows the identification and isolation of the transfected cells.

[1416] The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991)). Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

[1417] Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985)). Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3′ intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

[1418] Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

[1419] A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If a naturally occurring signal sequence is used to produce the polypeptide of the present invention, the vector does not need a second signal peptide. Alternatively, if a naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., International Publication No. WO 96/34891.)

[1420] The amplified fragment is isolated from a 1% agarose gel using a commercially available kit (“Geneclean,” BIO 101 Inc., La Jolla, Calif.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

[1421] The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. E. coli HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

[1422] Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μg of the expression plasmid pC6 or pC4 is cotransfected with 0.5 μg of the plasmid pSVneo using lipofectin (Felgner et al., supra). The plasmid pSV2-neo contains a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μM, 2 μM, 5 μM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100-200 μM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9 Protein Fusions

[1423] The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988)). Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

[1424] Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5′ and 3′ ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

[1425] For example, if pC4 (ATCC Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3′ BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

[1426] If the naturally occurring signal sequence is used to produce the polypeptide of the present invention, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., International Publication No. WO 96/34891.) Human IgG Fc region: GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGCCCA (SEQ ID NO: 1) GCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG GACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGTGGACGTA AGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGT GCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTG TGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTAC AAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCCATCGAGAAAACCATCTC CAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCC GGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTC TATCCAAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAA CTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAG CAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCT CCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGT CTCCGGGTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT

Example 10 Production of an Antibody from a Polypeptide

[1427] a) Hybridoma Technology

[1428] The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing a polypeptide of the present invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of a polypeptide of the present invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

[1429] Monoclonal antibodies specific for a polypeptide of the present invention are prepared using hybridoma technology (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with a polypeptide of the present invention or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56° C.), and supplemented with about 10 μg/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 μg/ml of streptomycin.

[1430] The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide of the present invention.

[1431] Alternatively, additional antibodies capable of binding to a polypeptide of the present invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide-specific antibody can be blocked by said polypeptide. Such antibodies comprise anti-idiotypic antibodies to the polypeptide-specific antibody and are used to immunize an animal to induce formation of further polypeptide-specific antibodies.

[1432] For in vivo use of antibodies in humans, an antibody is “humanized”. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Pat. No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., International Publication No. WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985)).

[1433] b) Isolation Of Antibody Fragments Directed Against a Polypeptide of the Present Invention from a Library of scFvs

[1434] Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against a polypeptide of the present invention to which the donor may or may not have been exposed (see e.g., U.S. Pat. No. 5,885,793 incorporated herein by reference in its entirety).

[1435] Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in International Publication No. WO 92/01047. To rescue phage displaying antibody fragments, approximately 10⁹ E. coli harboring the phagemid are used to inoculate 50 ml of 2× TY containing 1% glucose and 100 μg/ml of ampicillin (2× TY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2× TY-AMP-GLU, 2×108 TU of delta gene 3 helper (M13 delta gene III, see International Publication No. WO 92/01047) are added and the culture incubated at 37° C. for 45 minutes without shaking and then at 37° C. for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2× TY containing 100 μg/ml ampicillin and 50 ug/ml kanamycin and grown overnight. Phage are prepared as described in International Publication No. WO 92/01047.

[1436] M13 delta gene III is prepared as follows: M13 delta gene m helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 370 C without shaking and then for a further hour at 37° C. with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2× TY broth containing 100 μg ampicillin/ml and 25 μg kanamycin/ml (2× TY-AMP-KAN) and grown overnight, shaking at 37° C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 μm filter (Minisart NML; Sartorius) to give a final concentration of approximately 1013 transducing units/ml (ampicillin-resistant clones).

[1437] Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 μg/ml or 10 μg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37° C. and then washed 3 times in PBS. Approximately 10¹³ TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37° C. The E. coli are then plated on TYE plates containing 1% glucose and 100 μg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

[1438] Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., International Publication No. WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

Example 11 Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

[1439] RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X; and/or the nucleotide sequence of the cDNA contained in ATCC Deposit No:Z. Suggested PCR conditions consist of 35 cycles at 95 degrees C. for 30 seconds; 60-120 seconds at 52-58 degrees C.; and 60-120 seconds at 70 degrees C., using buffer solutions described in Sidransky et al., Science 252:706 (1991).

[1440] PCR products are then sequenced using primers labeled at their 5′ end with T4 polynucleotide kinase, employing SequiTherm Polymerase (Epicentre Technologies). The intron-exon boundaries of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations are then cloned and sequenced to validate the results of the direct sequencing.

[1441] PCR products are cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

[1442] Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5′-triphosphate (Boehringer Manheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-I DNA for specific hybridization to the corresponding genomic locus.

[1443] Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, Vt.) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, Ariz.) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991)). Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, N.C.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 12 Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

[1444] A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

[1445] For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

[1446] The coated wells are then incubated for >2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide.

[1447] Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate.

[1448] Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 13 Formulation

[1449] The invention also provides methods of treatment and/or prevention of diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

[1450] The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The “effective amount” for purposes herein is thus determined by such considerations.

[1451] As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1 ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

[1452] Therapeutics can be are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray. “Pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term “parenteral” as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

[1453] Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray. “Pharmaceutically acceptable carrier” refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term “parenteral” as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

[1454] Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

[1455] Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D-(−)-3-hydroxybutyric acid (EP 133,988).

[1456] In a preferred embodiment, polypeptide, polynucleotide, and antibody compositions of the invention are formulated in a biodegradable, polymeric drug delivery system, for example as described in U.S. Pat. Nos. 4,938,763; 5,278,201; 5,278,202; 5,324,519; 5,340,849; and 5,487,897 and in International Publication Numbers WOO1/35929, WOOO/24374, and WOOO/06117 which are hereby incorporated by reference in their entirety. In specific preferred embodiments the polypeptide, polynucleotide, and antibody compositions of the invention are formulated using the ATRIGEL® Biodegradable System of Atrix Laboratories, Inc. (Fort Collins, Colo.).

[1457] Examples of biodegradable polymers which can be used in the formulation of polypeptide, polynucleotide, and antibody compositions, include but are not limited to, polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), poly(methyl vinyl ether), poly(maleic anhydride), polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, and copolymers, terpolymers, or combinations or mixtures of the above materials. The preferred polymers are those that have a lower degree of crystallization and are more hydrophobic. These polymers and copolymers are more soluble in the biocompatible solvents than the highly crystalline polymers such as polyglycolide and chitin which also have a high degree of hydrogen-bonding. Preferred materials with the desired solubility parameters are the polylactides, polycaprolactones, and copolymers of these with glycolide in which there are more amorphous regions to enhance solubility. In specific preferred embodiments, the biodegradable polymers which can be used in the formulation of polypeptide, polynucleotide, and antibody compositions are poly(lactide-co-glycolides). Polymer properties such as molecular weight, hydrophobicity, and lactide/glycolide ratio may be modified to obtain the desired polypeptide, polynucleotide, or antibody release profile (See, e.g., Ravivarapu et al., Journal of Pharmaceutical Sciences 89:732-741 (2000), which is hereby incorporated by reference in its entirety).

[1458] It is also preferred that the solvent for the biodegradable polymer be non-toxic, water miscible, and otherwise biocompatible. Examples of such solvents include, but are not limited to, N-methyl-2-pyrrolidone, 2-pyrrolidone, C2 to C6 alkanols, C1 to C15 alchohols, dils, triols, and tetraols such as ethanol, glycerine propylene glycol, butanol; C3 to C15 alkyl ketones such as acetone, diethyl ketone and methyl ethyl ketone; C3 to C15 esters such as methyl acetate, ethyl acetate, ethyl lactate; alkyl ketones such as methyl ethyl ketone, C1 to C15 amides such as dimethylformamide, dimethylacetamide and caprolactam; C3 to C20 ethers such as tetrahydrofuran, or solketal; tweens, triacetin, propylene carbonate, decylmethylsulfoxide, dimethyl sulfoxide, oleic acid, 1-dodecylazacycloheptan-2-one, Other preferred solvents are benzyl alchohol, benzyl benzoate, dipropylene glycol, tributyrin, ethyl oleate, glycerin, glycofural, isopropyl myristate, isopropyl palmitate, oleic acid, polyethylene glycol, propylene carbonate, and triethyl citrate. The most preferred solvents are N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide, triacetin, and propylene carbonate because of the solvating ability and their compatibility.

[1459] Additionally, formulations comprising polypeptide, polynucleotide, and antibody compositions and a biodegradable polymer may also include release-rate modification agents and/or pore-forming agents. Examples of release-rate modification agents include, but are not limited to, fatty acids, triglycerides, other like hydrophobic compounds, organic solvents, plasticizing compounds and hydrophilic compounds. Suitable release rate modification agents include, for example, esters of mono-, di-, and tricarboxylic acids, such as 2-ethoxyethyl acetate, methyl acetate, ethyl acetate, diethyl phthalate, dimethyl phthalate, dibutyl phthalate, dimethyl adipate, dimethyl succinate, dimethyl oxalate, dimethyl citrate, triethyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, glycerol triacetate, di(n-butyl) sebecate, and the like; polyhydroxy alcohols, such as propylene glycol, polyethylene glycol, glycerin, sorbitol, and the like; fatty acids; triesters of glycerol, such as triglycerides, epoxidized soybean oil, and other epoxidized vegetable oils; sterols, such as cholesterol; alcohols, such as C.sub.6-C.sub.12 alkanols, 2-ethoxyethanol. The release rate modification agent may be used singly or in combination with other such agents. Suitable combinations of release rate modification agents include, but are not limited to, glycerin/propylene glycol, sorbitol/glycerine, ethylene oxide/propylene oxide, butylene glycol/adipic acid, and the like. Preferred release rate modification agents include, but are not limited to, dimethyl citrate, triethyl citrate, ethyl heptanoate, glycerin, and hexanediol. Suitable pore-forming agents that may be used in the polymer composition include, but are not limited to, sugars such as sucrose and dextrose, salts such as sodium chloride and sodium carbonate, polymers such as hydroxylpropylcellulose, carboxymethylcellulose, polyethylene glycol, and polyvinylpyrrolidone. Solid crystals that will provide a defined pore size, such as salt or sugar, are preferred.

[1460] In specific preferred embodiments the polypeptide, polynucleotide, and antibody compositions of the invention are formulated using the BEMA™ BioErodible Mucoadhesive System, MCA™ MucoCutaneous Absorption System, SMP™ Solvent MicroParticle System, or BCP™ BioCompatible Polymer System of Atrix Laboratories, Inc. (Fort Collins, Colo.).

[1461] Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (see generally, Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317-327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

[1462] In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

[1463] Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).

[1464] For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

[1465] Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

[1466] The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

[1467] The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

[1468] Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[1469] Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

[1470] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

[1471] The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG (e.g., THERACYS®), MPL and nonviable prepartions of Corynebacterium parvum. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diptheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration “in combination” further includes the separate administration of one of the compounds or agents given first, followed by the second.

[1472] The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, and/or therapeutic treatments described below. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration “in combination” further includes the separate administration of one of the compounds or agents given first, followed by the second.

[1473] In one embodiment, the Therapeutics of the invention are administered in combination with an anticoagulant. Anticoagulants that may be administered with the compositions of the invention include, but are not limited to, heparin, low molecular weight heparin, warfarin sodium (e.g., COUMADIN®), dicumarol, 4-hydroxycoumarin, anisindione (e.g., MIRADON™), acenocoumarol (e.g., nicoumalone, SINTHROME™), indan-1,3-dione, phenprocoumon (e.g., MARCUMAR™), ethyl biscoumacetate (e.g., TROMEXAN™), and aspirin. In a specific embodiment, compositions of the invention are administered in combination with heparin and/or warfarin. In another specific embodiment, compositions of the invention are administered in combination with warfarin. In another specific embodiment, compositions of the invention are administered in combination with warfarin and aspirin. In another specific embodiment, compositions of the invention are administered in combination with heparin. In another specific embodiment, compositions of the invention are administered in combination with heparin and aspirin.

[1474] In another embodiment, the Therapeutics of the invention are administered in combination with thrombolytic drugs. Thrombolytic drugs that may be administered with the compositions of the invention include, but are not limited to, plasminogen, lys-plasminogen, alpha2-antiplasmin, streptokinae (e.g., KABIKINASE™), antirespace (e.g., EMINASE™), tissue plasminogen activator (t-PA, altevase, ACTIVASE™), urokinase (e.g., ABBOKINASE™), sauruplase, (Prourokinase, single chain urokinase), and aminocaproic acid (e.g., AMICAR™). In a specific embodiment, compositions of the invention are administered in combination with tissue plasminogen activator and aspirin.

[1475] In another embodiment, the Therapeutics of the invention are administered in combination with antiplatelet drugs. Antiplatelet drugs that may be administered with the compositions of the invention include, but are not limited to, aspirin, dipyridamole (e.g., PERSANTINE™), and ticlopidine (e.g., TICLID™).

[1476] In specific embodiments, the use of anti-coagulants, thrombolytic and/or antiplatelet drugs in combination with Therapeutics of the invention is contemplated for the prevention, diagnosis, and/or treatment of thrombosis, arterial thrombosis, venous thrombosis, thromboembolism, pulmonary embolism, atherosclerosis, myocardial infarction, transient ischemic attack, unstable angina. In specific embodiments, the use of anticoagulants, thrombolytic drugs and/or antiplatelet drugs in combination with Therapeutics of the invention is contemplated for the prevention of occulsion of saphenous grafts, for reducing the risk of periprocedural thrombosis as might accompany angioplasty procedures, for reducing the risk of stroke in patients with atrial fibrillation including nonrheumatic atrial fibrillation, for reducing the risk of embolism associated with mechanical heart valves and or mitral valves disease. Other uses for the therapeutics of the invention, alone or in combination with antiplatelet, anticoagulant, and/or thrombolytic drugs, include, but are not limited to, the prevention of occlusions in extracorporeal devices (e.g., intravascular canulas, vascular access shunts in hemodialysis patients, hemodialysis machines, and cardiopulmonary bypass machines).

[1477] In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and/or protease inhibitors (PIs). NRTIs that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddl), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). NNRTIs that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

[1478] Additional NRTIs include LODENOSINE™ (F-ddA; an acid-stable adenosine NRTI; Triangle/Abbott; COVIRACIL™ (emtricitabine/FTC; structurally related to lamivudine (3TC) but with 3- to 10-fold greater activity in vitro; Triangle/Abbott); dOTC (BCH-10652, also structurally related to lamivudine but retains activity against a substantial proportion of lamivudine-resistant isolates; Biochem Pharma); Adefovir (refused approval for anti-HIV therapy by FDA; Gilead Sciences); PREVEON® (Adefovir Dipivoxil, the active prodrug of adefovir; its active form is PMEA-pp); TENOFOVIR™ (bis-POC PMPA, a PMPA prodrug; Gilead); DAPD/DXG (active metabolite of DAPD; Triangle/Abbott); D-D4FC (related to 3TC, with activity against AZT/3TC-resistant virus); GW420867X (Glaxo Wellcome); ZIAGENM (abacavir/159U89; Glaxo Wellcome Inc.); CS-87 (3′azido-2′,3′-dideoxyuridine; WO 99/66936); and S-acyl-2-thioethyl (SATE)-bearing prodrug forms of β-L-FD4C and β-L-FddC (WO 98/17281).

[1479] Additional NNRTIs include COACTINON™ (Emivirine/MKC-442, potent NNRTI of the HEPT class; Triangle/Abbott); CAPRAVIRINE™ (AG-1549/S-1153, a next generation NNRTI with activity against viruses containing the K103N mutation; Agouron); PNU-142721 (has 20- to 50-fold greater activity than its predecessor delavirdine and is active against K103N mutants; Pharmacia & Upjohn); DPC-961 and DPC-963 (second-generation derivatives of efavirenz, designed to be active against viruses with the K103N mutation; DuPont); GW-420867× (has 25-fold greater activity than HBY097 and is active against K103N mutants; Glaxo Wellcome); CALANOLIDE A (naturally occurring agent from the latex tree; active against viruses containing either or both the Y181C and K103N mutations); and Propolis (WO 99/49830).

[1480] Additional protease inhibitors include LOPINAVIR™ (ABT378/r; Abbott Laboratories); BMS-232632 (an azapeptide; Bristol-Myres Squibb); TIPRANAVIR™ (PNU-140690, a non-peptic dihydropyrone; Pharmacia & Upjohn); PD-178390 (a nonpeptidic dihydropyrone; Parke-Davis); BMS 232632 (an azapeptide; Bristol-Myers Squibb); L-756,423 (an indinavir analog; Merck); DMP-450 (a cyclic urea compound; Avid & DuPont); AG-1776 (a peptidomimetic with in vitro activity against protease inhibitor-resistant viruses; Agouron); VX-175/GW-433908 (phosphate prodrug of amprenavir; Vertex & Glaxo Welcome); CGP61755 (Ciba); and AGENERASE™ (amprenavir; Glaxo Wellcome Inc.).

[1481] Additional antiretroviral agents include fusion inhibitors/gp41 binders. Fusion inhibitors/gp41 binders include T-20 (a peptide from residues 643-678 of the HIV gp41 transmembrane protein ectodomain which binds to gp41 in its resting state and prevents transformation to the fusogenic state; Trimeris) and T-1249 (a second-generation fusion inhibitor; Trimeris).

[1482] Additional antiretroviral agents include fusion inhibitors/chemokine receptor antagonists. Fusion inhibitors/chemokine receptor antagonists include CXCR4 antagonists such as AMD 3100 (a bicyclam), SDF-1 and its analogs, and ALX40-4C (a cationic peptide), T22 (an 18 amino acid peptide; Trimeris) and the T22 analogs T134 and T140; CCR5 antagonists such as RANTES (9-68), AOP-RANTES, NNY-RANTES, and TAK-779; and CCR5/CXCR4 antagonists such as NSC 651016 (a distamycin analog). Also included are CCR2B, CCR3, and CCR6 antagonists. Chemokine recpetor agonists such as RANTES, SDF-1, MIP-1α, MIP-1β, etc., may also inhibit fusion.

[1483] Additional antiretroviral agents include integrase inhibitors. Integrase inhibitors include dicaffeoylquinic (DFQA) acids; L-chicoric acid (a dicaffeoyltartaric (DCTA) acid); quinalizarin (QLC) and related anthraquinones; ZINTEVIR™ (AR 177, an oligonucleotide that probably acts at cell surface rather than being a true integrase inhibitor; Arondex); and naphthols such as those disclosed in WO 98/50347.

[1484] Additional antiretroviral agents include hydroxyurea-like compunds such as BCX-34 (a purine nucleoside phosphorylase inhibitor; Biocryst); ribonucleotide reductase inhibitors such as DIDOX™ (Molecules for Health); inosine monophosphate dehydrogenase (IMPDH) inhibitors sucha as VX-497 (Vertex); and mycopholic acids such as CellCept (mycophenolate mofetil; Roche).

[1485] Additional antiretroviral agents include inhibitors of viral integrase, inhibitors of viral genome nuclear translocation such as arylene bis(methylketone) compounds; inhibitors of HIV entry such as AOP-RANTES, NNY-RANTES, RANTES-IgG fusion protein, soluble complexes of RANTES and glycosaminoglycans (GAG), and AMD-3100; nucleocapsid zinc finger inhibitors such as dithiane compounds; targets of HIV Tat and Rev; and pharmacoenhancers such as ABT-378.

[1486] Other antiretroviral therapies and adjunct therapies include cytokines and lymphokines such as MIP-1α, MIP-1β, SDF-1α, IL-2, PROLEUKIN™ (aldesleukin/L2-7001; Chiron), IL-4, IL-10, IL-12, and IL-13; interferons such as IFN-α2a; antagonists of TNFs, NFκB, GM-CSF, M-CSF, and IL-10; agents that modulate immune activation such as cyclosporin and prednisone; vaccines such as RemuneT (HIV Immunogen), APL 400-003 (Apollon), recombinant gp120 and fragments, bivalent (B/E) recombinant envelope glycoprotein, rgp120CM235, MN rgp120, SF-2 rgp120, gp120/soluble CD4 complex, Delta JR-FL protein, branched synthetic peptide derived from discontinuous gp120 C3/C4 domain, fusion-competent immunogens, and Gag, Pol, Nef, and Tat vaccines; gene-based therapies such as genetic suppressor elements (GSEs; WO 98/54366), and intrakines (genetically modified CC chemokines targetted to the ER to block surface expression of newly synthesized CCR5 (Yang et al., PNAS 94:11567-72 (1997); Chen et al., Nat. Med. 3:1110-16 (1997)); antibodies such as the anti-CXCR4 antibody 12G5, the anti-CCR5 antibodies 2D7, 5C7, PA8, PA9, PA10, PA11, PA12, and PA14, the anti-CD4 antibodies Q4120 and RPA-T4, the anti-CCR3 antibody 7B11, the anti-gp120 antibodies 17b, 48d, 447-52D, 257-D, 268-D and 50.1, anti-Tat antibodies, anti-TNF-α antibodies, and monoclonal antibody 33A; aryl hydrocarbon (AH) receptor agonists and antagonists such as TCDD, 3,3′,4,4′,5-pentachlorobiphenyl, 3,3′,4,4′-tetrachlorobiphenyl, and α-naphthoflavone (WO 98/30213); and antioxidants such as γ-L-glutamyl-L-cysteine ethyl ester (γ-GCE; WO 99/56764).

[1487] In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

[1488] In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTINM, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORINM, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic Pneumocystis carinii pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZD™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic Mycobacterium avium complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic Mycobacterium tuberculosis infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic Toxoplasma gondii infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

[1489] In a further embodiment, the Therapeutics of the invention are adrministered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rapamycin, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamethoxazole, and vancomycin.

[1490] In other embodiments, the Therapeutics of the invention are administered in combination with immunestimulants. Immunostimulants that may be adrministered in combination with the Therapeutics of the invention include, but are not limited to, levamisole (e.g., ERGAMISOL™), isoprinosine (e.g. INOSIPLEX™), interferons (e.g. interferon alpha), and interleukins (e.g., IL-2).

[1491] In other embodiments, Therapeutics of the invention are administered in combination with immunosuppressive agents. Immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells. Other immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, prednisolone, methotrexate, thalidomide, methoxsalen, rapamycin, leflunomide, mizoribine (BREDININ™), brequinar, deoxyspergualin, and azaspirane (SKF 105685), ORTHOCLONE OKT® 3 (muromonab-CD3), SANDIMMUNE™, NEORAL™, SANGDYA™ (cyclosporine), PROGRAF® (FK506, tacrolimus), CELLCEPT® (mycophenolate motefil, of which the active metabolite is mycophenolic acid), IMURAN™ (azathioprine), glucocorticosteroids, adrenocortical steroids such as DELTASONE™ (prednisone) and HYDELTRASOL™ (prednisolone), FOLEX™ and MEXATE™ (methotrxate), OXSORALEN-ULTRA™ (methoxsalen) and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

[1492] In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, ATGAM™ (antithymocyte glubulin), and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

[1493] In certain embodiments, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, corticosteroids (e.g. betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone), nonsteroidal anti-inflammatory drugs (e.g., diclofenac, diflunisal, etodolac, fenoprofen, floctafenine, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tenoxicam, tiaprofenic acid, and tolmetin.), as well as antihistamines, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

[1494] In an additional embodiment, the compositions of the invention are administered alone or in combination with an anti-angiogenic agent. Anti-angiogenic agents that may be administered with the compositions of the invention include, but are not limited to, Angiostatin (Entremed, Rockville, Md.), Troponin-1 (Boston Life Sciences, Boston, Mass.), anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel (Taxol), Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, VEGI, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter “d group” transition metals.

[1495] Lighter “d group” transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

[1496] Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

[1497] Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

[1498] A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include, but are not limited to, platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, (1991)); Sulphated Polysaccharide Peptidoglycan Complex (SP-PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, (1992)); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, (1992)); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, (1990)); Gold Sodium Thiomalate (“GST”; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, (1987)); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, (1987)); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4- chloroanthronilic acid disodium or “CCA”; (Takeuchi et al., Agents Actions 36:312-316, (1992)); and metalloproteinase inhibitors such as BB94.

[1499] Additional anti-angiogenic factors that may also be utilized within the context of the present invention include Thalidomide, (Celgene, Warren, N.J.); Angiostatic steroid; AGM-1470 (H. Brem and J. Folkman J Pediatr. Surg. 28:445-51 (1993)); an integrin alpha v beta 3 antagonist (C. Storgard et al., J. Clin. Invest. 103:47-54 (1999)); carboxynaminolmidazole; Carboxyamidotriazole (CAI) (National Cancer Institute, Bethesda, Md.); Conbretastatin A-4 (CA4P) (OXiGENE, Boston, Mass.); Squalamine (Magainin Pharmaceuticals, Plymouth Meeting, Pa.); TNP-470, (Tap Pharmaceuticals, Deerfield, Ill.); ZD-0101 AstraZeneca (London, UK); APRA (CT2584); Benefin, Byrostatin-1 (SC339555); CGP-41251 (PKC 412); CM11; Dexrazoxane (ICRF187); DMXAA; Endostatin; Flavopridiol; Genestein; GTE; ImmTher; Iressa (ZD1839); Octreotide (Somatostatin); Panretin; Penacillamine; Photopoint; PI-88; Prinomastat (AG-3340) Purlytin; Suradista (FCE26644); Tamoxifen (Nolvadex); Tazarotene; Tetrathiomolybdate; Xeloda (Capecitabine); and 5-Fluorouracil.

[1500] Anti-angiogenic agents that may be administed in combination with the compounds of the invention may work through a variety of mechanisms including, but not limited to, inhibiting proteolysis of the extracellular matrix, blocking the function of endothelial cell-extracellular matrix adhesion molecules, by antagonizing the function of angiogenesis inducers such as growth factors, and inhibiting integrin receptors expressed on proliferating endothelial cells. Examples of anti-angiogenic inhibitors that interfere with extracellular matrix proteolysis and which may be administered in combination with the compositons of the invention include, but are not Imited to, AG-3340 (Agouron, La Jolla, Calif.), BAY-12-9566 (Bayer, West Haven, Conn.), BMS-275291 (Bristol Myers Squibb, Princeton, N.J.), CGS-27032A (Novartis, East Hanover, N.J.), Marimastat (British Biotech, Oxford, UK), and Metastat (Aeterna, St-Foy, Quebec). Examples of anti-angiogenic inhibitors that act by blocking the function of endothelial cell-extracellular matrix adhesion molecules and which may be administered in combination with the compositons of the invention include, but are not Imited to, EMD-121974 (Merck KcgaA Darmstadt, Germany) and Vitaxin (Ixsys, La Jolla, Calif./Medimmune, Gaithersburg, Md.). Examples of anti-angiogenic agents that act by directly antagonizing or inhibiting angiogenesis inducers and which may be administered in combination with the compositons of the invention include, but are not lmited to, Angiozyme (Ribozyme, Boulder, Colo.), Anti-VEGF antibody (Genentech, S. San Francisco, Calif.), PTK-787/ZK-225846 (Novartis, Basel, Switzerland), SU-101 (Sugen, S. San Francisco, Calif.), SU-5416 (Sugen/Pharmacia Upjohn, Bridgewater, N.J.), and SU-6668 (Sugen). Other anti-angiogenic agents act to indirectly inhibit angiogenesis. Examples of indirect inhibitors of angiogenesis which may be administered in combination with the compositons of the invention include, but are not limited to, IM-862 (Cytran, Kirkland, Wash.), Interferon-alpha, IL-12 (Roche, Nutley, N.J.), and Pentosan polysulfate (Georgetown University, Washington, D.C.).

[1501] In particular embodiments, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of an autoimmune disease, such as for example, an autoimmune disease described herein.

[1502] In a particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of arthritis. In a more particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of rheumatoid arthritis.

[1503] In another embodiment, the polynucleotides encoding a polypeptide of the present invention are administered in combination with an angiogenic protein, or polynucleotides encoding an angiogenic protein. Examples of angiogenic proteins that may be administered with the compositions of the invention include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2, VEGF-3, epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin-like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

[1504] In additional embodiments, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to alkylating agents such as nitrogen mustards (for example, Mechlorethamine, cyclophosphamide, Cyclophosphamide Ifosfamide, Melphalan (L-sarcolysin), and Chlorambucil), ethylenimines and methylmelamines (for example, Hexamethylmelamine and Thiotepa), alkyl sulfonates (for example, Busulfan), nitrosoureas (for example, Carmustine (BCNU), Lomustine (CCNU), Semustine (methyl-CCNU), and Streptozocin (streptozotocin)), triazenes (for example, Dacarbazine (DTIC; dimethyltriazenoimidazolecarboxamide)), folic acid analogs (for example, Methotrexate (amethopterin)), pyrimidine analogs (for example, Fluorouacil (5-fluorouracil; 5-FU), Floxuridine (fluorodeoxyuridine; FudR), and Cytarabine (cytosine arabinoside)), purine analogs and related inhibitors (for example, Mercaptopurine (6-mercaptopurine; 6-MP), Thioguanine (6-thioguanine; TG), and Pentostatin (2′-deoxycoformycin)), vinca alkaloids (for example, Vinblastine (VLB, vinblastine sulfate)) and Vincristine (vincristine sulfate)), epipodophyllotoxins (for example, Etoposide and Teniposide), antibiotics (for example, Dactinomycin (actinomycin D), Daunorubicin (daunomycin; rubidomycin), Doxorubicin, Bleomycin, Plicamycin (mithramycin), and Mitomycin (mitomycin C), enzymes (for example, L-Asparaginase), biological response modifiers (for example, Interferon-alpha and interferon-alpha-2b), platinum coordination compounds (for example, Cisplatin (cis-DDP) and Carboplatin), anthracenedione (Mitoxantrone), substituted ureas (for example, Hydroxyurea), methylhydrazine derivatives (for example, Procarbazine (N-methylhydrazine; M1H), adrenocorticosteroids (for example, Prednisone), progestins (for example, Hydroxyprogesterone caproate, Medroxyprogesterone, Medroxyprogesterone acetate, and Megestrol acetate), estrogens (for example, Diethylstilbestrol (DES), Diethylstilbestrol diphosphate, Estradiol, and Ethinyl estradiol), antiestrogens (for example, Tamoxifen), androgens (Testosterone proprionate, and Fluoxymesterone), antiandrogens (for example, Flutamide), gonadotropin-releasing horomone analogs (for example, Leuprolide), other hormones and hormone analogs (for example, methyltestosterone, estramustine, estramustine phosphate sodium, chlorotrianisene, and testolactone), and others (for example, dicarbazine, glutamic acid, and mitotane).

[1505] In one embodiment, the compositions of the invention are administered in combination with one or more of the following drugs: infliximab (also known as Remicade™ Centocor, Inc.), Trocade (Roche, RO-32-3555), Leflunomide (also known as Aravam from Hoechst Marion Roussel), Kineret™ (an IL-1 Receptor antagonist also known as Anakinra from Amgen, Inc.)

[1506] In a specific embodiment, compositions of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or combination of one or more of the components of CHOP. In one embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies, human monoclonal anti-CD20 antibodies. In another embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies and CHOP, or anti-CD20 antibodies and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with Rituximab. In a further embodiment, compositions of the invention are administered with Rituximab and CHOP, or Rituximab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with tositumomab. In a further embodiment, compositions of the invention are administered with tositumomab and CHOP, or tositumomab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. The anti-CD20 antibodies may optionally be associated with radioisotopes, toxins or cytotoxic prodrugs.

[1507] In another specific embodiment, the compositions of the invention are administered in combination Zevalin™. In a further embodiment, compositions of the invention are administered with Zevalin™ and CHOP, or Zevalin™ and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. Zevalin™ may be associated with one or more radisotopes. Particularly preferred isotopes are ⁹⁰Y and

[1508] In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL2, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

[1509] In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-IBBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), OPG, and neutrokine-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD 153.

[1510] In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-6821 10; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are herein incorporated by reference in their entireties.

[1511] In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

[1512] In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, granulocyte macrophage colony stimulating factor (GM-CSF) (sargramostim, LEUKIN™, PROKINE™), granulocyte colony stimulating factor (G-CSF) (filgrastim, NEUPOGEN™), macrophage colony stimulating factor (M-CSF, CSF-1) erythropoietin (epoetin alfa, EPOGEN™, PROCRIT™), stem cell factor (SCF, c-kit ligand, steel factor), megakaryocyte colony stimulating factor, PIXY321 (a GMCSF/IL-3 fusion protein), interleukins, especially any one or more of IL-1 through IL-12, interferon-gamma, or thrombopoietin.

[1513] In certain embodiments, Therapeutics of the present invention are administered in combination with adrenergic blockers, such as, for example, acebutolol, atenolol, betaxolol, bisoprolol, carteolol, labetalol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol.

[1514] In another embodiment, the Therapeutics of the invention are administered in combination with an antiarrhythmic drug (e.g., adenosine, amidoarone, bretylium, digitalis, digoxin, digitoxin, diliazem, disopyramide, esmolol, flecainide, lidocaine, mexiletine, moricizine, phenytoin, procainamide, N-acetyl procainamide, propafenone, propranolol, quinidine, sotalol, tocainide, and verapamil).

[1515] In another embodiment, the Therapeutics of the invention are administered in combination with diuretic agents, such as carbonic anhydrase-inhibiting agents (e.g., acetazolamide, dichlorphenamide, and methazolamide), osmotic diuretics (e.g., glycerin, isosorbide, mannitol, and urea), diuretics that inhibit Na⁺-K⁺-2Cl⁻ symport (e.g., furosemide, bumetamide, azosemide, piretamide, tripamide, ethacrynic acid, muzolimine, and torsemide), thiazide and thiazide-like diuretics (e.g., bendroflumethiazide, benzthiazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, trichormethiazide, chlorthalidone, indapamide, metolazone, and quinethazone), potassium sparing diuretics (e.g., amiloride and triamterene), and mineralcorticoid receptor antagonists (e.g., spironolactone, canrenone, and potassium canrenoate).

[1516] In one embodiment, the Therapeutics of the invention are administered in combination with treatments for endocrine and/or hormone imbalance disorders. Treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, ¹²⁷I, radioactive isotopes of iodine such as ¹³¹I and ¹²³I; recombinant growth hormone, such as HUMATROPE™ (recombinant somatropin); growth hormone analogs such as PROTROPIN™ (somatrem); dopamine agonists such as PARLODEL™ (bromocriptine); somatostatin analogs such as SANDOSTATIN™ (octreotide); gonadotropin preparations such as PREGNYL™, A.P.L.™ and PROFASI™ (chorionic gonadotropin (CG)), PERGONAL™ (menotropins), and METRODIN™ (urofollitropin (uFSH)); synthetic human gonadotropin releasing hormone preparations such as FACTREL™ and LUTREPULSE™ (gonadorelin hydrochloride); synthetic gonadotropin agonists such as LUPRON™ (leuprolide acetate), SUPPRELIN™ (histrelin acetate), SYNAREL™ (nafarelin acetate), and ZOLADEX™ (goserelin acetate); synthetic preparations of thyrotropin-releasing hormone such as RELEFACT TRH™ and THYPINONE™ (protirelin); recombinant human TSH such as THYROGEN™; synthetic preparations of the sodium salts of the natural isomers of thyroid hormones such as L-T₄™, SYNTHROID™ and LEVOTHROID™ (levothyroxine sodium), L-T₃™, CYTOMEL™ and TRIOSTAT™ (liothyroine sodium), and THYROLAR™ (liotrix); antithyroid compounds such as 6-n-propylthiouracil (propylthiouracil), 1-methyl-2-mercaptoimidazole and TAPAZOLE™ (methimazole), NEO-MERCAZOLE™ (carbimazole); beta-adrenergic receptor antagonists such as propranolol and esmolol; Ca²⁺ channel blockers; dexamethasone and iodinated radiological contrast agents such as TELEPAQUE™ (iopanoic acid) and ORAGRAFIN™ (sodium ipodate).

[1517] Additional treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, estrogens or congugated estrogens such as ESTRACE™ (estradiol), ESTINYLm (ethinyl estradiol), PREMARIN™, ESTRATAB™, ORTHO-EST™, OGEN™ and estropipate (estrone), ESTROVIS™ (quinestrol), ESTRADERM™ (estradiol), DELESTROGENM and VALERGEN™ (estradiol valerate), DEPO-ESTRADIOL CYPIONATE™ and ESTROJECT LA™ (estradiol cypionate); antiestrogens such as NOLVADEX™ (tamoxifen), SEROPHENE™ and CLOMID™ (clomiphene); progestins such as DURALUTIN™ (hydroxyprogesterone caproate), MPA™ and DEPO-PROVERA” (medroxyprogesterone acetate), PROVERA™ and CYCRIN™ (MPA), MEGACE™ (megestrol acetate), NORLUTIN™ (norethindrone), and NORLUTATE™ and AYGESTIN™ (norethindrone acetate); progesterone implants such as NORPLANT SYSTEM™ (subdermal implants of norgestrel); antiprogestins such as RU 486™ (mifepristone); hormonal contraceptives such as ENOVID™ (norethynodrel plus mestranol), PROGESTASERT™ (intrauterine device that releases progesterone), LOESTRIN™, BREVICON™, MODICON™, GENORA™, NELONA™, NORINYL™, OVACON-35™ and OVACON-50™ (ethinyl estradiol/norethindrone), LEVLEN™, NORDETTE™, TR1-LEVLEN™and TRIPHASIL-21™ (ethinyl estradiol/levonorgestrel) LO/OVRAL™and OVRAL™(ethinyl estradiol/norgestrel), DEMULEN™ (ethinyl estradiol/ethynodiol diacetate), NORINYL™, ORTHO-NOVUMM, NORETN™, GENORA™, and NELOVA™ (norethindrone/mestranol), DESOGEN™ and ORTHO-CEPT™ (ethinyl estradiol/desogestrel), ORTHO-CYCLENM and ORTHO-TRICYCLEN™ (ethinyl estradiol/norgestimate), MICRONOR™ and NOR-QD™ (norethindrone), and OVRETTE™ (norgestrel).

[1518] Additional treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, testosterone esters such as methenolone acetate and testosterone undecanoate; parenteral and oral androgens such as TESTOJECT-50™ (testosterone), TESTEX™ (testosterone propionate), DELATESTRYL™ (testosterone enanthate), DEPO-TESTOSTERONE™ (testosterone cyplonate), DANOCRINE™ (danazol), HALOTESTIN™ (fluoxymesterone), ORETON METHYL™, TESTRED™ and VIRILON™ (methyltestosterone), and OXANDRIN™ (oxandrolone); testosterone transdermal systems such as TESTODERM™; androgen receptor antagonist and 5-alpha-reductase inhibitors such as ANDROCUR™ (cyproterone acetate), EULEXIN™ (flutamide), and PROSCAR™ (finasteride); adrenocorticotropic hormone preparations such as CORTROSYN™ (cosyntropin); adrenocortical steroids and their synthetic analogs such as ACLOVATE™ (alclometasone dipropionate), CYCLOCORT™ (amcinonide), BECLOVENT™ and VANCERIL™ (beclomethasone dipropionate), CELESTONE™ (betamethasone), BENISONE™ and UTICORT™ (betamethasone benzoate), DIPROSONE™ (betamethasone dipropionate), CELESTONE PHOSPHATE™ (betamethasone sodium phosphate), CELESTONE SOLUSPAN™ (betamethasone sodium phosphate and acetate), BETA-VAL™ and VALISONE™ (betamethasone valerate), TEMOVATE™ (clobetasol propionate), CLODERM™ (clocortolone pivalate), CORTEF™ and HYDROCORTONE™ (cortisol (hydrocortisone)), HYDROCORTONE ACETATE™ (cortisol (hydrocortisone) acetate), LOCOID™ (cortisol (hydrocortisone) butyrate), HYDROCORTONE PHOSPHATE™ (cortisol (hydrocortisone) sodium phosphate), A-HYDROCORT™ and SOLU CORTEFM (cortisol (hydrocortisone) sodium succinate), WESTCORT™ (cortisol (hydrocortisone) valerate), CORTISONE ACETATE™ (cortisone acetate), DESOWEN™ and TRIDESTLONm (desonide), TOPICORT™ (desoximetasone), DECADRON™ (dexamethasone), DECADRON LA™ (dexamethasone acetate), DECADRON PHOSPHATE™ and HEXADROL PHOSPHATE™ (dexamethasone sodium phosphate), FLORONE™ and MAXIFLOR™ (diflorasone diacetate), FLORINEF ACETATE™ (fludrocortisone acetate), AEROBID™ and NASALIDE™ (flunisolide), FLUONID™ and SYNALAR™ (fluocinolone acetonide), LIDEX™ (fluocinonide), FLUOR-OP™ and FML™ (fluorometholone), CORDRAN™ (flurandrenolide), HALOG™ (halcinonide), HMS LIZUIFILM™ (medrysone), MEDROL™ (methylprednisolone), DEPO-MEDROL™ and MEDROL ACETATE™ (methylprednisone acetate), A-METHAPRED™ and SOLUMEDROLM (methylprednisolone sodium succinate), ELOCON™ (mometasone furoate), HALDRONE™ (paramethasone acetate), DELTA-CORTEFM (prednisolone), ECONOPRED™ (prednisolone acetate), HYDELTRASOL™ (prednisolone sodium phosphate), HYDELTRA-T.B.A™ (prednisolone tebutate), DELTASONE™ (prednisone), ARISTOCORT™ and KENACORT™ (triamcinolone), KENALOG™ (trinamcinolone acetonide), ARISTOCORT™ and KENACORT DIACETATE™ (triamcinolone diacetate), and ARISTOSPAN” (triamcinolone hexacetonide); inhibitors of biosynthesis and action of adrenocortical steroids such as CYTADREN™ (aminoglutethimide), NIZORAL™ (ketoconazole), MODRASTANE™ (trilostane), and METOPIRONE™ (metyrapone); bovine, porcine or human insulin or mixtures thereof; insulin analogs; recombinant human insulin such as HUMULIN™ and NOVOLIN™; oral hypoglycemic agents such as ORAMIDE™ and ORINASE™ (tolbutamide), DIABINESE™ (chlorpropamide), TOLAMIDE™ and TOLINASE™ (tolazamide), DYMELOR™ (acetohexamide), glibenclamide, MICRONASE™, DIBETA™ and GLYNASE™ (glyburide), GLUCOTROL™ (glipizide), and DIAMICRON™ (gliclazide), GLUCOPHAGE™ (metformin), ciglitazone, pioglitazone, and alpha-glucosidase inhibitors; bovine or porcine glucagon; somatostatins such as SANDOSTATIN™ (octreotide); and diazoxides such as PROGLYCEM™ (diazoxide).

[1519] In one embodiment, the Therapeutics of the invention are administered in combination with treatments for uterine motility disorders. Treatments for uterine motility disorders include, but are not limited to, estrogen drugs such as conjugated estrogens (e.g., PREMARIN® and ESTRATAB®), estradiols (e.g., CLIMARA® and ALORA®), estropipate, and chlorotrianisene; progestin drugs (e.g., AMEN® (medroxyprogesterone), MICRONOR® (norethidrone acetate), PROMETRIUM® progesterone, and megestrol acetate); and estrogen/progesterone combination therapies such as, for example, conjugated estrogens/medroxyprogesterone (e.g., PREMPRO™ and PREMPHASE®) and norethindrone acetate/ethinyl estsradiol (e.g., FEMHRT™).

[1520] In an additional embodiment, the Therapeutics of the invention are administered in combination with drugs effective in treating iron deficiency and hypochromic anemias, including but not limited to, ferrous sulfate (iron sulfate, FEOSOL™), ferrous fumarate (e.g., FEOSTAT™), ferrous gluconate (e.g., FERGON™), polysaccharide-iron complex (e.g., NIFEREX™), iron dextran injection (e.g., INFED™), cupric sulfate, pyroxidine, riboflavin, Vitamin B₁₂, cyancobalamin injection (e.g., REDISOL™, RUBRAMIN PC™), hydroxocobalarnin, folic acid (e.g., FOLVITE™), leucovorin (folinic acid, 5-CHOH4PteGlu, citrovorum factor) or WELLCOVORIN (Calcium salt of leucovorin), transferrin or ferritin.

[1521] In certain embodiments, the Therapeutics of the invention are administered in combination with agents used to treat psychiatric disorders. Psychiatric drugs that may be administered with the Therapeutics of the invention include, but are not limited to, antipsychotic agents (e.g., chlorpromazine, chlorprothixene, clozapine, fluphenazine, haloperidol, loxapine, mesoridazine, molindone, olanzapine, perphenazine, pimozide, quetiapine, risperidone, thioridazine, thiothixene, trifluoperazine, and triflupromazine), antimanic agents (e.g., carbamazepine, divalproex sodium, lithium carbonate, and lithium citrate), antidepressants (e.g., amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, fluvoxamine, fluoxetine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine), antianxiety agents (e.g., alprazolam, buspirone, chlordiazepoxide, clorazepate, diazepam, halazepam, lorazepam, oxazepam, and prazepam), and stimulants (e.g., d-amphetamine, methylphenidate, and pemoline).

[1522] In other embodiments, the Therapeutics of the invention are administered in combination with agents used to treat neurological disorders. Neurological agents that may be administered with the Therapeutics of the invention include, but are not limited to, antiepileptic agents (e.g., carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproic acid, divalproex sodium, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide, diazepam, lorazepam, and clonazepam), antiparkinsonian agents (e.g., levodopa/carbidopa, selegiline, amantidine, bromocriptine, pergolide, ropinirole, pramipexole, benztropine; biperiden; ethopropazine; procyclidine; trihexyphenidyl, tolcapone), and ALS therapeutics (e.g. riluzole).

[1523] In another embodiment, Therapeutics of the invention are administered in combination with vasodilating agents and/or calcium channel blocking agents. Vasodilating agents that may be administered with the Therapeutics of the invention include, but are not limited to, Angiotensin Converting Enzyme (ACE) inhibitors (e.g., papaverine, isoxsuprine, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipnl, spirapril, trandolapril, and nylidrin), and nitrates (e.g., isosorbide dinitrate, isosorbide mononitrate, and nitroglycerin). Examples of calcium channel blocking agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to amlodipine, bepridil, diltiazem, felodipine, flunarizine, isradipine, nicardipine, nifedipine, nimodipine, and verapamil.

[1524] In certain embodiments, the Therapeutics of the invention are administered in combination with treatments for gastrointestinal disorders. Treatments for gastrointestinal disorders that may be administered with the Therapeutic of the invention include, but are not limited to, H₂ histamine receptor antagonists (e.g., TAGAMET™ (cimetidine), ZANTAC™ (ranitidine), PEPCLD (famotidine), and AXID™ (nizatidine)); inhibitors of H⁺, K⁺ ATPase (e.g., PREVACID™ (lansoprazole) and PRILOSEC™ (omeprazole)); Bismuth compounds (e.g., PEPTO-BISMOL™ (bismuth subsalicylate) and DE-NOL™ (bismuth subcitrate)); various antacids; sucralfate; prostaglandin analogs (e.g. CYTOTEC™ (misoprostol)); muscarinic cholinergic antagonists; laxatives (e.g., surfactant laxatives, stimulant laxatives, saline and osmotic laxatives); antidiarrheal agents (e.g., LOMOTIL™ (diphenoxylate), MOTOFEN™ (diphenoxin), and IMODIUM™ (loperamide hydrochloride)), synthetic analogs of somatostatin such as SANDOSTATIN™ (octreotide), antiemetic agents (e.g., ZOFRAN (ondansetron), KYTRIL™ (granisetron hydrochloride), tropisetron, dolasetron, metoclopramide, chlorpromazine, perphenazine, prochlorperazine, promethazine, thiethylperazine, triflupromazine, domperidone, halopendol, droperidol, trimethobenzamide, dexamethasone, methylprednisolone, dronabinol, and nabilone); D2 antagonists (e.g., metoclopramide, trimethobenzamide and chlorpromazine); bile salts; chenodeoxycholic acid; ursodeoxycholic acid, and pancreatic enzyme preparations such as pancreatin and pancrelipase.

[1525] In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 14 Method of Treating Decreased Levels of the Polypeptide

[1526] The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a polypeptide of the present invention in an individual can be treated by administering the agonist or antagonist of the present invention. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the agonist or antagonist to increase the activity level of the polypeptide in such an individual.

[1527] For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the agonist or antagonist for six consecutive days. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 13.

Example 15 Method of Treating Increased Levels of the Polypeptide

[1528] The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

[1529] In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, due to a variety of etiologies, such as cancer.

[1530] For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The antisense polynucleotides of the present invention can be formulated using techniques and formulations described herein (e.g. see Example 13), or otherwise known in the art.

Example 16 Method of Treatment Ssing Gene Therapy-ex vivo

[1531] One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C. for approximately one week.

[1532] At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

[1533] pMV-7 (Kirschmeier, P. T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

[1534] The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5′ and 3′ end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5′ primer contains an EcoRI site and the 3′ primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

[1535] The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

[1536] Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low,-then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

[1537] The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 17 Gene Therapy Using Endogenous Genes Corresponding to Polynucleotides of the Invention

[1538] Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Pat. No. 5,641,670, issued Jun. 24, 1997; International Publication NO: WO 96/29411, published Sep. 26, 1996; International Publication NO: WO 94/12650, published Aug. 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

[1539] Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5′ non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5′ end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5′ and 3′ ends. Preferably, the 3′ end of the first targeting sequence contains the same restriction enzyme site as the 5′ end of the amplified promoter and the 5′ end of the second targeting sequence contains the same restriction site as the 3′ end of the amplified promoter.

[1540] The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel, then purified by phenol extraction and ethanol precipitation.

[1541] In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

[1542] Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

[1543] Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM+10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂ HPO₄, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3×10⁶ cells/ml. Electroporation should be performed immediately following resuspension.

[1544] Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, N.Y.) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5′ end and a BamHI site on the 3′ end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5′ end and an Xba site at the 3′end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5′end and a HindIII site at the 3′end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter—XbaI and BamHI; fragment 1—XbaI; fragment 2—BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

[1545] Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 μg/ml. 0.5 ml of the cell suspension (containing approximately 1.5×10⁶ cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960° F. and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

[1546] Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

[1547] The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 18 Method of Treatment Using Gene Therapy—in vivo

[1548] Another aspect of the present invention is using in vivo gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to (i.e., associated with) a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Pat. No. 5,693,622, 5705151, 5580859; Tabata et al., Cardiovasc. Res. 35(3):470-479 (1997); Chao et al., Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

[1549] The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

[1550] The term “naked” polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P. L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

[1551] The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotidc synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

[1552] The polynucleotide construct can be delivered to the interstitial space of tissues within an animal, including muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

[1553] For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

[1554] The dose response effects of injected polynucleotide in muscle in vivo is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

[1555] Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

[1556] After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

Example 19 Transgenic Animals

[1557] The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

[1558] Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pleuripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, “Transgenic Animals,” Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

[1559] Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

[1560] The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, i.e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Bnefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

[1561] Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

[1562] Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

[1563] Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 20 Knock-Out Animals

[1564] Endogenous gene expression can also be reduced by inactivating or “knocking out” the gene and/or its promoter using targeted homologous recombination. (e.g., see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, supra). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

[1565] In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient in vivo. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

[1566] Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Pat. No. 5,399,349; and Mulligan & Wilson, U.S. Pat. No. 5,460,959 each of which is incorporated by reference herein in its entirety).

[1567] When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

[1568] Transgenic and “knock-out” animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 21 Assays Detecting Stimulation or Inhibition of B Cell Proliferation and Differentiation

[1569] Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

[1570] One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

[1571] In Vitro Assay—Agonists or antagonists of the invention can be assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the agonists or antagonists of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed Staphylococcus aureus Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

[1572] Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added 10⁵ B-cells suspended in culture medium (RPMI 1640 containing 10% FBS, 5×10⁻⁵M 2ME, 100U/ml penicillin, 10 ug/ml streptomycin, and 10⁻⁵ dilution of SAC) in a total volume of 150 ul. Proliferation or inhibition is quantitated by a 20 h pulse (1 uCi/well) with 3H-thymidine (6.7 C/mNM) beginning 72 h post factor addition. The positive and negative controls are IL2 and medium respectively.

[1573] In vivo Assay—BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of agonists or antagonists of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with agonists or antagonists of the invention identify the results of the activity of the agonists or antagonists on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

[1574] Flow cytometric analyses of the spleens from mice treated with agonist or antagonist is used to indicate whether the agonists or antagonists specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

[1575] Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and agonists or antagonists-treated mice.

[1576] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 22 T Cell Proliferation Assay

[1577] A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of ³H-thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 μl/well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C. (1 μg/ml in 0.05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells (5×10⁴/well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of agonists or antagonists of the invention (total volume 200 ul). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C., plates are spun for 2 min. at 1000 rpm and 100 μl of supernatant is removed and stored −20 degrees C. for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 ul of medium containing 0.5 uCi of ³H-thymidine and cultured at 37 degrees C. for 18-24 hr. Wells are harvested and incorporation of 3H-thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative control for the effects of agonists or antagonists of the invention.

[1578] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 23 Effect of Agonists or Antagonists of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells

[1579] Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF-α, causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FCγRII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

[1580] FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of agonist or antagonist of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

[1581] Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells (10⁶/ml) are treated with increasing concentrations of agonists or antagonists of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, Minn.)). The standard protocols provided with the kits are used.

[1582] Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increased expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

[1583] FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of agonists or antagonists of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

[1584] Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Agonists or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, Md.) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

[1585] Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated processes (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of 2×10⁶/ml in PBS containing PI at a final concentration of 5 μg/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

[1586] Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of 5×10⁵ cells/ml with increasing concentrations of agonists or antagonists of the invention and under the same conditions, but in the absence of agonists or antagonists. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in the presence of agonist or antagonist of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24 h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, Minn.)) and applying the standard protocols provided with the kit.

[1587] Oxidative burst. Purified monocytes are plated in 96-w plate at 2-1×10⁵ cell/well. Increasing concentrations of agonists or antagonists of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640+10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37° C. for 2 hours and the reaction is stopped by adding 20 μl 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H₂O₂ produced by the macrophages, a standard curve of a H₂O₂ solution of known molanty is performed for each experiment.

[1588] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 24 Biological Effects of Agonists or Antagonists of the Invention

[1589] Astrocyte and Neuronal Assays

[1590] Agonists or antagonists of the invention, expressed in Escherichia coli and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate an agonist or antagonist of the invention's activity on these cells.

[1591] Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons in vitro have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., “Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension.” Proc. Natl. Acad. Sci. USA 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of an agonist or antagonist of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

[1592] Fibroblast and endothelial cell assays.

[1593] Human lung fibroblasts are obtained from Clonetics (San Diego, Calif.) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, Calif.). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, Calif.) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE₂ assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or agonists or antagonists of the invention with or without IL-1a for 24 hours. The supernatants are collected and assayed for PGE₂ by EIA kit (Cayman, Ann Arbor, Mich.). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without agonists or antagonists of the invention IL-1α for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, Mass.).

[1594] Human lung fibroblasts are cultured with FGF-2 or agonists or antagonists of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10-2500 ng/ml which can be used to compare stimulation with agonists or antagonists of the invention.

[1595] Parkinson Models.

[1596] The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP+) and released. Subsequently, MPP+is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP+is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotidamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

[1597] It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

[1598] Based on the data with FGF-2, agonists or antagonists of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival in vitro and it can also be tested in vivo for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of an agonist or antagonist of the invention is first examined in vitro in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm² on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (Ni). The cultures are fixed with paraformaldehyde after 8 days in vitro and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

[1599] Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving in vitro. Therefore, if an agonist or antagonist of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the agonist or antagonist may be involved in Parkinson's Disease.

[1600] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 25 The Effect of Agonists or Antagonists of the Invention on the Growth of Vascular Endothelial Cells

[1601] On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at 2-5×10⁴ cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnique, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. An agonist or antagonist of the invention, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

[1602] An increase in the number of HUVEC cells indicates that the compound of the invention may proliferate vascular endothelial cells, while a decrease in the number of HUVEC cells indicates that the compound of the invention inhibits vascular endothelial cells.

[1603] The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

Example 26 Rat Corneal Wound Healing Model

[1604] This animal model shows the effect of an agonist or antagonist of the invention on neovascularization. The experimental protocol includes:

[1605] a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.

[1606] b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.

[1607] c) Making a pocket (its base is 1-1.5 mm form the edge of the eye).

[1608] d) Positioning a pellet, containing 50 ng-5 ug of an agonist or antagonist of the invention, within the pocket.

[1609] e) Treatment with an agonist or antagonist of the invention can also be applied topically to the corneal wounds in a dosage range of 20 mg-500 mg (daily treatment for five days).

[1610] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 27 Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models

[1611] Diabetic db+/db+ Mouse Model.

[1612] To demonstrate that an agonist or antagonist of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M. H. et al., J. Surg. Res. 52:389 (1992); Greenhalgh, D. G. et al., Am. J. Pathol. 136:1235 (1990)).

[1613] The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman et al. Proc. Natl. Acad. Sci. USA 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel et al., J. Immunol. 120:1375 (1978); Debray-Sachs, M. et al., Clin. Exp. Immunol. 51(1):1-7 (1983); Leiter et al., Am. J. of Pathol. 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. et al., Exp. Neurol. 83(2):221-232 (1984); Robertson et al., Diabetes 29(1):60-67 (1980); Giacomelli et al., Lab Invest. 40(4):460-473 (1979); Coleman, D. L., Diabetes 31 (Suppl): 1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel et al., J. Immunol. 120:1375-1377 (1978)).

[1614] The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, et al., Am. J. of Pathol. 136:1235-1246 (1990)).

[1615] Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

[1616] Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D. B., J. Exp. Med. 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

[1617] Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

[1618] An agonist or antagonist of the invention is administered using at a range different doses, from 4 mg to 500 mg per wound per day for 8 days in vehicle. Vehicle control groups received 50 mL of vehicle solution.

[1619] Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300 mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

[1620] Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

[1621] Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64 mm, the corresponding size of the dermal punch. Calculations are made using the following formula:

[Open area on day 8]−[Open area on day 1]/[Open area on day 1]

[1622] Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5rn) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with an agonist or antagonist of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D. G. et al., Am. J. Pathol. 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

[1623] Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

[1624] Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer served as a positive tissue control and human brain tissue is used as a negative tissue control. Each specimen included a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

[1625] Experimental data are analyzed using an unpaired t test. A p value of <0.05 is considered significant.

[1626] Steroid Impaired Rat Model

[1627] The inhibition of wound healing by steroids has been well documented in various in vitro and in vivo systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet al., J. Immunol. 115: 476-481 (1975); Werb et al., J. Exp. Med. 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert et al., An. Intern. Med. 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck et al., Growth Factors. 5: 295-304 (1991); Haynes et al., J. Clin. Invest. 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes et al., J. Clin. Invest. 61: 703-797 (1978); Wahl, “Glucocorticoids and wound healing”, In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck et al., Growth Factors. 5: 295-304 (1991); Haynes et al., J. Clin. Invest. 61: 703-797 (1978); Wahl, “Glucocorticoids and wound healing”, In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce et al., Proc. Natl. Acad. Sci. USA 86: 2229-2233 (1989)).

[1628] To demonstrate that an agonist or antagonist of the invention can accelerate the healing process, the effects of multiple topical applications of the agonist or antagonist on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

[1629] Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17 mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

[1630] The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

[1631] Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

[1632] The agonist or antagonist of the invention is administered using at a range different doses, from 4 mg to 500 mg per wound per day for 8 days in vehicle. Vehicle control groups received 50 mL of vehicle solution.

[1633] Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300 mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

[1634] Three groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

[1635] Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64 mm², the corresponding size of the dermal punch. Calculations are made using the following formula:

[Open area on day 8]−[Open area on day 1]/[Open area on day 1]

[1636] Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5 mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with an agonist or antagonist of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

[1637] Experimental data are analyzed using an unpaired t test. A p value of <0.05 is considered significant.

[1638] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 28 Lymphadema Animal Model

[1639] The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of an agonist or antagonist of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

[1640] Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ˜350 g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetnc measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

[1641] Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated or suture ligated.

[1642] Using a microscope, muscles in back of the leg (near the semitendinosis and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

[1643] Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of 0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

[1644] To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect of plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

[1645] Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people and those 2 readings are averaged. Readings are taken from both control and edematous limbs.

[1646] Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), and both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

[1647] Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca2⁺ comparison.

[1648] Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

[1649] Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezegel, dipped into cold methylbutane, placed into labeled sample bags at −80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics.

[1650] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 29 Suppression of TNF Alpha-Induced Adhesion Molecule Expression by an Agonist or Antagonist of the Invention

[1651] The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

[1652] Tumor necrosis factor alpha (TNF-a), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

[1653] The potential of an agonist or antagonist of the invention to mediate a suppression of TNF-a induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF-a treated ECs when co-stimulated with a member of the FGF family of proteins.

[1654] To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, Calif.) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C. humidified incubator containing 5% CO₂. HUVECs are seeded in 96-well plates at concentrations of 1×10⁴ cells/well in EGM medium at 37 degree C. for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

[1655] Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in tnplicate (in 10 ul volumes). Plates are incubated at 37 degree C. for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μl of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4° C. for 30 min.

[1656] Fixative is then removed from the wells and wells are washed 1× with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10 Al of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μglml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37° C. for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

[1657] Then add 20 μl of diluted ExtrAvidin-Alkaline Phosphotase (1:5,000 dilution) to each well and incubated at 37° C. for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100 μl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphotase in glycine buffer: 1:5,000 (10⁰)>10⁻⁰ ⁵>10⁻¹>10^(−1.5). 5 μl of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 μl of pNNP reagent must then be added to each of the standard wells. The plate must be incubated at 37° C. for 4 h. A volume of 50 μl of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

[1658] The studies described in this example tested activity of agonists or antagonists of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides or polypeptides of the invention (e.g., gene therapy).

Example 30 Production of Polypeptide of the Invention for High-Throughput Screening Assays

[1659] The following protocol produces a supernatant containing polypeptide of the present invention to be tested. This supernatant can then be used in the Screening Assays described in Examples 32-41.

[1660] First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1 mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50 ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate-off the Poly-D-Lysine solution and rinse with 1 ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

[1661] Plate 293T cells (do not carry cells past P+20) at 2×10⁵ cells/well in 0.5 ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1× Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

[1662] The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5 ml Optimem 1 (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2 ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8-10, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50 ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150 ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

[1663] Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with 0.5-1 ml PBS. Person A then aspirates off PBS rinse, and person B, using a12-channel pipetter with tips on every other channel, adds the 200 ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degree C. for 6 hours.

[1664] While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1× penstrep, or HGS CHO-5 media (116.6 mg/L of CaCl2 (anhyd); 0.00130 mg/L CuSO₄-5H₂O; 0.050 mg/L of Fe(NO₃)₃-9H₂O; 0.417 mg/L of FeSO₄-7H₂O; 311.80 mg/L of Kcl; 28.64 mg/L of MgCl₂; 48.84 mg/L of MgSO₄; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO₃; 62.50 mg/L of NaH₂PO₄—H₂O; 71.02 mg/L of Na₂HPO₄; 0.4320 mg/L of ZnSO₄.7H₂O; 0.002 mg/L of Arachidonic Acid; 1.022 mg/L of Cholesterol; 0.070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L-Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H₂O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H₂O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H₂O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalainine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tryrosine-2Na-2H₂O; and 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; 0.680 mg/L of Vitamin B₁₂; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal Acetate. Adjust osmolarity to 327 mOsm) with 2 mm glutamine and 1× penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in IL DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15 ml polystyrene conical.

[1665] The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5 ml appropriate media to each well. Incubate at 37 degree C. for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

[1666] On day four, using a 300 ul multichannel pipetter, aliquot 600 ul in one 1 ml deep well plate and the remaining supernatant into a 2 ml deep well. The supernatants from each well can then be used in the assays described in Examples 32-39.

[1667] It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide of the present invention directly (e.g., as a secreted protein) or by polypeptide of the present invention inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 31 Construction of GAS Reporter Construct

[1668] One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site “GAS” elements or interferon-sensitive responsive element (“ISRE”), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

[1669] GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or “STATs.” There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was onginally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

[1670] The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase (“Jaks”) family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

[1671] The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995)). A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class I includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xaa-Trp-Ser (SEQ ID NO: 2)).

[1672] Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway. Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway (See Table below). Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified. JAKs Ligand tyk2 Jak1 Jak2 Jak3 STATS GAS(elements) or ISRE IFN family IFN-a/B + + − − 1, 2, 3 ISRE IFN-g + + − 1 GAS (IRF1 > Lys6 > IFP) Il-10 + ? ? − 1, 3 gp130 family IL-6 (Pleiotropic) + + + ? 1, 3 GAS (IRF1 > Lys6 > IFP) Il-11 (Pleiotropic) ? + ? ? 1, 3 OnM (Pleiotropic) ? + + ? 1, 3 LIF (Pleiotropic) ? + + ? 1, 3 CNTF (Pleiotropic) −/+ + + ? 1, 3 G-CSF (Pleiotropic) ? + ? ? 1, 3 IL-12 (Pleiotropic) + − + + 1, 3 g-C family IL-2 (lymphocytes) − + − + 1, 3, 5 GAS IL-4 (lymph/myeloid) − + − + 6 GAS (IRF1 = IFP >> Ly6)(IgH) IL-7 (lymphocytes) − + − + 5 GAS IL-9 (lymphocytes) − + − + 5 GAS IL-13 (lymphocyte) − + ? ? 6 GAS IL-15 ? + ? + 5 GAS gp140 family IL-3 (myeloid) − − + − 5 GAS (IRF1 > IFP >> Ly6) IL-5 (myeloid) − − + − 5 GAS GM-CSF (myeloid) − − + − 5 GAS Growth hormone family GH ? − + − 5 PRL ? +/− + − 1, 3, 5 EPO ? − + − 5 GAS (B-CAS > IRF1 = IFP >> Ly6) Receptor Tyrosine Kinases EGF ? + + − 1, 3 GAS (IRF1) PDGF ? + + − 1, 3 CSF-1 ? + + − 1, 3 GAS (not IRF1)

[1673] To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 32-33, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5′ primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytoklnes (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5′ primer also contains 18 bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5′ primer is: 5′: GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAA ATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3′ (SEQ ID NO: 3)

[1674] The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5′:GCGGCAAGCTTTTTGCAAAGCCTAGGC:3′ (SEQ ID NO: 4)

[1675] PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence: 5′:CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATGA TTTCCCCGAAATATCTGCCATCTCAATTAGTCAGC AACCATAGTCCCGCCCCTA ACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCAT GGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAG CTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA GCTT:3′ (SEQ ID NO: 5)

[1676] With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or “SEAP.” Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

[1677] The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

[1678] Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 32-33.

[1679] Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing EGR and NF-KB promoter sequences are descnbed in Examples 34 and 35. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, I1-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 32 High-Throughput Screening Assay for T-Cell Activity

[1680] The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 31. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

[1681] Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml genticin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

[1682] Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI+10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life-Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

[1683] During the incubation period, count cell concentration, spin down the required number of cells (10⁷ per transfection), and resuspend in OPTI-MEM to a final concentration of 10⁷ cells/ml. Then add 1 ml of 1×10⁷ cells in OPTI-MtM to T25 flask and incubate at 37 degree C. for 6 hrs. After the incubation, add 10 ml of RPMI+15% serum.

[1684] The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI+10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptide of the present invention or polypeptide of the present invention induced polypeptides as produced by the protocol described in Example 30.

[1685] On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI+10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

[1686] Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

[1687] After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

[1688] The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at −20 degree C. until SEAP assays are performed according to Example 36. The plates containing the remaining treated cells are placed at 4 degree C. and serve as a source of material for repeating the assay on a specific well if desired.

[1689] As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

[1690] The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

Example 33 High-Throughput Screening Assay Identifying Myeloid Activity

[1691] The following protocol is used to assess myeloid activity of polypeptide of the present invention by determining whether polypeptide of the present invention proliferates and/or differentiates myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 31. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KGI can be used.

[1692] To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 31, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2×10⁷ U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

[1693] Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM Na₂HPO₄.7H₂O, 1 mM MgCl₂, and 675 uM CaCl₂. Incubate at 37 degrees C. for 45 min.

[1694] Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degree C. for 36 hr.

[1695] The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

[1696] These cells are tested by harvesting 1×10⁸ cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of 5×10⁵ cells/ml. Plate 200 ul cells per well in the 96-well plate (or 1×10⁵ cells/well).

[1697] Add 50 ul of the supernatant prepared by the protocol described in Example 30. Incubate at 37 degee C. for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 36.

Example 34 High-Throughput Screening Assay Identifying Neuronal Activity

[1698] When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed by polypeptide of the present invention.

[1699] Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells by polypeptide of the present invention can be assessed.

[1700] The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (−633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers: 5′ GCGCTCGAGGGATGACAGCGATAGAACCCCGG-3′ (SEQ ID NO: 6) 5′ GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3′ (SEQ ID NO: 7)

[1701] Using the GAS:SEAP/Neo vector produced in Example 31, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

[1702] To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

[1703] PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

[1704] Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 30. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

[1705] To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

[1706] The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as 5×10⁵ cells/ml.

[1707] Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to 1×10⁵ cells/well). Add 50 ul supernatant produced by Example 30, 37 degree C. for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 36.

Example 35 High-Throughput Screening Assay for T-Cell Activity

[1708] NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF-KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

[1709] In non-stimulated conditions, NF-KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I-KB is phosphorylated and degraded, causing NF-KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF-KB include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

[1710] Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 30. Activators or inhibitors of NF-KB would be useful in treating, preventing, and/or diagnosing diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

[1711] To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO: 8), 18 bp of sequence complementary to the 5′ end of the SV40 early promoter sequence, and is flanked with an XhoI site: 5′:GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTT CCATCCTGCCATCTCAATTAG:3′ (SEQ ID NO: 9)

[1712] The downstream primer is complementary to the 3′ end of the SV40 promoter and is flanked with a Hind III site: 5′:GCGGCAAGCTTTTTGCAAAGCCTAGGC:3′ (SEQ ID NO: 4)

[1713] PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence: 5′:CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCCATC TGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCC GCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTT TTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGT AGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:3′ (SEQ ID NO: 10)

[1714] Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

[1715] In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

[1716] Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 32. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 32. As a positive control, exogenous TNF alpha (0.1,1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 36 Assay for SEAP Activity

[1717] As a reporter molecule for the assays described in Examples 32-35, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

[1718] Prime a dispenser with the 2.5× Dilution Buffer and dispense 15 ul of 2.5× dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C. for 30 min. Separate the Optiplates to avoid uneven heating.

[1719] Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the Table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on a luminometer, thus one should treat 5 plates at each time and start the second set 10 minutes later.

[1720] Read the relative light unit in the luminometer. Set H112 as blank, and print the results. An increase in chemiluminescence indicates reporter activity. Reaction Buffer Formulation: # of plates Rxn buffer diluent (ml) CSPD (ml) 10 60 3 11 65 3.25 12 70 3.5 13 75 3.75 14 80 4 15 85 4.25 16 90 4.5 17 95 4.75 18 100 5 19 105 5.25 20 110 5.5 21 115 5.75 22 120 6 23 125 6.25 24 130 6.5 25 135 6.75 26 140 7 27 145 7.25 28 150 7.5 29 155 7.75 30 160 8 31 165 8.25 32 170 8.5 33 175 8.75 34 180 9 35 185 9.25 36 190 9.5 37 195 9.75 38 200 10 39 205 10.25 40 210 10.5 41 215 10.75 42 220 11 43 225 11.25 44 230 11.5 45 235 11.75 46 240 12 47 245 12.25 48 250 12.5 49 255 12.75 50 260 13

Example 37 High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

[1721] Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent

[1722] The following assay uses Fluorometnc Imaging Plate Reader (“FLIPR”) to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

[1723] For adherent cells, seed the cells at 10,000-20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO₂ incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

[1724] A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C. in a CO₂ incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

[1725] For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5×10⁶ cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C. water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1×10⁶ cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley Cell Wash with 200 ul, followed by an aspiration step to 100 ul final volume.

[1726] For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

[1727] To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event caused by the a molecule, either polypeptide of the present invention or a molecule induced by polypeptide of the present invention, which has resulted in an increase in the intracellular Ca⁺⁺ concentration.

Example 38 High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

[1728] The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

[1729] Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

[1730] Because of the wide range of known factors capable of stimulating tyrosine kinase activity, identifying whether polypeptide of the present invention or a molecule induced by polypeptide of the present invention is capable of activating tyrosine kinase signal transduction pathways is of interest. Therefore, the following protocol is designed to identify such molecules capable of activating the tyrosine kinase signal transduction pathways.

[1731] Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, Ill.). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, Mo.) or 10% Matrigel purchased from Becton Dickinson (Bedford,Mass.), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as descnbed by the manufacturer Alamar Biosciences, Inc. (Sacramento, Calif.) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford,Mass.) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

[1732] To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200 ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60 ng/ml) or 50 ul of the supernatant produced in Example 30, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Tn ton X-100, 0.1% SDS, 2 mM Na3VO4, 2 mM Na4P2O7 and a cocktail of protease inhibitors (# 1836170) obtained from Boeheringer Mannheim (Indianapolis, Ind.)) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4° C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degree C. at 16,000× g.

[1733] Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

[1734] Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

[1735] The tyrosine kinase reaction is set up by adding the following components in order. First, add 10 ul of 5uM Biotinylated Peptide, then 10 ul ATP/Mg₂+(5mM ATP/50 mM MgCl₂), then 10 ul of 5× Assay Buffer (40 mM imidazole hydrochloride, pH 7.3, 40 mM beta-glycerophosphate, 1 mM EGTA, 100 mM MnCl₂, 5 mM MnCl₂, 0.5 mg/ml BSA), then 5 ul of Sodium Vanadate(1 mM), and then 5 ul of water. Mix the components gently and preincubate the reaction mix at 30 degree C. for 2 min. Initial the reaction by adding 10 ul of the control enzyme or the filtered supernatant.

[1736] The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120 mm EDTA and place the reactions on ice.

[1737] Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degree C. for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300 ul/well of PBS four times. Next add 75 ul of anti-phospotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degree C. for one hour. Wash the well as above.

[1738] Next add 100 ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 39 High-Throughput Screening Assay Identifying Phosphorylation Activity

[1739] As a potential alternative and/or complement to the assay of protein tyrosine kinase activity described in Example 38, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p³⁸ MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

[1740] Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1 ml of protein G (1 ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100 ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degree C. until use.

[1741] A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6 ng/well) or 50 ul of the supernatants obtained in Example 30 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

[1742] After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10 ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1 ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europiurn-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation by polypeptide of the present invention or a molecule induced by polypeptide of the present invention.

Example 40 Assay for the Stimulation of Bone Marrow CD34+ Cell Proliferation

[1743] This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

[1744] It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a “survival” factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to in vitro stimulation with SCF+IL+3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

[1745] Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500 ml) Quality Biological, Inc., Gaithersburg, Md. Cat# 160-204-101). After several gentle centrifugation steps at 200× g, cells are allowed to rest for one hour. The cell count is adjusted to 2.5×10⁵ cells/ml. During this time, 100 μl of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, Minn., Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, Minn., Cat# 203-ML) at 30 ng/ml. After one hour, 10 μl of prepared cytokines, 50 μl of the supernatants prepared in Example 30 (supernatants at 1:2 dilution=50 μl) and 20 μl of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100 μl. The plates are then placed in a 37° C./5% CO₂ incubator for five days.

[1746] Eighteen hours before the assay is harvested, 0.5 μCi/well of [3H] Thymidine is added in a 10 μl volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60 μl Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film A bar code 15 sticker is affixed to the first plate for counting. The sealed plates are then loaded and the level of radioactivity determined via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

[1747] The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytolines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

[1748] The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the “Immune Activity” and “Infectious Disease” sections above, and elsewhere herein.

Example 41 Assay for Extracellular Matrix Enhanced Cell Response (EMECR)

[1749] The objective of the Extracellular Matrix Enhanced Cell Response (EMECR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoictic stem cells in the context of the extracellular matrix (ECM) induced signal.

[1750] Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM. Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in in vitro suspension culture. The ability of stem cells to undergo self-renewal in vitro is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the α₅.β₁ and α₄.β₁ integrin receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and are responsible for stimulating stem cell self-renewal havea not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

[1751] Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with fn fragment at a coating concentration of 0.2 μg/cm². Mouse bone marrow cells are plated (1,000 cells/well) in 0.2 ml of serum-free medium. Cells cultured in the presence of IL-3 (5 ng/ml)+SCF (50 ng/ml) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem cells is to be expected. Gene products of the invention (e.g., including, but not limited to, polynucleotides and polypeptides of the present invention, and supernatants produced in Example 30), are tested with appropriate negative controls in the presence and absence of SCF(5.0 ng/ml), where test factor supernatants represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment (5% CO₂, 7% O₂, and 88% N₂) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA. Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACScan.

[1752] One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

[1753] If a particular polypeptide of the present invention is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene encoding said polypeptide may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the “Immune Activity” and “Infectious Disease” sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

[1754] Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

[1755] Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

Example 42 Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation

[1756] The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNFa stimulation, in order to check for costimulatory or inhibitory activity.

[1757] Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100 μl culture media. NHDF culture media contains: Clonetics FB basal media, 1 mg/ml hFGF, 5 mg/ml insulin, 50 mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5 μg/ml hEGF, 5 mg/ml insulin, 1 μg/ml hFGF, 50 mg/ml gentamycin, 50 μg/ml Amphotericin B, 5%FBS. After incubation at 37° C. for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50 mg/ml gentamycin, 2% FBS, while growth arrest media for AoSMC contains SM basal media, 50 mg/ml gentamycin, 50 μg/ml Amphotericin B, 0.4% FBS. Incubate at 37° C. until day 2.

[1758] On day 2, serial dilutions and templates of the polypeptide of interest are designed such that they always include media controls and known-protein controls. For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFa is added to a final concentration of 2 ng/ml (NHDF) or 5 ng/ml (AoSMC). Add 1/3 vol media containing controls or polypeptides of the present invention and incubate at 37 degrees C./5% CO₂ until day 5.

[1759] Transfer 60 μl from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4 degrees C. until Day 6 (for L6 ELISA). To the remaining 100 μl in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10 μl). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530 nm and emission at 590 nm using the CytoFluor. This yields the growth stimulation/inhibition data.

[1760] On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100 ul/well of Anti-Human L6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

[1761] On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 μl/well of Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 μl/well of diluted Anti-Human L-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of L-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

[1762] Plates are washed with wash buffer and blotted on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100 μl/well. Cover the plate and incubate 1 h at RT. Plates are again washed with wash buffer and blotted on paper towels.

[1763] Add 100 μI/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay were tabulated and averaged.

[1764] A positive result in this assay suggests AoSMC cell proliferation and that the polypeptide of the present invention may be involved in dermal fibroblast proliferation and/or smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the polynucleotide/polypeptide of the present invention which gives a positive result. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the present invention and polynucleotides of the present invention may be used in wound healing and dermal regeneration, as well as the promotion of vasculogenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides and polynucleotides of the invention may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular agent (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; artheroscleric plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uvietis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides and polynucleotides of the invention may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

[1765] One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

Example 43 Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells

[1766] The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

[1767] Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100 μl of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 μl volumes). Plates are then incubated at 37° C. for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100 μl of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4° C. for 30 min. Fixative is removed from the wells and wells are washed 1× with PBS(+Ca,Mg)+0.5% BSA and drained. 10 μl of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10 μg/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37° C. for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. 20 μl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37° C. for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100 μl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphotase in glycine buffer: 1:5,000 (10⁰)>10⁻⁰ ⁵>10⁻¹>10⁻¹ ⁵. 5 μl of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 μl of pNNP reagent is then added to each of the standard wells. The plate is incubated at 37° C. for 4 h. A volume of 50 μl of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

Example 44 Alamar Blue Endothelial Cells Proliferation Assay

[1768] This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay is prepared in EGM-2MV with 10 ng/ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

[1769] Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37 degreesC. overnight. After the overnight incubation of the cells, the growth media is removed and replaced with GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM) in triplicate wells with additional bFGF to a concentration of 10 ng/ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 370 C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37° C. incubator for four hours. The plate(s) are then read at 530 nm excitation and 590 nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

[1770] Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form (i.e., stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity). The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

Example 45 Detection of Inhibition of a Mixed Lymphocyte Reaction

[1771] This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

[1772] Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

[1773] Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM®, density 1.0770 g/ml, Organon Teknika Corporation, West Chester, Pa.). PBMCs from two donors are adjusted to 2×10⁶ cells/ml in RPMI-1640 (Life Technologies, Grand Island, N.Y.) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is adjusted to 2×10⁵ cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50 μl) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, Minn., catalog number 202-IL) is added to a final concentration of 1 μg/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10 μg/ml. Cells are cultured for 7-8 days at 37° C. in 5% CO₂, and 1 μC of [³H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

[1774] Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

[1775] One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

Example 46 Assays for Protease Activity

[1776] The following assay may be used to assess protease activity of the polypeptides of the invention.

[1777] Gelatin and casein zymography are performed essentially as described (Heusen et al., Anal. Biochem., 102:196-202 (1980); Wilson et al., Journal of Urology, 149:653-658 (1993)). Samples are run on 10% polyacryamide/0.1% SDS gels containing 1% gelain orcasein, soaked in 2.5% triton at room temperature for 1 hour, and in 0.1M glycine, pH 8.3 at 37° C. 5 to 16 hours. After staining in amido black areas of proteolysis apear as clear areas agains the blue-black background. Trypsin (Sigma T8642) is used as a positive control.

[1778] Protease activity is also determined by monitoring the cleavage of n-a-benzoyl-L-arginine ethyl ester (BAEE) (Sigma B-4500. Reactions are set up in (25mMNaPO₄, 1M EDTA, and 1 mM BAEE), pH 7.5. Samples are added and the change in adsorbance at 260 nm is monitored on the Beckman DU-6 spectrophotometer in the time-drive mode. Trypsin is used as a positive control.

[1779] Additional assays based upon the release of acid-soluble peptides from casein or hemoglobin measured as adsorbance at 280 nm or calorimetrically using the Folin method are performed as described in Bergmeyer, et al., Methods of Enzymatic Analysis, 5 (1984). Other assays involve the solubilization of chromogenic substrates (Ward, Applied Science, 251-317 (1983)).

Example 47 Identifying Serine Protease Substrate Specificity

[1780] Methods known in the art or described herein may be used to determine the substrate specificity of the polypeptides of the present invention having serine protease activity. A preferred method of determining substrate specificity is by the use of positional scanning synthetic combinatorial libraries as described in GB 2 324 529 (incorporated herein in its entirety).

Example 48 Ligand Binding Assays

[1781] The following assay may be used to assess ligand binding activity of the polypeptides of the invention.

[1782] Ligand binding assays provide a direct method for ascertaining receptor pharmacology and are adaptable to a high throughput format. The purified ligand for a polypeptide is radiolabeled to high specific activity (50-2000 Ci/mmol) for binding studies. A determination is then made that the process of radiolabeling does not diminish the activity of the ligand towards its polypeptide. Assay conditions for buffers, ions, pH and other modulators such as nucleotides are optimized to establish a workable signal to noise ratio for both membrane and whole cell polypeptide sources. For these assays, specific polypeptide binding is defined as total associated radioactivity minus the radioactivity measured in the presence of an excess of unlabeled competing ligand. Where possible, more than one competing ligand is used to define residual nonspecific binding.

Example 49 Functional Assay in Xenopus Oocytes

[1783] Capped RNA transcripts from linearized plasmid templates encoding the polypeptides of the invention are synthesized in vitro with RNA polymerases in accordance with standard procedures. In vitro transcripts are suspended in water at a final concentration of 0.2 mg/ml. Ovarian lobes are removed from adult female toads, Stage V defolliculated oocytes are obtained, and RNA transcripts (10 ng/oocytc) are injected in a 50 nl bolus using a microinjection apparatus. Two electrode voltage clamps are used to measure the currents from individual Xenopus oocytes in response polypeptides and polypeptide agonist exposure. Recordings are made in Ca2+ free Barth's medium at room temperature. The Xenopus system can be used to screen known ligands and tissue/cell extracts for activating ligands.

Example 50 Microphysiometric Assays

[1784] Activation of a wide variety of secondary messenger systems results in extrusion of small amounts of acid from a cell. The acid formed is largely as a result of the increased metabolic activity required to fuel the intracellular signaling process. The pH changes in the media surrounding the cell are very small but are detectable by the CYTOSENSOR microphysiometer (Molecular Devices Ltd., Menlo Park, Calif.). The CYTOSENSOR is thus capable of detecting the activation of polypeptide which is coupled to an energy utilizing intracellular signaling pathway.

Example 51 Extract/Cell Supernatant Screening

[1785] A large number of mammalian receptors exist for which there remains, as yet, no cognate activating ligand (agonist). Thus, active ligands for these receptors may not be included within the ligands banks as identified to date. Accordingly, the polypeptides of the invention can also be functionally screened (using calcium, cAMP, microphysiometer, oocyte electrophysiology, etc., functional screens) against tissue extracts to identify its natural ligands. Extracts that produce positive functional responses can be sequentially subfractionated until an activating ligand is isolated and identified.

Example 52 Calcium and cAMP Functional Assays

[1786] Seven transmembrane receptors which are expressed in HEK 293 cells have been shown to be coupled functionally to activation of PLC and calcium mobilization and/or cAMP stimulation or inhibition. Basal calcium levels in the HEK 293 cells in receptor-transfected or vector control cells were observed to be in the normal, 100 nM to 200 nM, range. HEK 293 cells expressing recombinant receptors are loaded with fura 2 and in a single day>150 selected ligands or tissue/cell extracts are evaluated for agonist induced calcium mobilization. Similarly, HEK 293 cells expressing recombinant receptors are evaluated for the stimulation or inhibition of cAMP production using standard cAMP quantitation assays. Agonists presenting a calcium transient or cAMP fluctuation are tested in vector control cells to determine if the response is unique to the transfected cells expressing receptor.

Example 53 ATP-Binding Assay

[1787] The following assay may be used to assess ATP-binding activity of polypeptides of the invention.

[1788] ATP-binding activity of the polypeptides of the invention may be detected using the ATP-binding assay described in U.S. Pat. No. 5,858,719, which is herein incorporated by reference in its entirety. Briefly, ATP-binding to polypeptides of the invention is measured via photoaffinity labeling with 8-azido-ATP in a competition assay. Reaction mixtures containing 1 mg/ml of the ABC transport protein of the present invention are incubated with varying concentrations of ATP, or the non-hydrolyzable ATP analog adenyl-5′-imidodiphosphate for 10 minutes at 4° C. A mixture of 8-azido-ATP (Sigma Chem. Corp., St. Louis, Mo.) plus 8-azido-ATP (³²P-ATP) (5 mCi/μmol, ICN, Irvine Calif.) is added to a final concentration of 100 μM and 0.5 ml aliquots are placed in the wells of a porcelain spot plate on ice. The plate is irradiated using a short wave 254 nm UV lamp at a distance of 2.5 cm from the plate for two one-minute intervals with a one-minute cooling interval in between. The reaction is stopped by addition of dithiothreitol to a final concentration of 2 mM. The incubations are subjected to SDS-PAGE electrophoresis, dried, and autoradiographed. Protein bands corresponding to the particular polypeptides of the invention are excised, and the radioactivity quantified. A decrease in radioactivity with increasing ATP or adenly-5′-imidodiphosphate provides a measure of ATP affinity to the polypeptides.

Example 54 Small Molecule Screening

[1789] This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and polypeptide of the invention.

[1790] Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the invention. These methods comprise contacting such an agent with a polypeptide of the invention or fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the invention.

[1791] Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the invention, and is described in great detail in European Patent Application 84/03564, published on Sep. 13, 1984, which is herein incorporated by reference in its entirety. Briefly stated, large numbers of different small molecule test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with polypeptides of the invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

[1792] This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Example 55 Phosphorylation Assay

[1793] In order to assay for phosphorylation activity of the polypeptides of the invention, a phosphorylation assay as described in U.S. Pat. No. 5,958,405 (which is herein incorporated by reference) is utilized. Briefly, phosphorylation activity may be measured by phosphorylation of a protein substrate using gamma-labeled ³²P-ATP and quantitation of the incorporated radioactivity using a gamma radioisotope counter. The polypeptides of the invention are incubated with the protein substrate, ³²P-ATP, and a kinase buffer. The p incorporated into the substrate is then separated from free ³²P-ATP by electrophoresis, and the incorporated ³²P is counted and compared to a negative control. Radioactivity counts above the negative control are indicative of phosphorylation activity of the polypeptides of the invention.

Example 56 Detection of Phosphorylation Activity (Activation) of the Polypeptides of the Invention in the Presence of Polypeptide Ligands

[1794] Methods known in the art or described herein may be used to determine the phosphorylation activity of the polypeptides of the invention. A preferred method of determining phosphorylation activity is by the use of the tyrosine phosphorylation assay as described in U.S. Pat. No. 5,817,471 (incorporated herein by reference).

Example 57 Identification of Signal Transduction Proteins that Interact with Polypeptides of the Present Invention

[1795] The purified polypeptides of the invention are research tools for the identification, characterization and purification of additional signal transduction pathway proteins or receptor proteins. Briefly, labeled polypeptides of the invention are useful as reagents for the purification of molecules with which it interacts. In one embodiment of affinity purification, polypeptides of the invention are covalently coupled to a chromatography column. Cell-free extract derived from putative target cells, such as carcinoma tissues, is passed over the column, and molecules with appropriate affinity bind to the polypeptides of the invention. The protein complex is recovered from the column, dissociated, and the recovered molecule subjected to N-terminal protein sequencing. This amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

Example 58 IL-6 Bioassay

[1796] To test the proliferative effects of the polypeptides of the invention, the IL-6 Bioassay as described by Marz et al. is utilized (Proc. Natl. Acad. Sci., U.S.A., 95:3251-56 (1998), which is herein incorporated by reference). Briefly, IL-6 dependent B9 murine cells are washed three times in IL-6 free medium and plated at a concentration of 5,000 cells per well in 50 μl, and 50 μl of the L-6-like polypeptide is added. After 68 hrs. at 37° C., the number of viable cells is measured by adding the tetrazolium salt thiazolyl blue (MTT) and incubating for a further 4 hrs. at 37° C. B9 cells are lysed by SDS and optical density is measured at 570 nm. Controls containing IL-6 (positive) and no cytokine (negative) are utilized. Enhanced proliferation in the test sample(s) relative to the negative control is indicative of proliferative effects mediated by polypeptides of the invention.

Example 59 Support of Chicken Embryo Neuron Survival

[1797] To test whether sympathetic neuronal cell viability is supported by polypeptides of the invention, the chicken embryo neuronal survival assay of Senaldi et al is utilized (Proc. Natl. Acad. Sci., U.S.A., 96:11458-63 (1998), which is herein incorporated by reference). Briefly, motor and sympathetic neurons are isolated from chicken embryos, resuspended in L15 medium (with 10% FCS, glucose, sodium selenite, progesterone, conalbumin, putrescine, and insulin; Life Technologies, Rockville, Md.) and Dulbecco's modified Eagles medium [with 10% FCS, glutamine, penicillin, and 25 mM Hepes buffer (pH 7.2); Life Technologies, Rockville, Md.], respectively, and incubated at 37° C. in 5% CO₂ in the presence of different concentrations of the purified IL-6-like polypeptide, as well as a negative control lacking any cytokine. After 3 days, neuron survival is determined by evaluation of cellular morphology, and through the use of the calorimetric assay of Mosmann (Mosmann, T., J. Immunol. Methods, 65:55-63 (1983)). Enhanced neuronal cell viability as compared to the controls lacking cytokine is indicative of the ability of the inventive purified IL-6-like polypeptide(s) to enhance the survival of neuronal cells.

Example 60 Assay for Phosphatase Activity

[1798] The following assay may be used to assess serine/threonine phosphatase (PTPase) activity of the polypeptides of the invention.

[1799] In order to assay for serine/threonine phosphatase (PTPase) activity, assays can be utilized which are widely known to those skilled in the art. For example, the serine/threonine phosphatase (PSPase) activity is measured using a PSPase assay kit from New England Biolabs, Inc. Myelin basic protein (MyBP), a substrate for PSPase, is phosphorylated on serine and threonine residues with cAMP-dependent Protein Kinase in the presence of [³²P]ATP. Protein serine/threonine phosphatase activity is then determined by measuring the release of inorganic phosphate from ³²P-labeled MyBP.

Example 61 Interaction of Serine/Threonine Phosphatases with Other Proteins

[1800] The polypeptides of the invention with serine/threonine phosphatase activity as determined in Example 60 are research tools for the identification, characterization and purification of additional interacting proteins or receptor proteins, or other signal transduction pathway proteins. Briefly, labeled polypeptide(s) of the invention is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, polypeptide of the invention is covalently coupled to a chromatography column. Cell-free extract derived from putative target cells, such as neural or liver cells, is passed over the column, and molecules with appropriate affinity bind to the polypeptides of the invention. The polypeptides of the invention complex is recovered from the column, dissociated, and the recovered molecule subjected to N-terminal protein sequencing. This amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

Example 62 Assaying for Heparanase Activity

[1801] In order to assay for heparanase activity of the potypeptides of the invention, the heparanase assay described by Vlodavsky et al is utilized (Vlodavsky, I., et al., Nat. Med., 5:793-802 (t999)). Briefly, cell lysates, conditioned media or intact cells (1×10⁶ cells per 35-mm dish) are incubated for 18 hrs at 37° C., pH 6.2-6.6, with ³⁵S-labeled ECM or soluble ECM derived peak I proteoglycans. The incubation medium is centrifuged and the supernatant is analyzed by gel filtration on a Sepharose CL-6B column (0.9×30 cm). Fractions are eluted with PBS and their radioactivity is measured. Degradation fragments of heparan sulfate side chains are eluted from Sepharose 6B at 0.5<Kav<0.8 (peak II). Each experiment is done at least three times. Degradation fragments corresponding to “peak II,” as described by Vlodavsky et al., is indicative of the activity of the polypeptides of the invention in cleaving heparan sulfate.

Example 63 Immobilization of Biomolecules

[1802] This example provides a method for the stabilization of polypeptides of the invention in non-host cell lipid bilayer constucts (see, e.g., Bien et al., Nature Biotech 17:1105-1108 (1999), hereby incorporated by reference in its entirety herein) which can be adapted for the study of polypeptides of the invention in the various functional assays described above. Briefly, carbohydrate-specific chemistry for biotinylation is used to confine a biotin tag to the extracellular domain of the polypeptides of the invention, thus allowing uniform orientation upon immobilization. A 50uM solution of polypeptides of the invention in washed membranes is incubated with 20 mM NaIO4 and 1.5 mg/ml (4 mM) BACH or 2 mg/ml (7.5 mM) biotin-hydrazide for 1 hr at room temperature (reaction volume, 150 ul). Then the sample is dialyzed (Pierce Slidealizer Cassett, 10 kDa cutoff; Pierce Chemical Co., Rockford Ill.) at 4C first for 5 h, exchanging the buffer after each hour, and finally for 12 h against 500 ml buffer R (0.15 M NaCl, 1 mM MgCl2, 10 mM sodium phosphate, pH 7). Just before addition into a cuvette, the sample is diluted 1:5 in buffer ROG50 (Buffer R supplemented with 50 mM octylglucoside).

Example 64 TAQMAN

[1803] Quantitative PCR (QPCR). Total RNA from cells in culture are extracted by Trizol separation as recommended by the supplier (LifeTechnologies). (Total RNA is treated with DNase I (Life Technologies) to remove any contaminating genomic DNA before reverse transcription.) Total RNA (50 ng) is used in a one-step, 50 ul, RT-QPCR, consisting of Taqman Buffer A (Perkin-Elmer; 50 mM KCl/10 mM Tris, pH 8.3), 5.5 mM MgCl₂, 240 μM each dNTP, 0.4 units RNase inhibitor(Promega), 8%glycerol, 0.012% Tween-20, 0.05% gelatin, 0.3uM primers, 0.1uM probe, 0.025units Amplitaq Gold (Perkin-Elmer) and 2.5 units Superscript II reverse transcriptase (Life Technologies). As a control for genomic contamination, parallel reactions are setup without reverse transcriptase. The relative abundance of (unknown) and 18S RNAs are assessed by using the Applied Biosystems Prism 7700 Sequence Detection System (Livak, K. J., Flood, S. J., Marmaro, J., Giusti, W. & Deetz, K. (1995) PCR Methods Appl. 4, 357-362). Reactions are carried out at 48° C. for 30 min, 95° C. for 10 min, followed by 40 cycles of 95° C. for 15s, 60° C. for 1 min. Reactions are performed in triplicate.

[1804] Primers (f & r) and FRET probes sets are designed using Primer Express Software (Perkin-Elmer). Probes are labeled at the 5′-end with the reporter dye 6-FAM and on the 3′-end with the quencher dye TAMRA (Biosource International, Camarillo, Calif. or Perkin-Elmer).

Example 65 Assays for Metalloproteinase Activity

[1805] Metalloproteinases (EC 3.4.24.-) are peptide hydrolases which use metal ions, such as Zn²⁺, as the catalytic mechanism. Metalloproteinase activity of polypeptides of the present invention can be assayed according to the following methods.

[1806] Proteolysis of Alpha-2-Macroglobulin

[1807] To confirm protease activity, purified polypeptides of the invention are mixed with the substrate alpha-2-macroglobulin (0.2 unit/ml; Boehringer Mannheim, Germany) in 1× assay buffer (50 mM HEPES, pH 7.5, 0.2 M NaCl, 10 mM CaCl₂, 25 μM ZnCl₂ and 0.05% Brij-35) and incubated at 37° C. for 1-5 days. Trypsin is used as positive control. Negative controls contain only alpha-2-macroglobulin in assay buffer. The samples are collected and boiled in SDS-PAGE sample buffer containing 5% 2-mercaptoethanol for 5-min, then loaded onto 8% SDS-polyacrylamide gel. After electrophoresis the proteins are visualized by silver staining. Proteolysis is evident by the appearance of lower molecular weight bands as compared to the negative control.

[1808] Inhibition of Alpha-2-Macroglobulin Proteolysis by Inhibitors of Metalloproteinases

[1809] Known metalloproteinase inhibitors (metal chelators (EDTA, EGTA, AND HgCl₂), peptide metalloproteinase inhibitors (TIMP-1 and TIMP-2), and commercial small molecule MMP inhibitors) are used to characterize the proteolytic activity of polypeptides of the invention. The three synthetic MMP inhibitors used are: MMP inhibitor I, [IC₅₀=1.0 μM against MMP-1 and MMP-8; IC₅₀=30 μM against MMP-9; IC₅₀=150 μM against MMP-3]; MMP-3 (stromelysin-1) inhibitor I [IC₅₀=5 μM against MMP-3], and MMP-3 inhibitor II [K_(i)=130 nM against MMP-3]; inhibitors available through Calbiochem, catalog # 444250, 444218, and 444225, respectively). Briefly, different concentrations of the small molecule MMP inhibitors are mixed with purified polypeptides of the invention (50 μg/ml) in 22.9 μl of 1× HEPES buffer (50 mM HEPES, pH 7.5, 0.2 M NaCl, 10 mM CaCl₂, 25 μM ZnCl₂ and 0.05%Brij-35) and incubated at room temperature (24° C.) for 2-hr, then 7.1 μl of substrate alpha-2-macroglobulin (0.2 unit/ml) is added and incubated at 37° C. for 20-hr. The reactions are stopped by adding 4× sample buffer and boiled immediately for 5 minutes. After SDS-PAGE, the protein bands are visualized by silver stain.

[1810] Synthetic Fluorogenic Peptide Substrates Cleavage Assay

[1811] The substrate specificity for polypeptides of the invention with demonstrated metalloproteinase activity can be determined using synthetic fluorogenic peptide substrates (purchased from BACHEM Bioscience Inc). Test substrates include, M-1985, M-2225, M-2105, M-2110, and M-2255. The first four are MMP substrates and the last one is a substrate of tumor necrosis factor-α (TNF-α) converting enzyme (TACE). All the substrates are prepared in 1:1 dimethyl sulfoxide (DMSO) and water. The stock solutions are 50-500 μM. Fluorescent assays are performed by using a Perkin Elmer LS 50B luminescence spectrometer equipped with a constant temperature water bath. The excitation λ is 328 nm and the emission X is 393 nm. Briefly, the assay is carried out by incubating 176 μl 1× HEPES buffer (0.2 M NaCl, 10 mM CaCl₂, 0.05% Brij-35 and 50 mM HEPES, pH 7.5) with 4 μl of substrate solution (50 μM) at 25° C. for 15 minutes, and then adding 20 μl of a purified polypeptide of the invention into the assay cuvett. The final concentration of substrate is 1 μM. Initial hydrolysis rates are monitored for 30-min.

Example 66 Characterization of the cDNA Contained in a Deposited Plasmid

[1812] The size of the cDNA insert contained in a deposited plasmid may be routinely determined using techniques known in the art, such as PCR amplification using synthetic primers hybridizable to the 3′ and 5′ ends of the cDNA sequence. For example, two primers of 17-30 nucleotides derived from each end of the cDNA (i.e., hybridizable to the absolute 5′ nucleotide or the 3′ nucleotide end of the sequence of SEQ ID NO:X, respectively) are synthesized and used to amplify the cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 ul of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl₂, 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C. for 1 min; annealing at 55 degree C. for 1 min; elongation at 72 degree C. for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product. It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims. TABLE 8 Res Position I II III IV V VI VII VIII IX X XI XII XIII XIV Met 1 A A . . . . . −0.68 0.09 . . . −0.30 0.62 Lys 2 A A . . . . . −1.10 0.23 . . . −0.30 0.26 Ala 3 A A . . . . . −1.52 0.49 * . . −0.60 0.17 Leu 4 A A . . . . . −1.94 0.74 . . . −0.60 0.14 Cys 5 A A . . . . . −2.37 0.81 . . −0.60 0.06 Leu 6 A A . . . . . −1.98 1.50 * . . −0.60 0.05 Leu 7 . A B . . . . −2.88 1.43 * . . −0.60 0.09 Leu 8 . A B . . . . −3.10 1.39 . . . −0.60 0.12 Leu 9 . A B . . . . −2.63 1.50 . −0.60 0.12 Pro 10 . A B . . . . −2.78 1.24 . . . −0.60 0.15 Val 11 . A B . . . . −2.78 1.24 . . . −0.60 0.15 Leu 12 . A B . . . . −2.82 1.24 . . . −0.60 0.15 Gly 13 . A B . . . . −2.31 1.20 * . . −0.60 0.07 Leu 14 . A B . . . . −1.80 1.16 . . . −0.60 0.13 Leu 15 . A B . . . . −1.54 0.90 . . . −0.60 0.21 Val 16 . . B . . T . −1.00 0.21 . . . 0.10 0.42 Ser 17 . . B . . T . −1.00 0.27 . . F 0.25 0.73 Ser 18 A . . . T . −1.32 0.27 . . F 0.25 0.73 Lys 19 A . . . T −0.81 0.16 F 0.25 0.53 Thr 20 A . B . . . −0.60 −0.10 . . F 0.45 0.53 Leu 21 A . . B . . . 0.26 0.13 * . . −0.30 0.39 Cys 22 A . B . . . 0.56 −0.26 * . . 0.30 0.34 Ser 23 A . . B . . . 0.27 −0.26 * . . 0.30 0.40 Met 24 A A . . . . . −0.67 −0.24 * . . 0.30 0.49 Glu 25 A A . . . . −0.36 −0.24 * . 0.30 0.65 Glu 26 A A . . . . 0.46 −0.41 * * . 0.30 0.77 Ala 27 A A . . . . . 1.23 −0.80 * * . 0.75 1.36 Ile 28 A A . . . . . 0.64 −1.41 * * . 0.75 1.53 Asn 29 A A . . . . 1.24 −0.73 * * 0.60 0.62 Glu 30 A A . . . . 1.24 −0.33 * * F 0.60 1.06 Arg 31 A A . . . . 0.39 −0.83 * * F 0.90 2.63 Ile 32 A A . . . . . 0.39 −0.87 * * F 0.90 1.21 Gln 33 A A . . . . . 0.93 −0.77 * * F 0.75 0.71 Glu 34 A A . . . . . 0.63 −0.34 * * . 0.30 0.36 Val 35 A A . . . . . −0.18 0.04 * . . −0.30 0.68 Ala 36 A A . . . . −1.18 0.04 * * . −0.30 0.33 Gly 37 A A B . . . −0.99 0.33 * * . −0.30 0.13 Ser 38 A A . B . . . −0.88 1.11 * * . −0.60 0.15 Leu 39 A A B . . . −1.47 0.47 * * . −0.60 0.30 Ile 40 . A B B . . . −1.50 0.47 * * . −0.60 0.30 Phe 41 . A B B . . −1.21 0.73 * . −0.60 0.16 Arg 42 . A B B . . . −1.17 0.73 * * . −0.60 0.26 Ala 43 . A B B . . . −1.76 0.43 * * . −0.60 0.49 Ile 44 . A B B . . . −1.29 0.43 * * . −0.60 0.40 Ser 45 A . B . . C −1.21 0.07 * * . −0.10 0.20 Ser 46 . . B . . C −0.51 0.76 * * . −0.40 0.17 Ile 47 . . . B T . . −1.29 0.26 * * . 0.10 0.41 Gly 48 . A B . . . . −0.70 0.14 . . . −0.30 0.16 Leu 49 . A . . . . C −0.11 0.16 * . . −0.10 0.21 Glu 50 . A B . . . . −0.67 0.16 . . −0.30 0.40 Cys 51 . A B B . . . −0.68 0.11 . . . −0.30 0.30 Gln 52 . B B . . −0.09 0.17 * * . −0.30 0.53 Ser 53 . . B B . . . 0.37 −0.13 * * F 0.45 0.41 Val 54 . . B B . . . 0.83 −0.13 . * F 0.91 1.50 Thr 55 . . B B . . . 0.83 −0.27 . * F 1.07 0.85 Ser 56 . . . . T T . 0.69 −0.67 . * F 2.63 1.07 Arg 57 . . . . T T . 0.10 −0.37 . * F 2.64 1.18 Gly 58 . . . . T T . 0.09 −0.51 . * F 3.10 0.83 Asp 59 . . . . T T . 0.28 −0.51 . * F 2.79 0.89 Leu 60 . . B . . . . 0.38 −0.33 . * F 1.58 0.24 Ala 61 . . B . . . . 0.79 0.10 * * . 0.52 0.38 Thr 62 . . B . . . . 0.33 −0.33 * * . 0.81 0.45 Cys 63 . . B . . T . −0.02 0.10 * * . 0.10 0.54 Pro 64 . . . . T T . −0.61 0.20 * . F 0.65 0.46 Arg 65 . . . . T T . −0.66 0.20 * . F 0.65 0.32 Gly 66 . . T T . −0.38 0.36 . . 0.50 0.45 Phe 67 . . B B . . . −0.41 0.27 * . . −0.30 0.42 Ala 68 . . B B . . . −0.41 0.27 * . . −0.30 0.21 Val 69 . . B B . . . −0.51 0.84 * . . −0.60 0.11 Thr 70 . . B B . . . −1.29 0.90 * . . −0.60 0.19 Gly 71 . . B B . . . −1.29 0.69 . . . −0.60 0.10 Cys 72 . . . . T T . −0.89 0.61 . . . 0.20 0.13 Thr 73 . . . . T T . −0.89 0.36 . . . 0.50 0.12 Cys 74 . . . . T T . −0.70 0.37 . . . 0.50 0.13 Gly 75 . . . T T . −0.73 0.51 . . . 0.20 0.13 Ser 76 . . . T . . −0.69 0.37 . . . 0.30 0.09 Ala 77 . . . . T . . −0.31 0.27 . . . 0.30 0.22 Cys 78 . . . . T T . 0.00 0.61 . * . 0.20 0.23 Gly 79 . . . T T . −0.19 0.19 . * . 0.50 0.29 Ser 80 . . . . T T . 0.27 0.44 . * . 0.20 0.21 Trp 81 . B . . T . −0.02 −0.06 . * . 0.70 0.78 Asp 82 . A B B . . . 0.57 −0.13 . * . 0.30 0.79 Val 83 A A . B . . . 0.92 −0.56 . * . 0.75 1.02 Arg 84 A A . B . . . 0.96 −0.46 . * . 0.45 1.41 Ala 85 A A . . . . 0.59 −0.89 . * F 0.90 1.21 Glu 86 . A . . T . . 0.84 −0.31 . * F 0.85 0.88 Thr 87 . A . . T . . 0.18 −0.46 . * F 0.85 0.61 Thr 88 . A . . T . 1.03 0.11 . * . 0.10 0.32 Cys 89 . . . . T T . 0.26 0.01 . * . 0.50 0.32 His 90 . . . T T . 0.26 0.59 . . . 0.20 0.12 Cys 91 . . B . . T . −0.09 0.60 . . . −0.20 0.08 Gln 92 . B . . T . −0.38 0.54 . . . −0.20 0.16 Cys 93 . . . . T . . −0.07 0.59 . . . 0.00 0.11 Ala 94 . . . T . . 0.31 0.09 . . 0.30 0.35 Gly 95 . . . T T . 0.03 0.43 . . . 0.20 0.21 Met 96 . . . T T 0.36 0.51 . . 0.42 0.57 Asp 97 . . . T T . −0.23 0.37 . . . 0.94 0.56 Trp 98 . . . . T T . 0.54 0.37 . . 1.16 0.57 Thr 99 . . . . T . . 0.47 −0.06 . . . 1.93 1.14 Gly 100 . . . . T T . 0.14 −0.10 * . . 2.20 0.37 Ala 101 . . . . T T . 0.86 0.47 * . . 1.08 0.19 Arg 102 . . . T T . 0.00 −0.44 * . . 1.76 0.25 Cys 103 . . . . T T . 0.29 −0.29 * . . 1.54 0.19 Cys 104 . . . T . . 0.39 −0.31 * . 1.12 0.32 Arg 105 . . B . . . . 0.34 −0.39 * . . 0.50 0.26 Val 106 . B . . . 0.54 0.04 * . −0.10 0.61 Gln 107 . . B . . . . 0.04 −0.10 * . . 0.65 1.46 Pro 108 . . B . . . . 0.32 −0.24 . * . 0.50 0.95

[1813] Incorporation by Reference

[1814] The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. In addition, the sequence listing submitted herewith is incorporated herein by reference in its entirety. The specification and sequence listing of each of the following U.S. applications are herein incorporated by reference in their entirety: U.S. Provisional Application No. 60/262,066, filed on Jan. 18, 2001; U.S. application Ser. No. 09/722,329, filed on Nov. 28, 2000; U.S. application Ser. No. 09/262,109 filed on Mar. 4, 1999; PCT International Application PCT/US98/18360, filed on Sep. 3, 1998; U.S. Provisional Application No. 60/057,626, No. 60/057,663, and No. 60/057,669 (filed on Sep. 5, 1997); U.S. Provisional Application No. 60/058,666, No. 60/058,667, No. 60/058,973, and No. 60/058,974 (filed on Sep. 12, 1997); and, U.S. Provisional Application No. 60/090,112 (filed on Jun. 22, 1998).

1 206 1 733 DNA Homo sapiens 1 gggatccgga gcccaaatct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg 60 aattcgaggg tgcaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga 120 tctcccggac tcctgaggtc acatgcgtgg tggtggacgt aagccacgaa gaccctgagg 180 tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240 aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact 300 ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg 360 agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc 420 catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct 480 atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga 540 ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag ctcaccgtgg 600 acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc 660 acaaccacta cacgcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720 gactctagag gat 733 2 5 PRT Homo sapiens Site (3) Xaa equals any amino acid 2 Trp Ser Xaa Trp Ser 1 5 3 86 DNA Artificial Sequence Primer_Bind Synthetic sequence with 4 tandem copies of the GAS binding site found in the IRF1 promoter (Rothman et al., Immunity 1457-468 (1994)), 18 nucleotides complementary to the SV40 early promoter, and a Xho I restriction site. 3 gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60 cccgaaatat ctgccatctc aattag 86 4 27 DNA Artificial Sequence Primer_Bind Synthetic sequence complementary to the SV40 promter; includes a Hind III restriction site. 4 gcggcaagct ttttgcaaag cctaggc 27 5 271 DNA Artificial Sequence Protein_Bind Synthetic promoter for use in biological assays; includes GAS binding sites found in the IRF1 promoter (Rothman et al., Immunity 1457-468 (1994)). 5 ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60 aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc 120 gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180 ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240 ttttggaggc ctaggctttt gcaaaaagct t 271 6 32 DNA Artificial Sequence Primer_Bind Synthetic primer complementary to human genomic EGR-1 promoter sequence (Sakamoto et al., Oncogene 6867-871 (1991)); includes a Xho I restriction site. 6 gcgctcgagg gatgacagcg atagaacccc gg 32 7 31 DNA Artificial Sequence Primer_Bind Synthetic primer complementary to human genomic EGR-1 promoter sequence (Sakamoto et al., Oncogene 6867-871 (1991)); includes a Hind III restriction site. 7 gcgaagcttc gcgactcccc ggatccgcct c 31 8 12 DNA Homo sapiens 8 ggggactttc cc 12 9 73 DNA Artificial Sequence Primer_Bind Synthetic primer with 4 tandem copies of the NF-KB binding site (GGGGACTTTCCC), 18 nucleotides complementary to the 5′ end of the SV40 early promoter sequence, and a XhoI restriction site. 9 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60 ccatctcaat tag 73 10 256 DNA Artificial Sequence Protein_Bind Synthetic promoter for use in biological assays; includes NF-KB binding sites. 10 ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60 caattagtca gcaaccatag tcccgcccct aactccgccc atcccgcccc taactccgcc 120 cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240 cttttgcaaa aagctt 256 11 1110 DNA Homo sapiens 11 gaattcggca cgagcttggt tcggggggga gcaaaatcca gaatctgcta aacaccaatg 60 ctgtcactca gagtttgtgt atctgctgtc tgtggagctc tggaccaggc ttgagggacg 120 cctggggttt ccacccacat ctggggcaaa ccagaccccc aagtcactga catgtcggtt 180 tttctactaa tcacgttggc tttggcaatt ctgtatataa taagaagtat tgtgttctca 240 cttgcacttk ggcagaacgg ttcactccaa ggctgaatga ctgccacgga ccatccccca 300 gcaggggtcc tggggtttag tggtttgatt ctgagcacct ctamgcamag agccccttag 360 tgggttccct aactggacgg ctaaccctgs tgtggaatct gactkkwtct ggaccgaaga 420 ggacaggctg ctctggagaa atccttgggc cttgtgcctg atgctggctc gggccaccct 480 ggccaccctc ccttcatgcc ccatgggacc aggcagcagc atgggagggg gcagcttcca 540 gaacaccctt ctgctagggg ctkctggcct ccctgctggc acggccacat ccatggtctg 600 agtgtgtggt tggaatgttt tatcaacacc agtcctcaca gcttccccag atgagcgaag 660 gggaagggga tggtgtgtgg ggggattgcc tcccttgagg ccccccagct cccaggatac 720 ttgctggcgg agctctgcct gcggtggagg ccctatgact tgacctccat cttctccctg 780 ggcccctcgc tggccctcac tggcaggggc tcctgcacgc ctgcaaggcc agagcctccc 840 gccaggtgca ggagaagtaa atgcaggcca gagataaatc gtatttccct ctaactcgga 900 tgtggagtga gaggaaggaa gcaggagtgg agctgagtgt tagtgagagg tggctgagaa 960 ggcggggtcc cgcttcttgc ttccttgggc atttgctgta ggtgctgggt ttcagcctgg 1020 aagggtgcag cctctgcact aagtctggtt tggtgaacgt tcatggcccc caatataaac 1080 agtgttctgg gcgttctttg tgactctcga 1110 12 936 DNA Homo sapiens misc_feature (294)..(294) n equals a,t,g, or c 12 gaattcggca cgaggaattt aagataccga agtcttaaag tgacctggac gtgaaggaaa 60 aagtaagatg agaaataaag aaagcctttg taaggtggtt ttaaaagcct tatatgcaaa 120 ccttttaatc tgtgtttctg caagtgccat ccttgtacag tgttaagagg gtaacatggg 180 ttacctttgc accagcttca gtgttaagct caccctgttc tttgaagcac ccatgtcagt 240 attagaagaa taggcagcag ttccttagtt tacatatgtt tgkgcaatta tttnctgnac 300 ttttttgttc attaatttgt cagtattaca ccaaactgtt tttgcaacaa aaaaattttt 360 tttgcattca tttaatttta ggtcaaataa cattttattt atgtggctca ttttatattt 420 cctaatttta tttatttcat actgtagtgt acagtattat agttcttcaa tatatagata 480 tattttagta aaaaaggaac atgacgttga tcatttgggc aaattttacg taaagagaag 540 agcatttatt gtgttttgga acattaattg tgagatggga tttttcaatt ttattatttt 600 atttttgttt ttttccaatt actggaaatt ccaaatttgg gaacttttga tacgatcttg 660 tgaaaacact gtattttcga ctgaaaattc cactttcttc atcttgtttt ttagctaaaa 720 agagggactg ttaaatacaa tgtatgatac catgacaaaa atctttcctg aattgtcttt 780 gtaaaagtat tattgaattt tcaatttgta atttcttttg aaaatgacca tgctcgaata 840 aaaatgtagc caaactaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 900 aaaaaaaaaa aaaaaaaaaa aaaanaaaaa aaaaaa 936 13 921 DNA Homo sapiens 13 ggcacgaggg ccgtttgcgt cggaagcctg aagcatgggc gctgagtggg agctgggggc 60 cgargctggc ggttcgctgc tgctgtgcgc cgcgctgctg gcggcgggct gcgccctggg 120 cctgcgcctg ggccgcgggc agggggcggc ggaccgcggg gcgctcatct ggctctgcta 180 cgacgcgctg gtgcacttcg cgctggaagg cccttttgtc tacttgtctt tagtaggaaa 240 cgttgcaaat tccgatggct tgattgcttc tttatggaaa gaatatggca aagctgatgc 300 aagatgggtt tattttgatc caaccattgt gtctgtggaa attctgaccg tcgccctgga 360 tgggtctctg gcattgttcc tcatttatgc catagtcaaa gaaaaatatt accggcattt 420 cctgcagatc accctgtgcg tgtgcgagct gtatggctgc tggatgacct tcctcccaga 480 gtggctcacc agaagcccca acctcaacac cagcaactgg ctgtactgtt ggctttacct 540 gttttttttt aacggtgtgt gggttctgat cccaggactg ctactgtggc agtcatggct 600 agaactcaag aaaatgcatc agaaagaaac cagttcagtg aagaagtttc agtgaacttt 660 caaaaccagg cacgagccat tatctaactt catgaaccag aatgaatcaa atctttttgt 720 ttggccaaaa tgtaatacat tccagtctac actttgtttt tgtattgttg ctcctgaaca 780 acctgtttca aattggtttt aaggcgacca gttttcgttg tattgttgtt caattaaatg 840 gtgatatagg gaaaagagaa caaatttgaa tttgtaataa taaaatgttt aattataaaa 900 aaaaaaaaaa aaaaaaaaaa a 921 14 2541 DNA Homo sapiens 14 ggcggaaggg gaggacgtgg gatggtggcg gactggctgc agcagagcta ccaagcagtc 60 aaagagaagt cctctgaagc cttggagttt atgaagcggg acctgacgga gtttacccag 120 gtggtgcagc atgacacggc ctgtaccatc gcagccacgg ccagcgtggt caaggagaag 180 ctggctattg cagcctgttc ccggggcgct tgcttcctct gcccgttctc tatacagacg 240 gaaggctcct caggagcaac agagaagatg aagaaagggt tatctgactt cctaggggtg 300 atctcagaca cctttgcccc ttcgccagac aaaaccatcg actgcgatgt catcaccctg 360 atgggcacac cgtctggcac agctgagccc tatgatggca ccaaggctcg cctctatagc 420 ctgcagtcgg acccagcaac ctactgtaat gaaccagayg ggcccccgga attgtttgac 480 gcctggcttt cccagttctg cttggaggag aagaaggggg agatctcaga gctccttgta 540 ggcagcccct ccatccgggc cctctacacc aagatggttc cagcagctgt ttcccattca 600 gaattctggc atcggtattt ctataaagtc catcagttag agcaggagca ggcccggagg 660 acgccctgaa gcagcgggcg gaacagagca tctytgaaga gcccggctgg gaggaggagg 720 aagaggagct catgggcatt tcacccatat ctccaaaaga ggcaaaggtt cctgtggcca 780 aaatttctac attccctgaa ggagaacctg gcccccagag cccctgtgaa gagaatctgg 840 tgacttcagt tgagccccca gcagaggtga ctccatcaga gagcagtgag agcatctccc 900 tcgtgacaca gatcgccaac ccggccactg cacctgaggc acgagtgcta cccaaggacc 960 tgtcccaaaa gctgctagag gcatccttgg aggaacaggg cctggctgtg gatgtgggtg 1020 aractggacc ctcaccccct attcactcca agcccctaac gcctgctggc cacagattct 1080 ggtggctccc tgctggccct cttgggcctc tgctcacacc tgggaagggg ctctctaaat 1140 cccggccaga aactctgact tgtgccaaca ataggatgac ccaagggaga ggaaacctat 1200 cctcctcacc agaagagcct gtgtttttct gctgaacacc cactgttcct gaggactcct 1260 gctgggaagt cccaagggat agttctagcc cttctgcctg tgtagacaga agctaaacca 1320 ccagtctctc tcggaggaag ctgagacaac atactctgtc catacataag caggcaggga 1380 gggccatgcc acctaccctt ggctaaacag ggacagtgaa cacattttgg ttcctatccc 1440 agtgggtaag aggcacttat ctctgggaaa tttgcctctc ttgggactct ccccctccca 1500 ggcattttcc attcctggaa aggctccttt ggggttcaga atccagagac caaaccctga 1560 cccacctcct tcctttcctc cagcccacgc tggtctgtcc ccatgccttc ccagggcttc 1620 ttcatgtcag atgcacccaa gtccttagcc cagctgtgcc acctgcagga gttcgctctt 1680 gcgtttcttc ccctccccaa gaagggaggg ggctacttca ggcccttctg tgtgttgcct 1740 ggcaggatac cttgtccaac cagctaccca cctcaactcc cctgtagttt aggacacaaa 1800 acagctacca gcggtacaga gcggtgatca aagccgagta cttacaactc tggtaagcct 1860 agcttctccg cctcagccct tctgcttctg gaagggctat cctgggggtg aacttgaaac 1920 tctcatcagg cttctgcaaa agctcttctt cctgaagaca gacccagcct ttgtgctctc 1980 accctccact ctggtaaagc tgcacctctg ggggaatgag gggctgcagg aatctctgga 2040 gagcctggtg cttcacgatg ctgctctggt gattcttgta cctaatctgg tgtgctcacc 2100 aatgagtgaa agggatcgtg ggtcagggac accgagagag tgaggtcact tccacttcaa 2160 accttcagtg agggggtggg atggagagaa tgctgaatct tttttttgac gggatggggt 2220 ttttctcttt gtaattattt ctttagttta attaaccttt tggttgtttg tgcaatatta 2280 tatattttaa attataatgc atctccccag agtattttgt agctgggaaa agaaaaaagg 2340 aaaaaaagaa aaaaagattc taacagctgt tagttttata attaaaaaag aaagaaaaaa 2400 gaactttgtc ctgaaccttt tacagacttg ccgttaacag cattaaagtg attcacccga 2460 agctgaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaact cgaggggggg cccgtaccca 2520 atcgcctgtg atgtatcgta t 2541 15 1046 DNA Homo sapiens misc_feature (20)..(21) n equals a,t,g, or c 15 agtgaatcct gagtggggtn ntctttagcc taaacctgga gtcaccacag agcttttata 60 aacagtgaga aacctactac ttcctacaga aactgtgctg tctgcaaagc tcagcgtctg 120 ctccagcctg aatccccagg ccctgtccct gtacacacct agttttgagg tcaggacatc 180 acaaaacatc tgccaacatc gaaaagtcat caggagccac ccagacgtgg ggtgtattgg 240 tgggaagaag gagcatctta gtctgcttcc ttctgaggcc cacagttcca gaaggactag 300 cgtcctcaga gcatgtggta gtggctgttc ttgtcttttc ctggtggtgg ggcctggtga 360 cccctaacac caacggagct gttcccaggt tcatttcgtc cctttttctg tggtgagatg 420 aggctcctcc tgccctcctt gctgggtggt ctttctgttt tgaccacatc ccttggaagc 480 gtggctgggc tgcgtaactc cagagcagcc tggtggtagc tggggctgcc ttctgagttt 540 gggctggtgg atgctgagta tttgcattca gagccttagg cattgacctt ggctttctgg 600 gaccctacgc ccctctgttt gcctttgtca gtagagacct tctcacatta gggattcatt 660 ttttccaaga ctgtttgcta aggtgtgtgt caaacttcct cccagagcag tgacatggat 720 gggaattgtg agtgtgttga gagacctacc ctaaaagatg gggctgcagt catcctcagg 780 ggacctcctg ttctcagctc cacctcagcc acacttggct gtgggtcagc ttcttctgaa 840 tcagcatccg caggacagcg ccacccagcc ctgccacact tgcttcctcc gcgcttcttc 900 agaggctgga gcccaccccc atgctcgtcg tctgttctgc ttttttgatg cacttacttg 960 tccctttcag cgtattgctt atgtcctatg ttggttaaaa aaaaaaaaaa aaaactcgag 1020 ggggggcccg tacccaatcg ccctat 1046 16 982 DNA Homo sapiens misc_feature (4)..(4) n equals a,t,g, or c 16 tcgncccacg cgtccgcgga cgcgtgggtn nctaaccttt ggtttgcgga cggtcgggtg 60 tattctccgc cgcccccacg ccctcgaggt ccccgccacc gaaccagcgg cggaccggcc 120 cgcgcctccc gcggcattcc cgcaccggnt cgctcctcgc tggggcggga cctggcctgg 180 cggctctggt cactatgagt gaaacatctt tcaacctaat atcagaaaaa tgtgacattc 240 tatccattct tcgggaccat cctgaaaaca ggatttaccg gaggaaaatc gaggaactca 300 gcaaaaggtt caccgccatc cgcaagacca aaggggatgg gaactgcttc tacagggcct 360 tgggctattc ctacctggag tccctgctgg ggaagagcag ggagatcttc aagttcaaag 420 aacgcgtact gcagacccca aatgaccttc tggctgctgg ctttgaggag cacaagttca 480 gaaacttctt caatgctttt acagtgtggt ggaactggta gagaaggatg gctcagtgtc 540 cagcctgctg aargtgtttc aacgaccaga gtgcctcggg accacatcgt gcagttcctg 600 cgcctgctca mgtcggsctt catcaggaac cgagcagact tcttccggca cttcattgat 660 gargagatgg acatcaaaga cttctgcact cacgaagtag agcccatggc camggagtgt 720 gaccacatcc agatcacggc gttgtcgcag gccctgagca ttgccctgca agtggagtac 780 gtggacgaga tggataccgc cctgaaccac cacgtgttcc ctgaggccgc caccccttcc 840 gtttacctgc tctataaaac atcccactac aacatccttt atgcagccga taaacattga 900 ttaattttag gccatgcagt ggaacctgtc acctaatggn actgcattct gaatggaaaa 960 aaaaaaaaaa aaaaaaactc ga 982 17 3091 DNA Homo sapiens 17 aaaccggaaa gtttgtagga aaattgctgc acatggcctt tgcagaaaag agagccttca 60 aaacctctta cattccagta gaaaactctc tctgcaagtc cttaactttg ttcactcatt 120 ccaggaaggt gcttcaatat tggatattca cacagagccc agtttttcaa gtttgctttc 180 acagtcatcg tatgctgaca tgggtgttcc acttcctgca aaaaacttaa tatttaaaga 240 tggtgtctta tcagaakgga gtggacggtc accttcctca cttcttattg ctaatctcca 300 tttgcaataa tttggttaca ccatttgttg ctcacacttt ctgccttttt tctttcttaa 360 cgttagcttt atagtgtcag ccactaaaaa gcatcctgct gctgcagtgc aattcttgct 420 taactaatat taaaagttgg ggaacatatt catgttttct gaagttttgc tcattattgc 480 acatcttatt gcgacaaagt gctttttagc agccagcact gtatttttta ccttgagaca 540 atctgcattt cttttataaa actaagtata tactttatag gctttatgat gactgttatg 600 tttataagca gtcactatga aaattgcaat ggtaatttta tatgttagtt tatcaaacat 660 aaatcttgtt taattttata ttttgttacc tatactttgg gggatcaagg gaagagatgg 720 aactcttcct ctgaaaaggc ttcttggtac ttaaagtagt aaaactataa aacaataaac 780 atccagtatt gagagatgat atgatagggc attatgaatt cctatgggtg tctgtaaatt 840 atgtatgtca gttggacatt gtagaaggta tgtaaatcag catagttgtg tataacttaa 900 ccttgattta taaggtctta agattatgac tattcattga catctcatga gaagctttag 960 aagactttct atttttaaac accatttata tgtggacttc tgttgtcact gactttgggc 1020 tttatatttt catagagtct ttatggaaaa aatagaattt attttccact cttgtagcta 1080 tagctgctgc acactttcac cctgatttat ttttttgttt cttagctttg atgttttcaa 1140 accaaggatt gtgattttag gttagaatta catattagaa gcattaagac tatgtctttg 1200 gatcagaatg ctttagtgat aaacctactt tgaagacata ctcttaagca atctggatct 1260 taaatttatg tgaatacttt tttagaaaat gataaagaaa aatggaatta cttcaaagtg 1320 tttcttgagt cattgattct tttagcatct caaatgttaa ttagaataat tggaatcact 1380 ttttagactt ttcaagttac cttccttggg aagtttgtgc agtgttatag tttagtttag 1440 ctcctcttac agggtaatgg tttgctagtt taaaactgta accaaacgaa ctggtcagac 1500 aacatatatc taaaacactt aaaatgttag gaagtttggg aatgttataa cctaaacgtt 1560 tttgctggta actttttgtt atttatagat atttgtgtat ttaacataca tacttcagga 1620 aatatatgcc tttcctaaaa cttaaccatg cattcaatac catggcctat ctatagaatt 1680 gaatattttg gaccatgtta tctgtggcac agtcagtgct gtgtttgagg taaatgcagt 1740 aacggttagt tttctacttt gtcttataga aggtagaaac catgtgtatg ttatgtttgt 1800 ctataaaaga aaaaatacta atattaaata atttcttacg actctgagtc actcacttat 1860 ttttccaata attgatattg tacattccta gtgccattag gtatgtatgt atgtaacttt 1920 tacagttttt cagctgaaag ttgtaagtat tttttttttt tgatcggggc tctttaatct 1980 cattttaatt tcctttgttt gaactgtagt tatttattcc tatattaacc atctaaacca 2040 actgtaatga catgtacact aatacagaat tgaacatttg tagttgttgg cagtgaaccc 2100 agttgttggt gaatttaaag cttaaaatat gggaatgatt tgctgctata tttcctttga 2160 gagagaaagg aggaagaaat agaacctaat agtgatcatg aattttaggg aaagtaccga 2220 agaaccatgg ggtcccctct ggtttcttgt gttgaatgag gcaagggtaa tcatctgatt 2280 ccgagctgaa gacctctggt cctcttaagg agggagagtg catttttaga gcttttagca 2340 aaatgtgaaa agctgatgtt tgcgccttgc tttgtgaatt tggctttgtt ttacttatac 2400 attaactcat gtaatctctt aaatcttaca agcattgatc catttcaaca aaaaggtaaa 2460 tttaaaatgc agactttgtt atttgccaaa gaagattcat gaaaaattta cgtccaatta 2520 ttttgcaaat agttaatttc atttggcttt ttaccatgtt ccttcctttc tttttcccgc 2580 ttccttaatg taatttaaac cctggcaaac attctttaga aaccaagagg aaagaaagaa 2640 caaatatcaa aaaagacata gaatttaata ttgatacaat ttcacctcta aaatggattt 2700 gaagaaatgc aactttatat caaaaaatgt catctgattt cctttgtttc ttttttaaat 2760 tatgtaatca gatgatttta tgtttttttt tcaggggagc ggaatattgg tttcttttac 2820 ttgttgtttt cagttttctc tgccattcat gtttcttttt tgtgttcagt gtttcaaata 2880 caatttgtat ttaaggattt taaaatacca aactgtaact gagtacagtg gatcgttttc 2940 tgttaggatg ttaatattat acaatgaaat ctataaagtg ttgtcaattt gattattgac 3000 acatataaca tgtttacaaa taaactgtgg tattgatcaa gttactatga aaaaaaaaaa 3060 aaacccgggg ggggccccgg aacccaatcc c 3091 18 796 DNA Homo sapiens misc_feature (398)..(398) n equals a,t,g, or c 18 gaattcggca cgagctcgtg ccgaattcgg cacgagtcag attgaaggtg gttggttttt 60 attattattt agtgtgattg atagtatcta gaatggcagg tggtgcataa aagttaaaga 120 gaggggaaag attacttagt ttggttatac agttataaac accatgcagt gtattcggtg 180 gactgtgcta tttctgttta tcctttgggt tttggttttt gttttttttt ttgccttcac 240 agtgagactg caaatgattg ttctcataac gtatattatt aataaatgtg gtcctataat 300 ttatactgaa attaccttag gatatttttg cataatactc tcttactgct tacattctat 360 aaatttttca cgtgataatt gtctttgcgt aactgggnaa aaatgccgaa taacttcctt 420 tattatctgg aaaaattaaa tttgttcatt tatattttct acttactaaa ttgagttttt 480 aaaaagactt agtgtgacat ttgacagtgt ctttcaaacg aacttctcta acaagtttat 540 agttattttc ctgtttcaac actattagaa gtcttataaa ttatgctaat tagcatggca 600 gtcatgttac acactcttaa cattgccaaa gaactgttga tttcgtttga gaaaaccctg 660 ggactgtgtg tgtgtaggtt ttgttttgat tttaacaacc aaaaatagaa ataaaattag 720 aactgcgttt taagttctaa aaaaaaaatt taaaaaaaaa aaatttaaaa atttgggacn 780 aaggcgnggg ggtccc 796 19 822 DNA Homo sapiens 19 gatttaccac ctagaaatgg tgtttttaaa tttcttaata tatctccttc ttgtcttttt 60 ctatatatct ttatttcata gtcgagacaa ttttatactc tgaattttta tcatataagt 120 atctacccac attatcagga atgctttgta agcatcattt taatggcttc aaaatagtct 180 atgatttaga taacgatgat ttggccattt ttgtggtcac ctaccactta ttggagacat 240 attatattct gagaatatta tgccatttat aggcattaat tccaatatgc aaaagaactt 300 tgaaatgaag gcgttattat tcccaatttt acagatgctg aaactgaagc tcagagaggt 360 taagttgccc gaggccatac aggacaatag gggcaaagat ggttttgaat caatggatgt 420 ctgacgacaa aggccatgat ctcaccactg cactgcactg tctcctgaag ccctttgtgt 480 gaaatgatta aatacatcat gattatgtca cacttcactt acccttctcc aggtagttga 540 acatctggat gattttacat cgtcaaatac aaggttgtta acaattaaag gataaaacag 600 ggtgcggccg gaaaggcggc cgccccctcg cccatcatgc aatgcacatt cgtggggaac 660 ctggcgctaa gccattcgta gatgacctgc ttctggctcg gggtttcata tgtagcagag 720 cagctccctc gctgcaatct attgaaagtc agccctcgac acaagggttt gtaaaaaaat 780 aaataaataa aacaaaaaac aaaaaaaaaa aaaaaaactc ga 822 20 657 DNA Homo sapiens 20 cgcggcacga gacgaaatga ttcagttctg gacatggcaa gacatgtgcc actctatcgg 60 gcactgctgg aattgcttcg ggccattgct tcttgtgctg ccatggtgcc cctattgttg 120 cccctttcta cagagaacgg tgaagaggaa gaagaacagt cagaatgtca aacttctgtt 180 ggtacattgt tagccaaaat gaagacctgt gttgatacct ataccaaccg tttaaggtac 240 tatatacaat gttcatttct cttgagtttg cctctaacaa tgtttttaaa ataactccat 300 gggtgttttt gtttttcagt gatatgtgct ttttaaaagc mtatacaccc tcggctgggt 360 tgcggtggct cacacctgtg ggtccccagc actgtgggag gccgaggtgg gatggatccc 420 cgaggtcggg agatcgagac catcctggct aacatggtga aaccccgttc tactaaaaat 480 accaaaaaat tagccaggca tggtggcggg cacctgtggt cccagctgct cgggaggctg 540 aggcaggaga atggcgtgaa cccgggaggc ggaggttgca gtgagccgag atcgcgccac 600 tgcactccag cctgggtgac agagagctcc gtctcaaaaa aaaaaaaaaa aaaaaaa 657 21 632 DNA Homo sapiens misc_feature (557)..(557) n equals a,t,g, or c 21 ggcacgagcc gcagctcccc tcttccttcc tctgcagacg ctggcgctgt ctgccggagg 60 tgttgcccaa aaggccctag tggggcgtgg tcagctccac ctcctgatcc tgtgtgtcct 120 ccgacatgct gctgattcta gtgacccctg tccccaccag gctcagagcc agaccgcgcc 180 tggaccttct tgttctgact ccacgtgcct gcccggcctc cagggtgcgg gggcgccttt 240 cttgcaggcg gaccctgccc aggatggggc cagcctcgtg ctcagctttg gccacaaatg 300 cagcccctgg cccaccccac cctgccggcc ctgccttctc cagtatttcc cacatggcca 360 cgactcctca gtcactagag cctcctgctg ggaacagtgt cccccagagc ctcatgtcta 420 tcctagaccc tgcaagcagc tgggtcccca agagtgcatc tccccctaga gttgcctgcc 480 catgcccacc tgctttgtaa ccttcccagg agattcatgc ttgctctgca cagcagggyt 540 cgaggsccag gscatgnama sggaaytgcc ntcaggtttg ggtcaractg catcctgggg 600 gcatctgntg gaaatgtgag cacacaaacc aa 632 22 865 DNA Homo sapiens misc_feature (365)..(365) n equals a,t,g, or c 22 gaattcggca cgagtgccct cgtatctaca tgctcaccta taccctcacc cgacttttcc 60 ctcctcctca ccccatcaaa ggcaataatg cacctgtttt tattcatctg ggcctttggt 120 cttccccttc atatttcccg agacctcgct ttcttctttc tcttgtattt tttatttttc 180 tatctcttat gtgtccttct ctaaaagtta taaacatgca caaaatcttt ccatctcaaa 240 atataatacc ctttacctgg tgtcccctgc aggccatctt ctttatttat ttacttttgc 300 gccaggtctt cctctgaagc ccaggctggg tgcgtacgcg atcatggctc actgcagcct 360 cggantcccg ggctcaagcg atcctcctgc ttggaggatc agatttttta tccttgcaga 420 agtgataata tggcttcttc ctcatctcct aaacaccagt catctgacat acactgcaga 480 tctaaaatgg gccttacgtg ttctgccctt ccttgcctac ctgttgagct tgcaccgctt 540 ctgtgagtct ccccccaccc acaagagatc cttcttcctt cgcgctccac taacccgaca 600 taaatgttta tcatataaag ttttccgttg cactcttgtg tttatgtctc ctggcttctt 660 caccaagctg tgtgacagct gggccctgtc gcctccttcc tcgtatatgc agcgactatc 720 gcagagccgc ttaatctttg ttgaaggcag ctgcggttca gccctgaggg ccacgggacg 780 gacgccactc attcagycct accgggggcg ctgtggcagc cggcattggt tgccgtgccc 840 tccgcttgtc tcgctcagcc ctcga 865 23 1222 DNA Homo sapiens misc_feature (772)..(772) n equals a,t,g, or c 23 gaattcggca cgagcacatg wktatatata tattactgtt ttgcctccat tgaacatgcc 60 ttctacttcc taatttgtgc cagaattgac tagtagacgc tatgaatgca tcatgctctt 120 tggcccattt cgaacactca ggtatgtctg tactcttagt tcatctattc atcattgttt 180 ctacagttcc ctcatgcttt aaaaaatata tggcttttat aatttatcca gctttttctt 240 gtcattttaa taagagtatg tgtcttatac aactactaca ttcatcccag aagtagaagc 300 aaactattat aatcccatta tttttattcc tactattctc ttttcagaat ttcttttaga 360 tattccttgg atagttttat tcaatcctcc atggctttca gcttatctta tgttctatct 420 tttggttcat attctgcatt ctggataatt cttcatcttc actttctagt ttgttgatat 480 tccttttggt gactataagc tgctctttaa aatggtcaat aatgcctaag atgtttatta 540 tcttgccctt tgcagaaaaa aattttcagc ttttgctctg gaatgatttt gcatctcttc 600 caccaaactt ccagtgtatc aatggccaga aaataatcta tatgttaatt tgttaatttg 660 atggttcatg gttcaaggct gtataattta aaagtttgaa gtcaaacaac acatgatggg 720 ataatcctga tgttacagat tctcaaggga aaatatgttt ttgttttttc tnccaattgt 780 tctartattt acaganaaac ttcttaatta tactgggttg gtnaataart atttttcttw 840 actctttcaa tctangtcca rctatgcatc accccttcgc tgatgagcat taagaaaatc 900 caaatttggc ccgggcgcgg tggctcacgc ttgtaatccc agcactttgg gaggccgagg 960 cgggtggatc acgaggtcag gagatcgaga ccatcctggc taacacggtg aaaccccgtc 1020 tctactaaaa atacaaaaaa aaattagctg ggcgtgatgg cgggcgcctg tagtcccagc 1080 tactcgggag gctgcggcag gagaatggcg tgaacccggg aggcggagct tgcagtgagc 1140 caagattgcg ccactgcact cccgcctggg ccacagagcg agactccgtc tcaaaaaaaa 1200 aaaaaaaaaa aaaaaaactc ga 1222 24 1421 DNA Homo sapiens 24 ggcagaggga gcggagagcg tgctaaccaa tgacttgagg gagtaggggg ccgggtttgg 60 gccctcagtt gctaagggct acccgagtgg gaagcggttc aagagatggg gtgaagggtg 120 gttcaccggt tcttcaagtc ctcagccttc tggcccgmgg aagttaagca accaagaggc 180 gggcctaaga ccggaagcag gaaggagggc gcaggaagca gggcgccgca gcctgtcgta 240 cggtccttct gtgggtctgt cggtgccgag ggcaggatgg agaagctgcg gctcctgggc 300 ctccgctacc aggagtacgt gactcgtcac ccggccgcca cggcccagct ggagacagca 360 gtgcggggct tcagttacct gctggcaggt cgattcgccg attcgcacga gctgtcagag 420 ctggtgtact ctgcctctaa cctgcttgtg ctgctcaatg acgggatcct acggaaggag 480 cttcggaaaa agttgcctgt gtcgctgtcc cagcagaagc tgctgacatg gctgagcgtg 540 ctggagtgcg tggaggtgtt catggagatg ggagctgcca aggtgtgggg tgaagtgggc 600 cgctggcttg tcatcgccct catccagctg gccaaggctg tactgcggat gctcctgctg 660 ctctggttca aggctggcct ccagacttca ccccctatcg ttccactgga cagagagacc 720 aggcacagcc cccggatggt gaccacagcc ywggyaacca tgagcagtcc tacgtgggga 780 agcggtcaaa ccgggtggtg cgaaccctcc agaacacgcc gtccctgcac tccaggcact 840 ggggagctcc ccagcagcgg gagggacggc agcagcagca tcacgaggag ctgagtgcga 900 cccccacccc cctggggctt gcaggagacc atcgcagagt ttttgtacat tgcccggccg 960 ctgctgcact tgctcagcct gggcctktgg ggtcarargt cgtggaaacc ctggctcttg 1020 gctggtgttg tggacgtgac cagcctgagc ctcctgagtg acagaaaggg cctgacccgg 1080 arggagcggc gggagctgcg gcgccggamc atcctgctgc tctactacct gctgcgctct 1140 cctttctacg accgcttctc cgaggccagg atcctcttcc tgctccagtt gctggccgac 1200 cacgtccctg gcgttggcct ggtcacaagg ccgctcatgg attacttgcc cacctggcag 1260 aaaatctact tctacagttg gggctgacag actcccggaa ggagggtgtg gggaggggtg 1320 ggcagggagc ccctcttccc taataaaact gactccggca gcaaaaaaaa aaaaaaaaaa 1380 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaagggcggc c 1421 25 638 DNA Homo sapiens misc_feature (597)..(597) n equals a,t,g, or c 25 cggcacgagt ttatttccaa ggtaagtagg ggtagactag aatggacata gcagctcctg 60 tcttatttgc tttaaggctg caatttctgt tcattctctt acccatgcac tttgaaattt 120 cattgctctg caaagtttcc actgaaacat caggtcgaga agacaaaatg tagagaatag 180 caaaccaaaa atatactctt cagagagccc agtgatggaa attatattct acgtaaggcc 240 attaaccagc tacaaagcag tagcagctaa ctaacctggg gataaaagac catctgctgg 300 ctgcatactg attccaagca taatgggtct cccattccca cctccacctg gctccacaat 360 tccctgcatg tcttttaacc tcctcttctt cagactcaat gcttccttat gcaactccag 420 aaacccagta tcttatttaa acacacctgc catttgaagt agacaggtca aggagaggta 480 ggtccttctt ctggtataac ctcaggttca tcatgggaat atagataagc tgtttcactt 540 tcttggccta tttactctcc tgtaaaaaga gggagttgca ggagattctt caaagcnaaa 600 ctgaatattt tgatggattg aaaaaaanan aaaaaaaa 638 26 749 DNA Homo sapiens 26 aaggccaagc caatggtaga agaaaacagc tttattgaag gggcagtgtt atagctccag 60 ccctgttaca actctgatta ctcctgcaca gcaggctctg gcagagacta gcagctcagg 120 gcagttttgc agtcatttat akswaytygg cacgagggca gattaagggg tgatttgtgc 180 aaaaatttct agggaatggg taataacttt tgggtcatcg agtcaatgcc atggaagaga 240 ggggggataa ccccctggtg ttgcgatggc aacggtaaac tgacatggca actgatgagc 300 gtgtcttacg gaaagctcat tccaccccag ccctgtttca gctagtcctc aatttggtcc 360 agtgtccgag ccctgcctct ggagtcaagt cccacctcct acctcataag gagagacata 420 aatcaatgga atagaatcga gagttccaga aataaactca tacctcgatg atcaattgat 480 tttcaacaac agtgccaaga ccattcagtk gggggaaaga atcatatttt caacaaatgg 540 tgccagataa cgacatccaa aggagtgcaa ctgggcccct gtctcacacc atctacagaa 600 attaagtcaa agtgcctcaa acactaagag ctaagactat aacattctta gaagaataca 660 gggttacctc tttatgatct tgatttggta attgattttt agataacact aaaagcacaa 720 gcaacaatag gaaaaaaaaa aaaaaaaaa 749 27 788 DNA Homo sapiens misc_feature (290)..(290) n equals a,t,g, or c 27 aggggcmckg mctcccaccc accccatcac cagctttcca cttggaggcc ccctgtgccc 60 tgcagcctca gggtargccg tgggtcacca ggctggagar ggcccctgcc ttggccaggg 120 gtgcgaggtg acccggctgc attgctgggt gggagctgct gtctgttgtt caggggcctg 180 gcccccgccc tcccccccga ccccgacctc gcaaagsgca ctcccgggca gggtgtggtc 240 tggaargcgg ggctggcggg gacatgggtg ttctgcatct cctagcgcan ttcctgctgg 300 tggktggaag ggtgcctggt ttaggcgggg tcccaggagg gggtgagggg tgacaccttg 360 gggagggggc ctkcaaaggr cactgcctgt ggccacgtgg tgtctgtggg aattggtcct 420 ggggactttg atgggtgttt gcggccccag ttgccgccct gctccctctt ccagggctcc 480 tggcttgggc cccccgaccc ccctgctcag ctcgggaaaa tccccgtgcg gctccagccc 540 cgggtcacgc tcaggagcga tgagaggggc gccctggcca cgcttcagga aagcctgtgt 600 ctgcgcgcgg ggcaaggggc tccacgacaa aaggacaaga tttgacttaa attaagtttt 660 tcccttgagg atattttcat tttctttaaa agaatataat tttcttctaa gatcttggwa 720 aaaaaaaaaa aaaaaaaaaa aaaaaaaata cgtagggggg gtcccgtnac ccaattgtcc 780 tgacgtgg 788 28 941 DNA Homo sapiens 28 ggcacgagat tttggcaagt gctgttatgt gaacaccacc atcacaatca agatagtcta 60 tagttctagt accccctgcc ctgaaacttg cttgttctgt ttagtcagct cctctcccca 120 ccaccagccc ttgtcaactg actcattttc tgtctgtata gtttatatca tttccagaat 180 gtcatataaa tggaattcta gagtatgttt cctttggagt cgcacctttc acttaatgct 240 tctgagactc atctgtcttg ttgcatatat cagtacagaa gtcatttctt ttattgctga 300 gtagtaatct gtcatatgga tgttccacag tttgtttatc catttatcac tggtggggat 360 acttgggktt tcagttttca gtgattatga agaaagctgc tgtcaacatt tgcaaacagt 420 ttgtgtgtcc acattgtckt agtaaataac taggagtgga attgccgggt tgtatggtaa 480 cagtatactt atctatgaaa aactgacaga cttttctaaa ataactgtac cattttacat 540 tcccaccacc agtgtatgaa agtcccagtt ccttaacttc actgacaatt ggtatgtcag 600 ggtttggttt catttttatt ttgttgttag gatttcaaag ggttatagcg ggatttcatt 660 ttggttttaa tttacacttc cctaatggcc attgagcatc tccactgctc gtttgctatc 720 catttgccta ttttcttttg tgaactatgt tcaaatcttt tgtccatttt tttaaaacct 780 ggattgtttc ttattgattt ttgagagttc tttatatgtt ctggatagat atctttgtca 840 gttatgtgtt ttgcaaatat tgtataccat tatgtggctt gtgtttttat tccattaaca 900 gtatttttca cacaagaaaa aaaaaaaaaa aaaaaaaaaa a 941 29 835 DNA Homo sapiens 29 ggcacgagca caaaccctag aattcccagg gtacacctgt tagttgctaa agatatttca 60 agaacagtta tctctctggt aaagtttatt tgctcctgtg caaggtttca tttctttcaa 120 cagagtgaaa caacttgggg tacaatgtta ttgttagtat attttcttct tatgtctgta 180 atatttggca ctaaattctt tcctttaata atacacatgt ttaacccatg catacttaac 240 cttataaaac ttgttttttc tctcatgcct ggaagccatc aaactccaaa tgttcaggca 300 accagagcct cagatgatgg ctccgctttg ctaggaaccc ccagtagacc tctcggaagc 360 atccgacagc agtttacccc aaaagaatgc cccctgtcag caggaagcag ctaagaccag 420 tcattgtccc atattctcat ggcagttaga tacacctctt cagagagggg aaataatatg 480 ggagtgctag gaagggaaga acatggctgg ctagggctcc ataccctggc tagtcctggc 540 tagggctcca cactcacgga cctaactgag aacaggtatt tctcgcccaa atgttgcatt 600 tcccaagacc accctggctg gacattgaga ggaacacact gacaggcacc agcatgctgg 660 taggccactg actgacagaa caatgcagag tttggctggg gcagctggag gacagtctgg 720 gccactgagc agcctgactt caggggaaaa ccatctccct tctgactctc ccatctgctg 780 gtagctattt ccactcaata aaaccttgca ctcattaaaa aaaaaaaaaa aaaaa 835 30 553 DNA Homo sapiens 30 gtgtgccgga tttggttagc tgagcccacc gagaggcgcc tgcaggatga aagctctctg 60 tctcctcctc ctccctgtcc tggggctgtt ggtgtctagc aagaccctgt gctccatgga 120 agaagccatc aatgagagga tccaggaggt cgccggctcc ctaatattta gggcaataag 180 cagcattggc ctggagtgcc agagcgtcac ctccaggggg gacctggcta cttgcccccg 240 aggcttcgcc gtcaccggct gcacttgtgg ctccgcctgt ggctcgtggg atgtgcgcgc 300 cgagaccaca tgtcactgcc agtgcgcggg catggactgg accggagcgc gctgctgtcg 360 tgtgcagccc tgaggtcgcg cgcagtggca acagcgcggg cggaggcggc tccaggtccg 420 gagggttgcg ggggagctgg aaataaacct ggagatgatg atgatgatga tgatggaaaa 480 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 540 aaaaaaaaaa aaa 553 31 1346 DNA Homo sapiens misc_feature (637)..(637) n equals a,t,g, or c 31 ggtcgaccca cgcgtccgct gagagtagcc atgggctctg gaggagacag cctcctgggg 60 ggcaggggtt ccctgcctct gctgctcctg ctcatcatgg gaggcatggc tcaggactcc 120 ccgccccaga tcttagtcca cccccaggac cagctgttcc agggccctgg ccctgccagg 180 atgagctgcc gagcctcagg ccagccacct cccaccatcc gctggttgct gaatgggcag 240 cccctgagca tggtgccccc agacccacac cacctcctgc ctgatgggac ccttctgctg 300 ctacagcccc ctgcccgggg acatgcccac gatggccagg ccctgtccac agacctgggt 360 gtctacacat gtgaggccag caaccggctt ggcacggcag tcagcagagg cgctcggctg 420 tctgtggctg tcctccggga ggatttccag atccagcctc gggacatggt ggctgtggtg 480 ggtgagcagt ttactctgga atgtgggccg ccctggggcc acccagagcc cacagtctca 540 tggtggaaag atgggaaacc cctggccctc cagcccggaa ggcacacagt gtccgggggg 600 tccctgctga tggcaagagc agagaagagt gacgaangga cctacatgtg tgtggccacc 660 aacagcgcag gacacaggga gagccgcgca gcccgggttt ccatccagga gccccaggac 720 tacacggagc ctgtggagct tctggctgtg cgaattcagc tggaaaatgt gacactsctg 780 aacccggatc ctgcagargg ccccaagcct agaccggcgg tgtggctcar ctggaargtc 840 agtggccctn tgcgcctgcc caatcttaca cggccttgtt caggacccag actgccccgg 900 gaggccaggg agctccgtgg gcagaggagg aacacaggat aaaaatggaa gttctcaata 960 aaaagaagat gtattgggaa agaaaactac aaacttttac caaggaatgg cctgtttcct 1020 catttaaccg gccctttccc aattcgccct aagactttgg gggtggctct cttgtaatta 1080 atctgtgttg gcaaagaatg tctggaacat ggacttggcg gtcagtaacc tgtaacagag 1140 ctacaactag gaaaattaga gtggtagtag tcacttattt aagaattcat tcaggtaaac 1200 agctgcaccc tctgtacccc ttaagtggca aagaagctgt tatagtcttc tgaaaattat 1260 cactatgagt gctataattc tgaatataat gtctcttaat tagaattcat acaagaacca 1320 aaaaaaaaaa aaaaaaaagg gcggcc 1346 32 626 DNA Homo sapiens 32 ggcacgagaa acattttcct ttgggttttt tttttctttc ttttttctcc cctttactct 60 ttgggtggtg ttgcttttcc tttccttttc cctttgagat ttttttgttg ttgtttcctt 120 tttgtatttt actgatatca ccaggatagt ttactctcct tctagctttc tgcttaccgc 180 acactggata acacacacat acacacccac aaaaatgctc atgaacccaa tccggagaag 240 gttccagcag gtcccccacc ctcccctcct cctcctactt ctcctcttga cagcgaggac 300 aggaggggga caaggggaca cctgggcaga cccgccggct ctccccccac cccaccccgc 360 ccctcacatc atactccaat cataaccttg tatattacgc agtcattttg gttttcgcgg 420 acgcgcctac ctaagtacca tttacagaaa gtgactctgg ctggtcatta ttttgtttat 480 ttgttcccta tgcaaaaaaa aaatgaaaat gaaaaaaggg ggattccata aaagattcaa 540 taaaagacaa aaaaaaagaa aaaagaaaaa aatgtataaa aattaaacaa gctatgcttc 600 gactcttaaa aaaaaaaaaa aaaaaa 626 33 1018 DNA Homo sapiens 33 ccacgcgtcc gcggacgcgt ggctttgaac cattcaaata ccacattagg caagactgtg 60 ataggccttt tgtcttcaaa tacaacaggc ctccactgac ccatccctca aagcagaagg 120 accctttgag gagagtacag atgggattcc acagtggggt gggtggaatg gaaacctgta 180 ctagaccacc cagaggttcc ttctaaccca ctggtttggt ggggaactca cagtaattcc 240 aaatgtacaa tcagattcta gggtctgttt tcggaagaag caagaattat cagtggcacc 300 ctccccactg cccccagtgt aaaacaatag acattctgtg aaatgcaaag ctattctttg 360 gtttttctag tagtttatct cattttaccc tattcttcct ttaaggaaaa ctcaatcttt 420 atcacagtca attagagcga tcccaaggca tgggaccagg cctgcttgcc tatgtgtgat 480 ggcaattgga gatctggatt tagcactggg gtctcagcac cctgcaggtg tctgagacta 540 agtgatctgc cctccaggtg gcgatcacct tctgctccta ggtaccccca ctggcaaggc 600 caaggtctcc tccacgtttt ttctgcaatt aataatgtca tttaaaaaat gagcaaagcc 660 ttatccgaat cggatatagc aactaaagtc aatacatttt gcaggaggct aagtgtaaga 720 gtgtgtgtgt gtgtgtgtgc gtgcatgtgt gtgtgtgtgt atgtgtgtga ataagtcgac 780 ataaagtctt taattttgag caccttacca aacataacaa taatccatta tccttttggc 840 aacaccacaa agatcgcatc tgttaaacag gtacaagttg acatgaggtt agtttaattg 900 tacaccatga tattggtggt atttatgctg ttaagtccaa acctttatct gtctgttatt 960 cttaatgttg aataaacttt gaattttttc ctttcaaaaa aaaaaaaaaa aaaaaaaa 1018 34 767 DNA Homo sapiens misc_feature (292)..(292) n equals a,t,g, or c 34 cggcacgagg ggacagatgg ggtttagggg gttgtragcc ggggcttcar agctctgctg 60 tctgggggta ggggggagct ggaagctgga ggtgtggcag ccatggctct aggagccctg 120 agcctgaatg ctgcccttgc accctgggcc tcctcccctg gcccagacct ccccattctr 180 aaagagaagc agcccctctc tagttacccg tyttctgggg gagccaggtt ccgattaccc 240 accacctccc tgggcacacg tgaaagttct tcatttacca cctgtyttgt gncaggagcg 300 ggattgtgaa ggtcatggat gactaccagg tcatggatga atcctctaca acctcagctt 360 cgagatgaac ttcaatgaca agtgagtggg agcttggccc ccatgccagg tgcggggtgg 420 agcatgaggg gagctgctga gctgcagagg ctcccaaatg ccccagctgc cacagtctgt 480 gcaatctccc cagaaacacc ccactgagat ttcagaggcc agggctccac acatgggccg 540 ggaccagcca gggccaggtg gccgaaggaa ttcatttggg cctcttggcc tcagctgctc 600 cccaaccctg tctctgtcct gtcaatggcc tggcacatgt tttgcttgtt gttttttgaa 660 acagagtttt gctttgtcac tccagtctgg gcaatagtga gtcggtcaaa ttccatttcc 720 ccctccgccc catacctctt caaatgttta aaaaaaaaaa aaaaaaa 767 35 840 DNA Homo sapiens misc_feature (364)..(364) n equals a,t,g, or c 35 agattttttt ttttttaatg tccggagaag gaactctcag attactctcc tccctgcaaa 60 acgactattt accacctccc ctttgcttca acttggtctg agcgtcttta acctcaccat 120 tttgaatgtg cgcaaaatga ttaccagtca tctgagggag gccaaattaa aggtgcatct 180 gcaagaggag ctctggcctg acatcgctaa ctgagagcag ccctggcgga aaggtgctga 240 tcccgggagt agagcgactg ctgcggctcg agcggggtgt ctgcgtgccg agcctcactg 300 acaatcgggg aaaatgcaga cgcccagcaa aacgacggca acagaaggct cctcggggga 360 gggntgctgc aggcctgtgg cgtaagatgg ttccgctcta cgcgggktga cgggaaaccg 420 cagaagtggg tgtgaggtgt tggttggggg gcaaactctt gtacagtggc gagtgtaggg 480 gaaagccagc gggctccttg gccaagtcac caaggacagc agaagaggca gcagtaaaga 540 gcggcagcga agaccccgat accaaccaat gtcatctgtc ggggggcggc gggcgcgacc 600 gtcccggata ggagcgcggc ccgggtccgg gctggacagg gcccaggagg cgaagaaggc 660 ctcccacagc catcaacccc acccaccatg gccggcgcag caggccaggg acaagccccg 720 ctccttccga agctagagac agagaaactg aggagctgaa cgcagcaatt tcctcgcccc 780 gacccccaca ctcccgacag cggaacaagc cagactgaaa aaaaaaaaaa aaaaactcga 840 36 1148 DNA Homo sapiens misc_feature (820)..(820) n equals a,t,g, or c 36 atcagaccat cagaaggatt tgtataaaga gtgactctcc tatgaaggta aaggccaccc 60 ctcttcagtt ccagtgactg agatacattt ttccaatcct gggggcaaat acagacacag 120 caagttcctt cttccctttg gaaatttggc agctgccttc accagtgagc acaaagccac 180 atttcaaagg aaactgacaa attatcccca gctgccagaa gaagaaatcc tcactggacg 240 gcttcctgtt tcctgtggtt cattatctga ttggctgcag ggatgaaagt ttttaagttc 300 ataggactga tgatcctcct cacctctgcg ttttcagccg gttcaggaca aagtccaatg 360 actgtgctgt gctccataga ctggttcatg gtcacagtgc accccttcat gctaaacaac 420 gatgtgtgtg tacactttca tgaactacac ttgggcctgg gttgcccccc aaaccatgtt 480 cagccacacg cctaccagtt cacctaccgt gttactgaat gtggcatcag ggccaaagct 540 gtctctcagg acatggttat ctacagcact gagatacact actcttctaa gggcacgcca 600 tctaagtttg tgatcccagt gtcatgtgct gccccccaaa agtccccatg gctcaccaag 660 ccctgctcca tgagagtagc cagcaagagc agggccacag ccagaaggat gagaaatgct 720 acgaggtgtt cagcttgtca cagtccagtc aaaggcccaa ctgcgattgt ccaccttgtg 780 tcttcagtga agaagagcat acccaggtcc cttgtcaccn aagcaggggc tcaggaggct 840 caacctctgc agccatctca ctttcttgat atttctgagg attggtctct tcacacagat 900 gatatgattg ggtccatgtg atcctcaggt ttggggtctc ctgaagatgc tatttctaga 960 attagtatat agtgtacaaa tgtctgacaa ataagtgctc ttgtgaccct catgtgagca 1020 cttttgagaa agagaaacct atagcaactt catgaattaa gcctttttct atatttttat 1080 attcatgtgt aaacaaaaaa taaaataaaa ttctgatcgc ataaaaaaaa aaaaaaaaaa 1140 gggcggcc 1148 37 1367 DNA Homo sapiens misc_feature (15)..(15) n equals a,t,g, or c 37 atgtatagat catanaggca aacggtanct gacagtaccg gtccgaattc ccggtcgacc 60 cacgcgtccg tgtttctact ctttgactat tatgaataat gctgctaaga acattaatgt 120 acaagtttct gtgtggacat atgctttcat ttctcttatt ttcattttat tccacctagg 180 agtggaattg ctgggttgta tggtagtgtt atgtttaact gtttgagaaa ccaccaaatt 240 atttttgttt tctttttaag atgaggtctc gctatgttgc ccaggctggt cttgaactcc 300 tggcctcaag tgatcctccc acctcagcat cccaaagcgc tgggattaca ggcatgaggc 360 atgccaccat tacacacccg gccagccacc aaattatttt ccaaagcagc tacaccacct 420 tacattccca ccagcagtgt atgagcatcc catctctcta cacctcraca gtaattttgn 480 gtctgtctaa tttactatag ccattctagt gggtaagaac tcacacacac ttctgcttct 540 tcttggcaat gcatccatgt ggagccatgc tggggctttc caggactggc tgactttcac 600 ctccacttgt agaaagaagg acatatctgg caatactgta gccccagagc ttggtccagg 660 gcctagaact aaggatgcac ccctgaatgg ctcctggatg gataatgggc tgggtgaggg 720 aggtacatgg tgagggggat actggtttca gtgcaattgg agctcagtga tatctgaraa 780 rtctgggggc tggganggga gatgtgcata tctaaggaca ccacccaccg tatgataggg 840 twtagaagar gcagggtaac ctgtgtaraa atcagctccc arcctcctgc tcgganctta 900 ccctcaagga atgcagaacc cctgtgtatc cctttctcct cctgatatag tttagatatt 960 tatccccacc aaatcttcat gttgaattgt aatcccagtg ttggagatgg ggcctggtgg 1020 gaggagtttt ggtcatgggg gtggacccct catggcttgg tgctgtcctc actgtagtaa 1080 gttctcacaa gatctaattg tttaggtgtg tgccacctac cccctcccac tctctctctc 1140 ttttgctcct gcttttgcta tatgaggtac ctgatcctgc ttcaccgtcc accatgactg 1200 taagcttctt gaggcctccc cagaagccaa gcagatgcca gcnccatgct tgtacagcct 1260 gcagaaccat gaaccaatta aacctctttt ctttataaaa aaaaaaaaaa aaaaaaaaaa 1320 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaag ggcggcc 1367 38 921 DNA Homo sapiens 38 ggcacgagga cgatgatgtc atcaaacact tatatagtgc ttgtatgcca ggcactcctc 60 atcacagcta tgaatcgtgg tccaccaaat aagtgcaaca gagtttatct atttttaaat 120 ctttgccatc actactaatg ttgcagcgag tgttttcttg tacatacatc cttgcggaag 180 tgtttgggta tatacctacg gtagagttcc ttggttatgt ggtaccagca tcttcaccta 240 ccaactctgt ccaaatggtt accccaagtg tttgtatgac cctgtcagta tgtgcgaggg 300 gttttttact ccacatttcc tcccaaactt tttttttttt ttttgacaga gtctgggctc 360 tgtcgcccag gctagttgca gtggagctgg aatcgcgcca tggcattcca gcttggggca 420 acagagtgag gcttcatccc cctccaagag aaaagccaaa ctaataagat tcaaaatgta 480 aaataataaa ttggtgtttt tttatacttt gcccctatag tagtttcctt gcctcttcca 540 gcttctggtg gctgccccag cattccgagc gtgtggctgc gaaactccag tctcccccac 600 cttcacatca tcttctccat gtctccttac cttcctttgc ctctgtcttg aaaagacact 660 gtgatggcat ttaggaccca cccagctaat tcagtgtgtt ctcatctgca gatccttgat 720 caagtcacat ttgcagagac ctctttttca aataaggtaa catttccaaa ttcctgggat 780 taagacttga tatctttggg tggtcattat ttaacctact acaattgggc ctatccctag 840 gccatgccag cctgggtgat aaagcgagac tctgtctcaa aaaaaaaaaa aaaaaaaaaa 900 aaaaaaaaaa aaaaaaaaaa a 921 39 632 DNA Homo sapiens 39 tgacgtccac tgccttgtca ccagcgacct gcctgtcatg cccaccccct gaggaagcat 60 ggggacccta acaccctggt gccctgcacc agacaggccg tggtcaggcc caggccaccg 120 gccgggttct gccacagctt cccacgtgct tgctgacatg cgtgtgcctg tgtgtggtgt 180 ctgttgctgt gtcgtgaaac tgtgaccatc actcagtcca aacaagtgag tggccctcga 240 ggccacagtt atgcaacttt cagtgtgtgt cataacgacg tcactgcttt ttaactcgat 300 aactctttat tttagtaaaa tgcccaggag tcctggaagc tacgcggact tgcagaggtt 360 ttattttttg gccttagaat ctgcagaaat taggaggcac cgagcccagc gcagcagcct 420 cgggacccgg attgcgtttg ccttagcggg atatgtttat acagatgaat ataaaatgtt 480 tttttctttg ggctttttgc ttcttttttc ccccccttct caccttccct tctccccgac 540 cccacccccc aaaaaagcta cttcttcatt ccgtggtacg attatttttt ttaactaaag 600 gaagataaaa ttctaaaaaa aaaaaaaaaa aa 632 40 608 DNA Homo sapiens 40 ggtgaagtca tcatgagctt tttccaactc ctgatgaaaa ggaaggaact cattcccttg 60 gtggtgttca tgactgtggc ggcgggtgga gcctcatctt tcgctgtgta ttctctttgg 120 aaaaccgatg tgatccttga tcgaaaaaaa aatccagaac cttgggaaac tgtggaccct 180 actgtacctc aaaagcttat aacaatcaac caacaatgga aacccattga agagttgcaa 240 aatgtccaaa gggtgaccaa atgacgagcc ctcgcctctt tcttctgaag agtactctat 300 aaaatctagt ggaaacattt ctggcacaaa mtagattctg gacaccagtg tgcggaaatg 360 cttctgctac atttttaggg tttgtctaca ttttttgggc tctggataag gaattaaagg 420 agtgcagcaa taactgcact gttctaaaag tttgtggctt attttcttgt aaatttgaat 480 attgcatatt gaaatttttg tttatgatct atgaatgttt ttcttaaaat ttacaaagct 540 ttgtaaatta gattttcttt aataaaatgc catttgtgca agatttctca aaaaaaaaaa 600 aaaaaaaa 608 41 877 DNA Homo sapiens 41 ggcacgagaa cttcataaag atgattttta aaatgcccag ctctgagtgc aggtcctcag 60 ctttactcct gaatgtgagc ctcgctgagt ccgaagccgg tcgcaggcct gggaaaccag 120 ggtgggctga ggaggcaacg ggaggcagaa gggccagcag gaaggatggg acccaaggct 180 aggctggggg gtcagcagca gacatgggtt gaaggggagt gggtcatggg aagggcctgt 240 gcaggatgga gcccagcagg ggatgggaga ggacacaaag ccaggcagaa ggcggtgatg 300 gcagcagaga ggagcaccca ggggccgccg cttggccacg agtgtaggcc acccaggggc 360 cgccgcttgg ccacgagtgt aggcccacgg tgcccttcag cacagtgccc cagggctcgc 420 cagccaccca ggaccgagac tcgtagtgct ggggggctgc agctccttcc catcctttcc 480 tgggctgcct ctagccccca tctctccaaa ttagcagggg agctggagcc cctaagaccc 540 cagcctcaca tcatcctcac gcctctgttg ggagccatgc cctgctgcac ccgaatcttc 600 tgtttctccc tgaccatggg ctcctgaagt tcgaggcctg tggttgttcc tctcttcaac 660 ttggttgctg cggtgagttt ctgggaggtt tgtcttacta gattctgtgc ttccctccac 720 catgggaacc tggaatctct gttttgcttt ttagcatgca ggtaatttcc agcctttaca 780 tctgcctatc agacaaatcc tatcttcata cctcaggcag tatcaccccc aacgtgtggt 840 ctaaatttgg acttctgtat gcatgaactc acctcga 877 42 978 DNA Homo sapiens 42 acgagccaaa acactccctc cgctcccact tcacttagag tcaaggccaa agtctccact 60 caccatggcc caccgcagtt ggattctcag ctcctccctg ctcccaattc ccatcttttt 120 cctcctccct ccctcctctg cagccaccct agccacacca gggtcctaga atctgttccc 180 tggagatgtc cacgtggctt gctccctctt ctcctccagg tctctgctca gatgccacct 240 cctctgtgtt gaaagattcc tttagtccac ttaatttttc atctcagtgc ctaccatgtc 300 ctggcattct ttattattat tattattatt atttattagc ttgattttct gtggctccca 360 gaacaatgca agttcacgag ggaacaggga tttttgtctg tcctgtttac agctgcaccc 420 ccagtgccta caagggtgcc tggcccagag taggtgctca ggacaatttg ttcaatgaat 480 aaagaattca accaggtgcg gtggctcaca cctgtaatcc cggcactttg ggatgccaag 540 gtgggtagat cacatgaggt caggatttcg agaccagcct agccaacatg gtgaaccctg 600 tctctactaa aaatacagaa attagctggg catggtggcg tgcacctgta atcccagcta 660 cttgggaggc tgaggcagga gaactgcttg aacctggaag gcgggaggtt gcagtgagcc 720 aagatcgtgc cactgcactc caacctgaat gacagagcaa gactccatct caaaaactat 780 ataataataa taataattca accagatgtg gtggcttatg cctgtaatcc caacactttg 840 ggaggctgag gcaggaggat tgcttgagtc cacgagttca agaccagcct gggcaataaa 900 acaagacctc atctttacaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 960 aaaaaaaaaa aaaaaaaa 978 43 999 DNA Homo sapiens 43 gaattcggca cgagcaggag ggcaagtcaa attttatggg cctccaagac tctgcagaag 60 agactcccag gctgaataca agccttaggc cactggaata tgctggtttt cctaccattc 120 accgttttgg tacttatcag ttacattttt tcctcccact ccttcaaccc cttatttact 180 ctatgtgatt ttgagcaagt acttttacat ctaaagatat tttctcatcc ctaaaataag 240 aacaaggtga tagagaatca ctgtaactac aagtccaata gaataaggtt ctatttcaga 300 ttgtctcagc cttaatattt agtctactaa ctgggcaaca tttagattct attccaaatt 360 ccctcaaacc ctttctaaca tcaacagact aattccctta gccccactcc ttcctcatta 420 aaataaaatc actgggctgg gcactatggc tcctgcctgt aaccccagca cttcaggagg 480 ccaaggcagg aggatcactt ggggtaagga gtttgaaatc agcctgggga gcatagtgag 540 accccatctc taaaaaaaaa aaaagaatta accgggtgtg gtggtatgca tctgtagtcc 600 ctggtactgg ggaagctggg gcaggaggat tgcttgagcc taggagtttg aggttgcagt 660 gagctatctt tgttgcagtg agccatgttg ttgcaaataa ccagatctca ttcttttttt 720 tatggctgaa tagcactgca ttgtgtatat gtaccacata taccagcctg tgtgacaggg 780 caagacgtgt ttctaaaaaa aaaaattttt tttaaatact ctgcagtatt ttttcaaaat 840 ctacagtcac tttttcctaa taatcaactt taaaaaatat ttcaaaataa gcttgaattt 900 ggccctttgc tctcacaaca ccaaaacacc attttcccaa ttacagcaca gcaaacacac 960 gacattcatt tctgtcttct gaattttggg ggccccgta 999 44 510 DNA Homo sapiens 44 gaattcggca cagtcttcca cacttgcttg tcaaggtgat aaccctgaca tctgtcaagt 60 gtaatcctat tatgaatata gcaagagtta tttactgcca agtaagaaac agattagtta 120 tggccctggt aatttctgcc cctcccccaa acagcccatg taattgcttc ttttttatct 180 ttcttttcat tttgcctctc atttttcctc tcttcaaagg cctttttgct acttttgtct 240 ttttctaagt ttttctttat cttgttcttt tctttctgtt gtctcaaatt ctcacatttg 300 gccagtcttt ctcttgtcgt ctcccggggt gtaccttgga cccggaaaca cggagggagc 360 ttggctgagt gggttttcgg tgccgaaacc tcccgagggc ctccttccag tgatctcatt 420 gactgattta gagacggcat ctcgctccgt caccccggca gtggtgccgt cgtaactcac 480 tccctgcagc gtggacgctc ctggactcga 510 45 986 DNA Homo sapiens 45 ggcacgagct taagttgaat tataaaaatg atggatataa gtggtagctg tatctagtga 60 agtgtctgtc agtaagtgaa acattttttg gtggtggctt atccacaaac agtttagttg 120 tagaataaaa cttatgagtg acatctggaa agtaaccatg ctaagatggc aagcacactg 180 gaaacaatta ggccacttgg ctttcttttg ctgtattgtt ttataagcct actttacctc 240 ccagtcttgg aaacaagttt tagtttttta ttggtttgga gactagagcc aatagtataa 300 tgttctcaaa ggaaacagac ttgagttgtt ggattagagg aactaaccca acttatatga 360 tttttttttt gtttttgtcg tgtagttatg gcactgtctt atttggaaca tttgcaacta 420 ggggataata caacattttt aactctcatt tgacaaccta ctactaatca cagaccacaa 480 gggtaatgac caaatttatg tgggttttgc acccatagtt gtcctagccc aacttcaaac 540 tcttacgatt acttgggtaa cgctctggag gaccttcctt gagatcccta atatttaaga 600 tatttgatat cttgaagata gtataggata tagagattta ccaaatagga atataaggag 660 tatgttaaaa tgaccagata cctgtttgat agtttactga cctagcagat gtgtggaaaa 720 ggaatcagat cttgattctt ctgggtttat actggttgta aaacagaatg atacagaaaa 780 tgttttcctt gtttaactgg tagttgaaca tagaacttgg gtattataga tcacttttca 840 ctttttggaa tgttttgtat tgaaacttaa taaaacttta acatggcaaa aaaaaaaaaa 900 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 960 aaaaaaaaaa aaaaaaaaaa aaaaaa 986 46 747 DNA Homo sapiens 46 catacttttc aacattccct tctgtccttt ctttgttttt aaagaaagct ctgattttgt 60 ttcattttca gctggagact taaatgacac caagcaaagc ctacttagtt tagatctcca 120 gaaattggct ggtggaaaaa aatcaaacat gaagattgca gttttgtttt gtttttttct 180 gcttatcatt tttcaaactg actttggaaa aaatgaagaa attcctagga agcaaaggag 240 gaagatctac cacagaaggt tgaggaaaag ttcaacctca cacaagcaca gatcaaacag 300 acagcttgga attcmgcaaa caacagtttt tacaccagta gcaagacttc ctattgttaa 360 ctttgattat agcatggagg aaaagtttga atccttttca agttttcctg gagtagaatc 420 aagttataat gtgttaccag gaaagaaggg acactgtttg gtaaagggca taaccatgta 480 caacaaagct gtgtggtcgc ctgagccctg cactacctgc ctctgctcag atggaagagt 540 tctttgtgat gaaaccatgt gccatcccca gaggtgcccc caaacagtta tacctgaagg 600 ggaatgctgc ccggtctgtc cgctactggt acagagcttt agctaagcaa aatatcagtg 660 tgtgattaat ctttaacttc catttgtttt tgttactaat tttagattaa aattatgata 720 cattaaaaaa aaaaaaaaaa aactcga 747 47 340 DNA Homo sapiens 47 acgagcagca gccctggcat gttcctgccc cacaggaata gaatggaggg agctccagaa 60 actttccatc ccaaaggcag tctccgtggt tgaagcagac tggatttttg ctctgcccct 120 gaccccttgt ccctctttga gggaggggag ctatgctagg actccaacct cagggactcg 180 ggtggcctgc gctacttctt ttgatactga aaacttttaa ggtgggaggg tggcaaggga 240 tgtgcttaat aaatcaattc caagcctcaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 300 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 340 48 567 DNA Homo sapiens 48 ggcacgagag catttcctac ctagtgaaga aggggacagc cactgagtcc agcagagaga 60 tcccaatgtc cacactccct cgaaggaaca tggaatccat tgggctgggt atggcccgca 120 cagggggcat ggtggtcatc acggtgctgc tctctgtcgc ccatgttcct gctggtgctg 180 ggcttcatca ttgccctggc actgggctcc cgcaagtaag gaggtctgcc cggagcagca 240 gcttctccag gaagcccagg gcaccatcca gctccccagc ccacctgctc ccaggcccca 300 ggcctgtggc tcccttggtg ccctcgctcc tcctctgccc tcctctcccc tagagccctc 360 tcctccctct gtccctctcc ttgcccccag tgcctcacct tccaacactc cattattcct 420 ctcaccccac tcctgtcaga gttgactttc ctcccatttt accactttaa acacccccat 480 aacaattccc ccatccttca gtgaactaag tccctataat aaaggctgag cctgcatctg 540 ccaaaaaaaa aaaaaaaaaa aaaaaaa 567 49 1357 DNA Homo sapiens 49 agtaggatcc agtctgtggg gctcatttga gggagaatga gcacggggct tttggaggct 60 gcagcctagg gccaagggat ggaggctcac ctgagtgcag gttaggcagg tgaagtgtct 120 ccccggaaac caagctagag tgccccacct gctcggccct gccttctcgg atcggatcca 180 gcacatccag gcttctcctc ctcccgagga accagtggtg acagctgagg ccatgtgagt 240 aggatcctga atgaggcttt atctctggct gttcgtccca tcgtccaccg tggcaccagc 300 tccctcagcc agccgggatg ggaccagcga ctgagagagc cagaggcaga gaggtgaggg 360 tgaccatatc ctggactgtg agaggaatgg gactctgggc ctgtagctgc caagcaggtg 420 gcaggtgctc caggctgtga tctgcaccct ctgacccctg acattgacct cctaccctga 480 cccctgcctg accaagccat gtctgaacag gaggctcaag ccccaggggg ccgggggctg 540 cccccggaca tgctggcaga gcaggtggag ctgtggtggt cccagcagcc gcggcgctcg 600 gcgctctgct tcgtcgtggc cgtgggcctc gtggcaggct gtggcgcggg cggcgtkgca 660 ctgctgtyaa ccamcagcaa gccgctcarg tgaatggcgg ctaagcaamg ggcactgtgc 720 tctgtttgct ggctctsctg gttctggtga acagctgatg agctcggctg tcaggacatg 780 aactgcatcc gccaggccca ccatgtggcc ctgctgcgca gtggtggagg ggccgacgcc 840 ctcgtggtgc tgctcagtgg cctcgtgctg ctggtcaccg gcctgaccct ggccgggctg 900 gccgmcgccc ctgcccctgc tcggccgctg gcckccatgc tgtctgtggg cattgctctg 960 gctgccttgg gctcgctttt gctgctgggc ctgctgctgt atcaagtggg tgtgagcgga 1020 cactgcccct ccatctgtat ggccactccc tccacccaca gtggycatgg cggccatggc 1080 agcatcttca gcatctcagg acagttgtct gctggccggc gtcacgagac cacatccagc 1140 attgccagsc tcatctgacg gagccagagc cgtccttctt ctcacagcgg cctcagcgtc 1200 cccaragccg agccagggtg tgagtgcatg tgaacgttga gtacacatga gtgcgtgtat 1260 gcccccaggc tgggtcagct cttctgtgga ttgcatggcg tgtgattaaa agtcccatgt 1320 gttcccacac atccaaaaaa aaaaaaaaaa aactcga 1357 50 1075 DNA Homo sapiens misc_feature (79)..(79) n equals a,t,g, or c 50 gtgtcgcagc tctcttcgac gtacctgtcc tcaggagccg cggcggcgac tgcgcctcgg 60 acggccgtcg gggccgagna accatgagcc ccaggggcac gggctgctcc gccgggctgc 120 tgatgactgt cggctggctg cttctggcgg gcctccagtc cgcgcgcggg accaacgtca 180 ccgctgccgt ccaggatgcc ggcctggccc acgaaggcga gggcgaggag gagaccgaaa 240 acaacgacag cgagaccgcg gagaactacg ctccgcctga aaccgaggat gtttcaaata 300 ggaatgtcgt caaagaagta gaattcggaa tgtgcaccgt tacatgtggt attggtgtta 360 gagaagttat attaacaaat ggatgccctg gtggtgaatm caagtgtgtt gtacgggtar 420 aagaatgccg tggaccaaca gattgtggct ggggtaaacc aatttcagaa agtcttgaaa 480 gtgttagatt ggcatgtatt cacacatctc ccttaatcgt ttcaatatat gtggaactty 540 taagacagac cacaatccat tatacttgta aatgattcag caatcctaga agtacgcaag 600 gaangtcacc ccttgctttc gagtgtgaca cactggataa taatgaaata gtagcnacta 660 ttaaattcac agtctatacg agcagtgaat tgcagatgag aagatcaagc ctaccagcca 720 ctgatgcagc cctaattttt gtgctgacca taggagtcat tatctgtgta tttataattt 780 tcttattgat cttcataatc ataaattggg cagcagtcaa ggctttctgg ggggcaaaag 840 cctctacacc tgaggtacaa tccgagcaga gttctgtgag atacaaagat tcaacttctc 900 ttgaccaatt accaacagaa atgcctggtg aagatgatgc tttaagtgaa tggaatgaat 960 gatgtttgaa tgatatataa caaaccaaag gatattacag aatattagat tcattattac 1020 aaaaataaaa tacacattga aatactttaa aaaaaaaaaa aaaaaaaaaa ctcga 1075 51 1025 DNA Homo sapiens 51 ggcacgaggc cggaaagcag aaggttgcag tgaagctgag atggcgctac tgcagtccag 60 cctgggcgac agggcaagac tccacctcaa aaaaatatat aaaataaagt gggattcatc 120 caagagcttg gacatgatta actagtgtca aggagatatg tttatgccat tattatcctc 180 cttacttggt agggtacaac agaaacagaa caacaaggtg acagcctttt gctcaagtca 240 aaaagaaaat aagtccctca tcttaggttt aaagttgttc attcaggtag tacagacttg 300 catttggaag acttattctt gatcttctgt agctttgaca gcaaggacat cactacaatg 360 ggtacagaaa taacacattc tgatccttgc tgagatcctt gtatgggcct atcttaaatc 420 tagcctattg tctgtcttac cctttgattt ttataagtgg aaaacaggaa aaggctaacc 480 aagcaagagg aaggcataga ttcatcttcc tttcaatctt gactatagtt taaagagaat 540 accatgatct ttctgttcta ttcttggctt acttgaatat ttagccaggt ctctgcatct 600 tattcagtca gaaaacagac acagattcag ataactcaaa ggatgttact tgcttgagta 660 atccttgggc ctcgctttaa ctttgtagat ccaggaacag aattaagcag acagttcggt 720 ctacactgcc aaatttctta gggaaaaaga gggcaagtca gaaggaggaa gttggcattt 780 ggctcaaatg accaaattat ttaaggtctc tacacttcac tttgcaccaa gtagacccaa 840 gaatgattat aattcagcta cgtgtggtgg tgcagatcag tagtcctagc tattcaggag 900 gctgaggcgg gtggattggt tgagcccggg agtttgaggc tgcaatgggc tatgatctcg 960 ctgcgcttta gcctgggcaa cagaacaaga ccctgtctca aattaaaaaa aaaaaaaaaa 1020 aaaaa 1025 52 908 DNA Homo sapiens 52 ggcagagaaa tatgccaggt agacaccagc ccaagtaccc tcctccagaa gtctgtgact 60 accttgtcac tactttaggc ccattccaca aagcccatct ctggtttgag aattcatttt 120 gatctgtatc tacaccaccc aaagttaggc ctcctataat gtccaaaaca ttcctttcag 180 cctttttatt tcttactgta ctgtctctta ctgtactgtc tatctgcagt aattgaggac 240 ccataaaatt tagataacta catgtctttc tcttagaatt gtcactcagc ataatgagca 300 tttaacatac aaaggcaatg tactgttttg tgttgatcta tgtaaaagaa tacaattctt 360 ttttacataa ttagtgaaat tttatttttt attaggaaac actaaatagt gtaatatttc 420 tttgctttta aaaaaattcc tggtagcaaa tcaagattaa ataatkgctt cattttcttg 480 agcaatactg aagcaggatg aagtaagagg aatgccattc atttaaacat gctttgcttt 540 atgaattttg tctctttttt ggtctctttt tcttatattc aagttacaaa tgtacaagta 600 tccttactaa gagtgctcct tttgtatttt acatatatac agtatgaaaa tacattggaa 660 cactaggaaa gtttttaaat aacagttcta atttatcaga aaattgtgtt ttgggattga 720 gttctttgtc tcagcccaga atcccaggtc ctgggcctgg ttttctaatg ctgtcatctc 780 agttcgatat tttactttag aacctggaat ctcctactta atatatgacc atgactttga 840 aaggcaaaag aggaatcaag aataaataaa acaaacttaa tcttcatctt taaaaaaaaa 900 aaaaaaaa 908 53 1255 DNA Homo sapiens misc_feature (1236)..(1237) n equals a,t,g, or c 53 gaattcggca cgagaactct tggcttccag gttctagcac tcattactac catggacagc 60 agcttccttt taattcagtg ggattctgcc aggcaggctt ccaggggagc tgtggggtct 120 agtacaagtt tctcccctgt tgctgcttca gtggctttca ccctgcccaa tacatattta 180 atatgacacc atgtgtctct ttgtcagtct cctcatattg agcctaggaa ttggcaaaca 240 ctccatgaat atttacacat tgactttttt ttaagctctt aagagaggaa tatcccttgg 300 agtcctcttt ggagatttcc agtgtctcat catcaagcaa tatgtccttt cagctaataa 360 gatctttatg tttcataatc attgcttaat atccaaagat taaatttaga ccatggaaag 420 gaaaaaagat ctcaaagcaa ctcatgtccc taaaaggaaa tcacactcat caaacaaata 480 cgctgtgttc acacaaagat attactattt tctaccttca gtactggcag actttaagtg 540 ggatatgaaa agcctcagct gcttttgaat gtgggtactt taccctggta aacatagatt 600 ccactcttca gcttggccaa tgtttataat actcagccct gcagaaaagc gtcctacttg 660 gctctcttat cctccattgg cttagacagg aattggggaa atacgcatgt cagtattagc 720 aaaatcagca gcaaagggac agargcatat gaaagtcacc tcmcaaaggc aatgcatatt 780 aaccctatcc ttggaraaat atgtgcttcc ytccagaaga aggaatattc actccagtgt 840 aaamccactt aaattatctt ttccattatc ttgtttaata atcaaaattc ttagaggctg 900 atagggttac acccatttat aggcaaagaa atggaaaccc agagagataa aatgactttc 960 ccaaattctc ttagcaaaat ggagatagaa tcaaaactga atcccaatct ctggtcccca 1020 ttttgttaca atcacagtat ttttcacaat attatctcaa actttaccca tcgcgatgag 1080 gttcctggtc tcgcagctct ctcacagatg attttaagcc agggaaactg ctatttttta 1140 atgcttattg ttttctttgt ttaatatgta ttcattgtag agatttgggg aaaataaaat 1200 gaccaaaaat cttaaaaaaa aaaaaaaaaa actcgnnggg gggcccgtac ccaan 1255 54 1142 DNA Homo sapiens misc_feature (92)..(92) n equals a,t,g, or c 54 aattcggcag agctgcctgg aagttccagc tccgagttcc ctgggaggac tttttcagat 60 gttagggacc cgctccagag ccccctctgg tncaccctgg gttcctccag ccccaccgag 120 tcactcactg tgggaccctg cctctgaata atcaggaacg gtggcttcag agacgtctct 180 tgggccttcc ctctggccac gtctgcaccc acccctsctg ggcaccctcc tagcctgcca 240 tccctcacct gcagccaggc tctcagggaa ggtccatgct gcttggcctg agttcaaggc 300 tttctgcctg tagcctggac tcccgtggac ccccgtgggc aggtggcttc cccgtggcat 360 ctccacaccg cctctgcctg cccctgtgga ctgatgctat cgcgcaccgt cccacgaccc 420 caccccgagc tcctgaagcc ggggtctgag cctgcatcac ctctggcctc tcatccccca 480 ctctcctgag agcagtggtc acagcggccg gccgttctgc tgagaaggca gagaggcagg 540 ctcaggcctc agcgtggaca gcagggataa ggggcacgaa ggacggggac tcggcccctt 600 cagaattcct caggactctc aggtgcagct ttgccaaaaa ggaacttttc atgtcatgca 660 gttgagggga cttagtctca atcccaggct cctcttgact ctgggcagct ttaatcaggt 720 tgggcagcct ctgctacagc gtggagtggg atggctctct tccctcagcc acgccgcttg 780 tgaggacaga ggtgggggag tgggaagtgg gaagtcacca gagaacagga gagggatttg 840 agggcgcgac cccagcgctc tccacggacc agccagaggg actggagcca ggtgtgcatg 900 ggttcaaggc cctggccctg cccagcctct gtyttgggag ctcagcccca gggttcggtc 960 gtcagcagtt tcccaagaac aagatgtgat ggcatctgct gctgaaaccc tgatgaggac 1020 caggccccct gcaccgctgt cagcctgagg aattaaagct ttggtgctgg gaaraaaaaa 1080 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaac 1140 tc 1142 55 1923 DNA Homo sapiens misc_feature (144)..(144) n equals a,t,g, or c 55 aattcggcac agccttatgc cacagtagtg cctgtagcag agaaaggatt ccctcctcca 60 cctcagggcc cactgctgct gctctccagc ctgcagtttc ctctaaggct ctggattggc 120 tggaagagca acagagggct gggnaaagag cttctatata tacctcagga ggaaaggcat 180 cccagacagt tttgaagttt tcaaagactg gctctgctgt taagaagttg tacttaaagc 240 ggaggagcta agccacctgc caaaatgtgc aaaggacttg cagctttgcc ccactcatgc 300 ctggaaaggg ccaaggagat taagatcaag ttgggaattc tcctccagaa gccagactca 360 gttggtgacc ttgtcattcc gtacaatgag aagccagaga aaccagccaa gacccagaaa 420 acctcgctgg acgaggccct gcagtggcgt gattccctgg acaaactcct gcagaacaac 480 tatggacttg ccagtttcaa aagtttcctg aagtctgaat tcagtgagga aaaccttgag 540 ttctggattg cctgtgagga ttacaagaag atcaagtccc ctgccaagat ggctgagaag 600 gcaaagcaaa tttatgaaga attcattcaa acggaggctc ctaaagaggt gaatattgac 660 cacttcacta aggacatcac aatgaagaac ctggtggaac cttccctgag cagctttgac 720 atggcccaga aaagaatcca tgccctgatg gaaaaggatt ctctgcctcg ctttgtgcgc 780 tctgagtttt atcaggagtt aatcaagtag taatttagcc aggctatgaa atcatcctgt 840 gagttatttc ctccataata accctgcatt tcccattaat ctacatatct tcccacagca 900 gctttgctca gtgataccca catgggaaaa atcccagggg atgttgctta ctctttttgc 960 ccacactgct ttggatactt atctactgtc cgaagccttc tttccccact caattcttcc 1020 tgccctgtta ttaattaaga tatcttcagc ttgtagtcag acacaatcag aatcacagaa 1080 aaatcctgcc taaggcaaag aaatataaga caagactatg atatcaatga atgtgggtta 1140 agtaatagat ttccagctaa attggtctaa aaaagaatat taagtgtgga cagacctatt 1200 tcaaaggagc ttaattgatc tcacttgttt tagttctgat ccagggagat cacccctcta 1260 attatttctg aacttggtta ataaaagttt ataagatttt tatgaagcag ccactgtatg 1320 atattttaag caaatatgtt atttaaaata ttgatccttc ccttggacca ccttcatgtt 1380 agttgggtat tataaataag agatacaacc atgaatatat tatgtttata caaaatcaat 1440 ctgaacacaa ttcataaaga tttctctttt ataccttcct cactggcccc ctccacctgc 1500 ccatagtcac caaattctgt tttaaatcaa tgacctaaga tcaacaatga agtattttat 1560 aaatgtattt atgctgctag actgtgggtc aaatgtttcc attttcaaat tatttagaat 1620 tcttatgagt ttaaaatttg taaatttcta aatccaatca tgtaaaatga aactgttgct 1680 ccattggagt agtctcccac ctaaatatca agatggctat atgctaaaaa gagaaaatat 1740 ggtcaagtct aaaatggcta attgtcctat gatgctatta tcatagacta atgacattta 1800 tcttcaaaac accaaattgt ctttagaaaa attaatgtga ttacaggtag aggccttcta 1860 ggtgagacac ttttaaggta cactgcattt tgcaaaaaaa aaaaaaaaan gnaaattttt 1920 tgg 1923 56 1228 DNA Homo sapiens 56 gaattcggca cgagccattt tggtgtggga gtgggaggag ctgtgaatta tgacagttct 60 aattaatata attttgtctt tagtaaaaac aggccctgga cagcacttaa accacagtga 120 attggcaatt ctactaaacc tactacaatc taaaacaagt gttaatatgg ctgattttgt 180 ccaagtgttg aacattaagg taaactctga gactcaacag cagctaaata aaataaacct 240 tcctgctgga attttggcaa caggtgaaaa acagacagat ccatcaacac cacaacagga 300 gtcttcgaaa ccgttgggag gaattcagcc ttcttctcag accatccagc ctaaagtgga 360 gactgatgct gcccaggcgg ctgtgcagag tgcatttgca gttctgttga ctcagttaat 420 aaaggctcag cagtcaaagc agaaagatgt gctactagaa gagagggaaa atggatcggg 480 acatgaagcg tcattacaac tcaggccact ccagaaccta gcactccggt gtcgggtaag 540 tgtgcagata ccagaccact aacacagctg cattacatkg tctactcagt gttgctgact 600 atatataatg tgtatagttc agtgacattg ccaaaagatg tcctgaagaa tctcaggtaa 660 ctggcaatag gttggttttt cagtctgttt acttccagga atggattctt taacaaatta 720 tccatgtgag atagaactca ttrtgaatga taaagatatt tctaaggtaa acctatggtt 780 aagaaataat atttaactcc aaatacgaaa ggatgcttga ctaaggcata atttatgtac 840 acagtagctt ttgttcctca agcaatgaag tatacgtgaa ttctgcacct agccgtaatt 900 agctttaaaa agccaattac ggctgggtgc agtggctcac acctgtaatc ccagcacttt 960 gagaagctga agtgggaaga ttgcctgaac ccaggaattc agtacctatc tgtgcaacat 1020 agtgagaccc tgtctctaaa acaatttttt ttaattaact gggcatggta gcacatgcct 1080 gtgattccag ctacttggaa ggctgaggtg ggtggatcac ttgagcccag gaggtcaagg 1140 ctgcagtgag ctgtgatcac tccactgcac tccagtctgg gtgacagagt gagaccgtgt 1200 caccaaaaaa aaaaaaaaaa aactcgta 1228 57 1038 DNA Homo sapiens misc_feature (2)..(2) n equals a,t,g, or c 57 gnaattcggc acgagttaat gtataaaata tttctataat gaattttaat gggaattaga 60 gcatcataga aaaaatgctc ttactgttga aaacattatt tgttacattt tggtcaacta 120 atctttcaat aacttttagt aactataatg ttaagttgta ccagtggcag tcttatatag 180 taaatggcag ctgacagcat gaaaataaca tatctaatat tttgtgacta tcttattagg 240 aaaatcagag aatttcaaaa ccttgttagt ttttagggta tagtcacatt ttataaatgt 300 gcggtatatt tatacatgat ttgacgtttg tgwaaatatt ttccctggac ttttatttta 360 gatgagatct acagtgtagg caaacttata taatctgtca actccattag tgtcatagtc 420 agactcatcc ccatgctaaa attatagttg tkaaaatacg cttttgtaaa tagttgtgtt 480 aggtcattat caccaagtct tcaaggkatt acattataaa aaccttggkt tttattcttg 540 tgaatamccg ttttttccat gcaaagttaa aattcttcag cctttaattt ttttattaat 600 atataaggat gtgatgagta tgactacaaa acaggaaaaa ataaacagat ttcgtttgtg 660 gcttttgcta aattgttacc tgacaaaatc ttagccagtt cttcattttc gttttgagat 720 gaagatactt agttttagtc caggggctgg gcgcgatagc tgatgcctgt ggtcccagtg 780 ctttgcgggg ccgaggcagg tggatcactt aaggtcagga gtttgagacc agcctgccca 840 acatggtgaa acgttgtctc tactaaaaat acaaaaatta gacaggcgtg gtggcacaca 900 tctgtaattc cagctactca ggaggctaac acaggaaaat tccttgaacc tgggaggcag 960 aggttgcagt gagccattgc actccagcct gggcaacaca gtgagactct tgtctcaaaa 1020 aaaaaaaaaa aaactcga 1038 58 990 DNA Homo sapiens 58 gaattcggca cgagaatttt gaaagaagtt ctactgtgga taaaaagcta tgaaacagca 60 tcacatacta cagagaaacc ttttgggaaa ggaagagcca atagatatgg caaacatcat 120 tgttgtctta ttttcagaaa ttgccgcagc taccccagcc ttcagcagcc accaccctga 180 tccgtcagca gccagcaaca taaaagcaag gttctctacc agccaaaaga agaaaactct 240 ctgaaggctc aggtgtttta taaaattttt ttagcaataa aatatttttt aaagtatgta 300 tattttttag atgtaatgct actgcatagt taatcagcya tattatagtg aaaatagaac 360 ttttgtatgt actgggagac caaaacattc atgtgaataa cttttttgca atttttaact 420 tatttcagtg atctgggccc aaacctgaaa tatccgagcg gtatatttct ctctggcccc 480 aagttttgtg atattgttgt cctacatttt awttgtacat atgktataaa ctccacactg 540 tacttcygtk atttcattta agctgtcagt tatcttttta gagatttaga taaacagaga 600 catgttttta ttctttccat tgctgcttat tcctctgcgt aggttcatat ttcagkcctt 660 ttacttcaag agctctaaaa aaaatgtctt atagtgcagc tctattggta atcgattcct 720 ttagcttttg gatgtttaaa aagtgctttc tttaccttgc cttaattttt gaatgatatt 780 ttgctgagta atattctgag ttggtgattt tctctgacac tgcttttttt tttttttttt 840 tttttttttg tcatttgaca cagaatcttr cagtgagttg agatcgtgcc actgaactcc 900 agcttggggg acagagcaag actccatctc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 960 aaaaaaaaaa aaaaaaaaaa aaaaactcga 990 59 1767 DNA Homo sapiens misc_feature (26)..(26) n equals a,t,g, or c 59 aagaaaaaaa taggcctggt tgccanatta aggtcccctg ggctatttta aaccggattt 60 ggataccnag gtctttccan aggccgtatt ttgccccccg taacccntaa aaaaaaaaaa 120 agatttccaa aatgccgttt tcagaacctg ggttttaata gcagtattga atttgtaagc 180 ttagtagttg cagaaattga acactaggtg gcactcagtt atcttaacag gggaagtact 240 gatacaattg ttgacttttc ttttactatg tgtaagaaat accccaaaca tgaaaagatt 300 gttttgatca tatgcatgta tgtagaatat ttttgcagag cagaaagatt atgttagaag 360 tgtgattttt attttcagaa gtcatataca tgtaagctac aattttgagt gctttataaa 420 cacttaagat atatatataa attttaattt catagcaact tgtaaaaaat aaaatacttg 480 ttgaaaagcc tttttcaaca tatccctaag ctaagggaag aggaaggaat aacaactcag 540 tgaaaagatg gtctccagtt tctgaatgaa aaagctacag ctgagaaata aaataaaatg 600 tcatgctgca gaatatgtta tacccttatt ttgtgttaag gatatatttt attatgtgaa 660 tggttttgtt tttgtttttt gtttttgttt tttgcttgta ttgggaatta gctttactgg 720 taacttcctt atttagtttt tagtggtcaa ctctaataaa atgaaactag ggctgagcta 780 gttagccctc actagccaaa ctgaaactct atgcaacatt aaaagaagag atccatcatg 840 tagcttgtga cacttttatt ttattagtca ccggggaact tttcagtgat gaaaatacac 900 agggtaataa accttcacat ggcttcaaaa ggaaaacaag caaatcttct ctaatctact 960 cttactataa tttcctaagt gtacaccaaa ctctggattt aaaaatctga agtactatag 1020 aacattaagt tgaagaatgg aaattaagag tacgtattca tggtttatat ttcttattct 1080 atggagttcg tgaacacatc taggtggaat gcatctgaga ctaagggctg gtttttaatc 1140 ctcataagaa accagccttg aagaattaac aattctcttc attggtattc taaacctcct 1200 aagatattta ggcttctgta cataaaagtg tttttgctaa atttacagta tatatagatc 1260 ctttcatatt attttactaa gaatgtttga actttgcata tttgatatag ttcctggtag 1320 gaatagcaca gctcaaacat tagtttttct acttacctcc tctaacacgt ggtttgtctg 1380 gagagtttct aaaaattcag ctataacccc agttcatgta tttactggtg attgttcttg 1440 ctgaggtagt aacagcccaa tcttgggctg ttaaatccta ggaaatctcg aatcatagtg 1500 attaaaatag ttggggtaaa gttgtagctt atatgcaata ctacttggag gaattcttct 1560 actaatttgt atttaatgtg gaaattgtat agtttcattg atttaatcat aaataatgga 1620 aatggtctcc aagaagtttt atttttcatt tttttgctta tacactctga ttcctataat 1680 acagtgctat aagctatgca cagaaaataa aatgtttgaa atccaaaaaa aaaaaaaaaa 1740 aaaaaaaaaa aaaaaaaaaa anggggg 1767 60 1625 DNA Homo sapiens misc_feature (1336)..(1336) n equals a,t,g, or c 60 gaattcggca cgagaatcta ccagccatga gtgaagtcta cccttggaag actgattgtg 60 ctcagttcgg ctctaaataa aatctttcca ttaactctgg cttccagtgt tttgtactct 120 gggagaacca gtcctccaag ggagagtttt gtcagccagc tgaattgctg cttcagtgac 180 aaaatggaat tcactcaaat tgttctgagc tttaggacaa aagaaatgcc tgtcatcttc 240 ctgatagtga acttagcaaa gcaccgttta aaagaatggc tctcatcact cccgagtacc 300 ttgtcattac tgctcatctg tgctaagtgc cactgtctac ttctgatccc caaaacagtg 360 gsctctagcc tttgccttct gcctaactcc aagtagagtg ttctttttat aatccttcat 420 gttcatataa cactttagca tttacagagt gttttcacat gcttatttgt gaggtattat 480 cacagtgcta raaataagga aaggctgaga cctaccaaaa tgacagtgtt gtacgtgagc 540 aggctgagcc ttgaaagcag gacctctgtc tcccacatta gcgcttcatt ccatcacacc 600 tctgcaagga caggtagcct gctggggggc catggtggca ctggggtata aaatctctaa 660 actgctaata tcctcttttc cttctaggct gagaacatct ctaaggamct ctacatagaa 720 rtatatccag ggamctattc tgtcactgtg ggctcaaatg acttaaccaa gaaamtcatg 780 tggtagcagt tgattctgga caaagcgtgg amctggtcyt ccctgtgtga tgttgaccat 840 cactgccatc acatcacctt tttttaagta gtaagaataa agccactgta tgattctctt 900 aatagctata cattaatcct gtttttagtg ctgactgggt cagccttccg ggaactggag 960 tctgtctctt tcagtgcttt tttgtttgtt tggttggttg ttttttgaga cagcctgggc 1020 gacagagcca gactgtctca aataaataaa tatgagataa tgcagtcggg agaagggagg 1080 gagagaattt tattaaatgt gacgaactgc cccccccccc cccccagcag gagagcagca 1140 aaatttatgc aaatctttga cggggttttc cttgtcctgc caggattaaa agccatgagt 1200 ttcttgtcac atgcctttct atgccttcca tggctgggtc tcagggagcc ggaagcagct 1260 gctgaggagg gatgaaaatg tcagtgtgtg acgatgcctc atgggttcac cccccaaagc 1320 ctgggcacag ctggtnttgg gtctgccgtg cctcccttcc ttcctcctct tggggccact 1380 ggctgctcca gttccccatc cgtggcaagc cggtagagcc attcatcccc gcagccttyt 1440 tcctgaccct cgtacagttt caaatgcagc agacagccaa agcaatgagt ggggggctgt 1500 ggaacttcat ttcccaaagg cagcgccagt ggctcctgag caatgagaat gtcctgtcct 1560 gtccaccata ttcaaggcca gcagaagagc ccgattaaac cctcgcagca cctggcctcg 1620 tgccc 1625 61 1588 DNA Homo sapiens 61 actggaagat gtagagtggg aggactggga gtgagggagc cagagggagc agctccccca 60 cccatggcat ctctcgcctc cctcgctcgt ctcagcccag ccctggaaga ctgagaatgt 120 tcccccaaat ctcctctgcc aaccagagct ctgggcacag attctggtgg ctccctgctg 180 gccctcttgg gcytctgctc acacctggga aggggctctc taaatcccgg ccagaaactc 240 tgacttgtgc caacaatagg atgacccaag ggagaggaaa cctatcctcc tcaccagaag 300 agcctgtgtt tttctgctga acacccactg ttcctgagga ctcctgctgg gaagtcccaa 360 gggatagttc tagcccttct gcctgtgtag acagaagcta aaccaccagt ctctctcgga 420 ggaagctgag acaacatact ctgtccatac ataagcaggc agggagggcc atgccaccta 480 cccttggcta aacagggaca gtgaacacat tttggttcct atcccagtgg gtaagaggca 540 cttatctctg ggaaatttgc ctctcttggg actctccccc tcccaggcat tttccattcc 600 tggaaaggct cctttggggt tcagaatcca gagaccaaac cctgacccac ctccttcctt 660 tcctccagcc cacgctggtc tgtccccatg ccttcccagg gcttcttcat gtcagatgca 720 cccaagtcct tagcccagct gtgccacctg caggagttcg ctcttgcgtt tcttcccctc 780 cccaagaagg gagggggcta cttcaggccc ttctgtgtgt tgcctggcag gataccttgt 840 ccaaccagct acccacctca actcccctgt agtttaggac acaaaacagc taccagcggt 900 acagagcggt gatcaaagcc gagtacttac aactctggta agcctagctt ctccgcctca 960 gcccttctgc ttctggaagg gctatcctgg gggtgaactt gaaactctca tcaggcttct 1020 gcaaaagctc ttcttcctga agacagaccc agcctttgtg ctctcaccct ccactctggt 1080 aaagctgcac ctctggggga atgaggggct gcaggaatct ctggagagcc tggtgcttca 1140 cgatgctgct ctggtgattc ttgtacctaa tctggtgtgc tcaccaatga gtgaaaggga 1200 tcgtgggtca gggacaccga gagagtgagg tcacttccac ttcaaacctt cagtgagggg 1260 gtgggatgga gagaatgctg aatctttttt ttgacgggat ggggtttttc tctttgtaat 1320 tatttcttta gtttaattaa ccttttggtt gtttgtgcaa tattatatat tttaaattat 1380 aatgcatctc cccagagtat tttgtagctg ggaaaagaaa aaaggaaaaa aagaaaaaaa 1440 gattctaaca gctgttagtt ttataattaa aaaagaaaga aaaaagaact ttgtcctgaa 1500 ccttttacag acttgccgtt aacagcatta aagtgattca cccgaagctg aaaaaaaaaa 1560 aaaaaaaaaa aaaaaaaaaa aaactcga 1588 62 536 DNA Homo sapiens misc_feature (508)..(508) n equals a,t,g, or c 62 ggtcgaccca cgcgtccgcc cacgcgtccg gcttccttaa tgtaatttaa accctggcaa 60 acattcttta gaaaccaaga ggaaagaaag aacaaatatc aaaaaagaca tagaatttaa 120 tattgataca atttcacctc taaaatggat ttgaagaaat gcaactttat atcaaaaaat 180 gtcatctgat ttcctttgtt tcttttttaa attatgtaat cagatgattt tatgtttttt 240 tttcagggga gcggaatatt ggtttctttt acttgttgtt ttcagttttc tctgccattc 300 atgtttcttt tttgtgttca gtgtttcaaa tacaatttgt atttaaggat tttaaaatac 360 caaactgtaa ctgagtacag tggatcgttt tctgttagga tgttaatatt atacaatgaa 420 atctataaag tgttgtcaat ttgattattg acacatataa catgtttaca aataaactgt 480 ggtattgatc aaaaaaaaaa aaaaaaancc cggggggggc cccggaaccc aatccc 536 63 660 DNA Homo sapiens 63 gcacgagacc aagcaaagcc tacttagttt agatctccag aaattggctg gtggaaaaaa 60 atcaaacatg aagattgcag ttttgttttg tttttttctg cttatcattt ttcaaactga 120 ctttggaaaa aatgaagaaa ttcctaggaa gcaaaggagg aagatctacc acagaaggtt 180 gaggaaaagt tcaacctcac acaagcacag atcaaacaga cagcttggaa ttccgcaaac 240 aacagttttt acaccagtag caagacttcc tattgttaac tttgattata gcatggagga 300 aaagtttgaa tcctttcaag ttttcctgga gtagaatcaa gttataatgt gttaccagga 360 aagaagggac actgtttggt aaagggcata accatgtaca acaaagctgt gtggtcgcct 420 gagccctgca ctacctgcct ctgctcagat ggaagagttc tttgtgatga aaccatgtgc 480 catccccaga ggtgccccca aacagttata cctgaagggg aatgctgccc ggtctgtccg 540 ctactggtac agagctttag ctaagcaaaa tatcagtgtg tgattaatct ttaacttcca 600 tttgtttttg ttactaattt tagattaaaa ttatgataca ttaaaaaaaa aaaaaaaaaa 660 64 1038 DNA Homo sapiens 64 ggcacgaggc gcctcggacg gccgtcgggg ccgagaaacc atgagcccca ggggcacggg 60 ctgctccgcc gggctgctga tgactgtcgg ctggctgctt ctggcgggcc tccagtccgc 120 gcgcgggacc aacgtcaccg ctgccgtcca ggatgccggc ctggcccacg aaggcgaggg 180 cgaggaggag accgaaaaca acgacagcga gaccgcggag aactacgctc cgtctgaaac 240 cgaggatgtt tcaaatagga atstcgtcaa agaagtagaa ttcggaatgt gcaccgttac 300 atgtggtatt ggtgttagag aagttatatt aacaaatgga tgccctggtg gtgaatccaa 360 gtgtgttgta cgggtagaag aatgcccgtg gaccaacaga ttgtggctgg ggtaaaccaa 420 tttcagaaag tcttgaaagt gttagattgg catgtattca cacatctccc ttaaatcgtt 480 tcaaatatat gtggaacttc taagacaaga ccacaatcca ttatacttgt aaatgattca 540 gcaatcctag aagtacgcaa ggaaagtcac cccttggctt tcgagtgtga cacactggat 600 aataatgaaa tartagcaac tattaaattc acagtctata cgagcagtga attgcagatg 660 agaagatcaa gcctaccagc cactgatgcc agccctaatt tttgtgctga ccataggagt 720 cattatctgt gtatttataa ttttcttatt gatcttcata atcataaatt gggcagcagt 780 caaggctttc tggggggcaa aagcctctac acctgaggta caatccgagc agagttctgt 840 gagatacaaa gattcaactt ctcttgacca attaccaaca gaaatgcctg gtgaagatga 900 tgctttaagt gaatggaatg aatgatgttt gaatgatata taacaaacca aaggatatta 960 cagaatatta gattcattat tacaaaaata aaatacacat tgaaatactt taaaaaaaaa 1020 aaaaaaaaaa aaactcga 1038 65 1009 DNA Homo sapiens 65 aggttgcagt gaagctggag atggcgctac tgcagtccag cctgggcgac agggcaagac 60 tccacctcaa aaaaatatat aaaataaagt gggattcatc caagagcttg ggacatgatt 120 aactaktgtc aaggagatat gtymtgccat tattatcctc cttacttggt agggtacaac 180 agaaacagaa caacaaggtg acagcctttt gctcaagtca aaaagaaaat aagtccctca 240 tcttagttta aagttgttca ttcagtagta cagacttgca tttgaagact tattcttgat 300 cttctgtagc tttgacagca aggacatcac tacaatgggt acagaaataa cacattctga 360 tccttgctga gatccttgta tgggcctatc ttaaatctag cctattgtct gtcttaccct 420 ttgattttta taagtrgaaa acaggaaaag gctaaccaag caagaggaag gcatagattc 480 atcttccttt caatcttgac tatagtttaa agagaatacc atgatctttc tgttctattc 540 ttggcttact tgaatattta gccaggtctc tgcatcttat tcagtcagaa aacagacaca 600 gattcagata actcaaagga tgttacttgc ttgagtaatc cttgggcctc gctttaactt 660 tgtagatcca ggaacagaat taagcagaca gttcggtcta cactgccaaa tttcttaggg 720 aaaaagaggg caagtcagaa ggaggaagtt ggcatttggc tcaaatgacc aaattattta 780 aggtctctac acttcacttt gcaccaagta gacccaagaa tgattataat tcagctacgt 840 gtggtggtgc agatcagtag tcctagctat tcaggaggct gaggcgggtg gattggttga 900 gcccgggagt ttgaggctgc aatgggctat gatctcrgmc tgcgctttag cctgggcaac 960 agaacaagac cctgtctcaa attaaaaaaa aaaaaaaaaa aaaactcga 1009 66 34 PRT Homo sapiens SITE (27) Xaa equals any amino acid 66 Met Ser Val Phe Leu Leu Ile Thr Leu Ala Leu Ala Ile Leu Tyr Ile 1 5 10 15 Ile Arg Ser Ile Val Phe Ser Leu Ala Leu Xaa Gln Asn Gly Ser Leu 20 25 30 Gln Gly 67 32 PRT Homo sapiens 67 Met Arg Asn Lys Glu Ser Leu Cys Lys Val Val Leu Lys Ala Leu Tyr 1 5 10 15 Ala Asn Leu Leu Ile Cys Val Ser Ala Ser Ala Ile Leu Val Gln Cys 20 25 30 68 206 PRT Homo sapiens 68 Met Gly Ala Glu Trp Glu Leu Gly Ala Glu Ala Gly Gly Ser Leu Leu 1 5 10 15 Leu Cys Ala Ala Leu Leu Ala Ala Gly Cys Ala Leu Gly Leu Arg Leu 20 25 30 Gly Arg Gly Gln Gly Ala Ala Asp Arg Gly Ala Leu Ile Trp Leu Cys 35 40 45 Tyr Asp Ala Leu Val His Phe Ala Leu Glu Gly Pro Phe Val Tyr Leu 50 55 60 Ser Leu Val Gly Asn Val Ala Asn Ser Asp Gly Leu Ile Ala Ser Leu 65 70 75 80 Trp Lys Glu Tyr Gly Lys Ala Asp Ala Arg Trp Val Tyr Phe Asp Pro 85 90 95 Thr Ile Val Ser Val Glu Ile Leu Thr Val Ala Leu Asp Gly Ser Leu 100 105 110 Ala Leu Phe Leu Ile Tyr Ala Ile Val Lys Glu Lys Tyr Tyr Arg His 115 120 125 Phe Leu Gln Ile Thr Leu Cys Val Cys Glu Leu Tyr Gly Cys Trp Met 130 135 140 Thr Phe Leu Pro Glu Trp Leu Thr Arg Ser Pro Asn Leu Asn Thr Ser 145 150 155 160 Asn Trp Leu Tyr Cys Trp Leu Tyr Leu Phe Phe Phe Asn Gly Val Trp 165 170 175 Val Leu Ile Pro Gly Leu Leu Leu Trp Gln Ser Trp Leu Glu Leu Lys 180 185 190 Lys Met His Gln Lys Glu Thr Ser Ser Val Lys Lys Phe Gln 195 200 205 69 215 PRT Homo sapiens 69 Met Val Ala Asp Trp Leu Gln Gln Ser Tyr Gln Ala Val Lys Glu Lys 1 5 10 15 Ser Ser Glu Ala Leu Glu Phe Met Lys Arg Asp Leu Thr Glu Phe Thr 20 25 30 Gln Val Val Gln His Asp Thr Ala Cys Thr Ile Ala Ala Thr Ala Ser 35 40 45 Val Val Lys Glu Lys Leu Ala Ile Ala Ala Cys Ser Arg Gly Ala Cys 50 55 60 Phe Leu Cys Pro Phe Ser Ile Gln Thr Glu Gly Ser Ser Gly Ala Thr 65 70 75 80 Glu Lys Met Lys Lys Gly Leu Ser Asp Phe Leu Gly Val Ile Ser Asp 85 90 95 Thr Phe Ala Pro Ser Pro Asp Lys Thr Ile Asp Cys Asp Val Ile Thr 100 105 110 Leu Met Gly Thr Pro Ser Gly Thr Ala Glu Pro Tyr Asp Gly Thr Lys 115 120 125 Ala Arg Leu Tyr Ser Leu Gln Ser Asp Pro Ala Thr Tyr Cys Asn Glu 130 135 140 Pro Asp Gly Pro Pro Glu Leu Phe Asp Ala Trp Leu Ser Gln Phe Cys 145 150 155 160 Leu Glu Glu Lys Lys Gly Glu Ile Ser Glu Leu Leu Val Gly Ser Pro 165 170 175 Ser Ile Arg Ala Leu Tyr Thr Lys Met Val Pro Ala Ala Val Ser His 180 185 190 Ser Glu Phe Trp His Arg Tyr Phe Tyr Lys Val His Gln Leu Glu Gln 195 200 205 Glu Gln Ala Arg Arg Thr Pro 210 215 70 33 PRT Homo sapiens 70 Met Arg Leu Leu Leu Pro Ser Leu Leu Gly Gly Leu Ser Val Leu Thr 1 5 10 15 Thr Ser Leu Gly Ser Val Ala Gly Leu Arg Asn Ser Arg Ala Ala Trp 20 25 30 Trp 71 187 PRT Homo sapiens SITE (73) Xaa equals any amino acid 71 Met Gly Thr Ala Ser Thr Gly Pro Trp Ala Ile Pro Thr Trp Ser Pro 1 5 10 15 Cys Trp Gly Arg Ala Gly Arg Ser Ser Ser Ser Lys Asn Ala Tyr Cys 20 25 30 Arg Pro Gln Met Thr Phe Trp Leu Leu Ala Leu Arg Ser Thr Ser Ser 35 40 45 Glu Thr Ser Ser Met Leu Leu Gln Cys Gly Gly Thr Gly Arg Glu Gly 50 55 60 Trp Leu Ser Val Gln Pro Ala Glu Xaa Val Ser Thr Thr Arg Val Pro 65 70 75 80 Arg Asp His Ile Val Gln Phe Leu Arg Leu Leu Xaa Ser Xaa Phe Ile 85 90 95 Arg Asn Arg Ala Asp Phe Phe Arg His Phe Ile Asp Glu Glu Met Asp 100 105 110 Ile Lys Asp Phe Cys Thr His Glu Val Glu Pro Met Ala Xaa Glu Cys 115 120 125 Asp His Ile Gln Ile Thr Ala Leu Ser Gln Ala Leu Ser Ile Ala Leu 130 135 140 Gln Val Glu Tyr Val Asp Glu Met Asp Thr Ala Leu Asn His His Val 145 150 155 160 Phe Pro Glu Ala Ala Thr Pro Ser Val Tyr Leu Leu Tyr Lys Thr Ser 165 170 175 His Tyr Asn Ile Leu Tyr Ala Ala Asp Lys His 180 185 72 48 PRT Homo sapiens 72 Met Phe Ala Pro Cys Phe Val Asn Leu Ala Leu Phe Tyr Leu Tyr Ile 1 5 10 15 Asn Ser Cys Asn Leu Leu Asn Leu Thr Ser Ile Asp Pro Phe Gln Gln 20 25 30 Lys Gly Lys Phe Lys Met Gln Thr Leu Leu Phe Ala Lys Glu Asp Ser 35 40 45 73 91 PRT Homo sapiens SITE (79) Xaa equals any amino acid 73 Met Gln Cys Ile Arg Trp Thr Val Leu Phe Leu Phe Ile Leu Trp Val 1 5 10 15 Leu Val Phe Val Phe Phe Phe Ala Phe Thr Val Arg Leu Gln Met Ile 20 25 30 Val Leu Ile Thr Tyr Ile Ile Asn Lys Cys Gly Pro Ile Ile Tyr Thr 35 40 45 Glu Ile Thr Leu Gly Tyr Phe Cys Ile Ile Leu Ser Tyr Cys Leu His 50 55 60 Ser Ile Asn Phe Ser Arg Asp Asn Cys Leu Cys Val Thr Gly Xaa Lys 65 70 75 80 Cys Arg Ile Thr Ser Phe Ile Ile Trp Lys Asn 85 90 74 28 PRT Homo sapiens 74 Met Val Phe Leu Asn Phe Leu Ile Tyr Leu Leu Leu Val Phe Phe Tyr 1 5 10 15 Ile Ser Leu Phe His Ser Arg Asp Asn Phe Ile Leu 20 25 75 86 PRT Homo sapiens 75 Met Ala Arg His Val Pro Leu Tyr Arg Ala Leu Leu Glu Leu Leu Arg 1 5 10 15 Ala Ile Ala Ser Cys Ala Ala Met Val Pro Leu Leu Leu Pro Leu Ser 20 25 30 Thr Glu Asn Gly Glu Glu Glu Glu Glu Gln Ser Glu Cys Gln Thr Ser 35 40 45 Val Gly Thr Leu Leu Ala Lys Met Lys Thr Cys Val Asp Thr Tyr Thr 50 55 60 Asn Arg Leu Arg Tyr Tyr Ile Gln Cys Ser Phe Leu Leu Ser Leu Pro 65 70 75 80 Leu Thr Met Phe Leu Lys 85 76 124 PRT Homo sapiens 76 Met Leu Leu Ile Leu Val Thr Pro Val Pro Thr Arg Leu Arg Ala Arg 1 5 10 15 Pro Arg Leu Asp Leu Leu Val Leu Thr Pro Arg Ala Cys Pro Ala Ser 20 25 30 Arg Val Arg Gly Arg Leu Ser Cys Arg Arg Thr Leu Pro Arg Met Gly 35 40 45 Pro Ala Ser Cys Ser Ala Leu Ala Thr Asn Ala Ala Pro Gly Pro Pro 50 55 60 His Pro Ala Gly Pro Ala Phe Ser Ser Ile Ser His Met Ala Thr Thr 65 70 75 80 Pro Gln Ser Leu Glu Pro Pro Ala Gly Asn Ser Val Pro Gln Ser Leu 85 90 95 Met Ser Ile Leu Asp Pro Ala Ser Ser Trp Val Pro Lys Ser Ala Ser 100 105 110 Pro Pro Arg Val Ala Cys Pro Cys Pro Pro Ala Leu 115 120 77 38 PRT Homo sapiens 77 Met His Leu Phe Leu Phe Ile Trp Ala Phe Gly Leu Pro Leu His Ile 1 5 10 15 Ser Arg Asp Leu Ala Phe Phe Phe Leu Leu Tyr Phe Leu Phe Phe Tyr 20 25 30 Leu Leu Cys Val Leu Leu 35 78 64 PRT Homo sapiens 78 Met Asn Ala Ser Cys Ser Leu Ala His Phe Glu His Ser Gly Met Ser 1 5 10 15 Val Leu Leu Val His Leu Phe Ile Ile Val Ser Thr Val Pro Ser Cys 20 25 30 Phe Lys Lys Tyr Met Ala Phe Ile Ile Tyr Pro Ala Phe Ser Cys His 35 40 45 Phe Asn Lys Ser Met Cys Leu Ile Gln Leu Leu His Ser Ser Gln Lys 50 55 60 79 108 PRT Homo sapiens SITE (62) Xaa equals any amino acid 79 Met Gly Ala Ala Lys Val Trp Gly Glu Val Gly Arg Trp Leu Val Ile 1 5 10 15 Ala Leu Ile Gln Leu Ala Lys Ala Val Leu Arg Met Leu Leu Leu Leu 20 25 30 Trp Phe Lys Ala Gly Leu Gln Thr Ser Pro Pro Ile Val Pro Leu Asp 35 40 45 Arg Glu Thr Arg His Ser Pro Arg Met Val Thr Thr Ala Xaa Xaa Thr 50 55 60 Met Ser Ser Pro Thr Trp Gly Ser Gly Gln Thr Gly Trp Cys Glu Pro 65 70 75 80 Ser Arg Thr Arg Arg Pro Cys Thr Pro Gly Thr Gly Glu Leu Pro Ser 85 90 95 Ser Gly Arg Asp Gly Ser Ser Ser Ile Thr Arg Ser 100 105 80 43 PRT Homo sapiens 80 Met Asp Ile Ala Ala Pro Val Leu Phe Ala Leu Arg Leu Gln Phe Leu 1 5 10 15 Phe Ile Leu Leu Pro Met His Phe Glu Ile Ser Leu Leu Cys Lys Val 20 25 30 Ser Thr Glu Thr Ser Gly Arg Glu Asp Lys Met 35 40 81 49 PRT Homo sapiens 81 Met Ala Thr Asp Glu Arg Val Leu Arg Lys Ala His Ser Thr Pro Ala 1 5 10 15 Leu Phe Gln Leu Val Leu Asn Leu Val Gln Cys Pro Ser Pro Ala Ser 20 25 30 Gly Val Lys Ser His Leu Leu Pro His Lys Glu Arg His Lys Ser Met 35 40 45 Glu 82 29 PRT Homo sapiens SITE (9) Xaa equals any amino acid 82 Met Gly Val Leu His Leu Leu Ala Xaa Phe Leu Leu Val Xaa Gly Arg 1 5 10 15 Val Pro Gly Leu Gly Gly Val Pro Gly Gly Gly Glu Gly 20 25 83 41 PRT Homo sapiens 83 Met Ser Tyr Lys Trp Asn Ser Arg Val Cys Phe Leu Trp Ser Arg Thr 1 5 10 15 Phe His Leu Met Leu Leu Arg Leu Ile Cys Leu Val Ala Tyr Ile Ser 20 25 30 Thr Glu Val Ile Ser Phe Ile Ala Glu 35 40 84 89 PRT Homo sapiens 84 Met Leu Leu Leu Val Tyr Phe Leu Leu Met Ser Val Ile Phe Gly Thr 1 5 10 15 Lys Phe Phe Pro Leu Ile Ile His Met Phe Asn Pro Cys Ile Leu Asn 20 25 30 Leu Ile Lys Leu Val Phe Ser Leu Met Pro Gly Ser His Gln Thr Pro 35 40 45 Asn Val Gln Ala Thr Arg Ala Ser Asp Asp Gly Ser Ala Leu Leu Gly 50 55 60 Thr Pro Ser Arg Pro Leu Gly Ser Ile Arg Gln Gln Phe Thr Pro Lys 65 70 75 80 Glu Cys Pro Leu Ser Ala Gly Ser Ser 85 85 108 PRT Homo sapiens 85 Met Lys Ala Leu Cys Leu Leu Leu Leu Pro Val Leu Gly Leu Leu Val 1 5 10 15 Ser Ser Lys Thr Leu Cys Ser Met Glu Glu Ala Ile Asn Glu Arg Ile 20 25 30 Gln Glu Val Ala Gly Ser Leu Ile Phe Arg Ala Ile Ser Ser Ile Gly 35 40 45 Leu Glu Cys Gln Ser Val Thr Ser Arg Gly Asp Leu Ala Thr Cys Pro 50 55 60 Arg Gly Phe Ala Val Thr Gly Cys Thr Cys Gly Ser Ala Cys Gly Ser 65 70 75 80 Trp Asp Val Arg Ala Glu Thr Thr Cys His Cys Gln Cys Ala Gly Met 85 90 95 Asp Trp Thr Gly Ala Arg Cys Cys Arg Val Gln Pro 100 105 86 303 PRT Homo sapiens SITE (203) Xaa equals any amino acid 86 Met Gly Ser Gly Gly Asp Ser Leu Leu Gly Gly Arg Gly Ser Leu Pro 1 5 10 15 Leu Leu Leu Leu Leu Ile Met Gly Gly Met Ala Gln Asp Ser Pro Pro 20 25 30 Gln Ile Leu Val His Pro Gln Asp Gln Leu Phe Gln Gly Pro Gly Pro 35 40 45 Ala Arg Met Ser Cys Arg Ala Ser Gly Gln Pro Pro Pro Thr Ile Arg 50 55 60 Trp Leu Leu Asn Gly Gln Pro Leu Ser Met Val Pro Pro Asp Pro His 65 70 75 80 His Leu Leu Pro Asp Gly Thr Leu Leu Leu Leu Gln Pro Pro Ala Arg 85 90 95 Gly His Ala His Asp Gly Gln Ala Leu Ser Thr Asp Leu Gly Val Tyr 100 105 110 Thr Cys Glu Ala Ser Asn Arg Leu Gly Thr Ala Val Ser Arg Gly Ala 115 120 125 Arg Leu Ser Val Ala Val Leu Arg Glu Asp Phe Gln Ile Gln Pro Arg 130 135 140 Asp Met Val Ala Val Val Gly Glu Gln Phe Thr Leu Glu Cys Gly Pro 145 150 155 160 Pro Trp Gly His Pro Glu Pro Thr Val Ser Trp Trp Lys Asp Gly Lys 165 170 175 Pro Leu Ala Leu Gln Pro Gly Arg His Thr Val Ser Gly Gly Ser Leu 180 185 190 Leu Met Ala Arg Ala Glu Lys Ser Asp Glu Xaa Thr Tyr Met Cys Val 195 200 205 Ala Thr Asn Ser Ala Gly His Arg Glu Ser Arg Ala Ala Arg Val Ser 210 215 220 Ile Gln Glu Pro Gln Asp Tyr Thr Glu Pro Val Glu Leu Leu Ala Val 225 230 235 240 Arg Ile Gln Leu Glu Asn Val Thr Leu Leu Asn Pro Asp Pro Ala Glu 245 250 255 Gly Pro Lys Pro Arg Pro Ala Val Trp Leu Xaa Trp Lys Val Ser Gly 260 265 270 Pro Xaa Arg Leu Pro Asn Leu Thr Arg Pro Cys Ser Gly Pro Arg Leu 275 280 285 Pro Arg Glu Ala Arg Glu Leu Arg Gly Gln Arg Arg Asn Thr Gly 290 295 300 87 56 PRT Homo sapiens 87 Met Leu Met Asn Pro Ile Arg Arg Arg Phe Gln Gln Val Pro His Pro 1 5 10 15 Pro Leu Leu Leu Leu Leu Leu Leu Leu Thr Ala Arg Thr Gly Gly Gly 20 25 30 Gln Gly Asp Thr Trp Ala Asp Pro Pro Ala Leu Pro Pro Pro His Pro 35 40 45 Ala Pro His Ile Ile Leu Gln Ser 50 55 88 30 PRT Homo sapiens 88 Met Gln Ser Tyr Ser Leu Val Phe Leu Val Val Tyr Leu Ile Leu Pro 1 5 10 15 Tyr Ser Ser Phe Lys Glu Asn Ser Ile Phe Ile Thr Val Asn 20 25 30 89 68 PRT Homo sapiens SITE (37) Xaa equals any amino acid 89 Met Ala Leu Gly Ala Leu Ser Leu Asn Ala Ala Leu Ala Pro Trp Ala 1 5 10 15 Ser Ser Pro Gly Pro Asp Leu Pro Ile Leu Lys Glu Lys Gln Pro Leu 20 25 30 Ser Ser Tyr Pro Xaa Ser Gly Gly Ala Arg Phe Arg Leu Pro Thr Thr 35 40 45 Ser Leu Gly Thr Arg Glu Ser Ser Ser Phe Thr Thr Cys Xaa Val Xaa 50 55 60 Gly Ala Gly Leu 65 90 25 PRT Homo sapiens 90 Met Ile Thr Ser His Leu Arg Glu Ala Lys Leu Lys Val His Leu Gln 1 5 10 15 Glu Glu Leu Trp Pro Asp Ile Ala Asn 20 25 91 212 PRT Homo sapiens SITE (180) Xaa equals any amino acid 91 Met Lys Val Phe Lys Phe Ile Gly Leu Met Ile Leu Leu Thr Ser Ala 1 5 10 15 Phe Ser Ala Gly Ser Gly Gln Ser Pro Met Thr Val Leu Cys Ser Ile 20 25 30 Asp Trp Phe Met Val Thr Val His Pro Phe Met Leu Asn Asn Asp Val 35 40 45 Cys Val His Phe His Glu Leu His Leu Gly Leu Gly Cys Pro Pro Asn 50 55 60 His Val Gln Pro His Ala Tyr Gln Phe Thr Tyr Arg Val Thr Glu Cys 65 70 75 80 Gly Ile Arg Ala Lys Ala Val Ser Gln Asp Met Val Ile Tyr Ser Thr 85 90 95 Glu Ile His Tyr Ser Ser Lys Gly Thr Pro Ser Lys Phe Val Ile Pro 100 105 110 Val Ser Cys Ala Ala Pro Gln Lys Ser Pro Trp Leu Thr Lys Pro Cys 115 120 125 Ser Met Arg Val Ala Ser Lys Ser Arg Ala Thr Ala Arg Arg Met Arg 130 135 140 Asn Ala Thr Arg Cys Ser Ala Cys His Ser Pro Val Lys Gly Pro Thr 145 150 155 160 Ala Ile Val His Leu Val Ser Ser Val Lys Lys Ser Ile Pro Arg Ser 165 170 175 Leu Val Thr Xaa Ala Gly Ala Gln Glu Ala Gln Pro Leu Gln Pro Ser 180 185 190 His Phe Leu Asp Ile Ser Glu Asp Trp Ser Leu His Thr Asp Asp Met 195 200 205 Ile Gly Ser Met 210 92 44 PRT Homo sapiens 92 Met Asn Asn Ala Ala Lys Asn Ile Asn Val Gln Val Ser Val Trp Thr 1 5 10 15 Tyr Ala Phe Ile Ser Leu Ile Phe Ile Leu Phe His Leu Gly Val Glu 20 25 30 Leu Leu Gly Cys Met Val Val Leu Cys Leu Thr Val 35 40 93 40 PRT Homo sapiens 93 Met Ser Ser Asn Thr Tyr Ile Val Leu Val Cys Gln Ala Leu Leu Ile 1 5 10 15 Thr Ala Met Asn Arg Gly Pro Pro Asn Lys Cys Asn Arg Val Tyr Leu 20 25 30 Phe Leu Asn Leu Cys His His Tyr 35 40 94 115 PRT Homo sapiens 94 Met Gln Leu Ser Val Cys Val Ile Thr Thr Ser Leu Leu Phe Asn Ser 1 5 10 15 Ile Thr Leu Tyr Phe Ser Lys Met Pro Arg Ser Pro Gly Ser Tyr Ala 20 25 30 Asp Leu Gln Arg Phe Tyr Phe Leu Ala Leu Glu Ser Ala Glu Ile Arg 35 40 45 Arg His Arg Ala Gln Arg Ser Ser Leu Gly Thr Arg Ile Ala Phe Ala 50 55 60 Leu Ala Gly Tyr Val Tyr Thr Asp Glu Tyr Lys Met Phe Phe Ser Leu 65 70 75 80 Gly Phe Leu Leu Leu Phe Ser Pro Pro Ser His Leu Pro Phe Ser Pro 85 90 95 Thr Pro Pro Pro Lys Lys Ala Thr Ser Ser Phe Arg Gly Thr Ile Ile 100 105 110 Phe Phe Asn 115 95 83 PRT Homo sapiens 95 Met Ser Phe Phe Gln Leu Leu Met Lys Arg Lys Glu Leu Ile Pro Leu 1 5 10 15 Val Val Phe Met Thr Val Ala Ala Gly Gly Ala Ser Ser Phe Ala Val 20 25 30 Tyr Ser Leu Trp Lys Thr Asp Val Ile Leu Asp Arg Lys Lys Asn Pro 35 40 45 Glu Pro Trp Glu Thr Val Asp Pro Thr Val Pro Gln Lys Leu Ile Thr 50 55 60 Ile Asn Gln Gln Trp Lys Pro Ile Glu Glu Leu Gln Asn Val Gln Arg 65 70 75 80 Val Thr Lys 96 49 PRT Homo sapiens 96 Met Pro Ser Ser Glu Cys Arg Ser Ser Ala Leu Leu Leu Asn Val Ser 1 5 10 15 Leu Ala Glu Ser Glu Ala Gly Arg Arg Pro Gly Lys Pro Gly Trp Ala 20 25 30 Glu Glu Ala Thr Gly Gly Arg Arg Ala Ser Arg Lys Asp Gly Thr Gln 35 40 45 Gly 97 34 PRT Homo sapiens 97 Met Ala His Arg Ser Trp Ile Leu Ser Ser Ser Leu Leu Pro Ile Pro 1 5 10 15 Ile Phe Phe Leu Leu Pro Pro Ser Ser Ala Ala Thr Leu Ala Thr Pro 20 25 30 Gly Ser 98 44 PRT Homo sapiens 98 Met Leu Val Phe Leu Pro Phe Thr Val Leu Val Leu Ile Ser Tyr Ile 1 5 10 15 Phe Ser Ser His Ser Phe Asn Pro Leu Phe Thr Leu Cys Asp Phe Glu 20 25 30 Gln Val Leu Leu His Leu Lys Ile Phe Ser His Pro 35 40 99 42 PRT Homo sapiens 99 Met Ala Leu Val Ile Ser Ala Pro Pro Pro Asn Ser Pro Cys Asn Cys 1 5 10 15 Phe Phe Phe Ile Phe Leu Phe Ile Leu Pro Leu Ile Phe Pro Leu Phe 20 25 30 Lys Gly Leu Phe Ala Thr Phe Val Phe Phe 35 40 100 44 PRT Homo sapiens 100 Met Ala Ser Thr Leu Glu Thr Ile Arg Pro Leu Gly Phe Leu Leu Leu 1 5 10 15 Tyr Cys Phe Ile Ser Leu Leu Tyr Leu Pro Val Leu Glu Thr Ser Phe 20 25 30 Ser Phe Leu Leu Val Trp Arg Leu Glu Pro Ile Val 35 40 101 165 PRT Homo sapiens SITE (56) Xaa equals any amino acid 101 Met Lys Ile Ala Val Leu Phe Cys Phe Phe Leu Leu Ile Ile Phe Gln 1 5 10 15 Thr Asp Phe Gly Lys Asn Glu Glu Ile Pro Arg Lys Gln Arg Arg Lys 20 25 30 Ile Tyr His Arg Arg Leu Arg Lys Ser Ser Thr Ser His Lys His Arg 35 40 45 Ser Asn Arg Gln Leu Gly Ile Xaa Gln Thr Thr Val Phe Thr Pro Val 50 55 60 Ala Arg Leu Pro Ile Val Asn Phe Asp Tyr Ser Met Glu Glu Lys Phe 65 70 75 80 Glu Ser Phe Ser Ser Phe Pro Gly Val Glu Ser Ser Tyr Asn Val Leu 85 90 95 Pro Gly Lys Lys Gly His Cys Leu Val Lys Gly Ile Thr Met Tyr Asn 100 105 110 Lys Ala Val Trp Ser Pro Glu Pro Cys Thr Thr Cys Leu Cys Ser Asp 115 120 125 Gly Arg Val Leu Cys Asp Glu Thr Met Cys His Pro Gln Arg Cys Pro 130 135 140 Gln Thr Val Ile Pro Glu Gly Glu Cys Cys Pro Val Cys Pro Leu Leu 145 150 155 160 Val Gln Ser Phe Ser 165 102 62 PRT Homo sapiens 102 Met Leu Gly Leu Gln Pro Gln Gly Leu Gly Trp Pro Ala Leu Leu Leu 1 5 10 15 Leu Ile Leu Lys Thr Phe Lys Val Gly Gly Trp Gln Gly Met Cys Leu 20 25 30 Ile Asn Gln Phe Gln Ala Ser Lys Lys Lys Lys Lys Lys Lys Lys Lys 35 40 45 Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 50 55 60 103 74 PRT Homo sapiens 103 Met Val Val Ile Thr Val Leu Leu Ser Val Ala His Val Pro Ala Gly 1 5 10 15 Ala Gly Leu His His Cys Pro Gly Thr Gly Leu Pro Gln Val Arg Arg 20 25 30 Ser Ala Arg Ser Ser Ser Phe Ser Arg Lys Pro Arg Ala Pro Ser Ser 35 40 45 Ser Pro Ala His Leu Leu Pro Gly Pro Arg Pro Val Ala Pro Leu Val 50 55 60 Pro Ser Leu Leu Leu Cys Pro Pro Leu Pro 65 70 104 73 PRT Homo sapiens SITE (71) Xaa equals any amino acid 104 Met Leu Ser Val Gly Ile Ala Leu Ala Ala Leu Gly Ser Leu Leu Leu 1 5 10 15 Leu Gly Leu Leu Leu Tyr Gln Val Gly Val Ser Gly His Cys Pro Ser 20 25 30 Ile Cys Met Ala Thr Pro Ser Thr His Ser Gly His Gly Gly His Gly 35 40 45 Ser Ile Phe Ser Ile Ser Gly Gln Leu Ser Ala Gly Arg Arg His Glu 50 55 60 Thr Thr Ser Ser Ile Ala Xaa Leu Ile 65 70 105 163 PRT Homo sapiens SITE (106) Xaa equals any amino acid 105 Met Ser Pro Arg Gly Thr Gly Cys Ser Ala Gly Leu Leu Met Thr Val 1 5 10 15 Gly Trp Leu Leu Leu Ala Gly Leu Gln Ser Ala Arg Gly Thr Asn Val 20 25 30 Thr Ala Ala Val Gln Asp Ala Gly Leu Ala His Glu Gly Glu Gly Glu 35 40 45 Glu Glu Thr Glu Asn Asn Asp Ser Glu Thr Ala Glu Asn Tyr Ala Pro 50 55 60 Pro Glu Thr Glu Asp Val Ser Asn Arg Asn Val Val Lys Glu Val Glu 65 70 75 80 Phe Gly Met Cys Thr Val Thr Cys Gly Ile Gly Val Arg Glu Val Ile 85 90 95 Leu Thr Asn Gly Cys Pro Gly Gly Glu Xaa Lys Cys Val Val Arg Val 100 105 110 Xaa Glu Cys Arg Gly Pro Thr Asp Cys Gly Trp Gly Lys Pro Ile Ser 115 120 125 Glu Ser Leu Glu Ser Val Arg Leu Ala Cys Ile His Thr Ser Pro Leu 130 135 140 Ile Val Ser Ile Tyr Val Glu Leu Leu Arg Gln Thr Thr Ile His Tyr 145 150 155 160 Thr Cys Lys 106 54 PRT Homo sapiens 106 Met Phe Met Pro Leu Leu Ser Ser Leu Leu Gly Arg Val Gln Gln Lys 1 5 10 15 Gln Asn Asn Lys Val Thr Ala Phe Cys Ser Ser Gln Lys Glu Asn Lys 20 25 30 Ser Leu Ile Leu Gly Leu Lys Leu Phe Ile Gln Val Val Gln Thr Cys 35 40 45 Ile Trp Lys Thr Tyr Ser 50 107 25 PRT Homo sapiens 107 Met Ser Lys Thr Phe Leu Ser Ala Phe Leu Phe Leu Thr Val Leu Ser 1 5 10 15 Leu Thr Val Leu Ser Ile Cys Ser Asn 20 25 108 27 PRT Homo sapiens 108 Met Cys Leu Phe Val Ser Leu Leu Ile Leu Ser Leu Gly Ile Gly Lys 1 5 10 15 His Ser Met Asn Ile Tyr Thr Leu Thr Phe Phe 20 25 109 61 PRT Homo sapiens 109 Met Gln Leu Arg Gly Leu Ser Leu Asn Pro Arg Leu Leu Leu Thr Leu 1 5 10 15 Gly Ser Phe Asn Gln Val Gly Gln Pro Leu Leu Gln Arg Gly Val Gly 20 25 30 Trp Leu Ser Ser Leu Ser His Ala Ala Cys Glu Asp Arg Gly Gly Gly 35 40 45 Val Gly Ser Gly Lys Ser Pro Glu Asn Arg Arg Gly Ile 50 55 60 110 50 PRT Homo sapiens 110 Met Leu Leu Thr Leu Phe Ala His Thr Ala Leu Asp Thr Tyr Leu Leu 1 5 10 15 Ser Glu Ala Phe Phe Pro His Ser Ile Leu Pro Ala Leu Leu Leu Ile 20 25 30 Lys Ile Ser Ser Ala Cys Ser Gln Thr Gln Ser Glu Ser Gln Lys Asn 35 40 45 Pro Ala 50 111 170 PRT Homo sapiens 111 Met Thr Val Leu Ile Asn Ile Ile Leu Ser Leu Val Lys Thr Gly Pro 1 5 10 15 Gly Gln His Leu Asn His Ser Glu Leu Ala Ile Leu Leu Asn Leu Leu 20 25 30 Gln Ser Lys Thr Ser Val Asn Met Ala Asp Phe Val Gln Val Leu Asn 35 40 45 Ile Lys Val Asn Ser Glu Thr Gln Gln Gln Leu Asn Lys Ile Asn Leu 50 55 60 Pro Ala Gly Ile Leu Ala Thr Gly Glu Lys Gln Thr Asp Pro Ser Thr 65 70 75 80 Pro Gln Gln Glu Ser Ser Lys Pro Leu Gly Gly Ile Gln Pro Ser Ser 85 90 95 Gln Thr Ile Gln Pro Lys Val Glu Thr Asp Ala Ala Gln Ala Ala Val 100 105 110 Gln Ser Ala Phe Ala Val Leu Leu Thr Gln Leu Ile Lys Ala Gln Gln 115 120 125 Ser Lys Gln Lys Asp Val Leu Leu Glu Glu Arg Glu Asn Gly Ser Gly 130 135 140 His Glu Ala Ser Leu Gln Leu Arg Pro Leu Gln Asn Leu Ala Leu Arg 145 150 155 160 Cys Arg Val Ser Val Gln Ile Pro Asp His 165 170 112 39 PRT Homo sapiens 112 Met Leu Leu Leu Leu Lys Thr Leu Phe Val Thr Phe Trp Ser Thr Asn 1 5 10 15 Leu Ser Ile Thr Phe Ser Asn Tyr Asn Val Lys Leu Tyr Gln Trp Gln 20 25 30 Ser Tyr Ile Val Asn Gly Ser 35 113 64 PRT Homo sapiens 113 Met Lys Gln His His Ile Leu Gln Arg Asn Leu Leu Gly Lys Glu Glu 1 5 10 15 Pro Ile Asp Met Ala Asn Ile Ile Val Val Leu Phe Ser Glu Ile Ala 20 25 30 Ala Ala Thr Pro Ala Phe Ser Ser His His Pro Asp Pro Ser Ala Ala 35 40 45 Ser Asn Ile Lys Ala Arg Phe Ser Thr Ser Gln Lys Lys Lys Thr Leu 50 55 60 114 27 PRT Homo sapiens 114 Met Val Leu Phe Leu Phe Phe Val Phe Val Phe Cys Leu Tyr Trp Glu 1 5 10 15 Leu Ala Leu Leu Val Thr Ser Leu Phe Ser Phe 20 25 115 70 PRT Homo sapiens SITE (60) Xaa equals any amino acid 115 Met Glu Phe Thr Gln Ile Val Leu Ser Phe Arg Thr Lys Glu Met Pro 1 5 10 15 Val Ile Phe Leu Ile Val Asn Leu Ala Lys His Arg Leu Lys Glu Trp 20 25 30 Leu Ser Ser Leu Pro Ser Thr Leu Ser Leu Leu Leu Ile Cys Ala Lys 35 40 45 Cys His Cys Leu Leu Leu Ile Pro Lys Thr Val Xaa Ser Ser Leu Cys 50 55 60 Leu Leu Pro Asn Ser Lys 65 70 116 21 PRT Homo sapiens 116 Gly Ala Ala Gly Ile Ser Gly Glu Pro Gly Ala Ser Arg Cys Cys Ser 1 5 10 15 Gly Asp Ser Cys Thr 20 117 55 PRT Homo sapiens 117 Met Ser Ser Asp Phe Leu Cys Phe Phe Phe Lys Leu Cys Asn Gln Met 1 5 10 15 Ile Leu Cys Phe Phe Phe Arg Gly Ala Glu Tyr Trp Phe Leu Leu Leu 20 25 30 Val Val Phe Ser Phe Leu Cys His Ser Cys Phe Phe Phe Val Phe Ser 35 40 45 Val Ser Asn Thr Ile Cys Ile 50 55 118 88 PRT Homo sapiens 118 Met Lys Ile Ala Val Leu Phe Cys Phe Phe Leu Leu Ile Ile Phe Gln 1 5 10 15 Thr Asp Phe Gly Lys Asn Glu Glu Ile Pro Arg Lys Gln Arg Arg Lys 20 25 30 Ile Tyr His Arg Arg Leu Arg Lys Ser Ser Thr Ser His Lys His Arg 35 40 45 Ser Asn Arg Gln Leu Gly Ile Pro Gln Thr Thr Val Phe Thr Pro Val 50 55 60 Ala Arg Leu Pro Ile Val Asn Phe Asp Tyr Ser Met Glu Glu Lys Phe 65 70 75 80 Glu Ser Phe Gln Val Phe Leu Glu 85 119 124 PRT Homo sapiens SITE (75) Xaa equals any amino acid 119 Met Ser Pro Arg Gly Thr Gly Cys Ser Ala Gly Leu Leu Met Thr Val 1 5 10 15 Gly Trp Leu Leu Leu Ala Gly Leu Gln Ser Ala Arg Gly Thr Asn Val 20 25 30 Thr Ala Ala Val Gln Asp Ala Gly Leu Ala His Glu Gly Glu Gly Glu 35 40 45 Glu Glu Thr Glu Asn Asn Asp Ser Glu Thr Ala Glu Asn Tyr Ala Pro 50 55 60 Ser Glu Thr Glu Asp Val Ser Asn Arg Asn Xaa Val Lys Glu Val Glu 65 70 75 80 Phe Gly Met Cys Thr Val Thr Cys Gly Ile Gly Val Arg Glu Val Ile 85 90 95 Leu Thr Asn Gly Cys Pro Gly Gly Glu Ser Lys Cys Val Val Arg Val 100 105 110 Glu Glu Cys Pro Trp Thr Asn Arg Leu Trp Leu Gly 115 120 120 34 PRT Homo sapiens 120 Pro Leu Leu Ser Ser Leu Leu Gly Arg Val Gln Gln Lys Gln Asn Asn 1 5 10 15 Lys Val Thr Ala Phe Cys Ser Ser Gln Lys Glu Asn Lys Ser Leu Ile 20 25 30 Leu Val 121 19 PRT Homo sapiens 121 Gly Thr Pro Gly Val Ser Thr His Ile Trp Gly Lys Pro Asp Pro Gln 1 5 10 15 Val Thr Asp 122 206 PRT Homo sapiens 122 Met Gly Ala Glu Trp Glu Leu Gly Ala Glu Ala Gly Gly Ser Leu Leu 1 5 10 15 Leu Cys Ala Ala Leu Leu Ala Ala Gly Cys Ala Leu Gly Leu Arg Leu 20 25 30 Gly Arg Gly Gln Gly Ala Ala Asp Arg Gly Ala Leu Ile Trp Leu Cys 35 40 45 Tyr Asp Ala Leu Val His Phe Ala Leu Glu Gly Pro Phe Val Tyr Leu 50 55 60 Ser Leu Val Gly Asn Val Ala Asn Ser Asp Gly Leu Ile Ala Ser Leu 65 70 75 80 Trp Lys Glu Tyr Gly Lys Ala Asp Ala Arg Trp Val Tyr Phe Asp Pro 85 90 95 Thr Ile Val Ser Val Glu Ile Leu Thr Val Ala Leu Asp Gly Ser Leu 100 105 110 Ala Leu Phe Leu Ile Tyr Ala Ile Val Lys Glu Lys Tyr Tyr Arg His 115 120 125 Phe Leu Gln Ile Thr Leu Cys Val Cys Glu Leu Tyr Gly Cys Trp Met 130 135 140 Thr Phe Leu Pro Glu Trp Leu Thr Arg Ser Pro Asn Leu Asn Thr Ser 145 150 155 160 Asn Trp Leu Tyr Cys Trp Leu Tyr Leu Phe Phe Phe Asn Gly Val Trp 165 170 175 Val Leu Ile Pro Gly Leu Leu Leu Trp Gln Ser Trp Leu Glu Leu Lys 180 185 190 Lys Met His Gln Lys Glu Thr Ser Ser Val Lys Lys Phe Gln 195 200 205 123 55 PRT Homo sapiens 123 Met Asn Gln Ile Phe Leu Phe Gly Gln Asn Val Ile His Ser Ser Leu 1 5 10 15 His Phe Val Phe Val Leu Leu Leu Leu Asn Asn Leu Phe Gln Ile Gly 20 25 30 Phe Lys Ala Thr Ser Phe Arg Cys Ile Val Val Gln Leu Asn Gly Asp 35 40 45 Ile Gly Lys Arg Glu Gln Ile 50 55 124 202 PRT Homo sapiens SITE (23) Xaa equals any amino acid 124 Ser Pro Ser Val Arg Ala Gly Ala Gly Pro Glu Asp Ala Leu Lys Gln 1 5 10 15 Arg Ala Glu Gln Ser Ile Xaa Glu Glu Pro Gly Trp Glu Glu Glu Glu 20 25 30 Glu Glu Leu Met Gly Ile Ser Pro Ile Ser Pro Lys Glu Ala Lys Val 35 40 45 Pro Val Ala Lys Ile Ser Thr Phe Pro Glu Gly Glu Pro Gly Pro Gln 50 55 60 Ser Pro Cys Glu Glu Asn Leu Val Thr Ser Val Glu Pro Pro Ala Glu 65 70 75 80 Val Thr Pro Ser Glu Ser Ser Glu Ser Ile Ser Leu Val Thr Gln Ile 85 90 95 Ala Asn Pro Ala Thr Ala Pro Glu Ala Arg Val Leu Pro Lys Asp Leu 100 105 110 Ser Gln Lys Leu Leu Glu Ala Ser Leu Glu Glu Gln Gly Leu Ala Val 115 120 125 Asp Val Gly Glu Thr Gly Pro Ser Pro Pro Ile His Ser Lys Pro Leu 130 135 140 Thr Pro Ala Gly His Arg Phe Trp Trp Leu Pro Ala Gly Pro Leu Gly 145 150 155 160 Pro Leu Leu Thr Pro Gly Lys Gly Leu Ser Lys Ser Arg Pro Glu Thr 165 170 175 Leu Thr Cys Ala Asn Asn Arg Met Thr Gln Gly Arg Gly Asn Leu Ser 180 185 190 Ser Ser Pro Glu Glu Pro Val Phe Phe Cys 195 200 125 24 PRT Homo sapiens SITE (15) Xaa equals any amino acid 125 Gly Pro Glu Asp Ala Leu Lys Gln Arg Ala Glu Gln Ser Ile Xaa Glu 1 5 10 15 Glu Pro Gly Trp Glu Glu Glu Glu 20 126 24 PRT Homo sapiens 126 Ala Lys Val Pro Val Ala Lys Ile Ser Thr Phe Pro Glu Gly Glu Pro 1 5 10 15 Gly Pro Gln Ser Pro Cys Glu Glu 20 127 23 PRT Homo sapiens 127 Pro Ala Glu Val Thr Pro Ser Glu Ser Ser Glu Ser Ile Ser Leu Val 1 5 10 15 Thr Gln Ile Ala Asn Pro Ala 20 128 26 PRT Homo sapiens 128 Leu Ser Gln Lys Leu Leu Glu Ala Ser Leu Glu Glu Gln Gly Leu Ala 1 5 10 15 Val Asp Val Gly Glu Thr Gly Pro Ser Pro 20 25 129 27 PRT Homo sapiens 129 Trp Leu Pro Ala Gly Pro Leu Gly Pro Leu Leu Thr Pro Gly Lys Gly 1 5 10 15 Leu Ser Lys Ser Arg Pro Glu Thr Leu Thr Cys 20 25 130 229 PRT Homo sapiens SITE (117) Xaa equals any amino acid 130 Ile Gly Gly Glu Gly Pro Val Ser Pro Thr Ser Thr Ala Arg Pro Cys 1 5 10 15 Ser Ser Lys Asp Ala Ser Ser Ser Phe Trp Asp Arg Ser Leu Gly Ser 20 25 30 Thr Arg Ala Ser Gly Ala Val Ala Gly Leu Ala Ile Cys Val Thr Arg 35 40 45 Glu Met Leu Ser Leu Leu Ser Asp Gly Val Thr Ser Ala Gly Gly Ser 50 55 60 Thr Glu Val Thr Arg Phe Ser Ser Gln Gly Leu Trp Gly Pro Gly Ser 65 70 75 80 Pro Ser Gly Asn Val Glu Ile Leu Ala Thr Gly Thr Phe Ala Ser Phe 85 90 95 Gly Asp Met Gly Glu Met Pro Met Ser Ser Ser Ser Ser Ser Ser Gln 100 105 110 Pro Gly Ser Ser Xaa Met Leu Cys Ser Ala Arg Cys Phe Arg Ala Ser 115 120 125 Ser Gly Pro Ala Pro Ala Leu Thr Asp Gly Leu Tyr Arg Asn Thr Asp 130 135 140 Ala Arg Ile Leu Asn Gly Lys Gln Leu Leu Glu Pro Ser Trp Cys Arg 145 150 155 160 Gly Pro Gly Trp Arg Gly Cys Leu Gln Gly Ala Leu Arg Ser Pro Pro 165 170 175 Ser Ser Pro Pro Ser Arg Thr Gly Lys Ala Arg Arg Gln Thr Ile Pro 180 185 190 Gly Ala Xaa Leu Val His Tyr Ser Arg Leu Leu Gly Pro Thr Ala Gly 195 200 205 Tyr Arg Gly Glu Pro Trp Cys His His Arg Ala Gln Leu Cys Gln Thr 210 215 220 Val Cys Pro Ser Gly 225 131 26 PRT Homo sapiens 131 Ala Arg Pro Cys Ser Ser Lys Asp Ala Ser Ser Ser Phe Trp Asp Arg 1 5 10 15 Ser Leu Gly Ser Thr Arg Ala Ser Gly Ala 20 25 132 27 PRT Homo sapiens 132 Arg Phe Ser Ser Gln Gly Leu Trp Gly Pro Gly Ser Pro Ser Gly Asn 1 5 10 15 Val Glu Ile Leu Ala Thr Gly Thr Phe Ala Ser 20 25 133 25 PRT Homo sapiens 133 Tyr Arg Asn Thr Asp Ala Arg Ile Leu Asn Gly Lys Gln Leu Leu Glu 1 5 10 15 Pro Ser Trp Cys Arg Gly Pro Gly Trp 20 25 134 28 PRT Homo sapiens 134 Pro Gly Trp Arg Gly Cys Leu Gln Gly Ala Leu Arg Ser Pro Pro Ser 1 5 10 15 Ser Pro Pro Ser Arg Thr Gly Lys Ala Arg Arg Gln 20 25 135 7 PRT Homo sapiens 135 Gly Gly Arg Gly Gly Arg Gly 1 5 136 39 PRT Homo sapiens 136 Tyr Gln Lys Asn Val Thr Phe Tyr Pro Phe Phe Gly Thr Ile Leu Lys 1 5 10 15 Thr Gly Phe Thr Gly Gly Lys Ser Arg Asn Ser Ala Lys Gly Ser Pro 20 25 30 Pro Ser Ala Arg Pro Lys Gly 35 137 161 PRT Homo sapiens 137 Pro Leu Val Cys Gly Arg Ser Gly Val Phe Ser Ala Ala Pro Thr Pro 1 5 10 15 Ser Arg Ser Pro Pro Pro Asn Gln Arg Arg Thr Gly Pro Arg Leu Pro 20 25 30 Arg His Ser Arg Thr Gly Ser Leu Leu Ala Gly Ala Gly Pro Gly Leu 35 40 45 Ala Ala Leu Val Thr Met Ser Glu Thr Ser Phe Asn Leu Ile Ser Glu 50 55 60 Lys Cys Asp Ile Leu Ser Ile Leu Arg Asp His Pro Glu Asn Arg Ile 65 70 75 80 Tyr Arg Arg Lys Ile Glu Glu Leu Ser Lys Arg Phe Thr Ala Ile Arg 85 90 95 Lys Thr Lys Gly Asp Gly Asn Cys Phe Tyr Arg Ala Leu Gly Tyr Ser 100 105 110 Tyr Leu Glu Ser Leu Leu Gly Lys Ser Arg Glu Ile Phe Lys Phe Lys 115 120 125 Glu Arg Val Leu Gln Thr Pro Asn Asp Leu Leu Ala Ala Gly Phe Glu 130 135 140 Glu His Lys Phe Arg Asn Phe Phe Asn Ala Phe Thr Val Trp Trp Asn 145 150 155 160 Trp 138 23 PRT Homo sapiens 138 Val Phe Ser Ala Ala Pro Thr Pro Ser Arg Ser Pro Pro Pro Asn Gln 1 5 10 15 Arg Arg Thr Gly Pro Arg Leu 20 139 29 PRT Homo sapiens 139 Leu Ala Ala Leu Val Thr Met Ser Glu Thr Ser Phe Asn Leu Ile Ser 1 5 10 15 Glu Lys Cys Asp Ile Leu Ser Ile Leu Arg Asp His Pro 20 25 140 31 PRT Homo sapiens 140 Glu Glu Leu Ser Lys Arg Phe Thr Ala Ile Arg Lys Thr Lys Gly Asp 1 5 10 15 Gly Asn Cys Phe Tyr Arg Ala Leu Gly Tyr Ser Tyr Leu Glu Ser 20 25 30 141 20 PRT Homo sapiens 141 Asn Asp Leu Leu Ala Ala Gly Phe Glu Glu His Lys Phe Arg Asn Phe 1 5 10 15 Phe Asn Ala Phe 20 142 23 PRT Homo sapiens SITE (8) Xaa equals any amino acid 142 Arg Pro Leu Val Leu Leu Arg Xaa Arg Glu Ser Ala Phe Leu Glu Leu 1 5 10 15 Leu Ala Lys Cys Glu Lys Leu 20 143 8 PRT Homo sapiens 143 Phe Gly Tyr Thr Val Ile Asn Thr 1 5 144 29 PRT Homo sapiens 144 Glu Phe Gly Thr Ser Ala Leu Val Ser Thr Cys Ser Pro Ile Pro Ser 1 5 10 15 Pro Asp Phe Ser Leu Leu Leu Thr Pro Ser Lys Ala Ile 20 25 145 151 PRT Homo sapiens SITE (15) Xaa equals any amino acid 145 Arg Val Val His Arg Phe Phe Lys Ser Ser Ala Phe Trp Pro Xaa Glu 1 5 10 15 Val Lys Gln Pro Arg Gly Gly Pro Lys Thr Gly Ser Arg Lys Glu Gly 20 25 30 Ala Gly Ser Arg Ala Pro Gln Pro Val Val Arg Ser Phe Cys Gly Ser 35 40 45 Val Gly Ala Glu Gly Arg Met Glu Lys Leu Arg Leu Leu Gly Leu Arg 50 55 60 Tyr Gln Glu Tyr Val Thr Arg His Pro Ala Ala Thr Ala Gln Leu Glu 65 70 75 80 Thr Ala Val Arg Gly Phe Ser Tyr Leu Leu Ala Gly Arg Phe Ala Asp 85 90 95 Ser His Glu Leu Ser Glu Leu Val Tyr Ser Ala Ser Asn Leu Leu Val 100 105 110 Leu Leu Asn Asp Gly Ile Leu Arg Lys Glu Leu Arg Lys Lys Leu Pro 115 120 125 Val Ser Leu Ser Gln Gln Lys Leu Leu Thr Trp Leu Ser Val Leu Glu 130 135 140 Cys Val Glu Val Phe Met Glu 145 150 146 44 PRT Homo sapiens SITE (29) Xaa equals any amino acid 146 Pro Gly Cys Ile Ala Gly Trp Glu Leu Leu Ser Val Val Gln Gly Pro 1 5 10 15 Gly Pro Arg Pro Pro Pro Arg Pro Arg Pro Arg Lys Xaa His Ser Arg 20 25 30 Ala Gly Cys Gly Leu Glu Xaa Gly Ala Gly Gly Asp 35 40 147 102 PRT Homo sapiens SITE (12) Xaa equals any amino acid 147 Gly Val Thr Pro Trp Gly Gly Gly Leu Gln Arg Xaa Leu Pro Val Ala 1 5 10 15 Thr Trp Cys Leu Trp Glu Leu Val Leu Gly Thr Leu Met Gly Val Cys 20 25 30 Gly Pro Ser Cys Arg Pro Ala Pro Ser Ser Arg Ala Pro Gly Leu Gly 35 40 45 Pro Pro Thr Pro Leu Leu Ser Ser Gly Lys Ser Pro Cys Gly Ser Ser 50 55 60 Pro Gly Ser Arg Ser Gly Ala Met Arg Gly Ala Pro Trp Pro Arg Phe 65 70 75 80 Arg Lys Ala Cys Val Cys Ala Arg Gly Lys Gly Leu His Asp Lys Arg 85 90 95 Thr Arg Phe Asp Leu Asn 100 148 34 PRT Homo sapiens 148 Ala Thr Trp Cys Leu Trp Glu Leu Val Leu Gly Thr Leu Met Gly Val 1 5 10 15 Cys Gly Pro Ser Cys Arg Pro Ala Pro Ser Ser Arg Ala Pro Gly Leu 20 25 30 Gly Pro 149 27 PRT Homo sapiens 149 Pro Thr Pro Leu Leu Ser Ser Gly Lys Ser Pro Cys Gly Ser Ser Pro 1 5 10 15 Gly Ser Arg Ser Gly Ala Met Arg Gly Ala Pro 20 25 150 59 PRT Homo sapiens 150 Ala Arg Asp Phe Gly Lys Cys Cys Tyr Val Asn Thr Thr Ile Thr Ile 1 5 10 15 Lys Ile Val Tyr Ser Ser Ser Thr Pro Cys Pro Glu Thr Cys Leu Phe 20 25 30 Cys Leu Val Ser Ser Ser Pro His His Gln Pro Leu Ser Thr Asp Ser 35 40 45 Phe Ser Val Cys Ile Val Tyr Ile Ile Ser Arg 50 55 151 31 PRT Homo sapiens 151 Thr Ile Lys Ile Val Tyr Ser Ser Ser Thr Pro Cys Pro Glu Thr Cys 1 5 10 15 Leu Phe Cys Leu Val Ser Ser Ser Pro His His Gln Pro Leu Ser 20 25 30 152 48 PRT Homo sapiens 152 Gly Thr Ser Thr Asn Pro Arg Ile Pro Arg Val His Leu Leu Val Ala 1 5 10 15 Lys Asp Ile Ser Arg Thr Val Ile Ser Leu Val Lys Phe Ile Cys Ser 20 25 30 Cys Ala Arg Phe His Phe Phe Gln Gln Ser Glu Thr Thr Trp Gly Thr 35 40 45 153 22 PRT Homo sapiens 153 Leu Val Ala Lys Asp Ile Ser Arg Thr Val Ile Ser Leu Val Lys Phe 1 5 10 15 Ile Cys Ser Cys Ala Arg 20 154 9 PRT Homo sapiens 154 Leu Ser Pro Pro Arg Gly Ala Cys Arg 1 5 155 10 PRT Homo sapiens 155 Gly Arg Pro Thr Arg Pro Leu Arg Val Ala 1 5 10 156 120 PRT Homo sapiens 156 Ala Trp Cys Pro Gln Thr His Thr Thr Ser Cys Leu Met Gly Pro Phe 1 5 10 15 Cys Cys Tyr Ser Pro Leu Pro Gly Asp Met Pro Thr Met Ala Arg Pro 20 25 30 Cys Pro Gln Thr Trp Val Ser Thr His Val Arg Pro Ala Thr Gly Leu 35 40 45 Ala Arg Gln Ser Ala Glu Ala Leu Gly Cys Leu Trp Leu Ser Ser Gly 50 55 60 Arg Ile Ser Arg Ser Ser Leu Gly Thr Trp Trp Leu Trp Trp Val Ser 65 70 75 80 Ser Leu Leu Trp Asn Val Gly Arg Pro Gly Ala Thr Gln Ser Pro Gln 85 90 95 Ser His Gly Gly Lys Met Gly Asn Pro Trp Pro Ser Ser Pro Glu Gly 100 105 110 Thr Gln Cys Pro Gly Gly Pro Cys 115 120 157 25 PRT Homo sapiens 157 Cys Cys Tyr Ser Pro Leu Pro Gly Asp Met Pro Thr Met Ala Arg Pro 1 5 10 15 Cys Pro Gln Thr Trp Val Ser Thr His 20 25 158 18 PRT Homo sapiens 158 Ala Leu Gly Cys Leu Trp Leu Ser Ser Gly Arg Ile Ser Arg Ser Ser 1 5 10 15 Leu Gly 159 28 PRT Homo sapiens 159 Trp Asn Val Gly Arg Pro Gly Ala Thr Gln Ser Pro Gln Ser His Gly 1 5 10 15 Gly Lys Met Gly Asn Pro Trp Pro Ser Ser Pro Glu 20 25 160 121 PRT Homo sapiens 160 Leu Ser Ala Tyr Arg Thr Leu Asp Asn Thr His Ile His Thr His Lys 1 5 10 15 Asn Ala His Glu Pro Asn Pro Glu Lys Val Pro Ala Gly Pro Pro Pro 20 25 30 Ser Pro Pro Pro Pro Thr Ser Pro Leu Asp Ser Glu Asp Arg Arg Gly 35 40 45 Thr Arg Gly His Leu Gly Arg Pro Ala Gly Ser Pro Pro Thr Pro Pro 50 55 60 Arg Pro Ser His His Thr Pro Ile Ile Thr Leu Tyr Ile Thr Gln Ser 65 70 75 80 Phe Trp Phe Ser Arg Thr Arg Leu Pro Lys Tyr His Leu Gln Lys Val 85 90 95 Thr Leu Ala Gly His Tyr Phe Val Tyr Leu Phe Pro Met Gln Lys Lys 100 105 110 Asn Glu Asn Glu Lys Arg Gly Ile Pro 115 120 161 29 PRT Homo sapiens 161 Leu Ser Ala Tyr Arg Thr Leu Asp Asn Thr His Ile His Thr His Lys 1 5 10 15 Asn Ala His Glu Pro Asn Pro Glu Lys Val Pro Ala Gly 20 25 162 13 PRT Homo sapiens 162 Leu Asp Ser Glu Asp Arg Arg Gly Thr Arg Gly His Leu 1 5 10 163 28 PRT Homo sapiens 163 Ile Ile Thr Leu Tyr Ile Thr Gln Ser Phe Trp Phe Ser Arg Thr Arg 1 5 10 15 Leu Pro Lys Tyr His Leu Gln Lys Val Thr Leu Ala 20 25 164 10 PRT Homo sapiens 164 Val Ile Ile Leu Phe Ile Cys Ser Leu Cys 1 5 10 165 40 PRT Homo sapiens 165 Ile Asp Phe Phe Val Val Val Ser Phe Leu Tyr Phe Thr Asp Ile Thr 1 5 10 15 Arg Ile Val Tyr Ser Pro Ser Ser Phe Leu Leu Thr Ala His Trp Ile 20 25 30 Thr His Thr Tyr Thr Pro Thr Lys 35 40 166 40 PRT Homo sapiens 166 Ile Asp Phe Phe Val Val Val Ser Phe Leu Tyr Phe Thr Asp Ile Thr 1 5 10 15 Arg Ile Val Tyr Ser Pro Ser Ser Phe Leu Leu Thr Ala His Trp Ile 20 25 30 Thr His Thr Tyr Thr Pro Thr Lys 35 40 167 25 PRT Homo sapiens SITE (8) Xaa equals any amino acid 167 Gly Val Val Ser Arg Gly Phe Xaa Ala Leu Leu Ser Gly Gly Arg Gly 1 5 10 15 Glu Leu Glu Ala Gly Gly Val Ala Ala 20 25 168 45 PRT Homo sapiens 168 Asp Phe Phe Phe Phe Asn Val Arg Arg Arg Asn Ser Gln Ile Thr Leu 1 5 10 15 Leu Pro Ala Lys Arg Leu Phe Thr Thr Ser Pro Leu Leu Gln Leu Gly 20 25 30 Leu Ser Val Phe Asn Leu Thr Ile Leu Asn Val Arg Lys 35 40 45 169 30 PRT Homo sapiens SITE (5) Xaa equals any amino acid 169 Cys Ile Asp His Xaa Gly Lys Arg Xaa Leu Thr Val Pro Val Arg Ile 1 5 10 15 Pro Gly Arg Pro Thr Arg Pro Cys Phe Tyr Ser Leu Thr Ile 20 25 30 170 123 PRT Homo sapiens 170 Val Gln Gln Ser Leu Ser Ile Phe Lys Ser Leu Pro Ser Leu Leu Met 1 5 10 15 Leu Gln Arg Val Phe Ser Cys Thr Tyr Ile Leu Ala Glu Val Phe Gly 20 25 30 Tyr Ile Pro Thr Val Glu Phe Leu Gly Tyr Val Val Pro Ala Ser Ser 35 40 45 Pro Thr Asn Ser Val Gln Met Val Thr Pro Ser Val Cys Met Thr Leu 50 55 60 Ser Val Cys Ala Arg Gly Phe Leu Leu His Ile Ser Ser Gln Thr Phe 65 70 75 80 Phe Phe Phe Phe Asp Arg Val Trp Ala Leu Ser Pro Arg Leu Val Ala 85 90 95 Val Glu Leu Glu Ser Arg His Gly Ile Pro Ala Trp Gly Asn Arg Val 100 105 110 Arg Leu His Pro Pro Pro Arg Glu Lys Pro Asn 115 120 171 43 PRT Homo sapiens 171 Val Gln Gln Ser Leu Ser Ile Phe Lys Ser Leu Pro Ser Leu Leu Met 1 5 10 15 Leu Gln Arg Val Phe Ser Cys Thr Tyr Ile Leu Ala Glu Val Phe Gly 20 25 30 Tyr Ile Pro Thr Val Glu Phe Leu Gly Tyr Val 35 40 172 41 PRT Homo sapiens 172 Val Pro Ala Ser Ser Pro Thr Asn Ser Val Gln Met Val Thr Pro Ser 1 5 10 15 Val Cys Met Thr Leu Ser Val Cys Ala Arg Gly Phe Leu Leu His Ile 20 25 30 Ser Ser Gln Thr Phe Phe Phe Phe Phe 35 40 173 39 PRT Homo sapiens 173 Asp Arg Val Trp Ala Leu Ser Pro Arg Leu Val Ala Val Glu Leu Glu 1 5 10 15 Ser Arg His Gly Ile Pro Ala Trp Gly Asn Arg Val Arg Leu His Pro 20 25 30 Pro Pro Arg Glu Lys Pro Asn 35 174 182 PRT Homo sapiens 174 Ala Ser Leu Ser Pro Lys Pro Val Ala Gly Leu Gly Asn Gln Gly Gly 1 5 10 15 Leu Arg Arg Gln Arg Glu Ala Glu Gly Pro Ala Gly Arg Met Gly Pro 20 25 30 Lys Ala Arg Leu Gly Gly Gln Gln Gln Thr Trp Val Glu Gly Glu Trp 35 40 45 Val Met Gly Arg Ala Cys Ala Gly Trp Ser Pro Ala Gly Asp Gly Arg 50 55 60 Gly His Lys Ala Arg Gln Lys Ala Val Met Ala Ala Glu Arg Ser Thr 65 70 75 80 Gln Gly Pro Pro Leu Gly His Glu Cys Arg Pro Pro Arg Gly Arg Arg 85 90 95 Leu Ala Thr Ser Val Gly Pro Arg Cys Pro Ser Ala Gln Cys Pro Arg 100 105 110 Ala Arg Gln Pro Pro Arg Thr Glu Thr Arg Ser Ala Gly Gly Leu Gln 115 120 125 Leu Leu Pro Ile Leu Ser Trp Ala Ala Ser Ser Pro His Leu Ser Lys 130 135 140 Leu Ala Gly Glu Leu Glu Pro Leu Arg Pro Gln Pro His Ile Ile Leu 145 150 155 160 Thr Pro Leu Leu Gly Ala Met Pro Cys Cys Thr Arg Ile Phe Cys Phe 165 170 175 Ser Leu Thr Met Gly Ser 180 175 43 PRT Homo sapiens 175 Ala Ser Leu Ser Pro Lys Pro Val Ala Gly Leu Gly Asn Gln Gly Gly 1 5 10 15 Leu Arg Arg Gln Arg Glu Ala Glu Gly Pro Ala Gly Arg Met Gly Pro 20 25 30 Lys Ala Arg Leu Gly Gly Gln Gln Gln Thr Trp 35 40 176 42 PRT Homo sapiens 176 Val Glu Gly Glu Trp Val Met Gly Arg Ala Cys Ala Gly Trp Ser Pro 1 5 10 15 Ala Gly Asp Gly Arg Gly His Lys Ala Arg Gln Lys Ala Val Met Ala 20 25 30 Ala Glu Arg Ser Thr Gln Gly Pro Pro Leu 35 40 177 44 PRT Homo sapiens 177 Gly His Glu Cys Arg Pro Pro Arg Gly Arg Arg Leu Ala Thr Ser Val 1 5 10 15 Gly Pro Arg Cys Pro Ser Ala Gln Cys Pro Arg Ala Arg Gln Pro Pro 20 25 30 Arg Thr Glu Thr Arg Ser Ala Gly Gly Leu Gln Leu 35 40 178 53 PRT Homo sapiens 178 Leu Pro Ile Leu Ser Trp Ala Ala Ser Ser Pro His Leu Ser Lys Leu 1 5 10 15 Ala Gly Glu Leu Glu Pro Leu Arg Pro Gln Pro His Ile Ile Leu Thr 20 25 30 Pro Leu Leu Gly Ala Met Pro Cys Cys Thr Arg Ile Phe Cys Phe Ser 35 40 45 Leu Thr Met Gly Ser 50 179 39 PRT Homo sapiens 179 Ile Arg His Ser Leu Pro His Leu Leu Val Lys Val Ile Thr Leu Thr 1 5 10 15 Ser Val Lys Cys Asn Pro Ile Met Asn Ile Ala Arg Val Ile Tyr Cys 20 25 30 Gln Val Arg Asn Arg Leu Val 35 180 97 PRT Homo sapiens 180 Phe Leu Pro Leu Pro Gln Thr Ala His Val Ile Ala Ser Phe Leu Ser 1 5 10 15 Phe Phe Ser Phe Cys Leu Ser Phe Phe Leu Ser Ser Lys Ala Phe Leu 20 25 30 Leu Leu Leu Ser Phe Ser Lys Phe Phe Phe Ile Leu Phe Phe Ser Phe 35 40 45 Cys Cys Leu Lys Phe Ser His Leu Ala Ser Leu Ser Leu Val Val Ser 50 55 60 Arg Gly Val Pro Trp Thr Arg Lys His Gly Gly Ser Leu Ala Glu Trp 65 70 75 80 Val Phe Gly Ala Glu Thr Ser Arg Gly Pro Pro Ser Ser Asp Leu Ile 85 90 95 Asp 181 103 PRT Homo sapiens 181 Leu Leu Leu Phe Tyr Leu Ser Phe His Phe Ala Ser His Phe Ser Ser 1 5 10 15 Leu Gln Arg Pro Phe Cys Tyr Phe Cys Leu Phe Leu Ser Phe Ser Leu 20 25 30 Ser Cys Ser Phe Leu Ser Val Val Ser Asn Ser His Ile Trp Pro Val 35 40 45 Phe Leu Leu Ser Ser Pro Gly Val Tyr Leu Gly Pro Gly Asn Thr Glu 50 55 60 Gly Ala Trp Leu Ser Gly Phe Ser Val Pro Lys Pro Pro Glu Gly Leu 65 70 75 80 Leu Pro Val Ile Ser Leu Thr Asp Leu Glu Thr Ala Ser Arg Ser Val 85 90 95 Thr Pro Ala Val Val Pro Ser 100 182 54 PRT Homo sapiens 182 Phe Phe Ile Gly Leu Glu Thr Arg Ala Asn Ser Ile Met Phe Ser Lys 1 5 10 15 Glu Thr Asp Leu Ser Cys Trp Ile Arg Gly Thr Asn Pro Thr Tyr Met 20 25 30 Ile Phe Phe Leu Phe Leu Ser Cys Ser Tyr Gly Thr Val Leu Phe Gly 35 40 45 Thr Phe Ala Thr Arg Gly 50 183 10 PRT Homo sapiens 183 Pro Glu Gly Glu Cys Cys Pro Val Cys Pro 1 5 10 184 10 PRT Homo sapiens 184 Pro Glu Gly Glu Cys Cys Pro Val Cys Pro 1 5 10 185 49 PRT Homo sapiens 185 Ile Leu Phe Asn Ile Pro Phe Cys Pro Phe Phe Val Phe Lys Glu Ser 1 5 10 15 Ser Asp Phe Val Ser Phe Ser Ala Gly Asp Leu Asn Asp Thr Lys Gln 20 25 30 Ser Leu Leu Ser Leu Asp Leu Gln Lys Leu Ala Gly Gly Lys Lys Ser 35 40 45 Asn 186 72 PRT Homo sapiens 186 Arg Ala Ala Ala Leu Ala Cys Ser Cys Pro Thr Gly Ile Glu Trp Arg 1 5 10 15 Glu Leu Gln Lys Leu Ser Ile Pro Lys Ala Val Ser Val Val Glu Ala 20 25 30 Asp Trp Ile Phe Ala Leu Pro Leu Thr Pro Cys Pro Ser Leu Arg Glu 35 40 45 Gly Ser Tyr Ala Arg Thr Pro Thr Ser Gly Thr Arg Val Ala Cys Ala 50 55 60 Thr Ser Phe Asp Thr Glu Asn Phe 65 70 187 21 PRT Homo sapiens 187 Ser Arg Leu Asp Phe Cys Ser Ala Pro Asp Pro Leu Ser Leu Phe Glu 1 5 10 15 Gly Gly Glu Leu Cys 20 188 68 PRT Homo sapiens 188 Ile Ser Tyr Leu Val Lys Lys Gly Thr Ala Thr Glu Ser Ser Arg Glu 1 5 10 15 Ile Pro Met Ser Thr Leu Pro Arg Arg Asn Met Glu Ser Ile Gly Leu 20 25 30 Gly Met Ala Arg Thr Gly Gly Met Val Val Ile Thr Val Leu Leu Ser 35 40 45 Val Ala Met Phe Leu Leu Val Leu Gly Phe Ile Ile Ala Leu Ala Leu 50 55 60 Gly Ser Arg Lys 65 189 24 PRT Homo sapiens 189 Met Ala Arg Thr Gly Gly Met Val Val Ile Thr Val Leu Leu Ser Val 1 5 10 15 Ala Met Phe Leu Leu Val Leu Gly 20 190 25 PRT Homo sapiens 190 Asn Met Glu Ser Ile Gly Leu Gly Met Ala Arg Thr Gly Gly Met Val 1 5 10 15 Val Ile Thr Val Leu Leu Ser Val Ala 20 25 191 42 PRT Homo sapiens 191 His Glu Ser Ile Ser Tyr Leu Val Lys Lys Gly Thr Ala Thr Glu Ser 1 5 10 15 Ser Arg Glu Ile Pro Met Ser Thr Leu Pro Arg Arg Asn Met Glu Ser 20 25 30 Ile Gly Leu Gly Met Ala Arg Thr Gly Gly 35 40 192 62 PRT Homo sapiens SITE (52) Xaa equals any amino acid 192 Thr Ala Asp Glu Leu Gly Cys Gln Asp Met Asn Cys Ile Arg Gln Ala 1 5 10 15 His His Val Ala Leu Leu Arg Ser Gly Gly Gly Ala Asp Ala Leu Val 20 25 30 Val Leu Leu Ser Gly Leu Val Leu Leu Val Thr Gly Leu Thr Leu Ala 35 40 45 Gly Leu Ala Xaa Ala Pro Ala Pro Ala Arg Pro Leu Ala Xaa 50 55 60 193 146 PRT Homo sapiens SITE (64) Xaa equals any amino acid 193 Met Ser Glu Gln Glu Ala Gln Ala Pro Gly Gly Arg Gly Leu Pro Pro 1 5 10 15 Asp Met Leu Ala Glu Gln Val Glu Leu Trp Trp Ser Gln Gln Pro Arg 20 25 30 Arg Ser Ala Leu Cys Phe Val Val Ala Val Gly Leu Val Ala Gly Cys 35 40 45 Gly Ala Gly Gly Val Ala Leu Leu Ser Thr Thr Ser Ser Arg Ser Xaa 50 55 60 Glu Trp Arg Leu Ala Thr Gly Thr Val Leu Cys Leu Leu Ala Leu Leu 65 70 75 80 Val Leu Val Lys Gln Leu Met Ser Ser Ala Val Gln Asp Met Asn Cys 85 90 95 Ile Arg Gln Ala His His Val Ala Leu Leu Arg Ser Gly Gly Gly Ala 100 105 110 Asp Ala Leu Val Val Leu Leu Ser Gly Leu Val Leu Leu Val Thr Gly 115 120 125 Leu Thr Leu Ala Gly Leu Ala Ala Ala Pro Ala Pro Ala Arg Pro Leu 130 135 140 Ala Ala 145 194 27 PRT Homo sapiens SITE (26) Xaa equals any amino acid 194 Val Ala Ala Leu Phe Asp Val Pro Val Leu Arg Ser Arg Gly Gly Asp 1 5 10 15 Cys Ala Ser Asp Gly Arg Arg Gly Arg Xaa Thr 20 25 195 44 PRT Homo sapiens 195 Glu Gly Arg Glu Ala Gly Ser Gly Leu Ser Val Asp Ser Arg Asp Lys 1 5 10 15 Gly His Glu Gly Arg Gly Leu Gly Pro Phe Arg Ile Pro Gln Asp Ser 20 25 30 Gln Val Gln Leu Cys Gln Lys Gly Thr Phe His Val 35 40 196 42 PRT Homo sapiens SITE (1)...(5) Xaa equals any amino acid 196 Xaa Xaa Xaa Xaa Xaa Asn His Pro Val Ser Tyr Phe Leu His Asn Asn 1 5 10 15 Pro Ala Phe Pro Ile Asn Leu His Ile Phe Pro Gln Gln Leu Cys Ser 20 25 30 Val Ile Pro Thr Trp Glu Lys Ser Gln Gly 35 40 197 190 PRT Homo sapiens 197 Ser Gly Gly Ala Lys Pro Pro Ala Lys Met Cys Lys Gly Leu Ala Ala 1 5 10 15 Leu Pro His Ser Cys Leu Glu Arg Ala Lys Glu Ile Lys Ile Lys Leu 20 25 30 Gly Ile Leu Leu Gln Lys Pro Asp Ser Val Gly Asp Leu Val Ile Pro 35 40 45 Tyr Asn Glu Lys Pro Glu Lys Pro Ala Lys Thr Gln Lys Thr Ser Leu 50 55 60 Asp Glu Ala Leu Gln Trp Arg Asp Ser Leu Asp Lys Leu Leu Gln Asn 65 70 75 80 Asn Tyr Gly Leu Ala Ser Phe Lys Ser Phe Leu Lys Ser Glu Phe Ser 85 90 95 Glu Glu Asn Leu Glu Phe Trp Ile Ala Cys Glu Asp Tyr Lys Lys Ile 100 105 110 Lys Ser Pro Ala Lys Met Ala Glu Lys Ala Lys Gln Ile Tyr Glu Glu 115 120 125 Phe Ile Gln Thr Glu Ala Pro Lys Glu Val Asn Ile Asp His Phe Thr 130 135 140 Lys Asp Ile Thr Met Lys Asn Leu Val Glu Pro Ser Leu Ser Ser Phe 145 150 155 160 Asp Met Ala Gln Lys Arg Ile His Ala Leu Met Glu Lys Asp Ser Leu 165 170 175 Pro Arg Phe Val Arg Ser Glu Phe Tyr Gln Glu Leu Ile Lys 180 185 190 198 31 PRT Homo sapiens 198 Ala Leu Pro His Ser Cys Leu Glu Arg Ala Lys Glu Ile Lys Ile Lys 1 5 10 15 Leu Gly Ile Leu Leu Gln Lys Pro Asp Ser Val Gly Asp Leu Val 20 25 30 199 25 PRT Homo sapiens 199 Asp Ser Leu Asp Lys Leu Leu Gln Asn Asn Tyr Gly Leu Ala Ser Phe 1 5 10 15 Lys Ser Phe Leu Lys Ser Glu Phe Ser 20 25 200 29 PRT Homo sapiens 200 Glu Asn Leu Glu Phe Trp Ile Ala Cys Glu Asp Tyr Lys Lys Ile Lys 1 5 10 15 Ser Pro Ala Lys Met Ala Glu Lys Ala Lys Gln Ile Tyr 20 25 201 28 PRT Homo sapiens 201 Asp Ile Thr Met Lys Asn Leu Val Glu Pro Ser Leu Ser Ser Phe Asp 1 5 10 15 Met Ala Gln Lys Arg Ile His Ala Leu Met Glu Lys 20 25 202 16 PRT Homo sapiens 202 Ile Arg His Glu Asn Phe Glu Arg Ser Ser Thr Val Asp Lys Lys Leu 1 5 10 15 203 16 PRT Homo sapiens 203 Asn Ser Ile Thr Tyr Tyr Arg Glu Thr Phe Trp Glu Arg Lys Ser Gln 1 5 10 15 204 32 PRT Homo sapiens 204 Ile Trp Gln Thr Ser Leu Leu Ser Tyr Phe Gln Lys Leu Pro Gln Leu 1 5 10 15 Pro Gln Pro Ser Ala Ala Thr Thr Leu Ile Arg Gln Gln Pro Ala Thr 20 25 30 205 19 PRT Homo sapiens 205 Lys Gln Gly Ser Leu Pro Ala Lys Arg Arg Lys Leu Ser Glu Gly Ser 1 5 10 15 Gly Val Leu 206 51 PRT Homo sapiens 206 Val Lys Ser Thr Leu Gly Arg Leu Ile Val Leu Ser Ser Ala Leu Asn 1 5 10 15 Lys Ile Phe Pro Leu Thr Leu Ala Ser Ser Val Leu Tyr Ser Gly Arg 20 25 30 Thr Ser Pro Pro Arg Glu Ser Phe Val Ser Gln Leu Asn Cys Cys Phe 35 40 45 Ser Asp Lys 50 

What is claimed is:
 1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of: (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X; (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X; (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X; (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X; (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity; (f) a polynucleotide which is a variant of SEQ ID NO:X; (g) a polynucleotide which is an allelic variant of SEQ ID NO:X; (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y; (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
 2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.
 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
 7. A recombinant vector comprising the isolated nucleic acid molecule of claim
 1. 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim
 1. 9. A recombinant host cell produced by the method of claim
 8. 10. The recombinant host cell of claim 9 comprising vector sequences.
 11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of: (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z; (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity; (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z; (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z; (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z; (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z; (g) a variant of SEQ ID NO:Y; (h) an allelic variant of SEQ ID NO:Y; or (i) a species homologue of the SEQ ID NO:Y.
 12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
 13. An isolated antibody that binds specifically to the isolated polypeptide of claim
 11. 14. A recombinant host cell that expresses the isolated polypeptide of claim 1
 1. 15. A method of making an isolated polypeptide comprising: (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and (b) recovering said polypeptide.
 16. The polypeptide produced by claim
 15. 17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim
 1. 18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising: (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
 19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising: (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
 20. A method for identifying a binding partner to the polypeptide of claim 11 comprising: (a) contacting the polypeptide of claim 11 with a binding partner; and (b) determining whether the binding partner effects an activity of the polypeptide.
 21. The gene corresponding to the cDNA sequence of SEQ ID NO:X.
 22. A method of identifying an activity in a biological assay, wherein the method comprises: (a) expressing SEQ ID NO:X in a cell; (b) isolating the supernatant; (c) detecting an activity in a biological assay; and (d) identifying the protein in the supernatant having the activity.
 23. The product produced by the method of claim
 20. 